<SEC-DOCUMENT>0001213900-24-097450.txt : 20241113
<SEC-HEADER>0001213900-24-097450.hdr.sgml : 20241113
<ACCEPTANCE-DATETIME>20241113160528
ACCESSION NUMBER:		0001213900-24-097450
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		95
CONFORMED PERIOD OF REPORT:	20240930
FILED AS OF DATE:		20241113
DATE AS OF CHANGE:		20241113

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUCELL CORP /DE/
		CENTRAL INDEX KEY:			0000811641
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				010382980
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12934
		FILM NUMBER:		241454048

	BUSINESS ADDRESS:	
		STREET 1:		56 EVERGREEN DR
		CITY:			PORTLAND
		STATE:			ME
		ZIP:			04103
		BUSINESS PHONE:		2078782770

	MAIL ADDRESS:	
		STREET 1:		56 EVERGREEN DRIVE
		CITY:			PORTLAND
		STATE:			ME
		ZIP:			04103
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ea0220527-10q_immucell.htm
<DESCRIPTION>QUARTERLY REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Nov 11 21:15:33 UTC 2024 -->
<html xmlns:compsci="http://compsciresources.com" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:iccc="http://immucell.com/20240930" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>UNITED STATES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Washington, D.C. 20549</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 12pt"><b>FORM
<ix:nonNumeric contextRef="c0" name="dei:DocumentType" id="ixv-13825">10-Q</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="ixv-13826">&#9746;</ix:nonNumeric> <b>QUARTERLY REPORT PURSUANT TO SECTION
13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>For the quarterly period ended <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="ixv-13827">September 30,
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus" id="ixv-13828">2024</ix:nonNumeric></ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber" id="ixv-44"><b><span style="text-decoration:underline">001-12934</span></b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(Commission file number)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 12pt"><b><span style="text-decoration:underline"><span style="-sec-ix-hidden: hidden-fact-0">ImmuCell
Corporation</span></span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(Exact name of registrant as specified in its
charter)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="border-bottom: black 1.5pt solid; width: 49%; font-size: 10pt; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-68"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</span></ix:nonNumeric></td> <td style="width: 2%; font-size: 10pt">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 49%; font-size: 10pt; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityTaxIdentificationNumber" id="ixv-72"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">01-0382980</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State of Incorporation)</span></td> <td style="font-size: 10pt">&#160;</td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(I.R.S. Employer</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Identification No.)</p></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 49%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1" id="ixv-13829">56 Evergreen Drive</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown" id="ixv-13830">Portland</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressStateOrProvince" id="ixv-13831">ME</ix:nonNumeric></span></td> <td style="width: 2%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 49%; border-bottom: black 1.5pt solid; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode" id="ixv-91"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">04103</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive office)</span></td> <td>&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-decoration:underline"><ix:nonNumeric contextRef="c0" name="dei:CityAreaCode" id="ixv-13832">(207)</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:LocalPhoneNumber" id="ixv-13833">878-2770</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&#8217;s telephone number)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Exchange Act:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; width: 32%"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Title of each class</b></p></td> <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><span style="font-size: 10pt"><b>Trading symbol(s)</b></span></td> <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><span style="font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: center"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle" id="ixv-130"><span style="font-size: 10pt">Common Stock, $0.10 par value per share</span></ix:nonNumeric></td> <td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol" id="ixv-134"><span style="font-size: 10pt">ICCC</span></ix:nonNumeric></td> <td>&#160;</td> <td style="text-align: center"><span style="font-size: 10pt">The <ix:nonNumeric contextRef="c0" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-13834">Nasdaq</ix:nonNumeric> Capital Market</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
<ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus" id="ixv-13835">Yes</ix:nonNumeric> &#9746; No &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant has submitted electronically
every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months
(or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent" id="ixv-13836">Yes</ix:nonNumeric> &#9746; No &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company.
See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221;
and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer</span></td> <td style="width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td> <td style="width: 28%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer</span></td> <td style="width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr> <tr style="vertical-align: top"> <td><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="ixv-166"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer</span></ix:nonNumeric></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company</span></td> <td><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="ixv-173"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company</span></td> <td><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="ixv-181"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></ix:nonNumeric></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is a shell company (as
defined in Rule 12b-2 of the Exchange Act). Yes &#9744; No <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany" id="ixv-13837">&#9746;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The number of shares of the registrant&#8217;s common stock outstanding
as of October 30, 2024 was <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-13838">8,911,589</ix:nonFraction>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TABLE OF CONTENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>September
30, 2024 </b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_001">PART I: FINANCIAL INFORMATION</a></b></span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; width: 9%">&#160;</td>
    <td style="vertical-align: top; width: 82%">&#160;</td>
    <td style="vertical-align: bottom; width: 9%; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    1.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_002">Unaudited Financial Statements</a></span></td>
    <td style="vertical-align: bottom; text-align: center"/></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_003">Balance Sheets as of September 30, 2024 and December&#160;31, 2023</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_004">Statements of Operations during the three-month and nine-month periods ended September 30, 2024 and 2023</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_005">Statements of Stockholders&#8217; Equity during the three-month and nine-month periods ended September 30, 2024 and 2023</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_006">Statements of Cash Flows during the nine-month periods ended September 30, 2024 and 2023</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4-5</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_007">Notes to Unaudited Financial Statements</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-26</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    2.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_008">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27-47</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    3.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_009">Quantitative and Qualitative Disclosures about Market Risk</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    4.&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_010">Controls and Procedures</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_011">PART II: OTHER INFORMATION</a></b></span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td colspan="2" style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_012">ITEM 1 THROUGH 6.</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48-58</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_013">Signature</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.35pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.35pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.35pt; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b>

</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Part 1. FINANCIAL INFORMATION</b></p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>ITEM 1. UNAUDITED FINANCIAL STATEMENTS</b></p><div>

</div><div><a id="a_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>BALANCE SHEETS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>As
of<br/>
September 30, <br/>
&#160;2024</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<br/> December 31, <br/>
2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: center">ASSETS</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">CURRENT ASSETS:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; width: 76%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-13839">3,808,633</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-13840">978,741</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Trade accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-13841">2,307,913</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-13842">2,185,383</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in">Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd" id="ixv-13843">7,460,452</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd" id="ixv-13844">7,811,841</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-13845">310,488</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-13846">493,885</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left">Total current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd" id="ixv-13847">13,887,486</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd" id="ixv-13848">11,469,850</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Property, plant and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-13849">25,820,333</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-13850">27,575,683</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Operating lease right-of-use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-13851">4,592,718</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-13852">4,571,149</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in">Goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="0" unitRef="usd" id="ixv-13853">95,557</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="0" unitRef="usd" id="ixv-13854">95,557</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Intangible assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd" id="ixv-13855">23,880</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd" id="ixv-13856">38,208</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Other assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" unitRef="usd" id="ixv-13857">28,899</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" unitRef="usd" id="ixv-13858">57,655</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt">TOTAL ASSETS</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-13859">44,448,873</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-13860">43,808,102</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: center">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">CURRENT LIABILITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Current portion of debt obligations</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="0" unitRef="usd" id="ixv-13861">1,479,058</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="0" unitRef="usd" id="ixv-13862">1,428,807</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Current portion of operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd" id="ixv-13863">482,244</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd" id="ixv-13864">644,276</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Accounts payable and accrued expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-13865">2,504,535</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-13866">2,124,337</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left">Total current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-13867">4,465,837</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-13868">4,197,420</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">LONG-TERM LIABILITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Debt obligations, net of current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" scale="0" unitRef="usd" id="ixv-13869">9,422,961</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" scale="0" unitRef="usd" id="ixv-13870">10,540,496</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Operating lease liability, net of current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd" id="ixv-13871">4,148,404</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd" id="ixv-13872">4,077,109</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Total long-term liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="0" unitRef="usd" id="ixv-13873">13,571,365</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="0" unitRef="usd" id="ixv-13874">14,617,605</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">TOTAL LIABILITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd" id="ixv-13875">18,037,202</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd" id="ixv-13876">18,815,025</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">CONTINGENT LIABILITIES AND COMMITMENTS (See Note 11)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">STOCKHOLDER&#8217; EQUITY:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in">Common stock, $<ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-13877"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-13878">0.10</ix:nonFraction></ix:nonFraction> par value per share, <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-13879">15,000,000</ix:nonFraction> and <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-13880">15,000,000</ix:nonFraction> shares authorized, <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-13881">8,896,398</ix:nonFraction> and <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-13882">7,814,165</ix:nonFraction> shares issued and <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-13883">8,833,097</ix:nonFraction> and <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-13884">7,750,864</ix:nonFraction> shares outstanding, as of September 30, 2024 and December 31, 2023, respectively.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd" id="ixv-13885">889,641</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd" id="ixv-13886">781,417</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" unitRef="usd" id="ixv-13887">40,338,793</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" unitRef="usd" id="ixv-13888">36,357,239</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd" id="ixv-13889">14,678,281</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd" id="ixv-13890">12,007,097</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; padding-bottom: 1.5pt">Treasury stock, at cost, <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonShares" scale="0" unitRef="shares" id="ixv-13891"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonShares" scale="0" unitRef="shares" id="ixv-13892">63,301</ix:nonFraction></ix:nonFraction> shares as of both September 30, 2024 and December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonValue" scale="0" unitRef="usd" id="ixv-13893">138,482</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonValue" scale="0" unitRef="usd" id="ixv-13894">138,482</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">TOTAL STOCKHOLDERS&#8217; EQUITY</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-13895">26,411,671</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-13896">24,993,077</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd" id="ixv-13897">44,448,873</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd" id="ixv-13898">43,808,102</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 96.35pt"><i>&#160;</i></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><i>The accompanying notes are an integral part of these
unaudited financial statements.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 96.35pt"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 96.35pt"></p><div>

</div><!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 96.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>ImmuCell Corporation</b></p><div>

</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>STATEMENTS OF OPERATIONS
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: center; text-indent: 1.2pt"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>During the Three-Month<br/>
 Periods Ended September 30,</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>During the Nine-Month<br/>
 Periods Ended September 30,</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 52%; text-align: left">Product sales</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-13899">6,011,573</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-13900">5,396,500</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-13901">18,742,040</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-13902">12,375,708</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Costs of goods sold</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-13903">4,428,019</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-13904">4,129,619</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-13905">13,632,642</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-13906">9,764,164</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Gross margin</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-13907">1,583,554</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-13908">1,266,881</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-13909">5,109,398</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-13910">2,611,544</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Product development expenses</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-13911">786,136</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-13912">1,118,489</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-13913">3,079,189</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-13914">3,328,397</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Sales and marketing expenses</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="0" unitRef="usd" id="ixv-13915">844,045</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="0" unitRef="usd" id="ixv-13916">817,486</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="0" unitRef="usd" id="ixv-13917">2,629,925</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="0" unitRef="usd" id="ixv-13918">2,416,701</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Administrative expenses</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-13919">528,267</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-13920">514,952</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-13921">1,661,838</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-13922">1,611,026</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Operating expenses</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-13923">2,158,448</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-13924">2,450,927</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-13925">7,370,952</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-13926">7,356,124</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">NET OPERATING LOSS</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-13927">574,894</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-13928">1,184,046</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-13929">2,261,554</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-13930">4,744,580</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Other expenses (income), net</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-13931">125,456</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" unitRef="usd" id="ixv-13932">244,275</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-13933">405,610</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" unitRef="usd" id="ixv-13934">113,092</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">LOSS BEFORE INCOME TAXES</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-13935">700,350</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-13936">939,771</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-13937">2,667,164</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-13938">4,631,488</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Income tax expense</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-13939">1,340</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-13940">229</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-13941">4,020</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-13942">3,279</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt">NET LOSS</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-13943">701,690</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-13944">940,000</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-13945">2,671,184</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-13946">4,634,767</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Basic weighted average common shares outstanding</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-13947">8,164,423</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-13948">7,746,864</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-13949">7,908,425</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-13950">7,746,864</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in">Basic net loss per share</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-13951">0.09</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-13952">0.12</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-13953">0.34</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-13954">0.60</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Diluted weighted average common shares outstanding</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-13955">8,164,423</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-13956">7,746,864</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-13957">7,908,425</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-13958">7,746,864</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in">Diluted net loss per share</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-13959">0.09</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-13960">0.12</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-13961">0.34</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-13962">0.60</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.35pt; text-align: center"><span style="font-size: 10pt"><i>The
accompanying notes are an integral part of these unaudited financial statements</i></span><i>.</i></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.35pt"></p><div>

</div><!-- Field: Page; Sequence: 4; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>ImmuCell Corporation</b></p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>STATEMENTS
OF STOCKHOLDERS</b></span><b>&#8217; <span style="font-family: Times New Roman, Times, Serif">EQUITY</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>(Unaudited)</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.35pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font: normal 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: normal; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="10" style="font-weight: normal; text-align: center; border-bottom: Black 1.5pt solid"><b>Common Stock</b></td><td style="padding-bottom: 1.5pt; font-weight: normal"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="font-weight: normal; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="font-weight: normal; text-align: center; border-bottom: Black 1.5pt solid"><b>Treasury Stock</b></td><td style="padding-bottom: 1.5pt; font-weight: normal"><b>&#160;</b></td><td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: normal 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: normal; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="font-weight: normal; text-align: center; border-bottom: Black 1.5pt solid"><b>Shares</b></td><td style="padding-bottom: 1.5pt; font-weight: normal"><b>&#160;</b></td><td style="font-weight: normal; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="font-weight: normal; text-align: center; border-bottom: Black 1.5pt solid"><b>Amount</b></td><td style="padding-bottom: 1.5pt; font-weight: normal"><b>&#160;</b></td><td style="font-weight: normal; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="font-weight: normal; text-align: center; border-bottom: Black 1.5pt solid"><b>Additional<br/>
 paid-in capital</b></td><td style="padding-bottom: 1.5pt; font-weight: normal"><b>&#160;</b></td><td style="font-weight: normal; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="font-weight: normal; text-align: center; border-bottom: Black 1.5pt solid"><b>Accumulated<br/>
 Deficit</b></td><td style="padding-bottom: 1.5pt; font-weight: normal"><b>&#160;</b></td><td style="font-weight: normal; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="font-weight: normal; text-align: center; border-bottom: Black 1.5pt solid"><b>Shares</b></td><td style="padding-bottom: 1.5pt; font-weight: normal"><b>&#160;</b></td><td style="font-weight: normal; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="font-weight: normal; text-align: center; border-bottom: Black 1.5pt solid"><b>Amount</b></td><td style="padding-bottom: 1.5pt; font-weight: normal"><b>&#160;</b></td><td style="font-weight: normal; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="font-weight: normal; text-align: center; border-bottom: Black 1.5pt solid"><b>Total <br/>
Stockholders&#8217; Equity</b></td><td style="padding-bottom: 1.5pt; font-weight: normal"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="28" style="font: normal 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in">During the Three-Month Period Ended September 30, 2024:</td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: normal 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><b>BALANCE,</b></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: normal 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in; width: 40.5%">June 30, 2024</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-13963">7,896,381</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-13964">789,639</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-13965">36,780,897</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 7%; text-align: right">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-13966">13,976,591</ix:nonFraction></td><td style="width: 0.5%; text-align: left">)</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c10" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-13967">63,301</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 7%; text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-13968">138,482</ix:nonFraction></td><td style="width: 0.5%; text-align: left">)</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-13969">23,455,463</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: normal 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in; text-align: left"><b style="font: normal 10pt Times New Roman, Times, Serif">Net loss</b></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-3">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-13970">701,690</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-5">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-13971">701,690</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: normal 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in; text-align: left">At-The-Market Offering of common stock, net of $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="iccc:OfferingCostsOnFollowUpOfferingOfCommonStock" scale="0" unitRef="usd" id="ixv-13972">110,838</ix:nonFraction> of offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-13973">1,000,017</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-13974">100,002</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-13975">3,480,339</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-6">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-7">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-8">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-13976">3,580,341</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: normal 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Stock-based compensation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-9">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" unitRef="usd" id="ixv-13977">77,557</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-10">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-11">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" unitRef="usd" id="ixv-13978">77,557</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: normal 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><b>BALANCE,</b></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: normal 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in; padding-bottom: 4pt">September 30, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c16" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-13979">8,896,398</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-13980">889,641</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-13981">40,338,793</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-13982">14,678,281</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c19" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-13983">63,301</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-13984">138,482</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-13985">26,411,671</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: normal 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td colspan="12" style="font: normal 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in">During the Three-Month Period Ended September 30, 2023:</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: normal 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><b>BALANCE,</b></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: normal 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in">June 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c20" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-13986">7,814,165</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-13987">781,417</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-13988">36,150,137</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-13989">9,927,266</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c23" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-13990">67,301</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-13991">147,233</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-13992">26,857,055</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: normal 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in; text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-12">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-13">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c27" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-13993">940,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-14">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-13994">940,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: normal 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Stock-based
    compensation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-15">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" unitRef="usd" id="ixv-13995">96,434</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-16">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-17">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" unitRef="usd" id="ixv-13996">96,434</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: normal 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><b>BALANCE,</b></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: normal 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in; padding-bottom: 4pt">September 30, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c29" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-13997">7,814,165</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c29" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-13998">781,417</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c30" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-13999">36,246,571</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c31" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-14000">10,867,266</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c32" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-14001">67,301</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-14002">147,233</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c33" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-14003">26,013,489</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: normal 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td colspan="15" style="font: normal 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in">During the Nine-Month Period Ended September 30, 2024:</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: normal 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><b>BALANCE,</b></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: normal 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in">December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c34" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-14004">7,814,165</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-14005">781,417</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c35" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-14006">36,357,239</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c36" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-14007">12,007,097</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c37" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-14008">63,301</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c37" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-14009">138,482</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-14010">24,993,077</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: normal 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in; text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c40" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14011">2,671,184</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-20">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14012">2,671,184</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: normal 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in; text-align: left">At-The-Market Offering of common stock, net of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="iccc:OfferingCostsOnFollowUpOfferingOfCommonStock" scale="0" unitRef="usd" id="ixv-14013">275,640</ix:nonFraction> of offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c38" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-14014">1,082,233</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-14015">108,224</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c39" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-14016">3,724,866</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-21">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-22">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-23">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-14017">3,833,090</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: normal 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Stock-based
    compensation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-24">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c39" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" unitRef="usd" id="ixv-14018">256,688</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-25">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" unitRef="usd" id="ixv-14019">256,688</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: normal 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><b>BALANCE,</b></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: normal 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in; padding-bottom: 4pt">September 30, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c16" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-14020">8,896,398</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-14021">889,641</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-14022">40,338,793</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-14023">14,678,281</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c19" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-14024">63,301</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-14025">138,482</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-14026">26,411,671</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: normal 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="12" style="font: normal 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in">During the Nine-Month Period Ended September 30, 2023:</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: normal 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><b>BALANCE,</b></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: normal 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in">December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c42" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-14027">7,814,165</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c42" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-14028">781,417</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c43" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-14029">35,978,364</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-14030">6,232,499</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c45" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-14031">67,301</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-14032">147,233</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-14033">30,380,049</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: normal 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in; text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c49" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14034">4,634,767</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14035">4,634,767</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: normal 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Stock-based
    compensation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c48" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" unitRef="usd" id="ixv-14036">268,207</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" unitRef="usd" id="ixv-14037">268,207</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: normal 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><b>BALANCE,</b></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: normal 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in; padding-bottom: 4pt">September 30, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c29" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-14038">7,814,165</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c29" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-14039">781,417</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c30" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-14040">36,246,571</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c31" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-14041">10,867,266</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c32" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-14042">67,301</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-14043">147,233</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c33" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-14044">26,013,489</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><span style="font-size: 10pt"><i>The
accompanying notes are an integral part of these unaudited financial statements</i></span><i>.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>STATEMENTS
OF CASH FLOWS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>(Unaudited)</b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"><b>During the Nine-Month<br/> </b> <span style="font-family: Times New Roman, Times, Serif"><b>Periods
    Ended&#160;September</b></span><b> 30<span style="font-family: Times New Roman, Times, Serif">,</span></b></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">CASH FLOWS FROM OPERATING ACTIVITIES:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -0.125in; padding-left: 0.25in">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14045">2,671,184</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14046">4,634,767</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Adjustments to reconcile net loss to net cash provided by (used for) operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd" id="ixv-14047">1,999,005</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd" id="ixv-14048">2,027,788</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.375in">Amortization of intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd" id="ixv-14049">14,328</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd" id="ixv-14050">14,328</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.375in">Amortization of debt issuance costs and debt discounts</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCosts" scale="0" unitRef="usd" id="ixv-14051">31,859</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCosts" scale="0" unitRef="usd" id="ixv-14052">12,525</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.375in">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd" id="ixv-14053">256,688</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd" id="ixv-14054">268,207</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.375in">Loss on disposal of property, plant and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="0" sign="-" unitRef="usd" id="ixv-14055">14,557</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="0" sign="-" unitRef="usd" id="ixv-14056">8,099</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.375in">Non-cash rent (benefit) expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeExpense" scale="0" unitRef="usd" id="ixv-14057">112,306</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-14058">95,881</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Changes in:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.375in">Trade accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" unitRef="usd" id="ixv-14059">122,530</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" unitRef="usd" id="ixv-14060">105,985</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in">Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" sign="-" unitRef="usd" id="ixv-14061">351,389</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" unitRef="usd" id="ixv-14062">1,347,124</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.375in">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" sign="-" unitRef="usd" id="ixv-14063">183,397</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" unitRef="usd" id="ixv-14064">201,211</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.375in">Other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="0" sign="-" unitRef="usd" id="ixv-14065">28,756</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="0" sign="-" unitRef="usd" id="ixv-14066">6,587</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.375in">Accounts payable and accrued expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd" id="ixv-14067">386,995</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" sign="-" unitRef="usd" id="ixv-14068">95,493</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Net cash provided by (used for) operating activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" unitRef="usd" id="ixv-14069">360,954</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd" id="ixv-14070">3,951,165</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in">CASH FLOWS FROM INVESTING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -0.125in; padding-left: 0.25in">Purchase of property, plant and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-14071">269,509</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-14072">1,811,169</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" scale="0" unitRef="usd" id="ixv-14073">115,127</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in">Proceeds from sale of property, plant and equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-14074">4,500</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-14075">2,474</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Net cash used for investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd" id="ixv-14076">265,009</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd" id="ixv-14077">1,923,822</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in">CASH FLOWS FROM FINANCING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Proceeds from debt issuance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" unitRef="usd" id="ixv-14078">3,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Proceeds from At-The-Market Offering, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd" id="ixv-14079">3,833,090</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Proceeds from line of credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromLinesOfCredit" scale="0" unitRef="usd" id="ixv-14080">2,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Line of credit repayments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfLinesOfCredit" scale="0" unitRef="usd" id="ixv-14081">2,000,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Debt principal repayments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfDebt" scale="0" unitRef="usd" id="ixv-14082">1,094,106</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfDebt" scale="0" unitRef="usd" id="ixv-14083">829,015</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in">Payments of debt issuance costs and debt discounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="0" unitRef="usd" id="ixv-14084">5,037</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="0" unitRef="usd" id="ixv-14085">98,098</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd" id="ixv-14086">2,733,947</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd" id="ixv-14087">2,072,887</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="0" unitRef="usd" id="ixv-14088">2,829,892</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="0" sign="-" unitRef="usd" id="ixv-14089">3,802,100</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">BEGINNING CASH AND CASH EQUIVALENTS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-14090">978,741</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-14091">5,791,562</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in">ENDING CASH AND CASH EQUIVALENTS</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-14092">3,808,633</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c33" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-14093">1,989,462</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.4pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><i>The accompanying notes
are an integral part of these unaudited financial statements</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 83.25pt"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 83.25pt"></p><div>

</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 83.25pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>STATEMENTS
OF CASH FLOWS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SUPPLEMENTAL
DISCLOSURES OF CASH FLOW INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>(Unaudited)</b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 83.25pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">During the Nine-Month <br/> Periods Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">CASH PAID FOR:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Income taxes</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesPaid" scale="0" unitRef="usd" id="ixv-14094">5,905</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesPaid" scale="0" unitRef="usd" id="ixv-14095">7,205</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd" id="ixv-14096">404,077</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd" id="ixv-14097">303,752</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">NON-CASH ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Decrease in capital expenditures included in accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="iccc:ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses" scale="0" unitRef="usd" id="ixv-14098">6,797</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="iccc:ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses" scale="0" unitRef="usd" id="ixv-14099">56,441</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Increase in operating lease right-of-use asset and operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="iccc:DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-14100">103,115</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="iccc:DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-14101">2,090,298</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><i>The accompanying notes
are an integral part of these unaudited financial statements</i></span><i>.</i></p><div>




</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Unaudited Financial Statements (continued) </b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:NatureOfOperations" id="ixv-2967"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>1. BUSINESS OPERATIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">ImmuCell Corporation (the &#8220;Company&#8221;,
&#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;) was originally incorporated in Maine in 1982 and reincorporated in Delaware in
1987, in conjunction with an initial public offering of common stock. We are an animal health company whose purpose is to create scientifically
proven and practical products that improve the health and productivity of dairy and beef cattle. We focus on the two most critical stages
of dairy productivity, those being the first 30 days of life and the first 30 days of lactation. Our concentrated colostrum and purified
Nisin technologies offer unique animal health solutions during these periods when immunity is at its most vulnerable. As disclosed in
Note 17, &#8220;Segment Information&#8221;, one of our business segments is dedicated to Scours and the other is focused on Mastitis.
We manufacture and market the <b>First Defense<sup>&#174;</sup></b> product line, providing <b>Immediate Immunity&#8482;</b> to prevent
scours in newborn dairy and beef calves. We have expanded this line into four different products with formulations targeting <i>E. coli</i>,
coronavirus and rotavirus pathogens. We are also in the late stages of developing <b>Re-Tain<sup>&#174;</sup></b>, a treatment for lactating
dairy cows with subclinical mastitis. Mastitis is the most significant cause of economic loss to the dairy industry. These products help
reduce the need to use traditional antibiotics in food producing animals. We are subject to certain risks including dependence on key
individuals and third-party providers of critical goods and services, competition from other larger companies, the successful sale of
existing products and the development of new viable products with appropriate regulatory approvals, where applicable. A combination of
the conditions, trends and concerns related to or arising from inflation, rising interest rates and potential recessionary conditions
in the United States and/or internationally, could have a corresponding negative effect on our business and operations. We are experiencing
price increases in key components, supportive services, transportation and other supplies that are causing our costs of goods sold to
increase. We have experienced contamination events from time to time in our production process, beginning in the third quarter of 2022,
as disclosed previously. We implemented a production slowdown during 2023 to remediate this problem, which led to the recognition of lower
sales and gross margin. The last identified contamination event occurred during the first half of April of 2024, and we have been operating
without further contamination events since then and through the date of this filing.</p></ix:nonNumeric><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="ixv-2982"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="ixv-2987"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(a) Basis of Presentation</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have prepared the accompanying unaudited financial
statements reflecting all adjustments (which are of a normal recurring nature) that are, in our opinion, necessary in order to ensure
that the financial statements are not misleading. We follow accounting standards set by the Financial Accounting Standards Board (FASB).
The FASB sets Generally Accepted Accounting Principles (GAAP) that we follow to ensure we accurately report our financial condition, results
of operations, earnings per share and cash flows. References to GAAP in these footnotes are to the FASB <i>Accounting Standards Codification</i>&#8482;
(Codification). We believe that the disclosures are adequate to ensure that the information presented is not misleading.</p></ix:continuation>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="ixv-2996"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(b) Cash and Cash Equivalents</b> </p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We consider all highly liquid investment instruments
that mature within three months of their purchase dates to be cash equivalents. Cash equivalents are principally invested in securities
backed by the U.S. government. We hold no cash or cash equivalents in excess of Federal Deposit Insurance Corporation (FDIC) limits of
$<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashFDICInsuredAmount" scale="0" unitRef="usd" id="ixv-14102">250,000</ix:nonFraction> per financial institution per depositor. See Note 3.</p></ix:continuation>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ReceivablesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ReceivablesPolicyTextBlock" id="ixv-3004"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(c) Trade Accounts Receivable</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_ReceivablesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Accounts receivable are carried at the original
invoice amount less an estimate made for doubtful collection when applicable. Management determines the allowance for doubtful accounts
on a monthly basis by identifying troubled accounts and by using historical experience applied to an aging of accounts and other relevant
factors. Accounts receivable are considered to be past due if a portion of the receivable balance is outstanding for more than 30 days.
Past due accounts receivable are subject to an interest charge. It was not necessary to charge interest on past due accounts during the
nine-month periods ended September 30, 2024 or 2023 because the time past due was not significant, and there was no accrual for such interest
charges as of September 30, 2024 or December 31, 2023. Accounts receivable are written off when deemed uncollectible. No accounts receivable
were written off during the nine-month periods ended September 30, 2024 or 2023. Recoveries of accounts receivable previously written
off are recorded as income when received. No such recoveries were recorded during the nine-month periods ended September 30, 2024 or 2023.
As of September 30, 2024 and December 31, 2023, we determined that no allowance for doubtful accounts was necessary. See Note 4.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Unaudited Financial Statements (continued) </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>


</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_2" id="_SignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" continuedAt="_InventoryPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:InventoryPolicyTextBlock" id="ixv-3036"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(d) Inventory</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_InventoryPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Inventory includes raw materials, work-in-process
and finished goods and is recorded at the lower of cost, on the first-in, first-out method, or net realizable value (determined as the
estimated selling price in the normal course of business, less reasonably predictable costs of completion, disposal and transportation).
Work-in-process and finished goods inventories include materials, labor and manufacturing overhead. At each balance sheet date, we evaluate
our ending inventories for excess quantities and obsolescence. Inventories that we consider excess or obsolete are written down to estimated
net realizable value. Once inventory is written down and a new cost basis is established, it is not written back up. We believe that supplies
and raw materials for the production of our products are available from more than one vendor or farm. Our policy is to maintain more than
one source of supply for the components used in our products when feasible. See Note 5.</p></ix:continuation>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="ixv-3044"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(e) Property, Plant and Equipment, net</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We depreciate property, plant and equipment on the
straight-line method by charges to operations and costs of goods sold in amounts estimated to expense the cost of the assets from the
date they are first put into service to the end of the estimated useful lives of the assets. The facility we have constructed at 33 Caddie
Lane to produce the Nisin Drug Substance (DS) for <b>Re-Tain<sup>&#174;</sup></b> (<b>Building 33</b>) is being depreciated over 39 years
from when a Certificate of Occupancy was issued during the fourth quarter of 2017. We began depreciating the equipment for our Nisin DS
facility when it was placed in service during the third quarter of 2018. Approximately <ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage" scale="-2" unitRef="pure" id="ixv-14103">86</ix:nonFraction>% of these assets are being depreciated over
<ix:nonNumeric contextRef="c51" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-14104">10</ix:nonNumeric> years. We began depreciating the leasehold improvements to our new <b>First Defense<sup>&#174; </sup></b>production facility at 175
Industrial Way (<b>Building 175A</b>) over the remainder of the <ix:nonNumeric contextRef="c52" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-14105">10</ix:nonNumeric>-year lease term beginning when a Certificate of Occupancy was issued
during the second quarter of 2020. During August of 2022, this lease term was extended to January of 2043 in connection with a new lease
covering additional space at 175 Industrial Way (<b>Building 175B</b>). As a result, the net book value of these leasehold improvements
as of August 31, 2022 is now being depreciated over the remainder of the extended lease term. Significant repairs to property, plant and
equipment that benefit more than a current period are capitalized and depreciated over their useful lives. Insignificant repairs are expensed
when incurred. See Notes 2(h) and 7 for additional information.</p></ix:continuation>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock" id="ixv-3059"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(f) Operating Leases</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_LesseeLeasesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We account for our real estate leases using a right-of-use
model, which recognizes that at the date of commencement, a lessee has a financial obligation to make lease payments to the lessor for
the right to use the underlying asset during the lease term and recognizes a corresponding right-of-use (ROU) asset related to this right.
ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the future lease payments
over the expected lease term. The ROU asset is also adjusted for any lease prepayments made, lease incentives received and initial direct
costs incurred. For operating leases with lease payments that fluctuate over the lease term, the total lease costs are recognized on a
straight-line basis over the lease term. Our leases, at times, may include options to extend the term of the lease. When it is reasonably
certain that we will exercise the option, we include the impact of the option in the lease term for purposes of determining future lease
payments. For all underlying classes of assets, we made an accounting policy election to not recognize assets or liabilities for leases
with a term of twelve months or less and to account for all components in a lease arrangement as a single combined lease component. Short-term
lease payments are recognized on a straight-line basis. Certain of our lease agreements include variable rent payments, consisting primarily
of amounts paid to the lessor based on cost or consumption, such as maintenance and real estate taxes. These costs are recognized in the
period in which the obligation is incurred. Because our leases do not specify an implicit rate, we use an incremental borrowing rate based
on information available at the lease commencement date to determine the present value of the lease payments. We evaluate our ROU asset
for impairment when events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. See Notes
2(h) and 12 for additional information.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Unaudited Financial Statements (continued) </b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_3" id="_SignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" continuedAt="_GoodwillAndIntangibleAssetsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="ixv-3093"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(g) Intangible Assets and Goodwill</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_GoodwillAndIntangibleAssetsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We amortize intangible assets on the straight-line
method by charges to costs of goods sold in amounts estimated to expense the cost of the assets from the date they are first put into
service to the end of the estimated useful lives of the assets. We have recorded intangible assets related to customer relationships,
non-compete agreements and developed technology, each with defined useful lives. Amounts paid in excess of the fair value of the net assets
(including tax attributes) are recorded as goodwill under the acquisition method of accounting. We assess the impairment of intangible
assets that have indefinite lives (when applicable) and goodwill (at the reporting unit level) on an annual basis (as of December 31<sup>st</sup>)
and whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. We would record
an impairment charge if such an assessment were to indicate that the fair value of such assets was less than the carrying value. Judgment
is required in determining whether an event has occurred that may impair the value of goodwill or identifiable intangible assets. Factors
that could indicate that an impairment may exist include significant under-performance relative to plan or long-term projections, significant
changes in business strategy and significant negative industry or economic trends. Although we believe intangible assets and goodwill
are properly stated in the accompanying financial statements, changes in strategy or market conditions could significantly impact these
judgments and require an adjustment to the recorded balance in the future. <span style="-sec-ix-hidden: hidden-fact-50"><span style="-sec-ix-hidden: hidden-fact-51">No</span></span> goodwill impairments were recorded during the nine-month
periods ended September 30, 2024 or 2023. See Notes 2(h) and 8 for additional information.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="ixv-3103"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>(h) Valuation of Long-Lived Assets</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We periodically evaluate our long-lived assets,
consisting principally of property, plant and equipment, operating lease right-of-use asset and amortizable intangible assets, for potential
impairment. In accordance with the applicable accounting guidance for the treatment of long-lived assets, we review the carrying value
of our long-lived assets or asset group that is held and used, including intangible assets subject to amortization, for impairment whenever
events and circumstances indicate that the carrying value of the assets may not be recoverable. Under the held for use approach, the asset
or asset group to be tested for impairment should represent the lowest level for which identifiable cash flows are largely independent
of the cash flows of other groups of assets and liabilities. <span style="-sec-ix-hidden: hidden-fact-52"><span style="-sec-ix-hidden: hidden-fact-53">No</span></span> impairment was recognized during the nine-month periods ended September
30, 2024 or 2023.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="ixv-3113"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>(i) Fair Value Measurements</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-weight: normal">&#160;</span></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In determining fair value measurements, we follow
the provisions of Codification Topic 820, <i>Fair Value Measurements and Disclosures</i>. Codification Topic 820 defines fair value,
establishes a framework for measuring fair value under GAAP and enhances disclosures about fair value measurements. The topic provides
a consistent definition of fair value which focuses on an exit price, which is the price that would be received to sell an asset or paid
to transfer a liability in an orderly transaction between market participants at the measurement date. The topic also prioritizes, within
the measurement of fair value, the use of market-based information over entity-specific information and establishes a three-level hierarchy
for fair value measurements based on the nature of inputs used in the valuation of an asset or liability as of the measurement date.
As of September 30, 2024 and December 31, 2023, the carrying amounts of cash and cash equivalents, accounts receivable, inventory, prepaid
expenses and other current assets, other assets, accounts payable and accrued expenses approximate fair value because of their short-term
nature. The amount outstanding under our bank debt facilities is measured at carrying value in our accompanying balance sheets. Our bank
debt facilities are valued using Level 2 inputs. The three-level hierarchy is as follows:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.1pt">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.5in; text-align: left">Level 1</td>
    <td style="text-align: center; width: 0.25in">&#8212;</td><td style="text-align: left">  Pricing inputs are quoted prices available in active
markets for identical assets or liabilities as of the measurement date.</td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -43.9pt">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.5in; text-align: left">Level 2</td>
    <td style="text-align: center; width: 0.25in">&#8212;</td>
    <td style="text-align: left">Pricing inputs are quoted
prices for similar assets or liabilities, or inputs that are observable, either directly or indirectly, for substantially the full term
through corroboration with observable market data.</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -43.9pt">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.5in; text-align: left">Level 3</td>
    <td style="text-align: center; width: 0.25in">&#8212;</td>
    <td style="text-align: left">Pricing inputs are unobservable
for the assets or liabilities, that is, inputs that reflect the reporting entity&#8217;s own assumptions about the assumptions market
participants would use in pricing the asset or liability.</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -43.9pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Unaudited Financial Statements (continued) </b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_4" id="_SignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_6" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In certain cases, the inputs used to measure fair
value may fall into different levels of the fair value hierarchy. In such cases, the level of an asset or liability within the fair value
hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance
of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the investment.
We also hold money market accounts in our bank account, which are classified as cash equivalents and measured at fair value. The fair
value of these investments is based on their closing published net asset value.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_7" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We assess the levels of the investments at each
measurement date, and transfers between levels are recognized on the actual date of the event or change in circumstances that caused the
transfer in accordance with our accounting policy regarding the recognition of transfers between levels of the fair value hierarchy. During
the nine-month periods ended September 30, 2024 and 2023, there were no transfers between levels. As of September 30, 2024 and December
31, 2023, our Level 1 assets measured at fair value by quoted prices in active markets consisted of cash and money market accounts. There
were no assets or liabilities measured at fair value on a nonrecurring basis as of September 30, 2024 or December 31, 2023. The carrying
values of our cash and money market accounts as of September 30, 2024 and December 31, 2023 approximated their fair market values. Due
to inflation and the changing interest rate environment, the carrying values of our fixed rate bank debt as of September 30, 2024 and
December 31, 2023 differed from their fair market values. <ix:nonNumeric contextRef="c0" continuedAt="_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" id="ixv-14106">These values are reflected in the following tables:</ix:nonNumeric></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock-c0_cont_2" id="_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock-c0_cont_1"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_8" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_7"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 0.25in">Cash and money market accounts</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c53" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-14107">3,808,633</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">&#8212;</div></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">&#8212;</div></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c56" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-14108">3,808,633</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 20pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt">Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Bank debt</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c54" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-14109">9,703,821</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c56" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-14110">9,703,821</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock-c0_cont_2"><ix:continuation id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_8"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Cash and money market accounts</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c57" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-14111">978,741</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">&#8212;</div></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">&#8212;</div></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c60" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-14112">978,741</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 20pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt">Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Bank debt</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c58" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-14113">10,431,817</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c60" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-14114">10,431,817</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskCreditRisk-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk" id="ixv-3400"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(j) Concentration of Risk</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_2" id="_ConcentrationRiskCreditRisk-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Concentration of credit risk with respect to
accounts receivable is principally limited to certain customers to whom we make substantial sales. To reduce risk, we routinely assess
the financial strength of our customers and, as a consequence, believe that our accounts receivable credit risk exposure is limited. We
maintain an allowance for potential credit losses when deemed necessary, but historically we have not experienced significant credit losses
related to an individual customer or groups of customers in any particular industry or geographic area. <ix:nonNumeric contextRef="c0" continuedAt="_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock-c0_cont_1" escape="true" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="ixv-14115">Sales to significant customers
that amounted to 10% or more of total product sales are detailed in the following table:</ix:nonNumeric></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock-c0_cont_2" id="_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock-c0_cont_1"><ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_3" id="_ConcentrationRiskCreditRisk-c0_cont_2"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>During
the Three-Month <br/>
Periods Ended September 30,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>During
the Nine-Month<br/>
Periods Ended September 30,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">Company A</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c61" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-14116">43</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c62" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-14117">50</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c63" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-14118">44</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c64" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-14119">48</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Company B</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c65" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-14120">31</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c66" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-14121">29</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c67" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-14122">33</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c68" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-14123">31</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  </table></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_4" id="_ConcentrationRiskCreditRisk-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Trade accounts receivable due from significant
customers that amounted to 10% or more of our total trade accounts receivable are detailed in the following table:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock-c0_cont_2"><ix:continuation id="_ConcentrationRiskCreditRisk-c0_cont_4"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>As of <br/>
 September 30, 2024</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>As of  <br/>
December 31, 2023</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Company A</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c69" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-14124">37</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">%</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c70" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-14125">43</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Company B</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c71" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-14126">34</ix:nonFraction></td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c72" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-14127">36</ix:nonFraction></td>
    <td style="text-align: left">%</td></tr>
  </table><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:continuation></ix:continuation></ix:continuation><div>



</div><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Unaudited Financial Statements (continued) </b></p><div>


</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_5" id="_SignificantAccountingPoliciesTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="ixv-3541"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(k) Revenue Recognition</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We recognize revenue in accordance with Codification
Topic 606, <i>Revenue from Contracts with Customers (ASC 606)</i>. ASC 606 is a single comprehensive model for companies to use in accounting
for revenue arising from contracts with customers. The core principle is that we recognize the amount of revenue to which we expect to
be entitled for the transfer of promised goods or services to customers when a customer obtains control of promised goods or services
in an amount that reflects the consideration we expect to receive in exchange for those goods or services. In addition, the standard requires
disclosure of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. We conduct our
business with customers through valid purchase orders or sales orders which are considered contracts and are not interdependent on one
another. A performance obligation is a promise in a contract to transfer a distinct product to the customer. The transaction price is
the amount of consideration we expect to receive under the arrangement. Revenue is measured based on consideration specified in a contract
with a customer. The transaction price of a contract is allocated to each distinct performance obligation and recognized when or as the
customer receives the benefit of the performance obligation. Product transaction prices on a purchase or sales order are discrete and
stand-alone. We recognize revenue when we satisfy a performance obligation in a contract by transferring control over a product to a customer
when product ships to a customer. Amounts due are typically paid approximately 30 days from the time control is transferred. Shipping
and handling costs associated with outbound freight are accounted for as a fulfillment cost in costs of goods sold. We do not bill for
or collect sales tax because our sales are generally made to distributors and thus our sales to them are not subject to sales tax. We
generally have experienced an immaterial amount of product returns. See Note 14 for additional information.</p></ix:continuation>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="iccc_ExpenseRecognitionPolicyTextBlock-c0_cont_1" escape="true" name="iccc:ExpenseRecognitionPolicyTextBlock" id="ixv-3550"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(l) Expense Recognition</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:continuation id="iccc_ExpenseRecognitionPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We do not incur costs in connection with product
sales to customers that are eligible for capitalization. Advertising costs are expensed when incurred, which is generally during the month
in which the advertisement is published. All product development expenses are expensed as incurred, as are all related patent costs. We
capitalize costs to produce inventory during the production cycle, and these costs are charged to costs of goods sold when the inventory
is sold to a customer or is deemed to be in excess or obsolete.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock" id="ixv-3557"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>(m) Income Taxes </b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_2" id="_IncomeTaxPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We account for income taxes in accordance with
Codification Topic 740, <i>Income Taxes</i>, which requires that we recognize a current tax liability or asset for current taxes payable
or refundable and a deferred tax liability or asset for the estimated future tax effects of temporary differences and carryforwards to
the extent they are realizable. We consider future taxable income and feasible tax planning strategies in assessing the need for a valuation
allowance against our deferred tax assets at the end of each quarter. If we determine that it is more likely than not that we will realize
our deferred tax assets in the future in excess of the net recorded amount over a reasonably short period of time, a reduction of the
valuation allowance would increase income in the period such determination was made. Likewise, if we determine that it is more likely
than not that we will not realize all or part of our net deferred tax asset in the future, an increase to the valuation allowance would
be charged to income in the period such determination was made.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_IncomeTaxPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Codification Topic 740-10 clarifies the accounting
for income taxes by prescribing a minimum recognition threshold that a tax position must meet before being recognized in the financial
statements. In the ordinary course of business, there are transactions and calculations where the ultimate tax outcome is uncertain. In
addition, we are subject to periodic audits and examinations by the Internal Revenue Service and other taxing authorities. With few exceptions,
we are no longer subject to income tax examinations by tax authorities for years before 2021. We have evaluated the positions taken on
our filed tax returns and have concluded that no uncertain tax positions existed as of September 30, 2024 or December 31, 2023. Although
we believe that our estimates are reasonable, actual results could differ from these estimates. See Note 16.</p></ix:continuation>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="ixv-3569"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(n) Stock-Based Compensation</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We account for stock-based compensation in accordance
with Codification Topic 718, <i>Compensation-Stock Compensation</i>, which generally requires us to recognize non-cash compensation expense
for stock-based payments using the fair-value-based method. The fair value of each stock option grant has been estimated on the date of
grant using the Black-Scholes option pricing model. Accordingly, we recorded compensation expense pertaining to stock-based compensation
of $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd" id="ixv-14128">77,557</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd" id="ixv-14129">96,434</ix:nonFraction> during the three-month periods ended September 30, 2024 and 2023, respectively, and $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd" id="ixv-14130">256,688</ix:nonFraction> and $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd" id="ixv-14131">268,207</ix:nonFraction> during
the nine-month periods ended September 30, 2024 and 2023, respectively. See Note 13.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Unaudited Financial Statements (continued) </b></p><div>


</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock" id="ixv-3604"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(o) Net Loss Per Common Share</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_2" id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Net loss per common share has been computed in
accordance with Codification Topic 260-10, <i>Earnings Per Share</i>. The net loss per share has been computed by dividing the net loss
by the weighted average number of common shares outstanding during the period. All stock options have been excluded from the denominator
in the calculation of dilutive earnings per share when we are in a loss position because their inclusion would be anti-dilutive. <ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="ixv-14132">Outstanding
stock options that were not included in this calculation because the effect would be anti-dilutive amounted to <ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-14133">661,000</ix:nonFraction> and <ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-14134">616,500</ix:nonFraction> during
the three-month periods ended September 30, 2024 and 2023, respectively, and <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-14135">661,000</ix:nonFraction> and <ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-14136">616,500</ix:nonFraction> during the nine-month periods ended September
30, 2024 and 2023, respectively.</ix:nonNumeric></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-c0_cont_1"><ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>During the Three-Month <br/>
Periods Ended September 30, </b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>During the Nine-Month  <br/>
Periods Ended September 30, </b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Net loss attributable to stockholders</td>
    <td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="width: 9%; border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14137">701,690</ix:nonFraction></td>
    <td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="width: 9%; border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14138">940,000</ix:nonFraction></td>
    <td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="width: 9%; border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14139">2,671,184</ix:nonFraction></td>
    <td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="width: 9%; border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14140">4,634,767</ix:nonFraction></td>
    <td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Weighted average common shares outstanding - Basic</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-14141">8,164,423</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-14142">7,746,864</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-14143">7,908,425</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-14144">7,746,864</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Dilutive impact of share-based compensation awards</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">&#8212;</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">&#8212;</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">&#8212;</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">&#8212;</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Weighted average common shares outstanding - Diluted</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-14145">8,164,423</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-14146">7,746,864</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-14147">7,908,425</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-14148">7,746,864</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Net loss per share:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">Basic</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-14149">0.09</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-14150">0.12</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-14151">0.34</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-14152">0.60</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">Diluted</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-14153">0.09</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-14154">0.12</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-14155">0.34</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-14156">0.60</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  </table></ix:continuation></ix:continuation>



<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates" id="ixv-3809"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(p) Use of Estimates</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_UseOfEstimates-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The <span style="font-family: Times New Roman, Times, Serif">preparation
of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported
amounts of revenues and expenses during the period. Although we regularly assess these estimates, actual amounts could differ from those
estimates and are subject to change in the near term. Changes in estimates are recorded during the period in which they become known.
Significant estimates include our valuation of inventory, deferred tax assets and costs of goods sold</span>.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-3818"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(q) New Accounting Pronouncements Not Yet Adopted</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In November of 2023, the FASB issued ASU 2023-07,
<i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,</i> which is intended to improve reportable segment
disclosure requirements, primarily through enhanced disclosures about significant expenses. The amendments will require disclosure of
significant segment expenses that are regularly provided to our chief operating decision-maker and included within segment profit and
loss. The amendments are effective for annual periods beginning after December 15, 2023, and interim periods beginning after December
15, 2024, with early adoption permitted, and will be applied retrospectively to all prior periods presented in the financial statements.
We are currently evaluating ASU 2023-07 to determine its impact on our financial statements.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In December of 2023, the FASB issued ASU 2023-09<i>,
Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>, which includes amendments that further enhance income tax disclosures,
primarily through standardization and disaggregation of income tax rate reconciliation categories and income taxes paid by jurisdiction.
The amendments are effective for annual periods beginning after December 15, 2024, with early adoption permitted, and may be applied either
prospectively or retrospectively. We are currently evaluating ASU 2023-09 to determine its impact on our financial statements.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:CashAndCashEquivalentsDisclosureTextBlock" id="ixv-3832"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>3. CASH AND CASH EQUIVALENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Cash and cash equivalents amounted to $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-14157">3,808,633</ix:nonFraction>
and $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-14158">978,741</ix:nonFraction> as of September 30, 2024 and December 31, 2023, respectively. See Note 13.</p></ix:nonNumeric><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" id="ixv-3841"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>4. TRADE ACCOUNTS RECEIVABLE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Trade accounts receivable amounted to $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-14159">2,307,913</ix:nonFraction>
and $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-14160">2,185,383</ix:nonFraction> as of September 30, 2024 and December 31, 2023, respectively. No allowance for bad debt or product returns was recorded
as of September 30, 2024 or December 31, 2023. We anticipate no future events or conditions that would impact our ability to collect our
accounts receivable. Because of the generally short duration from the balance sheet date to the date of collection, our collection rate
is not expected to be significantly impacted by events occurring after the balance sheet date. The trade accounts receivable balances
included $<ix:nonFraction contextRef="c73" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-14161">35,364</ix:nonFraction> and $<ix:nonFraction contextRef="c74" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-14162">42,507</ix:nonFraction> due from a related party as of September 30, 2024 and December 31, 2023, respectively. See Note 18.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Unaudited Financial Statements (continued) </b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:InventoryDisclosureTextBlock" id="ixv-3873"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>5. INVENTORY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfInventoryCurrentTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="ixv-14163">Inventory consisted of the following:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.25pt; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_ScheduleOfInventoryCurrentTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of <br/> September 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of <br/> December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Raw materials</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterials" scale="0" unitRef="usd" id="ixv-14164">1,313,766</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterials" scale="0" unitRef="usd" id="ixv-14165">1,594,028</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">Work-in-process</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryWorkInProcess" scale="0" unitRef="usd" id="ixv-14166">6,124,394</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryWorkInProcess" scale="0" unitRef="usd" id="ixv-14167">5,815,194</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Finished goods</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoods" scale="0" unitRef="usd" id="ixv-14168">22,292</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoods" scale="0" unitRef="usd" id="ixv-14169">402,619</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd" id="ixv-14170">7,460,452</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd" id="ixv-14171">7,811,841</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-weight: normal">These <span style="font-family: Times New Roman, Times, Serif">inventory
figures are net of write-offs of scrapped inventory in the amounts of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryWriteDown" scale="0" unitRef="usd" id="ixv-14172">368,723</ix:nonFraction> and $<ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryWriteDown" scale="0" unitRef="usd" id="ixv-14173">527,133</ix:nonFraction> during the nine-month period ended September
30, 2024 and the year ended December 31, 2023, respectively, that resulted principally from contamination events and other production
process losses</span>. </span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:OtherCurrentAssetsTextBlock" id="ixv-3940"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>6. PREPAID EXPENSES AND OTHER CURRENT ASSETS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" continuedAt="_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="ixv-14174">Prepaid expenses and other current assets consisted
of the following:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.95pt; text-indent: -0.5in">&#160;</p>

<ix:continuation id="_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of <br/> September 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<br/> December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Prepaid expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" unitRef="usd" id="ixv-14175">277,146</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" unitRef="usd" id="ixv-14176">454,152</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Other receivables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" unitRef="usd" id="ixv-14177">33,342</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" unitRef="usd" id="ixv-14178">39,733</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-14179">310,488</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-14180">493,885</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="ixv-3991"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>7. PROPERTY, PLANT AND EQUIPMENT, net</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="ixv-14181">Property, plant and equipment consisted of the
following:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_PropertyPlantAndEquipmentTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Estimated Useful Lives <br/> (in years)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<br/> September 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<br/> December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt">Laboratory and manufacturing equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center"><ix:nonNumeric contextRef="c76" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-14182">3</ix:nonNumeric>-<ix:nonNumeric contextRef="c77" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-14183">10</ix:nonNumeric></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c78" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-14184">21,183,888</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-14185">20,953,601</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Buildings and improvements</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c80" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-14186">10</ix:nonNumeric>-<ix:nonNumeric contextRef="c81" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-14187">39</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c82" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-14188">20,858,708</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-14189">20,784,565</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c84" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-14190">3</ix:nonNumeric>-<ix:nonNumeric contextRef="c85" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-14191">10</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c86" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-14192">1,053,436</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c87" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-14193">1,036,374</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Construction in progress</td><td>&#160;</td>
    <td style="text-align: center"><div style="-sec-ix-hidden: hidden-fact-54">n/a</div></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c88" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-14194">2,588,630</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c89" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-14195">2,768,224</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Land</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt"><div style="-sec-ix-hidden: hidden-fact-55">n/a</div></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c90" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-14196">516,867</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c91" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-14197">516,867</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Property, plant and equipment, gross</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-14198">46,201,529</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-14199">46,059,631</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-14200">20,381,196</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-14201">18,483,948</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Property, plant and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-14202">25,820,333</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-14203">27,575,683</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of September 30, 2024 and December 31, 2023,
construction in progress consisted principally of payments toward the <b>First Defense<sup>&#174;</sup></b> production capacity expansion
project and equipment needed to bring the formulation and aseptic filling for <b>Re-Tain<sup>&#174;</sup></b> in-house. Property, plant
and equipment disposals were $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentDisposals" scale="0" unitRef="usd" id="ixv-14204">49,652</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentDisposals" scale="0" unitRef="usd" id="ixv-14205">43,503</ix:nonFraction> during the three-month periods ended September 30, 2024 and 2023, respectively, and $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentDisposals" scale="0" unitRef="usd" id="ixv-14206">120,814</ix:nonFraction>
and $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentDisposals" scale="0" unitRef="usd" id="ixv-14207">100,142</ix:nonFraction> during the nine-month periods ended September 30, 2024 and 2023, respectively. Depreciation expense was $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd" id="ixv-14208">670,346</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd" id="ixv-14209">695,635</ix:nonFraction>
during the three-month periods ended September 30, 2024 and 2023, respectively, and $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd" id="ixv-14210">1,999,005</ix:nonFraction> and $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd" id="ixv-14211">2,027,788</ix:nonFraction> during the nine-month periods
ended September 30, 2024 and 2023, respectively.</p></ix:nonNumeric><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Unaudited Financial Statements (continued) </b></p><div>


</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="ixv-4143"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>8. INTANGIBLE ASSETS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Intangible assets of $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-14212">191,040</ix:nonFraction> were valued using
the relief from royalty method and are being amortized to costs of goods sold over their useful lives, which are estimated to be <ix:nonNumeric contextRef="c2" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="ixv-14213">10</ix:nonNumeric> years.
Intangible amortization expense was $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd" id="ixv-14214"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd" id="ixv-14215">4,776</ix:nonFraction></ix:nonFraction> during both of the three-month periods ended September 30, 2024 and 2023 and $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd" id="ixv-14216"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd" id="ixv-14217">14,328</ix:nonFraction></ix:nonFraction> during
both of the nine-month periods ended September 30, 2024 and 2023. The net value of these intangibles was $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd" id="ixv-14218">23,880</ix:nonFraction> and $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd" id="ixv-14219">38,208</ix:nonFraction> as of September
30, 2024 and December 31, 2023, respectively. Intangible asset amortization expense is estimated to be $<ix:nonFraction contextRef="c92" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd" id="ixv-14220">19,104</ix:nonFraction> per year through December
31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="ixv-14221">Intangible assets as of September 30, 2024 consisted
of the following:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock-c0_cont_2" id="_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Gross Carrying<br/>
 Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Accumulated<br/>
 Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Net Book<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt">Developed technology</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c93" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-14222">184,100</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c93" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd" id="ixv-14223">161,087</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c93" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd" id="ixv-14224">23,013</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Customer relationships</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c94" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-14225">1,300</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c94" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd" id="ixv-14226">1,138</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c94" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd" id="ixv-14227">162</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Non-compete agreements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c95" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-14228">5,640</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c95" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd" id="ixv-14229">4,935</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c95" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd" id="ixv-14230">705</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 0.25in">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-14231">191,040</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd" id="ixv-14232">167,160</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd" id="ixv-14233">23,880</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><ix:continuation continuedAt="_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock-c0_cont_3" id="_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock-c0_cont_2">Intangible assets as of December 31, 2023 consisted
of the following:</ix:continuation></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Gross Carrying<br/>
 Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Accumulated<br/>
 Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Net Book<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt">Developed technology</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c96" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-14235">184,100</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c96" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd" id="ixv-14236">147,280</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c96" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd" id="ixv-14237">36,820</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Customer relationships</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c97" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-14238">1,300</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c97" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd" id="ixv-14239">1,040</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c97" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd" id="ixv-14240">260</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Non-compete agreements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c98" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-14241">5,640</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c98" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd" id="ixv-14242">4,512</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c98" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd" id="ixv-14243">1,128</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-14244">191,040</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd" id="ixv-14245">152,832</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd" id="ixv-14246">38,208</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="ixv-4301"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>9. ACCOUNTS PAYABLE AND ACCRUED EXPENSES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="ixv-14247">Accounts payable and accrued expenses consisted
of the following:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<br/> September 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<br/> December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Accounts payable &#8211; trade</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableTradeCurrent" scale="0" unitRef="usd" id="ixv-14248">876,836</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableTradeCurrent" scale="0" unitRef="usd" id="ixv-14249">874,558</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Accounts payable &#8211; capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="0" unitRef="usd" id="ixv-14250">6,378</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="0" unitRef="usd" id="ixv-14251">13,175</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Accrued payroll</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedPayrollTaxesCurrent" scale="0" unitRef="usd" id="ixv-14252">1,142,318</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedPayrollTaxesCurrent" scale="0" unitRef="usd" id="ixv-14253">942,999</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Accrued professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" unitRef="usd" id="ixv-14254">101,725</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" unitRef="usd" id="ixv-14255">97,800</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Accrued other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-14256">376,112</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-14257">192,754</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Income tax payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="0" unitRef="usd" id="ixv-14258">1,166</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="0" unitRef="usd" id="ixv-14259">3,051</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-14260">2,504,535</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-14261">2,124,337</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.75in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.75in"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.75in"><b>&#160;</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.75in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Unaudited Financial Statements (continued) </b></p><div>


</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.75in"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DebtDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:DebtDisclosureTextBlock" id="ixv-4415"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>10. BANK DEBT</b></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Loans #1 and #2</b>: During the first quarter
of 2020, we closed on a debt financing with Gorham Savings Bank (GSB) aggregating $<ix:nonFraction contextRef="c99" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredFinanceCostsCurrentNet" scale="0" unitRef="usd" id="ixv-14262">8,600,000</ix:nonFraction>, which was comprised of a $<ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EscrowDeposit" scale="0" unitRef="usd" id="ixv-14263">5,100,000</ix:nonFraction> mortgage
note (Loan #1) that bears interest at a fixed rate of <ix:nonFraction contextRef="c100" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" unitRef="pure" id="ixv-14264">3.50</ix:nonFraction>% per annum (with a <ix:nonNumeric contextRef="c101" format="ixt-sec:duryear" name="iccc:InterestPaymentsTerm" id="ixv-14265">10</ix:nonNumeric>-year term and 25-year amortization schedule and a balloon
principal payment of $<ix:nonFraction contextRef="c102" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" scale="0" unitRef="usd" id="ixv-14266">3,145,888</ix:nonFraction> due during the first quarter of 2030) and a $<ix:nonFraction contextRef="c103" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" scale="0" unitRef="usd" id="ixv-14267">3,500,000</ix:nonFraction> note (Loan #2) that bears interest at a fixed rate
of <ix:nonFraction contextRef="c103" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" unitRef="pure" id="ixv-14268">3.50</ix:nonFraction>% per annum (with a 7-year term and amortization schedule). The proceeds from the 2020 debt refinancing were used to repay all
bank debt outstanding at the time of closing and to provide some additional working capital. During the first quarter of 2022, we closed
on an additional $<ix:nonFraction contextRef="c104" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ParticipatingMortgageLoansUnamortizedDebtDiscountAmount" scale="0" unitRef="usd" id="ixv-14269">2,000,000</ix:nonFraction> in mortgage debt, which bears interest at the fixed rate of <ix:nonFraction contextRef="c104" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" unitRef="pure" id="ixv-14270">3.58</ix:nonFraction>% per annum. This was accomplished through
an amendment of the original mortgage note (Loan #1) that increased the then outstanding principal balance from $<ix:nonFraction contextRef="c105" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrincipalAmountOutstandingOnLoansManagedAndSecuritized" scale="0" unitRef="usd" id="ixv-14271">4,233,957</ix:nonFraction> to $<ix:nonFraction contextRef="c106" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrincipalAmountOutstandingOnLoansManagedAndSecuritized" scale="0" unitRef="usd" id="ixv-14272">6,233,957</ix:nonFraction>
bearing interest at the blended fixed rate of <ix:nonFraction contextRef="c2" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" unitRef="pure" id="ixv-14273">3.53</ix:nonFraction>% per annum. This increased the balloon payment from $<ix:nonFraction contextRef="c105" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" scale="0" unitRef="usd" id="ixv-14274">3,145,888</ix:nonFraction> to $<ix:nonFraction contextRef="c106" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" scale="0" unitRef="usd" id="ixv-14275">3,687,577</ix:nonFraction> and extended
the due date of the balloon payment from the first quarter of 2030 to the first quarter of 2032.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Line of Credit (LOC)</b>: Also during the first
quarter of 2020, GSB extended a $<ix:nonFraction contextRef="c107" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LineOfCredit" scale="0" unitRef="usd" id="ixv-14276">1,000,000</ix:nonFraction> LOC to us that is available, as needed, through September 11, 2025. Interest on borrowings
against the LOC is variable at the National Prime Rate per annum. There was no outstanding balance under this LOC as of September 30,
2024 or December 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Loan #3</b>: During the second quarter of 2020,
we received a loan from the Maine Technology Institute (MTI) in the aggregate principal amount of $<ix:nonFraction contextRef="c108" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd" id="ixv-14277">500,000</ix:nonFraction>. The first <ix:nonNumeric contextRef="c109" format="ixt-sec:duryear" name="us-gaap:DebtInstrumentTerm" id="ixv-14278">2.25</ix:nonNumeric> years of this
loan were interest-free with no interest accrual or required principal payments. Beginning during the fourth quarter of 2022, Loan #3
became subject to quarterly principal and interest payments at a fixed rate of <ix:nonFraction contextRef="c110" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeFixedInterestRate" scale="-2" unitRef="pure" id="ixv-14279">5</ix:nonFraction>% per annum over the final <ix:nonNumeric contextRef="c111" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="ixv-14280">five years</ix:nonNumeric> of the loan, through
the third quarter of 2027 if not repaid before then.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Loan #4</b>: During the fourth quarter of 2020,
we closed on a $<ix:nonFraction contextRef="c112" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredFinanceCostsCurrentNet" scale="0" unitRef="usd" id="ixv-14281">1,500,000</ix:nonFraction> note with GSB that bears interest at a fixed rate of <ix:nonFraction contextRef="c112" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" unitRef="pure" id="ixv-14282">3.50</ix:nonFraction>% per annum (with a <ix:nonNumeric contextRef="c113" format="ixt-sec:duryear" name="us-gaap:DebtInstrumentTerm" id="ixv-14283">7</ix:nonNumeric>-year term and amortization schedule).
Proceeds of $<ix:nonFraction contextRef="c114" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="0" unitRef="usd" id="ixv-14284">624,167</ix:nonFraction> were used to prepay a portion of the outstanding principal on our mortgage note (Loan #1), which reduced the outstanding
balance to <ix:nonFraction contextRef="c114" decimals="2" format="ixt:num-dot-decimal" name="iccc:LoanToValueRatio" scale="-2" unitRef="pure" id="ixv-14285">80</ix:nonFraction>% of the most recent appraised value of the property securing the debt, which allowed GSB to release the $<ix:nonFraction contextRef="c115" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredFinanceCostsCurrentNet" scale="0" unitRef="usd" id="ixv-14286">1,400,000</ix:nonFraction> that
had been held in escrow. The remaining proceeds were available for general working capital purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Loan #5</b>: On June 30, 2021, we executed definitive
agreements covering a second loan from the MTI in the aggregate principal amount of $<ix:nonFraction contextRef="c116" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd" id="ixv-14287">400,000</ix:nonFraction>, proceeds from which were received in July
of 2021. The first two years of this loan were interest-free with no interest accrual or required principal payments. Principal and interest
payments at a fixed rate of <ix:nonFraction contextRef="c116" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeFixedInterestRate" scale="-2" unitRef="pure" id="ixv-14288">5</ix:nonFraction>% per annum are due quarterly over the final <ix:nonNumeric contextRef="c117" format="ixt-sec:duryear" name="us-gaap:DebtInstrumentTerm" id="ixv-14289">5.5</ix:nonNumeric> years of the loan, beginning during the third quarter of
2023 and continuing through the fourth quarter of 2028 if not repaid before then.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Loan #6: </b>During the third quarter of 2023,
we closed on a $<ix:nonFraction contextRef="c118" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredFinanceCostsCurrentNet" scale="0" unitRef="usd" id="ixv-14290">2,000,000</ix:nonFraction> term loan bearing interest at a fixed rate of <ix:nonFraction contextRef="c118" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" unitRef="pure" id="ixv-14291">7</ix:nonFraction>% per annum from GSB. The Finance Authority of Maine (FAME) provided
$<ix:nonFraction contextRef="c118" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinancingReceivableLoanInProcess" scale="0" unitRef="usd" id="ixv-14292">1,000,000</ix:nonFraction> of loan insurance to GSB. This loan is repayable under a <ix:nonNumeric contextRef="c119" format="ixt-sec:duryear" name="us-gaap:DebtInstrumentTerm" id="ixv-14293">7</ix:nonNumeric>-year amortization schedule with a balloon payment of $<ix:nonFraction contextRef="c120" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" scale="0" unitRef="usd" id="ixv-14294">1,285,056</ix:nonFraction>
due during the third quarter of 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Loan #7:</b> Also during the third quarter of
2023, we closed on a $<ix:nonFraction contextRef="c121" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredFinanceCostsCurrentNet" scale="0" unitRef="usd" id="ixv-14295">1,000,000</ix:nonFraction> term loan bearing interest at a fixed rate of <ix:nonFraction contextRef="c121" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" unitRef="pure" id="ixv-14296">8</ix:nonFraction>% per annum from FAME. The loan is repayable under a <ix:nonNumeric contextRef="c122" format="ixt-sec:duryear" name="us-gaap:DebtInstrumentTerm" id="ixv-14297">7</ix:nonNumeric>-year
amortization schedule with a balloon payment of $<ix:nonFraction contextRef="c123" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" scale="0" unitRef="usd" id="ixv-14298">649,631</ix:nonFraction> due during the third quarter of 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Loans #1, #2, #4, #6 and #7 are secured by liens
on substantially all of our assets and are subject to certain restrictions and financial covenants. Loan #7 is subordinated to Loans #1,
#2, #4 and #6. Reflecting our poor financial performance during 2023 and into the first nine months of 2024, the debt service covenant
(DSC) requirements for the twelve-month periods ended December 31, 2023, June 30, 2024, September 30, 2024 and December 31, 2024 were
waived pre-emptively by our lenders. We are required to meet a minimum DSC ratio of <ix:nonFraction contextRef="c92" decimals="2" format="ixt:num-dot-decimal" name="iccc:DebtServiceCoverageRatio" scale="0" unitRef="pure" id="ixv-14299">1.35</ix:nonFraction> for the year ending December 31, 2025 and annually
thereafter. In connection with these credit facilities, we incurred aggregate debt issuance and debt discount costs of $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredFinanceCostsCurrentGross" scale="0" unitRef="usd" id="ixv-14300">173,305</ix:nonFraction> ($<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestCostsIncurred" scale="0" unitRef="usd" id="ixv-14301">5,037</ix:nonFraction>
and $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestCostsIncurred" scale="0" unitRef="usd" id="ixv-14302">0</ix:nonFraction> of which was incurred during the nine-month periods ended September 30, 2024 and 2023, respectively). The amortization of these
debt issuance and debt discount costs is being recorded as a component of interest expense, included in other expenses, net, and is being
amortized on a straight-line basis over the underlying terms of the notes. Loans #3 and #5 are unsecured and subordinated to our indebtedness
to GSB and FAME. Failure to make timely payments of principal and interest, or otherwise to comply with the terms of the agreements of
Loans #3 and #5, would entitle the MTI to accelerate the maturity of such debt and demand repayment in full. These loans may be prepaid
without penalty at any time.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Unaudited Financial Statements (continued) </b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_2" id="_DebtDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfDebtTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfDebtTableTextBlock" id="ixv-14303">Debt proceeds received and principal repayments
made (excluding our $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LineOfCredit" scale="0" unitRef="usd" id="ixv-14304">1,000,000</ix:nonFraction> line of credit) are reflected by loan during the periods as described in the tables below:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="_ScheduleOfDebtTableTextBlock-c0_cont_2" id="_ScheduleOfDebtTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>During the Three-Month <br/>
</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Period Ended September 30, 2024</b></p></td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>During
the Three-Month <br/>
Period Ended September 30, 2023</b></p></td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Proceeds&#160;from<br/>
 Debt Issuance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Debt&#160;Principal<br/>
 Repayments</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Proceeds&#160;from <br/>
Debt Issuance</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Debt&#160;Principal<br/>
 Repayments</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -10pt; padding-left: 10pt">Loan #1</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c125" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14305">57,671</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c126" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14306">55,619</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">Loan #2</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c127" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14307">128,534</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c128" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14308">124,020</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Loan #3</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c129" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14309">24,173</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c130" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14310">23,002</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">Loan #4</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c131" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14311">53,505</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c132" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14312">51,622</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt">Loan #5</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c133" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14313">16,719</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c134" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14314">15,909</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt">Loan #6</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c135" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14315">59,191</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c136" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" unitRef="usd" id="ixv-14316">2,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c136" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14317">36,582</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt">Loan #7</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c137" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14318">28,456</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c138" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" unitRef="usd" id="ixv-14319">1,000,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c138" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14320">18,983</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14321">368,249</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" unitRef="usd" id="ixv-14322">3,000,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14323">325,737</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<ix:continuation continuedAt="_ScheduleOfDebtTableTextBlock-c0_cont_3" id="_ScheduleOfDebtTableTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>During the Nine-Month </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Period Ended September 30, 2024</b></p></td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>During the Nine-Month </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Period Ended September 30, 2023</b></p></td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Proceeds&#160;from<br/>
 Debt Issuance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Debt&#160;Principal<br/>
 Repayments</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Proceeds&#160;from <br/>
Debt Issuance</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Debt&#160;Principal<br/>
 Repayments</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -10pt; padding-left: 10pt">Loan #1</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14324">172,017</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c140" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14325">166,527</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">Loan #2</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c141" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14326">382,324</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c142" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14327">369,154</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Loan #3</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c143" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14328">71,629</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c144" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14329">68,156</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">Loan #4</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c145" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14330">159,171</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c146" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14331">153,704</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt">Loan #5</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c147" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14332">49,542</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c148" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14333">15,909</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt">Loan #6</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c149" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14334">174,804</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c150" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" unitRef="usd" id="ixv-14335">2,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c150" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14336">36,582</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt">Loan #7</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c151" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14337">84,619</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c152" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" unitRef="usd" id="ixv-14338">1,000,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c152" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14339">18,983</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14340">1,094,106</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" unitRef="usd" id="ixv-14341">3,000,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14342">829,015</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_ScheduleOfDebtTableTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>During the Year<br/>
 Ended December 31,
                                                                                 2023</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>During
the Year<br/>
 Ended December 31, 2022</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Proceeds&#160;from<br/>
 Debt Issuance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Debt&#160;Principal<br/>
 Repayments</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Proceeds&#160;from <br/>
Debt Issuance</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Debt&#160;Principal<br/>
 Repayments</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -10pt; padding-left: 10pt">Loan #1</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c153" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14343">223,222</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c154" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" unitRef="usd" id="ixv-14344">2,000,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c154" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14345">199,013</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">Loan #2</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c155" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14346">494,455</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c156" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14347">477,237</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Loan #3</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c157" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14348">91,446</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c158" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14349">22,160</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">Loan #4</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c159" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14350">205,884</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c160" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14351">198,715</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt">Loan #5</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c161" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14352">32,017</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt">Loan #6</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c163" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" unitRef="usd" id="ixv-14353">2,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c163" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14354">93,054</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt">Loan #7</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c165" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" unitRef="usd" id="ixv-14355">1,000,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c165" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14356">45,696</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" unitRef="usd" id="ixv-14357">3,000,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14358">1,185,774</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c167" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" unitRef="usd" id="ixv-14359">2,000,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c167" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14360">897,125</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Unaudited Financial Statements (continued) </b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation id="_DebtDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="ixv-14361">Principal payments (net of debt issuance
and debt discount costs) due under bank loans outstanding as of September 30, 2024 (excluding our $<ix:nonFraction contextRef="c124" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LineOfCredit" scale="0" unitRef="usd" id="ixv-14362">1,000,000</ix:nonFraction> line of credit) are reflected
in the following table by the year that payments are due:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">During the<br/> Three-Month<br/> Period Ending<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">During the Years Ending December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2027</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2028</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Thereafter</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 16%">Loan #1</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c168" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" scale="0" unitRef="usd" id="ixv-14363">58,765</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c168" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="0" unitRef="usd" id="ixv-14364">239,876</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c168" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="0" unitRef="usd" id="ixv-14365">248,604</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c168" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="0" unitRef="usd" id="ixv-14366">257,649</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c168" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="0" unitRef="usd" id="ixv-14367">266,537</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c168" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" scale="0" unitRef="usd" id="ixv-14368">4,598,457</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c168" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="0" unitRef="usd" id="ixv-14369">5,669,888</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Loan #2</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c169" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" scale="0" unitRef="usd" id="ixv-14370">129,801</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c169" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="0" unitRef="usd" id="ixv-14371">530,738</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c169" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="0" unitRef="usd" id="ixv-14372">549,881</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c169" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="0" unitRef="usd" id="ixv-14373">140,436</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c169" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="0" unitRef="usd" id="ixv-14374">1,350,856</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Loan #3</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c170" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" scale="0" unitRef="usd" id="ixv-14375">24,476</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c170" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="0" unitRef="usd" id="ixv-14376">101,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c170" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="0" unitRef="usd" id="ixv-14377">106,146</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c170" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="0" unitRef="usd" id="ixv-14378">83,143</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c170" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="0" unitRef="usd" id="ixv-14379">314,765</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Loan #4</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c171" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" scale="0" unitRef="usd" id="ixv-14380">54,055</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c171" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="0" unitRef="usd" id="ixv-14381">220,994</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c171" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="0" unitRef="usd" id="ixv-14382">228,965</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c171" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="0" unitRef="usd" id="ixv-14383">240,442</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c171" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="0" unitRef="usd" id="ixv-14384">744,456</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Loan #5</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c172" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" scale="0" unitRef="usd" id="ixv-14385">16,929</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c172" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="0" unitRef="usd" id="ixv-14386">69,856</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c172" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="0" unitRef="usd" id="ixv-14387">73,415</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c172" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="0" unitRef="usd" id="ixv-14388">77,156</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c172" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="0" unitRef="usd" id="ixv-14389">81,086</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c172" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="0" unitRef="usd" id="ixv-14390">318,442</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Loan #6</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c173" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" scale="0" unitRef="usd" id="ixv-14391">60,581</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c173" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="0" unitRef="usd" id="ixv-14392">253,003</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c173" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="0" unitRef="usd" id="ixv-14393">1,418,558</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c173" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="0" unitRef="usd" id="ixv-14394">1,732,142</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Loan #7</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c174" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" scale="0" unitRef="usd" id="ixv-14395">29,617</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c174" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="0" unitRef="usd" id="ixv-14396">124,364</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c174" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="0" unitRef="usd" id="ixv-14397">715,704</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c174" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="0" unitRef="usd" id="ixv-14398">869,685</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Subtotal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c175" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" scale="0" unitRef="usd" id="ixv-14399">374,224</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c175" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="0" unitRef="usd" id="ixv-14400">1,539,831</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c175" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="0" unitRef="usd" id="ixv-14401">3,341,273</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c175" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="0" unitRef="usd" id="ixv-14402">798,826</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c175" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="0" unitRef="usd" id="ixv-14403">347,623</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c175" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" scale="0" unitRef="usd" id="ixv-14404">4,598,457</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c175" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="0" unitRef="usd" id="ixv-14405">11,000,234</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Debt issuance cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="iccc:DebtIssuanceCosts2024" scale="0" unitRef="usd" id="ixv-14406">5,583</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="iccc:DebtIssuanceCosts2025" scale="0" unitRef="usd" id="ixv-14407">21,314</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="iccc:DebtIssuanceCosts2026" scale="0" unitRef="usd" id="ixv-14408">13,580</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="iccc:DebtIssuanceCosts2027" scale="0" unitRef="usd" id="ixv-14409">5,420</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="iccc:DebtIssuanceCosts2028" scale="0" unitRef="usd" id="ixv-14410">3,513</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="iccc:DebtIssuanceCostshereafter" scale="0" unitRef="usd" id="ixv-14411">11,347</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredFinanceCostsNet" scale="0" unitRef="usd" id="ixv-14412">60,757</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Debt discount cost</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="iccc:DebtDiscountCost" scale="0" unitRef="usd" id="ixv-14413">5,223</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="iccc:DebtDiscountCost2025" scale="0" unitRef="usd" id="ixv-14414">20,891</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="iccc:DebtDiscountCost2026" scale="0" unitRef="usd" id="ixv-14415">11,344</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="iccc:DebtDiscountCostTotal" scale="0" unitRef="usd" id="ixv-14416">37,458</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="iccc:LongTermDebt2024" scale="0" unitRef="usd" id="ixv-14417">363,418</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="iccc:LongTermDebt2025" scale="0" unitRef="usd" id="ixv-14418">1,497,626</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="iccc:LongTermDebt2026" scale="0" unitRef="usd" id="ixv-14419">3,316,349</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="iccc:LongTermDebt2027" scale="0" unitRef="usd" id="ixv-14420">793,406</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="iccc:LongTermDebtTotal2028" scale="0" unitRef="usd" id="ixv-14421">344,110</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="iccc:LongTermDebtThereafter" scale="0" unitRef="usd" id="ixv-14422">4,587,110</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="0" unitRef="usd" id="ixv-14423">10,902,019</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:continuation><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-5477"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>11. CONTINGENT LIABILITIES AND COMMITMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our bylaws, as amended, in effect provide that the
Company will indemnify its officers and directors against any liability arising from their responsibilities as officers and directors
to the maximum extent permitted by Delaware law. In addition, we make similar indemnity undertakings with each director through a separate
indemnification agreement with that director. The maximum payment that we may be required to make under such provisions is theoretically
unlimited and is impossible to determine. We maintain directors&#8217; and officers&#8217; liability insurance, which may provide reimbursement
to the Company for payments made to, or on behalf of, officers and directors pursuant to the indemnification provisions. Our indemnification
obligations were grandfathered under the provisions of Codification Topic 460<i>, Guarantees</i>. Accordingly, we have recorded no liability
for such obligations as of September 30, 2024 or December 31, 2023. Since our incorporation, we have had no occasion to make any indemnification
payment to any of our officers or directors for any reason.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The development, manufacturing and marketing of
animal health care products entails an inherent risk that liability claims will be asserted against us during the normal course of business.
We are aware of no such claims against us as of the date of this filing. We believe that we have reasonable levels of liability insurance
to support our operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We enter into agreements with third parties in the
ordinary course of business under which we are obligated to indemnify such third parties from and against various risks and losses. The
precise terms of such indemnities vary with the nature of the agreement. In many cases, we limit the maximum amount of our indemnification
obligations, but in some cases those obligations may be theoretically unlimited. We have not incurred material expenses in discharging
any of these indemnification obligations and based on our analysis of the nature of the risks involved, we believe that the fair value
of the liabilities potentially arising under these agreements is minimal. Accordingly, we recorded no liabilities for such obligations
as of September 30, 2024 or December 31, 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Unaudited Financial Statements (continued) </b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We plan to purchase certain key parts (syringes)
and services (formulation, aseptic filling and final packaging) pertaining to <b>Re-Tain<sup>&#174;</sup></b> Drug Product (DP), our Nisin-based
intramammary treatment of subclinical mastitis in lactating dairy cows, exclusively from contractors. The contract for formulation, aseptic
filling and final packaging of DP is scheduled to terminate on November 30, 2024. We initiated an investment in the necessary equipment
to perform the DP formulation and aseptic filling services in-house, but this investment has been paused at the present time.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Effective March 28, 2022, we entered into an Amended
and Restated Separation and Deferred Compensation Agreement (the &#8220;Deferred Compensation Agreement&#8221;) with Mr. Brigham (our
President and CEO) that superseded and replaced in its entirety a March 2020 severance agreement between the Company and Mr. Brigham.
Upon separation from the Company for any reason, Mr. Brigham&#8217;s Deferred Compensation Agreement allows Mr. Brigham to be paid, among
other amounts, all earned and unused paid time off (which expense totaling $<ix:nonFraction contextRef="c176" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" scale="0" unitRef="usd" id="ixv-14424">222,379</ix:nonFraction> was accrued during the first quarter of 2022 and $<ix:nonFraction contextRef="c177" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" scale="0" unitRef="usd" id="ixv-14425"><ix:nonFraction contextRef="c178" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" scale="0" unitRef="usd" id="ixv-14426">230,162</ix:nonFraction></ix:nonFraction>
was included in accounts payable and accrued expenses on the accompanying balance sheets as of both September 30, 2024 and December 31,
2023) and to receive up to an additional $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherDeferredCompensationArrangementsLiabilityCurrent" scale="0" unitRef="usd" id="ixv-14427">300,000</ix:nonFraction> in deferred compensation (which amount is being accrued over the three-year period ending
in January 2025). This deferred compensation payment vested as to $<ix:nonFraction contextRef="c179" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherDeferredCompensationArrangementsLiabilityCurrent" scale="0" unitRef="usd" id="ixv-14428">100,000</ix:nonFraction> on January 1, 2023 and an additional $<ix:nonFraction contextRef="c180" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherDeferredCompensationArrangementsLiabilityCurrent" scale="0" unitRef="usd" id="ixv-14429">100,000</ix:nonFraction> on January 1,
2024. An additional $<ix:nonFraction contextRef="c177" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherDeferredCompensationArrangementsLiabilityCurrent" scale="0" unitRef="usd" id="ixv-14430">100,000</ix:nonFraction> will vest on January 1, 2025, provided that Mr. Brigham is employed by the Company as of such date. The vested
amounts would be paid upon the earlier of January 31, 2025 or within thirty (30) days following his separation from the Company. As of
September 30, 2024 and December 31, 2023, $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" scale="0" unitRef="usd" id="ixv-14431">275,000</ix:nonFraction> and $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" scale="0" unitRef="usd" id="ixv-14432">200,000</ix:nonFraction>, respectively, was included in accounts payable and accrued expenses on
the accompanying balance sheets. In addition, upon termination of Mr. Brigham&#8217;s employment (a) by the Company other than for cause,
(b) due to death or disability or (c) by Mr. Brigham for good reason, in each case as described and defined in the Deferred Compensation
Agreement, the Company agrees to pay Mr. Brigham <ix:nonFraction contextRef="c181" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" scale="-2" unitRef="pure" id="ixv-14433">100</ix:nonFraction>% of his then current annual base salary and a lump sum payment equal to the employer
portion of the costs of continued health benefits for Mr. Brigham and his covered dependents for a twelve-month period following termination,
and certain equity incentive awards granted to Mr. Brigham would continue to vest following such termination in accordance with the terms
of the Deferred Compensation Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Incentive
compensation agreements may be entered into with Mr. Brigham, Ms. Brockmann (our Vice President of Sales and Marketing) and Ms. Williams
(our Vice President of Manufacturing Operations) which, at times, allow these executives to earn incentive compensation if certain regulatory
and financial objectives are met during the year to which the agreement relates, as specified in their agreements. Amounts related to
these incentive compensation agreements are accrued over the period they are earned (when it is probable that the amounts will be earned)
based on our best estimate of the amounts expected to be </span>earned.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the commitments discussed above, we had committed $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="iccc:CapitalExpendituresCommitted" scale="0" unitRef="usd" id="ixv-14434">186,000</ix:nonFraction> to increase our production capacity for the <b>First Defense<sup>&#174;</sup></b>
product line, $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="iccc:PurchaseofInventory" scale="0" unitRef="usd" id="ixv-14435">1,818,000</ix:nonFraction> to the purchase of inventory, $<ix:nonFraction contextRef="c182" decimals="0" format="ixt:num-dot-decimal" name="iccc:CommitmentsRelatedToCommercialManufacture" scale="0" unitRef="usd" id="ixv-14436">22,000</ix:nonFraction> related to the commercial manufacture of <b>Re-Tain<sup>&#174;</sup></b>
and $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="iccc:CommitmentsRelatedToInformationTechnologyServicesAndOtherObligations" scale="0" unitRef="usd" id="ixv-14437">711,000</ix:nonFraction> to information technology services and other obligations as of September 30, 2024</span>.</p></ix:continuation><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Unaudited Financial Statements (continued) </b></p><div>


</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock" id="ixv-5551"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>12. OPERATING LEASE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On September 12, 2019, we entered into a lease
covering approximately <ix:nonFraction contextRef="c183" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AreaOfLand" scale="0" unitRef="sqft" id="ixv-14438">14,300</ix:nonFraction> square feet of office and warehouse space with a possession date of November 15, 2019 and a commencement
date of February 13, 2020. The property is located at 175 Industrial Way in Portland (<b>Building 175A</b>), which is a short distance
from our headquarters and manufacturing facility at 56 Evergreen Drive. We renovated this space to meet our needs in expanding our production
capacity for the <b>First Defense<sup>&#174;</sup></b> product line. The original lease term was <ix:nonNumeric contextRef="c184" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="ixv-14439">ten years</ix:nonNumeric> with a right to renew for a
second <ix:nonNumeric contextRef="c184" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="ixv-14440">10</ix:nonNumeric>-year term and a right of first offer to purchase. At the time we entered into this lease, we were not reasonably assured that
we would exercise this renewal option in place of other real estate options. For that reason, a 10-year period was reflected in the right-of-use
(ROU) asset and lease liability on our balance sheet. During the third quarter of 2022, we committed to lease an additional <ix:nonFraction contextRef="c185" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AreaOfLand" scale="0" unitRef="sqft" id="ixv-14441">15,400</ix:nonFraction> square
feet of space at 175 Industrial Way (<b>Building 175B</b>), which is connected to the original space, over a <ix:nonNumeric contextRef="c185" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="ixv-14442">20</ix:nonNumeric>-year term. The ROU asset
and lease liability for the committed space at <b>Building 175B</b> was recorded as of April 1, 2023 after construction of the building
shell was completed in accordance with the lease agreement. Monthly lease payments commenced as of August 1, 2023. In connection with
the lease commitment for space at <b>Building 175B, </b>the term of the original lease for <b>Building 175A</b> was extended by approximately
13 years. On November 14, 2023, June 11, 2024 and September 20, 2024, we amended this lease further to provide for certain tenant improvements
on the leased premises to be paid for by our landlord. These improvements will provide heat to an unfinished space, provide additional
warehouse space, and create a new primary shipping and receiving facility. As a result of these three amendments and in consideration
for the landlord agreeing to pay for the cost of those certain tenant improvements, we agreed to make additional rent payments of $<ix:nonFraction contextRef="c186" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRent" scale="0" unitRef="usd" id="ixv-14443">20,000</ix:nonFraction>
per month from November of 2023 through June of 2025 and a one-time additional rent payment of $<ix:nonFraction contextRef="c187" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRent" scale="0" unitRef="usd" id="ixv-14444">248,743</ix:nonFraction> in July of 2025. Because of these
modifications to the lease payments, the ROU asset and lease liability associated with the space at <b>Building 175B</b> were remeasured
as of the modification dates. Our leases include variable non-lease components. Such payments primarily include common area maintenance
charges. As of September 30, 2024, the balance of the operating lease ROU asset was $<ix:nonFraction contextRef="c184" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-14445">4,592,718</ix:nonFraction> and the operating lease liability was $<ix:nonFraction contextRef="c184" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-14446">4,630,648</ix:nonFraction>.
As of December 31, 2023, the balance of the operating lease ROU asset was $<ix:nonFraction contextRef="c188" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-14447">4,571,149</ix:nonFraction> and the operating lease liability was $<ix:nonFraction contextRef="c188" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-14448">4,721,385</ix:nonFraction>.
The calculated amount of the ROU asset and lease liability is impacted by the length of the lease term and the discount rate used for
the present value of the minimum lease payments. We elected not to separate lease and non-lease components for all classes of underlying
assets, and instead to account for them as a single lease component. <ix:nonNumeric contextRef="c0" continuedAt="_LeaseCostTableTextBlock-c0_cont_1" escape="true" name="us-gaap:LeaseCostTableTextBlock" id="ixv-14449">Variable lease cost primarily represents variable payments such as
real estate taxes and common area maintenance. The following tables describe our lease costs and other lease information:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_LeaseCostTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">During the Three-Month<br/> Periods Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">During the Nine-Month <br/> Periods Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>Lease Cost</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; text-indent: -10.1pt; padding-left: 0.25in">Operating lease cost</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="0" unitRef="usd" id="ixv-14450">106,880</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="0" unitRef="usd" id="ixv-14451">98,714</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="0" unitRef="usd" id="ixv-14452">320,639</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="0" unitRef="usd" id="ixv-14453">244,954</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 20.2pt">Variable lease cost</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:VariableLeaseCost" scale="0" unitRef="usd" id="ixv-14454">21,486</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:VariableLeaseCost" scale="0" unitRef="usd" id="ixv-14455">9,720</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:VariableLeaseCost" scale="0" unitRef="usd" id="ixv-14456">50,638</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:VariableLeaseCost" scale="0" unitRef="usd" id="ixv-14457">27,054</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt">Total lease cost</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="0" unitRef="usd" id="ixv-14458">128,366</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="0" unitRef="usd" id="ixv-14459">108,434</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="0" unitRef="usd" id="ixv-14460">371,277</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="0" unitRef="usd" id="ixv-14461">272,008</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Operating Lease</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt">Cash paid for operating lease liabilities</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="0" unitRef="usd" id="ixv-14462">144,315</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="0" unitRef="usd" id="ixv-14463">69,742</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="0" unitRef="usd" id="ixv-14464">432,945</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="0" unitRef="usd" id="ixv-14465">131,476</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Weighted average remaining lease term (in years)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c2" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-14466">18.3</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c33" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-14467">19.3</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c2" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-14468">18.3</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c33" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-14469">19.3</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -10.1pt; padding-left: 20.2pt">Weighted average discount rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-14470">6.6</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c33" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-14471">6.3</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-14472">6.6</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c33" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-14473">6.3</ix:nonFraction></td><td style="text-align: left">%</td></tr> </table></ix:continuation>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><ix:nonNumeric contextRef="c0" continuedAt="_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="ixv-14474">Future lease payments required under non-cancelable
operating leases in effect as of September 30, 2024 were as follows:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Amount</b></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">During the three-month period ending December 31, 2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="0" unitRef="usd" id="ixv-14475">144,315</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline">During the years ending December 31,</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" unitRef="usd" id="ixv-14476">711,623</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="0" unitRef="usd" id="ixv-14477">349,744</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="0" unitRef="usd" id="ixv-14478">356,732</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="0" unitRef="usd" id="ixv-14479">363,870</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="0" unitRef="usd" id="ixv-14480">5,949,488</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total lease payments (undiscounted cash flows)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" unitRef="usd" id="ixv-14481">7,875,772</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: imputed interest (discount effect of cash flows)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" unitRef="usd" id="ixv-14482">3,245,124</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total operating liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-14483">4,630,648</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Unaudited Financial Statements (continued) </b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_1" escape="true" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" id="ixv-5844"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>13. STOCKHOLDERS&#8217; EQUITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Common Stock Issuances</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">From February of 2016 to April of 2021, we sold
the aggregate of <ix:nonFraction contextRef="c189" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-14484">4,553,017</ix:nonFraction> shares of common stock in six different transactions raising gross proceeds of $<ix:nonFraction contextRef="c189" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd" id="ixv-14485">26,714,403</ix:nonFraction> at the weighted
average price of $<ix:nonFraction contextRef="c190" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" unitRef="usdPershares" id="ixv-14486">5.87</ix:nonFraction> per share. These funds have been essential to funding our business growth plans. The details of each transaction
are discussed below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1) During February of 2016, we sold <ix:nonFraction contextRef="c191" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-14487">1,123,810</ix:nonFraction> shares
of common stock at a price to the public of $<ix:nonFraction contextRef="c192" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-14488">5.25</ix:nonFraction> per share in an underwritten public offering pursuant to our effective shelf registration
statement on Form S-3, raising gross proceeds of $<ix:nonFraction contextRef="c191" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd" id="ixv-14489">5,900,003</ix:nonFraction> and resulting in net proceeds to the Company of $<ix:nonFraction contextRef="c191" decimals="0" format="ixt:num-dot-decimal" name="iccc:NetProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd" id="ixv-14490">5,313,224</ix:nonFraction> (after deducting
underwriting discounts and offering expenses incurred in connection with the equity financing).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2) During October of 2016, we sold, in a private
placement, <ix:nonFraction contextRef="c193" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-14491">659,880</ix:nonFraction> shares of common stock to nineteen institutional and accredited investors at $<ix:nonFraction contextRef="c194" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-14492">5.25</ix:nonFraction> per share, raising gross proceeds
of $<ix:nonFraction contextRef="c193" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd" id="ixv-14493">3,464,370</ix:nonFraction> and resulting in net proceeds to the Company of $<ix:nonFraction contextRef="c193" decimals="0" format="ixt:num-dot-decimal" name="iccc:NetProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd" id="ixv-14494">3,160,923</ix:nonFraction> (after deducting placement agent fees and other expenses incurred
in connection with the equity financing).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3) During July of 2017, we sold <ix:nonFraction contextRef="c195" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-14495">200,000</ix:nonFraction> shares of
our common stock at a price of $<ix:nonFraction contextRef="c196" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-14496">5.25</ix:nonFraction> per share in a public, registered sale to two related investors pursuant to our effective shelf registration
statement on Form S-3, raising gross proceeds of $<ix:nonFraction contextRef="c195" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd" id="ixv-14497">1,050,000</ix:nonFraction> and resulting in net proceeds of $<ix:nonFraction contextRef="c195" decimals="0" format="ixt:num-dot-decimal" name="iccc:NetProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd" id="ixv-14498">1,034,164</ix:nonFraction> (after deducting expenses incurred
in connection with the equity financing).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4) During December of 2017, we sold <ix:nonFraction contextRef="c197" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-14499">417,807</ix:nonFraction> shares
of common stock at a price to the public of $<ix:nonFraction contextRef="c198" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-14500">7.30</ix:nonFraction> per share in an underwritten public offering pursuant to our effective shelf registration
statement on Form S-3, raising gross proceeds of $<ix:nonFraction contextRef="c197" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd" id="ixv-14501">3,049,991</ix:nonFraction> and resulting in net proceeds to the Company of $<ix:nonFraction contextRef="c197" decimals="0" format="ixt:num-dot-decimal" name="iccc:NetProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd" id="ixv-14502">2,734,173</ix:nonFraction> (after deducting
underwriting discounts and offering expenses incurred in connection with the equity financing).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">5) During March of 2019, we sold <ix:nonFraction contextRef="c199" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-14503">1,636,364</ix:nonFraction> shares
of common stock at a price to the public of $<ix:nonFraction contextRef="c200" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-14504">5.50</ix:nonFraction> per share in an underwritten public offering pursuant to our effective shelf registration
statement on Form S-3, raising gross proceeds of $<ix:nonFraction contextRef="c199" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd" id="ixv-14505">9,000,002</ix:nonFraction> and resulting in net proceeds to the Company of $<ix:nonFraction contextRef="c199" decimals="0" format="ixt:num-dot-decimal" name="iccc:NetProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd" id="ixv-14506">8,303,436</ix:nonFraction> (after deducting
underwriting discounts and offering expenses incurred in connection with the equity financing).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">6) During April of 2021, we sold <ix:nonFraction contextRef="c201" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-14507">515,156</ix:nonFraction> shares
of our common stock at a price of $<ix:nonFraction contextRef="c202" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-14508">8.25</ix:nonFraction> per share in a public, registered sale to seven investors pursuant to our effective shelf registration
statement on Form S-3, raising gross proceeds of $<ix:nonFraction contextRef="c201" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd" id="ixv-14509">4,250,038</ix:nonFraction> and resulting in net proceeds of $<ix:nonFraction contextRef="c201" decimals="0" format="ixt:num-dot-decimal" name="iccc:NetProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd" id="ixv-14510">4,233,026</ix:nonFraction> (after deducting expenses incurred
in connection with the equity financing).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At-The-Market Offering</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On April 9, 2024, our shelf registration on Form
S-3 (File No. 333-278438) relating to the offer, issuance and sale by the Company of up to $<ix:nonFraction contextRef="c203" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIssuedPrincipal" scale="0" unitRef="usd" id="ixv-14511">20,000,000</ix:nonFraction> of securities was declared effective
by the Securities and Exchange Commission. Also on April 9, 2024, we entered into an At-The-Market Agreement (ATM Agreement) with Craig-Hallum
Capital Group LLC, pursuant to which we may offer and sell up to $<ix:nonFraction contextRef="c204" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-14512">11,000,000</ix:nonFraction> of shares of our common stock. Legal, accounting and other
fees in the amount of $<ix:nonFraction contextRef="c205" decimals="0" format="ixt:num-dot-decimal" name="iccc:FeesInitiallyCapitalizedAndLaterOffset" scale="0" unitRef="usd" id="ixv-14513">152,272</ix:nonFraction> associated with the completion of the shelf registration and the ATM Agreement were initially capitalized
and then were offset against the initial proceeds received during the second quarter of 2024. As of September 30, 2024, we had sold <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-14514">1,082,233</ix:nonFraction>
shares under the at the market offering conducted pursuant to the ATM Agreement. Net proceeds through September 30, 2024 from shares sold
pursuant to the ATM Agreement (net of the upfront legal, accounting and other fees), less sales commissions of $<ix:nonFraction contextRef="c206" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SalesCommissionsAndFees" scale="0" unitRef="usd" id="ixv-14515">123,368</ix:nonFraction>, were $<ix:nonFraction contextRef="c206" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd" id="ixv-14516">3,833,090</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stock Option Plans</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In June of 2010, our stockholders approved the 2010
Stock Option and Incentive Plan (the &#8220;2010 Plan&#8221;) pursuant to the provisions of the Internal Revenue Code of 1986, under which
employees and certain service providers may be granted options to purchase shares of the Company&#8217;s common stock at no less than
fair market value on the date of grant. At that time, <ix:nonFraction contextRef="c207" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-14517">300,000</ix:nonFraction> shares of common stock were reserved for issuance under the 2010 Plan and
subsequently no additional shares have been reserved for the 2010 Plan. Vesting requirements are determined by the Compensation and Stock
Option Committee of the Board of Directors on a case-by-case basis. All options granted under the 2010 Plan expire no later than <ix:nonNumeric contextRef="c208" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="ixv-14518">10</ix:nonNumeric> years
from the date of grant. The 2010 Plan expired in June of 2020, after which date no further options can be granted under the 2010 Plan.
However, options outstanding under the 2010 Plan at that time can be exercised in accordance with their terms. There were <ix:nonFraction contextRef="c207" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-14519">183,500</ix:nonFraction> and
<ix:nonFraction contextRef="c209" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-14520">188,500</ix:nonFraction> options outstanding under the 2010 Plan as of September 30, 2024 and December 31, 2023, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Unaudited Financial Statements (continued) </b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_2" id="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In June of 2017, our stockholders approved the 2017
Stock Option and Incentive Plan (the &#8220;2017 Plan&#8221;) pursuant to the provisions of the Internal Revenue Code of 1986, under which
employees and certain service providers may be granted options to purchase shares of the Company&#8217;s common stock at no less than
fair market value on the date of grant. At that time, <ix:nonFraction contextRef="c210" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-14521">300,000</ix:nonFraction> shares of common stock were reserved for issuance under the 2017 Plan. An
amendment to the 2017 Plan increasing the number of shares reserved for issuance under the 2017 Plan from <ix:nonFraction contextRef="c211" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-14522">300,000</ix:nonFraction> shares to <ix:nonFraction contextRef="c212" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-14523">650,000</ix:nonFraction> shares
was approved by a vote of stockholders at the Annual Meeting of Stockholders in June of 2022. Vesting requirements are determined by the
Compensation and Stock Option Committee of the Board of Directors on a case-by-case basis. All options granted under the 2017 Plan expire
no later than <ix:nonNumeric contextRef="c213" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="ixv-14524">10</ix:nonNumeric> years from the date of grant. The 2017 Plan expires in March of 2027, after which date no further options can be granted
under the 2017 Plan. However, options outstanding under the 2017 Plan at that time can be exercised in accordance with their terms. As
of September 30, 2024 and December 31, 2023, there were <ix:nonFraction contextRef="c214" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-14525">477,500</ix:nonFraction> and <ix:nonFraction contextRef="c215" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-14526">430,000</ix:nonFraction> options outstanding under the 2017 Plan, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="ixv-14527">Activity under the stock option plans described
above was as follows:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_2" id="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2010 Plan</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2017 Plan</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate Intrinsic Value<sup>(1)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding as of December 31, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c226" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-14528">202,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c227" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-14529">402,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c46" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-14530">7.19</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" id="ix_0_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" sign="-" unitRef="usd">661,310</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in">Grants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c229" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-14532">122,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c75" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-14533">5.16</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Terminations/forfeitures<b><sup>(2)</sup></b></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c228" decimals="INF" format="ixt:num-dot-decimal" id="ix_5_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" unitRef="shares">10,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c229" decimals="INF" format="ixt:num-dot-decimal" id="ix_6_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" unitRef="shares">94,500</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c75" decimals="2" format="ixt:num-dot-decimal" id="ix_7_fact" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">7.12</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 10.1pt">Exercises</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c228" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares" id="ixv-14537">4,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c75" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-14538">4.69</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c230" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-14539">188,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-14540">430,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-14541">6.82</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_1_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" sign="-" unitRef="usd">1,071,121</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10.1pt">Grants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c233" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-14543">73,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-14544">3.80</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Terminations/forfeitures<b><sup>(2)</sup></b></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c232" decimals="INF" format="ixt:num-dot-decimal" id="ix_8_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" unitRef="shares">5,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c233" decimals="INF" format="ixt:num-dot-decimal" id="ix_9_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" unitRef="shares">25,500</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" id="ix_10_fact" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">6.75</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 10.1pt">Exercises</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Outstanding as of September 30, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c234" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-14548">183,500</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c235" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-14549">477,500</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-14550">6.49</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" id="ix_2_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" sign="-" unitRef="usd">1,891,421</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Vested as of September 30, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c234" decimals="INF" format="ixt:num-dot-decimal" name="iccc:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested" scale="0" unitRef="shares" id="ixv-14552">183,500</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c235" decimals="INF" format="ixt:num-dot-decimal" name="iccc:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested" scale="0" unitRef="shares" id="ixv-14553">136,500</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="iccc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested" scale="0" unitRef="usdPershares" id="ixv-14554">6.97</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" id="ix_3_fact" name="iccc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue" scale="0" sign="-" unitRef="usd">1,068,740</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Vested and expected to vest as of September 30, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c234" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" unitRef="shares" id="ixv-14556">183,500</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c235" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" unitRef="shares" id="ixv-14557">477,500</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-14558">6.49</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" id="ix_4_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="0" sign="-" unitRef="usd">1,891,421</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Reserved for future grants</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c235" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-14560">154,500</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_3" id="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><sup>(1)</sup></td><td style="text-align: justify"><ix:footnote id="ix_0_footnote" xml:lang="en-US">Intrinsic value is the difference between the fair market value
of the underlying common stock as of the date indicated and as of the date of the option grant (which is equal to the option exercise
price).</ix:footnote></td>
</tr></table></ix:continuation>

<ix:continuation id="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><sup>(2)</sup></td><td style="text-align: justify"><ix:footnote id="ix_1_footnote" xml:lang="en-US">Terminations and forfeitures are recognized when they occur.</ix:footnote></td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" id="ixv-14563">The following table displays additional information
about the stock option plans described above:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average <br/> Fair Value at Grant Date</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-indent: -10pt; padding-left: 10pt">Non-vested stock options as of December 31, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c236" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" unitRef="shares" id="ixv-14564">337,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c236" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-14565">3.66</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c236" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-14566">7.14</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">Non-vested stock options as of September 30, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c237" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" unitRef="shares" id="ixv-14567">341,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c237" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-14568">3.14</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c237" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-14569">6.04</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock options granted during the nine-month period ended September 30, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c238" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-14570">73,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c238" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-14571">1.72</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c238" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-14572">3.80</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Stock options that vested during the nine-month period ended September 30, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c238" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" unitRef="shares" id="ixv-14573">54,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c238" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-14574">4.31</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c238" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-14575">9.73</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Stock options that were terminated or forfeited during the nine-month period ended September 30, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c238" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" scale="0" unitRef="shares" id="ixv-14576">30,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c238" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-14577">3.36</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c238" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-14578">6.75</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Unaudited Financial Statements (continued) </b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_3" id="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares" id="ixv-14579"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares" id="ixv-14580">No</ix:nonFraction></ix:nonFraction> stock options were exercised during the three-month
or nine-month periods ended September 30, 2024 and 2023. The weighted average remaining life of the options outstanding under the 2010
Plan and the 2017 Plan as of September 30, 2024 was approximately <ix:nonNumeric contextRef="c208" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-14581">5</ix:nonNumeric> years. The weighted average remaining life of the options exercisable
under these plans as of September 30, 2024 was approximately <ix:nonNumeric contextRef="c208" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="ixv-14582">2</ix:nonNumeric> years and 11 months. The exercise price of the options outstanding under
these plans as of September 30, 2024, ranged from $<ix:nonFraction contextRef="c216" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-14583">3.60</ix:nonFraction> to $<ix:nonFraction contextRef="c217" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-14584">10.04</ix:nonFraction> per share. The <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" unitRef="shares" id="ixv-14585">73,000</ix:nonFraction> stock options granted during the nine-month period
ended September 30, 2024 had an average exercise price of $<ix:nonFraction contextRef="c218" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-14586">3.80</ix:nonFraction> per share. The <ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" unitRef="shares" id="ixv-14587">108,000</ix:nonFraction> stock options granted during the nine-month period
ended September 30, 2023 had an average exercise price of $<ix:nonFraction contextRef="c33" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-14588">5.19</ix:nonFraction> per share. The weighted-average grant date fair values of options granted
during the nine-month periods ended September 30, 2024 and 2023 were $<ix:nonFraction contextRef="c219" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" scale="0" unitRef="usdPershares" id="ixv-14589">1.72</ix:nonFraction> and $<ix:nonFraction contextRef="c220" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" scale="0" unitRef="usdPershares" id="ixv-14590">2.80</ix:nonFraction> per share, respectively. As of September 30, 2024,
total unrecognized stock-based compensation related to non-vested stock options aggregated $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="0" unitRef="usd" id="ixv-14591">433,317</ix:nonFraction> which will be recognized over a weighted
average remaining period of approximately <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="ixv-14592">1</ix:nonNumeric> year and 5 months. <ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="ixv-14593">The fair value of each stock option grant has been estimated on the date
of grant using the Black-Scholes option pricing model, for the purpose discussed in Note 2(n), with the following weighted-average assumptions:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-c0_cont_2" id="_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">During the Three-Month<br/> Periods Ended September 30,</td><td style="padding-bottom: 3pt; font-weight: bold"><sup>&#160;</sup></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">During the Nine-Month <br/> Periods Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 3pt; font-weight: bold"><sup>&#160;</sup></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate<sup>(1)</sup></span></td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="4" format="ixt:num-dot-decimal" id="ix_11_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">3.48</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-119; font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="padding-bottom: 3pt; width: 1%; text-align: left"><sup>(4)</sup></td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" id="ix_12_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">3.70</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="4" format="ixt:num-dot-decimal" id="ix_13_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">3.48</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend yield<sup>(2)</sup></span></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" id="ix_14_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure">0</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" id="ix_15_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure">0</ix:nonFraction></td><td style="padding-bottom: 0pt; text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" id="ix_16_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure">0</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" id="ix_17_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure">0</ix:nonFraction></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility<sup>(2)</sup></span></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" id="ix_18_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">52</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-120; font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="padding-bottom: 3pt; text-align: left"><sup>(4)</sup></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" id="ix_19_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">51</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" id="ix_20_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">54</ix:nonFraction></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected life<sup>(3)</sup></span></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c4" format="ixt-sec:duryear" id="ix_21_fact" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">4.1</ix:nonNumeric> years</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-121; font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="padding-bottom: 3pt; text-align: left"><sup>(4)</sup></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" id="ix_22_fact" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">4.3</ix:nonNumeric> years</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c6" format="ixt-sec:duryear" id="ix_23_fact" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.2</ix:nonNumeric> years</td><td style="text-align: left">&#160;</td></tr> </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><sup>&#160;</sup></p>

<ix:continuation continuedAt="_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-c0_cont_3" id="_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><sup>(1)</sup></td><td style="text-align: justify"><ix:footnote id="ix_2_footnote" xml:lang="en-US">The risk-free interest rate is based on U.S. Treasury yields
for a maturity approximating the expected option term.</ix:footnote></td>
</tr></table></ix:continuation>

<ix:continuation continuedAt="_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-c0_cont_4" id="_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><sup>(2)</sup></td><td style="text-align: justify"><ix:footnote id="ix_3_footnote" xml:lang="en-US">The dividend yield and expected volatility are derived from
averages of our historical data.</ix:footnote></td>
</tr></table></ix:continuation>

<ix:continuation continuedAt="_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-c0_cont_5" id="_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><sup>(3)</sup></td><td style="text-align: left"><ix:footnote id="ix_4_footnote" xml:lang="en-US">The expected life is calculated utilizing the simplified method,
which uses the mid-point between the vesting period and the contractual term as the expected life.</ix:footnote></td>
</tr></table></ix:continuation>

<ix:continuation id="_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-c0_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><sup>(4)</sup></td><td style="text-align: justify"><ix:footnote id="ix_5_footnote" xml:lang="en-US">These values are not applicable because <span style="-sec-ix-hidden: hidden-fact-122">no</span> stock options were
granted during this period.</ix:footnote></td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Common Stock Rights Plan</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In September of 1995, our Board of Directors adopted
a Common Stock Rights Plan (the &#8220;Rights Plan&#8221;) and declared a dividend of one common share purchase right (a &#8220;Right&#8221;)
for each of the then outstanding shares of the common stock of the Company. Each Right entitles the registered holder to purchase from
the Company one share of common stock at an initial purchase price of $<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" scale="0" unitRef="usdPershares" id="ixv-14610">70.00</ix:nonFraction> per share, subject to adjustment. The description and terms
of the Rights are set forth in a Rights Agreement between the Company and Equiniti Trust Company, LLC, as Rights Agent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" name="iccc:ExercisableAndTransferableDescription" id="ixv-14611">The Rights (as amended) become exercisable and transferable
apart from the common stock upon the earlier of i) 10 days following a public announcement that a person or group (Acquiring Person) has,
without the prior consent of the Continuing Directors (as such term is defined in the Rights Agreement), acquired beneficial ownership
of 20% or more of the outstanding common stock or ii) 10 days following commencement of a tender offer or exchange offer the consummation
of which would result in ownership by a person or group of 20% or more of the outstanding common stock (the earlier of such dates being
called the Distribution Date).</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Upon the Distribution Date, the holder of each Right
not owned by the Acquiring Person would be entitled to purchase common stock at a discount to the initial purchase price of $<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:InvestmentCompanyPurchasePremiumPerShare" scale="0" unitRef="usdPershares" id="ixv-14612">70.00</ix:nonFraction> per
share, effectively equal to one half of the market price of a share of common stock on the date the Acquiring Person becomes an Acquiring
Person. If, after the Distribution Date, the Company should consolidate or merge with any other entity and the Company were not the surviving
company, or, if the Company were the surviving company, all or part of the Company&#8217;s common stock were changed or exchanged into
the securities of any other entity, or if more than <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostChangeDueToSubsequentInterimMeasurementWeightedAverageExpectedLongTermRateOfReturnOnPlanAssets" scale="-2" unitRef="pure" id="ixv-14613">50</ix:nonFraction>% of the Company&#8217;s assets or earning power were sold, each Right would entitle
its holder to purchase, at the Rights&#8217; then-current purchase price, a number of shares of the acquiring company&#8217;s common stock
having a market value at that time equal to twice the Right&#8217;s exercise price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">At any time after a person or group becomes an Acquiring
Person and prior to the acquisition by such person or group of <ix:nonFraction contextRef="c221" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" scale="-2" unitRef="pure" id="ixv-14614">50</ix:nonFraction>% or more of the outstanding common stock, the Board of Directors of
the Company may exchange the Rights (other than Rights owned by such person or group which have become void), in whole or in part, at
an exchange ratio of one share of common stock per Right (subject to adjustment). At any time prior to 14 days following the date that
any person or group becomes an Acquiring Person (subject to extension by the Board of Directors), the Board of Directors of the Company
may redeem the then outstanding Rights in whole, but not in part, at a price of $<ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="iccc:RightToAcquirePerShare" scale="0" unitRef="usdPershares" id="ixv-14615">0.005</ix:nonFraction> per Right, subject to adjustment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Unaudited Financial Statements (continued)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation id="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">During the third quarter of 2011, our Board of
Directors voted to authorize an amendment to the Rights Plan to increase the ownership threshold for determining &#8220;Acquiring Person&#8221;
status to <ix:nonFraction contextRef="c105" decimals="2" format="ixt:num-dot-decimal" name="iccc:AcquiringPersonPercentage" scale="-2" unitRef="pure" id="ixv-14616">20</ix:nonFraction>%. During the second quarter of 2015, our Board of Directors also voted to authorize an amendment to remove a provision that
prevented a new group of directors elected following the emergence of an Acquiring Person (an owner of more than <ix:nonFraction contextRef="c106" decimals="2" format="ixt:num-dot-decimal" name="iccc:AcquiringPersonPercentage" scale="-2" unitRef="pure" id="ixv-14617">20</ix:nonFraction>% of our stock) from
controlling the Rights Plan by maintaining exclusive authority over the Rights Plan with pre-existing directors. We did this because such
provisions have come to be viewed with disfavor by Delaware courts. Each time that we made such amendments we entered into amendments
to the Rights Agreement with the Rights Agent reflecting such extensions, threshold increases or provision changes. No other changes have
been made to the terms of the Rights or the Rights Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">At various times over the years, our Board of
Directors, which has the authority to amend the Rights Plan, has voted to authorize amendments to the Rights Plan to extend the expiration
date of the Rights Plan. <ix:nonNumeric contextRef="c0" name="us-gaap:EmployeeStockOwnershipPlanESOPPlanDescription" id="ixv-14618">Our Board of Directors decided to seek an advisory vote by stockholders at the Annual Meeting of Stockholders
held in June of 2022, as to whether to extend the Rights Plan by one year to September 19, 2023. Of the votes actually cast on this proposal,
65% voted in favor, 32% voted against and 3% abstained. On the basis of this vote, our Board of Directors voted to extend the Rights Plan
by one year to September 19, 2023. Our Board of Directors decided to seek another advisory vote by stockholders at the Annual Meeting
of Stockholders held in June of 2023, as to whether to extend the Rights Plan by another year to September 19, 2024. Of the votes actually
cast on this proposal, 65.10% voted in favor, 34.60% voted against and 0.30% abstained. On the basis of this vote, our Board of Directors
voted to extend the Rights Plan by one year to September 19, 2024. Recognizing that there might be a substantial number of broker non-votes,
our Board of Directors disclosed that it would be guided by the votes actually cast on these proposals in deciding whether to extend the
expiration date of such plan by one year.</ix:nonNumeric> Our Board of Directors determined not to further extend the Rights Plan because these plans
are generally considered not to be stockholder friendly. With no further extension, the Rights Plan expired as of September 19, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Authorized Common Stock</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">At the June 14, 2018 Annual Meeting of Stockholders,
our stockholders voted to approve an amendment to our Certificate of Incorporation to increase the number of shares of common stock authorized
for issuance from <ix:nonFraction contextRef="c222" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-14619">8,000,000</ix:nonFraction> to <ix:nonFraction contextRef="c223" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-14620">11,000,000</ix:nonFraction>. At the June 10, 2020 Annual Meeting of Stockholders, our stockholders voted to approve an amendment
to our Certificate of Incorporation to increase the number of shares of common stock authorized for issuance from <ix:nonFraction contextRef="c224" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-14621">11,000,000</ix:nonFraction> to <ix:nonFraction contextRef="c225" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-14622">15,000,000</ix:nonFraction>.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_RevenueFromContractWithCustomerTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="ixv-6466"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>14. REVENUE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
primarily offer the <b>First Defense</b></span><b><span style="font-family: Symbol"><sup>&#210;</sup></span></b> <span style="font-family: Times New Roman, Times, Serif">product
line to dairy and beef producers to prevent scours in newborn calves. Generally, our products are promoted to veterinarians as well as
dairy and beef producers by our sales team and then sold through distributors. Our primary market is North America. We do sell into select
international regions and may expand this international reach in the future. There were no material changes between the allocation and
timing of revenue recognition during the three-month or nine-month periods ended September 30, 2024 or 2023. We do not have any contract
assets for which we have satisfied the performance obligations, but do not yet have the right to bill for, or contract liabilities such
as customer advances. All trade receivables on our balance sheet are from contracts with customers. We incur no material costs to obtain
contracts.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Unaudited Financial Statements (continued) </b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&#160;</p><div>

</div><ix:continuation id="_RevenueFromContractWithCustomerTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" continuedAt="_RevenueFromExternalCustomersByGeographicAreasTableTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="ixv-14623">The following table presents our product sales disaggregated
by geographic area:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&#160;</p>

<ix:continuation id="_RevenueFromExternalCustomersByGeographicAreasTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><b>&#160;</b></td><td style="white-space: nowrap; font-weight: normal; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="14" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"><b>During the Three-Month<br/>
 Periods
    Ended September 30,</b></td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: normal"><b>&#160;</b></td><td style="white-space: nowrap; font-weight: normal; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="14" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"><b>During the Nine-Month<br/>
 Periods
    Ended September 30,</b></td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: normal"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="font-weight: normal; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"><b>2024</b></td><td style="padding-bottom: 1.5pt; font-weight: normal"><b>&#160;</b></td><td style="font-weight: normal; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"><b>%</b></td><td style="padding-bottom: 1.5pt; font-weight: normal"><b>&#160;</b></td><td style="font-weight: normal; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"><b>2023</b></td><td style="padding-bottom: 1.5pt; font-weight: normal"><b>&#160;</b></td><td style="font-weight: normal; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"><b>%</b></td><td style="padding-bottom: 1.5pt; font-weight: normal"><b>&#160;</b></td><td style="font-weight: normal; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"><b>2024</b></td><td style="padding-bottom: 1.5pt; font-weight: normal"><b>&#160;</b></td><td style="font-weight: normal; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"><b>%</b></td><td style="padding-bottom: 1.5pt; font-weight: normal"><b>&#160;</b></td><td style="font-weight: normal; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"><b>2023</b></td><td style="padding-bottom: 1.5pt; font-weight: normal"><b>&#160;</b></td><td style="font-weight: normal; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"><b>%</b></td><td style="padding-bottom: 1.5pt; font-weight: normal"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; text-align: left; text-indent: -10pt; padding-left: 10pt">United States</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c239" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14624">5,216,401</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c239" decimals="2" format="ixt:num-dot-decimal" name="iccc:RevenueSalesObligationPercentage" scale="-2" unitRef="pure" id="ixv-14625">87</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c240" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14626">4,923,265</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c240" decimals="2" format="ixt:num-dot-decimal" name="iccc:RevenueSalesObligationPercentage" scale="-2" unitRef="pure" id="ixv-14627">91</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c241" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14628">16,449,178</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c241" decimals="2" format="ixt:num-dot-decimal" name="iccc:RevenueSalesObligationPercentage" scale="-2" unitRef="pure" id="ixv-14629">88</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c242" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14630">11,173,686</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c242" decimals="2" format="ixt:num-dot-decimal" name="iccc:RevenueSalesObligationPercentage" scale="-2" unitRef="pure" id="ixv-14631">90</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c243" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14632">795,172</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c243" decimals="2" format="ixt:num-dot-decimal" name="iccc:RevenueSalesObligationPercentage" scale="-2" unitRef="pure" id="ixv-14633">13</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c244" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14634">473,235</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c244" decimals="2" format="ixt:num-dot-decimal" name="iccc:RevenueSalesObligationPercentage" scale="-2" unitRef="pure" id="ixv-14635">9</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c245" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14636">2,292,862</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c245" decimals="2" format="ixt:num-dot-decimal" name="iccc:RevenueSalesObligationPercentage" scale="-2" unitRef="pure" id="ixv-14637">12</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c246" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14638">1,202,022</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c246" decimals="2" format="ixt:num-dot-decimal" name="iccc:RevenueSalesObligationPercentage" scale="-2" unitRef="pure" id="ixv-14639">10</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Total Product Sales</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14640">6,011,573</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="iccc:RevenueSalesObligationPercentage" scale="-2" unitRef="pure" id="ixv-14641">100</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14642">5,396,500</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="iccc:RevenueSalesObligationPercentage" scale="-2" unitRef="pure" id="ixv-14643">100</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14644">18,742,040</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="iccc:RevenueSalesObligationPercentage" scale="-2" unitRef="pure" id="ixv-14645">100</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14646">12,375,708</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="iccc:RevenueSalesObligationPercentage" scale="-2" unitRef="pure" id="ixv-14647">100</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in"><ix:nonNumeric contextRef="c0" continuedAt="_DisaggregationOfRevenueTableTextBlock-c0_cont_1" escape="true" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="ixv-14648">The following table presents our product sales disaggregated
by major product category:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&#160;</p>

<ix:continuation id="_DisaggregationOfRevenueTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">During the Three-Month<br/> Periods Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">During the Nine-Month<br/> Periods Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt"><b>First
    Defense<span style="font-family: Times New Roman, Times, Serif"><sup>&#174;</sup> </span></b><span style="font-family: Times New Roman, Times, Serif"><span style="font-style: normal; font-weight: normal">product
    line</span></span></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c247" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14649">5,951,344</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c248" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" unitRef="pure" id="ixv-14650">99</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c249" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14651">5,360,063</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c250" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" unitRef="pure" id="ixv-14652">99</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c251" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14653">18,602,053</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c248" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" unitRef="pure" id="ixv-14654">99</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c252" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14655">12,253,555</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c250" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" unitRef="pure" id="ixv-14656">99</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Other animal health</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c253" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14657">60,229</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c254" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" unitRef="pure" id="ixv-14658">1</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c255" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14659">36,437</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c256" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" unitRef="pure" id="ixv-14660">1</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c257" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14661">139,987</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c254" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" unitRef="pure" id="ixv-14662">1</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c258" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14663">122,153</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c256" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" unitRef="pure" id="ixv-14664">1</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt">Total Product Sales</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14665">6,011,573</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" unitRef="pure" id="ixv-14666">100</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14667">5,396,500</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c33" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" unitRef="pure" id="ixv-14668">100</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14669">18,742,040</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" unitRef="pure" id="ixv-14670">100</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14671">12,375,708</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c33" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" unitRef="pure" id="ixv-14672">100</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table></ix:continuation></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock" id="ixv-6826"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>15. OTHER EXPENSES, NET</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="ixv-14673">Other expenses net, consisted of the following:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock-c0_cont_2" id="_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>During the Three-Month  <br/>
Periods Ended September 30,</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>During the Nine-Month <br/>
Periods Ended September 30,</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest expense<sup>(1)</sup></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" id="ix_24_fact" name="us-gaap:InterestExpense" scale="0" unitRef="usd">144,141</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" id="ix_25_fact" name="us-gaap:InterestExpense" scale="0" unitRef="usd">144,616</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" id="ix_26_fact" name="us-gaap:InterestExpense" scale="0" unitRef="usd">432,529</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" id="ix_27_fact" name="us-gaap:InterestExpense" scale="0" unitRef="usd">323,177</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Loss (gain) on disposal of property, plant and equipment</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">&#8212;</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDispositionOfAssets" scale="0" unitRef="usd" id="ixv-14678">68</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDispositionOfAssets" scale="0" sign="-" unitRef="usd" id="ixv-14679">14,557</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDispositionOfAssets" scale="0" sign="-" unitRef="usd" id="ixv-14680">8,099</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Interest income</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeOther" scale="0" unitRef="usd" id="ixv-14681">18,685</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeOther" scale="0" unitRef="usd" id="ixv-14682">23,696</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeOther" scale="0" unitRef="usd" id="ixv-14683">41,476</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeOther" scale="0" unitRef="usd" id="ixv-14684">79,134</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insurance recoveries<sup>(2)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">&#8212;</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" id="ix_28_fact" name="us-gaap:InsuranceRecoveries" scale="0" unitRef="usd">365,127</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">&#8212;</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" id="ix_29_fact" name="us-gaap:InsuranceRecoveries" scale="0" unitRef="usd">365,127</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Income - other</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">&#8212;</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-127">&#8212;</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-128">&#8212;</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherIncome" scale="0" unitRef="usd" id="ixv-14687">107</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Other expenses (income), net</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-14688">125,456</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" unitRef="usd" id="ixv-14689">244,275</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-14690">405,610</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" unitRef="usd" id="ixv-14691">113,092</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><sup>&#160;</sup></p>

<ix:continuation continuedAt="_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock-c0_cont_3" id="_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><sup>(1)</sup></td><td style="text-align: left"><ix:footnote id="ix_6_footnote" xml:lang="en-US">Interest expense includes amortization of debt issuance and
debt discount costs of $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="0" unitRef="usd" id="ixv-14693">10,805</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="0" unitRef="usd" id="ixv-14694">8,687</ix:nonFraction> during the three-month periods ended September 30, 2024 or 2023, respectively, and $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="0" unitRef="usd" id="ixv-14695">31,859</ix:nonFraction>
and $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="0" unitRef="usd" id="ixv-14696">12,525</ix:nonFraction> during the nine-month periods ended September 30, 2024 and 2023, respectively.</ix:footnote></td>
</tr></table></ix:continuation>

<ix:continuation id="_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0in"/><td style="width: 0.25in; text-align: left"><sup>(2)</sup></td><td style="text-align: left"><ix:footnote id="ix_7_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
income from insurance recoveries resulted from claim benefits paid to us under our business interruption policy related to product contamination
losses and a recovery from a vendor&#8217;s policy related to an equipment malfunction.</span></ix:footnote></td>
</tr></table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" id="ixv-6999"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>16. INCOME TAXES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our income tax expense aggregated $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-14697">1,340</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-14698">229</ix:nonFraction>
(amounting to less than <ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther" scale="-2" unitRef="pure" id="ixv-14699">1</ix:nonFraction>% of our loss before income taxes) during the three-month periods ended September 30, 2024 and 2023, respectively,
and $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-14700">4,020</ix:nonFraction> and $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-14701">3,279</ix:nonFraction> (amounting to less than <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther" scale="-2" unitRef="pure" id="ixv-14702">1</ix:nonFraction>% of our loss before income taxes) during the nine-month periods ended September 30, 2024
and 2023, respectively. As of December 31, 2023, we had federal net operating loss carryforwards of $<ix:nonFraction contextRef="c259" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" unitRef="usd" id="ixv-14703">17,759,519</ix:nonFraction> of which $<ix:nonFraction contextRef="c259" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" scale="0" unitRef="usd" id="ixv-14704">16,047,612</ix:nonFraction> do
not expire and of which $<ix:nonFraction contextRef="c259" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="0" unitRef="usd" id="ixv-14705">1,711,907</ix:nonFraction> <ix:nonNumeric contextRef="c260" name="us-gaap:TaxCreditCarryforwardDescription" id="ixv-14706">expire in 2034 through 2037</ix:nonNumeric> (if not utilized before then) and state net operating loss carryforwards
of $<ix:nonFraction contextRef="c261" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="0" unitRef="usd" id="ixv-14707">4,681,644</ix:nonFraction> that <ix:nonNumeric contextRef="c262" name="us-gaap:TaxCreditCarryforwardDescription" id="ixv-14708">expire in 2037 through 2038</ix:nonNumeric> (if not utilized before then). Additionally, we had federal general business tax credit
carryforwards of $<ix:nonFraction contextRef="c263" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="0" unitRef="usd" id="ixv-14709">726,474</ix:nonFraction> that <ix:nonNumeric contextRef="c264" name="us-gaap:TaxCreditCarryforwardDescription" id="ixv-14710">expire in 2028 through 2044</ix:nonNumeric> (if not utilized before then) and state tax credit carryforwards of $<ix:nonFraction contextRef="c265" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="0" unitRef="usd" id="ixv-14711">981,604</ix:nonFraction>
that <ix:nonNumeric contextRef="c266" name="us-gaap:TaxCreditCarryforwardDescription" id="ixv-14712">expire in 2024 through 2042</ix:nonNumeric> (if not utilized before then).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The provision for income taxes is determined using
the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the estimated future tax
effects of temporary differences between book and tax treatment of assets and liabilities and carryforwards to the extent they are realizable.
During the second quarter of 2018, we assessed our historical and near-term future profitability and recorded $<ix:nonFraction contextRef="c267" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeTaxExpense" scale="0" unitRef="usd" id="ixv-14713">563,252</ix:nonFraction> in non-cash income
tax expense to create a full valuation allowance against our net deferred tax assets (which consist largely of net operating loss carryforwards
and federal and state credits) based on applicable accounting standards and practices. At that time, we had incurred a net loss for six
consecutive quarters, had not been profitable on a year-to-date basis since the nine-month period ended September 30, 2017 and projected
additional net losses for some period going forward before returning to profitability. Should future profitability be realized at an adequate
level, we would be able to release this valuation allowance (resulting in a non-cash income tax benefit) and realize these deferred tax
assets before they expire. We will continue to assess the need for the valuation allowance at each quarter and, in the event that actual
results differ from these estimates, or we adjust these estimates in future periods, we may need to adjust our valuation allowance. Currently,
we adjust the valuation allowance at the end of each quarter to reduce the value of our deferred tax assets to <ix:nonFraction contextRef="c2" decimals="0" format="ixt:fixed-zero" name="us-gaap:DeferredTaxAssetsNet" scale="0" unitRef="usd" id="ixv-14714">zero</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Unaudited Financial Statements (continued) </b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation id="_IncomeTaxDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Net operating loss carryforwards, credits, and other
tax attributes are subject to review and possible adjustment by the Internal Revenue Service. Section 382 of the Internal Revenue Code
contains provisions that could place annual limitations on the future utilization of net operating loss carryforwards and credits in the
event of a change in ownership of the Company, as defined.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We file income tax returns in the U.S. federal jurisdiction
and several state jurisdictions. We currently have no tax examinations in progress. We also have not paid additional taxes, interest or
penalties as a result of tax examinations nor do we have any unrecognized tax benefits for any of the periods in the accompanying unaudited
financial statements.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SegmentReportingDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:SegmentReportingDisclosureTextBlock" id="ixv-7037"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>17. SEGMENT INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our business operations (being the development,
manufacture and sale of products that improve the health and productivity of dairy and beef cattle) are described in Note 1. Pursuant
to Codification Topic 280, <i>Segment Reporting</i>, we operate in the following <ix:nonFraction contextRef="c0" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" unitRef="pure" id="ixv-14715">two</ix:nonFraction> reportable business segments: i) Scours and ii) Mastitis.
The Scours segment consists of the <b>First Defense<sup>&#174;</sup></b> product line. The core technology underlying the Scours segment
is focused on polyclonal antibodies. The Mastitis segment includes our products, <b>CMT </b>and <b>Re-Tain<sup>&#174;</sup></b>. <b>Re-Tain<sup>&#174;
</sup></b>is projected to be the driver of this segment when approved for sale. The core technology underlying the Mastitis segment is
focused on a bacteriocin called Nisin. The category we define as &#8220;Other&#8221; includes unallocated administrative and overhead
expenses and other products. The significant accounting policies of these segments are described in Note 2. Product sales are the primary
factor we use in determining our reportable segments. The governing regulatory authority (Center for Veterinary Biologics, U.S. Department
of Agriculture for <b>First Defense<sup>&#174;</sup></b> or Center for Veterinary Medicine, U.S. Food and Drug Administration for <b>Re-Tain<sup>&#174;</sup></b>)
is also a factor in determining our reportable segments. Management monitors and evaluates segment performance from sales to net operating
income (loss) closely. We are not organized by geographic region. No segments have been aggregated. The revenues and expenses allocated
to each segment are in some cases direct and in other cases involve reasonable and consistent estimations by management. Each operating
segment is defined as the component of our business for which financial information is available and evaluated regularly by our chief
operating decision-maker in deciding how to allocate resources and in assessing performance. Our chief operating decision-maker is our
President and CEO.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfSegmentReportingInformationBySegmentTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="ixv-7055"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">During the Three-Month <br/>
Period Ended
    September 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Scours</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Mastitis</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Other</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">Product sales</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c268" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14716">5,951,344</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c269" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14717">60,229</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14718">6,011,573</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Costs of goods sold</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c268" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-14719">4,364,950</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c269" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-14720">63,069</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-14721">4,428,019</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt">Gross margin</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c268" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-14722">1,586,394</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c269" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" sign="-" unitRef="usd" id="ixv-14723">2,840</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-14724">1,583,554</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Product development expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c268" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-14725">59,140</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c269" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-14726">690,052</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c270" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-14727">36,944</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-14728">786,136</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Sales and marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c268" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="0" unitRef="usd" id="ixv-14729">699,584</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c269" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="0" unitRef="usd" id="ixv-14730">144,461</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="0" unitRef="usd" id="ixv-14731">844,045</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt">Administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-133">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-134">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c270" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-14732">528,267</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-14733">528,267</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c268" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-14734">758,724</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c269" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-14735">834,513</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c270" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-14736">565,211</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-14737">2,158,448</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt">NET OPERATING INCOME (LOSS)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c268" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" unitRef="usd" id="ixv-14738">827,670</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c269" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14739">837,353</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c270" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14740">565,211</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14741">574,894</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="_ScheduleOfSegmentReportingInformationBySegmentTextBlock-c0_cont_2" id="_ScheduleOfSegmentReportingInformationBySegmentTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>During the Three-Month <br/>
Period Ended
                                                                                                                                                                                    September 30, 2023</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Scours</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Mastitis</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Other</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">Product sales</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c271" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14742">5,360,063</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c272" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14743">36,437</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-135">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14744">5,396,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Costs of goods sold</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c271" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-14745">4,095,164</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c272" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-14746">34,455</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-136">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-14747">4,129,619</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt">Gross margin</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c271" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-14748">1,264,899</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c272" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-14749">1,982</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-137">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-14750">1,266,881</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Product development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-138">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c272" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-14751">1,082,346</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c273" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-14752">36,143</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-14753">1,118,489</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Sales and marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c271" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="0" unitRef="usd" id="ixv-14754">641,682</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c272" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="0" unitRef="usd" id="ixv-14755">175,804</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-139">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="0" unitRef="usd" id="ixv-14756">817,486</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt">Administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-140">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-141">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c273" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-14757">514,952</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-14758">514,952</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 20.2pt">Operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c271" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-14759">641,682</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c272" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-14760">1,258,150</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c273" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-14761">551,095</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-14762">2,450,927</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt">NET OPERATING INCOME (LOSS)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c271" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" unitRef="usd" id="ixv-14763">623,217</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c272" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14764">1,256,168</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c273" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14765">551,095</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14766">1,184,046</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Unaudited Financial Statements (continued) </b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_SegmentReportingDisclosureTextBlock-c0_cont_2" id="_SegmentReportingDisclosureTextBlock-c0_cont_1"><ix:continuation continuedAt="_ScheduleOfSegmentReportingInformationBySegmentTextBlock-c0_cont_3" id="_ScheduleOfSegmentReportingInformationBySegmentTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Scours</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Mastitis</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Other</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -10pt; padding-left: 10pt">Total Assets as of September 30, 2024</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c274" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-14767">23,672,583</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c275" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-14768">16,798,955</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c276" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-14769">3,977,335</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-14770">44,448,873</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">Total Assets as of September 30, 2023</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c277" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-14771">24,119,683</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c278" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-14772">18,132,922</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c279" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-14773">2,292,417</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c33" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-14774">44,545,022</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Depreciation and amortization expense during the three-month period ended September 30, 2024</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c268" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostDepreciationAmortizationAndDepletion" scale="0" unitRef="usd" id="ixv-14775">346,430</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c269" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostDepreciationAmortizationAndDepletion" scale="0" unitRef="usd" id="ixv-14776">319,815</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c270" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostDepreciationAmortizationAndDepletion" scale="0" unitRef="usd" id="ixv-14777">19,682</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostDepreciationAmortizationAndDepletion" scale="0" unitRef="usd" id="ixv-14778">685,927</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Depreciation and amortization expense during the three-month period ended September 30, 2023</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c271" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostDepreciationAmortizationAndDepletion" scale="0" unitRef="usd" id="ixv-14779">355,673</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c272" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostDepreciationAmortizationAndDepletion" scale="0" unitRef="usd" id="ixv-14780">328,381</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c273" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostDepreciationAmortizationAndDepletion" scale="0" unitRef="usd" id="ixv-14781">25,044</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostDepreciationAmortizationAndDepletion" scale="0" unitRef="usd" id="ixv-14782">709,098</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt">Capital Expenditures during the three-month period ended September 30, 2024</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c268" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="0" unitRef="usd" id="ixv-14783">87,286</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c269" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="0" unitRef="usd" id="ixv-14784">1,126</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-142">&#8212;</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="0" unitRef="usd" id="ixv-14785">88,412</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt">Capital Expenditures during the three-month period ended September 30, 2023</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c271" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="0" unitRef="usd" id="ixv-14786">341,386</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c272" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="0" unitRef="usd" id="ixv-14787">79,129</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-143">&#8212;</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="0" unitRef="usd" id="ixv-14788">420,515</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="_ScheduleOfSegmentReportingInformationBySegmentTextBlock-c0_cont_4" id="_ScheduleOfSegmentReportingInformationBySegmentTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">During the Nine-Month<br/>
 Period Ended
    September 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Scours</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Mastitis</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Other</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">Product sales</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c280" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14789">18,602,054</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c281" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14790">139,986</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-144">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14791">18,742,040</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Costs of goods sold</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c280" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-14792">13,487,348</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c281" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-14793">145,294</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-145">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-14794">13,632,642</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt">Gross margin</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c280" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-14795">5,114,706</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c281" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" sign="-" unitRef="usd" id="ixv-14796">5,308</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-146">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-14797">5,109,398</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Product development expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c280" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-14798">154,233</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c281" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-14799">2,821,525</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c282" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-14800">103,431</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-14801">3,079,189</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Sales and marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c280" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="0" unitRef="usd" id="ixv-14802">2,224,836</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c281" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="0" unitRef="usd" id="ixv-14803">405,089</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-147">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="0" unitRef="usd" id="ixv-14804">2,629,925</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt">Administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-148">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-149">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c282" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-14805">1,661,838</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-14806">1,661,838</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10.1pt">Operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c280" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-14807">2,379,069</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c281" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-14808">3,226,614</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c282" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-14809">1,765,269</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-14810">7,370,952</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt">NET OPERATING INCOME (LOSS)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c280" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" unitRef="usd" id="ixv-14811">2,735,637</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c281" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14812">3,231,922</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c282" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14813">1,765,269</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14814">2,261,554</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="_ScheduleOfSegmentReportingInformationBySegmentTextBlock-c0_cont_5" id="_ScheduleOfSegmentReportingInformationBySegmentTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>During the Nine-Month<br/>
 Period Ended
                                                                                                                                                                                    September 30, 2023</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Scours</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Mastitis</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Other</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">Product sales</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c283" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14815">12,253,555</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c284" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14816">122,153</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-150">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14817">12,375,708</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Costs of goods sold</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c283" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-14818">9,652,292</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c284" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-14819">111,872</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-151">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-14820">9,764,164</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt">Gross margin</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c283" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-14821">2,601,263</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c284" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-14822">10,281</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-152">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-14823">2,611,544</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Product development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c283" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-14824">2,543</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c284" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-14825">3,220,075</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c285" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-14826">105,779</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-14827">3,328,397</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Sales and marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c283" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="0" unitRef="usd" id="ixv-14828">1,890,404</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c284" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="0" unitRef="usd" id="ixv-14829">526,297</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-153">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="0" unitRef="usd" id="ixv-14830">2,416,701</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt">Administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-154">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-155">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c285" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-14831">1,611,026</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-14832">1,611,026</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 20.2pt">Operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c283" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-14833">1,892,947</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c284" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-14834">3,746,372</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c285" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-14835">1,716,805</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-14836">7,356,124</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt">NET OPERATING INCOME (LOSS)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c283" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" unitRef="usd" id="ixv-14837">708,316</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c284" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14838">3,736,091</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c285" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14839">1,716,805</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14840">4,744,580</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_ScheduleOfSegmentReportingInformationBySegmentTextBlock-c0_cont_6" id="_ScheduleOfSegmentReportingInformationBySegmentTextBlock-c0_cont_5"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Scours</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Mastitis</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Other</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -10pt; padding-left: 10pt">Total Assets as of September 30, 2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c274" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-14841">23,672,583</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c275" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-14842">16,798,955</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c276" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-14843">3,977,335</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-14844">44,448,873</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">Total Assets as of September 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c277" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-14845">24,119,683</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c278" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-14846">18,132,922</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c279" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-14847">2,292,417</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c33" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-14848">44,545,022</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Depreciation and amortization expense during the nine-month period ended September 30, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c280" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostDepreciationAmortizationAndDepletion" scale="0" unitRef="usd" id="ixv-14849">1,027,711</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c281" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostDepreciationAmortizationAndDepletion" scale="0" unitRef="usd" id="ixv-14850">958,260</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c282" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostDepreciationAmortizationAndDepletion" scale="0" unitRef="usd" id="ixv-14851">59,221</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostDepreciationAmortizationAndDepletion" scale="0" unitRef="usd" id="ixv-14852">2,045,192</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Depreciation and amortization expense during the nine-month period ended September 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c283" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostDepreciationAmortizationAndDepletion" scale="0" unitRef="usd" id="ixv-14853">1,020,909</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c284" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostDepreciationAmortizationAndDepletion" scale="0" unitRef="usd" id="ixv-14854">969,666</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c285" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostDepreciationAmortizationAndDepletion" scale="0" unitRef="usd" id="ixv-14855">64,066</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostDepreciationAmortizationAndDepletion" scale="0" unitRef="usd" id="ixv-14856">2,054,641</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt">Capital Expenditures during the nine-month period ended September 30, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c280" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="0" unitRef="usd" id="ixv-14857">235,600</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c281" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="0" unitRef="usd" id="ixv-14858">33,909</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-156">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="0" unitRef="usd" id="ixv-14859">269,509</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt">Capital Expenditures during the nine-month period ended September 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c283" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="0" unitRef="usd" id="ixv-14860">1,038,033</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c284" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="0" unitRef="usd" id="ixv-14861">773,136</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-157">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="0" unitRef="usd" id="ixv-14862">1,811,169</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>



</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Unaudited Financial Statements (continued) </b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_SegmentReportingDisclosureTextBlock-c0_cont_2"><ix:continuation continuedAt="_ScheduleOfSegmentReportingInformationBySegmentTextBlock-c0_cont_7" id="_ScheduleOfSegmentReportingInformationBySegmentTextBlock-c0_cont_6"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">During the Year Ended December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Scours</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Mastitis</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Other</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">Product sales</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c286" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14863">17,293,933</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c287" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14864">177,736</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-158">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14865">17,471,669</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Costs of goods sold</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c286" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-14866">13,453,514</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c287" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-14867">148,871</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-159">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-14868">13,602,385</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt">Gross margin</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c286" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-14869">3,840,419</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c287" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-14870">28,865</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-160">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-14871">3,869,284</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Product development expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c286" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-14872">11,103</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c287" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-14873">4,242,329</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c288" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-14874">141,420</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-14875">4,394,852</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Sales and marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c286" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="0" unitRef="usd" id="ixv-14876">2,447,137</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c287" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="0" unitRef="usd" id="ixv-14877">641,078</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-161">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="0" unitRef="usd" id="ixv-14878">3,088,215</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt">Administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-162">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-163">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c288" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-14879">2,134,295</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-14880">2,134,295</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10.1pt">Operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c286" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-14881">2,458,240</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c287" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-14882">4,883,407</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c288" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-14883">2,275,715</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-14884">9,617,362</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt">NET OPERATING INCOME (LOSS)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c286" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" unitRef="usd" id="ixv-14885">1,382,179</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c287" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14886">4,854,542</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c288" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14887">2,275,715</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14888">5,748,078</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_ScheduleOfSegmentReportingInformationBySegmentTextBlock-c0_cont_8" id="_ScheduleOfSegmentReportingInformationBySegmentTextBlock-c0_cont_7"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>During the Year Ended December 31, 2022</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Scours</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Mastitis</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Other</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">Product sales</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c289" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14889">18,411,949</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c290" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14890">154,558</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c291" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14891">1,455</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c167" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14892">18,567,962</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Costs of goods sold</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c289" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-14893">10,754,189</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c290" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-14894">136,347</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c291" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-14895">28,647</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c167" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-14896">10,919,183</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt">Gross margin</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c289" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-14897">7,657,760</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c290" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-14898">18,211</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c291" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" sign="-" unitRef="usd" id="ixv-14899">27,192</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c167" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-14900">7,648,779</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Product development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c289" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-14901">66,346</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c290" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-14902">4,317,921</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c291" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-14903">109,605</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c167" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-14904">4,493,872</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Sales and marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c289" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="0" unitRef="usd" id="ixv-14905">1,871,926</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c290" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="0" unitRef="usd" id="ixv-14906">1,318,107</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-164">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c167" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="0" unitRef="usd" id="ixv-14907">3,190,033</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt">Administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-165">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-166">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c291" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-14908">2,263,817</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c167" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-14909">2,263,817</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 20.2pt">Operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c289" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-14910">1,938,272</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c290" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-14911">5,636,028</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c291" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-14912">2,373,422</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c167" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-14913">9,947,722</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt">NET OPERATING INCOME (LOSS)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c289" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" unitRef="usd" id="ixv-14914">5,719,488</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c290" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14915">5,617,817</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c291" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14916">2,400,614</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c167" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14917">2,298,943</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_ScheduleOfSegmentReportingInformationBySegmentTextBlock-c0_cont_8"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Scours</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Mastitis</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Other</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -10pt; padding-left: 10pt">Total Assets as of December 31, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c292" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-14918">24,735,413</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c293" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-14919">17,827,839</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c294" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-14920">1,244,850</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-14921">43,808,102</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">Total Assets as of December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c295" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-14922">20,539,523</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c296" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-14923">18,315,492</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c297" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-14924">6,005,634</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-14925">44,860,649</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Depreciation and amortization expense during the year ended December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c286" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostDepreciationAmortizationAndDepletion" scale="0" unitRef="usd" id="ixv-14926">1,365,988</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c287" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostDepreciationAmortizationAndDepletion" scale="0" unitRef="usd" id="ixv-14927">1,287,600</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c288" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostDepreciationAmortizationAndDepletion" scale="0" unitRef="usd" id="ixv-14928">86,032</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostDepreciationAmortizationAndDepletion" scale="0" unitRef="usd" id="ixv-14929">2,739,620</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Depreciation and amortization expense during the year ended December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c289" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostDepreciationAmortizationAndDepletion" scale="0" unitRef="usd" id="ixv-14930">1,169,011</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c290" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostDepreciationAmortizationAndDepletion" scale="0" unitRef="usd" id="ixv-14931">1,263,318</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c291" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostDepreciationAmortizationAndDepletion" scale="0" unitRef="usd" id="ixv-14932">62,912</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c167" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostDepreciationAmortizationAndDepletion" scale="0" unitRef="usd" id="ixv-14933">2,495,241</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Capital Expenditures during the year ended December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c286" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="0" unitRef="usd" id="ixv-14934">1,096,819</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c287" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="0" unitRef="usd" id="ixv-14935">795,694</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-167">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="0" unitRef="usd" id="ixv-14936">1,892,513</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Capital Expenditures during the year ended December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c289" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="0" unitRef="usd" id="ixv-14937">3,497,834</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c290" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="0" unitRef="usd" id="ixv-14938">429,988</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c291" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="0" unitRef="usd" id="ixv-14939">47,452</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c167" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="0" unitRef="usd" id="ixv-14940">3,975,274</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="ixv-8745"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>18. RELATED PARTY TRANSACTIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">David
S. Tomsche (Chair of our Board of Directors) is a controlling owner of Leedstone Inc., a domestic distributor of our products (the <b>First
Defense</b></span><b><span style="font-family: Symbol"><sup>&#210;</sup> </span></b><span style="font-family: Times New Roman, Times, Serif">product
line and <b>CMT</b>). His affiliated company purchased $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" scale="0" unitRef="usd" id="ixv-14941">390,322</ix:nonFraction> and $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" scale="0" unitRef="usd" id="ixv-14942">128,521</ix:nonFraction> of products from us during the nine-month periods ended
September 30, 2024 and 2023, respectively, all on terms consistent with those offered to other distributors of similar status. Our accounts
receivable (subject to standard and customary payment terms) due from this affiliated company aggregated $<ix:nonFraction contextRef="c73" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNet" scale="0" unitRef="usd" id="ixv-14943">35,364</ix:nonFraction> and $<ix:nonFraction contextRef="c74" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNet" scale="0" unitRef="usd" id="ixv-14944">42,507</ix:nonFraction> as of September
30, 2024 and December 31, 2023, respectively.</span></p></ix:nonNumeric><div>



</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="ixv-8761"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>19. EMPLOYEE BENEFITS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have a 401(k) savings plan (the Plan) in which
all employees completing one month of service with the Company are eligible to participate. Participants may contribute up to the maximum
amount allowed by the Internal Revenue Service. We currently match <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="iccc:EmployeesSalaryPercentage" scale="-2" unitRef="pure" id="ixv-14945">100</ix:nonFraction>% of the first <ix:nonFraction contextRef="c298" decimals="2" format="ixt:num-dot-decimal" name="iccc:EmployeesSalaryPercentage" scale="-2" unitRef="pure" id="ixv-14946">3</ix:nonFraction>% of each employee&#8217;s salary that is contributed
to the Plan and <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="iccc:EmployeesSalaryContributionPercentage" scale="-2" unitRef="pure" id="ixv-14947">50</ix:nonFraction>% of the next <ix:nonFraction contextRef="c299" decimals="2" format="ixt:num-dot-decimal" name="iccc:EmployeesSalaryContributionPercentage" scale="-2" unitRef="pure" id="ixv-14948">2</ix:nonFraction>% of each employee&#8217;s salary that is contributed to the Plan. Under this matching plan, we paid
$<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="0" unitRef="usd" id="ixv-14949">55,989</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="0" unitRef="usd" id="ixv-14950">50,126</ix:nonFraction> into the Plan for the three-month periods ended September 30, 2024 and 2023, respectively, and $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="0" unitRef="usd" id="ixv-14951">159,504</ix:nonFraction> and $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="0" unitRef="usd" id="ixv-14952">135,698</ix:nonFraction>
for the nine-month periods ended September 30, 2024 and 2023, respectively.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SubsequentEventsTextBlock" id="ixv-8770"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>20. SUBSEQUENT EVENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have evaluated subsequent events through the
time of filing on the date we have issued this Quarterly Report on Form 10-Q. Subsequent to September 30, 2024 and through October 30,
2024, we sold an additional <ix:nonFraction contextRef="c300" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-14953">78,492</ix:nonFraction> shares raising an additional $<ix:nonFraction contextRef="c300" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd" id="ixv-14954">289,719</ix:nonFraction> in gross proceeds pursuant to the at the market offering conducted
pursuant to the ATM Agreement. See Note 13. As of the time of filing, there were no other material, reportable subsequent events.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">ImmuCell
Corporation</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_008"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">ITEM
2 - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
focus on the two most critical stages of dairy productivity, those being the first 30 days of life and the first 30 days of lactation.
Our concentrated colostrum and purified Nisin technologies offer unique animal health solutions during these periods when immunity is
at its most vulnerable. Both of our product lines present immediate growth opportunities and, in the future, may potentially be applied
in the human health sector, alongside the animal health sector that we currently serve. The following discussion and analysis of our
financial condition and results of operations should be read together with our unaudited financial statements and the related notes and
other financial information included in this Quarterly Report on Form 10-Q (Quarterly Report). Some of the information contained in this
discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy
for our business, includes forward-looking statements that involve risks and uncertainties. One should review the Cautionary Note below
for a discussion of some of the important factors that could cause actual results to differ materially from the results, objectives or
expectations described in or implied by the forward-looking statements contained in the following discussion and analysis.</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>OUTLINE
TO ITEM 2 &#8211; MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>Cautionary
                                            Note Regarding Forward-Looking Statements</b></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>Liquidity
                                            and Capital Resources</b></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>Capital
                                            Expenditure Investments</b></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>Production
                                            Contamination Events</b></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>Results
                                            of Operations (Subsections a through i)</b></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>Critical
                                            Accounting Policies and Estimates</b></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Cautionary
Note Regarding Forward-Looking Statements (Safe Harbor Statement):</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">This
Quarterly Report contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act
of 1995, as amended. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current
facts and will often include words such as &#8220;expects&#8221;, &#8220;may&#8221;, &#8220;anticipates&#8221;, &#8220;aims&#8221;, &#8220;intends&#8221;,
&#8220;would&#8221;, &#8220;could&#8221;, &#8220;should&#8221;, &#8220;will&#8221;, &#8220;plans&#8221;, &#8220;believes&#8221;, &#8220;estimates&#8221;,
&#8220;targets&#8221;, &#8220;projects&#8221;, &#8220;forecasts&#8221;, &#8220;seeks&#8221; and similar words and expressions. Such statements
include, but are not limited to, any forward-looking statements relating to: our plans and strategies for our business; projections of
future financial or operational performance; the timing and outcome of pending or anticipated applications for regulatory approvals;
future demand for our products; the consequences of the COVID-19 pandemic, and their direct and indirect impacts on our production activities,
operating results and financial condition and on the customers and markets that we serve; the impact of Russia&#8217;s unprovoked military
invasion of Ukraine (and attack on its people) and the war in the Middle East on the world economy including inflation and the price
and availability of grain and oil; the impact of the global supply-chain disruptions on our ability to obtain, in a timely and cost-effective
fashion, all the supplies and components we need to produce our products; the impact of inflation and rising interest rates on our operating
expenses and financial results; the scope and timing of ongoing and future product development work and commercialization of our products;
future costs of product development efforts; the estimated prevalence rate of subclinical mastitis and producers&#8217; level of interest
in treating subclinical mastitis given the current economic and market conditions; the expected efficacy of new products; estimates about
the market size for our products; future market share of and revenue generated by current products and products still in development;
our ability to increase production output and reduce costs of goods sold per unit; the adequacy of our own manufacturing facilities or
those of third parties with which we have contractual relationships to meet demand for our products on a timely basis; the impacts of
backlogs on customer relationships; the efficacy, success and timeline to complete our contamination remediation efforts; the likelihood,
severity or impact of future contamination events; the anticipated costs of (or time to complete) planned expansions of our manufacturing
facilities and the adequacy of our funds available for these projects; the robustness of our manufacturing processes and related technical
issues; estimates about our production capacity, efficiency and yield; the salability of products currently held in inventory pending
regulatory approval; future regulatory requirements relating to our products; future expense ratios and margins; the efficacy of our
investments in our business; future compliance with bank debt covenants; anticipated changes in our manufacturing capabilities and efficiencies;
our effectiveness in competing against competitors within both our existing and our anticipated product markets; projections about depreciation
expense and its impact on income for book and tax return purposes; and any other statements that are not historical facts. These statements
are intended to provide management's current expectation of future events as of the date of this earnings release, are based on management's
estimates, projections, beliefs and assumptions as of the date hereof; and are not guarantees of future performance. Such statements
involve known and unknown risks and uncertainties that may cause the Company's actual results, financial or operational performance or
achievements to be materially different from those expressed or implied by these forward-looking statements, including, but not limited
to, those risks and uncertainties relating to: difficulties or delays in development, testing, regulatory approval, production and marketing
of our products (including the <b>First Defense<sup>&#174;</sup></b> product line and <b>Re-Tain<sup>&#174;</sup></b>), competition within
our anticipated product markets, customer acceptance of our new and existing products, product performance, alignment between our manufacturing
resources and product demand (including the consequences of backlogs), uncertainty associated with the timing and volume of customer
orders as we come out of a prolonged backlog, adverse impacts of supply chain disruptions on our operations and customer and supplier
relationships, commercial and operational risks relating to our current and planned expansion of production capacity, and other risks
and uncertainties detailed from time to time in filings we make with the Securities and Exchange Commission (SEC), including our Quarterly
Reports on Form 10-Q, our Annual Reports on Form 10-K and our Current Reports on Form 8-K. Such statements involve risks and uncertainties
and are based on our current expectations, but actual results may differ materially due to various factors, including the risk factors
summarized under <b>PART II: OTHER INFORMATION, ITEM 1A-RISK FACTORS</b> and uncertainties otherwise referred to in this Quarterly Report.
In addition, there can be no assurance that future risks, uncertainties or developments affecting us will be those that we anticipate.
We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether
as a result of new information, future developments or otherwise.</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation </b></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Liquidity
and Capital Resources</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-weight: normal">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-weight: normal">We
are fortunate to be experiencing strong customer demand for the </span><span style="font-family: Times New Roman, Times, Serif">First
Defense<sup>&#174;</sup> <span style="font-weight: normal">product line, but the significant investments in facilities, equipment and staffing
necessary to double our production capacity have been challenging. Despite delays in the installation of certain equipment, we completed
these capacity-expanding investments around the end of 2022. In late 2022, we began experiencing production contamination events that
became more frequent during 2023 and continued through April of 2024. In July of 2023, we secured $3 million in debt financing to help
offset some of the lost sales and gross margin resulting from the slowdown implemented to mitigate the contamination events. With newly
implemented controls in place, we now believe that we have successfully remediated the issues underlying these contamination events.
Our next challenge is to resume our past production yields and achieve our gross margin goals of 35% to 40%, in comparison to the 27%
that we recorded during the nine-month period ended September 30, 2024. We believe that by both remediating the contamination events
and optimizing the operation of the new equipment installed to increase production output, we can improve process yields beginning during
the fourth quarter of 2024 and into 2025. We do not see one &#8220;smoking gun&#8221; as the root cause to the contamination and yield
losses. We think the solution is more about optimizing and controlling critical process parameters and multiple production inputs and
process steps. Concurrently, we are reducing product development expenses as we await approval of </span>Re-Tain<sup>&#174; </sup><span style="font-weight: normal">by
the Center for Veterinary Medicine, U.S. Food and Drug Administration (FDA). After an investment of about 25 years and approximately
$50 million in the development of this technology, we are committed to seeing this product through to regulatory approval and our previously
disclosed limited distribution, controlled launch strategy (Controlled Launch). At the same time, we are also in the very early stages
of exploring potential strategic partnerships that could offset some of our product development expenses and enhance a mass-market launch
of </span>Re-Tain<sup>&#174;</sup><span style="font-weight: normal">. We have decided that some stockholder ownership dilution is a necessary
cost to incur in order to improve our cash position. To that end, our at the market offering pursuant to the At-The-Market Offering Agreement
(ATM Agreement) has contributed meaningfully to our capital needs during 2024, as we stabilize our production systems at a higher output
level.</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-weight: normal">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-weight: normal">Net
cash provided by operating activities was $361,000 during the nine-month period ended September 30, 2024 in contrast to net cash (used
for) operating activities of ($4) million during the nine-month period ended September 30, 2023. The $4.3 million improvement in net
cash provided by operating activities between the two nine-month periods was largely caused by the $2 million decrease in the net loss
and a $1.7 million swing from cash (used for) inventory build to an inventory reduction. Our inventory balance decreased by $351,000
to $7.5 million as of September 30, 2024 from $7.8 million as of December 31, 2023. Interest expense (excluding amortization of debt
issuance and debt discount costs) was $401,000 and $311,000 during the nine-month periods ended September 30, 2024 and 2023, respectively.
Our debt bears interest at fixed rates. The blended interest rate on the debt outstanding as of September 30, 2024 and December 31, 2023
was 4.51% per annum. We anticipate that interest expense (excluding amortization of debt issuance and debt discount costs) will be $524,000
and $452,000 during the years ending December 31, 2024 and 2025, respectively. Our total non-cash depreciation, amortization and stock-based
compensation expense was approximately $2.3 million during both of the nine-month periods ended September 30, 2024 and 2023. We anticipate
that depreciation expense (largely pertaining to </span><span style="font-family: Times New Roman, Times, Serif">Re-Tain<sup>&#174;</sup><span style="font-weight: normal">),
while not affecting our cash flows from operations, will be a significant factor in creating annual net operating losses until and unless
product sales increase sufficiently to offset these non-cash expenses. </span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Net
cash used for investing activities was $265,000 during the nine-month period ended September 30, 2024 in comparison to net cash used
for investing activities of $1.9 million during the nine-month period ended September 30, 2023 consisting primarily of cash spent to
fund the purchase of property, plant and equipment. To conserve cash at this time, we have deferred all large dollar capital expenditure
projects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Net
cash provided by financing activities was $2.7 million during the nine-month period ended September 30, 2024 in comparison to net cash
provided by financing activities of $2.1 million during the nine-month period ended September 30, 2023. We had aggregate debt outstanding
(net of debt issuance and debt discount costs) of approximately $11 million and $12 million as of September 30, 2024 and December 31,
2023, respectively. Debt principal repayments (excluding the line of credit) aggregated $1.1 million and $829,000 during the nine-month
periods ended September 30, 2024 and 2023, respectively. We anticipate that debt principal repayments will aggregate approximately $1.5
million during both of the years ending December 31, 2024 and 2025. During the first quarter of 2024, the availability of our $1 million
line of credit, which bears interest at the National Prime Rate per annum, was extended until September 11, 2025. No draw on our line
of credit was outstanding as of September 30, 2024 or December 31, 2023. Financing activities included a $3 million debt financing during
the nine-month period ended September 30, 2023. See Note 10 to the accompanying unaudited financial statements for more information about
our bank debt. During the second quarter of 2024, we entered into an ATM Agreement with Craig-Hallum Capital Group LLC, pursuant to which
we may offer and sell up to $11 million of shares of our common stock. As of October 30, 2024, we had sold 1,160,725 shares under the
at the market offering conducted pursuant to the ATM Agreement. Net proceeds through October 30, 2024 (net of approximately $152,000
in upfront legal, accounting and other fees and approximately $132,000 in sales commissions) were approximately $4,114,000. Gross proceeds
from these sales during the three-month periods ended June 30, 2024 and September 30, 2024 were approximately $418,000 and $3.7 million,
respectively. The ATM Agreement gives our board the flexibility to evaluate the potential uses of the proceeds while considering the
cost of dilution in real time. This funding has provided a very productive financial bridge for us to fund our operations, while we work
to improve our gross margin and reduce product development expenses. While the capital raised is not enough to fund larger capital expenditure
investments, such as further increasing <b>First Defense<sup>&#174;</sup></b> production capacity or building our own facility for the
aseptic filling services for <b>Re-Tain<sup>&#174;</sup></b>, it has allowed us to release funding for certain smaller and necessary capital
expenditures. Further, as we fill the order backlog, we will require additional capital to fund an anticipated increase in inventory
levels.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Based
on our best estimates and projections, we believe that our cash and cash equivalents, together with gross margin anticipated to be earned
from ongoing product sales will be sufficient to meet our currently planned working capital and capital expenditure requirements and
to finance our ongoing business operations for at least 12 months (which is the period of time required to be addressed for such purposes
by accounting disclosure standards) from the date of this filing. The table below summarizes the changes in selected key accounts (in
thousands, except for percentages):</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>As
    of</b></span> <br/>
September
    30,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>As of</b></span> <br/>
<b>December
    31,</b></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Increase</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b> 2023</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Amount</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>%</b></span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash and cash equivalents</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,809</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">979</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,830</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">289</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net working capital</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,422</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,272</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,149</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">30</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">44,449</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">43,808</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">641</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stockholders&#8217; equity</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">26,412</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">24,993</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,419</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Common shares outstanding<sup>(1)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,833</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,751</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,082</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">14</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
                                            </span><span style="font-family: Times New Roman, Times, Serif">were 661,000 and 618,500
                                            shares of common stock reserved for issuance for stock options that were outstanding as of
                                            September 30, 2024 and December 31, 2023, <span style="font-size: 10pt">respectively.</span></span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Capital
Expenditure Investments</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">During
the three-year period ended December 31, 2016, we invested the aggregate of $4.2 million to construct a 7,100 square foot facility addition
at 56 Evergreen Drive (<b>Building 56</b>) and related equipment (primarily Freeze-Dryer #2) and cold storage capacity increasing our
freeze-drying capacity by 100% and making other improvements to our liquid processing capacity, which increased our annual production
capacity (in terms of annual sales dollars) to approximately $16.5 million. When we describe the production capacity for the <b>First
Defense<sup>&#174;</sup></b> product line in this Quarterly Report, it should be noted that the actual value of this capacity varies based
on biological and process yields, product format mix, selling price and other factors. During the first quarter of 2016, we completed
this investment, which also included the construction and equipping of a pilot plant for small-scale Drug Substance (DS) production for
<b>Re-Tain<sup>&#174;</sup></b> within <b>Building 56</b>. After construction of the DS production facility for <b>Re-Tain<sup>&#174;</sup></b>
at 33 Caddie Lane (<b>Building 33)</b> was completed, this space was converted for use in the production of the gel tube formats of the
<b>First Defense<sup>&#174;</sup></b> product line. After renovations of our leased facility at 175 Industrial Way (<b>Building 175A)
</b>were completed during the second quarter of 2020, this space was converted to double our liquid processing capacity.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">During
the four-year period ended December 31, 2018, we invested the aggregate of $21.6 million to construct a DS production facility for <b>Re-Tain<sup>&#174;
</sup></b>at <b>Building 33</b>. During the fourth quarter of 2017, we completed construction of the DS production facility. We began
equipment installation during the third quarter of 2017, and we completed this installation during the third quarter of 2018. The total
cost of this investment for the DS production facility and related processing equipment was $20.8 million plus $331,000 for the land
and $472,000 for the acquisition of an adjacent 4,080 square foot warehouse facility at 14 Wedge Way (<b>Building 14)</b>, which will
be used for packing, shipping and cold storage of <b>Re-Tain<sup>&#174;</sup></b> and other warehousing needs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">During
2018, it became clear that demand for <b>Tri-Shield First Defense<sup>&#174;</sup></b> was outpacing production. In response to this increasing
demand, we began a series of investments during 2019 to increase our production capacity for the <b>First Defense<sup>&#174;</sup></b>
product line from approximately $16.5 million to an estimate of approximately $30 million per year (with an option to increase further
to approximately $40 million in the future). The primary purpose of the additional investment in <b>First Defense<sup>&#174;</sup></b>
is to fulfill the current backlog and materially reduce the risk of another order backlog. Operating at very close to 100% of available
capacity is not efficient or sustainable. Our objective is to be in position to operate without significant contaminations at the capacity
level we choose to cover sales with adequate buffer stock, which would allow more time for necessary preventative maintenance. We also
need to meet or exceed our production yield assumptions to succeed. Our production process is a very complicated one, which makes it
difficult to scale-up quickly. We remain deeply committed to continuing to supply <b>First Defense<sup>&#174; </sup></b>to the market
over the long term, despite the current short supply that we have been experiencing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
primary purpose of the additional investments in <b>Re-Tain<sup>&#174; </sup></b>is to bring the formulation and aseptic filling capabilities
for <b>Re-Tain<sup>&#174;</sup></b> Drug Product (DP) into available space in our DS facility in order to lessen or eliminate our reliance
on third-party DP manufacturing services as well as to build out warehouse space at <b>Building 14</b> for packing and shipping facilities
for <b>Re-Tain<sup>&#174;</sup></b>. We began initial installation of the filling equipment during the first quarter of 2022 and then
paused this installation work pending concurrence with the FDA pertaining to our third submission of the Chemistry, Manufacturing and
Controls (CMC) Technical Section, which is discussed in greater detail below.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
amount and timing of these additional investments in <b>First Defense<sup>&#174;</sup></b> and <b>Re-Tain<sup>&#174; </sup></b>that were
initiated during 2019 are detailed in the following table (in thousands):</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Paid
    During the</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>First
    Defense<sup>&#174;</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Re-Tain<sup>&#174;</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%"><span style="font-family: Times New Roman, Times, Serif">Year Ended December 31, 2019</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">279</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">538</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">574</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,391</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Year Ended December 31, 2020</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,938</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">581</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">554</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,073</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Year Ended December 31, 2021</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,633</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">976</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,609</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Year Ended December 31, 2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,498</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">430</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">47</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,975</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Year Ended December 31, 2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,097</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">796</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,893</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Nine-Month Period Ended September 30,
    2024</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">236</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">34</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">270</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Total Paid through September 30, 2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,681</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,355</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,175</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,211</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Estimate to Complete<sup>(1)</sup></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,792</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,022</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">24</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,838</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total Project Cost</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,473</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,377</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,199</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">20,049</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(1)</sup></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
investments of approximately $3.5 million of these funds to increase <b>First Defense<sup>&#174; </sup></b>production capacity from approximately
$30 million to $40 million per year and approximately $2 million to build an in-house aseptic filling facility for <b>Re-Tain<sup>&#174;
</sup></b>have been deferred for the time being, due to the loss in gross margin earned caused by the slowdown in production output necessary
to remediate certain contamination events. These figures are estimates for the work to be completed based on historic quotations and
are not based on current cost quotations or contracts that have been updated or adjusted to account for inflation, project scope change
and other factors.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
first phase of the additional investments in <b>First Defense<sup>&#174;</sup> </b>beginning in 2019 included significant renovations
to a 14,300 square foot leased facility at <b>Building 175A</b>, some facility modifications at <b>Building 56</b> and the necessary
production equipment (including Freeze-Dryer #3) to increase our liquid processing capacity by 100% and our freeze-drying capacity by
50%. This resulted in increasing the annual production capacity of the <b>First Defense<sup>&#174;</sup></b> product line (in terms of
annual sales dollars) from approximately $16.5 million to approximately $23 million. Renovations of <b>Building 175A</b> to enable this
expansion were completed during the second quarter of 2020. By moving our powder and gel filling and assembly operations from <b>Building
56</b> into this new space, we created space at <b>Building 56</b> for the installation of the expanded freeze-drying capacity. The new
facilities are built to contemporary current Good Manufacturing Practices (cGMP) standards with efficient material and people flows.
A site license approval for this new facility was issued by the Center for Veterinary Biologics, U.S. Department of Agriculture (USDA)
during the third quarter of 2020. During the second quarter of 2021, we completed the relocation of our gel formulation equipment from
<b>Building 56</b> to <b>Building 175A</b>, which created the space necessary to double our liquid processing capacity at <b>Building
56</b>. We obtained site license approval of the expanded freeze-drying capacity (Freeze-Dryer #3) at <b>Building 56</b> from the USDA
during the third quarter of 2021, and we obtained site license approval of the expanded liquid processing capacity at <b>Building 56
</b>from the USDA during the third quarter of 2022. This investment also included equipment and vehicle purchases necessary to expand
and improve our colostrum collection capabilities and logistics.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
second phase of the additional investments in <b>First Defense</b><sup>&#174; </sup>included the installation of Freeze-Dryer #4 to further
increase the estimated annual production capacity of the <b>First Defense</b><sup>&#174;</sup> product line (in terms of annual sales
dollars) by an additional 33% from approximately $23 million to approximately $30 million. As of July of 2022, we had completed almost
all of the facility expansion work and new equipment installations needed to increase our production capacity to almost $30 million per
year. However, the most critical piece of new equipment (being Freeze-Dryer #4) was delivered six months late by the fabricator. Regardless,
by the end of 2022, we had Freeze-Dryer #4 installed and approved for use by the USDA. At the same time, Freeze-Dryer #2 stopped operating
requiring a six-month repair and netting us back to three operating freeze dryers during the first half of 2023. As of July of 2023,
we were back to four operating freeze dryers. This investment also included equipment and facility modifications to scale-up and upgrade
our vaccine manufacturing capacity and improve our quality laboratories at <b>Building 56</b> as well as the installation of new equipment
to increase the throughput of our gel filling operations at <b>Building 175A</b>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
third phase of the additional investments in <b>First Defense<sup>&#174;</sup></b> involved the construction of an additional 15,400 square
feet of space adjacent to and connected to <b>Building 175A</b> at 175 Industrial Way (<b>Building 175B</b>) and new equipment to further
increase our estimated annual <b>First Defense<sup>&#174;</sup></b> production capacity from approximately $30 million to approximately
$40 million with options for further expansion. Given the long lead time required for investments like this, we initiated this project
by entering into a lease amendment during the third quarter of 2022 covering a to-be-constructed building shell for approximately $250,000
per year. Construction of the building shell by our landlord was substantially complete as of April 1, 2023, and rent payments commenced
as of August 1, 2023. We made this lease commitment because of the unique proximity of the land adjacent to our currently leased space
and the high level of demand for properties of this type in the Portland market. We did not want to risk losing this opportunity to others.
The anticipated benefits to us from this new lease include: i) space for the potential to install Freeze-Dryers #5, #6, #7 and #8 if
justified by market demand in the future, ii) improved space and quality for our powder milling operations by separating our upstream
processes (liquid processing) at <b>Building 56</b> from our clean downstream processes (milling, formulation, filling and packaging)
and iii) much needed additional warehouse space. We have been running our equipment and staff close to 100% of capacity in order to fill
the backlog of orders. One of our objectives is to create a more sustainable production schedule. Freeze-Dryer #5 is the key piece of
equipment required to allow us to increase our estimated annual production capacity to above $30 million. Based on past experience, we
are planning for approximately 18 months of lead time for fabrication, installation, qualification and implementation of Freeze-Dryer
#5. However, due to the loss in gross margin during 2023 caused by the slowdown in production output necessary to remediate the product
contamination events discussed below, we have decided to defer most of this investment, for the time being. Instead, we initiated the
initial steps of this project with a reduced budget of approximately $700,000 at <b>Building 175B</b> during the third quarter of 2023.
This work was completed during the first quarter of 2024, which provided additional warehousing space and allowed us to move all shipping
and receiving functions out of <b>Building 56</b> to create more space for liquid processing at <b>Building 56</b>. In consideration
for our landlord agreeing to pay for the cost of those certain tenant improvements and after two negotiated amendments, we are now obligated
to make additional rent payments of $20,000 per month through June of 2025 and a final additional rent payment of $248,743 in July of
2025. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b>Production
Contamination Events</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
our increased production capacity was coming online, a first product contamination event likely related to our incoming raw material
(that is sourced from many different cows at many different farms) was detected by standard in-process quality control testing around
the end of the third quarter of 2022. We took immediate steps to address the contamination, and production ran without issue during the
balance of the fourth quarter of 2022. Subsequently, as we began to operate at a higher level of capacity at the beginning of 2023, we
were forced to slow down production again to remediate a second contamination event also likely related to our incoming raw material.
We then ran for approximately six months without contamination and then experienced a smaller third contamination event in September
of 2023 impacting two lots of Work-in-Progress inventory likely related to our increased level of liquid processing. Although all of
the incoming material utilized in this production phase had passed quality control testing, the product failed the quality control tests
later in the production process. We experienced a fourth contamination event impacting three lots of Work-in-Process inventory during
the first three and a half months of 2024. New remediation steps implemented in response to this fourth event during the second half
of April of 2024 appear to be very successful so far because we have run without contamination since then and through the date of the
filing of this Quarterly Report. Throughout these contamination events, all product that was sold to market had passed final release
testing to meet USDA-required quality standards.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
we look back at these production contamination events, we believe that the root cause of the initial contaminations was associated with
rapid growth at the farms where we acquire our raw material. Having largely remediated that problem, we experienced additional contaminations
that we believe were largely caused by our rapidly increased production capacity. Our proprietary production process allows us to create
an effective product out of a non-aseptic starting raw material. This requires a careful monitoring of the tradeoff between the benefit
of adding more heat for longer periods of time to reduce bacterial load against the alternative benefit of less heat for shorter periods
of time to preserve more antibody content. Although using more heat could potentially reduce bacterial load, our yield is higher when
we use less heat. For example, we know that putting our Work-in-Process inventory through freeze/thaw cycles is not beneficial to yield
and increases the risk of contamination. One effective improvement we have implemented, where appropriate, is to lengthen the time of
a heat treatment step instead of running two shorter heat treatment steps separated by a freeze/thaw. As we continue to optimize this
critical process parameter, we believe we can significantly reduce the risk of further contaminations and improve our gross margin.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Although
these types of losses are expected to happen from time to time in the production of a biological product such as ours, we believe that
the sudden and large contamination events were related in several different ways to our efforts to increase production output. We also
believe we have mitigated the risk of reoccurrence of such losses through the implementation of certain new quality control steps and
manufacturing process and facility improvements. To meet our goals, we must run without significant equipment failures or contamination
losses, and we must improve our production yields.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
production contamination events and other production process losses experienced resulted in scrapped inventory valued as shown in the
following table (in thousands):</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Approximate
    Cost of <br/> Work-in-Process Scrap</b></span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Approximate
    Retail Value of<br/> Finished Goods<sup>(1)</sup></b></span></td>
    <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Year Ended December 31, 2022</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">589</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,193</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Year Ended December 31, 2023</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">527</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,487</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Nine-Month Period Ended September 30, 2023</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">463</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,175</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Nine-Month Period Ended September 30, 2024</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">369</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,599</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(1)</sup></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">This
                                            estimate approximates the retail value of this work-in-process inventory in the event that
                                            additional costs had been incurred to complete the production process to prepare it for sale
                                            utilizing the approximate product format mix and selling prices effective during the period.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
believe that we have moved past the contamination events that materially affected our output since late 2022 largely because we have
not experienced another contamination since the first half of April of 2024. However, we still have more work to do to catch up to product
demand. As we continue to optimize our investments to increase production capacity and to implement the corrective actions being taken
in response to these contamination events, we aspire to reach an annual theoretical maximum production capacity of approximately $30
million per year going forward. While we produced far less than we needed during 2023, we believe that our remediation efforts are allowing
us to steadily ramp back up to full production capacity. As we resume full production, our goal is to be able to produce at least $6
million or more worth of product per quarter, which would annualize to about 80% or more of our estimated $30 million annual production
capacity to balance production output with regularly scheduled preventative maintenance. Finished goods produced increased steadily from
approximately $3.3 million to $4 million and further to $5.3 million during the first, second and third quarters of 2023, respectively,
before dropping modestly to $5.1 million during the fourth quarter of 2023. We were able to increase finished goods production to $7.2
million during the first quarter of 2024, which annualizes to approximately $28.7 million. This level of production will remain our aspirational
goal, but we do not expect that it can be repeated or exceeded on a regular basis. During the second quarter of 2024, finished goods
production decreased to $5.5 million, which annualizes to approximately $22 million. During the third quarter of 2024, finished goods
production decreased modestly to $5.4 million, which annualizes to approximately $21.8 million. During the nine-month period ended September
30, 2024, finished goods production was approximately $18.1 million, which annualizes to approximately $24.2 million (or approximately
81% of $30 million). During the trailing twelve-month period ended September 30, 2024, finished goods production was approximately $23.2
million (or approximately 77% of $30 million).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
learnings from the remediation of the contamination events have improved our production processes going forward. We have implemented
several important improvements at the source farm level including more product and environmental testing, more training of farm staff
and better enforcement of our protocols. While we never release product to the market that does not pass our final quality control release
tests, we had allowed product to advance in the production process at risk, while the in-process quality control tests were being performed.
We no longer advance product to the next stage at risk before the complete in-process quality control test results are available. While
this does add time to the overall production cycle, we believe that it has helped us reduce the cost of further contaminations. Notwithstanding
the challenges that contamination events have posed for us, we are excited to be approaching both our estimated full capacity of approximately
$30 million per year for <b>First Defense<sup>&#174;</sup></b> (with an option to increase our estimated full capacity to approximately
$40 million per year in the future with the additional capital investments discussed above) while, at the same time, advancing to the
final stages of a very significant FDA product development initiative with <b>Re-Tain<sup>&#174;</sup></b>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Since
February of 2023, we have been pursuing an insurance claim under our business interruption policy to offset a small portion of the losses
that we have incurred related to the contamination events discussed above. While our financial losses are far larger, we are seeking
an insurance benefit of approximately $700,000. To date, we have received $250,000. The balance of this claim remains under review by
our underwriter. We cannot estimate the likelihood of our success with this claim.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Results
of Operations </b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">a)
Product Sales</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
near-term goal is to increase and stabilize supply, regain lost business and re-establish our growth curve. If we are able to achieve
our goal of balancing supplies to meet projected demand by the end of 2024, we anticipate being able to achieve approximately $24 million
in sales during 2024. This projection not only aims to meet end-user demand but also to replenish the distribution chain with the necessary
buffer stock. This target would surpass our total product sales of approximately $17.5 million and $18.6 million achieved during the
years ended December 31, 2023 and 2022, respectively. Our longer-term goal is to exceed $35 million of annual total product sales as
soon as possible during the four-year period after the market launch of <b>Re-Tain<sup>&#174;</sup></b>. We do not solely benchmark our
sales expectations off trailing twelve-month sales results. Instead, we look at the sales of competitive products to assess the size
of the addressable market and plan for growth when projecting our future production capacity needs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Sales
during the three-month period ended March 31, 2023 were $3.4 million, representing a 12%, or $464,000, decrease from sales of $3.9 million
during the fourth quarter of 2022. Sales during the three-month period ended June 30, 2023 were $3.5 million, representing a 2%, or $86,000,
increase over sales during the first quarter of 2023. Sales during the three-month period ended September 30, 2023 were $5.4 million,
representing a 53%, or $1.9 million, increase over sales during the second quarter of 2023. Sales during the three-month period ended
December 31, 2023 were $5.1 million, representing a 6%, or $301,000, decrease from sales during the third quarter of 2023. Sales during
the second half of 2023 were stronger as we were able to increase production after remediating the large contamination events that occurred
during the first half of the year. Sales during the six-month period ended December 31, 2023 were $10.5 million, representing a 50%,
or $3.5 million, increase over sales of $7 million during the six-month period ended June 30, 2023. Sales during the three-month period
ended March 31, 2024 were $7.3 million, representing a 42%, or $2.2 million, increase over sales during the fourth quarter of 2023. Sales
during the three-month period ended June 30, 2024 were $5.5 million, representing a 25%, or $1.8 million, decrease from sales during
first quarter of 2024. Sales during the three-month period ended September 30, 2024 were $6.0 million, representing a 10%, or $539,000,
increase from sales during the second quarter of 2024. By increasing production capacity and mitigating contamination events, we were
able to significantly increase sales during the most recent nine-month period compared to the previous nine-month period. Sales during
the nine-month period ended September 30, 2024 were $18.7 million, representing a 34%, or $4.7 million, increase over sales of $14 million
during the nine-month period ended December 31, 2023. Quarter to quarter sales since the beginning of 2022 are displayed in the following
table:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b><img alt="" src="image_001.jpg"/></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">An
increase in selling price and product supply allowed us to capture an 11% increase in sales revenue during the third quarter of 2024
compared to the third quarter of 2023. Domestic sales during the three-month period ended September 30, 2024 increased by 6%, and international
sales increased by 68%, in comparison to the three-month period ended September 30, 2023. International sales aggregated 13% and 9% of
total sales during the three-month periods ended September 30, 2024 and 2023, respectively. The quarterly sales results are summarized
in the following table (in thousands, except for percentages):</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>During
    the Three-Month <br/>
    Periods Ended September 30,</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Increase</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">%</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total Product Sales</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,012</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,397</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">615</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">An
increase in selling price and product supply allowed us to capture a 51% increase in sales revenue during the nine-month period ended
September 30, 2024 compared to the nine-month period ended September 30, 2023. Domestic sales during the nine-month period ended September
30, 2024 increased by 47%, and international sales increased by 91%, in comparison to the nine-month period ended September 30, 2023.
International sales aggregated 12% and 10% of total sales during the nine-month periods ended September 30, 2024 and 2023, respectively.
The sales results for the nine-month periods are summarized in the following table (in thousands, except for percentages):</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>During
    the Nine-Month<br/>
     Periods Ended September 30,</b></span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Increase</b></span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">%</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total Product Sales</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,742</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,376</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,366</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">51</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">An
increase in selling price and product supply allowed us to capture a 46% increase in sales revenue during the trailing twelve-month period
ended September 30, 2024 compared to the trailing twelve-month period ended September 30, 2023. Domestic sales during the trailing twelve-month
period ended September 30, 2024 increased by 43%, and international sales increased by 84%, in comparison to the trailing twelve-month
period ended September 30, 2023. International sales aggregated 11% and 9% of total sales during the trailing twelve-month periods ended
September 30, 2024 and 2023, respectively. The sales results for the trailing twelve-month periods are summarized in the following table
(in thousands, except for percentages):</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center; font-weight: normal; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="6" style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: center; font-weight: normal"><span style="font-family: Times New Roman, Times, Serif"><b>During
    the Trailing Twelve-Month<br/>
 Periods Ended September 30,</b></span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: normal"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;Increase</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total Product Sales</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">23,838</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">16,287</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,551</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">46</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Sales
of the <b>First Defense<sup>&#174;</sup></b> product line aggregated 99% of our total sales during both of the three-month periods ended
September 30, 2024 and 2023 and during both of the nine-month periods ended September 30, 2024 and 2023 and during both of the trailing
twelve-month periods ended September 30, 2024 and 2023. Our sales are generally seasonal with highest demand expected during the first
quarter of each year. The compound annual growth rate (CAGR) of our total product sales was 10.8%, 9.7% and 6.2% during the twelve-year,
five-year, and four-year periods ended December 31, 2023, respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
obtained USDA approval of <b>Tri-Shield First Defense<sup>&#174;</sup></b> (the trivalent format of our product delivered via a gel tube,
which provides broader protection to calves) near the end of 2017. Around the time of this new product format launch, total product sales
during the years ended December 31, 2017 and 2018 were $10.4 million and $11 million, respectively. While this product is very well received
by the market for its effectiveness, it does require two separate liquid production processes for each dose of <b>Tri-Shield<sup>&#174;
</sup></b>manufactured and sold (in contrast to the bivalent product formats that require just one) which makes it more expensive to
produce. This new product format has become the highest revenue contributor, as demonstrated in the table below (in thousands, except
for percentages):</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">During the Three-Month <br/> Periods Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">During the Nine-Month<br/> Periods Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% of Total</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% of Total</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% of Total</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% of Total</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Tri-Shield<sup>&#174;</sup></b></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">3,890</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">65</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">2,876</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">53</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">11,535</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">62</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">6,547</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">53</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,122</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">35</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,521</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">47</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,207</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">38</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,829</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">47</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 4pt">Total Product Sales</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,012</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,397</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">18,742</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">12,376</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
likely lost some business beginning in 2022 and through the first half of 2024 as a result of the backlog. During the first half of 2023,
the impact of tight supplies hit even harder leaving our customers without product during their busiest calving season. The 2023 production
shortage caused largely by the contamination events discussed above may prove to be more detrimental to our growth curve than any prior
production shortage because it depleted distributor inventories and impacted more customers for a longer period of time. Our inability
to timely meet the needs of our customers could result in the loss of some customers who seek alternative scours management products
during this period of short supply, and some of these customers may not resume purchasing our product when we have eliminated the backlog.
While we worked to allocate product directly to certain large customers during this period of short supply, we likely lost some customers
that could not procure product. While backlog is a better problem to have than seeing product expiring on our shelves, it is nonetheless
a significant challenge when we do not get our customers everything that they want. Our sales team is resuming more normal sales growth
initiatives now, in anticipation of product supply exceeding customer demand over the next five to six months. We will work to regain
end-user customers that we may have lost while we were short on product and will aggressively compete for new business. As we emerge
from an extended period of time on backlog, we anticipate higher than normal sales fluctuations quarter to quarter. What is most important
to us at this time is that we achieve sales growth over the longer periods of time, even if we experience some quarter-to-quarter fluctuations.
</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
production slowdown during the first ten months of 2023, in part, caused an increase in the amount of our order backlog. We cannot be
certain that this backlog will be converted to sales. Valuation of the backlog is a non-GAAP estimate that is based on purchase orders
on hand at the time that could not be met because of a lack of available inventory. We are reporting this figure because it reflects
the orders on our books presently that we cannot ship. Quantification of the backlog during the current periods has become far less comparable
to prior periods. At times, customers have placed orders for more than a month&#8217;s worth of their demand, perhaps in reaction to
our ongoing backlog situation, whereas in the past they ordered more closely in line with their current demand. We are concerned that
this backlog amount may not be highly relevant at this time as it includes very old orders, redundancy in demand and orders that may
be cancelled given the time that has passed since they were originally placed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
backlog was reduced from approximately $2.4 million as of December 31, 2021 to approximately $205,000 as of September 30, 2022. In part
because of a first contamination event experienced around the end of the third quarter of 2022, our backlog increased to approximately
$2.5 million as of December 31, 2022. In part because of a second contamination event experienced during the first quarter of 2023, the
backlog continued to increase to approximately $7.5 million as of March 31, 2023, to approximately $8 million as of June 30, 2023, to
approximately $8.9 million as of September 30, 2023 and to approximately $9.4 million as of December 31, 2023. We were able to reduce
this backlog modestly to approximately $9.1 million as of March 31, 2024 and then reduce it further to approximately $8.9 million as
of June 30, 2024. We were able to reduce this backlog further to approximately $7.3 million and $6.8 million as of September 30, 2024
and October 30, 2024, respectively. As sales demand increased while our production output was reduced, the value of our order backlog
has increased as demonstrated in the following table:</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b><img alt="" src="image_002.jpg"/></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
also sell our own <b>CMT</b>, which is used to detect somatic cell counts in milk. Sales of <b>CMT</b> aggregated approximately 1% of
our total product sales during the periods reported. Sales of <b>CMT</b> increased by 65%, or $24,000, to $60,000 during the three-month
period ended September 30, 2024, in comparison to the three-month period ended September 30, 2023. Sales of <b>CMT</b> increased by 15%,
or $18,000, to $140,000 during the nine-month period ended September 30, 2024 in comparison to the nine-month period ended September
30, 2023. Sales of <b>CMT</b> increased by 23%, or $37,000, to $196,000 during the trailing twelve-month period ended September 30, 2024,
in comparison to the trailing twelve-month period ended September 30, 2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Effective
January 1, 2022, we increased our selling price of the <b>First Defense<sup>&#174; </sup></b>product line by approximately 5% and <b>CMT
</b>by approximately 7%. Effective January 1, 2023, we increased our selling price of the <b>First Defense<sup>&#174; </sup></b>product
line by approximately 4% (range of 2% to 8%) and <b>CMT</b> by approximately 5%. Effective November 15, 2023, we adjusted the pricing
of backlogged orders to accommodate our rising costs of goods and eliminate any irrelevant purchase orders. We notified distributors
that all pending orders would either be removed from our system or modified (with their authorization) to reflect the new pricing structure
representing an increase of approximately 8%. Subsequently, most distributors opted to increase the prices on these older purchase orders
to retain them on the list for fulfillment. The backlog of orders was worth approximately $9 million just before this price change. Also,
effective November 15, 2023, we increased our selling price for <b>CMT</b> by approximately 12%.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">b)
Gross Margin</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
change in our gross margin (product sales less costs of goods sold) and our gross margin as a percentage of product sales during the
three-month, the nine-month and the trailing twelve-month periods ended September 30, 2024 and 2023 are summarized in the following tables
(in thousands, except for percentages):</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">During the Three-Month<br/> Periods Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Increase</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Gross margin</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,584</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,267</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">317</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">25</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Percent of product sales</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12</td><td style="text-align: left">%</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>During
    the Nine-Month  <br/>
    Periods Ended September 30,</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Increase</b></span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">%</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Gross margin</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,109</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,612</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,498</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">96</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Percent of product sales</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">27</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">21</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">29</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">During&#160;the&#160;Trailing
    Twelve-Month<br/>
Periods Ended September&#160;30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Increase</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Gross margin</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,367</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,604</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,763</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">77</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Percent of product sales</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21</td><td style="text-align: left">%</td></tr>
  </table><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
gross margin during recent periods was significantly less than what we anticipate going forward. The 2023 reduction in production output
was largely the result of our decision to slow down our production rate while remediating the production contamination events discussed
above. During 2023, we did not benefit from spreading our fixed costs over higher volumes as we normally do. Further, we did not furlough
any labor during this production slowdown. As we build back sales during 2024, we are increasing the amount of gross margin earned compared
to prior periods and improving the gross margin as a percentage of sales compared to 2023. The gross margin as a percentage of product
sales was 22%, 41%, 45%, 45%, 49%, 47% and 50% during the years ended December 31, 2023, 2022, 2021, 2020, 2019, 2018 and 2017, respectively.
The 22% gross margin percentage during the year ended December 31, 2023 (including even lower gross margin percentages during the three-month
period ended March 31, 2023 and the six-month period ended June 30, 2023) was our lowest ever. Achieving process yield improvements (in
addition to running without significant equipment failures or product contaminations) will be essential to increasing our gross margin
in future periods. Some of the critical process parameters that we are investigating include optimizing: 1) the time and temperature
for pasteurization steps, 2) a critical filtration step and 3) the antibody content of incoming Work-in-Process inventory. As we fully
integrate and utilize our increased capacity and evaluate our product costs and selling price, we believe we could increase our gross
margin by approximately 8 to 13 percentage points in comparison to the 27% gross margin reported for the nine-month period ended September
30, 2024. Our immediate goal is to resume a 35% gross margin as soon as possible with the next goal being to achieve a 40% gross margin.
This goal has been reduced from prior projections given the lower rates experienced during 2023 and to date in 2024.</span>

</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">While
our biological and process yields continue to be variable, we have seen a favorable improvement to our finished goods yield recently.
The <b>Tri-Shield<sup>&#174;</sup></b> product format is more complex (i.e., three antibodies versus two antibodies for <b>Dual-Force<sup>&#174;</sup></b>)
making it more costly to produce, and both the bivalent and trivalent gel product formats are more expensive to produce than the bolus
format. These new formats are creating sales growth for us, and we are focused on increasing total gross margin dollars, even if that
is accomplished with a lower gross margin as a percentage of sales. A number of other factors contribute to the variability in our costs,
resulting in some fluctuations in gross margin percentages from quarter to quarter and from year to year. We also invest to sustain compliance
with cGMP in our production processes. Increasing production can be more expensive in the initial stages. To achieve our inventory production
growth objectives, we continue to acquire more raw material (colostrum) from many more cows at several new farms. Additionally, the biological
yields from our raw material are always variable, which impacts our costs of goods sold in a similar way. Just as our customers&#8217;
cows respond differently to commercial dam-level vaccines, depending on the time of year and immune competency, our source cows have
similar biological variances in response to our proprietary vaccines. As is the case with any vaccine program, animals respond less effectively
to their first exposure to a new vaccine, and thereafter the effectiveness of their immune response improves in response to subsequent
immunizations. While this variability impacts our costs of producing inventory, the commercial value of our <b>First Defense<sup>&#174;
</sup></b>product line is that we compensate for the variability in a cow&#8217;s immune response by standardizing each dose of finished
product. This ensures that every calf is equally protected, which is something that dam-level commercial scours vaccines cannot offer.
We continue to work on processing and yield improvements and other opportunities to reduce costs, while enhancing process knowledge and
robustness. Additionally, the significant global supply-chain disruptions that almost all industries are experiencing presently are a
challenge to us. The costs of our critical supplies, components, raw materials, utilities and services increased significantly during
2021 and that trend continued during 2022, 2023 and into 2024. We have little choice but to pay the higher prices and try to take on
more months of supply than we would have held previously if we could get our orders fulfilled timely. We believe that gross margin trends
going forward should be viewed over longer periods of time than just one quarter.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
following table displays the relationship between sales and gross margin during recent periods (in thousands except for percentages):</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Product
    Sales</b></span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Gross
    Margin<br/>
     Dollars</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Gross
    Margin<br/>
    Percentage</b></span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Year Ended December 31, 2021</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19,243</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,656</span></td>
    <td style="width: 2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">45</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Year Ended December 31, 2023</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,472</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,869</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">22</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Year Ended December
    31, 2022</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,568</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,649</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">41</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Decrease during 2023 under 2022</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="text-align: right">(<span style="font-family: Times New Roman, Times, Serif">1,096</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="text-align: right">(<span style="font-family: Times New Roman, Times, Serif">3,780</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)<sup>(1)</sup></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(19</span></td>
    <td style="text-align: left">)<span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Three-Month Period Ended March 31, 2023</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,447</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">301</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">9</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Three-Month Period Ended June 30, 2023</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,532</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,044</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">30</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Three-Month Period Ended
    September 30, 2023</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,397</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,267</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">23</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Nine-Month Period Ended September 30, 2023</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,376</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,612</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">21</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Three-Month Period Ended March 31, 2024</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,257</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,294</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">32</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Three-Month Period Ended June 30, 2024</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,473</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,231</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">22</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Three-Month Period Ended
    September 30, 2024</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,012</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,584</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">26</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Nine-Month Period Ended September 30, 2024</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,742</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,109</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">27</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(1)</sup></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">This
                                            $3.8 million decrease in gross margin earned resulted in a very sudden, material and unexpected
                                            decrease in our available cash.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Work-in-Process
inventory as a percentage of total inventory has ranged from 57% to 82%, and the dollar value of Work-in-Process inventory has increased
significantly since December 31, 2021. The hyper-immunized colostrum we purchase for use in the production of <b>First Defense<sup>&#174;
</sup></b>is the largest component of Work-in-Process inventory. As we began to increase our production capacity, we also increased the
supplier base that we work with in order to increase the amount of this critical ingredient. As certain contamination events discussed
above slowed the implementation of our increased capacity, we accumulated more colostrum than originally planned. While this is a good
safety measure to have in place to ensure that we do not run short of colostrum, we do expect to reduce this use of cash as we move forward
with our increased production rate. Also, we are developing what could potentially be a spray-dried alternative format of <b>First Defense<sup>&#174;
</sup></b>that would not require the liquid processing and freeze-drying production steps used to produce <b>First Defense<sup>&#174;
</sup></b>in a capsule or gel tube. If successful, this effort could expand our product portfolio with a bulk product designed to meet
the needs of large dairy and calf-ranch customers at a lower cost. This would help us turn some of this inventory to cash sooner. In
a frozen state, this colostrum has a 30-month useable shelf life. The increase in Work-in-Process inventory is demonstrated in the following
table (in thousands, except for percentages):</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">As
    of</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Value
    of <br/>
     Work-in-Process  <br/>
    Inventory</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>%
    of <br/>
    Total<br/>
     Inventory</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">December 31, 2021</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,902</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">62</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">December 31, 2022</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,469</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">57</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">December 31, 2023</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,815</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">74</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">March 31, 2024</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,506</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">77</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">June 30, 2024</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,609</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">77</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">September 30, 2024</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,124</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">82</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">c)
Product Development Expenses and Strategy</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Overview:
<span style="font-style: normal">The majority of our product development expenses pertain to the development of <b>Re-Tain<sup>&#174;</sup></b>.
During the three-month period ended September 30, 2024, product development expenses decreased by 30%, or $332,000, to $786,000 in comparison
to $1.1 million during the three-month period ended September 30, 2023. Product development expenses aggregated 13% and 21% of product
sales during the three-month periods ended September 30, 2024 and 2023, respectively. Product development expenses included non-cash
depreciation and stock-based compensation expenses of $367,000 and $391,000 during the three-month periods ended September 30, 2024 and
2023, respectively. Approximately $342,000 and $353,000 of these non-cash expenses were comprised of depreciation expenses pertaining
largely to our DS facility and equipment for <b>Re-Tain<sup>&#174; </sup></b>during the three-month periods ended September 30, 2024 and
2023, respectively. During the nine-month period ended September 30, 2024, product development expenses decreased by 7%, or $249,000,
to $3.1 million in comparison to $3.3 million during the nine-month period ended September 30, 2023. Product development expenses aggregated
16% and 27% of product sales during the nine-month periods ended September 30, 2024 and 2023, respectively. Product development expenses
included non-cash depreciation and stock-based compensation expenses of approximately $1.1 million during both of the nine-month periods
ended September 30, 2024 and 2023. Approximately $1 million of these non-cash expenses were comprised of depreciation expenses pertaining
largely to our DS facility and equipment for <b>Re-Tain<sup>&#174; </sup></b>during both of the nine-month periods ended September 30,
2024 and 2023. We began depreciating this asset when the Certificate of Occupancy for the new construction was issued during the fourth
quarter of 2017, but sales of our new product cannot be realized until we achieve FDA approval. Product development expenses (excluding
depreciation expense of $1.4 million) were $3 million during the year ended December 31, 2023, when we were in production mode. Beginning
during the second half of 2024, we implemented an aggressive idle of product development expenses pertaining to <b>Re-Tain</b></span><b><sup>&#174;
</sup></b><span style="font-style: normal">after the production of inventory intended for our Controlled Launch was completed. It is
our goal to reduce product development expenses (excluding depreciation) to approximately $2.5 million during the year ending December
31, 2024. This would represent a 17%, or $519,000, reduction from the 2023 expense (excluding depreciation). Product development expenses
(excluding depreciation) were $1.6 million during the six-month period ended June 30, 2024. This means that it is our objective to reduce
product development expenses by approximately 45%, or approximately $731,000, during the second half of 2024 in comparison to the first
half of 2024. It is our further objective to reduce product development expenses (excluding depreciation) to approximately $2 million
during the year ending December 31, 2025, which would be a 20%, or approximately $490,000, decrease from the projected 2024 level. This
aggressive idle strategy (as opposed to a complete shut down) allows us to continue our pursuit of FDA approval while reducing our cash
spend and ensuring no adverse impact to critical equipment. We have a plan to bring the DS plant back to full production mode in approximately
two to three months, subject to available funding.</span></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-style: normal"><b>ImmuCell
Corporation </b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">During
the third quarter of 2016, the City of Portland approved a Tax Increment Financing (TIF) credit enhancement package that reduces the
real estate taxes on <b>Building 33</b> (our DS production facility for <b>Re-Tain<sup>&#174;</sup></b>) by 65% over the eleven-year period
beginning on July 1, 2017 and ending June 30, 2028 and by 30% during the year ending June 30, 2029, at which time the rebate expires.
During the second quarter of 2017, the TIF was approved by the Maine Department of Economic and Community Development. The value of the
tax savings will increase (decrease) in proportion to any increases (decreases) in the assessment of the building for city real estate
tax purposes or the City&#8217;s tax rate. The following table discloses how much of the new taxes we have generated is being relieved
by the TIF and how much we are paying:</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>Assessed
    Value</b></span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Twelve-Month<br/>
    Period Ended</b></span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Total
    New Taxes<br/>
    Generated by<br/>
    the Project</b></span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Less:<br/>
    TIF Credit</b></span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Net
    Amount<br/>
    Paid by<br/>
    ImmuCell</b></span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%"><span style="font-family: Times New Roman, Times, Serif">$1.7 million @ April 1, 2017</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June 30, 2018</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">36,000</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">22,000</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,000</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">$4.0 million @ April 1, 2018</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">June 30, 2019</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">90,000</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">58,000</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">32,000</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">$4.0 million @ April 1, 2019</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">June 30, 2020</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">94,000</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">60,000</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">34,000</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">$4.0 million @ April 1, 2020</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">June 30, 2021</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">94,000</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">60,000</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">34,000</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">$4.3 million @ April 1, 2021</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">June 30, 2022</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">55,000</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">36,000</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">20,000</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">$4.3 million @ April 1, 2022</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">June 30, 2023</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">58,000</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">37,000</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">21,000</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">$4.3 million @ April 1, 2023</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">June 30, 2024</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">61,000</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">39,000</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">22,000</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">$4.3 million @ April 1, 2024</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June 30, 2025</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">64,000</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">41,000</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">23,000</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">552,000</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">353,000</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">199,000</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>


</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Development
objective: <span style="font-style: normal">As we work to change the way that mastitis is managed in the dairy industry, we aim to demonstrate
that our bacteriocin, Nisin A, which is designed specifically for subclinical mastitis, can provide producers the freedom to change when
and how mastitis is treated. <b>Re-Tain<sup>&#174; </sup></b>is not a broad-spectrum antibiotic used in human health. Rather, it consists
of a highly targeted active ingredient without an FDA-required milk discard or meat withhold. While milk prices vary, the cost of the
milk discard associated with traditional antibiotics ranges from approximately $36.00 (for 3.5 days of milk at 60 pounds per day at the
Class III milk price average of $17.02 per hundredweight during 2023) to approximately $150.00 (for 11 days of milk at 80 pounds per
day at the Class III milk price average of $17.02 per hundredweight during 2023) per treated animal. These high milk discard costs associated
with traditional antibiotic treatments lead producers to only treat mastitis after clinical signs develop. We expect that <b>Re-Tain<sup>&#174;
</sup></b>will be a first-of-its-kind product that can be used to economically treat at the earliest stage of infection, giving producers
the ability to get ahead of mastitis before clinical signs develop so the best cows stay at their best performance level and in the herd
longer.</span></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Development
status<span style="font-style: normal">: Approval by the FDA of the New Animal Drug Application (NADA) for <b>Re-Tain<sup>&#174;</sup></b>
is required before any sales of the product can be initiated. The NADA is comprised of five principal Technical Sections plus a sixty-day
administrative review at the end. Each Technical Section can be reviewed and approved separately. By statute, each Technical Section
submission is generally subject to one or more six-month review cycles by the FDA. Upon review and assessment by the FDA that all requirements
for a Technical Section have been met, the FDA may issue a Technical Section Complete Letter. The current status of our work on these
submissions to the FDA is as follows:</span></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">1)
Environmental Impact: During the third quarter of 2008, we received the Environmental Impact Technical Section Complete Letter from the
FDA. During the second quarter of 2021, we received further clarification through a new Environmental Impact Technical Section Complete
Letter covering the current dosage regimen and labeling.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-style: normal"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">2)
Target Animal Safety: During the second quarter of 2012, we received the Target Animal Safety Technical Section Complete Letter from
the FDA.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">3)
Effectiveness: During the third quarter of 2012, we received the Effectiveness Technical Section Complete Letter from the FDA. The anticipated
product label (which remains subject to FDA approval) carries claims for the treatment of subclinical mastitis associated with </span><span style="font-family: Times New Roman, Times, Serif">Streptococcus
agalactiae<span style="font-style: normal">, </span>Streptococcus dysgalactiae<span style="font-style: normal">, </span>Streptococcus
uberis<span style="font-style: normal">, and coagulase-negative staphylococci in lactating dairy cattle. </span></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">Subclinical
mastitis, and the study required to achieve an effectiveness claim for it, is defined under the FDA/Center for Veterinary Medicine Guidance
#49: Target Animal Safety and Drug Effectiveness Studies for Anti-Microbial Bovine Mastitis Products (Lactating and Non-Lactating Cow
Products).&#160;Trial eligibility requires both pretreatment samples to be positive for the mastitis pathogen (except for </span><span style="font-family: Times New Roman, Times, Serif">Staphylococcus
aureus <span style="font-style: normal">and </span>Streptococcus agalactiae<span style="font-style: normal">, where a single pretreatment
sample qualifies a cow for enrollment).&#160;For all pathogens, both samples taken between 14 and 28 days post treatment (and at least
5 days apart) must be negative to be judged a cure.&#160;These conservative criteria generally result in enrolling cows with chronic
subclinical disease, which rarely self-resolves</span>.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">4)
Human Food Safety: During the third quarter of 2018, we received the Human Food Safety Technical Section Complete Letter from the FDA
confirming, among other things, a zero milk discard period and a zero meat withhold period during and after treatment with our product.
Achieving this critical differentiating feature for our product encouraged us to continue the significant product development investment
necessary to bring <b>Re-Tain</b></span><b><span style="font-family: Times New Roman, Times, Serif"><sup>&#174;</sup></span></b><span style="font-family: Times New Roman, Times, Serif">
<span style="font-style: normal">to market. It would have been hard to justify an ongoing investment of this nature in a product without
this significant competitive advantage. During the second quarter of 2021, we updated this Technical Section Complete Letter with FDA
approval of the official analytical method to measure Nisin in milk.</span></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">5)
Chemistry, Manufacturing and Controls (CMC): The CMC Technical Section is very complex and comprehensive. Having previously achieved
the four different Technical Section Complete Letters from the FDA discussed above, approval of the CMC Technical Section is the fifth
and final significant step required before <b>Re-Tain</b></span><b><span style="font-family: Times New Roman, Times, Serif"><sup>&#174;
</sup></span></b><span style="font-family: Times New Roman, Times, Serif"><span style="font-style: normal">product sales can be initiated
in the United States. Implementing DS production, which is a required component of the CMC Technical Section, has been the most lengthy
part of this project. We previously entered into an agreement with a multi-national pharmaceutical ingredient manufacturer for our commercial-scale
supplies of DS. However, we determined during 2014 that the agreement did not offer us the most advantageous supply arrangement in terms
of either cost or long-term dependability. As a result, we presented this product development opportunity to a variety of large and small
animal health companies. While such a corporate partnership could have provided access to a much larger sales and marketing team and
allowed us to avoid the large investment in a commercial-scale production facility, we concluded that a partner would have taken an unduly
large share of the gross margin from all future product sales of <b>Re-Tain</b></span><b><sup>&#174;</sup></b><span style="font-style: normal">.
However, the regulatory and marketing feedback that we received from prospective partners, following their due diligence, was positive.
During the third quarter of 2014, we completed an investment in facility modifications and processing equipment necessary to produce
our DS at pilot-scale at our 56 Evergreen Drive facility. This small-scale facility was used to: i) expand our process knowledge and
controls, ii) establish operating ranges for critical process parameters, iii) conduct product stability studies, iv) optimize process
yields and v) determine the cost of production. We believe these efforts have reduced the risks associated with our investment in the
commercial-scale DS production facility. Having raised equity during 2016 and 2017, we were able to move away from these earlier partnering
strategies and assume control over the commercial-scale manufacturing process in our own facility. During the fourth quarter of 2015,
we acquired land near our existing Portland facility for the construction of a new commercial-scale DS production facility. We commenced
construction of this facility during the third quarter of 2016 and completed construction during the fourth quarter of 2017. Equipment
installation and qualification was initiated during the third quarter of 2017 and completed during the third quarter of 2018. Total construction
and equipment costs aggregated approximately $20.8 million. With construction of the facility complete, we continue to work with outside
parties to investigate improvements to our DS production yields as well as potential efficacy enhancements.</span></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-style: normal"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">Under
the FDA&#8217;s phased submission process, we made a first-phased DS submission (without the DP submission) during the first quarter
of 2019 that included data from the DS Registration Batches produced at commercial scale in our new DS manufacturing facility. This first-phased
submission was followed by a second-phased submission covering both DS and DP, during the first quarter of 2021. The second-phased DS
and DP submission responded to comments raised by the FDA regarding the first-phased DS submission and included detailed information
about the manufacturing process and controls for DP. One of the key components of the second-phased DS and DP submission was also demonstrating
stability of the product through expiry. During the third quarter of 2021, the FDA issued a Technical Section Incomplete Letter (Incomplete
Letter) with regard to this second-phased DS and DP submission. This response was not unexpected as it is common for the FDA to issue
queries and comments, especially related to an aseptic DP submission. We made a second DS and DP submission of the CMC Technical Section
during the first quarter of 2022. During the third quarter of 2022, we received an Incomplete Letter from the FDA with regards to this
second DS and DP submission of the CMC Technical Section. The Incomplete Letter required that internal and external laboratories re-develop
and qualify several analytical tests and associated controls. </span></p><div>



</div><p style="font: italic 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">We
made a third DS and DP submission of the CMC Technical Section during the third quarter of 2023. In late October of 2023, the FDA notified
us that it was refusing to review our third submission because Norbrook was identified as the DP manufacturer in our submission, but
the FDA was expecting that we would identify our own in-house services as the DP manufacturer (instead of Norbrook). This miscommunication
was due to a statement in our April of 2022 response to an FDA 483 inspectional observation in which we noted that Norbrook was expected
to exit the DP manufacturing agreement with us at the end of 2022, which would have required us to procure and install some long lead
time equipment (filler and labeler) in our DS suite in late 2022. Instead, we were able to extend the agreement with Norbrook to complete
the manufacture of DP inventory for the initial commercial sales under our Controlled Launch strategy. As a result, we continued to identify
Norbrook as our DP manufacturer. As a result of this miscommunication, we were required to re-submit our third submission the CMC Technical
Section in November of 2023. During May of 2024, the FDA issued another Incomplete Letter to us. Pursuant to this Incomplete Letter,
the FDA has provided some minor questions about our third submission requiring a fourth submission of the CMC Technical Section. The
FDA also noted that all inspectional observations at our DS facility and at the DP facility of our contract manufacturer must be cleared
before this fourth submission could be made. Subsequently, the FDA notified us during the second quarter of 2024 that the inspectional
observation at our DS facility had been cleared. </span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">We
anticipate making a Non-Administrative NADA submission that would include our fourth submission of the CMC Technical Section, together
with the minor technical sections covering All Other Information and Product Labeling during the fourth quarter of 2024. We are implementing
this filing strategy to eliminate the need for an Administrative NADA submission covering All Other Information and Product Labeling
at the end of the application process which would then be subject to an additional 60-day review at that time. By statute, this CMC Technical
Section submission would be subject to a review period of up to 180 days, but we believe that a shorter review period may be provided
because the responses to the CMC Incomplete Letter are not complex. We expect the FDA to complete this review only after it clears the
inspectional observations at the DP facility of our contract manufacturer, which is the critical path constraint.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">Upon
FDA approval, we intend to implement our Controlled Launch with product expiration dating estimated at between the second quarter of
2025 and the first quarter of 2026, subject to confirmation of final product shelf-life disposition by the FDA. While being prudent with
how much cash we invested in inventory that would have short expiry dating if market launch is delayed, we built DS inventory during
2022 and 2023 to support the initial commercial sales of <b>Re-Tain</b></span><b><span style="font-family: Times New Roman, Times, Serif"><sup>&#174;</sup></span></b><span style="font-family: Times New Roman, Times, Serif"><span style="font-style: normal">.
We presently have no agreement in place to aseptically fill new DP inventory. During the second half of 2024, we began to reduce operating
costs at our DS production facility until initial market acceptance (and perhaps the interest of a marketing partner) justifies a new
agreement for aseptic filling and the production of additional inventory. We do anticipate a pause in the supply of product to market
after the initial launch goods are sold and before the product is re-launched with DP produced by our in-house aseptic filling operations
(if that investment is re-funded) or by an alternative contractor that we have not identified to date. While we do not expect <b>Re-Tain</b></span><b><sup>&#174;
</sup></b><span style="font-style: normal">to make a significant contribution to our sales growth in the early years after market launch,
we do see value in achieving regulatory approval and testing market acceptance. </span></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">Our
DS manufacturing facility and that of our DP contract manufacturer (and our potential future DP manufacturing facility) are subject to
ongoing FDA inspections. During the third quarter of 2019, the FDA conducted a pre-approval inspection of our DS facility. This resulted
in the issuance of certain deficiencies as identified on the FDA&#8217;s Form 483. We submitted responses and data summaries in a phased
manner over the fourth quarter of 2019 and first quarter of 2020. During the first quarter of 2022, the FDA conducted another pre-approval
inspection of our DS facility. This also resulted in the issuance of certain deficiencies as identified on the FDA&#8217;s Form 483.
We have responded to all of the queries. Early during the first quarter of 2024, the FDA conducted another pre-approval inspection of
our DS facility. This resulted in the issuance of one deficiency as identified on the FDA&#8217;s Form 483. Since then, we have successfully
responded to this inspectional observation. The remaining critical path milestone is for Norbrook to successfully complete closure of
deficiencies at their DP facility, which is currently underway.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">We
have always believed that the fastest route to FDA approval and market launch is with the services of Norbrook, reducing our risk by
benefiting from their demonstrated expertise in aseptic filling. From 2010 to the present, we have worked with Norbrook under several
amended contract manufacturing agreements covering the DP formulation, aseptic filling and final packaging services. Under our current
agreement, Norbrook is providing DP for our Controlled Launch with production into 2024. </span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-style: normal"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">Our
potential alternative third-party options for the formulation and aseptic filling services that are presently being performed by Norbrook
are narrowed considerably because our product cannot be formulated or filled in a facility that also processes traditional antibiotics
(i.e., beta lactams). During the first quarter of 2022, we initiated an investment in the installation of equipment to produce DP at
our own facility at <b>Building 33</b>. Given the loss in gross margin during the first ten months of 2023 caused by the slowdown in
production output that was necessary to remediate the production contamination events discussed above and feedback from the FDA during
their 2022 inspection, we decided to defer the completion of this investment for the time being. If we decide to resume the in-house
strategy, we would anticipate FDA approval of this facility (which is a requirement for commercial manufacturing) at least two years
after we resume spending on this project, allowing for two six-month review cycles, subject to the timing of our installation and validation
work. This will be a post-approval submission. If we decide to complete our potential future DP manufacturing facility, such facility
will, upon completion, be subject to FDA inspection and approval. We anticipate it would have enough formulation and aseptic filling
capacity to exceed the expected production capacity of our DS facility, which is approximately $7 million to $10 million in annual sales.
This production capacity estimate is based on our assumptions as to product pricing and does not yet reflect inventory build strategies
in advance of product approval or ongoing yield improvement initiatives. Establishing our own DP formulation and aseptic filling capability
would provide us with the longer-term advantage of controlling the manufacturing process for <b>Re-Tain</b></span><b><span style="font-family: Times New Roman, Times, Serif"><sup>&#174;
</sup></span></b><span style="font-family: Times New Roman, Times, Serif"><span style="font-style: normal">in one facility, thereby potentially
reducing our manufacturing costs and eliminating international cold chain shipping logistics and costs. The DP formulation and aseptic
filling operation, if completed, will be located in existing facility space that we had intended to utilize to double our DS production
capacity if warranted by sales volumes following market launch. As a result, if we decide to complete this DP facility (rather than utilizing
a third party for these services), we would need to explore alternative strategies (in parallel with ongoing DS yield improvement initiatives)
to expand our DS production capacity. This integrated manufacturing capability for <b>Re-Tain</b></span><b><sup>&#174;</sup></b> <span style="font-style: normal">would
substantially reduce our dependence on third parties. Upon completion of our formulation and aseptic filling facility, the only significant
third-party input for <b>Re-Tain</b></span><b><sup>&#174;</sup></b> <span style="font-style: normal">would be the DP syringes. It is anticipated
that Hubert De Backer of Belgium (HDB) will supply these syringes in accordance with purchase orders that we submit. HDB is a syringe
supplier for many of the largest participants in the human and veterinary medical industries, and with whom Norbrook presently works.
Based on HDB&#8217;s performance history and reputation in the industry, we are confident that HDB will be a dependable supplier of syringes
in the quantity and of the quality needed for <b>Re-Tain</b></span><b><sup>&#174;</sup></b><span style="font-style: normal">. </span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Other
product development initiatives: Our second most important product development initiative has been focused on other improvements, line
extensions or additions to our <b>First Defense<sup>&#174;</sup></b> product line. The bolus format of <b>First Defense<sup>&#174;</sup></b>
and <b>Tri-Shield First Defense<sup>&#174;</sup></b> have been listed with the Organic Materials Research Institute (OMRI) since 2013
and 2019, respectively. This means they can be used on organic farms. During the third quarter of 2024, the gel tube format of <b>First
Defense<sup>&#174;</sup></b> also became OMRI listed. As discussed above, we are developing a potential spray-dried, bulk powder format
of <b>First Defense<sup>&#174;</sup></b>. During the third quarter of 2024, we entered into a research agreement with the Mayo Clinic,
a non-profit, educational, research and healthcare institution, to explore potential applications of Nisin in certain human surgical
situations. Subject to the availability of resources, we intend to begin new development projects that are aligned with our core competencies
and market focus. We also remain interested in acquiring, on suitable terms, other new products and technologies that fit with our sales
focus on the dairy and beef industries, subject to the availability of the needed funding.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">d)
Sales and Marketing Expenses and Selling Strategy</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
see ourselves as the &#8220;non-pharma&#8221; pharma company. Rather than offering variations of &#8220;copy-cat&#8221; technology like
vaccines and antibiotics, we have taken the path less traveled by developing first-of-their kind products fueled by novel active ingredients
such as polyclonal antibodies (for <b>First Defense</b><sup>&#174;</sup>) and bacteriocins (for <b>Re-Tain<sup>&#174;</sup></b>). While
we expect that <b>Re-Tain<sup>&#174;</sup></b> could be a significant market disrupter, we project the <b>First Defense</b><sup>&#174;
</sup>market could be larger, especially during the first years of our Controlled Launch of <b>Re-Tain</b><sup>&#174;</sup>. We anticipate
that these category developing innovations will drive greater value for the livestock industry and, in turn, for our stockholders. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">During
the three-month period ended September 30, 2024, sales and marketing expenses increased by 3%, or $27,000, to $844,000 in comparison
to $817,000 during the three-month period ended September 30, 2023, amounting to 14% and 15% of product sales during the three-month
periods ended September 30, 2024 and 2023, respectively. Sales and marketing expenses included non-cash depreciation and stock-based
compensation expenses of $44,000 and $35,000 during the three-month period ended September 30, 2024 and 2023, respectively. During the
nine-month period ended September 30, 2024, sales and marketing expenses increased by 9%, or $213,000, to $2.6 million in comparison
to $2.4 million during the nine-month period ended September 30, 2023, amounting to 14% and 20% of product sales during the nine-month
periods ended September 30, 2024 and 2023, respectively. Sales and marketing expenses included non-cash depreciation and stock-based
compensation expenses of $131,000 and $121,000 during the nine-month period ended September 30, 2024 and 2023, respectively. Our current
budgetary guideline is to keep sales and marketing expenses under 20% of total sales. We continue to leverage the efforts of our small
sales force by using animal health distributors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
<b>First Defense</b><sup>&#174;</sup> product line serves dairy and beef producers by protecting their calf crop from scours, the leading
cause of pre-weaning mortality and morbidity. When calves are healthy during this crucial development period, they mature into more productive
milking cows and more efficient beef generators. Our primary competition in this category is vaccines that are also regulated for effectiveness
and safety by the USDA. However, animal responses to vaccines are inherently variable. COVID breakthrough infections in humans have reminded
us that a vaccine does not guarantee immunity. That is true for our competitors as well. In the most controlled research settings, only
80% of animals respond to a vaccine. This leaves 20% of the calf crop unprotected when the scour prevention program relies on scour vaccines.
Those unprotected calves can be disease carriers. Not only are they more susceptible to death or likely to require life-saving treatment
(sometimes with antibiotics), but they also shed pathogens into the environment creating a greater disease pressure for their herd mates.
The <b>First Defense</b><sup>&#174;</sup> product line removes the inconsistency inherent with vaccine protection. We sell the only USDA-licensed
products in the scour prevention category that are therapeutic multi-valent polyclonal antibodies. This technology eliminates a producer&#8217;s
reliance on a variable vaccine response to generate antibodies and, instead, can protect every calf equally with a measured dose of antibody-driven
immunity against both bacterial and viral scour pathogens.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">During
the twelve-month period ended December 31, 2023, we treated more calves than our next largest calf-level competitive product, which is
a vaccine administered to the newborn at birth. Compared to the dam-level competitive products (which are vaccines given to the cow pre-calving),
we are second in sales dollars to the market leader. Despite these successes, there remains significant opportunity to displace more
competition within North America. There is also opportunity to grow our sales by expanding into international markets. We are being strategic
in how we invest in international market development in order not to divert our limited resources away from achieving domestic growth,
which is often more efficient to obtain.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
believe that <b>Re-Tain</b><sup>&#174;</sup> could revolutionize the way that mastitis is managed by making earlier treatment of subclinical
infections (while these cows are still producing saleable milk) economically feasible without an FDA-required milk discard or a meat
withhold during, or for a period of time after, treatment. No other FDA-approved mastitis treatment product on the market can offer this
value proposition. We believe we can demonstrate a return on investment to the dairy producer and the milk processor that will justify
a premium over other mastitis treatments on the market today, which are all sold subject to milk discard and meat withhold requirements.
By creating this value for our customers, we believe we can, in turn, create value for our stockholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>Re-Tain<sup>&#174;
</sup></b>could increase the lifetime profitability of a cow and reduce disease transfer to herd mates. It is common practice to move
sick cows from their regular herd group to a sick cow group for treatment and the related milk discard. This movement causes stress on
the cow and a reduction in milk production. While practices may vary farm-to-farm, there would be no requirement to move cows treated
with our product, allowing this costly drop in production to be avoided. It is generally current practice to treat mastitis only when
the disease has progressed to the clinical stage where the milk from an infected cow cannot be sold, leaving most subclinically infected
cows untreated. Without a milk discard cost, we expect producers to be more motivated to identify and treat cows at the subclinical stage.
This creates a substantial animal welfare benefit. By treating mastitis early at the subclinical level, producers could preserve optimal
milk yields. We also know that animals infected with subclinical mastitis have higher abortion rates and often progress to the clinical
disease state requiring antibiotic treatment and milk discard. We believe that societal animal welfare objectives will put more and more
pressure on the industry to treat cows with subclinical infections.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
over-use of antibiotics that are medically important to human healthcare is a growing public health concern of our society and an active
issue with the FDA, largely because of the growing evidence that this over-use contributes to antibiotic resistance and the rise of &#8220;super-bugs&#8221;.
Sustainability objectives require that less antibiotics be used in food producing animals, yet a new FDA-approved drug to treat mastitis
has not been developed in years. Our product improves sustainability by utilizing a bacteriocin as an alternative to traditional antibiotics
that are used in human medicine. In the big picture, we are introducing an entirely new class of antimicrobial as an animal drug, a bacteriocin,
that does not promote resistance against antibiotics used in human medicine making it more socially responsible. The industry could keep
treating this very significant disease with traditional antibiotics, but it takes innovation to bring a bacteriocin like Nisin to market.
<b>Re-Tain<sup>&#174;</sup></b> would, when introduced, offer a needed alternative to these traditional antibiotics, while at the same
time improving milk quality and the quantity of milk produced by treated cows. We believe our product fits very well with where the industry
is going to be in the coming years.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
with all new products, the market determines the value. Our objective is to gain market acceptance of this new product concept as we
develop a new product category. Despite our product&#8217;s exciting benefits, it will take time to change this longstanding treatment
paradigm and develop this new market. It will take time for the market to understand, evaluate, implement and adapt to the use and benefits
of <b>Re-Tain<sup>&#174;</sup></b>. Based on consultations with industry experts and key opinion leaders, we have opted to carefully control
the launch of this novel product into the first quarter of 2026 or so, as we seek to transform the way that mastitis is treated in the
dairy industry over the long term. Our goal is to help early adopters select treatment candidates, develop easy to use protocols, optimize
treatment results and realize a positive return on their investment. We intend to limit initial distribution of <b>Re-Tain<sup>&#174;
</sup></b>to a level that enables our sales team to select the optimal dairy farms at which to introduce <b>Re-Tain<sup>&#174; </sup></b>and
to limit the initial number of participating farms so that the desired levels of support and guidance relating to effective usage of
<b>Re-Tain<sup>&#174; </sup></b>can be provided with our available resources.&#160;We recognize that it will be important to manage expectations
from the producer to the milk processor because it is possible that processors may express reservations with regards to the zero milk
discard claim. Our Controlled Launch strategy reduces the amount of inventory that we would need to build at risk before regulatory approval
is achieved. This strategic choice means that we have elected not to pursue an alternative strategy that might have maximized short-term,
initial sales quickly through a mass market approach where we provide product to distribution and let them sell it to as many farms as
possible. While we are dedicated to increasing our sales revenue, we considered available product supply and the damage a mass market
strategy could cause to the long-term value of the product. We have seen products sold by much larger companies that were substantially
damaged by such failed market launch strategies. We continue to develop detailed launch plans, focusing on the readiness of dairy operators
to successfully introduce <b>Re-Tain<sup>&#174;</sup></b> to their herds. We believe that these prudent steps, while potentially leading
to lower initial <b>Re-Tain<sup>&#174;</sup></b> revenues, may create a smooth and successful launch and could safeguard the longer term
performance of our investment in <b>Re-Tain<sup>&#174;</sup></b>. We also believe that the operational adjustments and accommodations
that dairy farmers will need to make to effectively use <b>Re-Tain<sup>&#174;</sup></b> and avoid the potential problems described under
<b>PART II: OTHER INFORMATION, ITEM 1A &#8211; RISK FACTORS</b>, to this Quarterly Report will not be so burdensome as to deter its adoption
and usage. Our overarching objective is to minimize the risk of early-stage unsatisfactory outcomes that could harm the longer-term prospects
and market acceptance of <b>Re-Tain<sup>&#174;</sup></b>. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">e)
Administrative Expenses</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">During
the three-month period ended September 30, 2024, administrative expenses increased by 3%, or $13,000, to $528,000 in comparison to $515,000
during the three-month period ended September 30, 2023. Administrative expenses amounted to 9% and 10% of product sales during the three-month
periods ended September 30, 2024 and 2023, respectively. Administrative expenses included non-cash depreciation and stock-based compensation
expenses of $46,000 and $63,000 during the three-month periods ended September 30, 2024 and 2023, respectively. During the nine-month
period ended September 30, 2024, administrative expenses increased by 3%, or $51,000, to $1.7 million in comparison to $1.6 million during
the nine-month period ended September 30, 2023. Administrative expenses amounted to 9% and 13% of product sales during the nine-month
periods ended September 30, 2024 and 2023, respectively. Administrative expenses included non-cash depreciation and stock-based compensation
expenses of $147,000 and $160,000 during the nine-month periods ended September 30, 2024 and 2023, respectively. We strive to be efficient
with these expenses while funding all the legal, audit and other costs associated with being a publicly-held company with a team of four
employees. Prior to 2014, we had limited our investment in investor relations spending. Beginning in the second quarter of 2014, we initiated
an investment in a more active investor relations program. Given travel restrictions related to the COVID-19 pandemic, this initiative
has pivoted to a virtual meeting format, which is less expensive. Having experienced this efficiency, it is our intent to continue with
the same strategy, for the most part, even though travel restrictions have been eliminated. At the same time, we continue to provide
full disclosure of the status of our business and financial condition in three quarterly reports and one annual report each year, as
well as in Current Reports on Form 8-K when legally required or deemed appropriate by management. We believe these efforts have helped
us access the capital markets to fund our growth objectives. Considering inflation and all the necessary support services that fit into
this category, we believe that approximately $2 million to $2.5 million per year is an efficient budget goal to fund the administrative
expenses of a publicly-held company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">&#160;</span></p><div>

</div><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font: normal 10pt Times New Roman, Times, Serif">f)
Net Operating Loss</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">During
the three-month period ended September 30, 2024, our net operating loss was $575,000 in comparison to a net operating loss of $1.2 million
during the three-month period ended September 30, 2023. The $609,000 reduction in the net operating loss during the three-month period
ended September 30, 2024 compared to the three-month period ended September 30, 2023 was largely caused by a $317,000 increase in gross
margin and a $332,000 decrease in product development expenses. During the nine-month period ended September 30, 2024, our net operating
loss of $2.3 million was significantly less than our net operating loss of $4.7 million during the nine-month period ended September
30, 2023. The $2.5 million decrease in our net operating loss during the nine-month period ended September 30, 2024 compared to the nine-month
period ended September 30, 2023 was largely caused by the $2.5 million increase in gross margin.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">g)
Other Expenses, net </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">During
the three-month period ended September 30, 2024, other expenses, net, aggregated $125,000 in contrast to other (income), net, of ($244,000)
during the three-month period ended September 30, 2023. Interest expense decreased to $144,000 during the three-month period ended September
30, 2024 from $145,000 during the three-month period ended September 30, 2023. Non-cash amortization of debt issuance and debt discount
costs (which is included as a component of interest expense) was $11,000 and $9,000 during the three-month periods ended September 30,
2024 and 2023, respectively. Interest income was $19,000 and $24,000 during the three-month periods ended September 30, 2024 and 2023,
respectively. During the three-month period ended September 30, 2023, we benefited from $365,000 of insurance recoveries, compared to
no such benefit during the three-month period ended September 30, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">During
the nine-month period ended September 30, 2024, other expenses, net, aggregated $406,000 in contrast to other (income), net, of ($113,000)
during the nine-month period ended September 30, 2023. Interest expense increased to $433,000 during the nine-month period ended September
30, 2024 from $323,000 during the nine-month period ended September 30, 2023. Non-cash amortization of debt issuance and debt discount
costs (which is included as a component of interest expense) was $32,000 and $13,000 during the nine-month periods ended September 30,
2024 and 2023, respectively. We anticipate that our interest expense (excluding non-cash amortization of debt issuance and debt discount
costs) will be approximately $524,000 and $452,000 during the years ending December 31, 2024 and 2025, respectively. Interest income
was $41,000 and $79,000 during the nine-month periods ended September 30, 2024 and 2023, respectively. We incurred a $15,000 loss on
disposal of property, plant and equipment during the nine-month period ended September 30, 2024 compared to an $8,000 loss during the
nine-month period ended September 30, 2023. During the nine-month period ended September 30, 2023, we benefited from $365,000 of insurance
recoveries, compared to no such benefit during the nine-month period ended September 30, 2024. </span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">h)
Loss Before Income Taxes </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">During
the three-month period ended September 30, 2024, our loss before income taxes was $700,000 in comparison to a loss before income taxes
of $940,000 during the three-month period ended September 30, 2023. The $239,000 reduction in our loss before income taxes during the
three-month period ended September 30, 2024 compared to the three-month period ended September 30, 2023 was largely the result of a $317,000
improvement in gross margin and a $332,000 decrease in product development expenses that were offset, in part, by a $370,000 swing from
other income to other expenses. During the nine-month period ended September 30, 2024, our loss before income taxes was $2.7 million
in comparison to a loss before income taxes of $4.6 million during the nine-month period ended September 30, 2023. The $2 million decrease
in our net loss during the nine-month period ended September 30, 2024 compared to the nine-month period ended September 30, 2023 was
largely the result of the $2.5 million increase in gross margin that was reduced by a $519,000 swing from other income during the nine-month
period ended September 30, 2023 to other expenses during the nine-month period ended September 30, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">i)
Income Taxes and Net Loss</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">During
both of the three-month periods ended September 30, 2024 and 2023, we recorded income tax expense of less than $2,000, which is comprised
of minimum state tax liabilities. Our net loss of $702,000, or $0.09 per basic share, during the three-month period ended September 30,
2024 was in comparison to net loss of $940,000, or $0.12 per basic share, during the three-month period ended September 30, 2023. During
the nine-month periods ended September 30, 2024 and 2023, we recorded income tax expense of $4,000 and $3,000, respectively, which is
comprised of minimum state tax liabilities. Our net loss of $2.7 million, or $0.34 per basic share, during the nine-month period ended
September 30, 2024 was in comparison to net loss of $4.6 million, or $0.60 per basic share, during the nine-month period ended September
30, 2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have substantial net operating loss carryforwards that will largely offset future income tax liabilities. As of December 31, 2023, our
federal net operating loss carryforward was $17.8 million. As of December 31, 2023, our state net operating loss carryforward was $4.7
million. On December 22, 2017, the Tax Cuts and Jobs Act was signed into law. This legislation made significant changes in the U.S. tax
laws, including a reduction in the corporate tax rates, changes to net operating loss carryforwards and carrybacks, and a repeal of the
corporate alternative minimum tax. The legislation reduced the U.S. corporate tax rate from 34% to 21%. Our income tax rate differs from
this statutory tax rate primarily because we are currently providing for a full valuation allowance against our deferred tax assets.
While we are recording this full valuation allowance, we are not recognizing the benefit of our tax losses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition to the results discussed above from our Statements of Operations, we believe it is important to consider our Statements of Cash
Flows in the accompanying unaudited financial statements and the discussion under <b>Liquidity and Capital Resources</b>, above, to assess
the cash generating ability of our operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b>Critical
Accounting Policies and Estimates</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
unaudited financial statements are presented on the basis of accounting principles that are generally accepted in the United States.
All professional accounting standards that were effective and applicable to us as of September 30, 2024 have been taken into consideration
in preparing the financial statements. The preparation of financial statements requires that we make estimates and judgments that affect
the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an
on-going basis, we evaluate our estimates. Significant estimates include our valuation of inventory, deferred tax assets and costs of
goods sold. We base our estimates on historical experience and on various other assumptions that we believe are reasonable under the
circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are
not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We
have chosen to highlight certain policies that we consider critical to the operations of our business and understanding of our financial
statements. These critical accounting estimates have been consistently applied.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
sell products that provide <b>Immediate Immunity&#8482;</b> to newborn dairy and beef cattle. We recognize revenue in accordance with
the five step model in ASC 606. These include the following: i) identification of the contract with the customer, ii) identification
of the performance obligations in the contract, iii) determination of the transaction price, iv) allocation of the transaction price
to the separate performance obligations in the contract and v) recognition of revenue associated with performance obligations as they
are satisfied. We recognize revenue at the time of shipment (including to distributors) for substantially all products, as title and
risk of loss pass to the customer on delivery to the common carrier after concluding that collectability is reasonably assured. We do
not bill for or collect sales tax because our sales are generally made to distributors and thus our sales to them are not subject to
sales tax. We generally have experienced an immaterial amount of product returns.	</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Inventory
includes raw materials, work-in-process and finished goods and is recorded at the lower of cost, on the first-in, first-out method, or
net realizable value (determined as the estimated selling price in the normal course of business, less reasonably predictable costs of
completion, disposal and transportation). Work-in-process and finished goods inventories include materials, labor and manufacturing overhead.
Inventory is a critical accounting policy because of the estimates and assumptions used by management to determine its cost accounting
and because of the variability of the cost per dose due to fluctuations in the biological yield.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>ITEM 3
- QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.25pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Not
applicable</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_010"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>ITEM
4 - CONTROLS AND PROCEDURES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Disclosure
Controls and Procedures: </i>Disclosure controls and procedures are designed to ensure that information required to be disclosed by us
in the reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported, within the time periods
specified in the SEC&#8217;s rules and forms and (ii) accumulated and communicated to our management, including our principal executive
and principal financial officer, as appropriate to allow timely decisions regarding required disclosures. Because of its inherent limitations,
internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective
can provide only reasonable assurance with respect to financial statement preparation and presentation. Also, projections of any evaluation
of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that
the degree of compliance with the policies or procedures may deteriorate. Our management, with the participation of the individual who
serves as our principal executive and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the Exchange Act)) as of
September 30, 2024. Based on this evaluation, that officer concluded that our disclosure controls and procedures were effective as of
that date.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Changes
in Internal Controls over Financial Reporting: </i>Our principal executive and principal financial officer and our Director of Finance
and Administration periodically evaluate any change in internal control over financial reporting which has occurred during the prior
fiscal quarter. We have concluded that there was no change in our internal control over financial reporting that occurred during the
quarter ended September 30, 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over
financial reporting.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0"><b>ImmuCell Corporation</b></p><div>

</div><p style="margin: 0">&#160;</p><div>

</div><div><a id="a_011"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.25pt; text-align: center">PART II: OTHER INFORMATION</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 1 - LEGAL PROCEEDINGS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the ordinary course of business, we may become
subject to lawsuits, investigations and claims. Although we cannot predict with certainty the ultimate resolution of any such lawsuits,
investigations and claims against us, we do not believe that any pending or threatened legal proceedings to which we are or could become
a party will have a material adverse effect on our business, results of operations, or financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 1A - RISK FACTORS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>OUTLINE TO ITEM 1A - RISK FACTORS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 18pt">-</td><td><b>Financial Risks</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 18pt">-</td><td><b>Product Risks</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 18pt">-</td><td><b>Regulatory Risks</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 18pt">-</td><td><b>Economic Risks Pertaining to the Dairy and Beef Industries</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 18pt">-</td><td><b>Small Size of the Company</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 18pt">-</td><td><b>Global Risks</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 18pt">-</td><td><b>Risks Pertaining to Common Stock</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 18pt">-</td><td><b>Other Risks</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Financial Risks</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Gross margin on product sales:</i> One of
our goals is to achieve a gross margin as a percentage of total sales of 40% or more (including depreciation expense) after the initial
launch of new products. Depreciation expense will be a larger component of costs of goods sold for <b>Re-Tain<sup>&#174;</sup></b> than
it is for the <b>First Defense<sup>&#174;</sup></b> product line. Gross margins generally improve over time, but this anticipated improvement
may not be realized for <b>Re-Tain<sup>&#174;</sup></b>. Many factors discussed in this Quarterly Report (including contaminations, process
yields, inflation, cost increases, supply-chain disruptions and the rising price of oil and other commodities and supplies) impact our
costs of goods sold. There is a risk that we are not able to achieve our gross margin goal, which would adversely affect our operating
results and could impact our future operating plans. We missed our gross margin goal during the year ended December 31, 2023 and during
the first nine months of 2024 with realized gross margins of 22% and 27%, respectively. There is a risk that our plans to maintain or
improve our gross margin may not be realized due to cost increases, production yield losses, additional manufacturing contamination events,
production equipment failures, price inelasticity or any combination of these factors. In addition, such negative events, depending on
their severity, could deplete our cash resulting in an inability to fund our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Exposure to interest rates and debt service obligations:</i>
Rising interest rates could negatively affect the operating costs of dairy and beef producers and thus put further financial pressure
on an already stressed business sector, which could indirectly, but materially and adversely, affect our business. During the first quarter
of 2020, we removed the direct aspect of this particular exposure to our business by refinancing our bank debt (with the exception of
our line of credit) with fixed rate notes. Our mortgage debt outstanding as of September 30, 2024 was $5.7 million bearing interest at
the fixed rate of 3.53% per annum. Our equipment loans outstanding as of September 30, 2024 were $2.1 million bearing interest at the
fixed rate of 3.50% per annum. The outstanding balance on the two State of Maine loans as of September 30, 2024 was approximately $633,000
bearing interest at the fixed rate of 5% per annum. The $3 million in debt that we secured during the third quarter of 2023 bears interest
at the blended fixed rate of 7.33% per annum and had an outstanding balance of $2.6 million as of September 30, 2024. Our outstanding
debt as of September 30, 2024 aggregating $11 million (gross of debt issuance and debt discount costs) bears interest at the blended fixed
rate of 4.51% per annum. Increasing interest rates would negatively impact the cost of any future borrowings. This was experienced on
the new debt facilities aggregating $3 million that we closed during the third quarter of 2023. A decline in sales or gross margin, coupled
with this debt service burden, could impair our ability to fund our capital and operating needs and objectives. The additional debt we
incurred to fund our growth objectives has significantly increased our total debt service costs. We are obligated to make principal and
interest payments aggregating approximately $2 million during both of the years ending December 31, 2024 and 2025. See Note 10 to the
accompanying unaudited financial statements for more details about our debt.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Debt covenants:</i> Our debt with Gorham Savings
Bank and the Finance Authority of Maine is subject to certain financial covenants. We are required to meet a minimum debt service coverage
(DSC) ratio of 1.35. Our actual DSC ratios were (1.10), 0.44, 2.68 and 2.03 for the years ended December 31, 2023, 2022, 2021 and 2020,
respectively. Our actual DSC ratio was (0.08) for the trailing twelve-month period ended September 30, 2024. During the first quarter
of 2023, the DSC ratio covenant for the year ending December 31, 2023 was preemptively waived by our lender. Instead, we were required
to meet a minimum DSC ratio requirement of 1.35 for the twelve-month periods ending June 30, 2024, September 30, 2024 and December 31,
2024, and then again annually after that. During the first quarter of 2024, the DSC ratio covenant for the twelve-month period ended June
30, 2024 was preemptively waived by our lenders. During the third quarter of 2024, the DSC ratio covenant for the twelve-month period
ended September 30, 2024 was preemptively waived by our lenders. During the fourth quarter of 2024, the DSC ratio covenant for the twelve-month
period ending December 31, 2024 was preemptively waived by our lenders. Our next compliance obligation is for the year ending December
31, 2025. There is no assurance that we will be able to achieve the required DSC ratio going forward. If we are unable to do so or reach
a favorable agreement with our lenders regarding that requirement (including an amendment to or waiver of such requirement), we would
be in violation of that covenant, which could result in unfavorable amendments to the terms of our bank debt or have other adverse impacts
on our business and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Currency
exchange fluctuation: </i></span>We do not believe that currency exchange rates have had a significant effect on our revenues and expenses.
However, future increases in the value of the U.S. dollar could affect our customers and the demand for our products. We hope to increase
the level of our future sales of products outside the United States. The cost of our products to international customers could be affected
by currency fluctuations. The decline of the U.S. dollar against other currencies could make our products less expensive to international
customers. Conversely, a stronger U.S. dollar could make our products more costly for international customers. A weaker U.S. dollar makes
international purchases more expensive for us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Inflation, supply disruptions, tax rates and
economic downturns:</i> Inflation is having a material and adverse impact on almost all supplies we purchase and labor we hire and retain.
Continuing or increasing inflationary trends could materially reduce our gross margin on product sales if we are unable or unwilling to
impose offsetting price increases on our customers. The extent and duration of the negative impact on the economics of our customers and
on the demand for our products going forward are very difficult to assess. The dairy market, similar to many others, has been unstable
as a result of the pandemic. The price paid to producers for milk has been very volatile. The Class III milk price has been extremely
volatile since the onset of the pandemic. Market conditions have improved somewhat, but this volatility remains a concern. Additionally,
like most input costs, the cost of grain and other feed is rising, which puts a strain on the profitability of our customers. There is
also economic uncertainty for beef producers, as the supply chain is interrupted or otherwise adversely affected due to closures of processing
plants and reduced throughput. This is a very unusual situation for farmers who work so hard to improve production quality and efficiency
in order to help feed a growing population with high-quality and cost-effective proteins. The pandemic created risk and continues to create
uncertainty and challenges for us and has created or contributed to global supply-chain disruptions and has affected international trade,
while creating a worldwide health and economic crisis. Stock market valuations have declined and recovered somewhat but remain very volatile.
Inflation has increased significantly, and tax rates may increase. There is a risk of a period of economic downturn, the severity and
duration of which are difficult to know. Prior to the pandemic and the responsive federal economic stimulus programs, many feared the
United States had taken on too much national debt. Now the debt load is significantly higher. A combination of the conditions, trends
and concerns summarized above could have a corresponding negative effect on our business and operations, including the supply of the colostrum
we purchase to produce our <b>First Defense<sup>&#174;</sup></b> product line, the demand for our products in the U.S. market and our ability
to penetrate or maintain a profitable presence in international markets. Our exposure to this risk is mitigated to some extent by the
fact that our supply chain is not heavily dependent on foreign manufacturers, by our on-going cross-training of our employees, by qualifying
alternate suppliers and components and by our early and continued compliance with recommended hygiene.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Projection of net (loss) income:</i> Generally
speaking, our financial performance can differ significantly from management projections, due to numerous factors that are difficult to
predict or that are beyond our control. Weaker than expected sales of the <b>First Defense<sup>&#174;</sup></b> product line could lead
to deeper operating losses or less profits. The timing of FDA approval of <b>Re-Tain<sup>&#174;</sup></b> will have a material impact on
our net (loss) income until sufficient commercial sales are generated and sustained, unless we adequately reduce product development expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Risks associated with our funding strategy
for <b>Re-Tain</b></i><b><sup>&#174;</sup></b><i>:</i> The inability to maintain adequate cash and liquidity to support the commercialization
of <b>Re-Tain<sup>&#174;</sup></b> is a risk to our business. Achieving FDA approval of our pharmaceutical-grade Nisin produced at commercial-scale
is the most critical action remaining in front of us on our path to U.S. regulatory approval of <b>Re-Tain<sup>&#174;</sup></b>. Having
completed the construction and equipping of the DS production facility (as described in more detail in <b>PART I: ITEM 2</b> of this Quarterly
Report) at a cost of approximately $20.8 million, we will continue to incur product development expenses to operate and maintain this
facility until commercialization, although we are reducing these expenses now that production of inventory for our Controlled Launch is
complete.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Uncertainty of market size and product sales
estimates:</i> Estimating the size of the total addressable market and future sales growth potential for our <b>First Defense<sup>&#174;</sup></b>
product line is based on our experience and understanding of market dynamics but is inherently subjective. Estimating the size of the
market for any new product, such as <b>Re-Tain<sup>&#174;</sup></b>, involves more uncertainties than do projections for established products.
We do not know whether, or to what extent, our products will achieve, maintain or increase market acceptance and profitability. Some of
the uncertainties surrounding <b>Re-Tain<sup>&#174;</sup></b> include the product&#8217;s effectiveness against currently prevalent pathogens,
market acceptance, the effect of a premium selling price on market penetration, cost of manufacture, competition from new and existing
products sold by substantially larger competitors with greater market reach and promotional resources and other risks described under
&#8220;Product Risks&#8221; &#8211; &#8220;Sales risks pertaining to <b>Re-Tain<sup>&#174;</sup></b>&#8221; below. Since <b>Re-Tain<sup>&#174;</sup></b>
is a novel approach to treating mastitis, there are many uncertainties with regards to how quickly and to what extent we can develop the
subclinical mastitis treatment market. We believe that polypeptide antimicrobial technology may be viewed positively (relative to traditional
antibiotics). If realized, this may offset some of these risks and result in better overall market acceptance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Net deferred tax assets:</i> The realizability
of our net deferred tax assets is a subjective estimate that is contingent upon many variables. During the second quarter of 2018, we
recorded a full valuation allowance against our net deferred tax assets that significantly increased our net loss in comparison to other
periods. This non-cash expense could be reversed, and this valuation allowance could be reduced or eliminated, if warranted by our actual
and projected profitability in the future. We will continue to assess the need for the valuation allowance each quarter.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Product Risks</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Product risks generally:</i> We set objectives
for our products that we believe we can achieve, but the achievement of such goals is not a certainty. The sale of our products is subject
to production, financial, efficacy, regulatory, competitive and other market risks. Elevated standards to achieve and maintain regulatory
compliance required to sell our products continue to evolve. Failure to achieve acceptable biological yields from our production processes
can materially increase our costs of goods sold and reduce our production output, leading to lower margins and/or an order backlog that
could adversely affect our customer relationships and operating results. <b>First Defense<sup>&#174;</sup></b> is sold, and we expect <b>Re-Tain<sup>&#174;</sup></b>
to be sold, at significant price premiums relative to competitive products. There is no assurance that we will continue to achieve market
acceptance of the <b>First Defense<sup>&#174;</sup></b> product line, or achieve and sustain market acceptance of <b>Re-Tain<sup>&#174;</sup></b>,
at a profitable price level or that we can continue to manufacture our products at a low enough cost to result in a sufficient gross margin
to justify their continued manufacture and sale. As we bring <b>Re-Tain<sup>&#174;</sup></b> to market, these risks could be heightened
by the additional uncertainties associated with introducing a new product requiring a shift in customer behavior.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Contamination events, equipment failures and
gross margin from our production process:</i> During the first three and a half months of 2024 as well as during 2023 and late 2022, we
experienced certain contamination events and equipment failures in our production process that resulted in scrapped inventory and a slowdown
of our production process, which had a significant negative impact on our operating results. The realization of this risk following the
contamination events discussed above did result in a slowdown of our production output during 2023 to remediate this problem, which led
to less sales and gross margin during the year. We are at risk of further such production contaminations or equipment failures resulting
in more scrapped inventory. Additional contamination events or equipment failures causing significantly less production output, depending
on their severity, could deplete our cash resulting in an inability to fund our business operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Sales
risks pertaining to <b>Re-Tain</b></i></span><b><sup>&#174;</sup></b><span style="font-family: Times New Roman, Times, Serif"><i>: </i>Actual
or prospective <b>Re-Tain</b></span><b><sup>&#174; </sup></b><span style="font-family: Times New Roman, Times, Serif">customers may decide
to discontinue, reduce or avoid usage of <b>Re-Tain</b></span><b><sup>&#174; </sup></b><span style="font-family: Times New Roman, Times, Serif">due
to the following risks:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">1)
A rejection of a tank of milk by a positive milk inhibitor test because too much of the milk in a bulk tank is comprised of milk from
cows being treated with <b>Re-Tain</b></span><b><sup>&#174;</sup></b><span style="font-family: Times New Roman, Times, Serif">, when tested
randomly for inhibitors by a milk hauler, which could create legal liability. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2) A failed or stalled cheese tank occurs when
a Nisin susceptible cheese starter culture is impacted by residues in milk that exceed our on-farm treatment recommendations, which aims
to limit concentrations of bulk tanks or tankers to 1% of milk from cows treated with <b>Re-Tain<sup>&#174;</sup></b> or is not effectively
diluted through the milk collection and transportation system. After we study this potential impact during our Controlled Launch of <b>Re-Tain<sup>&#174;</sup></b>,
we may decide to seek a post-approval label change requiring a short discard of milk, which may be limited to just the treated quarter
of the cow.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">3)
Producers&#8217; current practice generally is to treat only clinical mastitis, which has the visual indicator of abnormal milk. In order
to gain market penetration for <b>Re-Tain<sup>&#174;</sup></b>, we will need to change that practice and increase awareness of the importance
of treating subclinical disease. This will require the producers&#8217; ability and willingness to diagnose without visual indicators.
Users of <b>Re-Tain<sup>&#174;</sup></b> could have unsatisfactory treatment outcomes if they lack the equipment needed to measure and
monitor somatic cell counts (SCC) of the herd or individual cows (for which data is needed). This risk limits our access to treatment
cows because about 40% of farms do not presently have access to this kind of testing at the cow level, and thus are not good candidates
for the use of <b>Re-Tain</b></span><b><sup>&#174;</sup></b><span style="font-family: Times New Roman, Times, Serif">.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4) Lower than anticipated treatment cure rates
could be experienced because the product is administered to cows that we would not identify as the best treatment candidates based on
SCC data or because the product is administered to cows that are infected with pathogens outside of our label claims.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">5) Off-label use of our product in cows infected
with clinical mastitis before we have run the required studies and achieved a label claim extension for this disease state, resulting
in negative treatment outcomes and potential legal liability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">6) Producers either do not choose to use it or
might use it improperly, rather than follow our label instructions to administer one dose after each of three consecutive milkings, or
they may limit use within the herd in an abundance of caution to avoid the negative outcomes described above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">7) Based on the anticipated product expiration
dating for <b>Re-Tain<sup>&#174;</sup></b>, we project that we will not have inventory available for sale after the first quarter of 2026
unless we secure additional DP supply following the November 30, 2024 expiration of our agreement with our current DP contract manufacturer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Reliance on sales of the <b>First Defense<sup>&#174;</sup></b>
product line:</i> We are reliant on the market acceptance of the <b>First Defense<sup>&#174;</sup></b> product line to generate product
sales and fund our operations. Our business would not have been profitable during the years ended December 31, 2012, 2013, 2015 and 2016,
during the nine-month periods ended September 30, 2017 or during the three-month periods ended March 31, 2019, December 31, 2020, June
30, 2021, September 30, 2021, December 31, 2021 and March 31, 2022 without the gross margin that we earned on sales of the <b>First Defense<sup>&#174;</sup></b>
product line. Our anticipated return to profitability is contingent upon the gross margin we earn from <b>First Defense<sup>&#174;</sup></b>
and prudent management of product development expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Concentration of sales:</i> Sales of the <b>First
Defense<sup>&#174;</sup></b> product line aggregated 99% of our total product sales during both of the years ended December 31, 2023 and
2022 and during both of the nine-month periods ended September 30, 2024 and 2023. Our primary customers for the majority of our product
sales (91% and 92% during the years ended December 31, 2023 and 2022, respectively, and 88% and 90% during the nine-month periods ended
September 30, 2024 and 2023, respectively) are in the U.S. dairy and beef industries. The concentration of our sales from one product
into just two markets (the dairy and beef markets) is a risk to our business. The animal health distribution segment has been aggressively
consolidating over the last few years, with larger distributors acquiring smaller distributors. A large portion of our product sales (79%
and 73% during the years ended December 31, 2023 and 2022, respectively, and 77% and 79% during the nine-month periods ended September
30, 2024 and 2023, respectively) was made to two large distributors. A large portion of our trade accounts receivable (70% and 79% as
of September 30, 2024 and December 31, 2023, respectively) was due from these two distributors. We have a good history with these distributors,
but the concentration of sales and accounts receivable with a small number of customers does present a risk to us, including risks related
to such customers experiencing financial difficulties or altering the basis on which they do business with us in a manner unfavorable
to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Production capacity constraints:</i> We invested
$9.7 million from 2019 to September 30, 2024 to increase our production capacity (in terms of annual sales dollars) for the <b>First Defense<sup>&#174;</sup></b>
product line from approximately $16.5 million to approximately $30 million based on current selling prices and estimated production yields.
We are making initial plans to further increase our production capacity. While previous capacity expansion investments have proceeded
very close to budget, there is a risk of cost overruns in our ongoing projects and any future production expansions that we may undertake,
and a risk that we will not be able to achieve our production capacity growth objectives on a timely basis, resulting in a continuing
or increasing shortfall in supply to the market. The inability to meet market demand for our products is a risk to our business. The historically
large backlog of orders, as well as any ongoing order backlog, presents a risk that we could lose customers during this period that are
not easily regained thereafter, when our production capacity is expected to meet or exceed sales demand. Our long-term capital plan to
continue to expand the <b>First Defense<sup>&#174;</sup></b> product line requires ongoing review of equipment capacity and utilization
across the manufacturing value stream at <b>Building 56</b> and our leased facilities at <b>Building 175A</b> and <b>175B</b>, as well
as assessment of costs, functional obsolescence and reliability of equipment. This review and assessment could identify a need to fund
unexpected equipment maintenance or replacement costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Product liability:</i> The manufacture and
sale of our products entails a risk of product liability. Our exposure to product liability is mitigated to some extent by the fact that
our products are directed towards the animal health market. We have maintained product liability insurance in an amount which we believe
is reasonable in relation to our potential exposure in this area. We have no history of claims of this nature being made.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>Regulatory Risks</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Regulatory requirements for the <b>First Defense<sup>&#174;</sup></b>
product line:</i> <b>First Defense<sup>&#174;</sup></b> is sold in the United States subject to a product license from the Center for Veterinary
Biologics, USDA, which was first obtained in 1991, with subsequent approvals of line extensions in 2017 and 2018. As a result, our operations
are subject to periodic inspection by the USDA, and we are at risk of an unfavorable outcome from such inspections. The potency of serial
lots is directly traceable to the original serial used to obtain the product performance claims (the Reference Standard). Due to the unique
nature of the label claims, host animal re-testing is not required as long as periodic laboratory analyses continue to support the stability
of stored Reference Standard. To date, these analyses have demonstrated strong stability. However, if the USDA were not to approve requalification
of the Reference Standard, additional clinical studies could be required to meet regulatory requirements and allow for continued sales
of the product, which could interrupt sales and adversely affect our operating results. Territories outside of the United States may require
additional regulatory oversight that we may not be able to meet with our current facilities, processes and resources. There is a risk
that we will become subject to regulatory actions in the future, including actions that result in our inability to ship product. In these
cases, the resulting interruption in sales could have a material and adverse effect on our operating results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Regulatory requirements for <b>Re-Tain</b></i><b><sup>&#174;</sup></b><i>:
</i>The commercial introduction of this product in the United States requires us to obtain FDA approval. Completing the development through
to approval of the NADA by the FDA involves risk. While four of the five required Technical Sections have been approved, the regulatory
development process timeline has been extensive (approximately 17 years from when the product rights were returned to us by a former partner
in 2007) and has involved multiple commercial production strategies and multiple submissions of the Chemistry, Manufacturing and Controls
(CMC) Technical Section. We received an Incomplete Letter from the FDA regarding this CMC Technical Section during the third quarter of
2022 that clarified the required path to product approval. During May of 2024, we received an Incomplete Letter from the FDA in response
to our November of 2023 re-submission. To reduce the risk associated with this process, we are working with a qualified contract manufacturer
(Norbrook) for alignment of the required validations and DP manufacture and have met with the FDA to clarify filing strategy and requirements.
Early during the first quarter of 2024, the FDA conducted another pre-approval inspection of our DS facility. This resulted in the issuance
of one deficiency as identified on the FDA&#8217;s Form 483. Since then, we have cleared the inspectional observation with the FDA. However,
our efforts continue to be subject to inspection and approval by the FDA and other factors outside of our control, and there remains a
risk that the required FDA approvals of our product and facilities could be delayed or not obtained. The facility of our contract manufacturer
is subject to similar inspectional obligations and is currently working to resolve certain inspectional observations at their facility
with the FDA. International regulatory approvals would be required for sales of <b>Re-Tain<sup>&#174;</sup></b> outside of the United States,
and there is a risk that these approvals would be or become too costly to pursue or be delayed or not obtained.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Regulatory requirements limiting access to
suppliers and customer base</i>: Maine, where our principal executive office and manufacturing facilities are located, has adopted product
reporting and phase-out requirements for per- and polyfluoroalkyl substances (&#8220;PFAS&#8221;). Maine&#8217;s statute establishes a
phased ban for products that contain intentionally added PFAS, with all products (subject to certain exceptions) other than cooling, heating,
ventilation, air conditioning or refrigeration equipment being banned by 2032 unless the Maine Department of Environmental Protection
(&#8220;DEP&#8221;) has determined that the use of PFAS within the product is a &#8220;currently unavoidable use.&#8221; Beginning January
1, 2032, the sale of products containing intentionally added but &#8220;currently unavoidable&#8221; PFAS also is banned if the manufacturer
of such products has failed to report to the DEP information concerning the presence of PFAS in those products. The phased bans may limit
our ability to access supplies and may limit those customers to whom we may sell our products. The U.S. Environmental Protection Agency
also has adopted a PFAS reporting law, which requires that importers of articles that contain PFAS report the presence of such substances
to the extent such information is known or reasonably ascertainable. This reporting requirement may limit our ability to import supplies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Economic Risks Pertaining to the Dairy and Beef Industries</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The industry data referred to below is compiled
from USDA databases.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Cattle count:</i> The January count of all
cattle and calves in the United States had steadily declined from 97,000,000 as of January 1, 2007 to 88,500,000 as of January 1, 2014.
Then this figure increased each year, reaching 94,800,000 as of January 1, 2019 before declining to 93,800,000 as of both January 1, 2020
and January 1, 2021. This count continued to decline to 92,100,000 as of January 1, 2022 and to 88,800,000 as of January 1, 2023. This
count dropped to 87,200,000 as of January 1, 2024. Reflecting seasonal trends, this figure was equal to 102,000,000, 101,000,000, 98,600,000
and 95,900,000 as of July 1, 2020, 2021, 2022 and 2023, respectively. A significant decline in the cattle count could negatively affect
the size of our addressable market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Herd size:</i> Prior to 1957, there were over
20,000,000 cows in the U.S. dairy herd. Prior to 1986, there were over 10,000,000 cows in the U.S. dairy herd. From 1998 through 2021,
the size (annual average) of the U.S. dairy herd ranged from the low of 9,011,000 in 2004 to the high of 9,448,000 in 2021. This average
declined to 9,402,000 during the year ended December 31, 2022 and then declined to 9,386,000 during the year ended December 31, 2023.
This average declined slightly to 9,330,000 during the nine-month period ended September 30, 2024. A significant decline in the herd size
could negatively affect the size of our addressable market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Milk cow price:</i> The all-time high value
(annual average) for a milk cow was $1,993 during 2015. Since then, this annual average value steadily declined to $1,205 during 2019
before increasing to $1,300 during 2020 and to $1,363 during 2021. This price for 2022 increased significantly to an average of $1,598,
which is a 17% increase over 2021. The 2023 average price of $1,763 represents a 10% increase over prior year. This year-to-date average
price increased to $2,243 through October of 2024. A significant decline in the milk cow price could negatively affect the size of our
addressable market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Milk price:</i> The dairy market, similar
to many others, has been unstable for several reasons including as a result of the pandemic. The price paid to producers for milk has
been very volatile. This market volatility, and the resulting impact on our primary end users, could negatively impact our ability to
maintain and grow sales at a profitable level. The Class III milk price (an industry benchmark that reflects the value of product used
to make cheese) is an important indicator because it defines our customers&#8217; revenue level. This annual average milk price level
(measured in dollars per hundred pounds of milk) reached its highest point (since these prices were first reported in 1980) during 2014
at $22.34 (peaking at $24.60 in September of 2014), which price level has never been repeated. During the year ended December 31, 2020,
this average milk price was equal to $18.16, but it was extremely volatile during the year due largely to disruption in demand related
to the COVID-19 pandemic. The one-month fluctuation of 73% from a low of $12.14 in May of 2020 to $21.04 in June of 2020 set an all-time
record for variability. The average price for 2021 decreased by 6% to $17.08. This price average increased by 29% to $21.96 during the
year ended December 31, 2022. The average price decreased by 22% to $17.02 during the year ended December 31, 2023. The average price
increased by 11% to $18.82 during the ten-month period ended October 31, 2024. The annual fluctuations in this milk price level are demonstrated
in the following table:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Average Class III Milk Price During the Years Ended December 31,</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold; text-align: center"/><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Decrease) Increase</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">2014</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">22.34</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">2015</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">15.80</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(29</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">2016</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">14.87</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">2017</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">16.17</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">2018</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">14.61</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">2019</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">16.96</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">2020</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">18.16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">2021</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">17.08</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">21.96</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">17.02</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(22</td><td style="text-align: left">)%</td></tr>
  </table><div>









</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Feed Costs:</i> The actual level of milk prices
may be less important than its level relative to feed costs. One measure of this relationship is known as the milk-to-feed price ratio,
which represents the amount of feed that one pound of milk can buy. An increase in feed costs also has a negative impact on the beef industry
and therefore could have a resulting negative impact on our business and results of operations. This ratio varies farm-to-farm based on
individual operating parameters. Since this ratio reached 3.24 in 2005, it has not exceeded 3.00. This ratio averaged 1.74 for 2021, amounting
to a significant decline of 25% from the 2020 average of 2.32. This average has not been lower since 2012. During 2022, this ratio improved
by 10% to 1.91. This ratio dropped to 1.68 during the year ended December 31, 2023. This ratio increased to 2.37 during the nine-month
period ended September 30, 2024. The following table demonstrates the annual volatility and the low values of this ratio recently:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Average Milk-To-Feed Price Ratio During the Years Ended December 31,</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold; text-align: center"/><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Decrease) Increase</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">2014</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2.54</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">2015</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(16</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">2016</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.26</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">2017</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.42</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">2018</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.05</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(15</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.32</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.74</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(25</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.91</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.69</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12</td><td style="text-align: left">)%</td></tr>
  </table><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Market volatility</i>: While the number of
cows in the U.S. herd and the production of milk per cow directly influence the supply of milk, the price for milk is also influenced
by very volatile international demand for milk products. Given our focus on the dairy and beef industries, the volatile market conditions
and the resulting financial insecurities of our primary end users are risks to our ability to maintain and grow sales at a profitable
level. These factors also heighten the challenge of selling premium-priced animal health products (such as <b>Tri-Shield<sup>&#174;</sup></b>
and <b>Re-Tain<sup>&#174;</sup></b>) into the dairy market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>Small Size of the Company</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Dependence on key personnel: </i>We are a
small company with approximately 79 employees (including 5 part-time employees). As such, we rely on certain key employees to support
multiple operational functions, with limited redundancy in capacity. The loss of any of these key employees could adversely affect our
operations until a qualified replacement is hired and trained, which could be even more challenging in the present difficult labor market.
Our competitive position will be highly influenced by our ability to attract, retain and motivate key scientific, manufacturing, managerial
and sales and marketing personnel. The cost of attracting and retaining the needed additional personnel in this current job market and
inflationary environment could adversely affect our margins and profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Reliance on outside party to provide certain
services under contract for us: </i>We are exposed to additional regulatory compliance risks through the subcontractors that we choose
to work with to produce <b>Re-Tain<sup>&#174;</sup></b>, who also need to satisfy certain regulatory requirements in order to provide us
with the products and services we need. One example of this outside reliance is Norbrook, our DP contract manufacturer. Because Norbrook
notified us of its intent to terminate its supply agreement with us, we initiated an investment of approximately $4 million during 2022
to construct and equip our own DP formulation and aseptic filling capability for <b>Re-Tain<sup>&#174;</sup></b> in our existing DS facility.
Due to the loss in gross margin during 2023 caused by the slowdown in production output necessary to remediate product contamination events,
we have decided to defer spending of approximately $2 million of these funds for the near term. The objective of this investment is to
end our reliance on an outside party to perform these services for us. Actual project costs could exceed our current estimates. Completion
of this project could be delayed due to a number of factors outside our control, including delays in equipment fabrication, equipment
delivery or facility construction. In addition, there is a risk that we fail to achieve regulatory approval of the new facility or that
such approval is delayed or requires significant additional expenditures to obtain. We are evaluating alternatives for DP supply going
forward, which include the resumption of the investment in our own in-house DP services (when prudent based on our cash reserves) or another
contract manufacturing agreement or a further extension with Norbrook. We anticipate a supply interruption under our Controlled Launch
of <b>Re-Tain<sup>&#174;</sup></b> after the DP supply provided from our contract manufacturer is consumed and until new supply from a
new contract manufacturing agreement or our own formulation and aseptic filling facility is implemented.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Competition from others:</i> Many of our competitors
are significantly larger and more diversified in the relevant markets than we are and have substantially greater financial, marketing,
manufacturing and human resources and more extensive product development and sales/distribution capabilities than we do, including greater
ability to withstand adverse economic or market conditions and declining revenues and/or profitability. Merck and Zoetis, among other
companies, sell products that compete directly with the <b>First Defense<sup>&#174;</sup></b> product line in preventing scours in newborn
calves. The scours product sold by Zoetis sells for approximately half the price of our product, although it does not have an <i>E. coli</i>
claim (which ours does). With <b>Tri-Shield<sup>&#174;</sup></b>, we can compete more effectively against vaccines that are given to the
mother cow (dam) to improve the quality of the colostrum that she produces for the newborn calf. Elanco, Merck and Zoetis provide these
dam vaccine products to the market. There are many companies competing in the mastitis treatment market, most notably Boehringer Ingelheim,
Merck and Zoetis. The mastitis products sold by these large companies are well established in the market and are priced lower than what
we expect for <b>Re-Tain<sup>&#174;</sup></b>, but all of them involve traditional antibiotics and are sold subject to a requirement to
discard milk during and for a period of time after treatment (unlike our product which does not carry an FDA-required milk discard or
meat withhold). There is no assurance that our products will compete successfully in these markets. We may not be aware of other companies
that compete with us or intend to compete with us in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Global Risks</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Russia&#8217;s unprovoked military invasion
of Ukraine and the war in the Middle East: </i>Russia&#8217;s unprovoked military invasion of Ukraine (and attack on its people) and the
war in the Middle East are having a significant negative impact on the world economy, worsening trends that were already moving in an
unfavorable direction. Among other exposures, an increasing price of oil could impact our transportation-related expenses materially and
could increase the cost of petroleum-based products that we purchase (mostly plastics). Both of these military actions could cause more
stress on the global economy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Climate change:</i> Our business, and our
activities and the activities of our customers and suppliers, could be disrupted by climate change. Potential physical risks from climate
change may include altered distribution and intensity of rainfall, prolonged droughts or flooding, increased frequency of wildfires and
other natural disasters, rising sea levels, and a rising heat index, any of which could cause negative impacts to our and our customers&#8217;
and suppliers&#8217; businesses. Increased temperatures and rising water levels may negatively impact our dairy and beef livestock customers
by increasing the prevalence of parasites and diseases that affect food animals. The physical changes caused by climate change may also
prompt changes in regulations or consumer preferences which in turn could have negative consequences for our and our customers&#8217;
businesses. Climate change may negatively impact our customers&#8217; operations, through climate-related impacts such as increased air
and water temperatures, rising water levels and increased incidence of disease in livestock. In addition, concerns regarding greenhouse
gas emissions and other potential environmental impacts of livestock production have led to some consumers opting to limit or avoid consuming
animal products. If such events affect our customers&#8217; businesses, they may purchase fewer of our products, and our revenues may
be negatively impacted. Climate driven changes could have a material adverse impact on the financial performance of our business and on
our customers. In addition, increased frequency of natural disasters and adverse weather conditions may disrupt our manufacturing processes
or our supply chain. These disruptions may have a material adverse effect on our business, financial condition, results of operations
and/or cash flows.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Bovine diseases: </i>The potential for epidemics
of bovine diseases such as Highly Pathogenic Avian Influenza (HPAI), Foot and Mouth Disease, Bovine Tuberculosis, Brucellosis and Bovine
Spongiform Encephalopathy (BSE) presents a risk to us and our customers. Documented cases of BSE in the United States have led to an overall
tightening of regulations pertaining to ingredients of animal origin, especially bovine. The <b>First Defense<sup>&#174;</sup></b> product
line is manufactured from concentrated bovine colostrum, which is not considered a BSE risk material. Future regulatory action to increase
protection of the human food supply could affect the <b>First Defense<sup>&#174;</sup></b> product line, although presently we do not anticipate
that this will be the case.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Pertaining to Common Stock</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-weight: normal"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-weight: normal"><i>Stock market
valuation and liquidity:</i> Our common stock trades on The Nasdaq Capital Market (Nasdaq: ICCC). Our average daily trading volume (which
was 44,808 shares per day during the 20-day period ended October 30, 2024) is lower, our bid/ask stock price spread can be larger and
our share price can be more volatile than what other companies experience, which could result in investors facing difficulty selling their
stock for proceeds that they may expect or desire. Our share price as of October 30, 2024 was $3.67. Most companies in the animal health
sector have market capitalization values that greatly exceed our market capitalization of approximately $32.7 million as of October 30,
2024. Our product sales during the trailing twelve-month period ended September 30, 2024 were $23.8 million. This means that our market
capitalization as of October 30, 2024 was equal to approximately 1.4 times our sales during the trailing twelve-month period ended September
30, 2024. Before gross margin from the sale of new products is achieved, our market capitalization may be heavily dependent on the perceived
potential for growth from our product under development and may therefore be negatively affected by the related uncertainties and risks.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-weight: normal"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-weight: normal"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-weight: normal"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-weight: normal"><i>Certain
provisions might discourage, delay or prevent a change in control of our Company or changes in our management:</i> Provisions of our certificate
of incorporation, our bylaws or Delaware law may discourage, delay or prevent a merger, acquisition or other change in control that stockholders
may consider favorable, including transactions in which stockholders might otherwise receive a premium for their shares of our common
stock. These provisions may also prevent or frustrate attempts by our stockholders to replace or remove our management. These provisions
include:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">limitations
                                            on the removal of directors;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">advance
                                            notice requirements for stockholder proposals and nominations;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            ability of our Board of Directors to alter or repeal our bylaws;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Section
                                            203 of the Delaware General Corporation Law, which prohibits a publicly-held Delaware corporation
                                            from engaging in a business combination with an interested stockholder (generally defined
                                            as a person which together with its affiliates owns, or within the last three years has owned,
                                            15% of our voting stock, for a period of three years after the date of the transaction in
                                            which the person became an interested stockholder) unless the business combination is approved
                                            in a prescribed manner.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-weight: normal">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-weight: normal">The existence
of the foregoing provisions and anti-takeover measures could depress the trading price of our common stock or limit the price that investors
might be willing to pay in the future for shares of our common stock. They could also deter potential acquirers of our Company, thereby
reducing the likelihood of obtaining a premium for our common stock in an acquisition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-weight: normal"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-weight: normal"><i>No expectation
to pay any dividends or repurchase stock for the foreseeable future:</i> We do not anticipate paying any dividends to, or repurchasing
stock from, our stockholders for the foreseeable future. Instead, we expect to use cash to fund product development costs and investments
in our facilities and production equipment, and to increase our working capital. Stockholders must be prepared to rely on market sales
of their common stock after price appreciation to earn an investment return, which may never occur. Any determination to pay dividends
or repurchase stock in the future will be made at the discretion of our Board of Directors and will depend on our financial condition,
results of operations, contractual restrictions, restrictions imposed by applicable laws, current and anticipated needs for liquidity
and other factors our Board of Directors deems relevant.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-weight: normal"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-weight: normal"><i>Possible
dilution:</i> We are accessing the capital markets and issuing additional common stock under an At-The-Market Offering Agreement in order
to fund our operations, as described elsewhere in this Quarterly Report. Such issuances have a dilutive effect on our existing stockholders.</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other Risks</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Access to raw materials and contract manufacturing
services: </i>Our objective is to maintain more than one source of supply for the components used to manufacture and test our products
that we obtain from third parties. However, we may experience difficulty in efficiently acquiring essential supplies. We have significantly
increased the number of farms from which we purchase colostrum for the <b>First Defense<sup>&#174;</sup></b> product line. A significant
reduction in farm capacity could make it difficult for us to produce enough inventory to meet customer demand. The specific antibodies
that we purify from colostrum for the <b>First Defense<sup>&#174;</sup></b> product line are not readily available from other sources.
We are and will be dependent on our manufacturing facilities and operations in Portland for the production of the <b>First Defense<sup>&#174;</sup></b>
product line and <b>Re-Tain<sup>&#174;</sup></b>. We will be dependent on one manufacturer for the supply of syringes for <b>Re-Tain<sup>&#174;</sup></b>.
We are currently dependent on a contract with Norbrook for the DP formulation and aseptic filling for supply of our Nisin DP through 2024.
Any facility used to perform these services will be subject to FDA inspection and approval, the outcome and timing of which are not within
our control. We anticipate that this FDA approval process would take at least two years. The potential alternative options for these services
are narrowed considerably because our product cannot be formulated or filled in a facility that also processes traditional antibiotics
(i.e., beta lactams). Any significant damage to or other disruption in the services at any of these third-party facilities or our own
facilities (including due to lack of financing, regulatory issues or non-compliance) would adversely affect the production of inventory
and result in significant added expenses and potential loss of future sales. We anticipate a supply interruption and adverse effects on
our Controlled Launch of <b>Re-Tain<sup>&#174; </sup></b>beginning during the first quarter of 2026 (subject to confirmation of final product
shelf-life disposition by the FDA). These goods represent the initial DP production from our contract manufacturer. The extent of the
interruption will be subject to the supply timeline from a new contract manufacturing agreement or from our own formulation and aseptic
filling facility for DP.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Failure to protect intellectual property:
</i>The protection and enforcement of our intellectual property rights may require the expenditure of significant financial, managerial
and operational resources. We rely on trademark, copyright and patent law, trade secret protection, agreements and other methods with
our employees and others to protect our proprietary rights. However, we may be unable to adequately protect our intellectual property
rights or prevent third parties from infringing or misappropriating our intellectual property rights. We may not be able to obtain registration
for all intellectual property we seek to register, and effective intellectual property protection may not be available in every country
in which our products are sold. In some cases, we have chosen (and may choose in the future) not to seek patent protection for certain
products or processes. Instead, we have sought (and may seek in the future) to maintain the confidentiality of any relevant proprietary
technology through trade secrets, operational safeguards and contractual agreements. Reliance upon trade secret, rather than patent protection
may cause us to be vulnerable to competitors who successfully replicate (knock off) our manufacturing techniques and processes. Further,
our confidentiality agreements may not effectively prevent disclosure of our proprietary information, technologies and processes and may
not provide an adequate remedy in the event of unauthorized disclosure of such information. Others may independently develop similar trade
secrets or technology or obtain access to our unpatented trade secrets or proprietary technology. Others may have filed patent applications
and may have been issued patents involving products or technologies potentially useful to us or necessary for us to commercialize our
products or achieve our business goals. If that were to be the case, there can be no assurance that we will be able to obtain licenses
to such patents on terms that are acceptable to us. Any of our intellectual property rights may be challenged by others or invalidated
through administrative process or litigation. Third parties may claim in the future, that we have infringed their intellectual property
rights, which could result in significant costs and potential damages and license requirements. We may initiate claims or litigation against
others for infringement, misappropriation or violation of our intellectual property rights or other proprietary rights or to establish
the validity of such rights. However, we may be unable to discover or determine the extent of any infringement, misappropriation or other
violation of our intellectual property rights and other proprietary rights. In addition, we may be unable to prevent third parties from
infringing upon, misappropriating or otherwise violating our intellectual property rights and other proprietary rights.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Increasing dependence on the continuous and
reliable operation of our information technology systems: </i>We rely on information systems throughout our company. Any disruption of
these systems or significant security breaches could adversely affect our business. Although we maintain information security policies
and employ system backup measures and engage in information system redundancy planning and processes, such policies, measures, planning
and processes, as well as our current disaster recovery plan may be ineffective or inadequate to address all eventualities. As information
systems and the use of software and related applications by us, our business partners, suppliers, and customers become more cloud-based,
we become inherently more susceptible to cyberattacks. There has been an increase in global cybersecurity vulnerabilities and threats,
including more sophisticated and targeted cyber-related attacks that pose a risk to the security of our information systems and networks
and the confidentiality, availability and integrity of data and information. There are reports of increased activity by hackers and scammers
since the COVID-19 pandemic. Russia&#8217;s unprovoked military invasion of Ukraine may elevate the risk of such cyberattacks. Any such
attack or breach could compromise our networks and the information stored thereon could be accessed, publicly disclosed, lost, or stolen.
While we have invested in our data and information technology infrastructure (including working with an information security technology
consultant to assess and enhance our security systems and procedures, and periodically training our employees in such systems and procedures),
there can be no assurance that these efforts will prevent a system disruption, attack, or security breach and, as such, the risk of system
disruptions and security breaches from a cyberattack remains. We have not experienced any material adverse effect on our business or operations
as a consequence of any such attack or breach but may incur increasing costs in performing the tasks described above. Given the unpredictability
of the timing, nature and scope of such disruptions and the evolving nature of cybersecurity threats, which vary in technique and sources,
if we or our business partners or suppliers were to experience a system disruption, attack or security breach that impacts any of our
critical functions, or our customers were to experience a system disruption, attack or security breach via any of our connected products
and services, we could potentially be subject to production downtimes, operational delays or other detrimental impacts on our operations.
Furthermore, any access to, public disclosure of, or other loss of data or information, including any of our (or our customers&#8217;
or suppliers&#8217;) confidential or proprietary information or personal data or information, as a result of an attack or security breach
could result in governmental actions or private claims or proceedings, which could damage our reputation, cause a loss of confidence in
our products and services, damage our ability to develop (and protect our rights to) our proprietary technologies and have a material
adverse effect on our business, financial condition, results of operations or prospects. While this exposure is common to all companies,
larger companies with greater resources may be better able to mitigate this risk than we can.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">ImmuCell Corporation</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">ITEM 2 - UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.25pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">None</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">ITEM 3 - DEFAULTS UPON SENIOR SECURITIES</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.25pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">None</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.25pt">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">ITEM 4 - MINE SAFETY DISCLOSURES</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">None</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.25pt">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">ITEM 5 - OTHER INFORMATION</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.25pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><ix:nonNumeric contextRef="c4" format="ixt:fixed-false" name="ecd:NonRule10b51ArrTrmntdFlag" id="ixv-14955"><ix:nonNumeric contextRef="c4" format="ixt:fixed-false" name="ecd:Rule10b51ArrTrmntdFlag" id="ixv-14956"><ix:nonNumeric contextRef="c4" format="ixt:fixed-false" name="ecd:NonRule10b51ArrAdoptedFlag" id="ixv-14957"><ix:nonNumeric contextRef="c4" format="ixt:fixed-false" name="ecd:Rule10b51ArrAdoptedFlag" id="ixv-14958">None</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.25pt">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">ITEM 6 &#8211; EXHIBITS</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit 3.2</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/811641/000121390024081304/ea021549201ex3-2_immucell.htm">Amended and Restated By-Laws of ImmuCell Corporation, amended through September 20, 2024 (incorporated by reference to Exhibit 3.2 of the Company&#8217;s Current Report on Form 8-K filed on September 24, 2024).</a></span></td>
    </tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit 10.1</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/811641/000121390024081304/ea021549201ex10-1_immucell.htm">Fifth Amendment of Indenture of Lease for Premises Located in Portland, Maine between the Company and TVP, LLC dated as of September 20, 2024 (incorporated by reference to Exhibit 10.1 of the Company&#8217;s Current Report on Form 8-K filed on September 24, 2024).</a></span></td>
    </tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit 31<sup>*</sup></span></td>
    <td>&#160;</td>
    <td><a href="ea022052701ex31_immucell.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certifications required by Rule 13a-14(a).</span></a></td>
    </tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit 32<sup>*</sup></span></td>
    <td>&#160;</td>
    <td><a href="ea022052701ex32_immucell.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification pursuant to Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></td>
    </tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Instance Document-the instance document does not
    appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td>
    </tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Schema Document.</span></td>
    </tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td>
    </tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td>
    </tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td>
    </tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td>
    </tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td>Cover Page Interactive Data File-the cover page
    interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
    </td></tr>
  </table><div>
</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">+</td><td style="text-align: justify">Management contract or compensatory plan or arrangement.</td>
</tr></table><div>



</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><sup>*</sup></td><td style="text-align: justify">Filed herewith.</td>
</tr></table><div>



</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.9pt; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.9pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.9pt; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ImmuCell Corporation</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.9pt; text-align: center">&#160;</p><div>

</div><div><a id="a_013"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SIGNATURE</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of Section
13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">ImmuCell
    Corporation</span></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">Registrant</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: November
    13, 2024</span></td>
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 36%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Michael
F. Brigham</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td> &#160;</td>
    <td>Michael F. Brigham</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President, Chief
    Executive Officer and<br/>
 Principal Financial Officer</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">59</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="c0" id="hidden-fact-0" name="dei:EntityRegistrantName">IMMUCELL CORP /DE/</ix:nonNumeric>
<ix:nonFraction contextRef="c2" id="hidden-fact-1" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-2" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c12" id="hidden-fact-3" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c13" id="hidden-fact-4" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c15" id="hidden-fact-5" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c14" id="hidden-fact-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c15" id="hidden-fact-7" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c15" id="hidden-fact-8" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c12" id="hidden-fact-9" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c14" id="hidden-fact-10" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c15" id="hidden-fact-11" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c25" id="hidden-fact-12" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c26" id="hidden-fact-13" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c28" id="hidden-fact-14" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c25" id="hidden-fact-15" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c27" id="hidden-fact-16" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c28" id="hidden-fact-17" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c38" id="hidden-fact-18" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c39" id="hidden-fact-19" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c41" id="hidden-fact-20" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c40" id="hidden-fact-21" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c41" id="hidden-fact-22" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c41" id="hidden-fact-23" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c38" id="hidden-fact-24" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c40" id="hidden-fact-25" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c41" id="hidden-fact-26" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c47" id="hidden-fact-27" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c48" id="hidden-fact-28" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c50" id="hidden-fact-29" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c47" id="hidden-fact-30" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c49" id="hidden-fact-31" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c50" id="hidden-fact-32" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-33" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-34" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-35" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-36" name="us-gaap:ProceedsFromLinesOfCredit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-37" name="us-gaap:RepaymentsOfLinesOfCredit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c54" id="hidden-fact-38" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c55" id="hidden-fact-39" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c53" id="hidden-fact-40" name="us-gaap:ShortTermBorrowings" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c55" id="hidden-fact-41" name="us-gaap:ShortTermBorrowings" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c58" id="hidden-fact-42" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c59" id="hidden-fact-43" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c57" id="hidden-fact-44" name="us-gaap:ShortTermBorrowings" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c59" id="hidden-fact-45" name="us-gaap:ShortTermBorrowings" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-46" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-47" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-48" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-49" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-50" name="us-gaap:GoodwillImpairmentLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-51" name="us-gaap:GoodwillImpairmentLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-52" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-53" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="usd" xsi:nil="true"/>
<ix:nonNumeric contextRef="c88" id="hidden-fact-54" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" xsi:nil="true"/>
<ix:nonNumeric contextRef="c90" id="hidden-fact-55" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" xsi:nil="true"/>
<ix:nonFraction contextRef="c125" id="hidden-fact-56" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c126" id="hidden-fact-57" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c127" id="hidden-fact-58" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c128" id="hidden-fact-59" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c129" id="hidden-fact-60" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c130" id="hidden-fact-61" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c131" id="hidden-fact-62" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c132" id="hidden-fact-63" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c133" id="hidden-fact-64" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c134" id="hidden-fact-65" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c135" id="hidden-fact-66" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c137" id="hidden-fact-67" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-68" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c139" id="hidden-fact-69" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c140" id="hidden-fact-70" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c141" id="hidden-fact-71" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c142" id="hidden-fact-72" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c143" id="hidden-fact-73" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c144" id="hidden-fact-74" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c145" id="hidden-fact-75" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c146" id="hidden-fact-76" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c147" id="hidden-fact-77" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c148" id="hidden-fact-78" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c149" id="hidden-fact-79" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c151" id="hidden-fact-80" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-81" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c153" id="hidden-fact-82" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c155" id="hidden-fact-83" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c156" id="hidden-fact-84" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c157" id="hidden-fact-85" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c158" id="hidden-fact-86" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c159" id="hidden-fact-87" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c160" id="hidden-fact-88" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c161" id="hidden-fact-89" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c162" id="hidden-fact-90" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c162" id="hidden-fact-91" name="us-gaap:RepaymentsOfBankDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c164" id="hidden-fact-92" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c164" id="hidden-fact-93" name="us-gaap:RepaymentsOfBankDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c166" id="hidden-fact-94" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c166" id="hidden-fact-95" name="us-gaap:RepaymentsOfBankDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c169" id="hidden-fact-96" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c169" id="hidden-fact-97" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c170" id="hidden-fact-98" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c170" id="hidden-fact-99" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c171" id="hidden-fact-100" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c171" id="hidden-fact-101" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c172" id="hidden-fact-102" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c173" id="hidden-fact-103" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c173" id="hidden-fact-104" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c173" id="hidden-fact-105" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c174" id="hidden-fact-106" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c174" id="hidden-fact-107" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c174" id="hidden-fact-108" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-109" name="iccc:DebtDiscountCost2027" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-110" name="iccc:DebtDiscountCost2028" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-111" name="iccc:DebtDiscountCostThereafter" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c228" id="hidden-fact-112" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c229" id="hidden-fact-113" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c232" id="hidden-fact-114" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c232" id="hidden-fact-115" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c233" id="hidden-fact-116" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-117" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c234" id="hidden-fact-118" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-119" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="pure" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-120" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="pure" xsi:nil="true"/>
<ix:nonNumeric contextRef="c5" id="hidden-fact-121" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-122" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-123" name="us-gaap:GainLossOnDispositionOfAssets" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-124" name="us-gaap:InsuranceRecoveries" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-125" name="us-gaap:InsuranceRecoveries" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-126" name="us-gaap:OtherIncome" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-127" name="us-gaap:OtherIncome" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-128" name="us-gaap:OtherIncome" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c270" id="hidden-fact-129" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c270" id="hidden-fact-130" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c270" id="hidden-fact-131" name="us-gaap:GrossProfit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c270" id="hidden-fact-132" name="us-gaap:SellingAndMarketingExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c268" id="hidden-fact-133" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c269" id="hidden-fact-134" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c273" id="hidden-fact-135" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c273" id="hidden-fact-136" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c273" id="hidden-fact-137" name="us-gaap:GrossProfit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c271" id="hidden-fact-138" name="us-gaap:OtherResearchAndDevelopmentExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c273" id="hidden-fact-139" name="us-gaap:SellingAndMarketingExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c271" id="hidden-fact-140" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c272" id="hidden-fact-141" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c270" id="hidden-fact-142" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c273" id="hidden-fact-143" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c282" id="hidden-fact-144" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c282" id="hidden-fact-145" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c282" id="hidden-fact-146" name="us-gaap:GrossProfit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c282" id="hidden-fact-147" name="us-gaap:SellingAndMarketingExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c280" id="hidden-fact-148" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c281" id="hidden-fact-149" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c285" id="hidden-fact-150" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c285" id="hidden-fact-151" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c285" id="hidden-fact-152" name="us-gaap:GrossProfit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c285" id="hidden-fact-153" name="us-gaap:SellingAndMarketingExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c283" id="hidden-fact-154" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c284" id="hidden-fact-155" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c282" id="hidden-fact-156" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c285" id="hidden-fact-157" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c288" id="hidden-fact-158" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c288" id="hidden-fact-159" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c288" id="hidden-fact-160" name="us-gaap:GrossProfit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c288" id="hidden-fact-161" name="us-gaap:SellingAndMarketingExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c286" id="hidden-fact-162" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c287" id="hidden-fact-163" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c291" id="hidden-fact-164" name="us-gaap:SellingAndMarketingExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c289" id="hidden-fact-165" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c290" id="hidden-fact-166" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c288" id="hidden-fact-167" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="usd" xsi:nil="true"/>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-15129">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:CurrentFiscalYearEndDate" id="ixv-15130">--12-31</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus" id="ixv-15131">Q3</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentTransitionReport" id="ixv-15132">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-15133">0000811641</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="iccc-20240930.xsd" xlink:type="simple"/></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><ix:relationship xmlns="" fromRefs="ix_0_fact ix_1_fact ix_2_fact ix_3_fact ix_4_fact" toRefs="ix_0_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_5_fact ix_6_fact ix_7_fact ix_8_fact ix_9_fact ix_10_fact" toRefs="ix_1_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_11_fact hidden-fact-119 ix_12_fact ix_13_fact" toRefs="ix_2_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_14_fact ix_15_fact ix_16_fact ix_17_fact ix_18_fact hidden-fact-120 ix_19_fact ix_20_fact" toRefs="ix_3_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_21_fact hidden-fact-121 ix_22_fact ix_23_fact" toRefs="ix_4_footnote"/>
<ix:relationship xmlns="" fromRefs="hidden-fact-119 hidden-fact-120 hidden-fact-121" toRefs="ix_5_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_24_fact ix_25_fact ix_26_fact ix_27_fact" toRefs="ix_6_footnote"/>
<ix:relationship xmlns="" fromRefs="hidden-fact-124 ix_28_fact hidden-fact-125 ix_29_fact" toRefs="ix_7_footnote"/>
<xbrli:context xmlns="" id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-10-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iccc:NisinDrugSubstanceMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyAMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyAMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyAMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyAMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyBMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyBMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyBMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyBMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyAMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyAMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyBMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyBMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:GorhamSavingsBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:GorhamSavingsBankMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:GorhamSavingsBankMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:MaineTechnologyInstituteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:MaineTechnologyInstituteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2027-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:MaineTechnologyInstituteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2027-09-30</xbrli:startDate>
    <xbrli:endDate>2027-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:GorhamSavingsBankMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:GorhamSavingsBankMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:MaineTechnologyInstituteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:MaineTechnologyInstituteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFiveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:GorhamSavingsBankMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFiveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-30</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:MortgageBankingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2026-01-01</xbrli:startDate>
    <xbrli:endDate>2026-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2026-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSevenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSevenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2026-01-01</xbrli:startDate>
    <xbrli:endDate>2026-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2026-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iccc:BankLoansMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFiveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFiveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSevenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSevenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbY2yHOqde+bt8NhnsjkMwInWzkiaYJmrGBX9ANHbqN6KcdyN7/tlo+8zitcBZOpZd5FWkDhY6SIAlueCv6TZ3/kC1CNAnKV2ZM7jOQVc9F1lsdJG5gYEVlBk/tvI9EzlbPJ58JKwU1IierSRHypv+o52xo9lJjv1QMjVMw9zPSP42NFNgXQ/4M9AGq8qRwbyg5efpEjDIG2QiPWZiVEuwmEr9vI/v4yr5EdbLxmwETHhexLV0wS3dJ] CSR-->
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFiveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFiveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSevenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSevenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c159">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c160">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c161">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFiveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c162">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFiveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c163">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c164">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c165">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSevenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c166">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSevenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c167">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c168">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c169">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c170">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c171">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c172">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFiveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c173">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c174">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSevenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c175">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:SubtotalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c176">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c177">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iccc:MrBrighamMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c178">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iccc:MrBrighamMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c179">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-01-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c180">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-01-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c181">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iccc:MrBrighamMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c182">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:ReTainMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c183">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-09-12</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c184">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c185">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c186">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-11-01</xbrli:startDate>
    <xbrli:endDate>2023-11-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c187">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-31</xbrli:startDate>
    <xbrli:endDate>2025-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c188">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c189">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2016-02-01</xbrli:startDate>
    <xbrli:endDate>2021-04-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c190">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c191">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2016-02-01</xbrli:startDate>
    <xbrli:endDate>2016-02-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c192">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2016-02-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c193">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2016-10-01</xbrli:startDate>
    <xbrli:endDate>2016-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c194">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2016-10-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c195">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-07-01</xbrli:startDate>
    <xbrli:endDate>2017-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c196">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2017-07-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c197">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-12-01</xbrli:startDate>
    <xbrli:endDate>2017-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c198">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2017-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c199">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-03-01</xbrli:startDate>
    <xbrli:endDate>2019-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c200">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c201">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2021-04-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c202">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c203">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iccc:CommonStockIssuancesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-09</xbrli:startDate>
    <xbrli:endDate>2024-04-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c204">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c205">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-09</xbrli:startDate>
    <xbrli:endDate>2024-04-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c206">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iccc:ATMAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c207">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlansMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c208">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlansMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c209">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlansMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c210">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlansMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c211">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlansMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c212">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlansMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c213">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlansMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c214">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlansMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c215">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlansMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c216">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlansMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c217">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlansMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c218">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c219">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c220">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c221">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">iccc:AcquiringPersonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c222">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-06-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c223">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-06-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c224">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-10</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c225">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-10</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c226">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c227">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c228">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c229">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c230">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c231">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c232">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c233">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c234">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c235">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c236">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c237">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c238">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c239">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c240">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c241">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c242">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c243">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">iccc:OtherStatesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c244">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">iccc:OtherStatesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c245">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">iccc:OtherStatesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c246">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">iccc:OtherStatesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c247">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:FirstDefenseProductLineMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c248">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:FirstDefenseProductLineMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c249">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:FirstDefenseProductLineMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c250">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:FirstDefenseProductLineMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c251">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:FirstDefenseProductLineMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c252">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:FirstDefenseProductLineMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c253">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:OtherAnimalHealthMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c254">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:OtherAnimalHealthMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c255">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:OtherAnimalHealthMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c256">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:OtherAnimalHealthMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c257">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:OtherAnimalHealthMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c258">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:OtherAnimalHealthMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c259">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c260">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c261">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c262">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c263">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">iccc:FederalGeneralBusinessMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c264">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">iccc:FederalGeneralBusinessMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c265">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">iccc:StateTaxCreditMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c266">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">iccc:StateTaxCreditMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c267">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-01-01</xbrli:startDate>
    <xbrli:endDate>2018-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c268">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:ScoursMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c269">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:MastitisMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c270">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c271">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:ScoursMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c272">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:MastitisMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c273">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c274">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:ScoursMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c275">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:MastitisMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c276">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c277">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:ScoursMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c278">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:MastitisMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c279">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c280">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:ScoursMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c281">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:MastitisMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c282">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c283">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:ScoursMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c284">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:MastitisMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c285">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c286">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:ScoursMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c287">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:MastitisMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c288">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c289">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:ScoursMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c290">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:MastitisMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c291">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c292">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:ScoursMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c293">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:MastitisMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c294">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c295">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:ScoursMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c296">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:MastitisMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c297">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c298">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iccc:EmployeeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c299">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iccc:EmployeeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c300">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">iccc:ATMAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-10-01</xbrli:startDate>
    <xbrli:endDate>2024-10-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:unit xmlns="" id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit xmlns="" id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="sqft">
  <xbrli:measure>utr:sqft</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>2
<FILENAME>ea022052701ex31_immucell.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Exhibit
31</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>CERTIFICATION
PURSUANT TO REQUIRED BY RULE 13a-14(a)</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">I, Michael
F. Brigham, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
                                            have reviewed this Quarterly Report on Form 10-Q of ImmuCell Corporation (the Company);</FONT></TD>
</TR></TABLE>
<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
                                            on my knowledge, this report does not contain any untrue statement of a material fact or
                                            omit to state a material fact necessary to make the statements made, in light of the circumstances
                                            under which such statements were made, not misleading with respect to the period covered
                                            by this report;</FONT></TD>
</TR></TABLE>
<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
                                            on my knowledge, the financial statements, and other financial information included in this
                                            report, fairly present in all material respects the financial condition, results of operations
                                            and cash flows of the Company as of, and for, the periods presented in this report;</FONT></TD>
</TR></TABLE>
<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
                                            am responsible for establishing and maintaining disclosure controls and procedures (as defined
                                            in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting
                                            (as defined in Exchange Act Rules 13a-15(f) ands 15d-15(f)) for the Company and have:</FONT></TD>
</TR></TABLE>
<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">designed
                                            such disclosure controls and procedures, or caused such disclosure controls and procedures
                                            to be designed under my supervision, to ensure that material information relating to the
                                            Company is made known to me by others within the Company, particularly during the period
                                            in which this report is being prepared;</FONT></TD>
</TR></TABLE>
<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">designed
                                            such internal control over financial reporting, or caused such internal control over financial
                                            reporting to be designed under my supervision, to provide reasonable assurance regarding
                                            the reliability of financial reporting and the preparation of financial statements for external
                                            purposes in accordance with generally accepted accounting principles;</FONT></TD>
</TR></TABLE>
<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluated
                                            the effectiveness of the Company&rsquo;s disclosure controls and procedures and presented
                                            in this report my conclusions about the effectiveness of the disclosure controls and procedures,
                                            as of the end of the period covered by this report based on such evaluation; and</FONT></TD>
</TR></TABLE>
<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disclosed
                                            in this report any change in the Company&rsquo;s internal control over financial reporting
                                            that occurred during the Company&rsquo;s most recent fiscal quarter (the Company&rsquo;s
                                            fourth fiscal quarter in the case of an annual report) that has materially affected, or is
                                            reasonably likely to materially affect, the Company&rsquo;s internal control over financial
                                            reporting; and</FONT></TD>
</TR></TABLE>
<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
                                            have disclosed, based on my most recent evaluation of internal control over financial reporting,
                                            to the Company&rsquo;s auditors and the audit committee of the Company&rsquo;s Board of Directors
                                            (or persons performing the equivalent function):</FONT></TD>
</TR></TABLE>
<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
                                            significant deficiencies and material weaknesses in the design or operation of internal control
                                            over financial reporting which are reasonably likely to adversely affect the Company&rsquo;s
                                            ability to record, process, summarize and report financial information; and</FONT></TD>
</TR></TABLE>
<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            fraud, whether or not material, that involves management or other employees who have a significant
                                            role in the Company&rsquo;s internal control over financial reporting.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Date: November
13, 2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font-size: 10pt; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Michael F. Brigham</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael F. Brigham</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President, Chief Executive
    Officer and <BR>
Principal Financial Officer</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT>&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>3
<FILENAME>ea022052701ex32_immucell.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32</B></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CERTIFICATION PURSUANT TO SECTION 1350, AS ADOPTED
PURSUANT TO SECTION 906 OF <BR>
THE SARBANES- OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In connection with the Quarterly Report on Form 10-Q of ImmuCell Corporation
(the &ldquo;Company&rdquo;) for the quarter ended September 30, 2024, as filed with the Securities and Exchange Commission on the date
hereof (the &ldquo;Report&rdquo;), I, Michael F. Brigham, President, Chief Executive Officer and Principal Financial Officer of the Company,
certify, pursuant to 18 U.S.C. &sect; 1350, as adopted pursuant to &sect; 906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: left">the Report fully complies with the requirements of Section
13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;); and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: left">the information contained in the Report fairly presents, in
all material respects, the financial condition, results of operations and cash flows of the Company.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This certification is provided pursuant to 18 U.S.C. Section 1350 and
Item 601(b)(32) of Regulation S-K (&ldquo;Item 601(b)(32)&rdquo;) promulgated under the Securities Act of 1933, as amended (the &ldquo;Securities
Act&rdquo;), and the Exchange Act. In accordance with clause (ii) of Item 601(b)(32), this certification (A) shall not be deemed &ldquo;filed&rdquo;
for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and (B) shall not be deemed
to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the Company specifically
incorporates it by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Michael F. Brigham</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael F. Brigham</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President, Chief Executive Officer and <BR>
Principal Financial Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">November 13, 2024</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A signed original of this written statement required by Section 906
has been provided to ImmuCell Corporation and will be retained by ImmuCell Corporation and furnished to the Securities and Exchange Commission
or its staff upon request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>iccc-20240930.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Nov 11 21:15:33 UTC 2024 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:iccc="http://immucell.com/20240930" targetNamespace="http://immucell.com/20240930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="iccc-20240930_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="iccc-20240930_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="iccc-20240930_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="iccc-20240930_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://immucell.com/role/ConsolidatedBalanceSheet" id="iccc_r_ConsolidatedBalanceSheet">
        <link:definition>995301 - Statement - Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ConsolidatedBalanceSheet_Parentheticals" id="iccc_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>995302 - Statement - Balance Sheets (Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ConsolidatedIncomeStatement" id="iccc_r_ConsolidatedIncomeStatement">
        <link:definition>995303 - Statement - Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ShareholdersEquityType2or3" id="iccc_r_ShareholdersEquityType2or3">
        <link:definition>995304 - Statement - Statements of Stockholders&#8217; Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ShareholdersEquityType2or3_Parentheticals" id="iccc_r_ShareholdersEquityType2or3_Parentheticals">
        <link:definition>995305 - Statement - Statements of Stockholders&#8217; Equity (Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ConsolidatedCashFlow" id="iccc_r_ConsolidatedCashFlow">
        <link:definition>995306 - Statement - Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/BusinessOperations" id="iccc_r_BusinessOperations">
        <link:definition>995307 - Disclosure - Business Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/SummaryofSignificantAccountingPolicies" id="iccc_r_SummaryofSignificantAccountingPolicies">
        <link:definition>995308 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/CashandCashEquivalents" id="iccc_r_CashandCashEquivalents">
        <link:definition>995309 - Disclosure - Cash and Cash Equivalents</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/TradeAccountsReceivable" id="iccc_r_TradeAccountsReceivable">
        <link:definition>995310 - Disclosure - Trade Accounts Receivable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/Inventory" id="iccc_r_Inventory">
        <link:definition>995311 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/PrepaidExpensesandOtherCurrentAssets" id="iccc_r_PrepaidExpensesandOtherCurrentAssets">
        <link:definition>995312 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/PropertyPlantandEquipmentNet" id="iccc_r_PropertyPlantandEquipmentNet">
        <link:definition>995313 - Disclosure - Property, Plant and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/IntangibleAssets" id="iccc_r_IntangibleAssets">
        <link:definition>995314 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/AccountsPayableandAccruedExpenses" id="iccc_r_AccountsPayableandAccruedExpenses">
        <link:definition>995315 - Disclosure - Accounts Payable and Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/BankDebt" id="iccc_r_BankDebt">
        <link:definition>995316 - Disclosure - Bank Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ContingentLiabilitiesandCommitments" id="iccc_r_ContingentLiabilitiesandCommitments">
        <link:definition>995317 - Disclosure - Contingent Liabilities and Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/OperatingLease" id="iccc_r_OperatingLease">
        <link:definition>995318 - Disclosure - Operating Lease</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/StockholdersEquity" id="iccc_r_StockholdersEquity">
        <link:definition>995319 - Disclosure - Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/Revenue" id="iccc_r_Revenue">
        <link:definition>995320 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/OtherExpensesNet" id="iccc_r_OtherExpensesNet">
        <link:definition>995321 - Disclosure - Other Expenses, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/IncomeTaxes" id="iccc_r_IncomeTaxes">
        <link:definition>995322 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/SegmentInformation" id="iccc_r_SegmentInformation">
        <link:definition>995323 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/RelatedPartyTransactions" id="iccc_r_RelatedPartyTransactions">
        <link:definition>995324 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/EmployeeBenefits" id="iccc_r_EmployeeBenefits">
        <link:definition>995325 - Disclosure - Employee Benefits</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/SubsequentEvents" id="iccc_r_SubsequentEvents">
        <link:definition>995326 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/AccountingPoliciesByPolicy" id="iccc_r_AccountingPoliciesByPolicy">
        <link:definition>996000 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/SummaryofSignificantAccountingPoliciesTables" id="iccc_r_SummaryofSignificantAccountingPoliciesTables">
        <link:definition>996001 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/InventoryTables" id="iccc_r_InventoryTables">
        <link:definition>996002 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/PrepaidExpensesandOtherCurrentAssetsTables" id="iccc_r_PrepaidExpensesandOtherCurrentAssetsTables">
        <link:definition>996003 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/PropertyPlantandEquipmentNetTables" id="iccc_r_PropertyPlantandEquipmentNetTables">
        <link:definition>996004 - Disclosure - Property, Plant and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/IntangibleAssetsTables" id="iccc_r_IntangibleAssetsTables">
        <link:definition>996005 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/AccountsPayableandAccruedExpensesTables" id="iccc_r_AccountsPayableandAccruedExpensesTables">
        <link:definition>996006 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/BankDebtTables" id="iccc_r_BankDebtTables">
        <link:definition>996007 - Disclosure - Bank Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/OperatingLeaseTables" id="iccc_r_OperatingLeaseTables">
        <link:definition>996008 - Disclosure - Operating Lease (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/StockholdersEquityTables" id="iccc_r_StockholdersEquityTables">
        <link:definition>996009 - Disclosure - Stockholders&#8217; Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/RevenueTables" id="iccc_r_RevenueTables">
        <link:definition>996010 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/OtherExpensesNetTables" id="iccc_r_OtherExpensesNetTables">
        <link:definition>996011 - Disclosure - Other Expenses, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/SegmentInformationTables" id="iccc_r_SegmentInformationTables">
        <link:definition>996012 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails" id="iccc_r_SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>996013 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable" id="iccc_r_ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable">
        <link:definition>996014 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Assets or Liabilities Measured at Fair Value on a Nonrecurring Basis</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofConcentrationofRiskTable" id="iccc_r_ScheduleofConcentrationofRiskTable">
        <link:definition>996015 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Concentration of Risk</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable" id="iccc_r_ScheduleofNetIncomeLossPerCommonShareTable">
        <link:definition>996016 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Net Income (Loss) Per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/CashandCashEquivalentsDetails" id="iccc_r_CashandCashEquivalentsDetails">
        <link:definition>996017 - Disclosure - Cash and Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/TradeAccountsReceivableDetails" id="iccc_r_TradeAccountsReceivableDetails">
        <link:definition>996018 - Disclosure - Trade Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/InventoryDetails" id="iccc_r_InventoryDetails">
        <link:definition>996019 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbY2yHOqde+bt8NhnsjkMwInWzkiaYJmrGBX9ANHbqN6KcdyN7/tlo+8zitcBZOpZd5FWkDhY6SIAlueCv6TZ3/kC1CNAnKV2ZM7jOQVc9F1lsdJG5gYEVlBk/tvI9EzlbPJ58JKwU1IierSRHypv+o52xo9lJjv1QMjVMw9zPSP42NFNgXQ/4M9AGq8qRwbyg5efpEjDIG2QiPWZiVEuwm65IIpyzdqsN8VoLuFDwN5G2I/0pGHli/] CSR-->
      <link:roleType roleURI="http://immucell.com/role/ScheduleofInventoryTable" id="iccc_r_ScheduleofInventoryTable">
        <link:definition>996020 - Disclosure - Inventory (Details) - Schedule of Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable" id="iccc_r_ScheduleofPrepaidExpensesandOtherCurrentAssetsTable">
        <link:definition>996021 - Disclosure - Prepaid Expenses and Other Current Assets (Details) - Schedule of Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/PropertyPlantandEquipmentNetDetails" id="iccc_r_PropertyPlantandEquipmentNetDetails">
        <link:definition>996022 - Disclosure - Property, Plant and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable" id="iccc_r_ScheduleofPropertyPlantandEquipmentTable">
        <link:definition>996023 - Disclosure - Property, Plant and Equipment, Net (Details) - Schedule of Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/IntangibleAssetsDetails" id="iccc_r_IntangibleAssetsDetails">
        <link:definition>996024 - Disclosure - Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofIntangibleAssetsTable" id="iccc_r_ScheduleofIntangibleAssetsTable">
        <link:definition>996025 - Disclosure - Intangible Assets (Details) - Schedule of Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable" id="iccc_r_ScheduleofAccountsPayableandAccruedExpensesTable">
        <link:definition>996026 - Disclosure - Accounts Payable and Accrued Expenses (Details) - Schedule of Accounts Payable and Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/BankDebtDetails" id="iccc_r_BankDebtDetails">
        <link:definition>996027 - Disclosure - Bank Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable" id="iccc_r_ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable">
        <link:definition>996028 - Disclosure - Bank Debt (Details) - Schedule of Debt Proceeds Received and Principal Repayments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable" id="iccc_r_ScheduleofPrincipalPaymentsBankLoansOutstandingTable">
        <link:definition>996029 - Disclosure - Bank Debt (Details) - Schedule of Principal Payments Bank Loans Outstanding</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails" id="iccc_r_ContingentLiabilitiesandCommitmentsDetails">
        <link:definition>996030 - Disclosure - Contingent Liabilities and Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/OperatingLeaseDetails" id="iccc_r_OperatingLeaseDetails">
        <link:definition>996031 - Disclosure - Operating Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable" id="iccc_r_ScheduleofLeaseCostsandOtherLeaseInformationTable">
        <link:definition>996032 - Disclosure - Operating Lease (Details) - Schedule of Lease Costs and Other Lease Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable" id="iccc_r_ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable">
        <link:definition>996033 - Disclosure - Operating Lease (Details) - Schedule of Future Lease Payments Required Under Non-Cancelable Operating Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/StockholdersEquityDetails" id="iccc_r_StockholdersEquityDetails">
        <link:definition>996034 - Disclosure - Stockholders&#8217; Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable" id="iccc_r_ScheduleofActivityUndertheStockOptionPlansTable">
        <link:definition>996035 - Disclosure - Stockholders&#8217; Equity (Details) - Schedule of Activity Under the Stock Option Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable" id="iccc_r_ScheduleofAdditionalInformationAbouttheStockOptionPlansTable">
        <link:definition>996036 - Disclosure - Stockholders&#8217; Equity (Details) - Schedule of Additional Information About the Stock Option Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofFairValueStockOptionGrantUsingBlackScholesOptionPricingModelwithWeightedAverageAssumptionsTable" id="iccc_r_ScheduleofFairValueStockOptionGrantUsingBlackScholesOptionPricingModelwithWeightedAverageAssumptionsTable">
        <link:definition>996037 - Disclosure - Stockholders&#8217; Equity (Details) - Schedule of Fair Value Stock Option Grant Using Black-Scholes Option Pricing Model with Weighted-Average Assumptions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyGeographicAreaTable" id="iccc_r_ScheduleofProductSalesDisaggregatedbyGeographicAreaTable">
        <link:definition>996038 - Disclosure - Revenue (Details) - Schedule of Product Sales Disaggregated by Geographic Area</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable" id="iccc_r_ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable">
        <link:definition>996039 - Disclosure - Revenue (Details) - Schedule of Product Sales Disaggregated by Major Product Category</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/OtherExpensesNetDetails" id="iccc_r_OtherExpensesNetDetails">
        <link:definition>996040 - Disclosure - Other Expenses, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofOtherExpensesNetTable" id="iccc_r_ScheduleofOtherExpensesNetTable">
        <link:definition>996041 - Disclosure - Other Expenses, Net (Details) - Schedule of Other Expenses Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/IncomeTaxesDetails" id="iccc_r_IncomeTaxesDetails">
        <link:definition>996042 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/SegmentInformationDetails" id="iccc_r_SegmentInformationDetails">
        <link:definition>996043 - Disclosure - Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofSegmentInformationTable" id="iccc_r_ScheduleofSegmentInformationTable">
        <link:definition>996044 - Disclosure - Segment Information (Details) - Schedule of Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/RelatedPartyTransactionsDetails" id="iccc_r_RelatedPartyTransactionsDetails">
        <link:definition>996045 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/EmployeeBenefitsDetails" id="iccc_r_EmployeeBenefitsDetails">
        <link:definition>996046 - Disclosure - Employee Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/SubsequentEventsDetails" id="iccc_r_SubsequentEventsDetails">
        <link:definition>996047 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd-sub/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei-sub/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-sub-2024.xsd"/>
  <xs:element name="ScheduleOfAssetsOrLiabilitiesMeasuredAtFairValueOnANonrecurringBasisAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ScheduleOfAssetsOrLiabilitiesMeasuredAtFairValueOnANonrecurringBasisAbstract"/>
  <xs:element name="ScheduleOfConcentrationOfRiskAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ScheduleOfConcentrationOfRiskAbstract"/>
  <xs:element name="ScheduleOfPropertyPlantAndEquipmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ScheduleOfPropertyPlantAndEquipmentAbstract"/>
  <xs:element name="ScheduleOfIntangibleAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ScheduleOfIntangibleAssetsAbstract"/>
  <xs:element name="ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsAbstract"/>
  <xs:element name="ScheduleOfPrincipalPaymentsBankLoansOutstandingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingAbstract"/>
  <xs:element name="ScheduleOfActivityUnderTheStockOptionPlansAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ScheduleOfActivityUnderTheStockOptionPlansAbstract"/>
  <xs:element name="ScheduleOfAdditionalInformationAboutTheStockOptionPlansAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ScheduleOfAdditionalInformationAboutTheStockOptionPlansAbstract"/>
  <xs:element name="ScheduleOfProductSalesDisaggregatedByGeographicAreaAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ScheduleOfProductSalesDisaggregatedByGeographicAreaAbstract"/>
  <xs:element name="ScheduleOfProductSalesDisaggregatedByMajorProductCategoryAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ScheduleOfProductSalesDisaggregatedByMajorProductCategoryAbstract"/>
  <xs:element name="ScheduleOfOtherExpensesNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ScheduleOfOtherExpensesNetAbstract"/>
  <xs:element name="ScheduleOfSegmentInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ScheduleOfSegmentInformationAbstract"/>
  <xs:element name="DuringTheYearsEndingDecember31Abstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_DuringTheYearsEndingDecember31Abstract"/>
  <xs:element name="OfferingCostsOnFollowUpOfferingOfCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_OfferingCostsOnFollowUpOfferingOfCommonStock"/>
  <xs:element name="ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses"/>
  <xs:element name="DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iccc_DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability"/>
  <xs:element name="ExpenseRecognitionPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ExpenseRecognitionPolicyTextBlock"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iccc_SummaryofSignificantAccountingPoliciesDetailsScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"/>
  <xs:element name="BankDebtDetailsScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iccc_BankDebtDetailsScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable"/>
  <xs:element name="BankDebtDetailsScheduleofPrincipalPaymentsBankLoansOutstandingTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iccc_BankDebtDetailsScheduleofPrincipalPaymentsBankLoansOutstandingTable"/>
  <xs:element name="DebtIssuanceCosts2024" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_DebtIssuanceCosts2024"/>
  <xs:element name="DebtIssuanceCosts2025" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_DebtIssuanceCosts2025"/>
  <xs:element name="DebtIssuanceCosts2026" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_DebtIssuanceCosts2026"/>
  <xs:element name="DebtIssuanceCosts2027" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_DebtIssuanceCosts2027"/>
  <xs:element name="DebtIssuanceCosts2028" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_DebtIssuanceCosts2028"/>
  <xs:element name="DebtIssuanceCostshereafter" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_DebtIssuanceCostshereafter"/>
  <xs:element name="DebtDiscountCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_DebtDiscountCost"/>
  <xs:element name="DebtDiscountCost2025" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_DebtDiscountCost2025"/>
  <xs:element name="DebtDiscountCost2026" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_DebtDiscountCost2026"/>
  <xs:element name="DebtDiscountCost2027" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_DebtDiscountCost2027"/>
  <xs:element name="DebtDiscountCost2028" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_DebtDiscountCost2028"/>
  <xs:element name="DebtDiscountCostThereafter" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_DebtDiscountCostThereafter"/>
  <xs:element name="DebtDiscountCostTotal" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_DebtDiscountCostTotal"/>
  <xs:element name="LongTermDebt2024" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iccc_LongTermDebt2024"/>
  <xs:element name="LongTermDebt2025" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iccc_LongTermDebt2025"/>
  <xs:element name="LongTermDebt2026" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iccc_LongTermDebt2026"/>
  <xs:element name="LongTermDebt2027" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iccc_LongTermDebt2027"/>
  <xs:element name="LongTermDebtTotal2028" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_LongTermDebtTotal2028"/>
  <xs:element name="LongTermDebtThereafter" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iccc_LongTermDebtThereafter"/>
  <xs:element name="StockholdersEquityDetailsScheduleofActivityUndertheStockOptionPlansTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iccc_StockholdersEquityDetailsScheduleofActivityUndertheStockOptionPlansTable"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue"/>
  <xs:element name="StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iccc_StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansTable"/>
  <xs:element name="StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansLineItems"/>
  <xs:element name="RevenueDetailsScheduleofProductSalesDisaggregatedbyGeographicAreaTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iccc_RevenueDetailsScheduleofProductSalesDisaggregatedbyGeographicAreaTable"/>
  <xs:element name="RevenueSalesObligationPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_RevenueSalesObligationPercentage"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iccc_SummaryofSignificantAccountingPoliciesDetailsTable"/>
  <xs:element name="TradeAccountsReceivableDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iccc_TradeAccountsReceivableDetailsTable"/>
  <xs:element name="IntangibleAssetsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iccc_IntangibleAssetsDetailsTable"/>
  <xs:element name="BankDebtDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iccc_BankDebtDetailsTable"/>
  <xs:element name="InterestPaymentsTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_InterestPaymentsTerm"/>
  <xs:element name="LoanToValueRatio" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_LoanToValueRatio"/>
  <xs:element name="DebtServiceCoverageRatio" type="xbrli:pureItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_DebtServiceCoverageRatio"/>
  <xs:element name="ContingentLiabilitiesandCommitmentsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iccc_ContingentLiabilitiesandCommitmentsDetailsTable"/>
  <xs:element name="CapitalExpendituresCommitted" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_CapitalExpendituresCommitted"/>
  <xs:element name="PurchaseofInventory" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_PurchaseofInventory"/>
  <xs:element name="CommitmentsRelatedToCommercialManufacture" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iccc_CommitmentsRelatedToCommercialManufacture"/>
  <xs:element name="CommitmentsRelatedToInformationTechnologyServicesAndOtherObligations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iccc_CommitmentsRelatedToInformationTechnologyServicesAndOtherObligations"/>
  <xs:element name="OperatingLeaseDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iccc_OperatingLeaseDetailsTable"/>
  <xs:element name="StockholdersEquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iccc_StockholdersEquityDetailsTable"/>
  <xs:element name="NetProceedsFromIssuanceOfCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_NetProceedsFromIssuanceOfCommonStock"/>
  <xs:element name="FeesInitiallyCapitalizedAndLaterOffset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_FeesInitiallyCapitalizedAndLaterOffset"/>
  <xs:element name="ExercisableAndTransferableDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ExercisableAndTransferableDescription"/>
  <xs:element name="RightToAcquirePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_RightToAcquirePerShare"/>
  <xs:element name="AcquiringPersonPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="iccc_AcquiringPersonPercentage"/>
  <xs:element name="IncomeTaxesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iccc_IncomeTaxesDetailsTable"/>
  <xs:element name="RelatedPartyTransactionsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iccc_RelatedPartyTransactionsDetailsTable"/>
  <xs:element name="EmployeeBenefitsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iccc_EmployeeBenefitsDetailsTable"/>
  <xs:element name="EmployeesSalaryPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_EmployeesSalaryPercentage"/>
  <xs:element name="EmployeesSalaryContributionPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_EmployeesSalaryContributionPercentage"/>
  <xs:element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iccc_SubsequentEventsDetailsTable"/>
  <xs:element name="ATMAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ATMAgreementMember"/>
  <xs:element name="AcquiringPersonMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_AcquiringPersonMember"/>
  <xs:element name="BankLoansMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_BankLoansMember"/>
  <xs:element name="CommonStockIssuancesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_CommonStockIssuancesMember"/>
  <xs:element name="CompanyAMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_CompanyAMember"/>
  <xs:element name="CompanyBMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_CompanyBMember"/>
  <xs:element name="DebtInstrumentRedemptionPeriodSevenMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_DebtInstrumentRedemptionPeriodSevenMember"/>
  <xs:element name="DebtInstrumentRedemptionPeriodSixMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_DebtInstrumentRedemptionPeriodSixMember"/>
  <xs:element name="EmployeeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_EmployeeMember"/>
  <xs:element name="EmployeeOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_EmployeeOneMember"/>
  <xs:element name="FederalGeneralBusinessMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_FederalGeneralBusinessMember"/>
  <xs:element name="FirstDefenseProductLineMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_FirstDefenseProductLineMember"/>
  <xs:element name="GorhamSavingsBankMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_GorhamSavingsBankMember"/>
  <xs:element name="MaineTechnologyInstituteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_MaineTechnologyInstituteMember"/>
  <xs:element name="MastitisMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_MastitisMember"/>
  <xs:element name="MrBrighamMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_MrBrighamMember"/>
  <xs:element name="NisinDrugSubstanceMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_NisinDrugSubstanceMember"/>
  <xs:element name="OtherAnimalHealthMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_OtherAnimalHealthMember"/>
  <xs:element name="OtherStatesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_OtherStatesMember"/>
  <xs:element name="ReTainMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ReTainMember"/>
  <xs:element name="ScoursMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ScoursMember"/>
  <xs:element name="StateTaxCreditMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_StateTaxCreditMember"/>
  <xs:element name="SubtotalMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_SubtotalMember"/>
  <xs:element name="TwoThousandSeventeenPlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_TwoThousandSeventeenPlanMember"/>
  <xs:element name="TwoThousandSeventeenPlansMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_TwoThousandSeventeenPlansMember"/>
  <xs:element name="TwoThousandTenPlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_TwoThousandTenPlanMember"/>
  <xs:element name="TwoThousandTenPlansMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_TwoThousandTenPlansMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>5
<FILENAME>iccc-20240930_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Nov 11 21:15:33 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ConsolidatedBalanceSheet" roleURI="http://immucell.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ConsolidatedIncomeStatement" roleURI="http://immucell.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ConsolidatedCashFlow" roleURI="http://immucell.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ScheduleofNetIncomeLossPerCommonShareTable" roleURI="http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ScheduleofInventoryTable" roleURI="http://immucell.com/role/ScheduleofInventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ScheduleofPrepaidExpensesandOtherCurrentAssetsTable" roleURI="http://immucell.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ScheduleofPropertyPlantandEquipmentTable" roleURI="http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ScheduleofAccountsPayableandAccruedExpensesTable" roleURI="http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ScheduleofLeaseCostsandOtherLeaseInformationTable" roleURI="http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable" roleURI="http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ScheduleofOtherExpensesNetTable" roleURI="http://immucell.com/role/ScheduleofOtherExpensesNetTable"/>
  <calculationLink xlink:role="http://immucell.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligations" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_TreasuryStockCommonValue" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://immucell.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_Revenues" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingAndMarketingExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GrossProfit" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://immucell.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="7" weight="-1"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbY2yHOqde+bt8NhnsjkMwInWzkiaYJmrGBX9ANHbqN6KcdyN7/tlo+8zitcBZOpZd5FWkDhY6SIAlueCv6TZ3/kC1CNAnKV2ZM7jOQVc9F1lsdJG5gYEVlBk/tvI9EzlbPJ58JKwU1IierSRHypv+o52xo9lJjv1QMjVMw9zPSP42NFNgXQ/4M9AGq8qRwbyg5efpEjDIG2QiPWZiVEuwml7rT7AKT6U10MgFAD4cdN/d0HmIW0DF3] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="9" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="10" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="11" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="12" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireOtherProductiveAssets" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfLinesOfCredit" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfDebt" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://immucell.com/role/ScheduleofInventoryTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterials" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcess" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoods" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://immucell.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedPayrollTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedPayrollTaxesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedPayrollTaxesCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="6" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://immucell.com/role/ScheduleofOtherExpensesNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_GainLossOnDispositionOfAssets" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOther"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_InterestIncomeOther" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InsuranceRecoveries" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InsuranceRecoveries"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_InsuranceRecoveries" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherIncome" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="5" weight="-1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>6
<FILENAME>iccc-20240930_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Nov 11 21:15:33 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ConsolidatedBalanceSheet" roleURI="http://immucell.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://immucell.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ConsolidatedIncomeStatement" roleURI="http://immucell.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ShareholdersEquityType2or3" roleURI="http://immucell.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ShareholdersEquityType2or3_Parentheticals" roleURI="http://immucell.com/role/ShareholdersEquityType2or3_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ConsolidatedCashFlow" roleURI="http://immucell.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_BusinessOperations" roleURI="http://immucell.com/role/BusinessOperations"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_SummaryofSignificantAccountingPolicies" roleURI="http://immucell.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_CashandCashEquivalents" roleURI="http://immucell.com/role/CashandCashEquivalents"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_TradeAccountsReceivable" roleURI="http://immucell.com/role/TradeAccountsReceivable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_Inventory" roleURI="http://immucell.com/role/Inventory"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_PrepaidExpensesandOtherCurrentAssets" roleURI="http://immucell.com/role/PrepaidExpensesandOtherCurrentAssets"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_PropertyPlantandEquipmentNet" roleURI="http://immucell.com/role/PropertyPlantandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_IntangibleAssets" roleURI="http://immucell.com/role/IntangibleAssets"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_AccountsPayableandAccruedExpenses" roleURI="http://immucell.com/role/AccountsPayableandAccruedExpenses"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_BankDebt" roleURI="http://immucell.com/role/BankDebt"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ContingentLiabilitiesandCommitments" roleURI="http://immucell.com/role/ContingentLiabilitiesandCommitments"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_OperatingLease" roleURI="http://immucell.com/role/OperatingLease"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_StockholdersEquity" roleURI="http://immucell.com/role/StockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_Revenue" roleURI="http://immucell.com/role/Revenue"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_OtherExpensesNet" roleURI="http://immucell.com/role/OtherExpensesNet"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_IncomeTaxes" roleURI="http://immucell.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_SegmentInformation" roleURI="http://immucell.com/role/SegmentInformation"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_RelatedPartyTransactions" roleURI="http://immucell.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_EmployeeBenefits" roleURI="http://immucell.com/role/EmployeeBenefits"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_SubsequentEvents" roleURI="http://immucell.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_AccountingPoliciesByPolicy" roleURI="http://immucell.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://immucell.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_InventoryTables" roleURI="http://immucell.com/role/InventoryTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_PrepaidExpensesandOtherCurrentAssetsTables" roleURI="http://immucell.com/role/PrepaidExpensesandOtherCurrentAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_PropertyPlantandEquipmentNetTables" roleURI="http://immucell.com/role/PropertyPlantandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_IntangibleAssetsTables" roleURI="http://immucell.com/role/IntangibleAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_AccountsPayableandAccruedExpensesTables" roleURI="http://immucell.com/role/AccountsPayableandAccruedExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_BankDebtTables" roleURI="http://immucell.com/role/BankDebtTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_OperatingLeaseTables" roleURI="http://immucell.com/role/OperatingLeaseTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_StockholdersEquityTables" roleURI="http://immucell.com/role/StockholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_RevenueTables" roleURI="http://immucell.com/role/RevenueTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_OtherExpensesNetTables" roleURI="http://immucell.com/role/OtherExpensesNetTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_SegmentInformationTables" roleURI="http://immucell.com/role/SegmentInformationTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable" roleURI="http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ScheduleofConcentrationofRiskTable" roleURI="http://immucell.com/role/ScheduleofConcentrationofRiskTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ScheduleofNetIncomeLossPerCommonShareTable" roleURI="http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ScheduleofInventoryTable" roleURI="http://immucell.com/role/ScheduleofInventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ScheduleofPrepaidExpensesandOtherCurrentAssetsTable" roleURI="http://immucell.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ScheduleofPropertyPlantandEquipmentTable" roleURI="http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ScheduleofIntangibleAssetsTable" roleURI="http://immucell.com/role/ScheduleofIntangibleAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ScheduleofAccountsPayableandAccruedExpensesTable" roleURI="http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable" roleURI="http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ScheduleofPrincipalPaymentsBankLoansOutstandingTable" roleURI="http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ScheduleofLeaseCostsandOtherLeaseInformationTable" roleURI="http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable" roleURI="http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ScheduleofActivityUndertheStockOptionPlansTable" roleURI="http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ScheduleofAdditionalInformationAbouttheStockOptionPlansTable" roleURI="http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ScheduleofFairValueStockOptionGrantUsingBlackScholesOptionPricingModelwithWeightedAverageAssumptionsTable" roleURI="http://immucell.com/role/ScheduleofFairValueStockOptionGrantUsingBlackScholesOptionPricingModelwithWeightedAverageAssumptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ScheduleofProductSalesDisaggregatedbyGeographicAreaTable" roleURI="http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyGeographicAreaTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable" roleURI="http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ScheduleofOtherExpensesNetTable" roleURI="http://immucell.com/role/ScheduleofOtherExpensesNetTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ScheduleofSegmentInformationTable" roleURI="http://immucell.com/role/ScheduleofSegmentInformationTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_CashandCashEquivalentsDetails" roleURI="http://immucell.com/role/CashandCashEquivalentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_TradeAccountsReceivableDetails" roleURI="http://immucell.com/role/TradeAccountsReceivableDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_InventoryDetails" roleURI="http://immucell.com/role/InventoryDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_PropertyPlantandEquipmentNetDetails" roleURI="http://immucell.com/role/PropertyPlantandEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_IntangibleAssetsDetails" roleURI="http://immucell.com/role/IntangibleAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_BankDebtDetails" roleURI="http://immucell.com/role/BankDebtDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ContingentLiabilitiesandCommitmentsDetails" roleURI="http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_OperatingLeaseDetails" roleURI="http://immucell.com/role/OperatingLeaseDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_StockholdersEquityDetails" roleURI="http://immucell.com/role/StockholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_OtherExpensesNetDetails" roleURI="http://immucell.com/role/OtherExpensesNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_IncomeTaxesDetails" roleURI="http://immucell.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_SegmentInformationDetails" roleURI="http://immucell.com/role/SegmentInformationDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_RelatedPartyTransactionsDetails" roleURI="http://immucell.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_EmployeeBenefitsDetails" roleURI="http://immucell.com/role/EmployeeBenefitsDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_SubsequentEventsDetails" roleURI="http://immucell.com/role/SubsequentEventsDetails"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:role="http://immucell.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Goodwill" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligations" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_Liabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockCommonValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TreasuryStockCommonShares" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_SellingAndMarketingExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_OperatingExpenses" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="14" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockCommonMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ShareholdersEquityType2or3_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="iccc_OfferingCostsOnFollowUpOfferingOfCommonStock" xlink:href="iccc-20240930.xsd#iccc_OfferingCostsOnFollowUpOfferingOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="iccc_OfferingCostsOnFollowUpOfferingOfCommonStock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireOtherProductiveAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLinesOfCredit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfDebt" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses" xlink:href="iccc-20240930.xsd#iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability" xlink:href="iccc-20240930.xsd#iccc_DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="iccc_DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/BusinessOperations" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/CashandCashEquivalents" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/TradeAccountsReceivable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesNetCurrentAbstract" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/Inventory" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/PrepaidExpensesandOtherCurrentAssets" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherCurrentAssetsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/PropertyPlantandEquipmentNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/IntangibleAssets" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/AccountsPayableandAccruedExpenses" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/BankDebt" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ContingentLiabilitiesandCommitments" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/OperatingLease" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/StockholdersEquity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/Revenue" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/OtherExpensesNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/IncomeTaxes" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/SegmentInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/RelatedPartyTransactions" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/EmployeeBenefits" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesPolicyTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_ExpenseRecognitionPolicyTextBlock" xlink:href="iccc-20240930.xsd#iccc_ExpenseRecognitionPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="iccc_ExpenseRecognitionPolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="16" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/InventoryTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/PrepaidExpensesandOtherCurrentAssetsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/PropertyPlantandEquipmentNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/IntangibleAssetsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/AccountsPayableandAccruedExpensesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/BankDebtTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/OperatingLeaseTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/StockholdersEquityTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/RevenueTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/OtherExpensesNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherExpensesAbstract" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/SegmentInformationTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <loc xlink:type="locator" xlink:label="iccc_SummaryofSignificantAccountingPoliciesDetailsScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable" xlink:href="iccc-20240930.xsd#iccc_SummaryofSignificantAccountingPoliciesDetailsScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="iccc_SummaryofSignificantAccountingPoliciesDetailsScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_SummaryofSignificantAccountingPoliciesDetailsScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_SummaryofSignificantAccountingPoliciesDetailsScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_ShortTermBorrowings" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ScheduleofConcentrationofRiskTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_MajorCustomersAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_CompanyAMember" xlink:href="iccc-20240930.xsd#iccc_CompanyAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="iccc_CompanyAMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_CompanyBMember" xlink:href="iccc-20240930.xsd#iccc_CompanyBMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="iccc_CompanyBMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ScheduleofInventoryTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryRawMaterials" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryWorkInProcess" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryFinishedGoods" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryNet" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ManufacturingFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ManufacturingFacilityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ManufacturingFacilityMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingImprovementsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LandMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LandMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ScheduleofIntangibleAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_DevelopedTechnologyRightsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRelationshipsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_CustomerRelationshipsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncompeteAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_NoncompeteAgreementsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedPayrollTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedPayrollTaxesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedPayrollTaxesCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:label="iccc_BankDebtDetailsScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable" xlink:href="iccc-20240930.xsd#iccc_BankDebtDetailsScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="iccc_BankDebtDetailsScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_BankDebtDetailsScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodFourMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFourMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFiveMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodFiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFiveMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtInstrumentRedemptionPeriodSixMember" xlink:href="iccc-20240930.xsd#iccc_DebtInstrumentRedemptionPeriodSixMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="iccc_DebtInstrumentRedemptionPeriodSixMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtInstrumentRedemptionPeriodSevenMember" xlink:href="iccc-20240930.xsd#iccc_DebtInstrumentRedemptionPeriodSevenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="iccc_DebtInstrumentRedemptionPeriodSevenMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfBankDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfBankDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfBankDebt" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <loc xlink:type="locator" xlink:label="iccc_BankDebtDetailsScheduleofPrincipalPaymentsBankLoansOutstandingTable" xlink:href="iccc-20240930.xsd#iccc_BankDebtDetailsScheduleofPrincipalPaymentsBankLoansOutstandingTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="iccc_BankDebtDetailsScheduleofPrincipalPaymentsBankLoansOutstandingTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_BankDebtDetailsScheduleofPrincipalPaymentsBankLoansOutstandingTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodFourMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFourMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFiveMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodFiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFiveMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtInstrumentRedemptionPeriodSixMember" xlink:href="iccc-20240930.xsd#iccc_DebtInstrumentRedemptionPeriodSixMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="iccc_DebtInstrumentRedemptionPeriodSixMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtInstrumentRedemptionPeriodSevenMember" xlink:href="iccc-20240930.xsd#iccc_DebtInstrumentRedemptionPeriodSevenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="iccc_DebtInstrumentRedemptionPeriodSevenMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_SubtotalMember" xlink:href="iccc-20240930.xsd#iccc_SubtotalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="iccc_SubtotalMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LongTermDebt" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtIssuanceCosts2024" xlink:href="iccc-20240930.xsd#iccc_DebtIssuanceCosts2024"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="iccc_DebtIssuanceCosts2024" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtIssuanceCosts2025" xlink:href="iccc-20240930.xsd#iccc_DebtIssuanceCosts2025"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbY2yHOqde+bt8NhnsjkMwInWzkiaYJmrGBX9ANHbqN6KcdyN7/tlo+8zitcBZOpZd5FWkDhY6SIAlueCv6TZ3/kC1CNAnKV2ZM7jOQVc9F1lsdJG5gYEVlBk/tvI9EzlbPJ58JKwU1IierSRHypv+o52xo9lJjv1QMjVMw9zPSP42NFNgXQ/4M9AGq8qRwbyg5efpEjDIG2QiPWZiVEuwm65IIpyzdqsMAvVRb3bLygVotY58EkisW] CSR-->
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="iccc_DebtIssuanceCosts2025" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtIssuanceCosts2026" xlink:href="iccc-20240930.xsd#iccc_DebtIssuanceCosts2026"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="iccc_DebtIssuanceCosts2026" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtIssuanceCosts2027" xlink:href="iccc-20240930.xsd#iccc_DebtIssuanceCosts2027"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="iccc_DebtIssuanceCosts2027" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtIssuanceCosts2028" xlink:href="iccc-20240930.xsd#iccc_DebtIssuanceCosts2028"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="iccc_DebtIssuanceCosts2028" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtIssuanceCostshereafter" xlink:href="iccc-20240930.xsd#iccc_DebtIssuanceCostshereafter"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="iccc_DebtIssuanceCostshereafter" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtDiscountCost" xlink:href="iccc-20240930.xsd#iccc_DebtDiscountCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="iccc_DebtDiscountCost" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtDiscountCost2025" xlink:href="iccc-20240930.xsd#iccc_DebtDiscountCost2025"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="iccc_DebtDiscountCost2025" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtDiscountCost2026" xlink:href="iccc-20240930.xsd#iccc_DebtDiscountCost2026"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="iccc_DebtDiscountCost2026" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtDiscountCost2027" xlink:href="iccc-20240930.xsd#iccc_DebtDiscountCost2027"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="iccc_DebtDiscountCost2027" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtDiscountCost2028" xlink:href="iccc-20240930.xsd#iccc_DebtDiscountCost2028"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="iccc_DebtDiscountCost2028" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtDiscountCostThereafter" xlink:href="iccc-20240930.xsd#iccc_DebtDiscountCostThereafter"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="iccc_DebtDiscountCostThereafter" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtDiscountCostTotal" xlink:href="iccc-20240930.xsd#iccc_DebtDiscountCostTotal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="iccc_DebtDiscountCostTotal" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_LongTermDebt2024" xlink:href="iccc-20240930.xsd#iccc_LongTermDebt2024"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="iccc_LongTermDebt2024" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_LongTermDebt2025" xlink:href="iccc-20240930.xsd#iccc_LongTermDebt2025"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="iccc_LongTermDebt2025" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_LongTermDebt2026" xlink:href="iccc-20240930.xsd#iccc_LongTermDebt2026"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="iccc_LongTermDebt2026" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_LongTermDebt2027" xlink:href="iccc-20240930.xsd#iccc_LongTermDebt2027"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="iccc_LongTermDebt2027" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_LongTermDebtTotal2028" xlink:href="iccc-20240930.xsd#iccc_LongTermDebtTotal2028"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="iccc_LongTermDebtTotal2028" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_LongTermDebtThereafter" xlink:href="iccc-20240930.xsd#iccc_LongTermDebtThereafter"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="iccc_LongTermDebtThereafter" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="28" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LeaseCostAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_VariableLeaseCost" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesOperatingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesOperatingAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LeasesOperatingAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DuringTheYearsEndingDecember31Abstract" xlink:href="iccc-20240930.xsd#iccc_DuringTheYearsEndingDecember31Abstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="iccc_DuringTheYearsEndingDecember31Abstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_DuringTheYearsEndingDecember31Abstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_DuringTheYearsEndingDecember31Abstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_DuringTheYearsEndingDecember31Abstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_DuringTheYearsEndingDecember31Abstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:label="iccc_StockholdersEquityDetailsScheduleofActivityUndertheStockOptionPlansTable" xlink:href="iccc-20240930.xsd#iccc_StockholdersEquityDetailsScheduleofActivityUndertheStockOptionPlansTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iccc_StockholdersEquityDetailsScheduleofActivityUndertheStockOptionPlansTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_StockholdersEquityDetailsScheduleofActivityUndertheStockOptionPlansTable" xlink:to="us-gaap_PlanNameAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_TwoThousandTenPlanMember" xlink:href="iccc-20240930.xsd#iccc_TwoThousandTenPlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="iccc_TwoThousandTenPlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_TwoThousandSeventeenPlanMember" xlink:href="iccc-20240930.xsd#iccc_TwoThousandSeventeenPlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="iccc_TwoThousandSeventeenPlanMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested" xlink:href="iccc-20240930.xsd#iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested" xlink:href="iccc-20240930.xsd#iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue" xlink:href="iccc-20240930.xsd#iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="iccc_StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansLineItems" xlink:href="iccc-20240930.xsd#iccc_StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansLineItems"/>
    <loc xlink:type="locator" xlink:label="iccc_StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansTable" xlink:href="iccc-20240930.xsd#iccc_StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iccc_StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansLineItems" xlink:to="iccc_StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ScheduleofFairValueStockOptionGrantUsingBlackScholesOptionPricingModelwithWeightedAverageAssumptionsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyGeographicAreaTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <loc xlink:type="locator" xlink:label="iccc_RevenueDetailsScheduleofProductSalesDisaggregatedbyGeographicAreaTable" xlink:href="iccc-20240930.xsd#iccc_RevenueDetailsScheduleofProductSalesDisaggregatedbyGeographicAreaTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="iccc_RevenueDetailsScheduleofProductSalesDisaggregatedbyGeographicAreaTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_RevenueDetailsScheduleofProductSalesDisaggregatedbyGeographicAreaTable" xlink:to="srt_StatementGeographicalAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_OtherStatesMember" xlink:href="iccc-20240930.xsd#iccc_OtherStatesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="iccc_OtherStatesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_RevenueSalesObligationPercentage" xlink:href="iccc-20240930.xsd#iccc_RevenueSalesObligationPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="iccc_RevenueSalesObligationPercentage" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_FirstDefenseProductLineMember" xlink:href="iccc-20240930.xsd#iccc_FirstDefenseProductLineMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="iccc_FirstDefenseProductLineMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_OtherAnimalHealthMember" xlink:href="iccc-20240930.xsd#iccc_OtherAnimalHealthMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="iccc_OtherAnimalHealthMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationPercentage" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ScheduleofOtherExpensesNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="iccc_ScheduleOfOtherExpensesNetAbstract" xlink:href="iccc-20240930.xsd#iccc_ScheduleOfOtherExpensesNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_ScheduleOfOtherExpensesNetAbstract" xlink:to="us-gaap_InterestExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_ScheduleOfOtherExpensesNetAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_ScheduleOfOtherExpensesNetAbstract" xlink:to="us-gaap_InterestIncomeOther" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InsuranceRecoveries" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InsuranceRecoveries"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_ScheduleOfOtherExpensesNetAbstract" xlink:to="us-gaap_InsuranceRecoveries" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_ScheduleOfOtherExpensesNetAbstract" xlink:to="us-gaap_OtherIncome" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iccc_ScheduleOfOtherExpensesNetAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ScheduleofSegmentInformationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_ScoursMember" xlink:href="iccc-20240930.xsd#iccc_ScoursMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="iccc_ScoursMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_MastitisMember" xlink:href="iccc-20240930.xsd#iccc_MastitisMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="iccc_MastitisMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllOtherSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherSegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_AllOtherSegmentsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_GrossProfit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SellingAndMarketingExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_OperatingExpenses" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_Assets" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostDepreciationAmortizationAndDepletion" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostDepreciationAmortizationAndDepletion"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_CostDepreciationAmortizationAndDepletion" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:label="iccc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="iccc-20240930.xsd#iccc_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="iccc_SummaryofSignificantAccountingPoliciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_NisinDrugSubstanceMember" xlink:href="iccc-20240930.xsd#iccc_NisinDrugSubstanceMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="iccc_NisinDrugSubstanceMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFDICInsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_CashFDICInsuredAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/CashandCashEquivalentsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/TradeAccountsReceivableDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <loc xlink:type="locator" xlink:label="iccc_TradeAccountsReceivableDetailsTable" xlink:href="iccc-20240930.xsd#iccc_TradeAccountsReceivableDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="iccc_TradeAccountsReceivableDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_TradeAccountsReceivableDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/InventoryDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryWriteDown" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/PropertyPlantandEquipmentNetDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisposals"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisposals" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_Depreciation" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/IntangibleAssetsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="iccc_IntangibleAssetsDetailsTable" xlink:href="iccc-20240930.xsd#iccc_IntangibleAssetsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="iccc_IntangibleAssetsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_IntangibleAssetsDetailsTable" xlink:to="srt_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/BankDebtDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionLineItems"/>
    <loc xlink:type="locator" xlink:label="iccc_BankDebtDetailsTable" xlink:href="iccc-20240930.xsd#iccc_BankDebtDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="iccc_BankDebtDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_BankDebtDetailsTable" xlink:to="srt_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_BankDebtDetailsTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_BankDebtDetailsTable" xlink:to="srt_RangeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_BankDebtDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_BankDebtDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_GorhamSavingsBankMember" xlink:href="iccc-20240930.xsd#iccc_GorhamSavingsBankMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="iccc_GorhamSavingsBankMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_MaineTechnologyInstituteMember" xlink:href="iccc-20240930.xsd#iccc_MaineTechnologyInstituteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="iccc_MaineTechnologyInstituteMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MortgageBankingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MortgageBankingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_MortgageBankingMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodFourMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFourMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtInstrumentRedemptionPeriodSixMember" xlink:href="iccc-20240930.xsd#iccc_DebtInstrumentRedemptionPeriodSixMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="iccc_DebtInstrumentRedemptionPeriodSixMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFiveMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodFiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFiveMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtInstrumentRedemptionPeriodSevenMember" xlink:href="iccc-20240930.xsd#iccc_DebtInstrumentRedemptionPeriodSevenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="iccc_DebtInstrumentRedemptionPeriodSevenMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_BankLoansMember" xlink:href="iccc-20240930.xsd#iccc_BankLoansMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="iccc_BankLoansMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsCurrentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DeferredFinanceCostsCurrentNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EscrowDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EscrowDeposit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_EscrowDeposit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_InterestPaymentsTerm" xlink:href="iccc-20240930.xsd#iccc_InterestPaymentsTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="iccc_InterestPaymentsTerm" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_LineOfCredit" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DerivativeFixedInterestRate" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_LoanToValueRatio" xlink:href="iccc-20240930.xsd#iccc_LoanToValueRatio"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="iccc_LoanToValueRatio" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivableLoanInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivableLoanInProcess"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_FinancingReceivableLoanInProcess" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtServiceCoverageRatio" xlink:href="iccc-20240930.xsd#iccc_DebtServiceCoverageRatio"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="iccc_DebtServiceCoverageRatio" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsCurrentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsCurrentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DeferredFinanceCostsCurrentGross" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestCostsIncurred" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestCostsIncurred"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_InterestCostsIncurred" order="17" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <loc xlink:type="locator" xlink:label="iccc_ContingentLiabilitiesandCommitmentsDetailsTable" xlink:href="iccc-20240930.xsd#iccc_ContingentLiabilitiesandCommitmentsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="iccc_ContingentLiabilitiesandCommitmentsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_ContingentLiabilitiesandCommitmentsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_ContingentLiabilitiesandCommitmentsDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_ReTainMember" xlink:href="iccc-20240930.xsd#iccc_ReTainMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="iccc_ReTainMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_MrBrighamMember" xlink:href="iccc-20240930.xsd#iccc_MrBrighamMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="iccc_MrBrighamMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_CapitalExpendituresCommitted" xlink:href="iccc-20240930.xsd#iccc_CapitalExpendituresCommitted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="iccc_CapitalExpendituresCommitted" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_PurchaseofInventory" xlink:href="iccc-20240930.xsd#iccc_PurchaseofInventory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="iccc_PurchaseofInventory" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_CommitmentsRelatedToCommercialManufacture" xlink:href="iccc-20240930.xsd#iccc_CommitmentsRelatedToCommercialManufacture"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="iccc_CommitmentsRelatedToCommercialManufacture" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_CommitmentsRelatedToInformationTechnologyServicesAndOtherObligations" xlink:href="iccc-20240930.xsd#iccc_CommitmentsRelatedToInformationTechnologyServicesAndOtherObligations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="iccc_CommitmentsRelatedToInformationTechnologyServicesAndOtherObligations" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/OperatingLeaseDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansAndLeasesReceivableDisclosureLineItems"/>
    <loc xlink:type="locator" xlink:label="iccc_OperatingLeaseDetailsTable" xlink:href="iccc-20240930.xsd#iccc_OperatingLeaseDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="iccc_OperatingLeaseDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_OperatingLeaseDetailsTable" xlink:to="srt_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_OperatingLeaseDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AreaOfLand" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfLand"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_AreaOfLand" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_PaymentsForRent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/StockholdersEquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <loc xlink:type="locator" xlink:label="iccc_StockholdersEquityDetailsTable" xlink:href="iccc-20240930.xsd#iccc_StockholdersEquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="iccc_StockholdersEquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_StockholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_StockholdersEquityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_StockholdersEquityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_StockholdersEquityDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_StockholdersEquityDetailsTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_StockholdersEquityDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_StockholdersEquityDetailsTable" xlink:to="srt_RangeAxis" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_StockholdersEquityDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_TwoThousandTenPlansMember" xlink:href="iccc-20240930.xsd#iccc_TwoThousandTenPlansMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="iccc_TwoThousandTenPlansMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_TwoThousandSeventeenPlansMember" xlink:href="iccc-20240930.xsd#iccc_TwoThousandSeventeenPlansMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="iccc_TwoThousandSeventeenPlansMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_ATMAgreementMember" xlink:href="iccc-20240930.xsd#iccc_ATMAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="iccc_ATMAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_CommonStockIssuancesMember" xlink:href="iccc-20240930.xsd#iccc_CommonStockIssuancesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="iccc_CommonStockIssuancesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_AcquiringPersonMember" xlink:href="iccc-20240930.xsd#iccc_AcquiringPersonMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="iccc_AcquiringPersonMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_NetProceedsFromIssuanceOfCommonStock" xlink:href="iccc-20240930.xsd#iccc_NetProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="iccc_NetProceedsFromIssuanceOfCommonStock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIssuedPrincipal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_FeesInitiallyCapitalizedAndLaterOffset" xlink:href="iccc-20240930.xsd#iccc_FeesInitiallyCapitalizedAndLaterOffset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="iccc_FeesInitiallyCapitalizedAndLaterOffset" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesCommissionsAndFees" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesCommissionsAndFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SalesCommissionsAndFees" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_ExercisableAndTransferableDescription" xlink:href="iccc-20240930.xsd#iccc_ExercisableAndTransferableDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="iccc_ExercisableAndTransferableDescription" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentCompanyPurchasePremiumPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentCompanyPurchasePremiumPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_InvestmentCompanyPurchasePremiumPerShare" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostChangeDueToSubsequentInterimMeasurementWeightedAverageExpectedLongTermRateOfReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostChangeDueToSubsequentInterimMeasurementWeightedAverageExpectedLongTermRateOfReturnOnPlanAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostChangeDueToSubsequentInterimMeasurementWeightedAverageExpectedLongTermRateOfReturnOnPlanAssets" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_RightToAcquirePerShare" xlink:href="iccc-20240930.xsd#iccc_RightToAcquirePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="iccc_RightToAcquirePerShare" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_AcquiringPersonPercentage" xlink:href="iccc-20240930.xsd#iccc_AcquiringPersonPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="iccc_AcquiringPersonPercentage" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription" order="30" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/OtherExpensesNetDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherExpensesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/IncomeTaxesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <loc xlink:type="locator" xlink:label="iccc_IncomeTaxesDetailsTable" xlink:href="iccc-20240930.xsd#iccc_IncomeTaxesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="iccc_IncomeTaxesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_IncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_FederalGeneralBusinessMember" xlink:href="iccc-20240930.xsd#iccc_FederalGeneralBusinessMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="iccc_FederalGeneralBusinessMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_StateTaxCreditMember" xlink:href="iccc-20240930.xsd#iccc_StateTaxCreditMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="iccc_StateTaxCreditMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_TaxCreditCarryforwardDescription" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeTaxExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeTaxExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OtherNoncashIncomeTaxExpense" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/SegmentInformationDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfReportableSegments" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:label="iccc_RelatedPartyTransactionsDetailsTable" xlink:href="iccc-20240930.xsd#iccc_RelatedPartyTransactionsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="iccc_RelatedPartyTransactionsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsReceivableNet" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/EmployeeBenefitsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <loc xlink:type="locator" xlink:label="iccc_EmployeeBenefitsDetailsTable" xlink:href="iccc-20240930.xsd#iccc_EmployeeBenefitsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="iccc_EmployeeBenefitsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_EmployeeBenefitsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_EmployeeMember" xlink:href="iccc-20240930.xsd#iccc_EmployeeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="iccc_EmployeeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_EmployeeOneMember" xlink:href="iccc-20240930.xsd#iccc_EmployeeOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="iccc_EmployeeOneMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_EmployeesSalaryPercentage" xlink:href="iccc-20240930.xsd#iccc_EmployeesSalaryPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="iccc_EmployeesSalaryPercentage" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_EmployeesSalaryContributionPercentage" xlink:href="iccc-20240930.xsd#iccc_EmployeesSalaryContributionPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="iccc_EmployeesSalaryContributionPercentage" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/SubsequentEventsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <loc xlink:type="locator" xlink:label="iccc_SubsequentEventsDetailsTable" xlink:href="iccc-20240930.xsd#iccc_SubsequentEventsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="iccc_SubsequentEventsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_SubsequentEventsDetailsTable" xlink:to="dei_LegalEntityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain_0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_ATMAgreementMember" xlink:href="iccc-20240930.xsd#iccc_ATMAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="iccc_ATMAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>iccc-20240930_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Nov 11 21:15:33 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Total Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total long-term liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">TOTAL LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">TOTAL STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross margin</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GrossProfit_lbl0" xml:lang="en-US">Gross margin</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">NET OPERATING LOSS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">NET OPERATING INCOME (LOSS)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">LOSS BEFORE INCOME TAXES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET LOSS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US">Net loss attributable to stockholders (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl1" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash provided by (used for) operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used for investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash (used for) provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">BEGINNING CASH AND CASH EQUIVALENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">ENDING CASH AND CASH EQUIVALENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Business Operations [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xml:lang="en-US">Schedule of Net Income (Loss) Per Common Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average common shares outstanding - Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Diluted weighted average common shares outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesNetCurrentAbstract_lbl" xml:lang="en-US">Trade Accounts Receivable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrentAbstract" xlink:to="us-gaap_ReceivablesNetCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventory [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNetAbstract_lbl" xml:lang="en-US">Schedule of Inventory [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl0" xml:lang="en-US">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract_lbl" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, plant and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property, plant and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xml:lang="en-US">Intangible Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_lbl" xml:lang="en-US">Accounts Payable and Accrued Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Schedule of Accounts Payable and Accrued Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Bank Debt [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Contingent Liabilities and Commitments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Operating Lease [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeDisclosureAbstract_lbl" xml:lang="en-US">Schedule of Lease Costs and Other Lease Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total lease cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US">Schedule of Future Lease Payments Required Under Non-Cancelable Operating Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total lease payments (undiscounted cash flows)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Outstanding, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Outstanding, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Options outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding, Beginning balance (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Weighted Average Exercise Price, Outstanding, Ending balance (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding, Beginning balance (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding, Ending balance (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_ScheduleOfAdditionalInformationAboutTheStockOptionPlansAbstract" xlink:href="iccc-20240930.xsd#iccc_ScheduleOfAdditionalInformationAboutTheStockOptionPlansAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ScheduleOfAdditionalInformationAboutTheStockOptionPlansAbstract_lbl" xml:lang="en-US">Schedule of Additional Information About the Stock Option Plans [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ScheduleOfAdditionalInformationAboutTheStockOptionPlansAbstract" xlink:to="iccc_ScheduleOfAdditionalInformationAboutTheStockOptionPlansAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Number of Shares, Non-vested stock options as of beginning balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl0" xml:lang="en-US">Number of Shares, Non-vested stock options as of ending balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Fair Value at Grant Date, Non-vested stock options as of beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Weighted Average Fair Value at Grant Date, Non-vested stock options as of ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Non-vested stock options as of beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Weighted Average Exercise Price, Non-vested stock options as of ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US">Schedule of Fair Value Stock Option Grant Using Black-Scholes Option Pricing Model with Weighted-Average Assumptions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Revenue [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpensesAbstract_lbl" xml:lang="en-US">Other Expenses, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpensesAbstract" xlink:to="us-gaap_OtherExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_ScheduleOfOtherExpensesNetAbstract" xlink:href="iccc-20240930.xsd#iccc_ScheduleOfOtherExpensesNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ScheduleOfOtherExpensesNetAbstract_lbl" xml:lang="en-US">Schedule of Other Expenses Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ScheduleOfOtherExpensesNetAbstract" xlink:to="iccc_ScheduleOfOtherExpensesNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other expenses (income), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Taxes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">Employee Benefits [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Trade accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl0" xml:lang="en-US">Trade accounts receivable, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating lease right of use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Intangible assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl0" xml:lang="en-US">Net Book Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl1" xml:lang="en-US">Net value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl" xml:lang="en-US">Current portion of debt obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Current portion of operating lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">LONG-TERM LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations_lbl" xml:lang="en-US">Debt obligations, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">CONTINGENT LIABILITIES AND COMMITMENTS (See Note 11)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">STOCKHOLDER&#8217; EQUITY:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.10 par value per share, 15,000,000 and 15,000,000 shares authorized, 8,896,398 and 7,814,165 shares issued and 8,833,097 and 7,750,864 shares outstanding, as of September 30, 2024 and December 31, 2023, respectively.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockCommonShares_lbl" xml:lang="en-US">Treasury stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonShares" xlink:to="us-gaap_TreasuryStockCommonShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Product sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">Costs of goods sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Product development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xml:lang="en-US">Sales and marketing expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Basic weighted average common shares outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted average common shares outstanding - Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic net loss per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Basic (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted net loss per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">At-The-Market Offering of common stock, net of offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">At-The-Market Offering of common stock, net of offering costs (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Shares sold under at-the-market offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xml:lang="en-US">Shares sold during period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1"/>
    <loc xlink:type="locator" xlink:label="iccc_OfferingCostsOnFollowUpOfferingOfCommonStock" xlink:href="iccc-20240930.xsd#iccc_OfferingCostsOnFollowUpOfferingOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_OfferingCostsOnFollowUpOfferingOfCommonStock_lbl" xml:lang="en-US">Offering costs on at-the-market offering of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_OfferingCostsOnFollowUpOfferingOfCommonStock" xlink:to="iccc_OfferingCostsOnFollowUpOfferingOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash provided by (used for) operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl0" xml:lang="en-US">Depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl0" xml:lang="en-US">Intangible amortization expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Amortization of debt issuance costs and debt discounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from sale of property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US">Proceeds from debt issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl0" xml:lang="en-US">Proceeds from Debt Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from At-The-Market Offering, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Gross proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" xml:lang="en-US">Gross proceeds from at-the-market offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xml:lang="en-US">Proceeds from line of credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">CASH PAID FOR:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">NON-CASH ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses" xlink:href="iccc-20240930.xsd#iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses_lbl" xml:lang="en-US">Decrease in capital expenditures included in accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses" xlink:to="iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability" xlink:href="iccc-20240930.xsd#iccc_DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability_lbl" xml:lang="en-US">Increase in operating lease right-of-use asset and operating lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability" xlink:to="iccc_DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockCommonValue_lbl" xml:lang="en-US">Treasury stock, at cost, 63,301 shares as of both September 30, 2024 and December 31, 2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonValue" xlink:to="us-gaap_TreasuryStockCommonValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Other expenses (income), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Loss on disposal of property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US">Non-cash rent (benefit) expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Trade accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xml:lang="en-US">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireOtherProductiveAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireOtherProductiveAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_lbl" xml:lang="en-US">Line of credit repayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLinesOfCredit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US">Debt principal repayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US">Payments of debt issuance costs and debt discounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockCommonMember_lbl" xml:lang="en-US">Treasury Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonMember" xlink:to="us-gaap_TreasuryStockCommonMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">BUSINESS OPERATIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock_lbl" xml:lang="en-US">Schedule of Assets or Liabilities Measured at Fair Value on a Nonrecurring Basis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and money market accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US">Liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermBorrowings_lbl" xml:lang="en-US">Bank debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xml:lang="en-US">Schedule of Concentration of Risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration risk, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Net Income (Loss) Per Common Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xml:lang="en-US">Dilutive impact of share-based compensation awards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract_lbl" xml:lang="en-US">Net loss per share:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xml:lang="en-US">TRADE ACCOUNTS RECEIVABLE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US">Raw materials</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US">Work-in-process</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished goods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">PREPAID EXPENSES AND OTHER CURRENT ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY, PLANT AND EQUIPMENT, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property, Plant and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property, plant and equipment, Estimated Useful Lives (in years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0" xml:lang="en-US">Useful life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property, plant and equipment, gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">INTANGIBLE ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Gross Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl0" xml:lang="en-US">Intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">ACCOUNTS PAYABLE AND ACCRUED EXPENSES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accounts Payable and Accrued Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Accounts payable &#8211; trade</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Accounts payable &#8211; capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedPayrollTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedPayrollTaxesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedPayrollTaxesCurrent_lbl" xml:lang="en-US">Accrued payroll</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedPayrollTaxesCurrent" xlink:to="us-gaap_AccruedPayrollTaxesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued professional fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xml:lang="en-US">Income tax payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">BANK DEBT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US">Schedule of Debt Proceeds Received and Principal Repayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfBankDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfBankDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepaymentsOfBankDebt_lbl" xml:lang="en-US">Debt Principal Repayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfBankDebt" xlink:to="us-gaap_RepaymentsOfBankDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xml:lang="en-US">Schedule of Principal Payments Bank Loans Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_lbl" xml:lang="en-US">During the Three-Month Period Ending December 31, 2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xml:lang="en-US">During the Three-Month Period Ending December 31, 2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US">During the Three-Month Period Ending December 31, 2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xml:lang="en-US">During the Three-Month Period Ending December 31, 2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xml:lang="en-US">During the Three-Month Period Ending December 31, 2028</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_lbl" xml:lang="en-US">During the Three-Month Period Ending ,Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">During the Three-Month Period Ending, Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtDiscountCost2028" xlink:href="iccc-20240930.xsd#iccc_DebtDiscountCost2028"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_DebtDiscountCost2028_lbl" xml:lang="en-US">Debt discount cost 2028</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCost2028" xlink:to="iccc_DebtDiscountCost2028_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtDiscountCostThereafter" xlink:href="iccc-20240930.xsd#iccc_DebtDiscountCostThereafter"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_DebtDiscountCostThereafter_lbl" xml:lang="en-US">Debt discount cost Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCostThereafter" xlink:to="iccc_DebtDiscountCostThereafter_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_LongTermDebt2024" xlink:href="iccc-20240930.xsd#iccc_LongTermDebt2024"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_LongTermDebt2024_lbl" xml:lang="en-US">Total During the Three-Month Period Ending December 31, 2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebt2024" xlink:to="iccc_LongTermDebt2024_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_LongTermDebt2025" xlink:href="iccc-20240930.xsd#iccc_LongTermDebt2025"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_LongTermDebt2025_lbl" xml:lang="en-US">Total 2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebt2025" xlink:to="iccc_LongTermDebt2025_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_LongTermDebt2026" xlink:href="iccc-20240930.xsd#iccc_LongTermDebt2026"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_LongTermDebt2026_lbl" xml:lang="en-US">Total 2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebt2026" xlink:to="iccc_LongTermDebt2026_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_LongTermDebt2027" xlink:href="iccc-20240930.xsd#iccc_LongTermDebt2027"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_LongTermDebt2027_lbl" xml:lang="en-US">Total 2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebt2027" xlink:to="iccc_LongTermDebt2027_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_LongTermDebtTotal2028" xlink:href="iccc-20240930.xsd#iccc_LongTermDebtTotal2028"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_LongTermDebtTotal2028_lbl" xml:lang="en-US">Total 2028</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebtTotal2028" xlink:to="iccc_LongTermDebtTotal2028_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_LongTermDebtThereafter" xlink:href="iccc-20240930.xsd#iccc_LongTermDebtThereafter"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_LongTermDebtThereafter_lbl" xml:lang="en-US">Total Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebtThereafter" xlink:to="iccc_LongTermDebtThereafter_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">CONTINGENT LIABILITIES AND COMMITMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">OPERATING LEASE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of Lease Costs and Other Lease Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US">Lease Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US">Variable lease cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesOperatingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesOperatingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeasesOperatingAbstract_lbl" xml:lang="en-US">Operating Lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LeasesOperatingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Cash paid for operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term (in years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Future Lease Payments Required Under Non-Cancelable Operating Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">During the three-month period ending December 31, 2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DuringTheYearsEndingDecember31Abstract" xlink:href="iccc-20240930.xsd#iccc_DuringTheYearsEndingDecember31Abstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_DuringTheYearsEndingDecember31Abstract_lbl" xml:lang="en-US">During the years ending December 31,</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DuringTheYearsEndingDecember31Abstract" xlink:to="iccc_DuringTheYearsEndingDecember31Abstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2028</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total operating liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl0" xml:lang="en-US">Operating lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Activity Under the Stock Option Plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Number of Shares, Stock options granted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xml:lang="en-US">Stock options granted during period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Grants (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Terminations/forfeitures (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercises (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested" xlink:href="iccc-20240930.xsd#iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested_lbl" xml:lang="en-US">Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested" xlink:to="iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested" xlink:href="iccc-20240930.xsd#iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested_lbl" xml:lang="en-US">Weighted Average Exercise Price, Vested (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested" xlink:to="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue" xlink:href="iccc-20240930.xsd#iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Vested (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue" xlink:to="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Vested and expected to vest (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Vested and expected to vest (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Reserved for future grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0" xml:lang="en-US">Common stock reserved for future issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Additional Information About the Stock Option Plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Fair Value at Grant Date, Stock options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Stock options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Number of Shares, Stock options that vested (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Fair Value at Grant Date, Stock options that vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Stock options that vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xml:lang="en-US">Number of Shares, Stock options that were forfeited (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Fair Value at Grant Date, Stock options that were forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Stock options that were forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value Stock Option Grant Using Black-Scholes Option Pricing Model with Weighted-Average Assumptions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US">REVENUE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl" xml:lang="en-US">Schedule of Product Sales Disaggregated by Geographic Area</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US">Total product Sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl0" xml:lang="en-US">Total product sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl1" xml:lang="en-US">Product sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl1"/>
    <loc xlink:type="locator" xlink:label="iccc_RevenueSalesObligationPercentage" xlink:href="iccc-20240930.xsd#iccc_RevenueSalesObligationPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_RevenueSalesObligationPercentage_lbl" xml:lang="en-US">Percentage of product sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_RevenueSalesObligationPercentage" xlink:to="iccc_RevenueSalesObligationPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Schedule of Product Sales Disaggregated by Major Product Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage_lbl" xml:lang="en-US">Percentage of product sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:to="us-gaap_RevenueRemainingPerformanceObligationPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_lbl" xml:lang="en-US">OTHER EXPENSES, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:to="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of Other Expenses Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">SEGMENT INFORMATION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US">Schedule of Segment Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Product development expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostDepreciationAmortizationAndDepletion" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostDepreciationAmortizationAndDepletion"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostDepreciationAmortizationAndDepletion_lbl" xml:lang="en-US">Depreciation and amortization expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostDepreciationAmortizationAndDepletion" xlink:to="us-gaap_CostDepreciationAmortizationAndDepletion_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Capital Expenditures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US">EMPLOYEE BENEFITS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtIssuanceCosts2024" xlink:href="iccc-20240930.xsd#iccc_DebtIssuanceCosts2024"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iccc_DebtIssuanceCosts2024_lbl" xml:lang="en-US">Debt issuance costs During the Three-Month Period Ending December 31, 2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCosts2024" xlink:to="iccc_DebtIssuanceCosts2024_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtIssuanceCosts2025" xlink:href="iccc-20240930.xsd#iccc_DebtIssuanceCosts2025"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iccc_DebtIssuanceCosts2025_lbl" xml:lang="en-US">Debt issuance costs 2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCosts2025" xlink:to="iccc_DebtIssuanceCosts2025_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtIssuanceCosts2026" xlink:href="iccc-20240930.xsd#iccc_DebtIssuanceCosts2026"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iccc_DebtIssuanceCosts2026_lbl" xml:lang="en-US">Debt issuance costs 2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCosts2026" xlink:to="iccc_DebtIssuanceCosts2026_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtIssuanceCosts2027" xlink:href="iccc-20240930.xsd#iccc_DebtIssuanceCosts2027"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iccc_DebtIssuanceCosts2027_lbl" xml:lang="en-US">Debt issuance costs 2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCosts2027" xlink:to="iccc_DebtIssuanceCosts2027_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtIssuanceCosts2028" xlink:href="iccc-20240930.xsd#iccc_DebtIssuanceCosts2028"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iccc_DebtIssuanceCosts2028_lbl" xml:lang="en-US">Debt issuance costs 2028</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCosts2028" xlink:to="iccc_DebtIssuanceCosts2028_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtIssuanceCostshereafter" xlink:href="iccc-20240930.xsd#iccc_DebtIssuanceCostshereafter"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iccc_DebtIssuanceCostshereafter_lbl" xml:lang="en-US">Debt issuance costs Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCostshereafter" xlink:to="iccc_DebtIssuanceCostshereafter_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US">Debt issuance costs, Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtDiscountCost" xlink:href="iccc-20240930.xsd#iccc_DebtDiscountCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iccc_DebtDiscountCost_lbl" xml:lang="en-US">Debt discount cost During the Three-Month Period Ending December 31, 2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCost" xlink:to="iccc_DebtDiscountCost_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtDiscountCost2025" xlink:href="iccc-20240930.xsd#iccc_DebtDiscountCost2025"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iccc_DebtDiscountCost2025_lbl" xml:lang="en-US">Debt discount cost 2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCost2025" xlink:to="iccc_DebtDiscountCost2025_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtDiscountCost2026" xlink:href="iccc-20240930.xsd#iccc_DebtDiscountCost2026"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iccc_DebtDiscountCost2026_lbl" xml:lang="en-US">Debt discount cost 2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCost2026" xlink:to="iccc_DebtDiscountCost2026_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtDiscountCost2027" xlink:href="iccc-20240930.xsd#iccc_DebtDiscountCost2027"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iccc_DebtDiscountCost2027_lbl" xml:lang="en-US">Debt discount cost 2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCost2027" xlink:to="iccc_DebtDiscountCost2027_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtDiscountCostTotal" xlink:href="iccc-20240930.xsd#iccc_DebtDiscountCostTotal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iccc_DebtDiscountCostTotal_lbl" xml:lang="en-US">Debt discount cost Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCostTotal" xlink:to="iccc_DebtDiscountCostTotal_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed interest (discount effect of cash flows)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Terminations/forfeitures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercises</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Stock options exercised during period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl" xml:lang="en-US">Loss (gain) on disposal of property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestIncomeOther_lbl" xml:lang="en-US">Interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InsuranceRecoveries" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InsuranceRecoveries"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InsuranceRecoveries_lbl" xml:lang="en-US">Insurance recoveries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InsuranceRecoveries" xlink:to="us-gaap_InsuranceRecoveries_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US">Income - other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember_lbl" xml:lang="en-US">Fair Value, Nonrecurring [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsNonrecurringMember" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_CompanyAMember" xlink:href="iccc-20240930.xsd#iccc_CompanyAMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_CompanyAMember_lbl" xml:lang="en-US">Company A [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_CompanyAMember" xlink:to="iccc_CompanyAMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Product sales [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_CompanyBMember" xlink:href="iccc-20240930.xsd#iccc_CompanyBMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_CompanyBMember_lbl" xml:lang="en-US">Company B [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_CompanyBMember" xlink:to="iccc_CompanyBMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US">Trade accounts receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ManufacturingFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ManufacturingFacilityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ManufacturingFacilityMember_lbl" xml:lang="en-US">Laboratory and manufacturing equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManufacturingFacilityMember" xlink:to="us-gaap_ManufacturingFacilityMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BuildingImprovementsMember_lbl" xml:lang="en-US">Buildings and improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingImprovementsMember" xlink:to="us-gaap_BuildingImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office furniture and equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US">Construction in progress [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LandMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LandMember_lbl" xml:lang="en-US">Land [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandMember" xlink:to="us-gaap_LandMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DevelopedTechnologyRightsMember_lbl" xml:lang="en-US">Developed technology [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DevelopedTechnologyRightsMember" xlink:to="us-gaap_DevelopedTechnologyRightsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRelationshipsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CustomerRelationshipsMember_lbl" xml:lang="en-US">Customer relationships [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerRelationshipsMember" xlink:to="us-gaap_CustomerRelationshipsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncompeteAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncompeteAgreementsMember_lbl" xml:lang="en-US">Non-compete agreements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncompeteAgreementsMember" xlink:to="us-gaap_NoncompeteAgreementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember_lbl" xml:lang="en-US">Loan #1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl" xml:lang="en-US">Loan #2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember_lbl" xml:lang="en-US">Loan #3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodFourMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFourMember_lbl" xml:lang="en-US">Loan #4 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFourMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFourMember_lbl0" xml:lang="en-US">Loans #4 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFourMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFiveMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodFiveMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFiveMember_lbl" xml:lang="en-US">Loan #5 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodFiveMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFiveMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtInstrumentRedemptionPeriodSixMember" xlink:href="iccc-20240930.xsd#iccc_DebtInstrumentRedemptionPeriodSixMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_DebtInstrumentRedemptionPeriodSixMember_lbl" xml:lang="en-US">Loan #6 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtInstrumentRedemptionPeriodSixMember" xlink:to="iccc_DebtInstrumentRedemptionPeriodSixMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtInstrumentRedemptionPeriodSevenMember" xlink:href="iccc-20240930.xsd#iccc_DebtInstrumentRedemptionPeriodSevenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_DebtInstrumentRedemptionPeriodSevenMember_lbl" xml:lang="en-US">Loan #7 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtInstrumentRedemptionPeriodSevenMember" xlink:to="iccc_DebtInstrumentRedemptionPeriodSevenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_SubtotalMember" xlink:href="iccc-20240930.xsd#iccc_SubtotalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_SubtotalMember_lbl" xml:lang="en-US">Subtotal [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_SubtotalMember" xlink:to="iccc_SubtotalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_TwoThousandTenPlanMember" xlink:href="iccc-20240930.xsd#iccc_TwoThousandTenPlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_TwoThousandTenPlanMember_lbl" xml:lang="en-US">2010 Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_TwoThousandTenPlanMember" xlink:to="iccc_TwoThousandTenPlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_TwoThousandSeventeenPlanMember" xlink:href="iccc-20240930.xsd#iccc_TwoThousandSeventeenPlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_TwoThousandSeventeenPlanMember_lbl" xml:lang="en-US">2017 Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_TwoThousandSeventeenPlanMember" xlink:to="iccc_TwoThousandSeventeenPlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Stock Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_US_lbl" xml:lang="en-US">United States [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_OtherStatesMember" xlink:href="iccc-20240930.xsd#iccc_OtherStatesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_OtherStatesMember_lbl" xml:lang="en-US">Other [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_OtherStatesMember" xlink:to="iccc_OtherStatesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_FirstDefenseProductLineMember" xlink:href="iccc-20240930.xsd#iccc_FirstDefenseProductLineMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_FirstDefenseProductLineMember_lbl" xml:lang="en-US">First Defense&#174; product line [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_FirstDefenseProductLineMember" xlink:to="iccc_FirstDefenseProductLineMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_OtherAnimalHealthMember" xlink:href="iccc-20240930.xsd#iccc_OtherAnimalHealthMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_OtherAnimalHealthMember_lbl" xml:lang="en-US">Other animal health [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_OtherAnimalHealthMember" xlink:to="iccc_OtherAnimalHealthMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_ScoursMember" xlink:href="iccc-20240930.xsd#iccc_ScoursMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_ScoursMember_lbl" xml:lang="en-US">Scours [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ScoursMember" xlink:to="iccc_ScoursMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_MastitisMember" xlink:href="iccc-20240930.xsd#iccc_MastitisMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_MastitisMember_lbl" xml:lang="en-US">Mastitis [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_MastitisMember" xlink:to="iccc_MastitisMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllOtherSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherSegmentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllOtherSegmentsMember_lbl" xml:lang="en-US">Other [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllOtherSegmentsMember" xlink:to="us-gaap_AllOtherSegmentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" xml:lang="en-US">Option Indexed to Issuer&apos;s Equity, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Acquisition [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Jurisdiction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFDICInsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Federal deposit insurance corporation limits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_lbl" xml:lang="en-US">Asset depreciated percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:to="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US">Goodwill impairments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xml:lang="en-US">Impairment of recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Anti-dilutive amounted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US">Inventory write off</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisposals"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals_lbl" xml:lang="en-US">Property, plant and equipment disposals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisposals" xlink:to="us-gaap_PropertyPlantAndEquipmentDisposals_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Intangible asset amortized, useful lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsCurrentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet_lbl" xml:lang="en-US">Debt financing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsCurrentNet" xlink:to="us-gaap_DeferredFinanceCostsCurrentNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EscrowDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EscrowDeposit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EscrowDeposit_lbl" xml:lang="en-US">Escrow account</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EscrowDeposit" xlink:to="us-gaap_EscrowDeposit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtPercentageBearingFixedInterestRate_lbl" xml:lang="en-US">Bearing interest percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:to="us-gaap_LongTermDebtPercentageBearingFixedInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_InterestPaymentsTerm" xlink:href="iccc-20240930.xsd#iccc_InterestPaymentsTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_InterestPaymentsTerm_lbl" xml:lang="en-US">Interest payments, term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_InterestPaymentsTerm" xlink:to="iccc_InterestPaymentsTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_lbl" xml:lang="en-US">Balloon principal payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount_lbl" xml:lang="en-US">Mortgage debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount" xlink:to="us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized_lbl" xml:lang="en-US">Outstanding principal balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized" xlink:to="us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCredit_lbl" xml:lang="en-US">Line of credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Principal payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Loan amortization, term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeFixedInterestRate_lbl" xml:lang="en-US">Interest fixed rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFixedInterestRate" xlink:to="us-gaap_DerivativeFixedInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xml:lang="en-US">Proceeds from issuance of loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_LoanToValueRatio" xlink:href="iccc-20240930.xsd#iccc_LoanToValueRatio"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_LoanToValueRatio_lbl" xml:lang="en-US">Loan to value ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LoanToValueRatio" xlink:to="iccc_LoanToValueRatio_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivableLoanInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivableLoanInProcess"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinancingReceivableLoanInProcess_lbl" xml:lang="en-US">Finance loan provided</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingReceivableLoanInProcess" xlink:to="us-gaap_FinancingReceivableLoanInProcess_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtServiceCoverageRatio" xlink:href="iccc-20240930.xsd#iccc_DebtServiceCoverageRatio"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_DebtServiceCoverageRatio_lbl" xml:lang="en-US">DSC ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtServiceCoverageRatio" xlink:to="iccc_DebtServiceCoverageRatio_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsCurrentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsCurrentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFinanceCostsCurrentGross_lbl" xml:lang="en-US">Debt issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsCurrentGross" xlink:to="us-gaap_DeferredFinanceCostsCurrentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestCostsIncurred" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestCostsIncurred"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestCostsIncurred_lbl" xml:lang="en-US">Incurred costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestCostsIncurred" xlink:to="us-gaap_InterestCostsIncurred_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl" xml:lang="en-US">Total accrued amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent_lbl" xml:lang="en-US">Deferred compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent" xlink:to="us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage_lbl" xml:lang="en-US">Deferred compensation agreement annual base salary percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_CapitalExpendituresCommitted" xlink:href="iccc-20240930.xsd#iccc_CapitalExpendituresCommitted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_CapitalExpendituresCommitted_lbl" xml:lang="en-US">Capital expenditures committed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_CapitalExpendituresCommitted" xlink:to="iccc_CapitalExpendituresCommitted_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_PurchaseofInventory" xlink:href="iccc-20240930.xsd#iccc_PurchaseofInventory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_PurchaseofInventory_lbl" xml:lang="en-US">Purchase of inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_PurchaseofInventory" xlink:to="iccc_PurchaseofInventory_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_CommitmentsRelatedToCommercialManufacture" xlink:href="iccc-20240930.xsd#iccc_CommitmentsRelatedToCommercialManufacture"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_CommitmentsRelatedToCommercialManufacture_lbl" xml:lang="en-US">Commitments related to commercial manufacture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_CommitmentsRelatedToCommercialManufacture" xlink:to="iccc_CommitmentsRelatedToCommercialManufacture_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_CommitmentsRelatedToInformationTechnologyServicesAndOtherObligations" xlink:href="iccc-20240930.xsd#iccc_CommitmentsRelatedToInformationTechnologyServicesAndOtherObligations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_CommitmentsRelatedToInformationTechnologyServicesAndOtherObligations_lbl" xml:lang="en-US">Commitments related to information technology services and other obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_CommitmentsRelatedToInformationTechnologyServicesAndOtherObligations" xlink:to="iccc_CommitmentsRelatedToInformationTechnologyServicesAndOtherObligations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AreaOfLand" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfLand"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AreaOfLand_lbl" xml:lang="en-US">Square feet (in Square Feet)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US">Renew term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Additional rent payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Common stock shares sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xml:lang="en-US">Weighted average price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Sale of stock, per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_NetProceedsFromIssuanceOfCommonStock" xlink:href="iccc-20240930.xsd#iccc_NetProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_NetProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Net proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_NetProceedsFromIssuanceOfCommonStock" xlink:to="iccc_NetProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIssuedPrincipal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal_lbl" xml:lang="en-US">Issuance and sale (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIssuedPrincipal" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_FeesInitiallyCapitalizedAndLaterOffset" xlink:href="iccc-20240930.xsd#iccc_FeesInitiallyCapitalizedAndLaterOffset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_FeesInitiallyCapitalizedAndLaterOffset_lbl" xml:lang="en-US">Legal, accounting and other fees amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_FeesInitiallyCapitalizedAndLaterOffset" xlink:to="iccc_FeesInitiallyCapitalizedAndLaterOffset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesCommissionsAndFees" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesCommissionsAndFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesCommissionsAndFees_lbl" xml:lang="en-US">Sales commissions (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesCommissionsAndFees" xlink:to="us-gaap_SalesCommissionsAndFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Stock option expiration period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining life of options outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining life of the options exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Stock options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl" xml:lang="en-US">Stock options granted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Stock-based compensation related to non-vested stock options (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted-average period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased_lbl" xml:lang="en-US">Common stock purchase price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_ExercisableAndTransferableDescription" xlink:href="iccc-20240930.xsd#iccc_ExercisableAndTransferableDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_ExercisableAndTransferableDescription_lbl" xml:lang="en-US">Exercisable and transferable, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ExercisableAndTransferableDescription" xlink:to="iccc_ExercisableAndTransferableDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentCompanyPurchasePremiumPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentCompanyPurchasePremiumPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentCompanyPurchasePremiumPerShare_lbl" xml:lang="en-US">Purchase price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentCompanyPurchasePremiumPerShare" xlink:to="us-gaap_InvestmentCompanyPurchasePremiumPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostChangeDueToSubsequentInterimMeasurementWeightedAverageExpectedLongTermRateOfReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostChangeDueToSubsequentInterimMeasurementWeightedAverageExpectedLongTermRateOfReturnOnPlanAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostChangeDueToSubsequentInterimMeasurementWeightedAverageExpectedLongTermRateOfReturnOnPlanAssets_lbl" xml:lang="en-US">Common stock were changed percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostChangeDueToSubsequentInterimMeasurementWeightedAverageExpectedLongTermRateOfReturnOnPlanAssets" xlink:to="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostChangeDueToSubsequentInterimMeasurementWeightedAverageExpectedLongTermRateOfReturnOnPlanAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_lbl" xml:lang="en-US">Acquisition percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:to="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_RightToAcquirePerShare" xlink:href="iccc-20240930.xsd#iccc_RightToAcquirePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_RightToAcquirePerShare_lbl" xml:lang="en-US">Price per Right (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_RightToAcquirePerShare" xlink:to="iccc_RightToAcquirePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_AcquiringPersonPercentage" xlink:href="iccc-20240930.xsd#iccc_AcquiringPersonPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_AcquiringPersonPercentage_lbl" xml:lang="en-US">Percentage of acquiring person</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_AcquiringPersonPercentage" xlink:to="iccc_AcquiringPersonPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription_lbl" xml:lang="en-US">Extend the rights plan, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of debt issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_lbl" xml:lang="en-US">Loss income before income taxes, rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_lbl"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbY2yHOqde+bt8NhnsjkMwInWzkiaYJmrGBX9ANHbqN6KcdyN7/tlo+8zitcBZOpZd5FWkDhY6SIAlueCv6TZ3/kC1CNAnKV2ZM7jOQVc9F1lsdJG5gYEVlBk/tvI9EzlbPJ58JKwU1IierSRHypv+o52xo9lJjv1QMjVMw9zPSP42NFNgXQ/4M9AGq8qRwbyg5efpEjDIG2QiPWZiVEuwml7rT7AKT6U27yRwMncuMIg==] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xml:lang="en-US">Net operating loss carryforwards not expire</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xml:lang="en-US">Net operating loss carryforwards expire</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardDescription_lbl" xml:lang="en-US">Expiration term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardDescription" xlink:to="us-gaap_TaxCreditCarryforwardDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeTaxExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeTaxExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNoncashIncomeTaxExpense_lbl" xml:lang="en-US">Non-cash income tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeTaxExpense" xlink:to="us-gaap_OtherNoncashIncomeTaxExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Value of our deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Reportable business segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" xml:lang="en-US">Related party products purchased</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNet_lbl" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_EmployeesSalaryPercentage" xlink:href="iccc-20240930.xsd#iccc_EmployeesSalaryPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_EmployeesSalaryPercentage_lbl" xml:lang="en-US">Employee&#8217;s salary percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_EmployeesSalaryPercentage" xlink:to="iccc_EmployeesSalaryPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_EmployeesSalaryContributionPercentage" xlink:href="iccc-20240930.xsd#iccc_EmployeesSalaryContributionPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_EmployeesSalaryContributionPercentage_lbl" xml:lang="en-US">Employee&#8217;s salary contribution percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_EmployeesSalaryContributionPercentage" xlink:to="iccc_EmployeesSalaryContributionPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_lbl" xml:lang="en-US">Employee benefits paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:to="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xml:lang="en-US">Trade Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Operating Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xml:lang="en-US">Intangible Assets and Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Valuation of Long-Lived Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_ExpenseRecognitionPolicyTextBlock" xlink:href="iccc-20240930.xsd#iccc_ExpenseRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_ExpenseRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Expense Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ExpenseRecognitionPolicyTextBlock" xlink:to="iccc_ExpenseRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss Per Common Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements Not Yet Adopted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_NisinDrugSubstanceMember" xlink:href="iccc-20240930.xsd#iccc_NisinDrugSubstanceMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_NisinDrugSubstanceMember_lbl" xml:lang="en-US">Nisin Drug Substance [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_NisinDrugSubstanceMember" xlink:to="iccc_NisinDrugSubstanceMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioForecastMember_lbl" xml:lang="en-US">Forecast [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_GorhamSavingsBankMember" xlink:href="iccc-20240930.xsd#iccc_GorhamSavingsBankMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_GorhamSavingsBankMember_lbl" xml:lang="en-US">Gorham Savings Bank [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_GorhamSavingsBankMember" xlink:to="iccc_GorhamSavingsBankMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_MaineTechnologyInstituteMember" xlink:href="iccc-20240930.xsd#iccc_MaineTechnologyInstituteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_MaineTechnologyInstituteMember_lbl" xml:lang="en-US">Maine Technology Institute [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_MaineTechnologyInstituteMember" xlink:to="iccc_MaineTechnologyInstituteMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MortgageBankingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MortgageBankingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MortgageBankingMember_lbl" xml:lang="en-US">Mortgage Note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MortgageBankingMember" xlink:to="us-gaap_MortgageBankingMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_BankLoansMember" xlink:href="iccc-20240930.xsd#iccc_BankLoansMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_BankLoansMember_lbl" xml:lang="en-US">Bank Loans [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_BankLoansMember" xlink:to="iccc_BankLoansMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_MrBrighamMember" xlink:href="iccc-20240930.xsd#iccc_MrBrighamMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_MrBrighamMember_lbl" xml:lang="en-US">Mr. Brigham [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_MrBrighamMember" xlink:to="iccc_MrBrighamMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_ReTainMember" xlink:href="iccc-20240930.xsd#iccc_ReTainMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_ReTainMember_lbl" xml:lang="en-US">Re-Tain [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ReTainMember" xlink:to="iccc_ReTainMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BuildingMember_lbl" xml:lang="en-US">Building [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingMember" xlink:to="us-gaap_BuildingMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_CommonStockIssuancesMember" xlink:href="iccc-20240930.xsd#iccc_CommonStockIssuancesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_CommonStockIssuancesMember_lbl" xml:lang="en-US">Common Stock Issuances [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_CommonStockIssuancesMember" xlink:to="iccc_CommonStockIssuancesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_ATMAgreementMember" xlink:href="iccc-20240930.xsd#iccc_ATMAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_ATMAgreementMember_lbl" xml:lang="en-US">ATM Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ATMAgreementMember" xlink:to="iccc_ATMAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_TwoThousandTenPlansMember" xlink:href="iccc-20240930.xsd#iccc_TwoThousandTenPlansMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_TwoThousandTenPlansMember_lbl" xml:lang="en-US">2010 Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_TwoThousandTenPlansMember" xlink:to="iccc_TwoThousandTenPlansMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="iccc_TwoThousandTenPlansMember_lbl0" xml:lang="en-US">Two Thousand Ten Plans [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_TwoThousandTenPlansMember" xlink:to="iccc_TwoThousandTenPlansMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="iccc_TwoThousandSeventeenPlansMember" xlink:href="iccc-20240930.xsd#iccc_TwoThousandSeventeenPlansMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_TwoThousandSeventeenPlansMember_lbl" xml:lang="en-US">2017 Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_TwoThousandSeventeenPlansMember" xlink:to="iccc_TwoThousandSeventeenPlansMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Stock Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl0" xml:lang="en-US">Employee Stock Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="iccc_AcquiringPersonMember" xlink:href="iccc-20240930.xsd#iccc_AcquiringPersonMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_AcquiringPersonMember_lbl" xml:lang="en-US">Acquiring Person [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_AcquiringPersonMember" xlink:to="iccc_AcquiringPersonMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Federal [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_FederalGeneralBusinessMember" xlink:href="iccc-20240930.xsd#iccc_FederalGeneralBusinessMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_FederalGeneralBusinessMember_lbl" xml:lang="en-US">Federal General Business [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_FederalGeneralBusinessMember" xlink:to="iccc_FederalGeneralBusinessMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_StateTaxCreditMember" xlink:href="iccc-20240930.xsd#iccc_StateTaxCreditMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_StateTaxCreditMember_lbl" xml:lang="en-US">State Tax Credit [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_StateTaxCreditMember" xlink:to="iccc_StateTaxCreditMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_EmployeeMember" xlink:href="iccc-20240930.xsd#iccc_EmployeeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_EmployeeMember_lbl" xml:lang="en-US">Employee [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_EmployeeMember" xlink:to="iccc_EmployeeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_EmployeeOneMember" xlink:href="iccc-20240930.xsd#iccc_EmployeeOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_EmployeeOneMember_lbl" xml:lang="en-US">Employee One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_EmployeeOneMember" xlink:to="iccc_EmployeeOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US">Measurement Frequency [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_SummaryofSignificantAccountingPoliciesDetailsScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable" xlink:href="iccc-20240930.xsd#iccc_SummaryofSignificantAccountingPoliciesDetailsScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_SummaryofSignificantAccountingPoliciesDetailsScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) - Schedule of Assets or Liabilities Measured at Fair Value on a Nonrecurring Basis [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_SummaryofSignificantAccountingPoliciesDetailsScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable" xlink:to="iccc_SummaryofSignificantAccountingPoliciesDetailsScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Schedule of Assets or Liabilities Measured at Fair Value on a Nonrecurring Basis [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US">Customer [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US">Concentration Risk Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US">Concentration Risk [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US">Schedule of Concentration of Risk [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Schedule of Property, Plant and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Intangible Asset, Finite-Lived [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Schedule of Intangible Assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_BankDebtDetailsScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable" xlink:href="iccc-20240930.xsd#iccc_BankDebtDetailsScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_BankDebtDetailsScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable_lbl" xml:lang="en-US">Bank Debt (Details) - Schedule of Debt Proceeds Received and Principal Repayments [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_BankDebtDetailsScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable" xlink:to="iccc_BankDebtDetailsScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Schedule of Debt Proceeds Received and Principal Repayments [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_BankDebtDetailsScheduleofPrincipalPaymentsBankLoansOutstandingTable" xlink:href="iccc-20240930.xsd#iccc_BankDebtDetailsScheduleofPrincipalPaymentsBankLoansOutstandingTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_BankDebtDetailsScheduleofPrincipalPaymentsBankLoansOutstandingTable_lbl" xml:lang="en-US">Bank Debt (Details) - Schedule of Principal Payments Bank Loans Outstanding [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_BankDebtDetailsScheduleofPrincipalPaymentsBankLoansOutstandingTable" xlink:to="iccc_BankDebtDetailsScheduleofPrincipalPaymentsBankLoansOutstandingTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermPurchaseCommitmentLineItems_lbl" xml:lang="en-US">Schedule of Principal Payments Bank Loans Outstanding [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_StockholdersEquityDetailsScheduleofActivityUndertheStockOptionPlansTable" xlink:href="iccc-20240930.xsd#iccc_StockholdersEquityDetailsScheduleofActivityUndertheStockOptionPlansTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_StockholdersEquityDetailsScheduleofActivityUndertheStockOptionPlansTable_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Details) - Schedule of Activity Under the Stock Option Plans [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_StockholdersEquityDetailsScheduleofActivityUndertheStockOptionPlansTable" xlink:to="iccc_StockholdersEquityDetailsScheduleofActivityUndertheStockOptionPlansTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Schedule of Activity Under the Stock Option Plans [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xml:lang="en-US">Derivative Contract [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansTable" xlink:href="iccc-20240930.xsd#iccc_StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansTable_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Details) - Schedule of Additional Information About the Stock Option Plans [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansTable" xlink:to="iccc_StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansLineItems" xlink:href="iccc-20240930.xsd#iccc_StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansLineItems_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Details) - Schedule of Additional Information About the Stock Option Plans [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansLineItems" xlink:to="iccc_StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_RevenueDetailsScheduleofProductSalesDisaggregatedbyGeographicAreaTable" xlink:href="iccc-20240930.xsd#iccc_RevenueDetailsScheduleofProductSalesDisaggregatedbyGeographicAreaTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_RevenueDetailsScheduleofProductSalesDisaggregatedbyGeographicAreaTable_lbl" xml:lang="en-US">Revenue (Details) - Schedule of Product Sales Disaggregated by Geographic Area [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_RevenueDetailsScheduleofProductSalesDisaggregatedbyGeographicAreaTable" xlink:to="iccc_RevenueDetailsScheduleofProductSalesDisaggregatedbyGeographicAreaTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xml:lang="en-US">Schedule of Product Sales Disaggregated by Geographic Area [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xml:lang="en-US">Disaggregation of Revenue [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl0" xml:lang="en-US">Schedule of Product Sales Disaggregated by Major Product Category [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentDomain_lbl" xml:lang="en-US">Segments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US">Schedule of Segment Information [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="iccc-20240930.xsd#iccc_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_SummaryofSignificantAccountingPoliciesDetailsTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="iccc_SummaryofSignificantAccountingPoliciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related and Nonrelated Parties [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_TradeAccountsReceivableDetailsTable" xlink:href="iccc-20240930.xsd#iccc_TradeAccountsReceivableDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_TradeAccountsReceivableDetailsTable_lbl" xml:lang="en-US">Trade Accounts Receivable (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_TradeAccountsReceivableDetailsTable" xlink:to="iccc_TradeAccountsReceivableDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl" xml:lang="en-US">Trade Accounts Receivable [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_IntangibleAssetsDetailsTable" xlink:href="iccc-20240930.xsd#iccc_IntangibleAssetsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_IntangibleAssetsDetailsTable_lbl" xml:lang="en-US">Intangible Assets (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_IntangibleAssetsDetailsTable" xlink:to="iccc_IntangibleAssetsDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl0" xml:lang="en-US">Intangible Assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_BankDebtDetailsTable" xlink:href="iccc-20240930.xsd#iccc_BankDebtDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_BankDebtDetailsTable_lbl" xml:lang="en-US">Bank Debt (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_BankDebtDetailsTable" xlink:to="iccc_BankDebtDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionLineItems_lbl" xml:lang="en-US">Bank Debt [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtConversionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_ContingentLiabilitiesandCommitmentsDetailsTable" xlink:href="iccc-20240930.xsd#iccc_ContingentLiabilitiesandCommitmentsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ContingentLiabilitiesandCommitmentsDetailsTable_lbl" xml:lang="en-US">Contingent Liabilities and Commitments (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ContingentLiabilitiesandCommitmentsDetailsTable" xlink:to="iccc_ContingentLiabilitiesandCommitmentsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US">Contingent Liabilities and Commitments [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_OperatingLeaseDetailsTable" xlink:href="iccc-20240930.xsd#iccc_OperatingLeaseDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_OperatingLeaseDetailsTable_lbl" xml:lang="en-US">Operating Lease (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_OperatingLeaseDetailsTable" xlink:to="iccc_OperatingLeaseDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansAndLeasesReceivableDisclosureLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansAndLeasesReceivableDisclosureLineItems_lbl" xml:lang="en-US">Operating Leases [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_LoansAndLeasesReceivableDisclosureLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" xml:lang="en-US">Option Indexed to Issuer&apos;s Equity, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_StockholdersEquityDetailsTable" xlink:href="iccc-20240930.xsd#iccc_StockholdersEquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_StockholdersEquityDetailsTable_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_StockholdersEquityDetailsTable" xlink:to="iccc_StockholdersEquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Stockholders&#8217; Equity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US">Income Tax Jurisdiction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_IncomeTaxesDetailsTable" xlink:href="iccc-20240930.xsd#iccc_IncomeTaxesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_IncomeTaxesDetailsTable_lbl" xml:lang="en-US">Income Taxes (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_IncomeTaxesDetailsTable" xlink:to="iccc_IncomeTaxesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxContingencyLineItems_lbl" xml:lang="en-US">Income Taxes [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_RelatedPartyTransactionsDetailsTable" xlink:href="iccc-20240930.xsd#iccc_RelatedPartyTransactionsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_RelatedPartyTransactionsDetailsTable_lbl" xml:lang="en-US">Related Party Transactions (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_RelatedPartyTransactionsDetailsTable" xlink:to="iccc_RelatedPartyTransactionsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transactions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_EmployeeBenefitsDetailsTable" xlink:href="iccc-20240930.xsd#iccc_EmployeeBenefitsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_EmployeeBenefitsDetailsTable_lbl" xml:lang="en-US">Employee Benefits (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_EmployeeBenefitsDetailsTable" xlink:to="iccc_EmployeeBenefitsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Employee Benefits [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_SubsequentEventsDetailsTable" xlink:href="iccc-20240930.xsd#iccc_SubsequentEventsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_SubsequentEventsDetailsTable_lbl" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_SubsequentEventsDetailsTable" xlink:to="iccc_SubsequentEventsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Events [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_AcquiringPersonPercentage_lbl0" xml:lang="en-US">Percentage of acquiring person.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_AcquiringPersonPercentage" xlink:to="iccc_AcquiringPersonPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_CapitalExpendituresCommitted_lbl0" xml:lang="en-US">Capital expenditures committed.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_CapitalExpendituresCommitted" xlink:to="iccc_CapitalExpendituresCommitted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses_lbl0" xml:lang="en-US">Change in capital expenditures included in accounts payable and accrued expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses" xlink:to="iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_CommitmentsRelatedToCommercialManufacture_lbl0" xml:lang="en-US">Commitments related to commercial manufacture.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_CommitmentsRelatedToCommercialManufacture" xlink:to="iccc_CommitmentsRelatedToCommercialManufacture_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_CommitmentsRelatedToInformationTechnologyServicesAndOtherObligations_lbl0" xml:lang="en-US">Commitments related to information technology services and other obligations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_CommitmentsRelatedToInformationTechnologyServicesAndOtherObligations" xlink:to="iccc_CommitmentsRelatedToInformationTechnologyServicesAndOtherObligations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_DebtDiscountCost_lbl0" xml:lang="en-US">Debt discount cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCost" xlink:to="iccc_DebtDiscountCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_DebtDiscountCost2025_lbl0" xml:lang="en-US">Amount of debt discount cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCost2025" xlink:to="iccc_DebtDiscountCost2025_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_DebtDiscountCost2026_lbl0" xml:lang="en-US">Amount of debt discount cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCost2026" xlink:to="iccc_DebtDiscountCost2026_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_DebtDiscountCost2027_lbl0" xml:lang="en-US">Amount of debt discount cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCost2027" xlink:to="iccc_DebtDiscountCost2027_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_DebtDiscountCost2028_lbl0" xml:lang="en-US">Represent the amount of debt discount cost 2028.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCost2028" xlink:to="iccc_DebtDiscountCost2028_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_DebtDiscountCostThereafter_lbl0" xml:lang="en-US">Amount of debt discount cost thereafter.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCostThereafter" xlink:to="iccc_DebtDiscountCostThereafter_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_DebtDiscountCostTotal_lbl0" xml:lang="en-US">Amount of total debt discount cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCostTotal" xlink:to="iccc_DebtDiscountCostTotal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_DebtIssuanceCosts2024_lbl0" xml:lang="en-US">Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCosts2024" xlink:to="iccc_DebtIssuanceCosts2024_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_DebtIssuanceCosts2025_lbl0" xml:lang="en-US">Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCosts2025" xlink:to="iccc_DebtIssuanceCosts2025_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_DebtIssuanceCosts2026_lbl0" xml:lang="en-US">Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCosts2026" xlink:to="iccc_DebtIssuanceCosts2026_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_DebtIssuanceCosts2027_lbl0" xml:lang="en-US">Amount of debt issuance costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCosts2027" xlink:to="iccc_DebtIssuanceCosts2027_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_DebtIssuanceCosts2028_lbl0" xml:lang="en-US">Represent the amount of debt issuance costs 2028.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCosts2028" xlink:to="iccc_DebtIssuanceCosts2028_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_DebtIssuanceCostshereafter_lbl0" xml:lang="en-US">Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCostshereafter" xlink:to="iccc_DebtIssuanceCostshereafter_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_DebtServiceCoverageRatio_lbl0" xml:lang="en-US">Ratio applied to the debt service coverage ratio.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtServiceCoverageRatio" xlink:to="iccc_DebtServiceCoverageRatio_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability_lbl0" xml:lang="en-US">Represent the amount of (Decrease) increase in operating lease right-of-use asset and operating lease liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability" xlink:to="iccc_DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_EmployeesSalaryContributionPercentage_lbl0" xml:lang="en-US">Employee&#8217;s salary contribution percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_EmployeesSalaryContributionPercentage" xlink:to="iccc_EmployeesSalaryContributionPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_EmployeesSalaryPercentage_lbl0" xml:lang="en-US">Employee&#8217;s salary percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_EmployeesSalaryPercentage" xlink:to="iccc_EmployeesSalaryPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_ExercisableAndTransferableDescription_lbl0" xml:lang="en-US">Exercisable and transferable, description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ExercisableAndTransferableDescription" xlink:to="iccc_ExercisableAndTransferableDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_ExpenseRecognitionPolicyTextBlock_lbl0" xml:lang="en-US">Entire disclosure of accounting policy for expense recognition.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ExpenseRecognitionPolicyTextBlock" xlink:to="iccc_ExpenseRecognitionPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_FeesInitiallyCapitalizedAndLaterOffset_lbl0" xml:lang="en-US">Fees initially capitalized and later offset. Fees include legal, accounting and fees categorized as other.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_FeesInitiallyCapitalizedAndLaterOffset" xlink:to="iccc_FeesInitiallyCapitalizedAndLaterOffset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_InterestPaymentsTerm_lbl0" xml:lang="en-US">Amount of interest payments term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_InterestPaymentsTerm" xlink:to="iccc_InterestPaymentsTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_LoanToValueRatio_lbl0" xml:lang="en-US">The ratio of loan to value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LoanToValueRatio" xlink:to="iccc_LoanToValueRatio_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_LongTermDebt2024_lbl0" xml:lang="en-US">Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebt2024" xlink:to="iccc_LongTermDebt2024_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_LongTermDebt2025_lbl0" xml:lang="en-US">Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebt2025" xlink:to="iccc_LongTermDebt2025_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_LongTermDebt2026_lbl0" xml:lang="en-US">Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebt2026" xlink:to="iccc_LongTermDebt2026_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_LongTermDebt2027_lbl0" xml:lang="en-US">Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebt2027" xlink:to="iccc_LongTermDebt2027_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_LongTermDebtThereafter_lbl0" xml:lang="en-US">Long term debt thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebtThereafter" xlink:to="iccc_LongTermDebtThereafter_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_LongTermDebtTotal2028_lbl0" xml:lang="en-US">Represent the amount of long term debt total.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebtTotal2028" xlink:to="iccc_LongTermDebtTotal2028_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_NetProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">The net proceeds incurred from issuance of common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_NetProceedsFromIssuanceOfCommonStock" xlink:to="iccc_NetProceedsFromIssuanceOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_OfferingCostsOnFollowUpOfferingOfCommonStock_lbl0" xml:lang="en-US">Offering costs on follow-up offering of common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_OfferingCostsOnFollowUpOfferingOfCommonStock" xlink:to="iccc_OfferingCostsOnFollowUpOfferingOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_PurchaseofInventory_lbl0" xml:lang="en-US">Represent the amount of purchase of inventory.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_PurchaseofInventory" xlink:to="iccc_PurchaseofInventory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_RevenueSalesObligationPercentage_lbl0" xml:lang="en-US">Percentage of product sales is an act of selling a product or service in return of money or compensation or service.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_RevenueSalesObligationPercentage" xlink:to="iccc_RevenueSalesObligationPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_RightToAcquirePerShare_lbl0" xml:lang="en-US">Right to Acquire, Per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_RightToAcquirePerShare" xlink:to="iccc_RightToAcquirePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested_lbl0" xml:lang="en-US">Share based compensation arrangement by share based payment award options exercisable weighted average vested.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested" xlink:to="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue_lbl0" xml:lang="en-US">Amount by which current fair value of underlying stock exceeds exercise price of fully vested options outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue" xlink:to="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested" xlink:to="iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_OtherStatesMember_lbl0" xml:lang="en-US">Continent of Other States.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_OtherStatesMember" xlink:to="iccc_OtherStatesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_ReTainMember_lbl0" xml:lang="en-US">Re-Tain [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ReTainMember" xlink:to="iccc_ReTainMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_TwoThousandSeventeenPlanMember_lbl0" xml:lang="en-US">Two thousand seventeen plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_TwoThousandSeventeenPlanMember" xlink:to="iccc_TwoThousandSeventeenPlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_TwoThousandTenPlanMember_lbl0" xml:lang="en-US">Two thousand ten plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_TwoThousandTenPlanMember" xlink:to="iccc_TwoThousandTenPlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl1" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_StateTaxCreditMember_lbl0" xml:lang="en-US">State Tax Credit Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_StateTaxCreditMember" xlink:to="iccc_StateTaxCreditMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DebtDiscountCostThereafter_lbl1" xml:lang="en-US">Debt Discount Cost Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCostThereafter" xlink:to="iccc_DebtDiscountCostThereafter_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerRelationshipsMember_lbl0" xml:lang="en-US">Customer Relationships [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerRelationshipsMember" xlink:to="us-gaap_CustomerRelationshipsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl1" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl0" xml:lang="en-US">Long-Term Debt and Lease Obligation, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_lbl0" xml:lang="en-US">Long-Term Debt, Maturity, after Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableLeaseCost_lbl0" xml:lang="en-US">Variable Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_EmployeesSalaryContributionPercentage_lbl1" xml:lang="en-US">Employees Salary Contribution Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_EmployeesSalaryContributionPercentage" xlink:to="iccc_EmployeesSalaryContributionPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl0" xml:lang="en-US">Accrued Professional Fees, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl2" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DevelopedTechnologyRightsMember_lbl0" xml:lang="en-US">Developed Technology Rights [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DevelopedTechnologyRightsMember" xlink:to="us-gaap_DevelopedTechnologyRightsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl0" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_FederalGeneralBusinessMember_lbl0" xml:lang="en-US">Federal General Business Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_FederalGeneralBusinessMember" xlink:to="iccc_FederalGeneralBusinessMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent_lbl0" xml:lang="en-US">Other Deferred Compensation Arrangements, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent" xlink:to="us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage_lbl0" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BuildingMember_lbl0" xml:lang="en-US">Building [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingMember" xlink:to="us-gaap_BuildingMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl2" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage_lbl0" xml:lang="en-US">Revenue, Remaining Performance Obligation, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:to="us-gaap_RevenueRemainingPerformanceObligationPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl0" xml:lang="en-US">Other Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl0" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl0" xml:lang="en-US">Accounts Payable, Trade, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostChangeDueToSubsequentInterimMeasurementWeightedAverageExpectedLongTermRateOfReturnOnPlanAssets_lbl0" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Change Due to Subsequent Interim Measurement, Weighted-Average Expected Long-Term Rate of Return on Plan Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostChangeDueToSubsequentInterimMeasurementWeightedAverageExpectedLongTermRateOfReturnOnPlanAssets" xlink:to="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostChangeDueToSubsequentInterimMeasurementWeightedAverageExpectedLongTermRateOfReturnOnPlanAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressMember_lbl0" xml:lang="en-US">Construction in Progress [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember_lbl0" xml:lang="en-US">Debt Instrument, Redemption, Period Three [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl0" xml:lang="en-US">Prepaid Expense, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_OtherAnimalHealthMember_lbl0" xml:lang="en-US">Other Animal Health Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_OtherAnimalHealthMember" xlink:to="iccc_OtherAnimalHealthMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_CapitalExpendituresCommitted_lbl1" xml:lang="en-US">Capital Expenditures Committed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_CapitalExpendituresCommitted" xlink:to="iccc_CapitalExpendituresCommitted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioForecastMember_lbl0" xml:lang="en-US">Forecast [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl0" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl0" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl2" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DebtInstrumentRedemptionPeriodSixMember_lbl0" xml:lang="en-US">Debt Instrument Redemption Period Six Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtInstrumentRedemptionPeriodSixMember" xlink:to="iccc_DebtInstrumentRedemptionPeriodSixMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet_lbl0" xml:lang="en-US">Debt Issuance Costs, Current, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsCurrentNet" xlink:to="us-gaap_DeferredFinanceCostsCurrentNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl1" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl0" xml:lang="en-US">Inventory, Finished Goods, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DebtIssuanceCosts2028_lbl1" xml:lang="en-US">Debt Issuance Costs2028</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCosts2028" xlink:to="iccc_DebtIssuanceCosts2028_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DebtIssuanceCosts2027_lbl1" xml:lang="en-US">Debt Issuance Costs2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCosts2027" xlink:to="iccc_DebtIssuanceCosts2027_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DebtIssuanceCosts2026_lbl1" xml:lang="en-US">Debt Issuance Costs2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCosts2026" xlink:to="iccc_DebtIssuanceCosts2026_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DebtIssuanceCosts2025_lbl1" xml:lang="en-US">Debt Issuance Costs2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCosts2025" xlink:to="iccc_DebtIssuanceCosts2025_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DebtIssuanceCosts2024_lbl1" xml:lang="en-US">Debt Issuance Costs2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCosts2024" xlink:to="iccc_DebtIssuanceCosts2024_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract_lbl0" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebt_lbl0" xml:lang="en-US">Repayments of Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonMember_lbl0" xml:lang="en-US">Treasury Stock, Common [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonMember" xlink:to="us-gaap_TreasuryStockCommonMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl0" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl0" xml:lang="en-US">Accrued Income Taxes, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals_lbl0" xml:lang="en-US">Property, Plant and Equipment, Disposals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisposals" xlink:to="us-gaap_PropertyPlantAndEquipmentDisposals_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestCostsIncurred_lbl0" xml:lang="en-US">Interest Costs Incurred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestCostsIncurred" xlink:to="us-gaap_InterestCostsIncurred_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_lbl0" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonValue_lbl0" xml:lang="en-US">Treasury Stock, Common, Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonValue" xlink:to="us-gaap_TreasuryStockCommonValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl0" xml:lang="en-US">UNITED STATES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl0" xml:lang="en-US">Goodwill, Impairment Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EscrowDeposit_lbl0" xml:lang="en-US">Escrow Deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EscrowDeposit" xlink:to="us-gaap_EscrowDeposit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl2" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Other Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased_lbl0" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <loc xlink:type="locator" xlink:label="iccc_ScheduleOfActivityUnderTheStockOptionPlansAbstract" xlink:href="iccc-20240930.xsd#iccc_ScheduleOfActivityUnderTheStockOptionPlansAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ScheduleOfActivityUnderTheStockOptionPlansAbstract_lbl" xml:lang="en-US">Schedule Of Activity Under The Stock Option Plans Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ScheduleOfActivityUnderTheStockOptionPlansAbstract" xlink:to="iccc_ScheduleOfActivityUnderTheStockOptionPlansAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl0" xml:lang="en-US">Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesOperatingAbstract_lbl0" xml:lang="en-US">Leases, Operating [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LeasesOperatingAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncome_lbl0" xml:lang="en-US">Other Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl1" xml:lang="en-US">Proceeds from Issuance of Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl0" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl0" xml:lang="en-US">Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl0" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl0" xml:lang="en-US">State and Local Jurisdiction [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl0" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl1" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_TwoThousandSeventeenPlanMember_lbl1" xml:lang="en-US">Two Thousand Seventeen Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_TwoThousandSeventeenPlanMember" xlink:to="iccc_TwoThousandSeventeenPlanMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_lbl0" xml:lang="en-US">Other Nonoperating Income and Expense [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:to="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_RightToAcquirePerShare_lbl1" xml:lang="en-US">Right To Acquire Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_RightToAcquirePerShare" xlink:to="iccc_RightToAcquirePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl0" xml:lang="en-US">Receivable [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedPayrollTaxesCurrent_lbl0" xml:lang="en-US">Accrued Payroll Taxes, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedPayrollTaxesCurrent" xlink:to="us-gaap_AccruedPayrollTaxesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesCommissionsAndFees_lbl0" xml:lang="en-US">Sales Commissions and Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesCommissionsAndFees" xlink:to="us-gaap_SalesCommissionsAndFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses_lbl1" xml:lang="en-US">Change In Capital Expenditures Included In Accounts Payable And Accrued Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses" xlink:to="iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl0" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_GorhamSavingsBankMember_lbl0" xml:lang="en-US">Gorham Savings Bank Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_GorhamSavingsBankMember" xlink:to="iccc_GorhamSavingsBankMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl0" xml:lang="en-US">Office Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_CommitmentsRelatedToCommercialManufacture_lbl1" xml:lang="en-US">Commitments Related To Commercial Manufacture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_CommitmentsRelatedToCommercialManufacture" xlink:to="iccc_CommitmentsRelatedToCommercialManufacture_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_TwoThousandTenPlanMember_lbl1" xml:lang="en-US">Two Thousand Ten Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_TwoThousandTenPlanMember" xlink:to="iccc_TwoThousandTenPlanMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations_lbl0" xml:lang="en-US">Long-Term Debt and Lease Obligation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_NisinDrugSubstanceMember_lbl0" xml:lang="en-US">Nisin Drug Substance Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_NisinDrugSubstanceMember" xlink:to="iccc_NisinDrugSubstanceMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl1" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Equity, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl0" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_TwoThousandSeventeenPlansMember_lbl0" xml:lang="en-US">Two Thousand Seventeen Plans Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_TwoThousandSeventeenPlansMember" xlink:to="iccc_TwoThousandSeventeenPlansMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MortgageBankingMember_lbl0" xml:lang="en-US">Mortgage Banking [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MortgageBankingMember" xlink:to="us-gaap_MortgageBankingMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock_lbl0" xml:lang="en-US">Fair Value Measurements, Nonrecurring [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DebtDiscountCostTotal_lbl1" xml:lang="en-US">Debt Discount Cost Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCostTotal" xlink:to="iccc_DebtDiscountCostTotal_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DebtDiscountCost2025_lbl1" xml:lang="en-US">Debt Discount Cost2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCost2025" xlink:to="iccc_DebtDiscountCost2025_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DebtDiscountCost2026_lbl1" xml:lang="en-US">Debt Discount Cost2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCost2026" xlink:to="iccc_DebtDiscountCost2026_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DebtDiscountCost2027_lbl1" xml:lang="en-US">Debt Discount Cost2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCost2027" xlink:to="iccc_DebtDiscountCost2027_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LandMember_lbl0" xml:lang="en-US">Land [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandMember" xlink:to="us-gaap_LandMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardDescription_lbl0" xml:lang="en-US">Tax Credit Carryforward, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardDescription" xlink:to="us-gaap_TaxCreditCarryforwardDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DebtDiscountCost2028_lbl1" xml:lang="en-US">Debt Discount Cost2028</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCost2028" xlink:to="iccc_DebtDiscountCost2028_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ATMAgreementMember_lbl0" xml:lang="en-US">ATMAgreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ATMAgreementMember" xlink:to="iccc_ATMAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_OtherStatesMember_lbl1" xml:lang="en-US">Other States Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_OtherStatesMember" xlink:to="iccc_OtherStatesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount_lbl0" xml:lang="en-US">Participating Mortgage Loans, Unamortized Debt Discount, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount" xlink:to="us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl0" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFourMember_lbl1" xml:lang="en-US">Debt Instrument, Redemption, Period Four [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFourMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="iccc_ScheduleOfSegmentInformationAbstract" xlink:href="iccc-20240930.xsd#iccc_ScheduleOfSegmentInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ScheduleOfSegmentInformationAbstract_lbl" xml:lang="en-US">Schedule Of Segment Information Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ScheduleOfSegmentInformationAbstract" xlink:to="iccc_ScheduleOfSegmentInformationAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl0" xml:lang="en-US">Long-Term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl0" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl0" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BuildingImprovementsMember_lbl0" xml:lang="en-US">Building Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingImprovementsMember" xlink:to="us-gaap_BuildingImprovementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWriteDown_lbl0" xml:lang="en-US">Inventory Write-down</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl0" xml:lang="en-US">Revenue Benchmark [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireOtherProductiveAssets_lbl0" xml:lang="en-US">Payments to Acquire Other Productive Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireOtherProductiveAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeFixedInterestRate_lbl0" xml:lang="en-US">Derivative, Fixed Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFixedInterestRate" xlink:to="us-gaap_DerivativeFixedInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl0" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_FirstDefenseProductLineMember_lbl0" xml:lang="en-US">First Defense Product Line Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_FirstDefenseProductLineMember" xlink:to="iccc_FirstDefenseProductLineMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="iccc_ScheduleOfIntangibleAssetsAbstract" xlink:href="iccc-20240930.xsd#iccc_ScheduleOfIntangibleAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ScheduleOfIntangibleAssetsAbstract_lbl" xml:lang="en-US">Schedule Of Intangible Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ScheduleOfIntangibleAssetsAbstract" xlink:to="iccc_ScheduleOfIntangibleAssetsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl0" xml:lang="en-US">Accounts Payable, Other, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_lbl0" xml:lang="en-US">Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ExercisableAndTransferableDescription_lbl1" xml:lang="en-US">Exercisable And Transferable Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ExercisableAndTransferableDescription" xlink:to="iccc_ExercisableAndTransferableDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_EmployeesSalaryPercentage_lbl1" xml:lang="en-US">Employees Salary Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_EmployeesSalaryPercentage" xlink:to="iccc_EmployeesSalaryPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_LongTermDebt2026_lbl1" xml:lang="en-US">Long Term Debt2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebt2026" xlink:to="iccc_LongTermDebt2026_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_LongTermDebt2025_lbl1" xml:lang="en-US">Long Term Debt2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebt2025" xlink:to="iccc_LongTermDebt2025_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl0" xml:lang="en-US">Schedule of Debt [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_LongTermDebt2024_lbl1" xml:lang="en-US">Long Term Debt2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebt2024" xlink:to="iccc_LongTermDebt2024_lbl1"/>
    <loc xlink:type="locator" xlink:label="iccc_ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsAbstract" xlink:href="iccc-20240930.xsd#iccc_ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsAbstract_lbl" xml:lang="en-US">Schedule Of Debt Proceeds Received And Principal Repayments Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsAbstract" xlink:to="iccc_ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_LongTermDebtThereafter_lbl1" xml:lang="en-US">Long Term Debt Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebtThereafter" xlink:to="iccc_LongTermDebtThereafter_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl1" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_LongTermDebt2027_lbl1" xml:lang="en-US">Long Term Debt2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebt2027" xlink:to="iccc_LongTermDebt2027_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBorrowings_lbl0" xml:lang="en-US">Short-Term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_TwoThousandTenPlansMember_lbl1" xml:lang="en-US">Two Thousand Ten Plans Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_TwoThousandTenPlansMember" xlink:to="iccc_TwoThousandTenPlansMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl0" xml:lang="en-US">Other Current Assets [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl0" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl0" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl2" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DuringTheYearsEndingDecember31Abstract_lbl0" xml:lang="en-US">During The Years Ending December31 Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DuringTheYearsEndingDecember31Abstract" xlink:to="iccc_DuringTheYearsEndingDecember31Abstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl0" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAbstract_lbl0" xml:lang="en-US">Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl0" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostAbstract_lbl0" xml:lang="en-US">Lease, Cost [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl0" xml:lang="en-US">Number of Reportable Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability_lbl1" xml:lang="en-US">Decrease Increase In Operating Lease Rightofuse Asset And Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability" xlink:to="iccc_DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl1" xml:lang="en-US">Inventory, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl0" xml:lang="en-US">Payments for Rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFiveMember_lbl0" xml:lang="en-US">Debt Instrument, Redemption, Period Five [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodFiveMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFiveMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="iccc_ScheduleOfAssetsOrLiabilitiesMeasuredAtFairValueOnANonrecurringBasisAbstract" xlink:href="iccc-20240930.xsd#iccc_ScheduleOfAssetsOrLiabilitiesMeasuredAtFairValueOnANonrecurringBasisAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ScheduleOfAssetsOrLiabilitiesMeasuredAtFairValueOnANonrecurringBasisAbstract_lbl" xml:lang="en-US">Schedule Of Assets Or Liabilities Measured At Fair Value On ANonrecurring Basis Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ScheduleOfAssetsOrLiabilitiesMeasuredAtFairValueOnANonrecurringBasisAbstract" xlink:to="iccc_ScheduleOfAssetsOrLiabilitiesMeasuredAtFairValueOnANonrecurringBasisAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl0" xml:lang="en-US">Amortization of Debt Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DebtServiceCoverageRatio_lbl1" xml:lang="en-US">Debt Service Coverage Ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtServiceCoverageRatio" xlink:to="iccc_DebtServiceCoverageRatio_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_BankLoansMember_lbl0" xml:lang="en-US">Bank Loans Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_BankLoansMember" xlink:to="iccc_BankLoansMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl0" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNet_lbl0" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl0" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl0" xml:lang="en-US">Operating Lease, Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl0" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DebtDiscountCost_lbl1" xml:lang="en-US">Debt Discount Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCost" xlink:to="iccc_DebtDiscountCost_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl0" xml:lang="en-US">Shareholders&apos; Equity and Share-Based Payments [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue" xlink:to="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ExpenseRecognitionPolicyTextBlock_lbl1" xml:lang="en-US">Expense Recognition Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ExpenseRecognitionPolicyTextBlock" xlink:to="iccc_ExpenseRecognitionPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl0" xml:lang="en-US">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl0" xml:lang="en-US">Cost of Goods and Services Sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_NetProceedsFromIssuanceOfCommonStock_lbl1" xml:lang="en-US">Net Proceeds From Issuance Of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_NetProceedsFromIssuanceOfCommonStock" xlink:to="iccc_NetProceedsFromIssuanceOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl1" xml:lang="en-US">Amortization of Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ManufacturingFacilityMember_lbl0" xml:lang="en-US">Manufacturing Facility [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManufacturingFacilityMember" xlink:to="us-gaap_ManufacturingFacilityMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_MrBrighamMember_lbl0" xml:lang="en-US">Mr Brigham Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_MrBrighamMember" xlink:to="iccc_MrBrighamMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="iccc_ScheduleOfPropertyPlantAndEquipmentAbstract" xlink:href="iccc-20240930.xsd#iccc_ScheduleOfPropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ScheduleOfPropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Schedule Of Property Plant And Equipment Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ScheduleOfPropertyPlantAndEquipmentAbstract" xlink:to="iccc_ScheduleOfPropertyPlantAndEquipmentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterials_lbl0" xml:lang="en-US">Inventory, Raw Materials, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl1" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashIncomeTaxExpense_lbl0" xml:lang="en-US">Other Noncash Income Tax Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeTaxExpense" xlink:to="us-gaap_OtherNoncashIncomeTaxExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl0" xml:lang="en-US">Liabilities, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl0" xml:lang="en-US">Other Noncash Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl1" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option and Stock Appreciation Rights, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl0" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl0" xml:lang="en-US">Accounts Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Other Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_FeesInitiallyCapitalizedAndLaterOffset_lbl1" xml:lang="en-US">Fees Initially Capitalized And Later Offset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_FeesInitiallyCapitalizedAndLaterOffset" xlink:to="iccc_FeesInitiallyCapitalizedAndLaterOffset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl0" xml:lang="en-US">Increase (Decrease) in Accrued Interest Receivable, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl0" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription_lbl0" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Plan Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl0" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl0" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl0" xml:lang="en-US">Proceeds from Lines of Credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtPercentageBearingFixedInterestRate_lbl0" xml:lang="en-US">Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:to="us-gaap_LongTermDebtPercentageBearingFixedInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl0" xml:lang="en-US">Debt Issuance Costs, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl0" xml:lang="en-US">Related Party Transaction, Purchases from Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal_lbl0" xml:lang="en-US">Debt Instrument, Issued, Principal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIssuedPrincipal" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal_lbl0"/>
    <loc xlink:type="locator" xlink:label="iccc_ScheduleOfProductSalesDisaggregatedByMajorProductCategoryAbstract" xlink:href="iccc-20240930.xsd#iccc_ScheduleOfProductSalesDisaggregatedByMajorProductCategoryAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ScheduleOfProductSalesDisaggregatedByMajorProductCategoryAbstract_lbl" xml:lang="en-US">Schedule Of Product Sales Disaggregated By Major Product Category Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ScheduleOfProductSalesDisaggregatedByMajorProductCategoryAbstract" xlink:to="iccc_ScheduleOfProductSalesDisaggregatedByMajorProductCategoryAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl0" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested" xlink:to="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl0" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl0" xml:lang="en-US">Long-Term Debt, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_InterestPaymentsTerm_lbl1" xml:lang="en-US">Interest Payments Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_InterestPaymentsTerm" xlink:to="iccc_InterestPaymentsTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl0" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentCompanyPurchasePremiumPerShare_lbl0" xml:lang="en-US">Investment Company, Purchase Premium, Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentCompanyPurchasePremiumPerShare" xlink:to="us-gaap_InvestmentCompanyPurchasePremiumPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl1" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpense_lbl0" xml:lang="en-US">Selling and Marketing Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl0" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ReTainMember_lbl1" xml:lang="en-US">Re Tain Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ReTainMember" xlink:to="iccc_ReTainMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl1" xml:lang="en-US">Operating Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_lbl0" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:to="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl0"/>
    <loc xlink:type="locator" xlink:label="iccc_ScheduleOfConcentrationOfRiskAbstract" xlink:href="iccc-20240930.xsd#iccc_ScheduleOfConcentrationOfRiskAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ScheduleOfConcentrationOfRiskAbstract_lbl" xml:lang="en-US">Schedule Of Concentration Of Risk Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ScheduleOfConcentrationOfRiskAbstract" xlink:to="iccc_ScheduleOfConcentrationOfRiskAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_AcquiringPersonMember_lbl0" xml:lang="en-US">Acquiring Person Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_AcquiringPersonMember" xlink:to="iccc_AcquiringPersonMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl0" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl0" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_EmployeeOneMember_lbl0" xml:lang="en-US">Employee One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_EmployeeOneMember" xlink:to="iccc_EmployeeOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_SubtotalMember_lbl0" xml:lang="en-US">Subtotal Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_SubtotalMember" xlink:to="iccc_SubtotalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_lbl0" xml:lang="en-US">Repayments of Lines of Credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLinesOfCredit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_CompanyBMember_lbl0" xml:lang="en-US">Company BMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_CompanyBMember" xlink:to="iccc_CompanyBMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized_lbl0" xml:lang="en-US">Loan, Managed and Securitized or Asset-Backed Financing Arrangement, Principal Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized" xlink:to="us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl0" xml:lang="en-US">Interest Expense, Operating and Nonoperating</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl0" xml:lang="en-US">Debt Instrument, Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfLand_lbl0" xml:lang="en-US">Area of Land</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_CommonStockIssuancesMember_lbl0" xml:lang="en-US">Common Stock Issuances Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_CommonStockIssuancesMember" xlink:to="iccc_CommonStockIssuancesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl0" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl0" xml:lang="en-US">Long-Term Debt, Maturity, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember_lbl0" xml:lang="en-US">Fair Value, Nonrecurring [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsNonrecurringMember" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancingReceivableLoanInProcess_lbl0" xml:lang="en-US">Financing Receivable, Loan in Process</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingReceivableLoanInProcess" xlink:to="us-gaap_FinancingReceivableLoanInProcess_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl0" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl0" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl0" xml:lang="en-US">Payments of Debt Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_MaineTechnologyInstituteMember_lbl0" xml:lang="en-US">Maine Technology Institute Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_MaineTechnologyInstituteMember" xlink:to="iccc_MaineTechnologyInstituteMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_PurchaseofInventory_lbl1" xml:lang="en-US">Purchaseof Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_PurchaseofInventory" xlink:to="iccc_PurchaseofInventory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl0" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl0" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl0" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl0" xml:lang="en-US">Nature of Operations [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCredit_lbl0" xml:lang="en-US">Long-Term Line of Credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl0" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl1" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonShares_lbl0" xml:lang="en-US">Treasury Stock, Common, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonShares" xlink:to="us-gaap_TreasuryStockCommonShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl0" xml:lang="en-US">Operating Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl0" xml:lang="en-US">Other Receivables, Net, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="iccc_ScheduleOfProductSalesDisaggregatedByGeographicAreaAbstract" xlink:href="iccc-20240930.xsd#iccc_ScheduleOfProductSalesDisaggregatedByGeographicAreaAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ScheduleOfProductSalesDisaggregatedByGeographicAreaAbstract_lbl" xml:lang="en-US">Schedule Of Product Sales Disaggregated By Geographic Area Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ScheduleOfProductSalesDisaggregatedByGeographicAreaAbstract" xlink:to="iccc_ScheduleOfProductSalesDisaggregatedByGeographicAreaAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfBankDebt_lbl0" xml:lang="en-US">Repayments of Bank Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfBankDebt" xlink:to="us-gaap_RepaymentsOfBankDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_LongTermDebtTotal2028_lbl1" xml:lang="en-US">Long Term Debt Total2028</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebtTotal2028" xlink:to="iccc_LongTermDebtTotal2028_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl0" xml:lang="en-US">Concentration Risk, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InsuranceRecoveries_lbl0" xml:lang="en-US">Insurance Recoveries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InsuranceRecoveries" xlink:to="us-gaap_InsuranceRecoveries_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_LoanToValueRatio_lbl1" xml:lang="en-US">Loan To Value Ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LoanToValueRatio" xlink:to="iccc_LoanToValueRatio_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_MastitisMember_lbl0" xml:lang="en-US">Mastitis Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_MastitisMember" xlink:to="iccc_MastitisMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember_lbl0" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested_lbl1" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested" xlink:to="iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostDepreciationAmortizationAndDepletion_lbl0" xml:lang="en-US">Cost, Depreciation, Amortization and Depletion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostDepreciationAmortizationAndDepletion" xlink:to="us-gaap_CostDepreciationAmortizationAndDepletion_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl1" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_EmployeeMember_lbl0" xml:lang="en-US">Employee Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_EmployeeMember" xlink:to="iccc_EmployeeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_lbl0" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Benefits Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:to="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl1" xml:lang="en-US">Gross Profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllOtherSegmentsMember_lbl0" xml:lang="en-US">Other Operating Segment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllOtherSegmentsMember" xlink:to="us-gaap_AllOtherSegmentsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl0" xml:lang="en-US">Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl1" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncompeteAgreementsMember_lbl0" xml:lang="en-US">Noncompete Agreements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncompeteAgreementsMember" xlink:to="us-gaap_NoncompeteAgreementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl0" xml:lang="en-US">Cash, FDIC Insured Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcess_lbl0" xml:lang="en-US">Inventory, Work in Process, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl0" xml:lang="en-US">Related Party [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl0" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DebtIssuanceCostshereafter_lbl1" xml:lang="en-US">Debt Issuance Costshereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCostshereafter" xlink:to="iccc_DebtIssuanceCostshereafter_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_AcquiringPersonPercentage_lbl1" xml:lang="en-US">Acquiring Person Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_AcquiringPersonPercentage" xlink:to="iccc_AcquiringPersonPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeOther_lbl0" xml:lang="en-US">Interest Income, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl0" xml:lang="en-US">Debt Instrument, Face Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_CompanyAMember_lbl0" xml:lang="en-US">Company AMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_CompanyAMember" xlink:to="iccc_CompanyAMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_RevenueSalesObligationPercentage_lbl1" xml:lang="en-US">Revenue Sales Obligation Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_RevenueSalesObligationPercentage" xlink:to="iccc_RevenueSalesObligationPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_OfferingCostsOnFollowUpOfferingOfCommonStock_lbl1" xml:lang="en-US">Offering Costs On Follow Up Offering Of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_OfferingCostsOnFollowUpOfferingOfCommonStock" xlink:to="iccc_OfferingCostsOnFollowUpOfferingOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl0" xml:lang="en-US">Customer Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ScoursMember_lbl0" xml:lang="en-US">Scours Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ScoursMember" xlink:to="iccc_ScoursMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_CommitmentsRelatedToInformationTechnologyServicesAndOtherObligations_lbl1" xml:lang="en-US">Commitments Related To Information Technology Services And Other Obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_CommitmentsRelatedToInformationTechnologyServicesAndOtherObligations" xlink:to="iccc_CommitmentsRelatedToInformationTechnologyServicesAndOtherObligations_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl0" xml:lang="en-US">Income Taxes Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl0" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_lbl0" xml:lang="en-US">Property, Plant and Equipment, Salvage Value, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:to="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingAbstract" xlink:href="iccc-20240930.xsd#iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingAbstract_lbl" xml:lang="en-US">Schedule Of Principal Payments Bank Loans Outstanding Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingAbstract" xlink:to="iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Other Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl1" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DebtInstrumentRedemptionPeriodSevenMember_lbl0" xml:lang="en-US">Debt Instrument Redemption Period Seven Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtInstrumentRedemptionPeriodSevenMember" xlink:to="iccc_DebtInstrumentRedemptionPeriodSevenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsCurrentGross_lbl0" xml:lang="en-US">Debt Issuance Costs, Gross, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsCurrentGross" xlink:to="us-gaap_DeferredFinanceCostsCurrentGross_lbl0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>iccc-20240930_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Nov 11 21:15:33 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ConsolidatedBalanceSheet" roleURI="http://immucell.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://immucell.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ConsolidatedIncomeStatement" roleURI="http://immucell.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ShareholdersEquityType2or3" roleURI="http://immucell.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ShareholdersEquityType2or3_Parentheticals" roleURI="http://immucell.com/role/ShareholdersEquityType2or3_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ConsolidatedCashFlow" roleURI="http://immucell.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_BusinessOperations" roleURI="http://immucell.com/role/BusinessOperations"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_SummaryofSignificantAccountingPolicies" roleURI="http://immucell.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_CashandCashEquivalents" roleURI="http://immucell.com/role/CashandCashEquivalents"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_TradeAccountsReceivable" roleURI="http://immucell.com/role/TradeAccountsReceivable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_Inventory" roleURI="http://immucell.com/role/Inventory"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_PrepaidExpensesandOtherCurrentAssets" roleURI="http://immucell.com/role/PrepaidExpensesandOtherCurrentAssets"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_PropertyPlantandEquipmentNet" roleURI="http://immucell.com/role/PropertyPlantandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_IntangibleAssets" roleURI="http://immucell.com/role/IntangibleAssets"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_AccountsPayableandAccruedExpenses" roleURI="http://immucell.com/role/AccountsPayableandAccruedExpenses"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_BankDebt" roleURI="http://immucell.com/role/BankDebt"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ContingentLiabilitiesandCommitments" roleURI="http://immucell.com/role/ContingentLiabilitiesandCommitments"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_OperatingLease" roleURI="http://immucell.com/role/OperatingLease"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_StockholdersEquity" roleURI="http://immucell.com/role/StockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_Revenue" roleURI="http://immucell.com/role/Revenue"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_OtherExpensesNet" roleURI="http://immucell.com/role/OtherExpensesNet"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_IncomeTaxes" roleURI="http://immucell.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_SegmentInformation" roleURI="http://immucell.com/role/SegmentInformation"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_RelatedPartyTransactions" roleURI="http://immucell.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_EmployeeBenefits" roleURI="http://immucell.com/role/EmployeeBenefits"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_SubsequentEvents" roleURI="http://immucell.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_AccountingPoliciesByPolicy" roleURI="http://immucell.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://immucell.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_InventoryTables" roleURI="http://immucell.com/role/InventoryTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_PrepaidExpensesandOtherCurrentAssetsTables" roleURI="http://immucell.com/role/PrepaidExpensesandOtherCurrentAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_PropertyPlantandEquipmentNetTables" roleURI="http://immucell.com/role/PropertyPlantandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_IntangibleAssetsTables" roleURI="http://immucell.com/role/IntangibleAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_AccountsPayableandAccruedExpensesTables" roleURI="http://immucell.com/role/AccountsPayableandAccruedExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_BankDebtTables" roleURI="http://immucell.com/role/BankDebtTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_OperatingLeaseTables" roleURI="http://immucell.com/role/OperatingLeaseTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_StockholdersEquityTables" roleURI="http://immucell.com/role/StockholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_RevenueTables" roleURI="http://immucell.com/role/RevenueTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_OtherExpensesNetTables" roleURI="http://immucell.com/role/OtherExpensesNetTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_SegmentInformationTables" roleURI="http://immucell.com/role/SegmentInformationTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable" roleURI="http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ScheduleofConcentrationofRiskTable" roleURI="http://immucell.com/role/ScheduleofConcentrationofRiskTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ScheduleofNetIncomeLossPerCommonShareTable" roleURI="http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ScheduleofInventoryTable" roleURI="http://immucell.com/role/ScheduleofInventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ScheduleofPrepaidExpensesandOtherCurrentAssetsTable" roleURI="http://immucell.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ScheduleofPropertyPlantandEquipmentTable" roleURI="http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ScheduleofIntangibleAssetsTable" roleURI="http://immucell.com/role/ScheduleofIntangibleAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ScheduleofAccountsPayableandAccruedExpensesTable" roleURI="http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable" roleURI="http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ScheduleofPrincipalPaymentsBankLoansOutstandingTable" roleURI="http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ScheduleofLeaseCostsandOtherLeaseInformationTable" roleURI="http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable" roleURI="http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ScheduleofActivityUndertheStockOptionPlansTable" roleURI="http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ScheduleofAdditionalInformationAbouttheStockOptionPlansTable" roleURI="http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ScheduleofFairValueStockOptionGrantUsingBlackScholesOptionPricingModelwithWeightedAverageAssumptionsTable" roleURI="http://immucell.com/role/ScheduleofFairValueStockOptionGrantUsingBlackScholesOptionPricingModelwithWeightedAverageAssumptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ScheduleofProductSalesDisaggregatedbyGeographicAreaTable" roleURI="http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyGeographicAreaTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable" roleURI="http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ScheduleofOtherExpensesNetTable" roleURI="http://immucell.com/role/ScheduleofOtherExpensesNetTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ScheduleofSegmentInformationTable" roleURI="http://immucell.com/role/ScheduleofSegmentInformationTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_CashandCashEquivalentsDetails" roleURI="http://immucell.com/role/CashandCashEquivalentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_TradeAccountsReceivableDetails" roleURI="http://immucell.com/role/TradeAccountsReceivableDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_InventoryDetails" roleURI="http://immucell.com/role/InventoryDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_PropertyPlantandEquipmentNetDetails" roleURI="http://immucell.com/role/PropertyPlantandEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_IntangibleAssetsDetails" roleURI="http://immucell.com/role/IntangibleAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_BankDebtDetails" roleURI="http://immucell.com/role/BankDebtDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_ContingentLiabilitiesandCommitmentsDetails" roleURI="http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_OperatingLeaseDetails" roleURI="http://immucell.com/role/OperatingLeaseDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_StockholdersEquityDetails" roleURI="http://immucell.com/role/StockholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_OtherExpensesNetDetails" roleURI="http://immucell.com/role/OtherExpensesNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_IncomeTaxesDetails" roleURI="http://immucell.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_SegmentInformationDetails" roleURI="http://immucell.com/role/SegmentInformationDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_RelatedPartyTransactionsDetails" roleURI="http://immucell.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_EmployeeBenefitsDetails" roleURI="http://immucell.com/role/EmployeeBenefitsDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20240930.xsd#iccc_r_SubsequentEventsDetails" roleURI="http://immucell.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#cover" roleURI="http://xbrl.sec.gov/dei/role/document/Cover"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#ai" roleURI="http://xbrl.sec.gov/dei/role/document/AuditInformation"/>
  <presentationLink xlink:role="http://immucell.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Goodwill" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_Liabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockCommonValue" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TreasuryStockCommonShares" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_SellingAndMarketingExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_OperatingExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_TreasuryStockCommonMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="4.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ShareholdersEquityType2or3_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="OfferingCostsOnFollowUpOfferingOfCommonStock" xlink:href="iccc-20240930.xsd#iccc_OfferingCostsOnFollowUpOfferingOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="OfferingCostsOnFollowUpOfferingOfCommonStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireOtherProductiveAssets" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLinesOfCredit" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfDebt" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses" xlink:href="iccc-20240930.xsd#iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability" xlink:href="iccc-20240930.xsd#iccc_DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/BusinessOperations" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/CashandCashEquivalents" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/TradeAccountsReceivable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesNetCurrentAbstract" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/Inventory" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/PrepaidExpensesandOtherCurrentAssets" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherCurrentAssetsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/PropertyPlantandEquipmentNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/IntangibleAssets" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/AccountsPayableandAccruedExpenses" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/BankDebt" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ContingentLiabilitiesandCommitments" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/OperatingLease" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/StockholdersEquity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/Revenue" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/OtherExpensesNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/IncomeTaxes" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/SegmentInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/RelatedPartyTransactions" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/EmployeeBenefits" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExpenseRecognitionPolicyTextBlock" xlink:href="iccc-20240930.xsd#iccc_ExpenseRecognitionPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ExpenseRecognitionPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/InventoryTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/PrepaidExpensesandOtherCurrentAssetsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/PropertyPlantandEquipmentNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/IntangibleAssetsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/AccountsPayableandAccruedExpensesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/BankDebtTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/OperatingLeaseTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/StockholdersEquityTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/RevenueTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/OtherExpensesNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherExpensesAbstract" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/SegmentInformationTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfAssetsOrLiabilitiesMeasuredAtFairValueOnANonrecurringBasisAbstract" xlink:href="iccc-20240930.xsd#iccc_ScheduleOfAssetsOrLiabilitiesMeasuredAtFairValueOnANonrecurringBasisAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable" xlink:href="iccc-20240930.xsd#iccc_SummaryofSignificantAccountingPoliciesDetailsScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAssetsOrLiabilitiesMeasuredAtFairValueOnANonrecurringBasisAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_ShortTermBorrowings" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ScheduleofConcentrationofRiskTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfConcentrationOfRiskAbstract" xlink:href="iccc-20240930.xsd#iccc_ScheduleOfConcentrationOfRiskAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfConcentrationOfRiskAbstract" xlink:to="us-gaap_ConcentrationRiskTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_MajorCustomersAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="CompanyAMember" xlink:href="iccc-20240930.xsd#iccc_CompanyAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="CompanyAMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CompanyBMember" xlink:href="iccc-20240930.xsd#iccc_CompanyBMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="CompanyBMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_SalesRevenueNetMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_AccountsReceivableMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ScheduleofInventoryTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryRawMaterials" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryWorkInProcess" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryFinishedGoods" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyPlantAndEquipmentAbstract" xlink:href="iccc-20240930.xsd#iccc_ScheduleOfPropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ManufacturingFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ManufacturingFacilityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ManufacturingFacilityMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingImprovementsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_OfficeEquipmentMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ConstructionInProgressMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LandMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LandMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ScheduleofIntangibleAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfIntangibleAssetsAbstract" xlink:href="iccc-20240930.xsd#iccc_ScheduleOfIntangibleAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIntangibleAssetsAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_DevelopedTechnologyRightsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRelationshipsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_CustomerRelationshipsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncompeteAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_NoncompeteAgreementsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedPayrollTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedPayrollTaxesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedPayrollTaxesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsAbstract" xlink:href="iccc-20240930.xsd#iccc_ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="BankDebtDetailsScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable" xlink:href="iccc-20240930.xsd#iccc_BankDebtDetailsScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsAbstract" xlink:to="BankDebtDetailsScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankDebtDetailsScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodFourMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFourMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFiveMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodFiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFiveMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentRedemptionPeriodSixMember" xlink:href="iccc-20240930.xsd#iccc_DebtInstrumentRedemptionPeriodSixMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="DebtInstrumentRedemptionPeriodSixMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentRedemptionPeriodSevenMember" xlink:href="iccc-20240930.xsd#iccc_DebtInstrumentRedemptionPeriodSevenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="DebtInstrumentRedemptionPeriodSevenMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankDebtDetailsScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfBankDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfBankDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfBankDebt" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfPrincipalPaymentsBankLoansOutstandingAbstract" xlink:href="iccc-20240930.xsd#iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:label="BankDebtDetailsScheduleofPrincipalPaymentsBankLoansOutstandingTable" xlink:href="iccc-20240930.xsd#iccc_BankDebtDetailsScheduleofPrincipalPaymentsBankLoansOutstandingTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrincipalPaymentsBankLoansOutstandingAbstract" xlink:to="BankDebtDetailsScheduleofPrincipalPaymentsBankLoansOutstandingTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankDebtDetailsScheduleofPrincipalPaymentsBankLoansOutstandingTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodFourMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFourMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFiveMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodFiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFiveMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentRedemptionPeriodSixMember" xlink:href="iccc-20240930.xsd#iccc_DebtInstrumentRedemptionPeriodSixMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="DebtInstrumentRedemptionPeriodSixMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentRedemptionPeriodSevenMember" xlink:href="iccc-20240930.xsd#iccc_DebtInstrumentRedemptionPeriodSevenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="DebtInstrumentRedemptionPeriodSevenMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SubtotalMember" xlink:href="iccc-20240930.xsd#iccc_SubtotalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="SubtotalMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankDebtDetailsScheduleofPrincipalPaymentsBankLoansOutstandingTable" xlink:to="us-gaap_LongTermPurchaseCommitmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbY2yHOqde+bt8NhnsjkMwInWzkiaYJmrGBX9ANHbqN6KcdyN7/tlo+8zitcBZOpZd5FWkDhY6SIAlueCv6TZ3/kC1CNAnKV2ZM7jOQVc9F1lsdJG5gYEVlBk/tvI9EzlbPJ58JKwU1IierSRHypv+o52xo9lJjv1QMjVMw9zPSP42NFNgXQ/4M9AGq8qRwbyg5efpEjDIG2QiPWZiVEuwmP+z4hKqvuUe6aF0/JyDDimbgO/xeq8np] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LongTermDebt" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtIssuanceCosts2024" xlink:href="iccc-20240930.xsd#iccc_DebtIssuanceCosts2024"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="DebtIssuanceCosts2024" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DebtIssuanceCosts2025" xlink:href="iccc-20240930.xsd#iccc_DebtIssuanceCosts2025"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="DebtIssuanceCosts2025" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DebtIssuanceCosts2026" xlink:href="iccc-20240930.xsd#iccc_DebtIssuanceCosts2026"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="DebtIssuanceCosts2026" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DebtIssuanceCosts2027" xlink:href="iccc-20240930.xsd#iccc_DebtIssuanceCosts2027"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="DebtIssuanceCosts2027" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DebtIssuanceCosts2028" xlink:href="iccc-20240930.xsd#iccc_DebtIssuanceCosts2028"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="DebtIssuanceCosts2028" order="11.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DebtIssuanceCostshereafter" xlink:href="iccc-20240930.xsd#iccc_DebtIssuanceCostshereafter"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="DebtIssuanceCostshereafter" order="12.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" order="13.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DebtDiscountCost" xlink:href="iccc-20240930.xsd#iccc_DebtDiscountCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="DebtDiscountCost" order="14.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DebtDiscountCost2025" xlink:href="iccc-20240930.xsd#iccc_DebtDiscountCost2025"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="DebtDiscountCost2025" order="15.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DebtDiscountCost2026" xlink:href="iccc-20240930.xsd#iccc_DebtDiscountCost2026"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="DebtDiscountCost2026" order="16.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DebtDiscountCost2027" xlink:href="iccc-20240930.xsd#iccc_DebtDiscountCost2027"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="DebtDiscountCost2027" order="17.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DebtDiscountCost2028" xlink:href="iccc-20240930.xsd#iccc_DebtDiscountCost2028"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="DebtDiscountCost2028" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtDiscountCostThereafter" xlink:href="iccc-20240930.xsd#iccc_DebtDiscountCostThereafter"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="DebtDiscountCostThereafter" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtDiscountCostTotal" xlink:href="iccc-20240930.xsd#iccc_DebtDiscountCostTotal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="DebtDiscountCostTotal" order="20.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="LongTermDebt2024" xlink:href="iccc-20240930.xsd#iccc_LongTermDebt2024"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="LongTermDebt2024" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LongTermDebt2025" xlink:href="iccc-20240930.xsd#iccc_LongTermDebt2025"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="LongTermDebt2025" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LongTermDebt2026" xlink:href="iccc-20240930.xsd#iccc_LongTermDebt2026"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="LongTermDebt2026" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LongTermDebt2027" xlink:href="iccc-20240930.xsd#iccc_LongTermDebt2027"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="LongTermDebt2027" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LongTermDebtTotal2028" xlink:href="iccc-20240930.xsd#iccc_LongTermDebtTotal2028"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="LongTermDebtTotal2028" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LongTermDebtThereafter" xlink:href="iccc-20240930.xsd#iccc_LongTermDebtThereafter"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="LongTermDebtThereafter" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LeaseCostAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_VariableLeaseCost" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesOperatingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesOperatingAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LeasesOperatingAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DuringTheYearsEndingDecember31Abstract" xlink:href="iccc-20240930.xsd#iccc_DuringTheYearsEndingDecember31Abstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="DuringTheYearsEndingDecember31Abstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DuringTheYearsEndingDecember31Abstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DuringTheYearsEndingDecember31Abstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DuringTheYearsEndingDecember31Abstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DuringTheYearsEndingDecember31Abstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfActivityUnderTheStockOptionPlansAbstract" xlink:href="iccc-20240930.xsd#iccc_ScheduleOfActivityUnderTheStockOptionPlansAbstract"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDetailsScheduleofActivityUndertheStockOptionPlansTable" xlink:href="iccc-20240930.xsd#iccc_StockholdersEquityDetailsScheduleofActivityUndertheStockOptionPlansTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfActivityUnderTheStockOptionPlansAbstract" xlink:to="StockholdersEquityDetailsScheduleofActivityUndertheStockOptionPlansTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofActivityUndertheStockOptionPlansTable" xlink:to="us-gaap_PlanNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoThousandTenPlanMember" xlink:href="iccc-20240930.xsd#iccc_TwoThousandTenPlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandTenPlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoThousandSeventeenPlanMember" xlink:href="iccc-20240930.xsd#iccc_TwoThousandSeventeenPlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandSeventeenPlanMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofActivityUndertheStockOptionPlansTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested" xlink:href="iccc-20240930.xsd#iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested" xlink:href="iccc-20240930.xsd#iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue" xlink:href="iccc-20240930.xsd#iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="15.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfAdditionalInformationAboutTheStockOptionPlansAbstract" xlink:href="iccc-20240930.xsd#iccc_ScheduleOfAdditionalInformationAboutTheStockOptionPlansAbstract"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansTable" xlink:href="iccc-20240930.xsd#iccc_StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansTable"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansLineItems" xlink:href="iccc-20240930.xsd#iccc_StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAdditionalInformationAboutTheStockOptionPlansAbstract" xlink:to="StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_StockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansTable" xlink:to="StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ScheduleofFairValueStockOptionGrantUsingBlackScholesOptionPricingModelwithWeightedAverageAssumptionsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyGeographicAreaTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfProductSalesDisaggregatedByGeographicAreaAbstract" xlink:href="iccc-20240930.xsd#iccc_ScheduleOfProductSalesDisaggregatedByGeographicAreaAbstract"/>
    <loc xlink:type="locator" xlink:label="RevenueDetailsScheduleofProductSalesDisaggregatedbyGeographicAreaTable" xlink:href="iccc-20240930.xsd#iccc_RevenueDetailsScheduleofProductSalesDisaggregatedbyGeographicAreaTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfProductSalesDisaggregatedByGeographicAreaAbstract" xlink:to="RevenueDetailsScheduleofProductSalesDisaggregatedbyGeographicAreaTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueDetailsScheduleofProductSalesDisaggregatedbyGeographicAreaTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_US" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherStatesMember" xlink:href="iccc-20240930.xsd#iccc_OtherStatesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="OtherStatesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueDetailsScheduleofProductSalesDisaggregatedbyGeographicAreaTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RevenueSalesObligationPercentage" xlink:href="iccc-20240930.xsd#iccc_RevenueSalesObligationPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="RevenueSalesObligationPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfProductSalesDisaggregatedByMajorProductCategoryAbstract" xlink:href="iccc-20240930.xsd#iccc_ScheduleOfProductSalesDisaggregatedByMajorProductCategoryAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfProductSalesDisaggregatedByMajorProductCategoryAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="FirstDefenseProductLineMember" xlink:href="iccc-20240930.xsd#iccc_FirstDefenseProductLineMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="FirstDefenseProductLineMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherAnimalHealthMember" xlink:href="iccc-20240930.xsd#iccc_OtherAnimalHealthMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="OtherAnimalHealthMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ScheduleofOtherExpensesNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfOtherExpensesNetAbstract" xlink:href="iccc-20240930.xsd#iccc_ScheduleOfOtherExpensesNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherExpensesNetAbstract" xlink:to="us-gaap_InterestExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherExpensesNetAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherExpensesNetAbstract" xlink:to="us-gaap_InterestIncomeOther" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InsuranceRecoveries" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InsuranceRecoveries"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherExpensesNetAbstract" xlink:to="us-gaap_InsuranceRecoveries" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherExpensesNetAbstract" xlink:to="us-gaap_OtherIncome" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherExpensesNetAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ScheduleofSegmentInformationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfSegmentInformationAbstract" xlink:href="iccc-20240930.xsd#iccc_ScheduleOfSegmentInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSegmentInformationAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ScoursMember" xlink:href="iccc-20240930.xsd#iccc_ScoursMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="ScoursMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MastitisMember" xlink:href="iccc-20240930.xsd#iccc_MastitisMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="MastitisMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllOtherSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherSegmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_AllOtherSegmentsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_GrossProfit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SellingAndMarketingExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_OperatingExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_Assets" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostDepreciationAmortizationAndDepletion" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostDepreciationAmortizationAndDepletion"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_CostDepreciationAmortizationAndDepletion" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="iccc-20240930.xsd#iccc_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="NisinDrugSubstanceMember" xlink:href="iccc-20240930.xsd#iccc_NisinDrugSubstanceMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="NisinDrugSubstanceMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFDICInsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_CashFDICInsuredAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/CashandCashEquivalentsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/TradeAccountsReceivableDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="TradeAccountsReceivableDetailsTable" xlink:href="iccc-20240930.xsd#iccc_TradeAccountsReceivableDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesNetCurrentAbstract" xlink:to="TradeAccountsReceivableDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TradeAccountsReceivableDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TradeAccountsReceivableDetailsTable" xlink:to="us-gaap_AccountsNotesAndLoansReceivableLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/InventoryDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryWriteDown" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/PropertyPlantandEquipmentNetDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisposals"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisposals" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_Depreciation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/IntangibleAssetsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <loc xlink:type="locator" xlink:label="IntangibleAssetsDetailsTable" xlink:href="iccc-20240930.xsd#iccc_IntangibleAssetsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="IntangibleAssetsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsTable" xlink:to="srt_StatementScenarioAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioForecastMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/BankDebtDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="BankDebtDetailsTable" xlink:href="iccc-20240930.xsd#iccc_BankDebtDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="BankDebtDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankDebtDetailsTable" xlink:to="srt_StatementScenarioAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioForecastMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankDebtDetailsTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodFourMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFourMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentRedemptionPeriodSixMember" xlink:href="iccc-20240930.xsd#iccc_DebtInstrumentRedemptionPeriodSixMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="DebtInstrumentRedemptionPeriodSixMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFiveMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodFiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFiveMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentRedemptionPeriodSevenMember" xlink:href="iccc-20240930.xsd#iccc_DebtInstrumentRedemptionPeriodSevenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="DebtInstrumentRedemptionPeriodSevenMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankDebtDetailsTable" xlink:to="srt_RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankDebtDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BankLoansMember" xlink:href="iccc-20240930.xsd#iccc_BankLoansMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="BankLoansMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankDebtDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="GorhamSavingsBankMember" xlink:href="iccc-20240930.xsd#iccc_GorhamSavingsBankMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="GorhamSavingsBankMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MaineTechnologyInstituteMember" xlink:href="iccc-20240930.xsd#iccc_MaineTechnologyInstituteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="MaineTechnologyInstituteMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MortgageBankingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MortgageBankingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="us-gaap_MortgageBankingMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankDebtDetailsTable" xlink:to="us-gaap_DebtConversionLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsCurrentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DeferredFinanceCostsCurrentNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EscrowDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EscrowDeposit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_EscrowDeposit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InterestPaymentsTerm" xlink:href="iccc-20240930.xsd#iccc_InterestPaymentsTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="InterestPaymentsTerm" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_LineOfCredit" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DerivativeFixedInterestRate" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LoanToValueRatio" xlink:href="iccc-20240930.xsd#iccc_LoanToValueRatio"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="LoanToValueRatio" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivableLoanInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivableLoanInProcess"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_FinancingReceivableLoanInProcess" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtServiceCoverageRatio" xlink:href="iccc-20240930.xsd#iccc_DebtServiceCoverageRatio"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="DebtServiceCoverageRatio" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsCurrentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsCurrentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DeferredFinanceCostsCurrentGross" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestCostsIncurred" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestCostsIncurred"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_InterestCostsIncurred" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="ContingentLiabilitiesandCommitmentsDetailsTable" xlink:href="iccc-20240930.xsd#iccc_ContingentLiabilitiesandCommitmentsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="ContingentLiabilitiesandCommitmentsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MrBrighamMember" xlink:href="iccc-20240930.xsd#iccc_MrBrighamMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="MrBrighamMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ReTainMember" xlink:href="iccc-20240930.xsd#iccc_ReTainMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="ReTainMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsTable" xlink:to="us-gaap_OtherCommitmentsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CapitalExpendituresCommitted" xlink:href="iccc-20240930.xsd#iccc_CapitalExpendituresCommitted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="CapitalExpendituresCommitted" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseofInventory" xlink:href="iccc-20240930.xsd#iccc_PurchaseofInventory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="PurchaseofInventory" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommitmentsRelatedToCommercialManufacture" xlink:href="iccc-20240930.xsd#iccc_CommitmentsRelatedToCommercialManufacture"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="CommitmentsRelatedToCommercialManufacture" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommitmentsRelatedToInformationTechnologyServicesAndOtherObligations" xlink:href="iccc-20240930.xsd#iccc_CommitmentsRelatedToInformationTechnologyServicesAndOtherObligations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="CommitmentsRelatedToInformationTechnologyServicesAndOtherObligations" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/OperatingLeaseDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="OperatingLeaseDetailsTable" xlink:href="iccc-20240930.xsd#iccc_OperatingLeaseDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansAndLeasesReceivableDisclosureLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="OperatingLeaseDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseDetailsTable" xlink:to="srt_StatementScenarioAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioForecastMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseDetailsTable" xlink:to="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AreaOfLand" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfLand"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_AreaOfLand" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_PaymentsForRent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/StockholdersEquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDetailsTable" xlink:href="iccc-20240930.xsd#iccc_StockholdersEquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="StockholdersEquityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ATMAgreementMember" xlink:href="iccc-20240930.xsd#iccc_ATMAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ATMAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AcquiringPersonMember" xlink:href="iccc-20240930.xsd#iccc_AcquiringPersonMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="AcquiringPersonMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoThousandTenPlansMember" xlink:href="iccc-20240930.xsd#iccc_TwoThousandTenPlansMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandTenPlansMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoThousandSeventeenPlansMember" xlink:href="iccc-20240930.xsd#iccc_TwoThousandSeventeenPlansMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandSeventeenPlansMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="srt_RangeAxis" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CommonStockIssuancesMember" xlink:href="iccc-20240930.xsd#iccc_CommonStockIssuancesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="CommonStockIssuancesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_ClassOfStockLineItems" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetProceedsFromIssuanceOfCommonStock" xlink:href="iccc-20240930.xsd#iccc_NetProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="NetProceedsFromIssuanceOfCommonStock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIssuedPrincipal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FeesInitiallyCapitalizedAndLaterOffset" xlink:href="iccc-20240930.xsd#iccc_FeesInitiallyCapitalizedAndLaterOffset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="FeesInitiallyCapitalizedAndLaterOffset" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesCommissionsAndFees" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesCommissionsAndFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SalesCommissionsAndFees" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="21.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisableAndTransferableDescription" xlink:href="iccc-20240930.xsd#iccc_ExercisableAndTransferableDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ExercisableAndTransferableDescription" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentCompanyPurchasePremiumPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentCompanyPurchasePremiumPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_InvestmentCompanyPurchasePremiumPerShare" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostChangeDueToSubsequentInterimMeasurementWeightedAverageExpectedLongTermRateOfReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostChangeDueToSubsequentInterimMeasurementWeightedAverageExpectedLongTermRateOfReturnOnPlanAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostChangeDueToSubsequentInterimMeasurementWeightedAverageExpectedLongTermRateOfReturnOnPlanAssets" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RightToAcquirePerShare" xlink:href="iccc-20240930.xsd#iccc_RightToAcquirePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="RightToAcquirePerShare" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AcquiringPersonPercentage" xlink:href="iccc-20240930.xsd#iccc_AcquiringPersonPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="AcquiringPersonPercentage" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/OtherExpensesNetDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherExpensesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/IncomeTaxesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsTable" xlink:href="iccc-20240930.xsd#iccc_IncomeTaxesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FederalGeneralBusinessMember" xlink:href="iccc-20240930.xsd#iccc_FederalGeneralBusinessMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="FederalGeneralBusinessMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StateTaxCreditMember" xlink:href="iccc-20240930.xsd#iccc_StateTaxCreditMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="StateTaxCreditMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeTaxContingencyLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_TaxCreditCarryforwardDescription" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeTaxExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeTaxExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OtherNoncashIncomeTaxExpense" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/SegmentInformationDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfReportableSegments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDetailsTable" xlink:href="iccc-20240930.xsd#iccc_RelatedPartyTransactionsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="RelatedPartyTransactionsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsReceivableNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/EmployeeBenefitsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="EmployeeBenefitsDetailsTable" xlink:href="iccc-20240930.xsd#iccc_EmployeeBenefitsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="EmployeeBenefitsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="EmployeeMember" xlink:href="iccc-20240930.xsd#iccc_EmployeeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="EmployeeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EmployeeOneMember" xlink:href="iccc-20240930.xsd#iccc_EmployeeOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="EmployeeOneMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitsDetailsTable" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="EmployeesSalaryPercentage" xlink:href="iccc-20240930.xsd#iccc_EmployeesSalaryPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="EmployeesSalaryPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EmployeesSalaryContributionPercentage" xlink:href="iccc-20240930.xsd#iccc_EmployeesSalaryContributionPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="EmployeesSalaryContributionPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/SubsequentEventsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsTable" xlink:href="iccc-20240930.xsd#iccc_SubsequentEventsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SubsequentEventsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="dei_LegalEntityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ATMAgreementMember" xlink:href="iccc-20240930.xsd#iccc_ATMAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="ATMAgreementMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/dei/role/document/Cover" xlink:type="extended"/>
  <presentationLink xlink:role="http://xbrl.sec.gov/dei/role/document/AuditInformation" xlink:type="extended"/>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &[ M # 2(  A$! Q$!_\0
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M'2O_ )$H_P"$*\&_]"EX9_\ !#I7_P B5TU% ',_\(5X-_Z%+PS_ ."'2O\
MY$H_X0KP;_T*7AG_ ,$.E?\ R)7344 <S_PA7@W_ *%+PS_X(=*_^1*/^$*\
M&_\ 0I>&?_!#I7_R)7344 <S_P (5X-_Z%+PS_X(=*_^1*/^$*\&_P#0I>&?
M_!#I7_R)7344 <S_ ,(5X-_Z%+PS_P""'2O_ )$H_P"$*\&_]"EX9_\ !#I7
M_P B5TU% ',_\(5X-_Z%+PS_ ."'2O\ Y$H_X0KP;_T*7AG_ ,$.E?\ R)73
M44 <S_PA7@W_ *%+PS_X(=*_^1*/^$*\&_\ 0I>&?_!#I7_R)7344 <S_P (
M5X-_Z%+PS_X(=*_^1*/^$*\&_P#0I>&?_!#I7_R)7344 <S_ ,(5X-_Z%+PS
M_P""'2O_ )$H_P"$*\&_]"EX9_\ !#I7_P B5TU% ',_\(5X-_Z%+PS_ ."'
M2O\ Y$H_X0KP;_T*7AG_ ,$.E?\ R)7344 <S_PA7@W_ *%+PS_X(=*_^1*/
M^$*\&_\ 0I>&?_!#I7_R)7344 <S_P (5X-_Z%+PS_X(=*_^1*/^$*\&_P#0
MI>&?_!#I7_R)7344 <S_ ,(5X-_Z%+PS_P""'2O_ )$H_P"$*\&_]"EX9_\
M!#I7_P B5TU% ',_\(5X-_Z%+PS_ ."'2O\ Y$H_X0KP;_T*7AG_ ,$.E?\
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MX=-N9(9X)H[99(IHI%62.2-E>-U5E8, :]&KF?&O_(F^+?\ L6=>_P#35=T
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MX%^('BSX$_"'Q;\"_%>E?%;Q+K_PVT_X@^%/&TGA/Q+JOBNW\7^%? WQ6O\
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M_@ATK_Y$KIJ* .9_X0KP;_T*7AG_ ,$.E?\ R)1_PA7@W_H4O#/_ ((=*_\
MD2NFHH YG_A"O!O_ $*7AG_P0Z5_\B4?\(5X-_Z%+PS_ ."'2O\ Y$KIJ* .
M9_X0KP;_ -"EX9_\$.E?_(E'_"%>#?\ H4O#/_@ATK_Y$KIJ* .9_P"$*\&_
M]"EX9_\ !#I7_P B4?\ "%>#?^A2\,_^"'2O_D2NFHH YG_A"O!O_0I>&?\
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MD>:..YAE@=[:XFM+A$F1HV>WNK:2*XMIE#$Q7%O+'-#(%DBD1U5A-10!\;_
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M=V_@K3_@?\'OA#H<NK>)+KPQX0GN-=\;:3XSU6P3PIIUCHUUINF:CXGLM?\
MM:O,OBXE[;>#I_%&E^<=4\ 7UGX[M889#&]]:>'C+-XAT@#<B.^N>%)M>T6
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MHUG3M7\)VS^%S;R7G]N7UEXML-#U72+ 643WK3:Q86&VR O& MG25O.?AO\
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M$_A_X?>(M?N-93PS8>-K"P\6?#CXF?#6;Q-X)U.Z>RLO&G@8_$KP?X1C\?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK1_$^@>"?B7X.^'OCG7=&U G3_#<NHZ;K6G:9>7]N/P[IEKXOL?B!\"?C_\
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M"?B#\7O@KX9MO@UX:_9X\8>'?A=KG@X6_P 3O@IX.34;;PKX#\9Z[\0O GQ
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MU>QNM-U&RFU[3/*NK*]@>VNH'VWBL%EAD="R,KKG<C*P!';U_"K^UU_R=?\
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M:5_\EUTU% ',_P#":^#?^AM\,_\ @^TK_P"2Z/\ A-?!O_0V^&?_  ?:5_\
M)==-10!S/_":^#?^AM\,_P#@^TK_ .2Z/^$U\&_]#;X9_P#!]I7_ ,EUTU%
M',_\)KX-_P"AM\,_^#[2O_DNC_A-?!O_ $-OAG_P?:5_\EUTU% ',_\ ":^#
M?^AM\,_^#[2O_DNC_A-?!O\ T-OAG_P?:5_\EUTU% ',_P#":^#?^AM\,_\
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M?'GB)?AGHOQ_^!_PU\::OX/_ &L/B7K5YX>UGQM>^&_A]!\%+W]BNPTCPM\
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M?%4Z0:AJ=E93/"WPY^%,:S+%<SQNT3/'(BR!2A>-U!RC ?R\U_4]_P $/O\
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MCIX7[_8_A-X\SCG']I^,/AQC=_=W?V2WE_W]LF<^6,>LU]&?CYS/_":^#?\
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MF>38VN_W7#/B?D6)EB. ^(:<I*7U>CC\5.OPAG<Z:BZV4\04?:\ZPM+D_P!
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M&ILQFDO=)T.6!/#6C3)=-)<6E]#I<^O0LR^?KEW+&LU?//\ P7  '[)_P]
M '[0WA, #@ #X;?%G  [ 5^R5?C;_P %P?\ DU#X??\ 9PWA/_U6WQ9K]0\*
M,%A,#QWPC1P>&HX:DLYHWC1IQAS-87,O>G*SG4EWG4J5).[][4_$O%KB3/\
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MS:C#J\%E<:;Y4R7\5M)#*B>&_#?]JWX$_%6YU6U\*>+]4M)=)\&P_$9V\=^
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M^+'@1?#9\8W$E]X-\0R>$(/^$MZKP+^S+^T'H%W\-?A!JUQ\((?V?/A%\?\
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M-\>R:E\D%MI,6N6R:=%H'B768=++MJ8L=,\$^-;&XN6G_L("'^@*OBO]OO\
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M)5]CB:%7#XRAAL12J4*MZ=2%6A3E&<9PE",H3C#F?LGC+_H/>&?_  DM5_\
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MEJO_ ,VM=-17^>I_:1S/V3QE_P!![PS_ .$EJO\ \VM?CW_P6Q@U^/\ 96\
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MTF]EU;Q!I&IKI.O)976GW0\/>%/B/._A+8VC#0O$%W=VJ@'Q#X@^*'_!,?\
M:=_;FLOC/XJ^%W[4_AKX:^,_C%X?\+ZC\4$U70M/_9W^(OQ0T<Z=!H.J>/-"
MN] N/$'AW3M<MVCU35X-.\9V>L?V3>6NN:OX7T+^TO$93^P4 * J@!0
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M$C3I_P *M%%%?Z:'^<!_4]_P0^_Y-0^(/_9PWBS_ -5M\)J_9*OQM_X(??\
M)J'Q!_[.&\6?^JV^$U?LE7\$>)G_ "<#BW_L<UO_ %&RT_L/@/\ Y(WAO_L5
MT_\ T_C@HHHKX8^M/XV_^"K'_)_'QY_[I=_ZICX=U^>=?H9_P58_Y/X^//\
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MP&_[JC_ZN?XB5^AE?YZ\:_\ )8\5_P#91YU_ZL<0?VEPM_R3'#O_ &(\J_\
M4&B%<SXU_P"1-\6_]BSKW_IJNZZ:N9\:_P#(F^+?^Q9U[_TU7=?,GO!X*_Y$
MWPE_V+.@_P#IJM*Z:N9\%?\ (F^$O^Q9T'_TU6E=-0 5^4O[;'_!5OX$?LF?
M$+P;\)4\5:'JWQ(@^*OPUTCXS^&M4\-?$:8_#WX.>+;"36/$7CZSU70_#D^B
M:SK.C:/<:-?67AW3=3U75[E-1 &BW#H\:?JU7Y$?\%0/A%^S3!I/P5^(WBW]
MGKX;^.OB]XY_:M^ G@GP_K-]IGA+PI-XS\0ZC<W>DZ7H7QC\=2^!/%FO>(_A
M3%H&GSPZ_P"%;J&>#5+73-(T]9;>"VB4 ''?'+_@N)^QOX>^&^K:G^SS\2;7
MXQ?%M=2\,VGACX<7?PT^-7A^/Q+'J/B72=/UN"+6-;\#^'M-L[RTT&YU+4+#
MS]1S<WUI;V<=M<R7*Q']I(9#+#%*T;Q-)&DABD!#QEU#&-P0"'0G:P(!!!&*
M_,K]JSP?^R[^PS\(G_:A\#_L:_LPMJ?PS\9> 9]3NM'^%OP\\$>*-'T7Q#XL
MTOPO?:WX+\0:+X(FOT\4:1/K-K>Z=;H;,7,,-V#=0.J!OTUAE2>&*>/)CFC2
M5"1@[)%#KD=CM(R.QH S]8US1?#UI'J&OZOI>AV$NH:1I$5[K&H6FFVDNJZ_
MJMGH6A:9'<WLT$+ZAK>MZCI^CZ19*YN=2U6_L]/LXIKNZ@A?4K\U/VS?#'B/
M4/B1X?UWXI>"?VA/B3^R=I_@?13>V7[-/CCQ5X<\6?"WXQ:?\3=&U"S^+/C/
MP7\-/&G@GXJ?$S0-!TK^P->\/#P;;?$BY^'U_P"#-;\2K\/9;R[M-9M/-OVQ
M/C+K?CC]F;5O"W[-OQD\9G3?#'[+=]^TCXQ^/7AG6M2T?QM/X*T/PI<WWP@T
M^'Q;H*>&KK1/&7QG\6:-/K>O265GIMRO@SP;X\TNYTK1W\0:8$ /UTHKY5_:
M/^*_BCX._L;?%7XP>&&-UXR\$_ [5O%&AW-Y!_::IXAM_# DL-4OH+@LM[#9
M7\D>I7RW!=)H8)C.LB%U;X5_:(\6>.OV%;--<^&WQ)^+'Q G\8?LE?'_ ,1Z
MW9?%WXE>-OC ?^%I?"#2? ^L>%/BKINF^/-<UVT\&VS3>+]?M_&&@>"(_#7@
M6]6Z\.V[>%E33--%H ?LI17XU_M$>+/'7["MFFN?#;XD_%CX@3^,/V2OC_XC
MUNR^+OQ*\;?& _\ "TOA!I/@?6/"GQ5TW3?'FN:[:>#;9IO%^OV_C#0/!$?A
MKP+>K=>';=O"RIIFFBT^B_!GAK5_@!^TI\ O >B_$SXN>/?#?QM^#GQ0/CZP
M^*_Q4\<_%*XN?&_PM_X5_J^C_$?0X/'&N:[#X$.IP^+?$ND>)M&\!)X8\%W4
M^I^&((_#,1TS2VLP#]":*_/OQGHVI_M"_M4?&3X0>(/'OQ=\"^"O@S\"?A;K
M?A>U^%'Q1\??"&XO_&_QEUCXGQ:CXVUG6OAUXB\-:MXH;PKI_P .]'T_PSH6
MO7NH>$+:ZN_$4^H^']1NIX9K?YO_ &<O%GCK]MZ\M=#^*OQ)^+'A>#X??LE?
M!7Q''>_"#XE>-O@N/%?Q2^+.K?%/1_$7Q5O]2^%VN>$KOQ);6D/PMTNX\'Z!
MJ4EQX%MFUG7;B?PM=/<VQM #]E**_(_X7?$OQW^U'<_L4?#GXB>,?'FCZ1XS
M_9A^(WQR^)VK_"_QGXJ^$FJ?$OQKX"\1?#GX9Z0O_":_#'5_"7BK3/"MW<>,
MM<\=7&D>%M7T&SU6\E\,&]CET:%M*E^O/V,_$WB;6OA=XJ\->*O$>K^,KWX2
M_&SXS_!K3/&&OW\FKZ_XC\+_  Y\?:OHGA*\U_7)_P#2_$'B&P\.)IFA>(M>
MOVFU75]=TG4K[5[N^U6:\OK@ ^M***Y^X\3:=:SRV\EMX@:2&1HW:W\)^*KN
M!F4X)BNK31IK:>,G[LL$LD3CE'8$&@#H*_A5_:Z_Y.O_ &GO^SAOC3_ZLGQ+
M7]PG_"6Z5_SZ>)O_  BO&7_RAK^';]K.9+C]JG]IB>,2JD_[0/QFF19X)K:9
M4D^(WB1U$UM<QQ7%O* P$D$\4<T3YCEC1U91_0OT>?\ D=<3_P#8FR__ -6U
M0_%O&K_D59#_ -C3&_\ JM@?/U?H9_P2G_Y/X^ W_=4?_5,?$2OSSK] _P#@
MEI=Q6/[=_P "[J=+IXHO^%G;EL[*\U&Y._X.?$*-?+L]/M[J[FPS@OY,#^7&
M&EDVQ([K_0O&O_)'<5_]DYG7_JNQ!^+<+?\ )3\._P#8\RK_ -3J)_9;17,_
M\);I7_/IXF_\(KQE_P#*&C_A+=*_Y]/$W_A%>,O_ )0U_GJ?VD=-7X8_\%"/
M"VN_L@_M-?"3_@HK\--+N9]!NM6TWX>_M$:%I<9/]M:3>VPTR'5+E&<6Z2Z[
MX;MAH<-Y=&#3[#Q5X>\%WCB74+YVE_:C_A+=*_Y]/$W_ (17C+_Y0UYS\7O#
M7P_^-GPR\;_"CQQI'B6]\+^._#][H.J1CP3XP,UO]H4266IV3-H)$6I:/J$5
MIJVEW&";;4;*UN ,QBO,S? 2S#!3I4I^RQ=&<,5@:_6AC<._:4)W_DE).C56
MTJ5::DFM']KP!Q33X3XCP^-QM!XW(<PP^)R/BC+-7',N&\WIK"9KA^5-)UZ-
M*<,PP,])TL?E^%J4Y0FU->F^%?%&@^-_#'A[QEX6U*WUCPUXJT73/$6@:K:-
MNMM1T?6;*'4-.O820#LN+2XBE"L%==VUU5@0.%3_ (J/XQS/_K-.^&?A);93
MUB/BWQ[.EQ< ]Q?:)X6T*R*GY0MGXUD'[PRGROR9_P""87QOUSX,ZU\5?V"/
MC?<ZI%XN^"&L:UK/PTOI]!UU9==^'MU=?VE?):Z>UE)JT&G1KJ-IXUT(7MOY
M_P#PCOB>:-C!::&D:>\_%G]O[X0?LM?#^ZUO6XM5\9?&[XN:OJ/CKPK\(],L
M=2L?$.KV?B*=-,\!3ZO<WFG%-'T.V\(Z9X8T@ZCY5[=ZE<V-S%H&F:C)%/;V
MF6%SG"U,KCF6+J0PD::E2QD*KL\/C*,G1Q&&Y=9RJ*O"4:5.,9U*D9TN2,N:
MYW9YX<YYA..*O!F0X7$<05<7*CC>'<3@J:G3S?A[,J,,PRG.56]S#T<)4RVO
M2JXW%5JM#"X.KAL=&O5H^R5,^]OC#\9_AG\!/ NJ_$CXL>+--\(>$](4+)>W
MSL]S?WLB2/;:3HNFVZRZAK6LW@BD^R:7IEO<WDRQRRB(003RQ_B?<ZQ^U'_P
M5OUN;3/#8\0?LY?L*66IM!J6LW"+'XQ^+<-A=,LEL$BE-OK<KRPE'TRVGG\#
M>&+Q6DU6\\7:YI5E9OL_"3]DCXN?M@?$#3OVC_\ @HM+XK33+*9KSX<?LS:5
MX4\:V?AW0--ED6>WC\26MGIMRFF6$JI;RW.B1WUYXGUXQ6P\::U$MK/H,_[9
MZ7K/AC1--L-&T71-8TC2-*L[;3M+TK2_A_XJT_3=-T^SA2WL[&PL;3P[%:V=
MG:P1QP6UK;Q1P00HD42(BJHX?8XW/_>Q4:V79,]88*\J6/S.&ZECI1:G@\)-
M6:P<)*O6B_\ :)TXMTSZ9YAPWX5)T<BK9;Q?XCP3C7XD4*>/X5X+KV<9T>&:
M5:$Z'$/$&'DY0EQ#B:4\JR^O!O*,/BJU..,7&_ G]G_X4?LW> K#X=?"+PI9
M>&= M-DU[.H%QK7B+5/*2*?7/$NKR*+O6=7N510]S<MY=O"L=EI\%GIUO;6<
M'LU<S_PENE?\^GB;_P (KQE_\H:/^$MTK_GT\3?^$5XR_P#E#7T5*E2H4X4:
M-.%*E3BH4Z=.,80A"*LHQC%))+R6KNVVVV_R#'8[&YGC,3F&8XO$X['8RM/$
M8O&8NM4Q&)Q->I+FJ5:U:K.=2I.3ZRE9)1A",(0A3I_Y^M%%%?Z:'\"G[)?\
M$/O^3K_B#_V;SXL_]63\)J_J>K^5/_@B=J-OIG[5/C^>YCOI$?\ 9^\50A=/
MTO4]6F#M\1OA2X+6VE6E[<)%B-@T[Q+"KE(VD#R1J_\ 4-_PENE?\^GB;_PB
MO&7_ ,H:_B[QR_Y.!B?^Q-D?_J-C#^I?"7_DC:'_ &-,V_\ 3^&/F']K?]B#
MX)_MA>&5L/'VE'1?&^E6KQ>$?BAX>A@@\7>') SRPVTTQ")K_A_[0[R7'A[5
M6DM?WUQ/IDVDZI(FIP_FQX(_:D_:<_X)P^*]&^#/[;EAJ_Q3^ %[=+H_PY_:
M-\/V][K5_IMDBXL[76)I-][J\=E;1EK_ ,-:RZ^-=*MX;NXT*[\7:/:Z;!/^
MXO\ PENE?\^GB;_PBO&7_P H:Y7QM9_#KXD^%M9\$>/O"%]XN\)>(;1K'6?#
M^O?#WQ7J&FW]NS*Z^9!/X?8)/!,D=S9W<)CNK*[BAO+.:"Z@BF3\&QV4>UKO
M,,NK?V?FB23KPCS8?&1CM1S'#IQCB*;M955RXFC?FIU7RJ)_2?#/'_U++8\*
M<7Y=_K;P1.I*4,LKU_8YMP]6JZ3S+A'.)QJULHQD>9U*F!DZN39ARNEC,##V
MCKKI? _CKP=\2O"NC>-_ 'B71_%_A+Q!:)?:/K^@WT-_IU[ V58)-"S>7<02
M*]O>6<ZQ7=C=Q36EY!!=0RPIU=?S[>+?V?/VB_\ @G;XQU;XO_L.7'C3XH?
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M#+*>58&M%*O5IOL:^>?VNO\ DU#]I[_LWGXT_P#JMO$M>P?\);I7_/IXF_\
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M6T<MQ<2D*1'!!%)-*^(XHW=E4_W$_P#"6Z5_SZ>)O_"*\9?_ "AK^>OI#?\
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MFBBBO[W/X\/[)/\ @E/_ ,F#_ ;_ +JC_P"KG^(E?H97YK_\$M/$5A8_L(?
MNUGM]=>6+_A9VYK/POXEU&V._P",?Q"D7R[S3])NK.;"N _DSOY<@:*3;*CH
MOZ!?\);I7_/IXF_\(KQE_P#*&O\ /7C7_DL>*_\ LH\Z_P#5CB#^TN%O^28X
M=_[$>5?^H-$Z:N9\:_\ (F^+?^Q9U[_TU7=;UI=17MO%=0K<)',"R+=V=W87
M  9E/FVE]!;W<)RI(6:&-F7#J"C*QP?&O_(F^+?^Q9U[_P!-5W7S)[P>"O\
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M!G7P\JM-5J:J1JX6"<Z4I1C./+5G[KDE>SOIK^7G[;_[:WP(^.7Q4^&'Q_\
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MV^&OP>\5?!KX*67@3X4Q_#7QAX=T[Q!HVD>%M+\;_$SQ'J7Q"^(?A[XF>/\
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M?_JMS _A5HHHK_1T_AX_J>_X(??\FH?$'_LX;Q9_ZK;X35^R5?C;_P $/O\
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M/^28P/\ V/,-_P"H.8'YYU^AG_!*?_D_CX#?]U1_]4Q\1*_/.OT,_P""4_\
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MS<"S@EM]!;Q$R+=BVF\AY&224PW"Q02>0Q/\Q%?T,?\ !!G_ )NK_P"Z&_\
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M_P G\? ;_NJ/_JF/B)7YYU^AG_!*?_D_CX#?]U1_]4Q\1*_ICC7_ )([BO\
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MTU !7Y=?\%;?'/CCPK^S9X*\*^#/B!?_  DL_C3^T%\)O@MX^^*VG7$]A/\
M#SX>>-;W5#XC\12:K!/9MI5D@TVTL=1NFU#34FT^]NK!KZ%;T[OU%K\^/^"F
M_P 5OV>/A5^RQKLG[4?PN\:?%GX0>._$V@^ M8\/>!K33I=5T_4]134-;T3Q
M%+J6H^(_"Z^'H])O_#Z/8ZW9ZH+VWUN72K:*"2.[F9 #\C?VCO\ @GA\,?\
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M^1UQ/_V)LO\ _5M4/Q;QJ_Y%60_]C3&_^JV!\_5^AG_!*?\ Y/X^ W_=4?\
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MSHM&E^T;_P#A;NWSO[7TG5-OD[&\O[/Y&?-?S?-Q%Y?W/C#_ ,FZXA_[I?\
MZN, ?)>&7_);9+_W4/\ U68P_HKHKF?[!U7_ *'7Q-_X">#?_F2H_L'5?^AU
M\3?^ G@W_P"9*OX;/ZT.FK^6'_@N#_R=?\/O^S>?"?\ ZLGXLU_3Q_8.J_\
M0Z^)O_ 3P;_\R5?R\_\ !;&TN++]JGP!%<ZI?:L[?L_>%9!<ZA'ID<R(?B-\
M5E$"KI6G:9;F)2C2*7@>;?(X:9D$:1_K_@;_ ,G PW_8FSS_ -1L&?FGBU_R
M1M?_ +&F4_\ I_$GX]T445_:)_+1_H845S/]@ZK_ -#KXF_\!/!O_P R5']@
MZK_T.OB;_P !/!O_ ,R5?YGG]X'35\\_M=?\FH?M/?\ 9O/QI_\ 5;>):]@_
ML'5?^AU\3?\ @)X-_P#F2KY^_:ST74HOV5OVF)9/%WB&Y2/]G[XS2/;3VWA-
M8;A$^'/B1F@F:V\,6]PL4H!CD,$\$P1B8IHWVNOIY)_R.LE_['.3_P#JVRHX
M,U_Y%6:?]BO,_P#U6Y@?P[4445_HZ?P\?U/?\$/O^34/B#_V<-XL_P#5;?":
MOV2K\5?^")VF7M[^RMX_EMO$.L:2B_M ^*HS;:?!H$D+N/AS\*6,[-JNAZG<
M"5@ZQL$G2'9&A6%7,CR?L)_8.J_]#KXF_P# 3P;_ /,E7\$>)G_)P.+?^QS6
M_P#4;+3^P^ _^2-X;_[%=/\ ]/XXZ:BN9_L'5?\ H=?$W_@)X-_^9*C^P=5_
MZ'7Q-_X">#?_ )DJ^&/K3^0'_@JQ_P G\?'G_NEW_JF/AW7YYU^@?_!4NWEM
M?V[_ (Z03WMUJ,J?\*QW7EXEFES-N^#GP]=?,73[2QM!Y:L(D\FUBS&BF3?*
M7D?\_*_T*X*_Y([A3_LG,E_]5V'/XMXI_P"2GXB_['F:_P#J=6/H;]D7_DZ_
M]F'_ +.&^"W_ *LGPU7]U5?PH?LF1O+^U3^S/%'/+;/)^T#\&8TN8!"TUN[_
M !&\-JL\*W,-Q;M+$2)(Q/!/"74"6&1-R-_<3_8.J_\ 0Z^)O_ 3P;_\R5?S
MU](;_D=<,?\ 8FS#_P!6U,_:?!7_ )%6??\ 8TP7_JMF=-17,_V#JO\ T.OB
M;_P$\&__ #)4?V#JO_0Z^)O_  $\&_\ S)5_/1^TGPS_ ,%6/^3!_CS_ -TN
M_P#5S_#NOXVZ_L(_X*EZ3?VO["'QTGG\4:[J,2?\*QW6=Y;^&DMIMWQC^'J+
MYC:?X=L;P>6S"5/)NHLR(HDWQ%XW_CWK^OO #_DCLR_[*/%_^J[*S^:?&3_D
MI\#_ -B/#?\ J=F 5_4]_P $/O\ DU#X@_\ 9PWBS_U6WPFK^6&OZAO^")VF
M7M[^RMX_EMO$.L:2B_M ^*HS;:?!H$D+N/AS\*6,[-JNAZG<"5@ZQL$G2'9&
MA6%7,CR>GXY?\F_Q/_8YR/\ ]2<8<'A+_P EE0_[%>;?^F,,?M517,_V#JO_
M $.OB;_P$\&__,E1_8.J_P#0Z^)O_ 3P;_\ ,E7\7']2G35_&W_P58_Y/X^/
M/_=+O_5,?#NOZ_O[!U7_ *'7Q-_X">#?_F2K^/C_ (*EV\MK^W?\=()[VZU&
M5/\ A6.Z\O$LTN9MWP<^'KKYBZ?:6-H/+5A$GDVL68T4R;Y2\C_N7@!_R6.9
M?]DYB_\ U8Y6?DOC)_R3&!_['F&_]0<P/S\K]#/^"4__ "?Q\!O^ZH_^J8^(
ME?GG7Z!_\$M+>6Z_;O\ @7!!>W6G2O\ \+.VWEFEF]S#M^#GQ"=O+74+2^M#
MYBJ8G\ZUEQ&[&/9*$D3^F.-?^2.XK_[)S.O_ %78@_!^%O\ DI^'?^QYE7_J
M=1/[+:*YG^P=5_Z'7Q-_X">#?_F2H_L'5?\ H=?$W_@)X-_^9*O\]3^TCIJ_
M&W_@N#_R:A\/O^SAO"?_ *K;XLU^MG]@ZK_T.OB;_P !/!O_ ,R5?CW_ ,%L
M=,O;+]E;P!+<^(=8U9&_:!\*QBVU"#0(X4<_#GXK,)U;2M#TRX,JA&C4/.\.
MR1RT+.(WC^Y\,_\ DX'"7_8YH_\ J-F1\EQY_P D;Q)_V*ZG_I_ G\O-%%%?
MWN?QX?V2?\$I_P#DP?X#?]U1_P#5S_$2OT,K\U_^"6FDW]U^PA\"YX/%&NZ=
M$_\ PL[;9V=OX:>VAV_&/XA(WEMJ'AV^O#YC*97\ZZEQ(["/9$$C3] O[!U7
M_H=?$W_@)X-_^9*O\]>-?^2QXK_[*/.O_5CB#^TN%O\ DF.'?^Q'E7_J#1.F
MKF?&O_(F^+?^Q9U[_P!-5W6]:02V]O%#->7%_)&"'N[M;1+B8EF8-*MC:V5H
M"H(0>3:PKM4%E+[F;!\:_P#(F^+?^Q9U[_TU7=?,GO!X*_Y$WPE_V+.@_P#I
MJM*Z:N9\%?\ (F^$O^Q9T'_TU6E=-0 5^/\ _P %1OC'^PUXK\)V_P"RA^TG
M^UWXI^ FJZOJNB>+=>T;X7V/BWQ!KFIZ+!:WT=CX<^(%OX5\'>,=+L/#FJSZ
MG8>(HM'\6QV)O9M)T?7+:&2WM(KI?V K^1;3?VFO^"<7PK_:7_;R3]MKX':]
M\:?BSXB_:N^*^F:-K]WX"\/_ !!TS2/ACH-^F@^&M&TD>(_%>E1^'M5T^YM-
M8BEOM(TRWU*33UT:)M7F2QM8+( _0;X7_P#!(WX<^)_ 7@[Q'\(_^"B7[8.L
M?#.^T:PE\$WG@GXNZ<_A*30+91;6=MHB:39+I]M8V2V[6'V&WCA&GR6\EC)!
M;S6\D,?[P1)Y44<6^23RXT3S)6WROL4+OD? W2-C<[8&YB3@9K^4O_@GW_P5
MM_8]_9/\"?%?X0ZIH_QIM_ %S^T5\2O%?P-T^P\-Z5KY\-_![Q5<:3-X8T76
MKK4/'$=Y#JMA<PZG-J%K"-1 -P+@W^HWUS=2M_5G#*D\,4\>3'-&DJ$C!V2*
M'7([':1D=C0!0O=$T;4;[1]4U#2-,O\ 4_#US=7N@:C>V%K=7VAWE]I]UI-[
M=Z/=SQ27&F7-YI5]>Z9=3V4D$MQI]Y=64KO;7$L;Z=%% &;;:+H]EJ6IZS9Z
M3IEIK&MI81ZSJMM86L&I:NFEQ2P:8FIWT4275^FG0SSPV"W<LHLXII8[<1I(
MX.E110 5FZQHNC^(=-NM&U_2=,US1[Y$CO=*UBPM=3TV\2.5)XTNK&]BGM;A
M$FBCF19HG"RQI(H#HI&E10 4444 %%%% !1110 5_"K^UU_R=?\ M/?]G#?&
MG_U9/B6O[JJ_A5_:Z_Y.O_:>_P"SAOC3_P"K)\2U_0OT>?\ D=<3_P#8FR__
M -6U0_%O&K_D59#_ -C3&_\ JM@?/-?H9_P2G_Y/X^ W_=4?_5,?$2OSSK]#
M/^"4_P#R?Q\!O^ZH_P#JF/B)7]"\:_\ )'<5_P#9.9U_ZKL0?BW"W_)3\._]
MCS*O_4ZB?V24445_GJ?VD%?C;_P7!_Y-0^'W_9PWA/\ ]5M\6:_9*OQM_P""
MX/\ R:A\/O\ LX;PG_ZK;XLU]SX9_P#)P.$O^QS1_P#4;,CY+CS_ )(WB3_L
M5U/_ $_@3^6&BBBO[W/X\/[JOV1?^34/V8?^S>?@M_ZK;PU7T-7SS^R+_P F
MH?LP_P#9O/P6_P#5;>&J^AJ_SBSO_D=9U_V.<X_]6V:G]PY5_P BK*_^Q7EG
M_JMR\****\P[S_//HHHK_3 _@\_9+_@A]_R=?\0?^S>?%G_JR?A-7]3U?RP_
M\$/O^3K_ (@_]F\^+/\ U9/PFK^IZOXN\<O^3@8G_L39'_ZC8P_J7PE_Y(VA
M_P!C3-O_ $_A@HHHK\@/TL_GG_X+S?\ -JG_ '7+_P!X]7\\]?T,?\%YO^;5
M/^ZY?^\>K^>>O[D\'O\ DW7#W_=4_P#5QCS^2_$W_DMLZ_[I_P#ZK,&%?Z&%
M?YY]?Z&%?F?TB?\ FD?^Z[_[RC[SP3_YJ7_ND?\ O1"BBBOYG/W@^>?VNO\
MDU#]I[_LWGXT_P#JMO$M?PJU_=5^UU_R:A^T]_V;S\:?_5;>):_A5K^J_H\_
M\B7B?_L<Y?\ ^JFH?SQXU?\ (UR'_L5XW_U90"OZ&/\ @@S_ ,W5_P#=#?\
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M]_R:A\0?^SAO%G_JMOA-7[)5_!'B9_R<#BW_ +'-;_U&RT_L/@/_ )(WAO\
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MG^>?1117^F!_!Y^R7_!#[_DZ_P"(/_9O/BS_ -63\)J_J>K^6'_@A]_R=?\
M$'_LWGQ9_P"K)^$U?U/5_%WCE_R<#$_]B;(__4;&']2^$O\ R1M#_L:9M_Z?
MPP4445^0'Z6?SS_\%YO^;5/^ZY?^\>K^>>OZ&/\ @O-_S:I_W7+_ -X]7\\]
M?W)X/?\ )NN'O^ZI_P"KC'G\E^)O_);9U_W3_P#U68,*_P!#"O\ //K_ $,*
M_,_I$_\ -(_]UW_WE'WG@G_S4O\ W2/_ 'HA1117\SG[P?//[77_ ":A^T]_
MV;S\:?\ U6WB6OX5:_NJ_:Z_Y-0_:>_[-Y^-/_JMO$M?PJU_5?T>?^1+Q/\
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MHHHK^]S^/#^R3_@E/_R8/\!O^ZH_^KG^(E?H97YY_P#!*?\ Y,'^ W_=4?\
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M?X&_"^'6+?PWX4U?58-<\'0?#F\C^(_Q!^)/QB6U^'<"RH/A]H8^+GB[QO\
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M\"YX+*ZU&5/^%G;;.S>S2YFW?!SXA(WEMJ%W8V@\M6,K^==19C1A'OE*1O\
MGY7Z&?\ !*?_ )/X^ W_ '5'_P!4Q\1*_H7C7_DCN*_^R<SK_P!5V(/Q;A;_
M )*?AW_L>95_ZG43^O[^WM5_Z$KQ-_X%^#?_ )K:/[>U7_H2O$W_ (%^#?\
MYK:Z:BO\]3^TCF?[>U7_ *$KQ-_X%^#?_FMK\>_^"V.IWM[^RMX BN?#VL:2
MB_M ^%9!<ZA/H$D+N/AS\5E$"KI6N:G<"5@[2*7@2'9&X:97,:2?M57XV_\
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MC5M4V^3L7S/M'D9\U/*\W$OE_P _5?T,?\%YO^;5/^ZY?^\>K^>>O[D\'O\
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M3S%%(BAD?:C?4]?//[77_)J'[3W_ &;S\:?_ %6WB6O3R3_D=9+_ -CG)_\
MU;94<&:_\BK-/^Q7F?\ ZK<P/X5:***_T=/X>/ZAO^")VIWME^RMX_BMO#VL
M:LC?M ^*I#<Z?/H$<*.?AS\*5,#+JNN:9<&50BR,4@>'9(@69G$B1_L)_;VJ
M_P#0E>)O_ OP;_\ -;7Y)_\ !#[_ )-0^(/_ &<-XL_]5M\)J_9*OX(\3/\
MDX'%O_8YK?\ J-EI_8? ?_)&\-_]BNG_ .G\<<S_ &]JO_0E>)O_  +\&_\
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MC*G_  L[;9V;V:7,V[X.?$)&\MM0N[&T'EJQE?SKJ+,:,(]\I2-_S\K]#/\
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MK_D3?"7_ &+.@_\ IJM*Z:N9\%?\B;X2_P"Q9T'_ --5I734 %%%% !1110
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M,8?T,4445_#9_6@5_+#_ ,%P?^3K_A]_V;SX3_\ 5D_%FOZGJ_EA_P""X/\
MR=?\/O\ LWGPG_ZLGXLU^O\ @;_R<##?]B;//_4;!GYIXM?\D;7_ .QIE/\
MZ?Q)^-M%%%?VB?RT?Z&%%%%?YGG]X!7SS^UU_P FH?M/?]F\_&G_ -5MXEKZ
M&KYY_:Z_Y-0_:>_[-Y^-/_JMO$M>GDG_ ".LE_['.3_^K;*C@S7_ )%6:?\
M8KS/_P!5N8'\*M%%%?Z.G\/']3W_  0^_P"34/B#_P!G#>+/_5;?":OV2K\;
M?^"'W_)J'Q!_[.&\6?\ JMOA-7[)5_!'B9_R<#BW_L<UO_4;+3^P^ _^2-X;
M_P"Q73_]/XX****^&/K3^-O_ (*L?\G\?'G_ +I=_P"J8^'=?GG7Z&?\%6/^
M3^/CS_W2[_U3'P[K\\Z_T*X*_P"2.X4_[)S)?_5=AS^+>*?^2GXB_P"QYFO_
M *G5CZ&_9%_Y.O\ V8?^SAO@M_ZLGPU7]U5?PJ_LB_\ )U_[,/\ V<-\%O\
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M%%?WN?QX?V2?\$I_^3!_@-_W5'_U<_Q$K]#*_//_ ()3_P#)@_P&_P"ZH_\
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MK^%6OZK^CS_R)>)_^QSE_P#ZJ:A_/'C5_P C7(?^Q7C?_5E *_H8_P""#/\
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M&?\ !5C_ )/X^//_ '2[_P!4Q\.Z_/.O]"N"O^2.X4_[)S)?_5=AS^+>*?\
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M )%6:?\ 8KS/_P!5N8'\*M%%%?Z.G\/']0W_  1.T.RU/]E;Q_/<SZQ&Z?M
M^*H0NG^(=?TF$HOPY^%+@M;:5J=E;O+F1@T[Q-,R!(VD*1QJG["?\(EI7_/W
MXF_\+7QE_P#+ZOR3_P""'W_)J'Q!_P"SAO%G_JMOA-7[)5_!'B9_R<#BW_L<
MUO\ U&RT_L/@/_DC>&_^Q73_ /3^..9_X1+2O^?OQ-_X6OC+_P"7U'_"):5_
MS]^)O_"U\9?_ "^KIJ*^&/K3^-+_ (*EVD5C^W?\=+6![IXHO^%8[6O+V\U&
MY._X.?#V1O,O-0N+J[FPSD)YT[^7&%BCVQ(B+^?E?H9_P58_Y/X^//\ W2[_
M -4Q\.Z_/.O]"N"O^2.X4_[)S)?_ %78<_BWBG_DI^(O^QYFO_J=6/H']DR%
M+C]JG]F>"0RJD_[0/P9A=H)YK:94D^(WAM&,-S;217%O* Q,<\$L<T3XDBD1
MU5A_<3_PB6E?\_?B;_PM?&7_ ,OJ_A[_ &1?^3K_ -F'_LX;X+?^K)\-5_=5
M7\]?2&_Y'7#'_8FS#_U;4S]I\%?^15GW_8TP7_JMF<S_ ,(EI7_/WXF_\+7Q
ME_\ +ZC_ (1+2O\ G[\3?^%KXR_^7U=-17\]'[2?FO\ \%2_#MA8_L(?'2Z@
MN-=>6+_A6.U;SQ1XEU&V._XQ_#V-O,L]0U:ZLYL*Y*>= _ER!98]LJ(Z_P >
M]?V2?\%6/^3!_CS_ -TN_P#5S_#NOXVZ_K[P _Y([,O^RCQ?_JNRL_FGQD_Y
M*? _]B/#?^IV8!7]0W_!$[0[+4_V5O'\]S/K$;I^T#XJA"Z?XAU_282B_#GX
M4N"UMI6IV5N\N9&#3O$TS($C:0I'&J?R\U_4]_P0^_Y-0^(/_9PWBS_U6WPF
MKT_'+_DW^)_['.1_^I.,.#PE_P"2RH?]BO-O_3&&/UL_X1+2O^?OQ-_X6OC+
M_P"7U'_"):5_S]^)O_"U\9?_ "^KIJ*_BX_J4YG_ (1+2O\ G[\3?^%KXR_^
M7U?Q\?\ !4NTBL?V[_CI:P/=/%%_PK':UY>WFHW)W_!SX>R-YEYJ%Q=7<V&<
MA/.G?RXPL4>V)$1?[+:_C;_X*L?\G\?'G_NEW_JF/AW7[EX ?\ECF7_9.8O_
M -6.5GY+XR?\DQ@?^QYAO_4',#\\Z_0/_@EI:17W[=_P+M9WNDBE_P"%G;FL
M[V\TZY&SX.?$*1?+O-/N+6[ARR /Y,Z>9&6BDW1.Z-^?E?H9_P $I_\ D_CX
M#?\ =4?_ %3'Q$K^F.-?^2.XK_[)S.O_ %78@_!^%O\ DI^'?^QYE7_J=1/Z
M_O\ A$M*_P"?OQ-_X6OC+_Y?4?\ "):5_P _?B;_ ,+7QE_\OJZ:BO\ /4_M
M(YG_ (1+2O\ G[\3?^%KXR_^7U?CW_P6QT.RTS]E;P!/;3ZQ([_M ^%82NH>
M(=?U:$(WPY^*SDK;:KJ=[;I+F-0LZ1+,J%XUD"22*_[55^-O_!<'_DU#X??]
MG#>$_P#U6WQ9K[GPS_Y.!PE_V.:/_J-F1\EQY_R1O$G_ &*ZG_I_ G\L-%%%
M?WN?QX?V$?\ !+3P[87W["'P+NI[C74EE_X6=N6S\4>)=.MAL^,?Q"C7R[/3
M]6M;.'*H"_DP)YDA:63=*[NWZ!?\(EI7_/WXF_\ "U\9?_+ZOAG_ ()3_P#)
M@_P&_P"ZH_\ JY_B)7Z&5_GKQK_R6/%?_91YU_ZL<0?VEPM_R3'#O_8CRK_U
M!HE>TM8K*WBM86N'CA!5&N[R[O[@@LS'S;N^GN+N8Y8@---(RKA%(1548/C7
M_D3?%O\ V+.O?^FJ[KIJYGQK_P B;XM_[%G7O_35=U\R>\'@K_D3?"7_ &+.
M@_\ IJM*Z:N9\%?\B;X2_P"Q9T'_ --5I734 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5_"K^UU_R=?^T]_V<-\:?_5D^):_NJK^%7]KK_DZ
M_P#:>_[.&^-/_JR?$M?T+]'G_D=<3_\ 8FR__P!6U0_%O&K_ )%60_\ 8TQO
M_JM@?/-?H9_P2G_Y/X^ W_=4?_5,?$2OSSK]#/\ @E/_ ,G\? ;_ +JC_P"J
M8^(E?T+QK_R1W%?_ &3F=?\ JNQ!^+<+?\E/P[_V/,J_]3J)_9)1117^>I_:
M05^-O_!<'_DU#X??]G#>$_\ U6WQ9K]DJ_&W_@N#_P FH?#[_LX;PG_ZK;XL
MU]SX9_\ )P.$O^QS1_\ 4;,CY+CS_DC>)/\ L5U/_3^!/Y8:***_O<_CP_NJ
M_9%_Y-0_9A_[-Y^"W_JMO#5?0U?//[(O_)J'[,/_ &;S\%O_ %6WAJOH:O\
M.+._^1UG7_8YSC_U;9J?W#E7_(JRO_L5Y9_ZK<O"BBBO,.\_SSZ***_TP/X/
M/V2_X(??\G7_ !!_[-Y\6?\ JR?A-7]3U?RP_P#!#[_DZ_X@_P#9O/BS_P!6
M3\)J_J>K^+O'+_DX&)_[$V1_^HV,/ZE\)?\ DC:'_8TS;_T_A@HHHK\@/TL_
MGG_X+S?\VJ?]UR_]X]7\\]?T,?\ !>;_ )M4_P"ZY?\ O'J_GGK^Y/![_DW7
M#W_=4_\ 5QCS^2_$W_DMLZ_[I_\ ZK,&%?Z&%?YY]?Z&%?F?TB?^:1_[KO\
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M7,_V]JO_ $)7B;_P+\&__-;1_;VJ_P#0E>)O_ OP;_\ -;7\3G]5G35^-O\
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MZ_H8_P""#/\ S=7_ -T-_P#>PU\I_P##ES]L3_G]^#__ (6VK_\ S)5^I_\
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M7X-_^:VOX(/[#.FKYY_:Z_Y-0_:>_P"S>?C3_P"JV\2U[!_;VJ_]"5XF_P#
MOP;_ /-;7E?QTT7Q7\3O@E\8_AMH/A+5;37?B%\*_B%X'T6[U?4/"UOI-KJW
MBSPEJ^@Z=<:I/9>(M0O(=.AO-0ADO9K2PO;F.V65X+2YE5(7]#*:M.AFN55Z
MTXTZ-#-,LK5:DKJ-.E1S++JU6I)I2:C3I4JDY-1D^6$K1;LGQYC3G5R[,:5.
M+G4JY?CZ5.$;<TZE7 XVG3A&[2YIU*D(1NTN::NTKM?PDT5^MG_#ES]L3_G]
M^#__ (6VK_\ S)4?\.7/VQ/^?WX/_P#A;:O_ /,E7]S_ /$3/#__ **W)O\
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ML3_G]^#_ /X6VK__ #)5]4?L4?\ !,S]IC]F_P#:;^&GQH\<1^ -5\+^#/\
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MPCH=WX:TQ-1>+Q3K*>-(_P"S'UN>6'1/#R6UMJ$FI:]/#II2!Y4<@'V5117
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M?%.'6V_:O^(R:6?"%IXOM/![12Q#]CB2[C\2/=WL-V-+2.72Q;B53K_FJJN
M?=-%?)_P?_:D\$>,?$OB7X=^//B#\)_#7Q63XN_%KP5X'^&J>+=(TCQOXJ\)
M^ ?%NO:#I>M:;X0UG7[CQ)KT\UGX?U*74]3TBP739;C3=3DM[.RBLYX(.O\
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M1)KF*PO9((V:5+2Y9!"]BB@#\@-;_9<^)WQ-\5?%N^^%OP4UO]BR#XJ?L_\
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MQCXWU/Q+X5MHKR=M7L;#5=,O?#DNK22V]MH>J*EI!<7-Q+8-%;?%]K^RU^T
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M6VH:!H5]%<:39_75% !7P1\%?V6+[1_&O[0_Q!\7W/Q0\*>*O%_[0?Q/\7>
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M-=$\!^*?#=WK>BV=EX8\3:>/$VM^%?U=HH _+[2_V9?B=I'_  2WTS]G+2/
M>E:5\7[#X5:7'=^ [75O"VGP:AXWLO%%KXQUS3O^$@L+^7PF^M>)+^"]9]:N
M-7&EWFMZC]MU;6((IKN_C]B3X:>)_B/\;/%7QD\3_!FZ\+0^(_V2H_A9I.G^
M/;CX8:QXMT+Q%J'CCQY>^)/!EW-X0\7^-M)@M=:TFY\,W^I3Z3K]]X;U2UDT
MZWO=0>_TZZL=/^WZ* / ?V4_!OBWX=?LQ?L\^ /'UA)I?CCP3\%/ACX4\7Z9
M+J%CJTNG>)/#_@W1]*UJQ?5-+O-1TW4&M=0M;B WNGW][97)C\ZVNIX725O?
MJ** /B#XF?LV77Q6_:WT/X@>)8_B+IGPWTC]G/5/!T?B/X<?&_XC?!S4V\;W
M/Q,TW6X=$OYOA%\0_ _C+5K%]!CNK\1ZDE[X92XBB8LNJQVP7Q'X]_LO_$SQ
M]<_M<:9IO@.+Q3X9^*WB/]A9/"]GKGB#PUJ$'B[PU\(?'F@ZA\4XM73Q+KKW
M$T6D^'K2]DU"+Q5Y=UXH3SH-.36[JY,4OZFT4 ?%7[5?@OQ-J>N_#CQA\,_
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M5L[%;SSO-L&NH8Y9$^G:* /S)^&/[,_C_P %>&O^"=UE;?#S2_#VH?!/Q_\
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M_&?C'QSKOBW4[KPKK*6RV4UUK<CSZ+8:7X7OS=^&=)TW2+7TCQ1\$_AUXO\
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MBD&M:]\1-;NO$GBW58=3;5SK.BW=]KUY/JUC)H&HZ7_PC]Z+>;PZ-*-I:>0
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M'O;76OAVOBV[\36+ZK']+:E^QU^S]KGBMO&WB'PEK.N^(9/&WA7XGRK?>/\
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M<?L\Z58>,K >#_$&L-\0]1^'&K^.M8\6_%+XM>-_%?BW4_A%XE'BWX<7^O\
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M\=_"B]\9O\1?$-YXJN_A3\-?&NA_!WXJ:II'P_GN=2'@_P 2:]>Z!I/C#6?
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M$>';<>#M,TW3?#'AS1_'6J6FG>(O$<C>*+B6WM+>\ -KP3\5/VA--^-OQ ^
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MPYKNL^#=:TKPY)>3Z^^F:G>Z=96$X!\QZ+^UM\8-<\+>%O 5G:_"A_CWXO\
MVJ/B3^S%HOCB#2?%%S\&+VW^%6F>(O&GB_XJVO@E?&,?BNYMK'P=X9U+0V\
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M&+_RD:%_\K* /N2BOAO_ (7#\1O^AB_\I&A?_*RC_A</Q&_Z&+_RD:%_\K*
M/N2BOAO_ (7#\1O^AB_\I&A?_*RC_A</Q&_Z&+_RD:%_\K* /N2BOAO_ (7#
M\1O^AB_\I&A?_*RC_A</Q&_Z&+_RD:%_\K* /N2BOAO_ (7#\1O^AB_\I&A?
M_*RC_A</Q&_Z&+_RD:%_\K* /N2BOAO_ (7#\1O^AB_\I&A?_*RC_A</Q&_Z
M&+_RD:%_\K* /N2BOAO_ (7#\1O^AB_\I&A?_*RC_A</Q&_Z&+_RD:%_\K*
M/N2BOAO_ (7#\1O^AB_\I&A?_*RC_A</Q&_Z&+_RD:%_\K* /N2BOAO_ (7#
M\1O^AB_\I&A?_*RC_A</Q&_Z&+_RD:%_\K* /N2BOAO_ (7#\1O^AB_\I&A?
M_*RC_A</Q&_Z&+_RD:%_\K* /N2BOAO_ (7#\1O^AB_\I&A?_*RC_A</Q&_Z
M&+_RD:%_\K* /N2BOAO_ (7#\1O^AB_\I&A?_*RC_A</Q&_Z&+_RD:%_\K*
M/N2BOAO_ (7#\1O^AB_\I&A?_*RC_A</Q&_Z&+_RD:%_\K* /N2BOAO_ (7#
M\1O^AB_\I&A?_*RC_A</Q&_Z&+_RD:%_\K* /N2BOAO_ (7#\1O^AB_\I&A?
M_*RC_A</Q&_Z&+_RD:%_\K* /N2BOAO_ (7#\1O^AB_\I&A?_*RC_A</Q&_Z
M&+_RD:%_\K* /N2BOAO_ (7#\1O^AB_\I&A?_*RC_A</Q&_Z&+_RD:%_\K*
M/N2BOAO_ (7#\1O^AB_\I&A?_*RC_A</Q&_Z&+_RD:%_\K* /N2BOAO_ (7#
M\1O^AB_\I&A?_*RC_A</Q&_Z&+_RD:%_\K* /N2BOAO_ (7#\1O^AB_\I&A?
M_*RC_A</Q&_Z&+_RD:%_\K* /N2BOAO_ (7#\1O^AB_\I&A?_*RC_A</Q&_Z
M&+_RD:%_\K* /N2BOAO_ (7#\1O^AB_\I&A?_*RC_A</Q&_Z&+_RD:%_\K*
M/N2BOAO_ (7#\1O^AB_\I&A?_*RC_A</Q&_Z&+_RD:%_\K* /N2BOAO_ (7#
M\1O^AB_\I&A?_*RC_A</Q&_Z&+_RD:%_\K* /N2BOAO_ (7#\1O^AB_\I&A?
M_*RC_A</Q&_Z&+_RD:%_\K* /N2BOAO_ (7#\1O^AB_\I&A?_*RC_A</Q&_Z
M&+_RD:%_\K* /N2BOAO_ (7#\1O^AB_\I&A?_*RC_A</Q&_Z&+_RD:%_\K*
M/N2BOAO_ (7#\1O^AB_\I&A?_*RC_A</Q&_Z&+_RD:%_\K* /N2BOAO_ (7#
M\1O^AB_\I&A?_*RC_A</Q&_Z&+_RD:%_\K* /N2BOAO_ (7#\1O^AB_\I&A?
M_*RC_A</Q&_Z&+_RD:%_\K* /N2BOAO_ (7#\1O^AB_\I&A?_*RC_A</Q&_Z
M&+_RD:%_\K* /N2BOAO_ (7#\1O^AB_\I&A?_*RC_A</Q&_Z&+_RD:%_\K*
M/N2BOAO_ (7#\1O^AB_\I&A?_*RC_A</Q&_Z&+_RD:%_\K* /N2BOAO_ (7#
M\1O^AB_\I&A?_*RC_A</Q&_Z&+_RD:%_\K* /N2BOAO_ (7#\1O^AB_\I&A?
M_*RC_A</Q&_Z&+_RD:%_\K* /N2BOAO_ (7#\1O^AB_\I&A?_*RC_A</Q&_Z
M&+_RD:%_\K* /N2BOAO_ (7#\1O^AB_\I&A?_*RC_A</Q&_Z&+_RD:%_\K*
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'R.K $ '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &[ M # 2(  A$! Q$!_\0
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M^&-QXU;0/"\7Q'\+^,O!]O)J.MW.EVU[J^N>$=>D30K+4;*PLK+5-3M=<T<
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MXF_\(KQE_P#*&@ _X0KP;_T*7AG_ ,$.E?\ R)1_PA7@W_H4O#/_ ((=*_\
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M\^%FKNTTYUW0-6T;5O ^DWFFZKX=NI[:75-%U'2-5O?H>@ KY:_;)N_ FF_
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MGP@\9?%?1/A;XQ^#'P8TGXA?%_3_ !7\7OB[HMCXG\6:AJ.B^-='T[QIXO\
M'-[J.H_$U[[6M3NO$&HZ!KUE)\L?$C2O#+_LU?":7Q!\*_@-X=DTWP/^U1\'
M?@%^S)^T]\6_"W@3XEZ;X]N_BJH\%?$K]DGPY\&-(_:;D\<_%SPW<#3?ASX6
MT?PK8^$_B!H>N0V!\*>,M(TS78KK6@#^ERBOR\_:<\1?!*ZMOV7O#/[6GBSX
M2:]\)/"'C&?PW^TI9_$_6/#-[\*-)^+D_P"S_J?B/X?V'QKL/$%[=^&M*&I7
M-]-XF\'V'Q(*Z/<>(-0\%:O8B;Q-<^![J7\]])@^&/\ PC&@Z9\3(=-_X:*L
MOAO^RA-_P3ST_P =QWO_  M^T\+P?%_Q2WA"7X#VGB$?\)=;ZA#8V/AMOB\^
MF1IXBC\#6>CGX]$>![>SV '])=%?BS^RF/A'<?M(_#6[\"CPM/\ M2PZQ^V!
M9_MJ76B>1+\48='_ .%@RQ^&;7X]S1;M3CL?^$ILO!*?!2#Q:PB_X0^TD7X-
MK_PKJ#6PG[*7VLZ/I=SH]EJ>JZ;IUYXAU&32- M+Z^M;2YUS5H=+U+6Y=+T>
M"XECEU/48M%T?5]7DLK))[E-+TK4M0:(6EC<RQ &E1110 4444 %%%% !111
M0 4444 %<SXU_P"1-\6_]BSKW_IJNZZ:N9\:_P#(F^+?^Q9U[_TU7= !X*_Y
M$WPE_P!BSH/_ *:K2NFKF?!7_(F^$O\ L6=!_P#35:5TU !1110 4444 %%%
M?.D/[4WPFDU[XEZ7,_CK3_#WPG\.ZOXC\6?%/5/AC\0=/^#,B^&=3U'2?&.A
M^'?BM<^'(_!7BCQ-X/OK!;?6]$T'5KZZDN[F73=&&KZMH/BRP\/ 'T717F'P
MT^,7@#XMZ3K>L>#-1UD1^&=5;1/$VE>,/!GC;X:>*_#6IC2[#7(K;Q'X*^)/
MAWPEXPT'[9HFJZ9K6G3:MH5G;ZGH]_9ZIITMU87$5PWE^D?MD_L[:YH/BKQ)
MIWC36FTKPC9^$=2NC>?#/XJZ7J/B32OB#K5YX<^'^L?#31-4\$V>M_%[1O'V
MOV%SHO@;6/A5IWC/3/&&J"&P\.76I7-U:QS 'T_17RYJ_P"V=^SKH?A'0_&^
MH^,?$2Z)KR^.)DM[3X4_%[4_%&@67PRU8:%\2-5\>^!M,\!WGC?X:Z'\/]9:
M'2_&VO?$/P]X8T;PK?75E;ZY?6,E]9K/ZK\2/C#\/_A1H>C>(/&&J:JUIXEU
M2#1?#&G^$/"'C'XD^*/%.J7&FWVM+9^%_!?PXT#Q7XP\220Z)I>J:[>MH>AW
M\>G:%IFHZU?O;:78W5W$ >G45\VW'[77[/D%UX MD\=W5_%\2]&\">(?#6JZ
M+X(^(.O>'++1?BAJZ^'_ (<ZEXX\4Z)X4U#PW\+[;QOKWF:'X8;XF:KX1.L:
MQ:W^F62S7VG7\%MTDW[1?P@@^*L'P7D\2ZE_PGMQJR^'4CC\%^.IO"$?BM_"
MD_CN/P3=?$V'PU)\,[+QY+X,@?Q3#X$O/%\'B^707M]4CT5K2[M99@#VZBBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>/?A=XY3Y@J-MDU#P?I'C#1K?(9\27.IPP[H77S-SP":O^(@\%QQ53 XGB+
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MNK^(M.T34/"^FWIG^T^+]=N/#ND>5$)(SJ-MX9\1>+)1=/N7R(/[)\+ZH5E
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MS_X26J__ #:T?9/&7_0>\,_^$EJO_P VM=-10!S/V3QE_P!![PS_ .$EJO\
M\VM'V3QE_P!![PS_ .$EJO\ \VM=-69K5S;66CZM>7LUY;6=IIE_<W=QIT%U
M=:A;VT%K++/-86UC;W=]<7D42.]K!9VMS=2SJD=O;S3,D; '-6-_K6J76L6.
MF^,_ ^HWOA[4(M)U^SL= N[NZT/59]+T[7(=,UBWM_'4DNF:A-HNL:1J\5E>
MI!<R:7JFG:@D1M+ZVFETOLGC+_H/>&?_  DM5_\ FUK^=N+7_@5HO[/OQN^%
MOPUC_8J^)/A*=?V<-3\1_MG?#O0="T_X._$'5+CXHVW]D>'/^"DUKIK^(&>X
ML[BRO-4^,]YJWQ2UJ]\?:#XSUK5]7\/_  :;Q.(3].?#/Q5X1T7_ ()K_%?P
M=X)\1^ K/5+BU_:/U73+3]G_ %I[/X:^+_!.@^//[0^+OBK]D/1=#FB\2K\$
M= T/Q9)I^CVO@@:O>^"=5O)/#^F^)?$.LKI7B?7@#]B/LGC+_H/>&?\ PDM5
M_P#FUH^R>,O^@]X9_P#"2U7_ .;6OPXN8?"NI>&?V@_!?[%'P03XN_L/^-?&
M/AFX\<0?LJ:U^S]H_P ,6DT#X,VEW\0_#/@RS\?_ !+^&7P^U?PYX^UBV^'?
MA_XQ-\-[_6;9K+3_ (B>'[W3H_B'KGB"]LN*UG5OAGXETWPI<_%7PO9>%?VH
MS\#/V%;C]B'PI\0KCPG?_&'3=5LO$]Q!JFH? 4^%?$/BRP%SJ/BO2X]9^*LO
M@+6[J[B^'SZ$/CBFG^![6VTZQ /W\^R>,O\ H/>&?_"2U7_YM:/LGC+_ *#W
MAG_PDM5_^;6OR?\ V[/$G[+7C#QRB?M"Z]\,?%'PUB_9V_:*\.?"-?$^J:?K
M>A1_M/>&?%?ASP[KV@_#X64]UL_::\/+';Z%X+TOP\!\9=)U"/Q3IGP[@M]2
M7Q? /GJV&DW/C^T^WC1KC_@IUI_QW\-&T\_^S9?V@['X0/\ LR:6-5,&[==V
MWP$?0[[7Q?;-GPA;XGWET)L_&&X7> ?O+]D\9?\ 0>\,_P#A):K_ /-K1]D\
M9?\ 0>\,_P#A):K_ /-K7Y5?\$\1\!9OB%9W_P"S(/"$NA7G[)WPH'[25[X$
MPZW7[0J:_J<UJ/C%<\W4_P"T*EK=>/YOB%_PEKM\65BN=-D^)F!-X2+?KW0!
MS/V3QE_T'O#/_A):K_\ -K7$>(_A<OBJ[34]6;PFNNPQ^5:^)M)\->(- \5V
M<8"@1V?BC0O'NG:];1#8F8(=06!]B"2-U4"O7:_$?]LG_@LMX$^&?BY?V=OV
M,O",W[7/[56M7\V@:=X>\%6^H^(/ /A/68U?SX];U/P\3=>+]3TW8\M_X?\
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M@_\ 9PWBS_U6WPFK]DJ_B[Q,_P"3@<6_]CFM_P"HV6G]2\!_\D;PW_V*Z?\
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M?B#1OA9XVU_PUK]FCLBW/]E:_I6FWEWILDD5OJ]C%<Z7<R1P7<CKX)7Z&?\
M!*?_ )/X^ W_ '5'_P!4Q\1*_L7Q%R_ YKP#QIEN982ACL!C>%L]H8K"8FG&
MK1K4IY=7;C.$U)7C*,*E.<>6I2K4J-:E4I5J-*K3_GKPKXJXDX&\2^ >,>#\
MZS'ASBCAGB_A_.<ASS*L34PF899F6!S*A5P^)P]:FU_T\HUZ-2-7#8O"8C&8
M+&8?%8+&XS"XC]"O^":G[7OQ5_9G^,-Q_P $K_VZ[PV'Q)\%O#IG[-/Q4U&X
MGET3XH^"I/.'AGPM;Z[>[3J"7=A 1\.+^Y:.XGAMKKX;ZM#IWB[P]8:1J']#
M5?FS_P %+?\ @GMX4_;P^$,-MIEU;^#?V@/AJ;GQ!\#_ (G0M+976D:['Y=V
MWA?6]0LU^WKX4\0W5K:>?/;%KWP]JT&G^)-,2>6QNM-U3P;_ ()7?\%"?%7Q
MN7Q+^R%^U=;7'@K]M?X!?:_#_BK2_$"16-Y\4=$\.LEE-XLL55S;W?BG3XA;
M2^+8-/:2QUJTNK/QSX;>XT/5+ZWT'_+;(,=B^$<UP_!.>XBKB<NQ?.N",^Q4
MW*>+P]*+F^&,TQ$K)YSEE%)9?6J2C+-LMI4W'FQ>%J0E_L?XN<+\._2'X#SC
MZ3WA3D^ R7C+(/JM3Z47A-D="-##\/9SF%:.'I^.7 V4T>:<?#7CC,JDI<79
M;A*56EX?<;8[%JM[#A[/<'B:'[/T445^EG\1'&?#SQ-<^,?!FA>(;ZV@L]2O
M+>>#5K2U,C6UKK&F7ESI6L6]N96:7R(=3L;N.(2LTJQJJR,SAB>SKR;X4_Z"
M?B3X:^[_ ,(W\5/%ICC_ +L/C-=.^)B%,\F)G\<2A"/D1E>!,"':OK- !7,^
M-?\ D3?%O_8LZ]_Z:KNNFKF?&O\ R)OBW_L6=>_]-5W0 >"O^1-\)?\ 8LZ#
M_P"FJTKIJYGP5_R)OA+_ +%G0?\ TU6E=-0 4444 %%%% !7YVVO[0_Q:M/%
M7[25QK7C7X>6/B;P#X!^).K_  \_93\3?#'Q%X"\9M9_#W6?$$7ASXMV'Q=\
M4>/K#3OBYX \9Z5'I]UXKU7P/X-C\(>')[S0/"\?B3P[XFT;Q++XI_1*OC+4
M?V-M/\8ZAXQD^*WQI^+GQ1T:_L_&6C?"W1==N/!>ES?!71/'4&CR:S_PCGB7
MP_X0TWQ1XQ\0V>IZ8?[ \0?$G5O%@TOP]%I>@OIE[<0:YK/B0 S_ -EO]I?7
M/B[\*_BK\2]?\0^"_B)X:\":S?Q^'?&?@#X<^./@PWB?2]+\":%XJU>QU7X2
M?%+QCXT\<>#=9TO4=0NK&SN?$.M6L/BC29=)\2:5I=MHE_8W^I>7VW[3'[2.
MF+X4\.>)4^"%YXS^.GA/X.>*OA'J6A^$?'EEX8^&S?$OQA'H'B71OB-IU_\
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ME93/"WPY^%,:S+%<SQNT3/'(BR!2A>-U!RC ?L)_PFO@W_H;?#/_ (/M*_\
MDNOR3_X(??\ )J'Q!_[.&\6?^JV^$U?LE7\7>)G_ "<#BW_L<UO_ %&RT_J7
M@/\ Y(WAO_L5T_\ T_CCF?\ A-?!O_0V^&?_  ?:5_\ )='_  FO@W_H;?#/
M_@^TK_Y+KIJ*^&/K3\U_^"I?BCPUJ/["'QTL]/\ $6A7UY-_PK'R;6SU:PNK
MF7R_C'\/99/+@@N'E?9$CR/M4[8T9VPJDC^/>O[)/^"K'_)@_P >?^Z7?^KG
M^'=?QMU_7W@!_P D=F7_ &4>+_\ 5=E9_-/C)_R4^!_[$>&_]3LP/H']DR>&
MV_:I_9GN;F:*WM[?]H'X,SSSSR)%#!#%\1O#<DLTTLA5(XHT5GDD=E1$4LQ
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MLR0K\.?BM&TS16T\CK$KR1HTA4('D12<NH/[55^-O_!<'_DU#X??]G#>$_\
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M/$=M/_;6F^1+JUA<^*/#FMQF3[3Y?G0Z;8>$VVAB[)-\RHJ(9/5/^$U\&_\
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M<O\ !C)I99QEFV">BI<3^+V?2SSQ3X@J5(J+Q')Q+PY@JE7FJ4\NH7@J?%^
M?AQ\/OA5X:LO!OPQ\#>$?AWX2T[/V'PSX)\.:1X6T&U9@JO)#I6B6EE9)+*$
M4S3"'S9F :5W;FO+?VNO^34/VGO^S>?C3_ZK;Q+7T-7SS^UU_P FH?M/?]F\
M_&G_ -5MXEK]/R"G3HYOD5*C3IT:5/-\FA3I4J<*5*G".;94HPITZ4*=.G"*
MTC"%.$8K112T/X_XBQN-S+"Y[F&8XS&9CC\;@LWQ.,Q^88O%8_'8S$UL!F,Z
MV)Q>-QV)QF,Q6(JS;G5KXK%XFO5FW*I6J2U/X5:***_T@/X5/]#"BBBO\SS^
M\ HHHH _C;_X*L?\G\?'G_NEW_JF/AW7YYU^AG_!5C_D_CX\_P#=+O\ U3'P
M[K\\Z_T*X*_Y([A3_LG,E_\ 5=AS^+>*?^2GXB_['F:_^IU8_J>_X(??\FH?
M$'_LX;Q9_P"JV^$U?LE7XV_\$/O^34/B#_V<-XL_]5M\)J_9*OXN\3/^3@<6
M_P#8YK?^HV6G]2\!_P#)&\-_]BNG_P"G\<%%%%?#'UI^>?\ P58_Y,'^//\
MW2[_ -7/\.Z_C;K^R3_@JQ_R8/\ 'G_NEW_JY_AW7\;=?U]X ?\ )'9E_P!E
M'B__ %796?S3XR?\E/@?^Q'AO_4[,#Z&_9%_Y.O_ &8?^SAO@M_ZLGPU7]U5
M?PJ_LB_\G7_LP_\ 9PWP6_\ 5D^&J_NJKX;Z0W_(ZX8_[$V8?^K:F?6^"O\
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MS]Q;>*FGE:TUGP_#;-(Q@BN/#.HW4\<1/R)+<1^++2.:11@-(EK K'D1(.
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M7\]'[2=-7\*O[77_ "=?^T]_V<-\:?\ U9/B6O[A/LGC+_H/>&?_  DM5_\
MFUK^';]K,3+^U3^TPMS)%+<+^T#\9A/+!"]O#),/B-XD$LD,$D]R\$3ON:.%
M[FX>-"$:>4J9&_H7Z//_ ".N)_\ L39?_P"K:H?BWC5_R*LA_P"QIC?_ %6P
M/GZO[)/^"4__ "8/\!O^ZH_^KG^(E?QMU_81_P $M+?Q*_["'P+;3]6T*ULS
M_P +.\F"\\.W]]<ICXQ_$(2>9=0>*-.BEW2AW3;9P[(V6-O,9#*_W/C_ /\
M)'9;_P!E'A/_ %79H?)>#?\ R4^._P"Q'B?_ %.R\_2BBN9^R>,O^@]X9_\
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M:\%<QCX:^#?TNOI!5;4<9P'X'XOPIX$Q<O=G3\3/I*YB_"?+:N"J.SCC\KX
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M&G_U9/B6O[JJ_A5_:Z_Y.O\ VGO^SAOC3_ZLGQ+7]"_1Y_Y'7$__ &)LO_\
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MN+5[B'PK;@'V[1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4_\ R8/\!O\ NJ/_ *N?XB5_&W7]DG_!*?\ Y,'^ W_=4?\ U<_Q$K[GQ_\
M^2.RW_LH\)_ZKLT/DO!O_DI\=_V(\3_ZG9>?H91117\@G]+!7XV_\%P?^34/
MA]_V<-X3_P#5;?%FOV2K\;?^"X/_ ":A\/O^SAO"?_JMOBS7W/AG_P G X2_
M['-'_P!1LR/DN//^2-XD_P"Q74_]/X$_EAK]#/\ @E/_ ,G\? ;_ +JC_P"J
M8^(E?GG7Z&?\$I_^3^/@-_W5'_U3'Q$K^T>-?^2.XK_[)S.O_5=B#^6N%O\
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M*-IX4@\'P>._LZ^#E\?'4(]/MH=3_P"$>;Q^? C>*XT\8MX2;Q0B:JOTE10
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M^A2\,_\ @ATK_P"1*Z:B@#F?^$*\&_\ 0I>&?_!#I7_R)1_PA7@W_H4O#/\
MX(=*_P#D2NFHH YG_A"O!O\ T*7AG_P0Z5_\B4?\(5X-_P"A2\,_^"'2O_D2
MNFHH YG_ (0KP;_T*7AG_P $.E?_ ")1_P (5X-_Z%+PS_X(=*_^1*Z:B@#F
M?^$*\&_]"EX9_P#!#I7_ ,B4?\(5X-_Z%+PS_P""'2O_ )$KIJ* .9_X0KP;
M_P!"EX9_\$.E?_(E'_"%>#?^A2\,_P#@ATK_ .1*Z:B@#F?^$*\&_P#0I>&?
M_!#I7_R)1_PA7@W_ *%+PS_X(=*_^1*Z:B@#F?\ A"O!O_0I>&?_  0Z5_\
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M&EWUUJ=X 3:VLH!(_K=@A6W@AMT+%((HX4+D%BL2!%+$!06(4$D* 3G  XH
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M=-10!S/VOQE_T ?#/_A6ZK_\Q5'VOQE_T ?#/_A6ZK_\Q5=-10!S/VOQE_T
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MZK^AC_@@S_S=7_W0W_WL-?T+XP_\FZXA_P"Z7_ZN, ?BWAE_R6V2_P#=0_\
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M&N7NF3+-_P *Y^%(:-8+;P]JR/$$$;+,;E'9W=# HC623]A/M?C+_H ^&?\
MPK=5_P#F*K\D_P#@A]_R:A\0?^SAO%G_ *K;X35^R5?Q=XF?\G XM_['-;_U
M&RT_J7@/_DC>&_\ L5T__3^..9^U^,O^@#X9_P#"MU7_ .8JC[7XR_Z /AG_
M ,*W5?\ YBJZ:BOACZT_-?\ X*EW'B5_V$/CHNH:3H5K9G_A6/G3V?B*_OKE
M,?&/X>F/R[6?POIT4NZ4(C[KR'9&S2+YC((G_CWK^R3_ (*L?\F#_'G_ +I=
M_P"KG^'=?QMU_7W@!_R1V9?]E'B__5=E9_-/C)_R4^!_[$>&_P#4[,#Z!_9,
M,R_M4_LSM;1Q2W"_M _!DP13S/;PR3#XC>&S%'-/'!<O!$[[5DF2VN'C0EU@
ME*B-O[B?M?C+_H ^&?\ PK=5_P#F*K^'O]D7_DZ_]F'_ +.&^"W_ *LGPU7]
MU5?#?2&_Y'7#'_8FS#_U;4SZWP5_Y%6??]C3!?\ JMF<S]K\9?\ 0!\,_P#A
M6ZK_ /,51]K\9?\ 0!\,_P#A6ZK_ /,57345_/1^TG,_:_&7_0!\,_\ A6ZK
M_P#,57\.W[69F;]JG]IAKF.**X;]H'XS&>*"9[B&.8_$;Q(98X9Y(+9YXD?<
ML<SVUN\B .T$18QK_=?7\*O[77_)U_[3W_9PWQI_]63XEK^A?H\_\CKB?_L3
M9?\ ^K:H?BWC5_R*LA_[&F-_]5L#YYK^PC_@EI<>)4_80^!:Z?I.A75F/^%G
M>3/>>(K^QN7S\8_B$9/,M8/"^HQ1;92Z)MO)M\:K(WELYB3^/>O[)/\ @E/_
M ,F#_ ;_ +JC_P"KG^(E?<^/_P#R1V6_]E'A/_5=FA\EX-_\E/CO^Q'B?_4[
M+S[F^U^,O^@#X9_\*W5?_F*H^U^,O^@#X9_\*W5?_F*KIJ*_D$_I8YG[7XR_
MZ /AG_PK=5_^8JOQ[_X+8SZ_)^RMX 75=,T>RMQ^T#X5*2Z?KE[J<S3?\*Y^
M*P6-H+GP]I*)$4,C-,+EW5T1! PD:2/]JJ_&W_@N#_R:A\/O^SAO"?\ ZK;X
MLU]SX9_\G X2_P"QS1_]1LR/DN//^2-XD_[%=3_T_@3^6&OT#_X):/>)^W?\
M"VT^WM;J['_"SO)@O+N6QMGS\'/B$)/,NH++498ML1=TVV<V^15C;RU<RI^?
ME?H9_P $I_\ D_CX#?\ =4?_ %3'Q$K^T>-?^2.XK_[)S.O_ %78@_EKA;_D
MI^'?^QYE7_J=1/Z_OM?C+_H ^&?_  K=5_\ F*H^U^,O^@#X9_\ "MU7_P"8
MJNFHK_/4_M(YG[7XR_Z /AG_ ,*W5?\ YBJ/M?C+_H ^&?\ PK=5_P#F*KIJ
M* /\\^BBBO\ 3 _@\_NG_9!,I_9._9B,J1H__#/GP; 6.1I5,0^'?AT0N6:*
M$B22$1R2QA"L,K/$DLZ(LTGL?C7_ )$WQ;_V+.O?^FJ[KQ_]D7_DU#]F'_LW
MGX+?^JV\-5[!XU_Y$WQ;_P!BSKW_ *:KNO\ .+._^1UG7_8YSC_U;9J?W#E7
M_(JRO_L5Y9_ZK<O#P5_R)OA+_L6=!_\ 35:5TU<SX*_Y$WPE_P!BSH/_ *:K
M2NFKS#O"OR8_X+*Z(=1_96\':[KNA:WXI^$?@/\ :+^#7C?]H'PUX?\ M3:G
MK7P4TK5[^U\66L45HT,CQI=ZCH]Q+(UY8160A&H27MLEHTJ_K/4-Q;V]W;SV
MEW!#=6MU#+;W-M<1)-;W%O,C1S03PR*T<L,T;-'+%(K)(C,CJ5)! /Y6OVR/
MC=_P2N^+7P=\+^ OV$_ 'P[D_:S\0_$3X6?\*0N?@[^SWK/PO\8^'_%$'CC2
M4-WK7B1_ 'A);V$65MJ%D=(N[_6YKK4;K2]933I88[?6(/ZI;83"W@%P0UP(
M8A.PVX,P1?-(V@+@ON(V@+CH .*\0\#?LQ_LS_#?Q.?''PV_9]^!W@3QB&OH
MQXN\$_"OP'X:\21&\5K34X8M>T/0K+4X$NPLD5_!%=(EPYG^TH\DDI;W6@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _G@_X+V:_JOQ4;]BK]A/
MPC>RQ>(_VEOC_H]]K L]K2V.@:+=V'@W2I]21V5%TR;6/'MUKH:13 K^"KBX
MGE@CM#YO] _A[0=)\*Z!H?AC0;./3M"\-Z/IF@Z+I\.XQ6.DZ/90:?IUG%N+
M-Y=K9V\,";F+;4&23DU_/#X/;_AKC_@X$\:^)BS:CX"_80^#DGAK2I<^;IK>
M-I;"31;JREB61XH]4M/&'Q0\;SQ3%5E9_ =N92K6=O&O]&U?G?!?_"GGO'7$
M[]Z&,SV'#>6SW7]F<)8=8"HZ;_DK9UB\TJ-QTE*C>\K)Q_LGZ3'_ !@WA5]%
M+P,I_N<5P[X4XKQJXTPR]V:XX^D+F\N*\%3Q<%9_6LL\-,@X$P48U5[2A2S%
MT^6E[2<*Q7\L/_!<'_DZ_P"'W_9O/A/_ -63\6:_J>K^6'_@N#_R=?\ #[_L
MWGPG_P"K)^+-?U'X&_\ )P,-_P!B;//_ %&P9_G7XM?\D;7_ .QIE/\ Z?Q)
M^-M?T,?\$&?^;J_^Z&_^]AK^>>OZ&/\ @@S_ ,W5_P#=#?\ WL-?T+XP_P#)
MNN(?^Z7_ .KC 'XMX9?\EMDO_=0_]5F,/Z&****_AL_K0*^>?VNO^34/VGO^
MS>?C3_ZK;Q+7T-7SS^UU_P FH?M/?]F\_&G_ -5MXEKT\D_Y'62_]CG)_P#U
M;94<&:_\BK-/^Q7F?_JMS _A5HHHK_1T_AX_T,****_S//[P"BBB@#^-O_@J
MQ_R?Q\>?^Z7?^J8^'=?GG7Z&?\%6/^3^/CS_ -TN_P#5,?#NOSSK_0K@K_DC
MN%/^R<R7_P!5V'/XMXI_Y*?B+_L>9K_ZG5C^I[_@A]_R:A\0?^SAO%G_ *K;
MX35^R5?C;_P0^_Y-0^(/_9PWBS_U6WPFK]DJ_B[Q,_Y.!Q;_ -CFM_ZC9:?U
M+P'_ ,D;PW_V*Z?_ *?QP4445\,?6GYY_P#!5C_DP?X\_P#=+O\ U<_P[K^-
MNO[)/^"K'_)@_P >?^Z7?^KG^'=?QMU_7W@!_P D=F7_ &4>+_\ 5=E9_-/C
M)_R4^!_[$>&_]3LP/H;]D7_DZ_\ 9A_[.&^"W_JR?#5?W55_"K^R+_R=?^S#
M_P!G#?!;_P!63X:K^ZJOAOI#?\CKAC_L39A_ZMJ9];X*_P#(JS[_ +&F"_\
M5;,****_GH_:0K^%7]KK_DZ_]I[_ +.&^-/_ *LGQ+7]U5?PJ_M=?\G7_M/?
M]G#?&G_U9/B6OZ%^CS_R.N)_^Q-E_P#ZMJA^+>-7_(JR'_L:8W_U6P/GFO[)
M/^"4_P#R8/\  ;_NJ/\ ZN?XB5_&W7]DG_!*?_DP?X#?]U1_]7/\1*^Y\?\
M_DCLM_[*/"?^J[-#Y+P;_P"2GQW_ &(\3_ZG9>?H91117\@G]+!7XV_\%P?^
M34/A]_V<-X3_ /5;?%FOV2K\;?\ @N#_ ,FH?#[_ +.&\)_^JV^+-?<^&?\
MR<#A+_L<T?\ U&S(^2X\_P"2-XD_[%=3_P!/X$_EAK]#/^"4_P#R?Q\!O^ZH
M_P#JF/B)7YYU^AG_  2G_P"3^/@-_P!U1_\ 5,?$2O[1XU_Y([BO_LG,Z_\
M5=B#^6N%O^2GX=_['F5?^IU$_LDHHHK_ #U/[2"BBB@#_//HHHK_ $P/X//[
MJOV1?^34/V8?^S>?@M_ZK;PU7L'C7_D3?%O_ &+.O?\ IJNZ\?\ V1?^34/V
M8?\ LWGX+?\ JMO#5>P>-?\ D3?%O_8LZ]_Z:KNO\XL[_P"1UG7_ &.<X_\
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MK_G[\3?^%KXR_P#E]1_PB6E?\_?B;_PM?&7_ ,OJ .FHKF?^$2TK_G[\3?\
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MAY)&?^B/ W_DX&&_[$V>?^HV#/XZ\6O^2-K_ /8TRG_T_B3\>Z_H8_X(,_\
M-U?_ '0W_P![#7\\]?T"_P#!"K2;75/^&I?M,NIQ>1_PI'9_9VM:SH^[S?\
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MS]^)O_"U\9?_ "^K^03^ECIJ_&W_ (+@_P#)J'P^_P"SAO"?_JMOBS7ZV?\
M"):5_P _?B;_ ,+7QE_\OJ_'O_@MCH=EIG[*W@">VGUB1W_:!\*PE=0\0Z_J
MT(1OAS\5G)6VU74[VW27,:A9TB694+QK($DD5_N?#/\ Y.!PE_V.:/\ ZC9D
M?)<>?\D;Q)_V*ZG_ *?P)_+S7Z&?\$I_^3^/@-_W5'_U3'Q$K\\Z_0/_ ():
M6D5]^W?\"[6=[I(I?^%G;FL[V\TZY&SX.?$*1?+O-/N+6[ARR /Y,Z>9&6BD
MW1.Z-_:/&O\ R1W%?_9.9U_ZKL0?RUPM_P E/P[_ -CS*O\ U.HG]EM%<S_P
MB6E?\_?B;_PM?&7_ ,OJ/^$2TK_G[\3?^%KXR_\ E]7^>I_:1TU%<S_PB6E?
M\_?B;_PM?&7_ ,OJ/^$2TK_G[\3?^%KXR_\ E]0!_GZT445_I@?P>?W5?LB_
M\FH?LP_]F\_!;_U6WAJO8/&O_(F^+?\ L6=>_P#35=UXY^R#&L7[)W[,2J9"
M#^SY\&Y"9)99FW3?#OP[*X#RN[B,.["*(,(H(@D,*1PQQQK['XU_Y$WQ;_V+
M.O?^FJ[K_.+._P#D=9U_V.<X_P#5MFI_<.5?\BK*_P#L5Y9_ZK<O#P5_R)OA
M+_L6=!_]-5I735S/@K_D3?"7_8LZ#_Z:K2NFKS#O"OE/]L+XQ_'3X'_"W3O&
M/[/O[/\ J'[1_C2X\8Z7HFH>!=,U6?2;JP\.7FF:W<WGB426UAJ5Q<)8ZA8Z
M7I[V\=MTU03NZI"<_5; E6"MM8J0K8#;20<-@\'!YP>#C!K\6+S]BK_@J@9K
MJX3_ (*G+:VOF3S(C_ SPP$MK?<SJKR-. %ACP&=B!A2Q(% 'S/\;?B?_P %
M/_V[_".F?L]G]@5?V?;36O''@7Q#=?&;QGXFDF_X5PWA+Q1IOB&V\6>'[C5[
M/P_-8:SI<NGDFYT./5]?GTV6_P!,TK3I+G458?T>0H\<,4<DAFD2-$>4C:97
M50K2%<MM+L"Q&3@G&3UK\*H_V9_^"BXD0M_P6'\'NH=2R#X7_#_+@,,K_P A
M/^(<?C7[K1*Z11K+)YLBQHLDNP1^:ZJ \FQ<JF]@6V*<+G X% #Z*** "BBB
M@ HHHH **** "BBOG+XX?'S6_A;KG@WP3X ^"OC[X^_$KQE;W_B*#P-X#U[X
M8^$KC2_A[X7\0>$-&\=^--0\0_%OQU\/_##G08_&6E1Z/X<L=6N];\1ZW>6%
M@T.CZ&VL^*=" /HVBOG'6OVC]/\ #7QF\'_"+Q'\*_BSH6F^/O$<W@CP?\8-
M2L/ </PLU[X@0> =:^),O@FR5/B!)\33?_\ ",>'-?>#Q')\-8_ %YJVD7FA
M67C&YU=8[23=^*'Q^\&?"GQG\*O .LV'B'6_$OQ:\2V^@Z59^&K?1[K_ (1O
M3I]1TO0CXT\7#5-;T>:Q\(P^)O$'AGPR]SI,.MZS+K'B/3Q9Z'=6%MK-_I0!
M[C17R[#^U%:#XC>*_AKJOP2^.^@ZKH_@GX@>/_!6I:AX<\%7MA\8] ^&>O:!
MX9\3_P#"NM)\/?$'7/&EA?MK/BKP[;Z#9_%'PG\-7\36NK0:MH#:AHT-YJ%M
MTOPB_:#T'XIZ/\2KS5O!WC;X/^(/@[XFF\*_$_P/\4I/ A\1^#[U?!OASX@V
ME]>ZE\-?'/Q(\#:CH^I^#/%>B:]9:EH7C'5H5AN)[._%EJEA?V-L >^T5\):
M5^WSX(U#1]0O[_X+?M >&]8O]%^&OB3X3>"_$'A[X<V_BWX_>'_B[XFN/"/@
M'4OA=:6'Q1U'2]+;4-8BM&\0Z1\8-7^%7B#X=Z5JVEZ[\2M(\'Z+/-?V[-4_
M;X\(V/AN/4]/^!/[1'B7Q?I5G\5=6^)7PE\/:!\+[GXC?!S0O@QKEMX?\>:U
MX\BO?BUI_@S4H([R_P!,N?"6E?#/QG\0_$OQ(TG4K?6/ASH?BO3(-0NK( ^\
M**SM'U?3/$&DZ7KVBWL&I:/K>G6.KZ3J-JV^VO\ 3-2MHKRPO;=\#?!=6LT4
M\38&Z.13@9K1H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *_G)_X*8?\93?\%4/^"=G[%=OC4/"_@.^N/CY\3]/1/,LKBQBOI_$<^E:R
M7CDCB8>$/A7J%E:A@JLOCR*(L\MW;B/^C:OYR/\ @F1_QE+_ ,%2/^"BO[:]
MR!J'AGP5J4/P#^%^H2J)+2XTR+4+?0+;5=(RBK;7"^#?A7I%U=! DJQ>.K@2
MF62\N)&_._$'_A1_U4X5C[W^LO%& >-AO?)>'K\19KSK_GU5^HY=A9W7++ZQ
MR._,X3_LGZ('_&'+Q^\?*O[K_B"?@3Q;'AG%/W?9^)GC!R^#G 7U>;M;'8%<
M5\8Y]A_9OVU+^R%B(>S]E#$T/Z-Z***_1#^-@K^6'_@N#_R=?\/O^S>?"?\
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MZ^\ /^2.S+_LH\7_ .J[*S^:?&3_ )*? _\ 8CPW_J=F!]#?LB_\G7_LP_\
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M1K([! % %=37,_V]JO\ T)7B;_P+\&__ #6T?V]JO_0E>)O_  +\&_\ S6T
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MOE9B\S^A?&'_ )-UQ#_W2_\ U<8 _%O#+_DMLE_[J'_JLQA_1717,_V]JO\
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M5XF_\"_!O_S6T?V]JO\ T)7B;_P+\&__ #6T ?R _P#!5C_D_CX\_P#=+O\
MU3'P[K\\Z_0/_@J7<2W7[=_QTGGLKK3I7_X5CNL[Q[-[F';\'/AZB^8VGW=]
M:'S%42IY-U+B-U$FR4/&GY^5_H5P5_R1W"G_ &3F2_\ JNPY_%O%/_)3\1?]
MCS-?_4ZL?U/?\$/O^34/B#_V<-XL_P#5;?":OV2K\5?^")VIWME^RMX_BMO#
MVL:LC?M ^*I#<Z?/H$<*.?AS\*5,#+JNN:9<&50BR,4@>'9(@69G$B1_L)_;
MVJ_]"5XF_P# OP;_ /-;7\7>)G_)P.+?^QS6_P#4;+3^I> _^2-X;_[%=/\
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MT_XF^.H?B)XPT[XG>&?#7C72M2\1:?HND^&?#T@T;6-'FT>.#PMX9T'1]!T
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M:8 _76BOR+^#WQ'_ &'[W]MCXM^/OA)\3?V??AUJ_P +/!/QH\)_'62W\?\
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MI#?\CKAC_L39A_ZMJ9];X*_\BK/O^QI@O_5;,****_GH_:0K^%7]KK_DZ_\
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M^2-XD_[%=3_T_@3^6&OT,_X)3_\ )_'P&_[JC_ZICXB5^>=?H9_P2G_Y/X^
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MJ_&W_@A]_P FH?$'_LX;Q9_ZK;X35^R5?Q=XF?\ )P.+?^QS6_\ 4;+3^I>
M_P#DC>&_^Q73_P#3^."BBBOACZT_//\ X*L?\F#_ !Y_[I=_ZN?X=U_&W7]D
MG_!5C_DP?X\_]TN_]7/\.Z_C;K^OO #_ )([,O\ LH\7_P"J[*S^:?&3_DI\
M#_V(\-_ZG9@?0W[(O_)U_P"S#_V<-\%O_5D^&J_NJK^%7]D7_DZ_]F'_ +.&
M^"W_ *LGPU7]U5?#?2&_Y'7#'_8FS#_U;4SZWP5_Y%6??]C3!?\ JMF%%%%?
MST?M(5_"K^UU_P G7_M/?]G#?&G_ -63XEK^ZJOX5?VNO^3K_P!I[_LX;XT_
M^K)\2U_0OT>?^1UQ/_V)LO\ _5M4/Q;QJ_Y%60_]C3&_^JV!\\U_9)_P2G_Y
M,'^ W_=4?_5S_$2OXVZ_LD_X)3_\F#_ ;_NJ/_JY_B)7W/C_ /\ )'9;_P!E
M'A/_ %79H?)>#?\ R4^._P"Q'B?_ %.R\_0RBBBOY!/Z6"OQM_X+@_\ )J'P
M^_[.&\)_^JV^+-?LE7XV_P#!<'_DU#X??]G#>$__ %6WQ9K[GPS_ .3@<)?]
MCFC_ .HV9'R7'G_)&\2?]BNI_P"G\"?RPU^AG_!*?_D_CX#?]U1_]4Q\1*_/
M.OT,_P""4_\ R?Q\!O\ NJ/_ *ICXB5_:/&O_)'<5_\ 9.9U_P"J[$'\M<+?
M\E/P[_V/,J_]3J)_9)1117^>I_:04444 ?YY]%%%?Z8'\'G]U7[(O_)J'[,/
M_9O/P6_]5MX:KV#QK_R)OBW_ +%G7O\ TU7=>/\ [(O_ ":A^S#_ -F\_!;_
M -5MX:KV#QK_ ,B;XM_[%G7O_35=U_G%G?\ R.LZ_P"QSG'_ *MLU/[ARK_D
M597_ -BO+/\ U6Y>'@K_ )$WPE_V+.@_^FJTKIJYGP5_R)OA+_L6=!_]-5I7
M35YAWA1110 4444 %?G?H7P=_:.L/B]\3?BOX8^'?P*^$OB6ST3XB:5ITWAK
MXF>/AX"_:I\7ZW9:5=?#GX@_&CX<Z-X)L+'P5/X1E,EAK?B>2?XB_%:]N[?5
M_#FDZ]!X(BTG4=>_1"B@#X<^&OAKXW^&?"</PP^)WPQ\)7/B7XS>)/&+?%#X
ME^ ?BSXD\>0K9:OX'U5O$/Q)\1ZEK_P!^%>GZ=JD6L0^#_A[\/\ X:6EO=1V
MWA.33TT[6O['\"7]LWF5M^S1^TMJ=CX,\3>)/^%&6?Q"^!WA?X,^%/A=HFA^
M,O'UYX-^(:?#7QC9:_XJUSQ]KU_\-K+6_ARWC/1].M-,\/Z!X=\/?$H>!M3^
MT:KJ/B'Q]:RQZ3;_ *844 ?FS-^SC^TKI%WXD\=>&5^!MY\0?C)H/QH\._$_
M0==\9>/K/P;\/4^)6N:!>>$M7\!:[I_PWO-;^)+>"='T5[+Q%HOB'0?A@/'V
MI3KJ&F:Y\.K5#IC>B7W@SXR7'_"NKSX6^"?"SWG[,7BZY\ ^#K;XO>,?$G@;
M3?C)X"D^$%GX.\1>*O[3\/?#/QEJW@6]T[QC<M;>'Y/^$5\7Z1XLTOPQJ.H6
MLMCIWBG1-5TW[BHH _,K3?V1_CCX;T2^^'FE:O\ "C6/!WQ:\-_"RU^,OBW4
M-9\7Z)XE\'>(O"OC+7_$WCR7X8^#;;PEKVE^,=%\3:?KAT?PC%XJ\;>#+[PA
M>6PUK69O&L$O]A1^LO\  CXOR?%6[LC)\-E^"%S^T+IW[1O_  DH\0^)V^*H
MU2P\*:=;_P#"O?\ A!_^$.7PB-/E\<:?'K'_  G?_"P6N$\*,_AO_A!&U=E\
M51_;E% !7\;'_!5-&3]O;X]*TLDQ,GPS</((@P63X._#V1(@(HXD\N!&6&(E
M3*8HT,TDTQDE?^R>OXV_^"K'_)_'QY_[I=_ZICX=U^Y> '_)8YE_V3F+_P#5
MCE9^2^,G_),8'_L>8;_U!S _/.OZAO\ @B=IE[>_LK>/Y;;Q#K&DHO[0/BJ,
MVVGP:!)"[CX<_"EC.S:KH>IW E8.L;!)TAV1H5A5S(\G\O-?U/?\$/O^34/B
M#_V<-XL_]5M\)J_7_'+_ )-_B?\ L<Y'_P"I.,/S3PE_Y+*A_P!BO-O_ $QA
MC];/[!U7_H=?$W_@)X-_^9*C^P=5_P"AU\3?^ G@W_YDJZ:BOXN/ZE.9_L'5
M?^AU\3?^ G@W_P"9*OR&_P""S-FGAG]FOP?X@N;/PEXVU'4OBYHG@R5OB9\*
M_@Y\1(K30M4\&?$#6KR/2$\6?#S4VT6];4= TRXBU/2GL]0MS P@N(_,?/[/
MU^-O_!<'_DU#X??]G#>$_P#U6WQ9KZW@/+LNS?C+AK+<VP&"S3+L9FE*CC,O
MS'"8;'8'%47A\?)TL3A,71Q&&KTW*$).%6C./-",K*48M>/Q!GV>\,9'FV?\
M,YWG/#F>Y9@IXG+<[X?S;,\CSC+L1&M@XJO@,UR?'Y7F6#K*,I1]IA<=0FX3
MG"3E"<X3_D:L_"/B#X>ZW>>//@3XMUGX4?$(M:7%GJWAF];3(XY=/U_2?%-M
M%8RV\1NO#^W7-"TJYBDT62U@BBMGTY[272KJZLY/V3_X)M_\%8?VM/C9^UO\
M)_@!^TW\;TT6S\0W_B?1=4CN_!'P=\+VWB/4HO WB:\\)V=IK%KX%M'M-7U7
MQ3:Z%;:?:6EUY7B"[N;:STPSMJ*6%?EG7JO[/_[)'A7]M#X[>!/@AKVNW_@O
M4/%5AX\_L/QUHUM!=:IX=UGP[\.O%WBW09YK69HAJ>CC7=#L/[5TO[39W%SI
M[W<>G:CI6H20ZC;_ *?XG>!>"X8P.<<=^#V6\/\ #^9X'),R_M_@;$X&E3X+
MXKRR-&OB:]7 86,:E/@_C'!N57$Y/Q#DM/"8;$8B,,%G6!JX6JL31_4/!_Z7
MV!\7Z>6^"WTU\TXLX[X;S3.<M_U%^D3@ZKS;QT\%\_E#"Y7@IYIFU6.'S'Q?
M\(\72HX/"<5^'?%V.S/-<!E\*N;\$9[@LUPOU#&_W:_V#JO_ $.OB;_P$\&_
M_,E6#XINK/P3X:U_QCXL^)>MZ#X8\+Z/J.O^(-:OX/!T=EI>CZ3:2WVH7]RZ
M^$6816UK#+*PC1Y'"[(T>1E4_@1^S#_P4-^._P"PE\5=(_8>_P""J!FM;=Q%
MI_P3_:UFGN+_ ,*^+= AEBL=.;QIXFN(XCJ^C@26MM-XXO5@\0^%[N6&T^)U
MA");KQ)8_O-\7[:#Q1\'/'MG9> 8?C3IWB+P3JUJ?AU9>(M*T'_A8VB:QISP
MWF@:1XFU*\LM%L;W7-)N9XM$U"^U?1],:^ELS<^(-#M9'UFR_F#AOB?+N)<-
M6J855\)C\#5^K9ODN/@L/FN3XU+WL-CL,W=)M.6&Q5+VF#QE'DK8:O.,G"'U
M_C1X&<8^".=9=A<\J99Q#PEQ3@GG?AWXE\)XF6;< ^(_#,YVH9WPOG<(>SG4
MIQE3HYSD./\ J7$7#>8K$99G>58:M0AB,3X#IG[4_@B_\")\0[RR_;0T/2)?
M&>O>"K?1]2_8F^/]UXXFN-$+3V_B,^ /#_[-^M^,K3P3XATEK35] \77^B6F
MC3K?)H.HW.F>,;#6_#6EUM-_;(_9YU:;X>QV/QM^),D/Q,TCP5KOA[4Y?@OX
MUM-"T?2_B3X@N_"GPZN/B5XAO/@C!H7P;D\?>)+&ZT3P5:?%W4? ]YXJU%%M
MM"M[^2:$2>-?#71/VJ=6_9R^+6D>'-$^.GAO2_BCKW@[PM\ /#/[1?C3P%?_
M +1?P'^%/CRV\.Z!\1_%_C3QEI_B?Q9>ZO<_#FRUCQ3XW^'NB>/_ !W\2OC3
M)/H=CH7C74Y]3NX=!T;/^/W[*?B?6_'_ (5^'WP-T/\ : \ ^ /%&F_ +0OB
M3KGA3Q+^S!IW[-3>!_@?XK_M/2])\3Z3XWM/%O[3VG^--)\):5)H/AZ#X'^'
MO!WAW7-1U+PBGB3QAIMM8Z[KFB_1GXP?5W@3]H'X4?$KXA:Q\+_!WQ>\=W_B
M[2/^$M,0U#X<:EX<\,>)QX!U^U\*^/&^'7C_ ,2_"?1_ /Q23P/XDOK/0O&+
M_#?Q-XJ3POJEU;V6N&PGE1&CO/VAOA'8?%Z+X&W?QB\<1?$"75O^$</_ !;K
M4'\"6WB[_A"[GXC+X%O_ (N1_"A_A+IOQ"?P#:R^,H_A]J'C>V\:R>&VM]8C
MT%K&\M)I_C;P_P##KQ7\#?BYX@^-.N:-^U!HO[/7[-?ASX]:CX$^&_Q#\0?L
ML>);?QGXL^+?BFQN--\/?LWZ3\(Y+_XLZ[IWB&Z@U2UT+3_VF/BEIFO#6?%/
MP^\-:)X8%Q_:UWX4VO&GP1^.?CGQ+XX^#,?PHU?1O 7C;]I63]H.+X^W_BKX
M<2^#=+\*7_PUL7E\(W?@NS\9S?%.7XDVGC^W/A5].@\''P)+X=W^,H_B+]L6
M/PC* >\Z)^V3^SOXA\.^,/%6F?''XBMH_@JQ\$ZM=F^^#GC'2-3\4Z/\2]>O
MO"WPUUSX4:!J_P $['7_ (V:%\1_$FG76@_#[6_@[IGCK2O&^L+!IWA>\U6Z
MO+.*?W3X6^-O#?QF\'6?CSX>?$GQIJGAV[U+7]%?^U_"-IX-U_2M=\*ZYJ'A
MGQ+H'B/P?XU^'7A[Q?X5\0:#KVE:AI6K:#XET+2=7L+NUDCN;*,%"WYJ1_"7
M]I_Q+%\)/B1J?[.'B+POK_[,/@7]G7PA#\-+WXD_!C4O$/QKU;P)\0=,U7XF
M7_PRUW2?']UX/TKP[IOAK28K_P  WGQ6UWX<:WXTU>ZDT;Q'X;^'-K;+K5S^
M@/[,/A7QMH7A;X@>)OB!X3NO 'B'XK?&+Q_\4%\ ZEJ_A[7M<\':+KMQ8:5X
M>T?Q+J_A'5=>\)W/B6;1-!L-8UVW\,:]X@T+2=1U2?1-.\0^((--76[\ ]M_
ML'5?^AU\3?\ @)X-_P#F2H_L'5?^AU\3?^ G@W_YDJZ:B@#F?[!U7_H=?$W_
M (">#?\ YDJ/[!U7_H=?$W_@)X-_^9*NFHH YG^P=5_Z'7Q-_P" G@W_ .9*
MC^P=5_Z'7Q-_X">#?_F2KIJ* .9_L'5?^AU\3?\ @)X-_P#F2H_L'5?^AU\3
M?^ G@W_YDJZ:OQ^_X+"?MKZ_^S;\%-%^"7P4>]U3]J;]J2_;X9_"?1?#Y,WB
M31--UJ>WT/6_&%C!"RSP:L\VIVOAGP9('@G?Q3JT6J61GC\.:E''Y&?9W@N'
M<HQ^<YA*2PV!HNI[.FN:OB:\Y1I87!X:GJZN*QN*JX?"X:E&,I3JUX^ZXPG;
M]$\)O#'B;QE\1>%/#3A&E1EG7%.9PPBQ>+FZ.69+EF'I5<?GW$F=XIN-/ Y%
MPUD6"S;/LYQM:I1I8?+\LJWJPJXC#*7Y]?&;^V/^"P7_  42L/V7_#_BC7]<
M_8B_8RUC_A)?C3XF@;2(].\=?$.WEO-*GTS3KO1](TZQNCJNH6U_X"\,2SK<
M2P>']/\ B;XPT2]N+:]M+9_Q2CC2)$BB1(XXT6...-0B1H@"HB(H"JBJ JJH
M 4    5_9U_P3<_8F\/?L)_LQ^%/A5"ME?\ Q%US9XR^,GBFV"RMK_Q"U:TM
MQJ%I:WA199O#_A:WB@\->'%*PI-8Z>^L2VL.IZSJ;S?QD5^\_1!R3&X'#<=9
MYGL(/BCB:MD&8YPU::R^BH9K'+,@PTW>4<)DN"E3P[C&2C5QT\=B91E4FIG@
M?M!_$_AGBG//#;PM\*JU:/@7X&Y7Q!P5X;\\?85.+LPGB<MK\=>+6<T(<D*F
M?^)O$]#&9Q&K5A.M@.%L-PIDM&=+"X;V"*_N)_9,T74I?V5OV9Y8_%WB&V23
M]G[X,R);06WA-H;='^'/AME@A:Y\,7%PT40(CC,\\\Q1099I'W.W\.U?W5?L
MB_\ )J'[,/\ V;S\%O\ U6WAJOTGZ0W_ ")>&/\ L<YA_P"JFF?RGX*_\C7/
MO^Q7@O\ U93/8/[!U7_H=?$W_@)X-_\ F2H_L'5?^AU\3?\ @)X-_P#F2KIJ
M*_E0_H<YG^P=5_Z'7Q-_X">#?_F2K^7G_@MC:7%E^U3X BN=4OM6=OV?O"L@
MN=0CTR.9$/Q&^*RB!5TK3M,MS$I1I%+P/-OD<-,R"-(_ZK*_EA_X+@_\G7_#
M[_LWGPG_ .K)^+-?K_@;_P G PW_ &)L\_\ 4;!GYIXM?\D;7_[&F4_^G\2?
MC;7] O\ P0JL+J^_X:E^S:UJ>C^5_P *1W_V=%HTOVC?_P +=V^=_:^DZIM\
MG8WE_9_(SYK^;YN(O+_GZK^AC_@@S_S=7_W0W_WL-?T+XP_\FZXA_P"Z7_ZN
M, ?BWAE_R6V2_P#=0_\ 59C#]\O[!U7_ *'7Q-_X">#?_F2H_L'5?^AU\3?^
M G@W_P"9*NFHK^&S^M#F?[!U7_H=?$W_ (">#?\ YDJ^?OVL]%U*+]E;]IB6
M3Q=XAN4C_9^^,TCVT]MX36&X1/ASXD9H)FMO#%O<+%* 8Y#!/!,$8F*:-]KK
M]3U\\_M=?\FH?M/?]F\_&G_U6WB6O3R3_D=9+_V.<G_]6V5'!FO_ "*LT_[%
M>9_^JW,#^%6BBBO]'3^'C_0*_L'5?^AU\3?^ G@W_P"9*C^P=5_Z'7Q-_P"
MG@W_ .9*NFHK_,\_O YG^P=5_P"AU\3?^ G@W_YDJ/[!U7_H=?$W_@)X-_\
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M6/\ DP?X\_\ =+O_ %<_P[K^-NOZ^\ /^2.S+_LH\7_ZKLK/YI\9/^2GP/\
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M/DO!O_DI\=_V(\3_ .IV7GW-_8.J_P#0Z^)O_ 3P;_\ ,E1_8.J_]#KXF_\
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MJQVLU>LU]D?S6%%,DDCACDFFD2**)'DEED=4CCC12SR2.Q"HB*"SNQ"JH))
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M  7!_P"3K_A]_P!F\^$__5D_%FOU_P #?^3@8;_L39Y_ZC8,_-/%K_DC:_\
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MLF?M :_K7Q ^!_QZ^%7CK1/&$GP6\)^-K'XQ_$SQ[9?$2X^,_CUO#OQ4\7>
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M96/\.U?W5?LB_P#)J'[,/_9O/P6_]5MX:KT_I#?\B7AC_L<YA_ZJ:9P>"O\
MR-<^_P"Q7@O_ %93/8/^$MTK_GT\3?\ A%>,O_E#1_PENE?\^GB;_P (KQE_
M\H:Z:BOY4/Z'.9_X2W2O^?3Q-_X17C+_ .4-?R\_\%L=1M]3_:I\ 3VT=]&B
M?L_>%82NH:7J>DS%U^(WQ6<E;;5;2RN'BQ(H6=(FA9P\:R%XY%3^JROY8?\
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MIGUO@K_R*L^_[&F"_P#5;,YG_A+=*_Y]/$W_ (17C+_Y0T?\);I7_/IXF_\
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M,/\ V;S\%O\ U6WAJO8/&O\ R)OBW_L6=>_]-5W7^<6=_P#(ZSK_ +'.<?\
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M .IU8_J>_P""'W_)J'Q!_P"SAO%G_JMOA-7[)5^-O_!#[_DU#X@_]G#>+/\
MU6WPFK]DJ_B[Q,_Y.!Q;_P!CFM_ZC9:?U+P'_P D;PW_ -BNG_Z?QP4445\,
M?6GYY_\ !5C_ ),'^//_ '2[_P!7/\.Z_C;K^R3_ (*L?\F#_'G_ +I=_P"K
MG^'=?QMU_7W@!_R1V9?]E'B__5=E9_-/C)_R4^!_[$>&_P#4[,#Z&_9%_P"3
MK_V8?^SAO@M_ZLGPU7]U5?PJ_LB_\G7_ +,/_9PWP6_]63X:K^ZJOAOI#?\
M(ZX8_P"Q-F'_ *MJ9];X*_\ (JS[_L:8+_U6S"BBBOYZ/VD*_A5_:Z_Y.O\
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MKW_IJNZ_SBSO_D=9U_V.<X_]6V:G]PY5_P BK*_^Q7EG_JMR\/!7_(F^$O\
ML6=!_P#35:5TU<SX*_Y$WPE_V+.@_P#IJM*Z:O,.\**** "BBB@ HHHH ***
M* "BBB@#Q?XN_'CP3\&/^$?M_$6F?$+Q1KGB>[5-)\)_"KX9>//BSXP?2+?4
M]'TW7_%EUX9^'N@>(-6L?"7A1=<L+SQ!KMY;0VT:S6VEZ8-4\2:GHVAZE!)^
MT;\'XOBG;?!E_$FJ#QW=ZI'X?CB'@CQZ_A*+Q5+X3F\>1>";SXE)X8;X;:?X
M^E\%P/XIC\!7_BVV\92:$]OJ2:&;6ZM9)O"OVOM)\<ZAJG@:7X:?"SXV:O\
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MG+*V$I>RPE;$5*S=:IB*D5)1J0Y8\EYNZ35M?C. > >(^'>(Z69YG2P,,)#
MX^A*5#'TL14]IB*5&%)*E"C3DXN5.7-+FM%6;3N?7M%<S]D\9?\ 0>\,_P#A
M):K_ /-K1]D\9?\ 0>\,_P#A):K_ /-K7\WG[B=-7XV_\%P?^34/A]_V<-X3
M_P#5;?%FOUL^R>,O^@]X9_\ "2U7_P";6OFC]JC]DS3_ -KSX>Z-\-OB3XVO
M-$T+1/&6G^.+2[\#Z'!INK2:MINB>(M!@M[B?7M3\2V;Z<]GXEOY)H8["*Y:
MYBM'2[CBCFAG^GX+S7!Y%Q9D&<9A*K'!9=F-/$XJ5&E*O55*-'&4VZ=&,H2J
M2YJ].T5.+:<G?W7?P.*<NQ.;\.9SEF"5.6+QV!G0P\:M14:;J2JX6:4ZLHRC
M"/+2G[SBU>RMKI_$97Z&?\$I_P#D_CX#?]U1_P#5,?$2OUL_X<:? +_HK_Q@
M_+P7_P#,U7LO[/W_  2D^%O[-_Q=\)?&CP/\3_'^J^*/!G]O?V78>*[/P[?:
M!/\ \)%X9UKPI>_;[72+'0M1E\K3M=NYK7[/JMKLO8[:2;SX$EMIOZ0XD\9.
M!\TX=SW+<)B,VEBLPR?,L%AHU,FQ%*FZ^*P=:C152K+%2C3@ZDXJ4W&2BKR:
M:5C\.R+PPXLR_.\HQV)HY<L/@LSP.*KN&9T:DU1P^)IU:CA36'BYR4(OE@I)
MR=DFKW/U3HKF?LGC+_H/>&?_  DM5_\ FUH^R>,O^@]X9_\ "2U7_P";6OY(
M/Z0.FHKF?LGC+_H/>&?_  DM5_\ FUH^R>,O^@]X9_\ "2U7_P";6@#^'O\
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MH5$HJ<5.+Y9J*4E9I*]CIJ*YG[)XR_Z#WAG_ ,)+5?\ YM:/LGC+_H/>&?\
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M-1BZE?!XNA34I--1BZE:"E)IJ,6Y--1:?\$]%?T\?\.-/@%_T5_XP?EX+_\
MF:H_X<:? +_HK_Q@_+P7_P#,U7]B?\1R\/\ _H)SG_PQXG_YL/YD_P"(2\9?
M\^,K_P##M0_^9C]N**YG[)XR_P"@]X9_\)+5?_FUH^R>,O\ H/>&?_"2U7_Y
MM:_BX_J4Z:BN9^R>,O\ H/>&?_"2U7_YM:/LGC+_ *#WAG_PDM5_^;6@#^0'
M_@JQ_P G\?'G_NEW_JF/AW7YYU_6[^T#_P $I/A;^TA\7?%OQH\<?$_Q_I7B
MCQG_ &#_ &I8>%+/P[8Z!!_PCOAG1?"EE]@M=7L==U&+S=.T*TFNOM&JW6^]
MDN9(?(@>*VA\:_X<:? +_HK_ ,8/R\%__,U7];\-^,G ^5\.Y%EN+Q&;1Q67
MY/EN"Q,:>38BK35?"X.C1K*G5CBHQJ052$E&:C%25I)).Q_-^>^&'%F89WF^
M.PU'+GA\;F>.Q5!SS.C3FZ.(Q-2K3<Z;P\G"3A)<T')N+NFW:YTW_!#[_DU#
MX@_]G#>+/_5;?":OV2KY"_97_9,T_P#9#^'NL_#;X;>-KS6]"UOQEJ'CB[N_
M'&AP:EJT>K:EHGAW09[>WGT'4_#5FFG)9^&K"2*&2PEN5N9;MWNY(I(88/I?
M[)XR_P"@]X9_\)+5?_FUK^;^-,UP>>\69_G&7RJRP68YC4Q.%E6I2H572E1P
M=-.I1E*<J<N:A4O%SDTE%W]Y6_<>%LNQ.4<.9-EF-5..+P.!A0Q$:515J:J1
MJXJ;4*L8QC./+5A[RBE>ZMIKTU%<S]D\9?\ 0>\,_P#A):K_ /-K1]D\9?\
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MFF:A:22VM[8WUI-%<6MS!(\4T,B2(Q5@:^);_P ?^.K[QY\,/%WQ-U;X/_\
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M#^/O O[07@GXD^#5T"W\'+XR\4>*7\?>!/$7A_Q-XZ\-:/X=\=6-WKU_\+?
M>J_\)'X0OEU'7],^^/@=\.?$OPF^&^C^ ?%7Q-\3?&#4=#O-=,'C_P ;&YG\
M::SINIZYJ&KV$?BK4+C5-3CU75],AOQIAU#3XM$TI[.TL[?3/#NB65O#91@'
MK=<SXU_Y$WQ;_P!BSKW_ *:KNNFKF?&O_(F^+?\ L6=>_P#35=T '@K_ )$W
MPE_V+.@_^FJTKIJYGP5_R)OA+_L6=!_]-5I734 %%%% !1110 4444 %%%%
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M*/$VNZW\/K(>!O-TQ=8\+>*=;3P9\7-:E\,^*=#:T@DO=1^&/QB\5_$GP%X
M^(UA??"O]M[X5ZS9WNO>#9].O=9^'GQPTWP+/HTD^J:)?V]Q)HOB/X@?"+19
M-2M] \5:38RZ?J?[/_B:VUBU&I:M+:Q_<_PT^&OAGX4^%;?PIX82_FB-W>ZO
MK>NZW>R:MXH\7>)M6E^U:[XN\7:Y.JW.M^)==O"UUJ-_,(XU_<V-A;6.E6=A
M86H!0^$/P<^&_P !_ NE?#CX5>&+7PKX2TC<\%C!/>7UU=7+QPPR7^JZMJ5Q
M>:KJ^H/;V]K:+>:C>7,T-A9V.FVS0Z=I]C:6_IM%% !117&>)_'GA_PCJ_@W
M0M8DO$U+Q_J^J>'O"<4-G+);ZGK^E>&-;\82:*U^WEZ?8ZA>:#X<UN[TV+4+
MJU2^;3KF*&0R(10!RWQ8^+=A\,;71[&#0]7\6>.?&;ZAIGPW\%Z3;744GC/Q
M19I:RC03K_V.YTC0!%9W,_B#5M0U1U32O!V@^+?%C6USI7A367MOD^\O/BQ\
M1_$^K^/X_A1X+/Q-^%-YXD_9W^.?[/VI^-[;Q;X'^*WPX\:>'_!'Q/LK_P"&
M'Q#\2^$_!UI<ZK%HNM:5?V5OXO\ !/A?1?$7VCQIX%\91:<VE:'XKTG&\4_%
M+Q=\1/AW#\/OC7H?A3X"_M=>$)/!?Q=^#VE7WBFW7P!XZ\;Z7K&E?\(A9> O
M%^JRV*ZK!KVOZU;?!'XK>$3(WB;0CXTO;"&/4]!\5^#/$WB'V_X4?"KX=?$+
MQQ9_M=P7GBO5+SXD>'_"7B[PKX+\4&*VT3X9:_-X#L/!VLZQ9^'EM+:X@^(=
MQX=MH_".LZEKSWVI^&K:+Q!H7A[^P[;Q'XLAUH QOV??V8_#_AW3_AQXT^(O
M@E;;Q[\,#\1M'^$&D:WXGN/&=W\'_AEXM\5WVH^%/!"ZBE]=>']3UWP;X5DM
MO"NEZ]9QZA=>&/#L][X+T+Q)JNB_:]5UO[/HHH ***0G ).< $\ D\>@ ))]
M  2>@&: (YIDMX9IY!*R0Q23.L,,US,R1H7816]O'+<7$I"D1PP1232OB.*-
MW95/Y^_&_P"*?BGXJ?"W5=6\/:#X=U#]DCXF^"_!_@SQ;XMFU#5M/^)?BOP9
M^T1:6?@W5O%_PVMHU-AX;'PNL/&NF:GK&F^,M+GUGQ%>6GB31+.S\.W^@64W
MB'T3Q#^T_K.G?\(E\5-!\!7/B;]EF^\$:5XA\<_$NP&H+XU\%WFOZKK=D^I3
M> &M3J]QH'PRC\.O'\9M-FM;7Q7X1'B33]2MM,U"'PMXPL;+SOP7X?\ AW\0
M;GX\?LN1>+VUSX3_ !">[^,_PM\3_#7Q39YT32O$WB73M7^)O@OPYXHT-KR#
M3M:^'WQ7N[+QU:^2X.D^&OC!X,TS3X5M]+#* 8.@_"'QQ\7O%RV'Q-\%^$66
M;P-\5/V??VD?B]\,/&ND:=X'_: ^&MSX<U3PEI/AN+PAX?U9O&_A+XE:)XCO
M(]3NK77;:S_X4Z;?QSX3\'>-?$5GXH\ROO[P9X,\+?#SPMHG@KP5HEEX=\+^
M';);#2-(L%<06L =YI9))9GEN;R]O+F6>^U+4KZ>YU'5-1N;K4=1NKJ^NKBX
ME/!G@SPM\//"VB>"O!6B67AWPOX=LEL-(TBP5Q!:P!WFEDDEF>6YO+V\N99[
M[4M2OI[G4=4U&YNM1U&ZNKZZN+B7IZ "BBB@ KP_XG_&"^\):WIGP\\!^$)/
M'_Q?\265MJOAGPCJ.H:IX0\*OH(OKFSUSQ7XG^($'A?Q7!H'A7PHUO!'XCO-
M.T#Q+K-IJ.O^#-'M] N]2\9>'X+S1^)?Q+O/#AUKP5X*TV+7?C)J/PN\=>//
MAEX6U9)['0?%=_X1?1])-C<ZV9+:VCM[+Q%XI\)QZ_!!=IJ5KI&L+?6T,IVB
MOCOQG\?;/5[#P[XO\3:>GPV_:A_9H\3OJ/COX*'5(+W6_&OP_P!3T#5KGXJ6
M7PR\T65[\5/ ?BSX:^'/$7Q4^'%YH5E]NU/Q9\+-%TK7=.T7Q+X8\2Z%IH!4
MN=)\9?%>U\5_$Q/@KH_Q)\,?&/2M6^#_ .T=^S-KOBW08O$/ASQU\#?%WB[P
M$/%GPL\>:^GAW0M=T:WUB*\AD&IR>#I[C2D\(_$GP?<:#XG.IZ!KGTQ\#?@%
MI_@J/PI\2/B#:0>)/VAF^%?A'X?>-/B!>ZMJ'B"]FM]!M(UN;:PO+_R+-+[4
M)([&'Q9XETG1M!N_'ESH>D:EKEH%T[2K+3KOPF_9\\#?#_QIXX^*VGZSK?C'
MQ#\0];\3^(-&U+Q!=6UU8^!_#?CS6HO%^M^%? -E:6UK:Z3HNO>(MFO:[J+Q
MW'B#Q+/;Z';:YJU]I?A;PMI^B_1- !1110 5S7C/Q=H?@'PCXG\<^)[BYM/#
MG@_0-6\3:_=VFGW^JW-KHVB6,^I:E<Q:;I=M>:C>-;V=M--Y%G:SSN$.R,T[
MQCXHTWP/X1\4^-=9CU&;1_"'AS7/%&JPZ1IUUJ^K2Z;X?TRZU:^CTO2;&.6]
MU347M;25;+3K.*6ZO;DQ6UO&\TJ*?F+Q/^T?J_@SQK'JOC_P=H\'[)_C&W\*
MZ)X2^/&GZM%JEC8Z[XGT72]4M=9^(NF+YUKHGPF\83>(K7PCX>\</)%:Z/XJ
MT:^@\7VMEX?\2^'M> !Q/Q$\8>./CE.OP=UKP2?A+X;^(VMZCK?[//Q?'B5O
M%6M7OQ$_9W\=:!\2/"&I^._A9/X4T*QTGPAXLO/!0\=>%K2R\?>*(O'/PYTF
M^L?$3>!]4UZQT\XVA_L]ZU\:?%WCN?XW_!S1OA[X&^('A/PM%\8O#GA'XD'5
MO"7QM^*W@/QYX-\8?#GXI>$;GPI/H/B/1;+0;+PQJ>F:UJWB6S\-^+_&VCZK
MX2\/Z_I]UIG@BTEESO _PB\'_&_PQHOP-UCQWXGN/"G[,_Q';5/"&K>"]>MT
ML?BY^S]XO\'>/?"'@3PO>>+; W=Y=^&++1-8\3?!GQA>Z-JMCXAUZ_\ A1X@
M:XN[*U\1B9_T5L+"QTJQLM+TNRM--TS3;2VL-.TZPMH;.QL+&SA2WM+*RM+=
M([>UM+6WCC@MK:"..&"&-(HD5%50 -TW3=.T;3K#2-(L++2M)TJRM=-TO2]-
MM8+'3M-TZQ@CM;*PL+*UCBMK.RL[:**WM;6WBC@MX(XX88TC15%VBB@ HHKY
M^^)?Q9\56W_"=^"/@EX8TOQQ\</!4/POUI_!?C"_N_"/ARZ\)^/_ !/=V#>(
M)?$OV:YD&DKI'ACQS;0ZGH^GZZ]CXDT1;.[TJZ1)X& *7Q$^-WBNP\4:C\-O
M@K\-(OBM\4- M5UKQ/HOBCQ1JGPK\'>'?#<VE0:CI%_>^/&\#>-XKG4/&-W/
M-H/@6PT[0KNPUW6]"\9V^H:WH-KX)\37FG_'?B'P%XW^*OP\UWQ'\+_ ,'Q(
M^''[2]KX9_:(^%FI77BO2/AU\7/V8/CCXE\*Z1+H_C.35-2C,E]X;TW4++3_
M !!]OT2[U#QIX9U"'Q-X*3PMXW\%ZK;:7H_I%_\ 'OP'J7Q&^%/QF\/7TOAW
MQ;;WL_P-_:(^#>OW5C8_$OPEX;USQ'X;TC2=3\3^#8+JZO+N7X1_&+QIX#AC
M\3::]WX47X=?&/Q+XTT?6M7\/:]H6H7OT5\ /V=/!_[/N@WFG:)JGB#Q;K^I
MQ6%AJOC;QC=V]_XCN?#^@O?)X0\(6C6EM96&C^$/!MCJ%U:>'_#^DV=I91W-
M[K'B#4%O_%'B+Q%K>J@'1_#7X*>!?AGJ_C/QAHVAV,7C_P")U]8ZW\2?%<;7
M\UUXAUNWM$CF%DNIWNH2:#X=_M&34]8LO"VE36VAV.JZUK6IPV8U'5]2N[KU
MVBB@ HHKCO'OCSPS\-/#<WB[QA>R:;X>MM6\,Z/>ZBMM/<PZ?+XJ\3:1X4T^
M^U P(_V+2+34M:LY]:U:X\NPT;2H[S5M1F@L;.XF0 G\8^-?#7@+2[/6O%>H
M'2M*OO$?A7PI#?-:WES;QZWXT\1:9X3\.07DMI!.EA;7^OZQING'4+XV^GVT
MUW#]IN80ZD_ 'Q+\0?M!>)?%_P /-1\6>'?A7\.=4\,S>/?V@_@;_P )%KVK
M)I_AZ;X:Z5<> _%?P]^/^JJ;W1[1_B#\(/BSX@US3_&_A"WFL/A7KVG7_P!L
ML/%R>'M/O/%7>^-?BTFL7GQ)^!W[6O@NP^$_PK^+C?$3P9\)_B<WB.&#PWXC
M\/:<FM:+=:-XN\07+K9_#?XHW^DZ1=_$WX>RSWJZ=KWA:]L)-'O+/QKX5UW1
M(;G@7P'X3_:G\%?##5OCE'+XG\=? +Q3X@\*^,-,T^_>R\%>-_%FE6VFPQ^(
M=>T2S+V/B3P+\0M&B\%?&3PMX>N+JZT273/$'AM=4BU&&&XLG ,'X<?LS^&O
MB-/KNH_%'X/#P=\+E^)_A#XV_#;X+:EXPT?Q#HFA_%9/!_BS0_B%XOM[7P!K
MNH^#9_ /CAO&+WEOX%GNKO0M;UV+Q#XZ\0^&;'5?%UUI\/W]110 4444 %?'
M7Q+_ &JM6\-'Q]JOPX^%=U\2/!WP.M-=U3X_>(M2\1:CX!G\'V7AFZNGUS0_
M 6EWW@K7(?B7\0-/\,:=?>.W\*S:KX+TR?P=>^$-4M/%5Q)XZ\,6U]U/Q$^-
MGCM(;AO@/\.D^+&J_#[XH7GA+XT>$[[4E\)^(=&\/Z3X)?Q=>Q>$?[6:VM=1
M\9Z[::UX*U#P#;:B8/#'B>QUE([S7M!MKZ+7;#Y]N/&7PJ^)GQ(U./P-XTLM
M4^'/[8OPSU#X4_$[2-':*/Q=\/?BS;^%_'.E>"O$?C#PA?H=7\':UXJ\#^#_
M (F?#'Q'_P )?I&G7%EXM^#?@CP;=6CZC!>VUH 5[_X$?%;1M3\#>!O"_A#0
M_%6B_#WXP6/Q!^!_[0^D^+-&\.>*/A-X(\2>-;?Q1\2_AW\1-$F U;Q;::MX
M2U+Q)X,L9/#4.N:?\1] U/PY)XYL_#7B;1F\=7/VK\)_@Q\-O@CH6I>'?AGX
M:@\.Z?K.OZGXGUF0W5]J>IZQK>JS;YKW5=9U:YO=5U VELEMI.D0W5Y+;Z+H
M.GZ9H.E16>D:;8V<$_PJ^%OA_P"$OA<>'M&N=4UG4+^\;6O%OC#Q%<17WBOQ
MSXIN+6TL[[Q1XGU"&"U@GU&XM;"QL+.SL;2QT3P_H>GZ3X9\-:7H_AK1=(TF
MR]*H **** "O*?BY\7-$^$6AZ??ZAI6O^(]=\2WFJZ#X$\(^&]+N]0U?QIXQ
ML/"7B3QC9>$M/N$A.FZ=J.M:;X6U6+3KG6KNPL'NHTA:XWLJGI_%7CKPYX+N
M_!MGXBNYK%O'?BZV\#Z!<BTN)K'_ (2.^T;6]:TZTU.]BC:VTF+4TT&YTO3;
MF_D@@OO$%[H^A6SR:GJ]A;S?#GBOXG:W\1/ >O?"+]HG3_"_[-?QOO;'3_B;
M\#O$FL>((I_ -[KV@:YI?B7X<ZCH_B:YGM89O'?PT\7'PQH'Q9^'B7S7FI W
M5WX>EUWP-XLAG@ +FI:I\9/B3XR7Q6WPU\$>&_CC^SO_ &SX*\8_!Z]\>CQK
M\./BY\$_CYIW@S7+]?"7Q%U3P/X-N=*\27NI_#[2[?1;SQ#X&L+"+Q)X,\4^
M"=52;PMXHB\90=3\!?V8O#UA#X1\6?$+X:CPU??"WQ=\1[W]GGX>:QXJC\6#
MX'^!/'Z^!;F^\*;M%U"Z\(7\EIXG\&3:[X,MH)=>L_AKH-_H_A;PEJ=K!HL9
MCZ/X9_#[P?\ &?Q5X4_:JUN/Q);Z[J?@GPGI,GPGUBZLI/#'P^^)OP_U3QUI
M7B#4K^RMK.*36OB!X-U?Q)XF\"P:EJ5Y?Z=H+:9J%]X:M[6\U2:_/UU0 444
M4 %%%?(_C#]HSQ7:1^$?B'\./AQ>_$;X&6*?$&V^->KZ:FH0_$OP/J'@_P 6
M6?@RXA\-> ?(DU3Q1J7@_6=-\9S?$#PE]DMO$)TC17F\(C7/$%M;>%]= .<\
M6?M'3^++=/[+^%E[X@_9M\5^(?!_P:\8_%BY\5ZGX.\4V?B#XO:AIW@6%_"G
MP\O_  89]>\,^%/%?BS0O!GQ$\1W7C3PKK'@OQ4_B738?#>K7?@;Q(++SC0O
M@-\5]3\;?"?PWXU\&:'=V_PQT7Q+\+O%?[1_A?Q/H^BV_P :OV=;SP/XF\,V
MWPR\9> -.>W\1VGC.;Q-<^%-=U.P@MSX-\+^(O#VL^+?!'BK2CJUQX%NYK;2
MOA]\8-=^*?P6\#?%&T;X7?'.Y\.?M"_#GQ[\)-<\/ZS?>"?B9X1\2?#3Q[\2
M=$L;F2#Q!X?TN^UC4-3^%?QIT:WU:QFN]>N?B5X]U?\ LV2QL8YW^[? 7@/P
MK\,_">D>"?!>EKI/A[18IUM;<W%U?7=S=7MW/J.JZOJ^J7\USJ6M:]KFJW=[
MK/B#7M6N[S5]=UJ^OM6U6\N]0O+BXD *WPV^&W@GX1>"= ^'GP[T"T\->$?#
M5H;32]+M&FF;,DKW%Y?W]]=RW%_JVL:I>S7&I:SK6J75WJNL:I=76I:G>75[
M<SSR=Q110 445Y7\1?B;;^#IF\+Z1IUSKWQ*UWX??$GQG\//"@@EM[7QAJ/P
M[L]$DN/#,.MSFWTBVUK4;SQ+HZV.F7.H6][=Z<FM:K;H=/T+5;JT *_Q+^)E
MSX4?_A$?!VBIXL^+FO>%]6\1> _!E]<76AZ5KEOH_B'PAX7U;4=1\3O8W-C8
MZ/X8O_'/A_5?%"6:ZAKUKX>:ZOM.T74)E@MYOA*X3XH:[\2/BA=?$7P%\*OB
MG>Z@WAG]F+XY_![3]7L=#TOXK^%[#P[JGQG^%?C_ ."R?$W5H-/M/$=EHGQ5
M\;:-X[^%GBKQ.BZF?#=WXHT+QA9_\(U8#Q'V?CWXNWOB/0-,F\5:-IO@/]KS
M]F[Q7H_C>U^%D&O6Z#XJZ=-8ZQIOBG3?@QJ>K1V$OQ%\'?&OX<)XXTCP5";9
M-0T'Q]::3:^,-+TGQ1X(EC@^I/"7PL^%FK_$&7]I+1!=^(?$'CSPQX?N= U>
M^U&YO-#TK1KO0+&U36/"&BSK'::'J7BGP_#HUKKNL1P_VMJ6FZ?8Z<]Q#8I/
M:3 '!? /]G72_"2>"/BA\2-&.L?'O1_AQ;_#8>*-:\1:EXMU;P]X#T[Q)XKU
MCPIX9EU.[N9-,U3Q=HGA[Q-#X7\8?$.SLTUOQK<:?<3WNJWNG3Q1M]7T44 %
M<SXU_P"1-\6_]BSKW_IJNZZ:N9\:_P#(F^+?^Q9U[_TU7= !X*_Y$WPE_P!B
MSH/_ *:K2NFKF?!7_(F^$O\ L6=!_P#35:5TU !1110 4444 %%%% !1110
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M06D.C>,+:71I732?^$RT"6RU;P>GBF*SEO;;3;CQ!::!J2:+XDU#^T/<Z**
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M9EB@C=R%K\Y/B%\:_&^LZ)^T7?>.].\"^*_@K\+O$7Q"^'7[1/P 'AW4]/\
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M_'<-AXBU'^R-&O)7M/#NL>)+<:/;^);ZUMH=7O[/2=-TB^NY+*PCMZ]:HHH
M**** "N9\:_\B;XM_P"Q9U[_ --5W735S/C7_D3?%O\ V+.O?^FJ[H /!7_(
MF^$O^Q9T'_TU6E=-7PG:?%7Q[IMI:Z=9:]Y-G86\-E:0_P!EZ-)Y5M:QK!!%
MYDNG22R>7%&B[Y7>1L;G=F))L?\ "X?B-_T,7_E(T+_Y64 ?<E%?#?\ PN'X
MC?\ 0Q?^4C0O_E91_P +A^(W_0Q?^4C0O_E90!]R45\-_P#"X?B-_P!#%_Y2
M-"_^5E'_  N'XC?]#%_Y2-"_^5E 'W)17PW_ ,+A^(W_ $,7_E(T+_Y64?\
M"X?B-_T,7_E(T+_Y64 ?<E%?#?\ PN'XC?\ 0Q?^4C0O_E91_P +A^(W_0Q?
M^4C0O_E90!]R45\-_P#"X?B-_P!#%_Y2-"_^5E'_  N'XC?]#%_Y2-"_^5E
M'W)17PW_ ,+A^(W_ $,7_E(T+_Y64?\ "X?B-_T,7_E(T+_Y64 ?<E%?#?\
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M ,+A^(W_ $,7_E(T+_Y64?\ "X?B-_T,7_E(T+_Y64 ?<E%?#?\ PN'XC?\
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# /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390143325088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Oct. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">IMMUCELL CORP /DE/<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000811641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-12934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">01-0382980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityContactPersonnelLineItems', window );"><strong>Entity Contact Personnel [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">56 Evergreen Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Portland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">ME<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">04103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPhoneFaxNumbersLineItems', window );"><strong>Entity Phone Fax Numbers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(207)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">878-2770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.10 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ICCC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,911,589<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityContactPersonnelLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityContactPersonnelLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPhoneFaxNumbersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPhoneFaxNumbersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390146539280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 3,808,633<span></span>
</td>
<td class="nump">$ 978,741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade accounts receivable</a></td>
<td class="nump">2,307,913<span></span>
</td>
<td class="nump">2,185,383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">7,460,452<span></span>
</td>
<td class="nump">7,811,841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">310,488<span></span>
</td>
<td class="nump">493,885<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">13,887,486<span></span>
</td>
<td class="nump">11,469,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">25,820,333<span></span>
</td>
<td class="nump">27,575,683<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">4,592,718<span></span>
</td>
<td class="nump">4,571,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">95,557<span></span>
</td>
<td class="nump">95,557<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">23,880<span></span>
</td>
<td class="nump">38,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">28,899<span></span>
</td>
<td class="nump">57,655<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">44,448,873<span></span>
</td>
<td class="nump">43,808,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of debt obligations</a></td>
<td class="nump">1,479,058<span></span>
</td>
<td class="nump">1,428,807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability</a></td>
<td class="nump">482,244<span></span>
</td>
<td class="nump">644,276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">2,504,535<span></span>
</td>
<td class="nump">2,124,337<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">4,465,837<span></span>
</td>
<td class="nump">4,197,420<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG-TERM LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Debt obligations, net of current portion</a></td>
<td class="nump">9,422,961<span></span>
</td>
<td class="nump">10,540,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">4,148,404<span></span>
</td>
<td class="nump">4,077,109<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long-term liabilities</a></td>
<td class="nump">13,571,365<span></span>
</td>
<td class="nump">14,617,605<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">18,037,202<span></span>
</td>
<td class="nump">18,815,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">CONTINGENT LIABILITIES AND COMMITMENTS (See Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDER&#8217; EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.10 par value per share, 15,000,000 and 15,000,000 shares authorized, 8,896,398 and 7,814,165 shares issued and 8,833,097 and 7,750,864 shares outstanding, as of September 30, 2024 and December 31, 2023, respectively.</a></td>
<td class="nump">889,641<span></span>
</td>
<td class="nump">781,417<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">40,338,793<span></span>
</td>
<td class="nump">36,357,239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(14,678,281)<span></span>
</td>
<td class="num">(12,007,097)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury stock, at cost, 63,301 shares as of both September 30, 2024 and December 31, 2023</a></td>
<td class="num">(138,482)<span></span>
</td>
<td class="num">(138,482)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">26,411,671<span></span>
</td>
<td class="nump">24,993,077<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">$ 44,448,873<span></span>
</td>
<td class="nump">$ 43,808,102<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390146142128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Unaudited) (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">8,896,398<span></span>
</td>
<td class="nump">7,814,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">8,833,097<span></span>
</td>
<td class="nump">7,750,864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock</a></td>
<td class="nump">63,301<span></span>
</td>
<td class="nump">63,301<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390142895408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product sales</a></td>
<td class="nump">$ 6,011,573<span></span>
</td>
<td class="nump">$ 5,396,500<span></span>
</td>
<td class="nump">$ 18,742,040<span></span>
</td>
<td class="nump">$ 12,375,708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Costs of goods sold</a></td>
<td class="nump">4,428,019<span></span>
</td>
<td class="nump">4,129,619<span></span>
</td>
<td class="nump">13,632,642<span></span>
</td>
<td class="nump">9,764,164<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross margin</a></td>
<td class="nump">1,583,554<span></span>
</td>
<td class="nump">1,266,881<span></span>
</td>
<td class="nump">5,109,398<span></span>
</td>
<td class="nump">2,611,544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Product development expenses</a></td>
<td class="nump">786,136<span></span>
</td>
<td class="nump">1,118,489<span></span>
</td>
<td class="nump">3,079,189<span></span>
</td>
<td class="nump">3,328,397<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="nump">844,045<span></span>
</td>
<td class="nump">817,486<span></span>
</td>
<td class="nump">2,629,925<span></span>
</td>
<td class="nump">2,416,701<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Administrative expenses</a></td>
<td class="nump">528,267<span></span>
</td>
<td class="nump">514,952<span></span>
</td>
<td class="nump">1,661,838<span></span>
</td>
<td class="nump">1,611,026<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">2,158,448<span></span>
</td>
<td class="nump">2,450,927<span></span>
</td>
<td class="nump">7,370,952<span></span>
</td>
<td class="nump">7,356,124<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">NET OPERATING LOSS</a></td>
<td class="num">(574,894)<span></span>
</td>
<td class="num">(1,184,046)<span></span>
</td>
<td class="num">(2,261,554)<span></span>
</td>
<td class="num">(4,744,580)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other expenses (income), net</a></td>
<td class="nump">125,456<span></span>
</td>
<td class="num">(244,275)<span></span>
</td>
<td class="nump">405,610<span></span>
</td>
<td class="num">(113,092)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">LOSS BEFORE INCOME TAXES</a></td>
<td class="num">(700,350)<span></span>
</td>
<td class="num">(939,771)<span></span>
</td>
<td class="num">(2,667,164)<span></span>
</td>
<td class="num">(4,631,488)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">1,340<span></span>
</td>
<td class="nump">229<span></span>
</td>
<td class="nump">4,020<span></span>
</td>
<td class="nump">3,279<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">$ (701,690)<span></span>
</td>
<td class="num">$ (940,000)<span></span>
</td>
<td class="num">$ (2,671,184)<span></span>
</td>
<td class="num">$ (4,634,767)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average common shares outstanding (in Shares)</a></td>
<td class="nump">8,164,423<span></span>
</td>
<td class="nump">7,746,864<span></span>
</td>
<td class="nump">7,908,425<span></span>
</td>
<td class="nump">7,746,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share (in Dollars per share)</a></td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.34)<span></span>
</td>
<td class="num">$ (0.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average common shares outstanding (in Shares)</a></td>
<td class="nump">8,164,423<span></span>
</td>
<td class="nump">7,746,864<span></span>
</td>
<td class="nump">7,908,425<span></span>
</td>
<td class="nump">7,746,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share (in Dollars per share)</a></td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.34)<span></span>
</td>
<td class="num">$ (0.6)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390145054816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Stockholders&#8217; Equity (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 781,417<span></span>
</td>
<td class="nump">$ 35,978,364<span></span>
</td>
<td class="num">$ (6,232,499)<span></span>
</td>
<td class="num">$ (147,233)<span></span>
</td>
<td class="nump">$ 30,380,049<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="nump">7,814,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,634,767)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,634,767)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">268,207<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">268,207<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2023</a></td>
<td class="nump">$ 781,417<span></span>
</td>
<td class="nump">36,246,571<span></span>
</td>
<td class="num">(10,867,266)<span></span>
</td>
<td class="num">$ (147,233)<span></span>
</td>
<td class="nump">26,013,489<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2023</a></td>
<td class="nump">7,814,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2023</a></td>
<td class="nump">$ 781,417<span></span>
</td>
<td class="nump">36,150,137<span></span>
</td>
<td class="num">(9,927,266)<span></span>
</td>
<td class="num">$ (147,233)<span></span>
</td>
<td class="nump">26,857,055<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2023</a></td>
<td class="nump">7,814,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(940,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(940,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">96,434<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">96,434<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2023</a></td>
<td class="nump">$ 781,417<span></span>
</td>
<td class="nump">36,246,571<span></span>
</td>
<td class="num">(10,867,266)<span></span>
</td>
<td class="num">$ (147,233)<span></span>
</td>
<td class="nump">26,013,489<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2023</a></td>
<td class="nump">7,814,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 781,417<span></span>
</td>
<td class="nump">36,357,239<span></span>
</td>
<td class="num">(12,007,097)<span></span>
</td>
<td class="num">$ (138,482)<span></span>
</td>
<td class="nump">$ 24,993,077<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="nump">7,814,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,301<span></span>
</td>
<td class="nump">7,750,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,671,184)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (2,671,184)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">At-The-Market Offering of common stock, net of offering costs</a></td>
<td class="nump">$ 108,224<span></span>
</td>
<td class="nump">3,724,866<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,833,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">At-The-Market Offering of common stock, net of offering costs (in Shares)</a></td>
<td class="nump">1,082,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,082,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">256,688<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 256,688<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2024</a></td>
<td class="nump">$ 889,641<span></span>
</td>
<td class="nump">40,338,793<span></span>
</td>
<td class="num">(14,678,281)<span></span>
</td>
<td class="num">$ (138,482)<span></span>
</td>
<td class="nump">$ 26,411,671<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2024</a></td>
<td class="nump">8,896,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,301<span></span>
</td>
<td class="nump">8,833,097<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2024</a></td>
<td class="nump">$ 789,639<span></span>
</td>
<td class="nump">36,780,897<span></span>
</td>
<td class="num">(13,976,591)<span></span>
</td>
<td class="num">$ (138,482)<span></span>
</td>
<td class="nump">$ 23,455,463<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2024</a></td>
<td class="nump">7,896,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(701,690)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(701,690)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">At-The-Market Offering of common stock, net of offering costs</a></td>
<td class="nump">$ 100,002<span></span>
</td>
<td class="nump">3,480,339<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,580,341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">At-The-Market Offering of common stock, net of offering costs (in Shares)</a></td>
<td class="nump">1,000,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">77,557<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">77,557<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2024</a></td>
<td class="nump">$ 889,641<span></span>
</td>
<td class="nump">$ 40,338,793<span></span>
</td>
<td class="num">$ (14,678,281)<span></span>
</td>
<td class="num">$ (138,482)<span></span>
</td>
<td class="nump">$ 26,411,671<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2024</a></td>
<td class="nump">8,896,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,301<span></span>
</td>
<td class="nump">8,833,097<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390147732528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Stockholders&#8217; Equity (Unaudited) (Parentheticals) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_OfferingCostsOnFollowUpOfferingOfCommonStock', window );">Offering costs on at-the-market offering of common stock</a></td>
<td class="nump">$ 110,838<span></span>
</td>
<td class="nump">$ 275,640<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_OfferingCostsOnFollowUpOfferingOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offering costs on follow-up offering of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_OfferingCostsOnFollowUpOfferingOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390145109184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,671,184)<span></span>
</td>
<td class="num">$ (4,634,767)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by (used for) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">1,999,005<span></span>
</td>
<td class="nump">2,027,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">14,328<span></span>
</td>
<td class="nump">14,328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs and debt discounts</a></td>
<td class="nump">31,859<span></span>
</td>
<td class="nump">12,525<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">256,688<span></span>
</td>
<td class="nump">268,207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property, plant and equipment</a></td>
<td class="nump">14,557<span></span>
</td>
<td class="nump">8,099<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Non-cash rent (benefit) expense</a></td>
<td class="num">(112,306)<span></span>
</td>
<td class="nump">95,881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade accounts receivable</a></td>
<td class="num">(122,530)<span></span>
</td>
<td class="num">(105,985)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">351,389<span></span>
</td>
<td class="num">(1,347,124)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">183,397<span></span>
</td>
<td class="num">(201,211)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other assets</a></td>
<td class="nump">28,756<span></span>
</td>
<td class="nump">6,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">386,995<span></span>
</td>
<td class="num">(95,493)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used for) operating activities</a></td>
<td class="nump">360,954<span></span>
</td>
<td class="num">(3,951,165)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property, plant and equipment</a></td>
<td class="num">(269,509)<span></span>
</td>
<td class="num">(1,811,169)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherProductiveAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(115,127)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property, plant and equipment</a></td>
<td class="nump">4,500<span></span>
</td>
<td class="nump">2,474<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used for investing activities</a></td>
<td class="num">(265,009)<span></span>
</td>
<td class="num">(1,923,822)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from debt issuance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from At-The-Market Offering, net</a></td>
<td class="nump">3,833,090<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from line of credit</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Line of credit repayments</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(2,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Debt principal repayments</a></td>
<td class="num">(1,094,106)<span></span>
</td>
<td class="num">(829,015)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs and debt discounts</a></td>
<td class="num">(5,037)<span></span>
</td>
<td class="num">(98,098)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used for) provided by financing activities</a></td>
<td class="nump">2,733,947<span></span>
</td>
<td class="nump">2,072,887<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</a></td>
<td class="nump">2,829,892<span></span>
</td>
<td class="num">(3,802,100)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">BEGINNING CASH AND CASH EQUIVALENTS</a></td>
<td class="nump">978,741<span></span>
</td>
<td class="nump">5,791,562<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">ENDING CASH AND CASH EQUIVALENTS</a></td>
<td class="nump">3,808,633<span></span>
</td>
<td class="nump">1,989,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>CASH PAID FOR:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes</a></td>
<td class="nump">5,905<span></span>
</td>
<td class="nump">7,205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">404,077<span></span>
</td>
<td class="nump">303,752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>NON-CASH ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses', window );">Decrease in capital expenditures included in accounts payable and accrued expenses</a></td>
<td class="nump">6,797<span></span>
</td>
<td class="nump">56,441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability', window );">Increase in operating lease right-of-use asset and operating lease liability</a></td>
<td class="nump">$ 103,115<span></span>
</td>
<td class="nump">$ 2,090,298<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in capital expenditures included in accounts payable and accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of (Decrease) increase in operating lease right-of-use asset and operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390146656256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Operations<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Business Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">BUSINESS OPERATIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>1. BUSINESS OPERATIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">ImmuCell Corporation (the &#8220;Company&#8221;,
&#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;) was originally incorporated in Maine in 1982 and reincorporated in Delaware in
1987, in conjunction with an initial public offering of common stock. We are an animal health company whose purpose is to create scientifically
proven and practical products that improve the health and productivity of dairy and beef cattle. We focus on the two most critical stages
of dairy productivity, those being the first 30 days of life and the first 30 days of lactation. Our concentrated colostrum and purified
Nisin technologies offer unique animal health solutions during these periods when immunity is at its most vulnerable. As disclosed in
Note 17, &#8220;Segment Information&#8221;, one of our business segments is dedicated to Scours and the other is focused on Mastitis.
We manufacture and market the <b>First Defense<sup>&#174;</sup></b> product line, providing <b>Immediate Immunity&#8482;</b> to prevent
scours in newborn dairy and beef calves. We have expanded this line into four different products with formulations targeting <i>E. coli</i>,
coronavirus and rotavirus pathogens. We are also in the late stages of developing <b>Re-Tain<sup>&#174;</sup></b>, a treatment for lactating
dairy cows with subclinical mastitis. Mastitis is the most significant cause of economic loss to the dairy industry. These products help
reduce the need to use traditional antibiotics in food producing animals. We are subject to certain risks including dependence on key
individuals and third-party providers of critical goods and services, competition from other larger companies, the successful sale of
existing products and the development of new viable products with appropriate regulatory approvals, where applicable. A combination of
the conditions, trends and concerns related to or arising from inflation, rising interest rates and potential recessionary conditions
in the United States and/or internationally, could have a corresponding negative effect on our business and operations. We are experiencing
price increases in key components, supportive services, transportation and other supplies that are causing our costs of goods sold to
increase. We have experienced contamination events from time to time in our production process, beginning in the third quarter of 2022,
as disclosed previously. We implemented a production slowdown during 2023 to remediate this problem, which led to the recognition of lower
sales and gross margin. The last identified contamination event occurred during the first half of April of 2024, and we have been operating
without further contamination events since then and through the date of this filing.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390237390784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(a) Basis of Presentation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have prepared the accompanying unaudited financial
statements reflecting all adjustments (which are of a normal recurring nature) that are, in our opinion, necessary in order to ensure
that the financial statements are not misleading. We follow accounting standards set by the Financial Accounting Standards Board (FASB).
The FASB sets Generally Accepted Accounting Principles (GAAP) that we follow to ensure we accurately report our financial condition, results
of operations, earnings per share and cash flows. References to GAAP in these footnotes are to the FASB <i>Accounting Standards Codification</i>&#8482;
(Codification). We believe that the disclosures are adequate to ensure that the information presented is not misleading.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(b) Cash and Cash Equivalents</b> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We consider all highly liquid investment instruments
that mature within three months of their purchase dates to be cash equivalents. Cash equivalents are principally invested in securities
backed by the U.S. government. We hold no cash or cash equivalents in excess of Federal Deposit Insurance Corporation (FDIC) limits of
$250,000 per financial institution per depositor. See Note 3.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(c) Trade Accounts Receivable</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Accounts receivable are carried at the original
invoice amount less an estimate made for doubtful collection when applicable. Management determines the allowance for doubtful accounts
on a monthly basis by identifying troubled accounts and by using historical experience applied to an aging of accounts and other relevant
factors. Accounts receivable are considered to be past due if a portion of the receivable balance is outstanding for more than 30 days.
Past due accounts receivable are subject to an interest charge. It was not necessary to charge interest on past due accounts during the
nine-month periods ended September 30, 2024 or 2023 because the time past due was not significant, and there was no accrual for such interest
charges as of September 30, 2024 or December 31, 2023. Accounts receivable are written off when deemed uncollectible. No accounts receivable
were written off during the nine-month periods ended September 30, 2024 or 2023. Recoveries of accounts receivable previously written
off are recorded as income when received. No such recoveries were recorded during the nine-month periods ended September 30, 2024 or 2023.
As of September 30, 2024 and December 31, 2023, we determined that no allowance for doubtful accounts was necessary. See Note 4.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(d) Inventory</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Inventory includes raw materials, work-in-process
and finished goods and is recorded at the lower of cost, on the first-in, first-out method, or net realizable value (determined as the
estimated selling price in the normal course of business, less reasonably predictable costs of completion, disposal and transportation).
Work-in-process and finished goods inventories include materials, labor and manufacturing overhead. At each balance sheet date, we evaluate
our ending inventories for excess quantities and obsolescence. Inventories that we consider excess or obsolete are written down to estimated
net realizable value. Once inventory is written down and a new cost basis is established, it is not written back up. We believe that supplies
and raw materials for the production of our products are available from more than one vendor or farm. Our policy is to maintain more than
one source of supply for the components used in our products when feasible. See Note 5.</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(e) Property, Plant and Equipment, net</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We depreciate property, plant and equipment on the
straight-line method by charges to operations and costs of goods sold in amounts estimated to expense the cost of the assets from the
date they are first put into service to the end of the estimated useful lives of the assets. The facility we have constructed at 33 Caddie
Lane to produce the Nisin Drug Substance (DS) for <b>Re-Tain<sup>&#174;</sup></b> (<b>Building 33</b>) is being depreciated over 39 years
from when a Certificate of Occupancy was issued during the fourth quarter of 2017. We began depreciating the equipment for our Nisin DS
facility when it was placed in service during the third quarter of 2018. Approximately 86% of these assets are being depreciated over
10 years. We began depreciating the leasehold improvements to our new <b>First Defense<sup>&#174; </sup></b>production facility at 175
Industrial Way (<b>Building 175A</b>) over the remainder of the 10-year lease term beginning when a Certificate of Occupancy was issued
during the second quarter of 2020. During August of 2022, this lease term was extended to January of 2043 in connection with a new lease
covering additional space at 175 Industrial Way (<b>Building 175B</b>). As a result, the net book value of these leasehold improvements
as of August 31, 2022 is now being depreciated over the remainder of the extended lease term. Significant repairs to property, plant and
equipment that benefit more than a current period are capitalized and depreciated over their useful lives. Insignificant repairs are expensed
when incurred. See Notes 2(h) and 7 for additional information.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(f) Operating Leases</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We account for our real estate leases using a right-of-use
model, which recognizes that at the date of commencement, a lessee has a financial obligation to make lease payments to the lessor for
the right to use the underlying asset during the lease term and recognizes a corresponding right-of-use (ROU) asset related to this right.
ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the future lease payments
over the expected lease term. The ROU asset is also adjusted for any lease prepayments made, lease incentives received and initial direct
costs incurred. For operating leases with lease payments that fluctuate over the lease term, the total lease costs are recognized on a
straight-line basis over the lease term. Our leases, at times, may include options to extend the term of the lease. When it is reasonably
certain that we will exercise the option, we include the impact of the option in the lease term for purposes of determining future lease
payments. For all underlying classes of assets, we made an accounting policy election to not recognize assets or liabilities for leases
with a term of twelve months or less and to account for all components in a lease arrangement as a single combined lease component. Short-term
lease payments are recognized on a straight-line basis. Certain of our lease agreements include variable rent payments, consisting primarily
of amounts paid to the lessor based on cost or consumption, such as maintenance and real estate taxes. These costs are recognized in the
period in which the obligation is incurred. Because our leases do not specify an implicit rate, we use an incremental borrowing rate based
on information available at the lease commencement date to determine the present value of the lease payments. We evaluate our ROU asset
for impairment when events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. See Notes
2(h) and 12 for additional information.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(g) Intangible Assets and Goodwill</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We amortize intangible assets on the straight-line
method by charges to costs of goods sold in amounts estimated to expense the cost of the assets from the date they are first put into
service to the end of the estimated useful lives of the assets. We have recorded intangible assets related to customer relationships,
non-compete agreements and developed technology, each with defined useful lives. Amounts paid in excess of the fair value of the net assets
(including tax attributes) are recorded as goodwill under the acquisition method of accounting. We assess the impairment of intangible
assets that have indefinite lives (when applicable) and goodwill (at the reporting unit level) on an annual basis (as of December 31<sup>st</sup>)
and whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. We would record
an impairment charge if such an assessment were to indicate that the fair value of such assets was less than the carrying value. Judgment
is required in determining whether an event has occurred that may impair the value of goodwill or identifiable intangible assets. Factors
that could indicate that an impairment may exist include significant under-performance relative to plan or long-term projections, significant
changes in business strategy and significant negative industry or economic trends. Although we believe intangible assets and goodwill
are properly stated in the accompanying financial statements, changes in strategy or market conditions could significantly impact these
judgments and require an adjustment to the recorded balance in the future. <span style="-sec-ix-hidden: hidden-fact-50"><span style="-sec-ix-hidden: hidden-fact-51">No</span></span> goodwill impairments were recorded during the nine-month
periods ended September 30, 2024 or 2023. See Notes 2(h) and 8 for additional information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>(h) Valuation of Long-Lived Assets</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We periodically evaluate our long-lived assets,
consisting principally of property, plant and equipment, operating lease right-of-use asset and amortizable intangible assets, for potential
impairment. In accordance with the applicable accounting guidance for the treatment of long-lived assets, we review the carrying value
of our long-lived assets or asset group that is held and used, including intangible assets subject to amortization, for impairment whenever
events and circumstances indicate that the carrying value of the assets may not be recoverable. Under the held for use approach, the asset
or asset group to be tested for impairment should represent the lowest level for which identifiable cash flows are largely independent
of the cash flows of other groups of assets and liabilities. <span style="-sec-ix-hidden: hidden-fact-52"><span style="-sec-ix-hidden: hidden-fact-53">No</span></span> impairment was recognized during the nine-month periods ended September
30, 2024 or 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>(i) Fair Value Measurements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In determining fair value measurements, we follow
the provisions of Codification Topic 820, <i>Fair Value Measurements and Disclosures</i>. Codification Topic 820 defines fair value,
establishes a framework for measuring fair value under GAAP and enhances disclosures about fair value measurements. The topic provides
a consistent definition of fair value which focuses on an exit price, which is the price that would be received to sell an asset or paid
to transfer a liability in an orderly transaction between market participants at the measurement date. The topic also prioritizes, within
the measurement of fair value, the use of market-based information over entity-specific information and establishes a three-level hierarchy
for fair value measurements based on the nature of inputs used in the valuation of an asset or liability as of the measurement date.
As of September 30, 2024 and December 31, 2023, the carrying amounts of cash and cash equivalents, accounts receivable, inventory, prepaid
expenses and other current assets, other assets, accounts payable and accrued expenses approximate fair value because of their short-term
nature. The amount outstanding under our bank debt facilities is measured at carrying value in our accompanying balance sheets. Our bank
debt facilities are valued using Level 2 inputs. The three-level hierarchy is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.1pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.5in; text-align: left">Level 1</td>
    <td style="text-align: center; width: 0.25in">&#8212;</td><td style="text-align: left">  Pricing inputs are quoted prices available in active
markets for identical assets or liabilities as of the measurement date.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -43.9pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.5in; text-align: left">Level 2</td>
    <td style="text-align: center; width: 0.25in">&#8212;</td>
    <td style="text-align: left">Pricing inputs are quoted
prices for similar assets or liabilities, or inputs that are observable, either directly or indirectly, for substantially the full term
through corroboration with observable market data.</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -43.9pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.5in; text-align: left">Level 3</td>
    <td style="text-align: center; width: 0.25in">&#8212;</td>
    <td style="text-align: left">Pricing inputs are unobservable
for the assets or liabilities, that is, inputs that reflect the reporting entity&#8217;s own assumptions about the assumptions market
participants would use in pricing the asset or liability.</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -43.9pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In certain cases, the inputs used to measure fair
value may fall into different levels of the fair value hierarchy. In such cases, the level of an asset or liability within the fair value
hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance
of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the investment.
We also hold money market accounts in our bank account, which are classified as cash equivalents and measured at fair value. The fair
value of these investments is based on their closing published net asset value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We assess the levels of the investments at each
measurement date, and transfers between levels are recognized on the actual date of the event or change in circumstances that caused the
transfer in accordance with our accounting policy regarding the recognition of transfers between levels of the fair value hierarchy. During
the nine-month periods ended September 30, 2024 and 2023, there were no transfers between levels. As of September 30, 2024 and December
31, 2023, our Level 1 assets measured at fair value by quoted prices in active markets consisted of cash and money market accounts. There
were no assets or liabilities measured at fair value on a nonrecurring basis as of September 30, 2024 or December 31, 2023. The carrying
values of our cash and money market accounts as of September 30, 2024 and December 31, 2023 approximated their fair market values. Due
to inflation and the changing interest rate environment, the carrying values of our fixed rate bank debt as of September 30, 2024 and
December 31, 2023 differed from their fair market values. These values are reflected in the following tables:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 0.25in">Cash and money market accounts</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">3,808,633</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">&#8212;</div></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">&#8212;</div></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">3,808,633</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 20pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt">Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Bank debt</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,703,821</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,703,821</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Cash and money market accounts</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">978,741</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">&#8212;</div></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">&#8212;</div></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">978,741</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 20pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt">Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Bank debt</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,431,817</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,431,817</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(j) Concentration of Risk</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Concentration of credit risk with respect to
accounts receivable is principally limited to certain customers to whom we make substantial sales. To reduce risk, we routinely assess
the financial strength of our customers and, as a consequence, believe that our accounts receivable credit risk exposure is limited. We
maintain an allowance for potential credit losses when deemed necessary, but historically we have not experienced significant credit losses
related to an individual customer or groups of customers in any particular industry or geographic area. Sales to significant customers
that amounted to 10% or more of total product sales are detailed in the following table:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>During
the Three-Month <br/>
Periods Ended September 30,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>During
the Nine-Month<br/>
Periods Ended September 30,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">Company A</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">43</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">50</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">44</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">48</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Company B</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31</td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Trade accounts receivable due from significant
customers that amounted to 10% or more of our total trade accounts receivable are detailed in the following table:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>As of <br/>
 September 30, 2024</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>As of  <br/>
December 31, 2023</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Company A</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">37</td>
    <td style="width: 1%; text-align: left">%</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">43</td>
    <td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Company B</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">34</td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">36</td>
    <td style="text-align: left">%</td></tr>
  </table><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(k) Revenue Recognition</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We recognize revenue in accordance with Codification
Topic 606, <i>Revenue from Contracts with Customers (ASC 606)</i>. ASC 606 is a single comprehensive model for companies to use in accounting
for revenue arising from contracts with customers. The core principle is that we recognize the amount of revenue to which we expect to
be entitled for the transfer of promised goods or services to customers when a customer obtains control of promised goods or services
in an amount that reflects the consideration we expect to receive in exchange for those goods or services. In addition, the standard requires
disclosure of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. We conduct our
business with customers through valid purchase orders or sales orders which are considered contracts and are not interdependent on one
another. A performance obligation is a promise in a contract to transfer a distinct product to the customer. The transaction price is
the amount of consideration we expect to receive under the arrangement. Revenue is measured based on consideration specified in a contract
with a customer. The transaction price of a contract is allocated to each distinct performance obligation and recognized when or as the
customer receives the benefit of the performance obligation. Product transaction prices on a purchase or sales order are discrete and
stand-alone. We recognize revenue when we satisfy a performance obligation in a contract by transferring control over a product to a customer
when product ships to a customer. Amounts due are typically paid approximately 30 days from the time control is transferred. Shipping
and handling costs associated with outbound freight are accounted for as a fulfillment cost in costs of goods sold. We do not bill for
or collect sales tax because our sales are generally made to distributors and thus our sales to them are not subject to sales tax. We
generally have experienced an immaterial amount of product returns. See Note 14 for additional information.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(l) Expense Recognition</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We do not incur costs in connection with product
sales to customers that are eligible for capitalization. Advertising costs are expensed when incurred, which is generally during the month
in which the advertisement is published. All product development expenses are expensed as incurred, as are all related patent costs. We
capitalize costs to produce inventory during the production cycle, and these costs are charged to costs of goods sold when the inventory
is sold to a customer or is deemed to be in excess or obsolete.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>(m) Income Taxes </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We account for income taxes in accordance with
Codification Topic 740, <i>Income Taxes</i>, which requires that we recognize a current tax liability or asset for current taxes payable
or refundable and a deferred tax liability or asset for the estimated future tax effects of temporary differences and carryforwards to
the extent they are realizable. We consider future taxable income and feasible tax planning strategies in assessing the need for a valuation
allowance against our deferred tax assets at the end of each quarter. If we determine that it is more likely than not that we will realize
our deferred tax assets in the future in excess of the net recorded amount over a reasonably short period of time, a reduction of the
valuation allowance would increase income in the period such determination was made. Likewise, if we determine that it is more likely
than not that we will not realize all or part of our net deferred tax asset in the future, an increase to the valuation allowance would
be charged to income in the period such determination was made.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Codification Topic 740-10 clarifies the accounting
for income taxes by prescribing a minimum recognition threshold that a tax position must meet before being recognized in the financial
statements. In the ordinary course of business, there are transactions and calculations where the ultimate tax outcome is uncertain. In
addition, we are subject to periodic audits and examinations by the Internal Revenue Service and other taxing authorities. With few exceptions,
we are no longer subject to income tax examinations by tax authorities for years before 2021. We have evaluated the positions taken on
our filed tax returns and have concluded that no uncertain tax positions existed as of September 30, 2024 or December 31, 2023. Although
we believe that our estimates are reasonable, actual results could differ from these estimates. See Note 16.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(n) Stock-Based Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We account for stock-based compensation in accordance
with Codification Topic 718, <i>Compensation-Stock Compensation</i>, which generally requires us to recognize non-cash compensation expense
for stock-based payments using the fair-value-based method. The fair value of each stock option grant has been estimated on the date of
grant using the Black-Scholes option pricing model. Accordingly, we recorded compensation expense pertaining to stock-based compensation
of $77,557 and $96,434 during the three-month periods ended September 30, 2024 and 2023, respectively, and $256,688 and $268,207 during
the nine-month periods ended September 30, 2024 and 2023, respectively. See Note 13.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(o) Net Loss Per Common Share</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Net loss per common share has been computed in
accordance with Codification Topic 260-10, <i>Earnings Per Share</i>. The net loss per share has been computed by dividing the net loss
by the weighted average number of common shares outstanding during the period. All stock options have been excluded from the denominator
in the calculation of dilutive earnings per share when we are in a loss position because their inclusion would be anti-dilutive. Outstanding
stock options that were not included in this calculation because the effect would be anti-dilutive amounted to 661,000 and 616,500 during
the three-month periods ended September 30, 2024 and 2023, respectively, and 661,000 and 616,500 during the nine-month periods ended September
30, 2024 and 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>During the Three-Month <br/>
Periods Ended September 30, </b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>During the Nine-Month  <br/>
Periods Ended September 30, </b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Net loss attributable to stockholders</td>
    <td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="width: 9%; border-bottom: Black 4pt double; text-align: right">(701,690</td>
    <td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="width: 9%; border-bottom: Black 4pt double; text-align: right">(940,000</td>
    <td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="width: 9%; border-bottom: Black 4pt double; text-align: right">(2,671,184</td>
    <td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="width: 9%; border-bottom: Black 4pt double; text-align: right">(4,634,767</td>
    <td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Weighted average common shares outstanding - Basic</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">8,164,423</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">7,746,864</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">7,908,425</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">7,746,864</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Dilutive impact of share-based compensation awards</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">&#8212;</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">&#8212;</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">&#8212;</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">&#8212;</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Weighted average common shares outstanding - Diluted</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">8,164,423</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">7,746,864</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">7,908,425</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">7,746,864</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Net loss per share:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">Basic</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(0.09</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(0.12</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(0.34</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(0.60</td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">Diluted</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(0.09</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(0.12</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(0.34</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(0.60</td>
    <td style="text-align: left">)</td></tr>
  </table>



<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(p) Use of Estimates</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The <span style="font-family: Times New Roman, Times, Serif">preparation
of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported
amounts of revenues and expenses during the period. Although we regularly assess these estimates, actual amounts could differ from those
estimates and are subject to change in the near term. Changes in estimates are recorded during the period in which they become known.
Significant estimates include our valuation of inventory, deferred tax assets and costs of goods sold</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(q) New Accounting Pronouncements Not Yet Adopted</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In November of 2023, the FASB issued ASU 2023-07,
<i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,</i> which is intended to improve reportable segment
disclosure requirements, primarily through enhanced disclosures about significant expenses. The amendments will require disclosure of
significant segment expenses that are regularly provided to our chief operating decision-maker and included within segment profit and
loss. The amendments are effective for annual periods beginning after December 15, 2023, and interim periods beginning after December
15, 2024, with early adoption permitted, and will be applied retrospectively to all prior periods presented in the financial statements.
We are currently evaluating ASU 2023-07 to determine its impact on our financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In December of 2023, the FASB issued ASU 2023-09<i>,
Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>, which includes amendments that further enhance income tax disclosures,
primarily through standardization and disaggregation of income tax rate reconciliation categories and income taxes paid by jurisdiction.
The amendments are effective for annual periods beginning after December 15, 2024, with early adoption permitted, and may be applied either
prospectively or retrospectively. We are currently evaluating ASU 2023-09 to determine its impact on our financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390145422080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">CASH AND CASH EQUIVALENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>3. CASH AND CASH EQUIVALENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Cash and cash equivalents amounted to $3,808,633
and $978,741 as of September 30, 2024 and December 31, 2023, respectively. See Note 13.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390143429904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade Accounts Receivable<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrentAbstract', window );"><strong>Trade Accounts Receivable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">TRADE ACCOUNTS RECEIVABLE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>4. TRADE ACCOUNTS RECEIVABLE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Trade accounts receivable amounted to $2,307,913
and $2,185,383 as of September 30, 2024 and December 31, 2023, respectively. No allowance for bad debt or product returns was recorded
as of September 30, 2024 or December 31, 2023. We anticipate no future events or conditions that would impact our ability to collect our
accounts receivable. Because of the generally short duration from the balance sheet date to the date of collection, our collection rate
is not expected to be significantly impacted by events occurring after the balance sheet date. The trade accounts receivable balances
included $35,364 and $42,507 due from a related party as of September 30, 2024 and December 31, 2023, respectively. See Note 18.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due to entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/310-10/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390145427008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>5. INVENTORY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Inventory consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.25pt; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of <br/> September 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of <br/> December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Raw materials</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,313,766</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,594,028</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">Work-in-process</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,124,394</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,815,194</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Finished goods</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,292</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">402,619</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,460,452</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,811,841</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-weight: normal">These <span style="font-family: Times New Roman, Times, Serif">inventory
figures are net of write-offs of scrapped inventory in the amounts of $368,723 and $527,133 during the nine-month period ended September
30, 2024 and the year ended December 31, 2023, respectively, that resulted principally from contamination events and other production
process losses</span>. </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390231495904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expenses and Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">PREPAID EXPENSES AND OTHER CURRENT ASSETS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>6. PREPAID EXPENSES AND OTHER CURRENT ASSETS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Prepaid expenses and other current assets consisted
of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.95pt; text-indent: -0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of <br/> September 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<br/> December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Prepaid expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">277,146</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">454,152</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Other receivables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">33,342</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">39,733</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">310,488</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">493,885</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390237962704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY, PLANT AND EQUIPMENT, net</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>7. PROPERTY, PLANT AND EQUIPMENT, net</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Property, plant and equipment consisted of the
following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Estimated Useful Lives <br/> (in years)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<br/> September 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<br/> December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt">Laboratory and manufacturing equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">3-10</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">21,183,888</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">20,953,601</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Buildings and improvements</td><td>&#160;</td>
    <td style="text-align: center">10-39</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,858,708</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,784,565</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: center">3-10</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,053,436</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,036,374</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Construction in progress</td><td>&#160;</td>
    <td style="text-align: center"><div style="-sec-ix-hidden: hidden-fact-54">n/a</div></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,588,630</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,768,224</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Land</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt"><div style="-sec-ix-hidden: hidden-fact-55">n/a</div></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">516,867</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">516,867</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Property, plant and equipment, gross</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46,201,529</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46,059,631</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(20,381,196</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(18,483,948</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Property, plant and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">25,820,333</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">27,575,683</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of September 30, 2024 and December 31, 2023,
construction in progress consisted principally of payments toward the <b>First Defense<sup>&#174;</sup></b> production capacity expansion
project and equipment needed to bring the formulation and aseptic filling for <b>Re-Tain<sup>&#174;</sup></b> in-house. Property, plant
and equipment disposals were $49,652 and $43,503 during the three-month periods ended September 30, 2024 and 2023, respectively, and $120,814
and $100,142 during the nine-month periods ended September 30, 2024 and 2023, respectively. Depreciation expense was $670,346 and $695,635
during the three-month periods ended September 30, 2024 and 2023, respectively, and $1,999,005 and $2,027,788 during the nine-month periods
ended September 30, 2024 and 2023, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390146944640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>8. INTANGIBLE ASSETS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Intangible assets of $191,040 were valued using
the relief from royalty method and are being amortized to costs of goods sold over their useful lives, which are estimated to be 10 years.
Intangible amortization expense was $4,776 during both of the three-month periods ended September 30, 2024 and 2023 and $14,328 during
both of the nine-month periods ended September 30, 2024 and 2023. The net value of these intangibles was $23,880 and $38,208 as of September
30, 2024 and December 31, 2023, respectively. Intangible asset amortization expense is estimated to be $19,104 per year through December
31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Intangible assets as of September 30, 2024 consisted
of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Gross Carrying<br/>
 Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Accumulated<br/>
 Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Net Book<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt">Developed technology</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">184,100</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(161,087</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">23,013</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Customer relationships</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,138</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">162</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Non-compete agreements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,640</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,935</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">705</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 0.25in">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">191,040</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(167,160</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">23,880</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Intangible assets as of December 31, 2023 consisted
of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Gross Carrying<br/>
 Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Accumulated<br/>
 Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Net Book<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt">Developed technology</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">184,100</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(147,280</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">36,820</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Customer relationships</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,040</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">260</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Non-compete agreements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,640</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,512</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,128</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">191,040</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(152,832</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">38,208</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390146688416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accounts Payable and Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCOUNTS PAYABLE AND ACCRUED EXPENSES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>9. ACCOUNTS PAYABLE AND ACCRUED EXPENSES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Accounts payable and accrued expenses consisted
of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<br/> September 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<br/> December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Accounts payable &#8211; trade</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">876,836</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">874,558</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Accounts payable &#8211; capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,378</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,175</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Accrued payroll</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,142,318</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">942,999</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Accrued professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">101,725</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">97,800</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Accrued other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">376,112</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">192,754</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Income tax payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,166</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,051</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,504,535</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,124,337</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390146693152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Bank Debt<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Bank Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">BANK DEBT</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>10. BANK DEBT</b></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Loans #1 and #2</b>: During the first quarter
of 2020, we closed on a debt financing with Gorham Savings Bank (GSB) aggregating $8,600,000, which was comprised of a $5,100,000 mortgage
note (Loan #1) that bears interest at a fixed rate of 3.50% per annum (with a 10-year term and 25-year amortization schedule and a balloon
principal payment of $3,145,888 due during the first quarter of 2030) and a $3,500,000 note (Loan #2) that bears interest at a fixed rate
of 3.50% per annum (with a 7-year term and amortization schedule). The proceeds from the 2020 debt refinancing were used to repay all
bank debt outstanding at the time of closing and to provide some additional working capital. During the first quarter of 2022, we closed
on an additional $2,000,000 in mortgage debt, which bears interest at the fixed rate of 3.58% per annum. This was accomplished through
an amendment of the original mortgage note (Loan #1) that increased the then outstanding principal balance from $4,233,957 to $6,233,957
bearing interest at the blended fixed rate of 3.53% per annum. This increased the balloon payment from $3,145,888 to $3,687,577 and extended
the due date of the balloon payment from the first quarter of 2030 to the first quarter of 2032.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Line of Credit (LOC)</b>: Also during the first
quarter of 2020, GSB extended a $1,000,000 LOC to us that is available, as needed, through September 11, 2025. Interest on borrowings
against the LOC is variable at the National Prime Rate per annum. There was no outstanding balance under this LOC as of September 30,
2024 or December 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Loan #3</b>: During the second quarter of 2020,
we received a loan from the Maine Technology Institute (MTI) in the aggregate principal amount of $500,000. The first 2.25 years of this
loan were interest-free with no interest accrual or required principal payments. Beginning during the fourth quarter of 2022, Loan #3
became subject to quarterly principal and interest payments at a fixed rate of 5% per annum over the final five years of the loan, through
the third quarter of 2027 if not repaid before then.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Loan #4</b>: During the fourth quarter of 2020,
we closed on a $1,500,000 note with GSB that bears interest at a fixed rate of 3.50% per annum (with a 7-year term and amortization schedule).
Proceeds of $624,167 were used to prepay a portion of the outstanding principal on our mortgage note (Loan #1), which reduced the outstanding
balance to 80% of the most recent appraised value of the property securing the debt, which allowed GSB to release the $1,400,000 that
had been held in escrow. The remaining proceeds were available for general working capital purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Loan #5</b>: On June 30, 2021, we executed definitive
agreements covering a second loan from the MTI in the aggregate principal amount of $400,000, proceeds from which were received in July
of 2021. The first two years of this loan were interest-free with no interest accrual or required principal payments. Principal and interest
payments at a fixed rate of 5% per annum are due quarterly over the final 5.5 years of the loan, beginning during the third quarter of
2023 and continuing through the fourth quarter of 2028 if not repaid before then.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Loan #6: </b>During the third quarter of 2023,
we closed on a $2,000,000 term loan bearing interest at a fixed rate of 7% per annum from GSB. The Finance Authority of Maine (FAME) provided
$1,000,000 of loan insurance to GSB. This loan is repayable under a 7-year amortization schedule with a balloon payment of $1,285,056
due during the third quarter of 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Loan #7:</b> Also during the third quarter of
2023, we closed on a $1,000,000 term loan bearing interest at a fixed rate of 8% per annum from FAME. The loan is repayable under a 7-year
amortization schedule with a balloon payment of $649,631 due during the third quarter of 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Loans #1, #2, #4, #6 and #7 are secured by liens
on substantially all of our assets and are subject to certain restrictions and financial covenants. Loan #7 is subordinated to Loans #1,
#2, #4 and #6. Reflecting our poor financial performance during 2023 and into the first nine months of 2024, the debt service covenant
(DSC) requirements for the twelve-month periods ended December 31, 2023, June 30, 2024, September 30, 2024 and December 31, 2024 were
waived pre-emptively by our lenders. We are required to meet a minimum DSC ratio of 1.35 for the year ending December 31, 2025 and annually
thereafter. In connection with these credit facilities, we incurred aggregate debt issuance and debt discount costs of $173,305 ($5,037
and $0 of which was incurred during the nine-month periods ended September 30, 2024 and 2023, respectively). The amortization of these
debt issuance and debt discount costs is being recorded as a component of interest expense, included in other expenses, net, and is being
amortized on a straight-line basis over the underlying terms of the notes. Loans #3 and #5 are unsecured and subordinated to our indebtedness
to GSB and FAME. Failure to make timely payments of principal and interest, or otherwise to comply with the terms of the agreements of
Loans #3 and #5, would entitle the MTI to accelerate the maturity of such debt and demand repayment in full. These loans may be prepaid
without penalty at any time.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Debt proceeds received and principal repayments
made (excluding our $1,000,000 line of credit) are reflected by loan during the periods as described in the tables below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>During the Three-Month <br/>
</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Period Ended September 30, 2024</b></p></td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>During
the Three-Month <br/>
Period Ended September 30, 2023</b></p></td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Proceeds&#160;from<br/>
 Debt Issuance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Debt&#160;Principal<br/>
 Repayments</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Proceeds&#160;from <br/>
Debt Issuance</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Debt&#160;Principal<br/>
 Repayments</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -10pt; padding-left: 10pt">Loan #1</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">57,671</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">55,619</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">Loan #2</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">128,534</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">124,020</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Loan #3</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,173</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,002</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">Loan #4</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53,505</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51,622</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt">Loan #5</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,719</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,909</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt">Loan #6</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">59,191</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36,582</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt">Loan #7</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">28,456</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,000,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,983</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">368,249</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,000,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">325,737</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>During the Nine-Month </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Period Ended September 30, 2024</b></p></td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>During the Nine-Month </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Period Ended September 30, 2023</b></p></td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Proceeds&#160;from<br/>
 Debt Issuance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Debt&#160;Principal<br/>
 Repayments</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Proceeds&#160;from <br/>
Debt Issuance</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Debt&#160;Principal<br/>
 Repayments</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -10pt; padding-left: 10pt">Loan #1</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">172,017</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">166,527</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">Loan #2</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">382,324</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">369,154</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Loan #3</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71,629</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68,156</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">Loan #4</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">159,171</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">153,704</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt">Loan #5</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49,542</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,909</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt">Loan #6</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">174,804</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36,582</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt">Loan #7</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">84,619</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,000,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,983</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,094,106</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,000,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">829,015</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>During the Year<br/>
 Ended December 31,
                                                                                 2023</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>During
the Year<br/>
 Ended December 31, 2022</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Proceeds&#160;from<br/>
 Debt Issuance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Debt&#160;Principal<br/>
 Repayments</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Proceeds&#160;from <br/>
Debt Issuance</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Debt&#160;Principal<br/>
 Repayments</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -10pt; padding-left: 10pt">Loan #1</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">223,222</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,000,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">199,013</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">Loan #2</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">494,455</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">477,237</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Loan #3</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">91,446</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,160</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">Loan #4</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">205,884</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">198,715</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt">Loan #5</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,017</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt">Loan #6</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">93,054</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt">Loan #7</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,000,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">45,696</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,000,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,185,774</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,000,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">897,125</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Principal payments (net of debt issuance
and debt discount costs) due under bank loans outstanding as of September 30, 2024 (excluding our $1,000,000 line of credit) are reflected
in the following table by the year that payments are due:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">During the<br/> Three-Month<br/> Period Ending<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">During the Years Ending December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2027</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2028</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Thereafter</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 16%">Loan #1</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">58,765</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">239,876</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">248,604</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">257,649</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">266,537</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,598,457</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,669,888</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Loan #2</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">129,801</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">530,738</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">549,881</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">140,436</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,350,856</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Loan #3</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,476</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">101,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">106,146</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">83,143</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">314,765</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Loan #4</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">54,055</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">220,994</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">228,965</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">240,442</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">744,456</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Loan #5</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,929</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">69,856</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73,415</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">77,156</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">81,086</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">318,442</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Loan #6</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60,581</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">253,003</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,418,558</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,732,142</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Loan #7</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">29,617</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">124,364</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">715,704</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">869,685</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Subtotal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">374,224</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,539,831</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,341,273</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">798,826</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">347,623</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,598,457</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,000,234</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Debt issuance cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,583</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(21,314</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(13,580</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,420</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,513</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11,347</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(60,757</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Debt discount cost</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,223</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(20,891</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(11,344</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(37,458</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">363,418</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,497,626</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,316,349</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">793,406</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">344,110</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,587,110</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,902,019</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390231507984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingent Liabilities and Commitments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Contingent Liabilities and Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">CONTINGENT LIABILITIES AND COMMITMENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>11. CONTINGENT LIABILITIES AND COMMITMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our bylaws, as amended, in effect provide that the
Company will indemnify its officers and directors against any liability arising from their responsibilities as officers and directors
to the maximum extent permitted by Delaware law. In addition, we make similar indemnity undertakings with each director through a separate
indemnification agreement with that director. The maximum payment that we may be required to make under such provisions is theoretically
unlimited and is impossible to determine. We maintain directors&#8217; and officers&#8217; liability insurance, which may provide reimbursement
to the Company for payments made to, or on behalf of, officers and directors pursuant to the indemnification provisions. Our indemnification
obligations were grandfathered under the provisions of Codification Topic 460<i>, Guarantees</i>. Accordingly, we have recorded no liability
for such obligations as of September 30, 2024 or December 31, 2023. Since our incorporation, we have had no occasion to make any indemnification
payment to any of our officers or directors for any reason.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The development, manufacturing and marketing of
animal health care products entails an inherent risk that liability claims will be asserted against us during the normal course of business.
We are aware of no such claims against us as of the date of this filing. We believe that we have reasonable levels of liability insurance
to support our operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We enter into agreements with third parties in the
ordinary course of business under which we are obligated to indemnify such third parties from and against various risks and losses. The
precise terms of such indemnities vary with the nature of the agreement. In many cases, we limit the maximum amount of our indemnification
obligations, but in some cases those obligations may be theoretically unlimited. We have not incurred material expenses in discharging
any of these indemnification obligations and based on our analysis of the nature of the risks involved, we believe that the fair value
of the liabilities potentially arising under these agreements is minimal. Accordingly, we recorded no liabilities for such obligations
as of September 30, 2024 or December 31, 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We plan to purchase certain key parts (syringes)
and services (formulation, aseptic filling and final packaging) pertaining to <b>Re-Tain<sup>&#174;</sup></b> Drug Product (DP), our Nisin-based
intramammary treatment of subclinical mastitis in lactating dairy cows, exclusively from contractors. The contract for formulation, aseptic
filling and final packaging of DP is scheduled to terminate on November 30, 2024. We initiated an investment in the necessary equipment
to perform the DP formulation and aseptic filling services in-house, but this investment has been paused at the present time.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Effective March 28, 2022, we entered into an Amended
and Restated Separation and Deferred Compensation Agreement (the &#8220;Deferred Compensation Agreement&#8221;) with Mr. Brigham (our
President and CEO) that superseded and replaced in its entirety a March 2020 severance agreement between the Company and Mr. Brigham.
Upon separation from the Company for any reason, Mr. Brigham&#8217;s Deferred Compensation Agreement allows Mr. Brigham to be paid, among
other amounts, all earned and unused paid time off (which expense totaling $222,379 was accrued during the first quarter of 2022 and $230,162
was included in accounts payable and accrued expenses on the accompanying balance sheets as of both September 30, 2024 and December 31,
2023) and to receive up to an additional $300,000 in deferred compensation (which amount is being accrued over the three-year period ending
in January 2025). This deferred compensation payment vested as to $100,000 on January 1, 2023 and an additional $100,000 on January 1,
2024. An additional $100,000 will vest on January 1, 2025, provided that Mr. Brigham is employed by the Company as of such date. The vested
amounts would be paid upon the earlier of January 31, 2025 or within thirty (30) days following his separation from the Company. As of
September 30, 2024 and December 31, 2023, $275,000 and $200,000, respectively, was included in accounts payable and accrued expenses on
the accompanying balance sheets. In addition, upon termination of Mr. Brigham&#8217;s employment (a) by the Company other than for cause,
(b) due to death or disability or (c) by Mr. Brigham for good reason, in each case as described and defined in the Deferred Compensation
Agreement, the Company agrees to pay Mr. Brigham 100% of his then current annual base salary and a lump sum payment equal to the employer
portion of the costs of continued health benefits for Mr. Brigham and his covered dependents for a twelve-month period following termination,
and certain equity incentive awards granted to Mr. Brigham would continue to vest following such termination in accordance with the terms
of the Deferred Compensation Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Incentive
compensation agreements may be entered into with Mr. Brigham, Ms. Brockmann (our Vice President of Sales and Marketing) and Ms. Williams
(our Vice President of Manufacturing Operations) which, at times, allow these executives to earn incentive compensation if certain regulatory
and financial objectives are met during the year to which the agreement relates, as specified in their agreements. Amounts related to
these incentive compensation agreements are accrued over the period they are earned (when it is probable that the amounts will be earned)
based on our best estimate of the amounts expected to be </span>earned.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the commitments discussed above, we had committed $186,000 to increase our production capacity for the <b>First Defense<sup>&#174;</sup></b>
product line, $1,818,000 to the purchase of inventory, $22,000 related to the commercial manufacture of <b>Re-Tain<sup>&#174;</sup></b>
and $711,000 to information technology services and other obligations as of September 30, 2024</span>.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390146255040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Lease<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Operating Lease [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">OPERATING LEASE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>12. OPERATING LEASE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On September 12, 2019, we entered into a lease
covering approximately 14,300 square feet of office and warehouse space with a possession date of November 15, 2019 and a commencement
date of February 13, 2020. The property is located at 175 Industrial Way in Portland (<b>Building 175A</b>), which is a short distance
from our headquarters and manufacturing facility at 56 Evergreen Drive. We renovated this space to meet our needs in expanding our production
capacity for the <b>First Defense<sup>&#174;</sup></b> product line. The original lease term was ten years with a right to renew for a
second 10-year term and a right of first offer to purchase. At the time we entered into this lease, we were not reasonably assured that
we would exercise this renewal option in place of other real estate options. For that reason, a 10-year period was reflected in the right-of-use
(ROU) asset and lease liability on our balance sheet. During the third quarter of 2022, we committed to lease an additional 15,400 square
feet of space at 175 Industrial Way (<b>Building 175B</b>), which is connected to the original space, over a 20-year term. The ROU asset
and lease liability for the committed space at <b>Building 175B</b> was recorded as of April 1, 2023 after construction of the building
shell was completed in accordance with the lease agreement. Monthly lease payments commenced as of August 1, 2023. In connection with
the lease commitment for space at <b>Building 175B, </b>the term of the original lease for <b>Building 175A</b> was extended by approximately
13 years. On November 14, 2023, June 11, 2024 and September 20, 2024, we amended this lease further to provide for certain tenant improvements
on the leased premises to be paid for by our landlord. These improvements will provide heat to an unfinished space, provide additional
warehouse space, and create a new primary shipping and receiving facility. As a result of these three amendments and in consideration
for the landlord agreeing to pay for the cost of those certain tenant improvements, we agreed to make additional rent payments of $20,000
per month from November of 2023 through June of 2025 and a one-time additional rent payment of $248,743 in July of 2025. Because of these
modifications to the lease payments, the ROU asset and lease liability associated with the space at <b>Building 175B</b> were remeasured
as of the modification dates. Our leases include variable non-lease components. Such payments primarily include common area maintenance
charges. As of September 30, 2024, the balance of the operating lease ROU asset was $4,592,718 and the operating lease liability was $4,630,648.
As of December 31, 2023, the balance of the operating lease ROU asset was $4,571,149 and the operating lease liability was $4,721,385.
The calculated amount of the ROU asset and lease liability is impacted by the length of the lease term and the discount rate used for
the present value of the minimum lease payments. We elected not to separate lease and non-lease components for all classes of underlying
assets, and instead to account for them as a single lease component. Variable lease cost primarily represents variable payments such as
real estate taxes and common area maintenance. The following tables describe our lease costs and other lease information:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">During the Three-Month<br/> Periods Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">During the Nine-Month <br/> Periods Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>Lease Cost</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; text-indent: -10.1pt; padding-left: 0.25in">Operating lease cost</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">106,880</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">98,714</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">320,639</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">244,954</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 20.2pt">Variable lease cost</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,486</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,720</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">50,638</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">27,054</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt">Total lease cost</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">128,366</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">108,434</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">371,277</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">272,008</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Operating Lease</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt">Cash paid for operating lease liabilities</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">144,315</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">69,742</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">432,945</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">131,476</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Weighted average remaining lease term (in years)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">18.3</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">19.3</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">18.3</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">19.3</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -10.1pt; padding-left: 20.2pt">Weighted average discount rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6.6</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6.3</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6.6</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6.3</td><td style="text-align: left">%</td></tr> </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">Future lease payments required under non-cancelable
operating leases in effect as of September 30, 2024 were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Amount</b></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">During the three-month period ending December 31, 2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">144,315</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline">During the years ending December 31,</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">711,623</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">349,744</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">356,732</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">363,870</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,949,488</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total lease payments (undiscounted cash flows)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,875,772</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: imputed interest (discount effect of cash flows)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,245,124</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total operating liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,630,648</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390146097168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders&#8217; Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>13. STOCKHOLDERS&#8217; EQUITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Common Stock Issuances</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">From February of 2016 to April of 2021, we sold
the aggregate of 4,553,017 shares of common stock in six different transactions raising gross proceeds of $26,714,403 at the weighted
average price of $5.87 per share. These funds have been essential to funding our business growth plans. The details of each transaction
are discussed below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1) During February of 2016, we sold 1,123,810 shares
of common stock at a price to the public of $5.25 per share in an underwritten public offering pursuant to our effective shelf registration
statement on Form S-3, raising gross proceeds of $5,900,003 and resulting in net proceeds to the Company of $5,313,224 (after deducting
underwriting discounts and offering expenses incurred in connection with the equity financing).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2) During October of 2016, we sold, in a private
placement, 659,880 shares of common stock to nineteen institutional and accredited investors at $5.25 per share, raising gross proceeds
of $3,464,370 and resulting in net proceeds to the Company of $3,160,923 (after deducting placement agent fees and other expenses incurred
in connection with the equity financing).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3) During July of 2017, we sold 200,000 shares of
our common stock at a price of $5.25 per share in a public, registered sale to two related investors pursuant to our effective shelf registration
statement on Form S-3, raising gross proceeds of $1,050,000 and resulting in net proceeds of $1,034,164 (after deducting expenses incurred
in connection with the equity financing).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4) During December of 2017, we sold 417,807 shares
of common stock at a price to the public of $7.30 per share in an underwritten public offering pursuant to our effective shelf registration
statement on Form S-3, raising gross proceeds of $3,049,991 and resulting in net proceeds to the Company of $2,734,173 (after deducting
underwriting discounts and offering expenses incurred in connection with the equity financing).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">5) During March of 2019, we sold 1,636,364 shares
of common stock at a price to the public of $5.50 per share in an underwritten public offering pursuant to our effective shelf registration
statement on Form S-3, raising gross proceeds of $9,000,002 and resulting in net proceeds to the Company of $8,303,436 (after deducting
underwriting discounts and offering expenses incurred in connection with the equity financing).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">6) During April of 2021, we sold 515,156 shares
of our common stock at a price of $8.25 per share in a public, registered sale to seven investors pursuant to our effective shelf registration
statement on Form S-3, raising gross proceeds of $4,250,038 and resulting in net proceeds of $4,233,026 (after deducting expenses incurred
in connection with the equity financing).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At-The-Market Offering</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On April 9, 2024, our shelf registration on Form
S-3 (File No. 333-278438) relating to the offer, issuance and sale by the Company of up to $20,000,000 of securities was declared effective
by the Securities and Exchange Commission. Also on April 9, 2024, we entered into an At-The-Market Agreement (ATM Agreement) with Craig-Hallum
Capital Group LLC, pursuant to which we may offer and sell up to $11,000,000 of shares of our common stock. Legal, accounting and other
fees in the amount of $152,272 associated with the completion of the shelf registration and the ATM Agreement were initially capitalized
and then were offset against the initial proceeds received during the second quarter of 2024. As of September 30, 2024, we had sold 1,082,233
shares under the at the market offering conducted pursuant to the ATM Agreement. Net proceeds through September 30, 2024 from shares sold
pursuant to the ATM Agreement (net of the upfront legal, accounting and other fees), less sales commissions of $123,368, were $3,833,090.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stock Option Plans</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In June of 2010, our stockholders approved the 2010
Stock Option and Incentive Plan (the &#8220;2010 Plan&#8221;) pursuant to the provisions of the Internal Revenue Code of 1986, under which
employees and certain service providers may be granted options to purchase shares of the Company&#8217;s common stock at no less than
fair market value on the date of grant. At that time, 300,000 shares of common stock were reserved for issuance under the 2010 Plan and
subsequently no additional shares have been reserved for the 2010 Plan. Vesting requirements are determined by the Compensation and Stock
Option Committee of the Board of Directors on a case-by-case basis. All options granted under the 2010 Plan expire no later than 10 years
from the date of grant. The 2010 Plan expired in June of 2020, after which date no further options can be granted under the 2010 Plan.
However, options outstanding under the 2010 Plan at that time can be exercised in accordance with their terms. There were 183,500 and
188,500 options outstanding under the 2010 Plan as of September 30, 2024 and December 31, 2023, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In June of 2017, our stockholders approved the 2017
Stock Option and Incentive Plan (the &#8220;2017 Plan&#8221;) pursuant to the provisions of the Internal Revenue Code of 1986, under which
employees and certain service providers may be granted options to purchase shares of the Company&#8217;s common stock at no less than
fair market value on the date of grant. At that time, 300,000 shares of common stock were reserved for issuance under the 2017 Plan. An
amendment to the 2017 Plan increasing the number of shares reserved for issuance under the 2017 Plan from 300,000 shares to 650,000 shares
was approved by a vote of stockholders at the Annual Meeting of Stockholders in June of 2022. Vesting requirements are determined by the
Compensation and Stock Option Committee of the Board of Directors on a case-by-case basis. All options granted under the 2017 Plan expire
no later than 10 years from the date of grant. The 2017 Plan expires in March of 2027, after which date no further options can be granted
under the 2017 Plan. However, options outstanding under the 2017 Plan at that time can be exercised in accordance with their terms. As
of September 30, 2024 and December 31, 2023, there were 477,500 and 430,000 options outstanding under the 2017 Plan, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Activity under the stock option plans described
above was as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2010 Plan</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2017 Plan</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate Intrinsic Value<sup>(1)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding as of December 31, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">202,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">402,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7.19</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(661,310</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in">Grants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">122,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5.16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Terminations/forfeitures<b><sup>(2)</sup></b></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(94,500</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7.12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 10.1pt">Exercises</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">4.69</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">188,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">430,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6.82</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(1,071,121</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10.1pt">Grants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.80</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Terminations/forfeitures<b><sup>(2)</sup></b></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(25,500</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 10.1pt">Exercises</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Outstanding as of September 30, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">183,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">477,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">6.49</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">(1,891,421</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Vested as of September 30, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">183,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">136,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">6.97</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">(1,068,740</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Vested and expected to vest as of September 30, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">183,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">477,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">6.49</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">(1,891,421</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Reserved for future grants</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">154,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><sup>(1)</sup></td><td style="text-align: justify">Intrinsic value is the difference between the fair market value
of the underlying common stock as of the date indicated and as of the date of the option grant (which is equal to the option exercise
price).</td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><sup>(2)</sup></td><td style="text-align: justify">Terminations and forfeitures are recognized when they occur.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table displays additional information
about the stock option plans described above:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average <br/> Fair Value at Grant Date</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-indent: -10pt; padding-left: 10pt">Non-vested stock options as of December 31, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">337,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3.66</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7.14</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">Non-vested stock options as of September 30, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">341,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6.04</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock options granted during the nine-month period ended September 30, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.72</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.80</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Stock options that vested during the nine-month period ended September 30, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">54,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4.31</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9.73</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Stock options that were terminated or forfeited during the nine-month period ended September 30, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.36</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">No stock options were exercised during the three-month
or nine-month periods ended September 30, 2024 and 2023. The weighted average remaining life of the options outstanding under the 2010
Plan and the 2017 Plan as of September 30, 2024 was approximately 5 years. The weighted average remaining life of the options exercisable
under these plans as of September 30, 2024 was approximately 2 years and 11 months. The exercise price of the options outstanding under
these plans as of September 30, 2024, ranged from $3.60 to $10.04 per share. The 73,000 stock options granted during the nine-month period
ended September 30, 2024 had an average exercise price of $3.80 per share. The 108,000 stock options granted during the nine-month period
ended September 30, 2023 had an average exercise price of $5.19 per share. The weighted-average grant date fair values of options granted
during the nine-month periods ended September 30, 2024 and 2023 were $1.72 and $2.80 per share, respectively. As of September 30, 2024,
total unrecognized stock-based compensation related to non-vested stock options aggregated $433,317 which will be recognized over a weighted
average remaining period of approximately 1 year and 5 months. The fair value of each stock option grant has been estimated on the date
of grant using the Black-Scholes option pricing model, for the purpose discussed in Note 2(n), with the following weighted-average assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">During the Three-Month<br/> Periods Ended September 30,</td><td style="padding-bottom: 3pt; font-weight: bold"><sup>&#160;</sup></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">During the Nine-Month <br/> Periods Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 3pt; font-weight: bold"><sup>&#160;</sup></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate<sup>(1)</sup></span></td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3.48</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-119; font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="padding-bottom: 3pt; width: 1%; text-align: left"><sup>(4)</sup></td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3.70</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3.48</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend yield<sup>(2)</sup></span></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="padding-bottom: 0pt; text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility<sup>(2)</sup></span></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">52</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-120; font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="padding-bottom: 3pt; text-align: left"><sup>(4)</sup></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">51</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">54</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected life<sup>(3)</sup></span></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">4.1 years</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-121; font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="padding-bottom: 3pt; text-align: left"><sup>(4)</sup></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">4.3 years</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6.2 years</td><td style="text-align: left">&#160;</td></tr> </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><sup>&#160;</sup></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><sup>(1)</sup></td><td style="text-align: justify">The risk-free interest rate is based on U.S. Treasury yields
for a maturity approximating the expected option term.</td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><sup>(2)</sup></td><td style="text-align: justify">The dividend yield and expected volatility are derived from
averages of our historical data.</td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><sup>(3)</sup></td><td style="text-align: left">The expected life is calculated utilizing the simplified method,
which uses the mid-point between the vesting period and the contractual term as the expected life.</td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><sup>(4)</sup></td><td style="text-align: justify">These values are not applicable because <span style="-sec-ix-hidden: hidden-fact-122">no</span> stock options were
granted during this period.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Common Stock Rights Plan</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In September of 1995, our Board of Directors adopted
a Common Stock Rights Plan (the &#8220;Rights Plan&#8221;) and declared a dividend of one common share purchase right (a &#8220;Right&#8221;)
for each of the then outstanding shares of the common stock of the Company. Each Right entitles the registered holder to purchase from
the Company one share of common stock at an initial purchase price of $70.00 per share, subject to adjustment. The description and terms
of the Rights are set forth in a Rights Agreement between the Company and Equiniti Trust Company, LLC, as Rights Agent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Rights (as amended) become exercisable and transferable
apart from the common stock upon the earlier of i) 10 days following a public announcement that a person or group (Acquiring Person) has,
without the prior consent of the Continuing Directors (as such term is defined in the Rights Agreement), acquired beneficial ownership
of 20% or more of the outstanding common stock or ii) 10 days following commencement of a tender offer or exchange offer the consummation
of which would result in ownership by a person or group of 20% or more of the outstanding common stock (the earlier of such dates being
called the Distribution Date).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Upon the Distribution Date, the holder of each Right
not owned by the Acquiring Person would be entitled to purchase common stock at a discount to the initial purchase price of $70.00 per
share, effectively equal to one half of the market price of a share of common stock on the date the Acquiring Person becomes an Acquiring
Person. If, after the Distribution Date, the Company should consolidate or merge with any other entity and the Company were not the surviving
company, or, if the Company were the surviving company, all or part of the Company&#8217;s common stock were changed or exchanged into
the securities of any other entity, or if more than 50% of the Company&#8217;s assets or earning power were sold, each Right would entitle
its holder to purchase, at the Rights&#8217; then-current purchase price, a number of shares of the acquiring company&#8217;s common stock
having a market value at that time equal to twice the Right&#8217;s exercise price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">At any time after a person or group becomes an Acquiring
Person and prior to the acquisition by such person or group of 50% or more of the outstanding common stock, the Board of Directors of
the Company may exchange the Rights (other than Rights owned by such person or group which have become void), in whole or in part, at
an exchange ratio of one share of common stock per Right (subject to adjustment). At any time prior to 14 days following the date that
any person or group becomes an Acquiring Person (subject to extension by the Board of Directors), the Board of Directors of the Company
may redeem the then outstanding Rights in whole, but not in part, at a price of $0.005 per Right, subject to adjustment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">During the third quarter of 2011, our Board of
Directors voted to authorize an amendment to the Rights Plan to increase the ownership threshold for determining &#8220;Acquiring Person&#8221;
status to 20%. During the second quarter of 2015, our Board of Directors also voted to authorize an amendment to remove a provision that
prevented a new group of directors elected following the emergence of an Acquiring Person (an owner of more than 20% of our stock) from
controlling the Rights Plan by maintaining exclusive authority over the Rights Plan with pre-existing directors. We did this because such
provisions have come to be viewed with disfavor by Delaware courts. Each time that we made such amendments we entered into amendments
to the Rights Agreement with the Rights Agent reflecting such extensions, threshold increases or provision changes. No other changes have
been made to the terms of the Rights or the Rights Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">At various times over the years, our Board of
Directors, which has the authority to amend the Rights Plan, has voted to authorize amendments to the Rights Plan to extend the expiration
date of the Rights Plan. Our Board of Directors decided to seek an advisory vote by stockholders at the Annual Meeting of Stockholders
held in June of 2022, as to whether to extend the Rights Plan by one year to September 19, 2023. Of the votes actually cast on this proposal,
65% voted in favor, 32% voted against and 3% abstained. On the basis of this vote, our Board of Directors voted to extend the Rights Plan
by one year to September 19, 2023. Our Board of Directors decided to seek another advisory vote by stockholders at the Annual Meeting
of Stockholders held in June of 2023, as to whether to extend the Rights Plan by another year to September 19, 2024. Of the votes actually
cast on this proposal, 65.10% voted in favor, 34.60% voted against and 0.30% abstained. On the basis of this vote, our Board of Directors
voted to extend the Rights Plan by one year to September 19, 2024. Recognizing that there might be a substantial number of broker non-votes,
our Board of Directors disclosed that it would be guided by the votes actually cast on these proposals in deciding whether to extend the
expiration date of such plan by one year. Our Board of Directors determined not to further extend the Rights Plan because these plans
are generally considered not to be stockholder friendly. With no further extension, the Rights Plan expired as of September 19, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Authorized Common Stock</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">At the June 14, 2018 Annual Meeting of Stockholders,
our stockholders voted to approve an amendment to our Certificate of Incorporation to increase the number of shares of common stock authorized
for issuance from 8,000,000 to 11,000,000. At the June 10, 2020 Annual Meeting of Stockholders, our stockholders voted to approve an amendment
to our Certificate of Incorporation to increase the number of shares of common stock authorized for issuance from 11,000,000 to 15,000,000.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390146255040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>14. REVENUE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
primarily offer the <b>First Defense</b></span><b><span style="font-family: Symbol"><sup>&#210;</sup></span></b> <span style="font-family: Times New Roman, Times, Serif">product
line to dairy and beef producers to prevent scours in newborn calves. Generally, our products are promoted to veterinarians as well as
dairy and beef producers by our sales team and then sold through distributors. Our primary market is North America. We do sell into select
international regions and may expand this international reach in the future. There were no material changes between the allocation and
timing of revenue recognition during the three-month or nine-month periods ended September 30, 2024 or 2023. We do not have any contract
assets for which we have satisfied the performance obligations, but do not yet have the right to bill for, or contract liabilities such
as customer advances. All trade receivables on our balance sheet are from contracts with customers. We incur no material costs to obtain
contracts.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table presents our product sales disaggregated
by geographic area:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><b>&#160;</b></td><td style="white-space: nowrap; font-weight: normal; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="14" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"><b>During the Three-Month<br/>
 Periods
    Ended September 30,</b></td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: normal"><b>&#160;</b></td><td style="white-space: nowrap; font-weight: normal; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="14" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"><b>During the Nine-Month<br/>
 Periods
    Ended September 30,</b></td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: normal"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="font-weight: normal; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"><b>2024</b></td><td style="padding-bottom: 1.5pt; font-weight: normal"><b>&#160;</b></td><td style="font-weight: normal; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"><b>%</b></td><td style="padding-bottom: 1.5pt; font-weight: normal"><b>&#160;</b></td><td style="font-weight: normal; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"><b>2023</b></td><td style="padding-bottom: 1.5pt; font-weight: normal"><b>&#160;</b></td><td style="font-weight: normal; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"><b>%</b></td><td style="padding-bottom: 1.5pt; font-weight: normal"><b>&#160;</b></td><td style="font-weight: normal; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"><b>2024</b></td><td style="padding-bottom: 1.5pt; font-weight: normal"><b>&#160;</b></td><td style="font-weight: normal; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"><b>%</b></td><td style="padding-bottom: 1.5pt; font-weight: normal"><b>&#160;</b></td><td style="font-weight: normal; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"><b>2023</b></td><td style="padding-bottom: 1.5pt; font-weight: normal"><b>&#160;</b></td><td style="font-weight: normal; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"><b>%</b></td><td style="padding-bottom: 1.5pt; font-weight: normal"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; text-align: left; text-indent: -10pt; padding-left: 10pt">United States</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">5,216,401</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">87</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">4,923,265</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">91</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">16,449,178</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">88</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">11,173,686</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">90</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">795,172</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">473,235</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,292,862</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,202,022</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Total Product Sales</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,011,573</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,396,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">18,742,040</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">12,375,708</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in">The following table presents our product sales disaggregated
by major product category:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">During the Three-Month<br/> Periods Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">During the Nine-Month<br/> Periods Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt"><b>First
    Defense<span style="font-family: Times New Roman, Times, Serif"><sup>&#174;</sup> </span></b><span style="font-family: Times New Roman, Times, Serif"><span style="font-style: normal; font-weight: normal">product
    line</span></span></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">5,951,344</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">99</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">5,360,063</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">99</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">18,602,053</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">99</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">12,253,555</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">99</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Other animal health</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">60,229</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">36,437</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">139,987</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">122,153</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt">Total Product Sales</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,011,573</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,396,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">18,742,040</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">12,375,708</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390146253984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Expenses, Net<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpensesAbstract', window );"><strong>Other Expenses, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock', window );">OTHER EXPENSES, NET</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>15. OTHER EXPENSES, NET</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Other expenses net, consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>During the Three-Month  <br/>
Periods Ended September 30,</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>During the Nine-Month <br/>
Periods Ended September 30,</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest expense<sup>(1)</sup></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">144,141</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">144,616</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">432,529</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">323,177</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Loss (gain) on disposal of property, plant and equipment</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">&#8212;</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(68</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">14,557</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">8,099</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Interest income</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(18,685</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(23,696</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(41,476</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(79,134</td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insurance recoveries<sup>(2)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">&#8212;</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(365,127</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">&#8212;</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(365,127</td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Income - other</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">&#8212;</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-127">&#8212;</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-128">&#8212;</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(107</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Other expenses (income), net</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">125,456</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">(244,275</td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">405,610</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">(113,092</td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><sup>&#160;</sup></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><sup>(1)</sup></td><td style="text-align: left">Interest expense includes amortization of debt issuance and
debt discount costs of $10,805 and $8,687 during the three-month periods ended September 30, 2024 or 2023, respectively, and $31,859
and $12,525 during the nine-month periods ended September 30, 2024 and 2023, respectively.</td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0in"></td><td style="width: 0.25in; text-align: left"><sup>(2)</sup></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
income from insurance recoveries resulted from claim benefits paid to us under our business interruption policy related to product contamination
losses and a recovery from a vendor&#8217;s policy related to an equipment malfunction.</span></td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390144677392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>16. INCOME TAXES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our income tax expense aggregated $1,340 and $229
(amounting to less than 1% of our loss before income taxes) during the three-month periods ended September 30, 2024 and 2023, respectively,
and $4,020 and $3,279 (amounting to less than 1% of our loss before income taxes) during the nine-month periods ended September 30, 2024
and 2023, respectively. As of December 31, 2023, we had federal net operating loss carryforwards of $17,759,519 of which $16,047,612 do
not expire and of which $1,711,907 expire in 2034 through 2037 (if not utilized before then) and state net operating loss carryforwards
of $4,681,644 that expire in 2037 through 2038 (if not utilized before then). Additionally, we had federal general business tax credit
carryforwards of $726,474 that expire in 2028 through 2044 (if not utilized before then) and state tax credit carryforwards of $981,604
that expire in 2024 through 2042 (if not utilized before then).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The provision for income taxes is determined using
the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the estimated future tax
effects of temporary differences between book and tax treatment of assets and liabilities and carryforwards to the extent they are realizable.
During the second quarter of 2018, we assessed our historical and near-term future profitability and recorded $563,252 in non-cash income
tax expense to create a full valuation allowance against our net deferred tax assets (which consist largely of net operating loss carryforwards
and federal and state credits) based on applicable accounting standards and practices. At that time, we had incurred a net loss for six
consecutive quarters, had not been profitable on a year-to-date basis since the nine-month period ended September 30, 2017 and projected
additional net losses for some period going forward before returning to profitability. Should future profitability be realized at an adequate
level, we would be able to release this valuation allowance (resulting in a non-cash income tax benefit) and realize these deferred tax
assets before they expire. We will continue to assess the need for the valuation allowance at each quarter and, in the event that actual
results differ from these estimates, or we adjust these estimates in future periods, we may need to adjust our valuation allowance. Currently,
we adjust the valuation allowance at the end of each quarter to reduce the value of our deferred tax assets to zero.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Net operating loss carryforwards, credits, and other
tax attributes are subject to review and possible adjustment by the Internal Revenue Service. Section 382 of the Internal Revenue Code
contains provisions that could place annual limitations on the future utilization of net operating loss carryforwards and credits in the
event of a change in ownership of the Company, as defined.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We file income tax returns in the U.S. federal jurisdiction
and several state jurisdictions. We currently have no tax examinations in progress. We also have not paid additional taxes, interest or
penalties as a result of tax examinations nor do we have any unrecognized tax benefits for any of the periods in the accompanying unaudited
financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390143596832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT INFORMATION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>17. SEGMENT INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our business operations (being the development,
manufacture and sale of products that improve the health and productivity of dairy and beef cattle) are described in Note 1. Pursuant
to Codification Topic 280, <i>Segment Reporting</i>, we operate in the following two reportable business segments: i) Scours and ii) Mastitis.
The Scours segment consists of the <b>First Defense<sup>&#174;</sup></b> product line. The core technology underlying the Scours segment
is focused on polyclonal antibodies. The Mastitis segment includes our products, <b>CMT </b>and <b>Re-Tain<sup>&#174;</sup></b>. <b>Re-Tain<sup>&#174;
</sup></b>is projected to be the driver of this segment when approved for sale. The core technology underlying the Mastitis segment is
focused on a bacteriocin called Nisin. The category we define as &#8220;Other&#8221; includes unallocated administrative and overhead
expenses and other products. The significant accounting policies of these segments are described in Note 2. Product sales are the primary
factor we use in determining our reportable segments. The governing regulatory authority (Center for Veterinary Biologics, U.S. Department
of Agriculture for <b>First Defense<sup>&#174;</sup></b> or Center for Veterinary Medicine, U.S. Food and Drug Administration for <b>Re-Tain<sup>&#174;</sup></b>)
is also a factor in determining our reportable segments. Management monitors and evaluates segment performance from sales to net operating
income (loss) closely. We are not organized by geographic region. No segments have been aggregated. The revenues and expenses allocated
to each segment are in some cases direct and in other cases involve reasonable and consistent estimations by management. Each operating
segment is defined as the component of our business for which financial information is available and evaluated regularly by our chief
operating decision-maker in deciding how to allocate resources and in assessing performance. Our chief operating decision-maker is our
President and CEO.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">During the Three-Month <br/>
Period Ended
    September 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Scours</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Mastitis</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Other</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">Product sales</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,951,344</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">60,229</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,011,573</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Costs of goods sold</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,364,950</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">63,069</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,428,019</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt">Gross margin</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,586,394</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,840</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,583,554</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Product development expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">59,140</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">690,052</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36,944</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">786,136</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Sales and marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">699,584</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">144,461</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">844,045</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt">Administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-133">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-134">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">528,267</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">528,267</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">758,724</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">834,513</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">565,211</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,158,448</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt">NET OPERATING INCOME (LOSS)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">827,670</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(837,353</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(565,211</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(574,894</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>During the Three-Month <br/>
Period Ended
                                                                                                                                                                                    September 30, 2023</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Scours</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Mastitis</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Other</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">Product sales</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,360,063</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">36,437</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-135">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,396,500</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Costs of goods sold</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,095,164</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">34,455</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-136">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,129,619</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt">Gross margin</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,264,899</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,982</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-137">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,266,881</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Product development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-138">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,082,346</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36,143</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,118,489</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Sales and marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">641,682</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">175,804</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-139">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">817,486</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt">Administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-140">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-141">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">514,952</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">514,952</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 20.2pt">Operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">641,682</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,258,150</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">551,095</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,450,927</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt">NET OPERATING INCOME (LOSS)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">623,217</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,256,168</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(551,095</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,184,046</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Scours</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Mastitis</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Other</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -10pt; padding-left: 10pt">Total Assets as of September 30, 2024</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">23,672,583</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">16,798,955</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">3,977,335</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">44,448,873</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">Total Assets as of September 30, 2023</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">24,119,683</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">18,132,922</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">2,292,417</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">44,545,022</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Depreciation and amortization expense during the three-month period ended September 30, 2024</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">346,430</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">319,815</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">19,682</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">685,927</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Depreciation and amortization expense during the three-month period ended September 30, 2023</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">355,673</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">328,381</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">25,044</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">709,098</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt">Capital Expenditures during the three-month period ended September 30, 2024</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">87,286</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">1,126</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-142">&#8212;</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">88,412</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt">Capital Expenditures during the three-month period ended September 30, 2023</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">341,386</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">79,129</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-143">&#8212;</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">420,515</td>
    <td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">During the Nine-Month<br/>
 Period Ended
    September 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Scours</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Mastitis</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Other</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">Product sales</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">18,602,054</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">139,986</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-144">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">18,742,040</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Costs of goods sold</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,487,348</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">145,294</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-145">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,632,642</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt">Gross margin</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,114,706</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,308</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-146">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,109,398</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Product development expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">154,233</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,821,525</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">103,431</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,079,189</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Sales and marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,224,836</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">405,089</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-147">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,629,925</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt">Administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-148">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-149">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,661,838</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,661,838</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10.1pt">Operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,379,069</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,226,614</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,765,269</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,370,952</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt">NET OPERATING INCOME (LOSS)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,735,637</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(3,231,922</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,765,269</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(2,261,554</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>During the Nine-Month<br/>
 Period Ended
                                                                                                                                                                                    September 30, 2023</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Scours</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Mastitis</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Other</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">Product sales</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">12,253,555</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">122,153</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-150">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">12,375,708</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Costs of goods sold</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,652,292</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">111,872</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-151">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,764,164</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt">Gross margin</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,601,263</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,281</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-152">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,611,544</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Product development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,543</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,220,075</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">105,779</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,328,397</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Sales and marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,890,404</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">526,297</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-153">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,416,701</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt">Administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-154">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-155">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,611,026</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,611,026</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 20.2pt">Operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,892,947</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,746,372</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,716,805</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,356,124</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt">NET OPERATING INCOME (LOSS)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">708,316</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(3,736,091</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,716,805</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(4,744,580</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Scours</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Mastitis</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Other</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -10pt; padding-left: 10pt">Total Assets as of September 30, 2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">23,672,583</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">16,798,955</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,977,335</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">44,448,873</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">Total Assets as of September 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">24,119,683</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">18,132,922</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,292,417</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">44,545,022</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Depreciation and amortization expense during the nine-month period ended September 30, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,027,711</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">958,260</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">59,221</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,045,192</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Depreciation and amortization expense during the nine-month period ended September 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,020,909</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">969,666</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">64,066</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,054,641</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt">Capital Expenditures during the nine-month period ended September 30, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">235,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">33,909</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-156">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">269,509</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt">Capital Expenditures during the nine-month period ended September 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,038,033</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">773,136</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-157">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,811,169</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">During the Year Ended December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Scours</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Mastitis</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Other</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">Product sales</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">17,293,933</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">177,736</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-158">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">17,471,669</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Costs of goods sold</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,453,514</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">148,871</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-159">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,602,385</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt">Gross margin</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,840,419</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,865</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-160">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,869,284</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Product development expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,103</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,242,329</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">141,420</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,394,852</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Sales and marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,447,137</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">641,078</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-161">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,088,215</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt">Administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-162">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-163">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,134,295</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,134,295</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10.1pt">Operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,458,240</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,883,407</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,275,715</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,617,362</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt">NET OPERATING INCOME (LOSS)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,382,179</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(4,854,542</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(2,275,715</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(5,748,078</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>During the Year Ended December 31, 2022</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Scours</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Mastitis</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Other</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">Product sales</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">18,411,949</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">154,558</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,455</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">18,567,962</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Costs of goods sold</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,754,189</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">136,347</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">28,647</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,919,183</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt">Gross margin</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,657,760</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,211</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(27,192</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,648,779</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Product development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66,346</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,317,921</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">109,605</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,493,872</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Sales and marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,871,926</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,318,107</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-164">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,190,033</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt">Administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-165">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-166">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,263,817</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,263,817</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 20.2pt">Operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,938,272</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,636,028</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,373,422</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,947,722</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt">NET OPERATING INCOME (LOSS)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,719,488</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(5,617,817</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(2,400,614</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(2,298,943</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Scours</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Mastitis</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Other</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -10pt; padding-left: 10pt">Total Assets as of December 31, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">24,735,413</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">17,827,839</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,244,850</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">43,808,102</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">Total Assets as of December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">20,539,523</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">18,315,492</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6,005,634</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">44,860,649</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Depreciation and amortization expense during the year ended December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,365,988</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,287,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">86,032</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,739,620</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Depreciation and amortization expense during the year ended December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,169,011</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,263,318</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">62,912</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,495,241</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Capital Expenditures during the year ended December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,096,819</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">795,694</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-167">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,892,513</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Capital Expenditures during the year ended December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,497,834</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">429,988</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">47,452</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,975,274</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390227757120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>18. RELATED PARTY TRANSACTIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">David
S. Tomsche (Chair of our Board of Directors) is a controlling owner of Leedstone Inc., a domestic distributor of our products (the <b>First
Defense</b></span><b><span style="font-family: Symbol"><sup>&#210;</sup> </span></b><span style="font-family: Times New Roman, Times, Serif">product
line and <b>CMT</b>). His affiliated company purchased $390,322 and $128,521 of products from us during the nine-month periods ended
September 30, 2024 and 2023, respectively, all on terms consistent with those offered to other distributors of similar status. Our accounts
receivable (subject to standard and customary payment terms) due from this affiliated company aggregated $35,364 and $42,507 as of September
30, 2024 and December 31, 2023, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390146965856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Employee Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">EMPLOYEE BENEFITS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>19. EMPLOYEE BENEFITS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have a 401(k) savings plan (the Plan) in which
all employees completing one month of service with the Company are eligible to participate. Participants may contribute up to the maximum
amount allowed by the Internal Revenue Service. We currently match 100% of the first 3% of each employee&#8217;s salary that is contributed
to the Plan and 50% of the next 2% of each employee&#8217;s salary that is contributed to the Plan. Under this matching plan, we paid
$55,989 and $50,126 into the Plan for the three-month periods ended September 30, 2024 and 2023, respectively, and $159,504 and $135,698
for the nine-month periods ended September 30, 2024 and 2023, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/710/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/712/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390238080592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>20. SUBSEQUENT EVENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have evaluated subsequent events through the
time of filing on the date we have issued this Quarterly Report on Form 10-Q. Subsequent to September 30, 2024 and through October 30,
2024, we sold an additional 78,492 shares raising an additional $289,719 in gross proceeds pursuant to the at the market offering conducted
pursuant to the ATM Agreement. See Note 13. As of the time of filing, there were no other material, reportable subsequent events.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390146674992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (701,690)<span></span>
</td>
<td class="num">$ (940,000)<span></span>
</td>
<td class="num">$ (2,671,184)<span></span>
</td>
<td class="num">$ (4,634,767)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390143583712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390145953376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(a) Basis of Presentation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have prepared the accompanying unaudited financial
statements reflecting all adjustments (which are of a normal recurring nature) that are, in our opinion, necessary in order to ensure
that the financial statements are not misleading. We follow accounting standards set by the Financial Accounting Standards Board (FASB).
The FASB sets Generally Accepted Accounting Principles (GAAP) that we follow to ensure we accurately report our financial condition, results
of operations, earnings per share and cash flows. References to GAAP in these footnotes are to the FASB <i>Accounting Standards Codification</i>&#8482;
(Codification). We believe that the disclosures are adequate to ensure that the information presented is not misleading.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(b) Cash and Cash Equivalents</b> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We consider all highly liquid investment instruments
that mature within three months of their purchase dates to be cash equivalents. Cash equivalents are principally invested in securities
backed by the U.S. government. We hold no cash or cash equivalents in excess of Federal Deposit Insurance Corporation (FDIC) limits of
$250,000 per financial institution per depositor. See Note 3.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Trade Accounts Receivable</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(c) Trade Accounts Receivable</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Accounts receivable are carried at the original
invoice amount less an estimate made for doubtful collection when applicable. Management determines the allowance for doubtful accounts
on a monthly basis by identifying troubled accounts and by using historical experience applied to an aging of accounts and other relevant
factors. Accounts receivable are considered to be past due if a portion of the receivable balance is outstanding for more than 30 days.
Past due accounts receivable are subject to an interest charge. It was not necessary to charge interest on past due accounts during the
nine-month periods ended September 30, 2024 or 2023 because the time past due was not significant, and there was no accrual for such interest
charges as of September 30, 2024 or December 31, 2023. Accounts receivable are written off when deemed uncollectible. No accounts receivable
were written off during the nine-month periods ended September 30, 2024 or 2023. Recoveries of accounts receivable previously written
off are recorded as income when received. No such recoveries were recorded during the nine-month periods ended September 30, 2024 or 2023.
As of September 30, 2024 and December 31, 2023, we determined that no allowance for doubtful accounts was necessary. See Note 4.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(d) Inventory</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Inventory includes raw materials, work-in-process
and finished goods and is recorded at the lower of cost, on the first-in, first-out method, or net realizable value (determined as the
estimated selling price in the normal course of business, less reasonably predictable costs of completion, disposal and transportation).
Work-in-process and finished goods inventories include materials, labor and manufacturing overhead. At each balance sheet date, we evaluate
our ending inventories for excess quantities and obsolescence. Inventories that we consider excess or obsolete are written down to estimated
net realizable value. Once inventory is written down and a new cost basis is established, it is not written back up. We believe that supplies
and raw materials for the production of our products are available from more than one vendor or farm. Our policy is to maintain more than
one source of supply for the components used in our products when feasible. See Note 5.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, net</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(e) Property, Plant and Equipment, net</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We depreciate property, plant and equipment on the
straight-line method by charges to operations and costs of goods sold in amounts estimated to expense the cost of the assets from the
date they are first put into service to the end of the estimated useful lives of the assets. The facility we have constructed at 33 Caddie
Lane to produce the Nisin Drug Substance (DS) for <b>Re-Tain<sup>&#174;</sup></b> (<b>Building 33</b>) is being depreciated over 39 years
from when a Certificate of Occupancy was issued during the fourth quarter of 2017. We began depreciating the equipment for our Nisin DS
facility when it was placed in service during the third quarter of 2018. Approximately 86% of these assets are being depreciated over
10 years. We began depreciating the leasehold improvements to our new <b>First Defense<sup>&#174; </sup></b>production facility at 175
Industrial Way (<b>Building 175A</b>) over the remainder of the 10-year lease term beginning when a Certificate of Occupancy was issued
during the second quarter of 2020. During August of 2022, this lease term was extended to January of 2043 in connection with a new lease
covering additional space at 175 Industrial Way (<b>Building 175B</b>). As a result, the net book value of these leasehold improvements
as of August 31, 2022 is now being depreciated over the remainder of the extended lease term. Significant repairs to property, plant and
equipment that benefit more than a current period are capitalized and depreciated over their useful lives. Insignificant repairs are expensed
when incurred. See Notes 2(h) and 7 for additional information.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Operating Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(f) Operating Leases</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We account for our real estate leases using a right-of-use
model, which recognizes that at the date of commencement, a lessee has a financial obligation to make lease payments to the lessor for
the right to use the underlying asset during the lease term and recognizes a corresponding right-of-use (ROU) asset related to this right.
ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the future lease payments
over the expected lease term. The ROU asset is also adjusted for any lease prepayments made, lease incentives received and initial direct
costs incurred. For operating leases with lease payments that fluctuate over the lease term, the total lease costs are recognized on a
straight-line basis over the lease term. Our leases, at times, may include options to extend the term of the lease. When it is reasonably
certain that we will exercise the option, we include the impact of the option in the lease term for purposes of determining future lease
payments. For all underlying classes of assets, we made an accounting policy election to not recognize assets or liabilities for leases
with a term of twelve months or less and to account for all components in a lease arrangement as a single combined lease component. Short-term
lease payments are recognized on a straight-line basis. Certain of our lease agreements include variable rent payments, consisting primarily
of amounts paid to the lessor based on cost or consumption, such as maintenance and real estate taxes. These costs are recognized in the
period in which the obligation is incurred. Because our leases do not specify an implicit rate, we use an incremental borrowing rate based
on information available at the lease commencement date to determine the present value of the lease payments. We evaluate our ROU asset
for impairment when events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. See Notes
2(h) and 12 for additional information.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(g) Intangible Assets and Goodwill</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We amortize intangible assets on the straight-line
method by charges to costs of goods sold in amounts estimated to expense the cost of the assets from the date they are first put into
service to the end of the estimated useful lives of the assets. We have recorded intangible assets related to customer relationships,
non-compete agreements and developed technology, each with defined useful lives. Amounts paid in excess of the fair value of the net assets
(including tax attributes) are recorded as goodwill under the acquisition method of accounting. We assess the impairment of intangible
assets that have indefinite lives (when applicable) and goodwill (at the reporting unit level) on an annual basis (as of December 31<sup>st</sup>)
and whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. We would record
an impairment charge if such an assessment were to indicate that the fair value of such assets was less than the carrying value. Judgment
is required in determining whether an event has occurred that may impair the value of goodwill or identifiable intangible assets. Factors
that could indicate that an impairment may exist include significant under-performance relative to plan or long-term projections, significant
changes in business strategy and significant negative industry or economic trends. Although we believe intangible assets and goodwill
are properly stated in the accompanying financial statements, changes in strategy or market conditions could significantly impact these
judgments and require an adjustment to the recorded balance in the future. <span style="-sec-ix-hidden: hidden-fact-50"><span style="-sec-ix-hidden: hidden-fact-51">No</span></span> goodwill impairments were recorded during the nine-month
periods ended September 30, 2024 or 2023. See Notes 2(h) and 8 for additional information.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Valuation of Long-Lived Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>(h) Valuation of Long-Lived Assets</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We periodically evaluate our long-lived assets,
consisting principally of property, plant and equipment, operating lease right-of-use asset and amortizable intangible assets, for potential
impairment. In accordance with the applicable accounting guidance for the treatment of long-lived assets, we review the carrying value
of our long-lived assets or asset group that is held and used, including intangible assets subject to amortization, for impairment whenever
events and circumstances indicate that the carrying value of the assets may not be recoverable. Under the held for use approach, the asset
or asset group to be tested for impairment should represent the lowest level for which identifiable cash flows are largely independent
of the cash flows of other groups of assets and liabilities. <span style="-sec-ix-hidden: hidden-fact-52"><span style="-sec-ix-hidden: hidden-fact-53">No</span></span> impairment was recognized during the nine-month periods ended September
30, 2024 or 2023.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>(i) Fair Value Measurements</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In determining fair value measurements, we follow
the provisions of Codification Topic 820, <i>Fair Value Measurements and Disclosures</i>. Codification Topic 820 defines fair value,
establishes a framework for measuring fair value under GAAP and enhances disclosures about fair value measurements. The topic provides
a consistent definition of fair value which focuses on an exit price, which is the price that would be received to sell an asset or paid
to transfer a liability in an orderly transaction between market participants at the measurement date. The topic also prioritizes, within
the measurement of fair value, the use of market-based information over entity-specific information and establishes a three-level hierarchy
for fair value measurements based on the nature of inputs used in the valuation of an asset or liability as of the measurement date.
As of September 30, 2024 and December 31, 2023, the carrying amounts of cash and cash equivalents, accounts receivable, inventory, prepaid
expenses and other current assets, other assets, accounts payable and accrued expenses approximate fair value because of their short-term
nature. The amount outstanding under our bank debt facilities is measured at carrying value in our accompanying balance sheets. Our bank
debt facilities are valued using Level 2 inputs. The three-level hierarchy is as follows:</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.5in; text-align: left">Level 1</td>
    <td style="text-align: center; width: 0.25in">&#8212;</td><td style="text-align: left">  Pricing inputs are quoted prices available in active
markets for identical assets or liabilities as of the measurement date.</td>
</tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.5in; text-align: left">Level 2</td>
    <td style="text-align: center; width: 0.25in">&#8212;</td>
    <td style="text-align: left">Pricing inputs are quoted
prices for similar assets or liabilities, or inputs that are observable, either directly or indirectly, for substantially the full term
through corroboration with observable market data.</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.5in; text-align: left">Level 3</td>
    <td style="text-align: center; width: 0.25in">&#8212;</td>
    <td style="text-align: left">Pricing inputs are unobservable
for the assets or liabilities, that is, inputs that reflect the reporting entity&#8217;s own assumptions about the assumptions market
participants would use in pricing the asset or liability.</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -43.9pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In certain cases, the inputs used to measure fair
value may fall into different levels of the fair value hierarchy. In such cases, the level of an asset or liability within the fair value
hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance
of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the investment.
We also hold money market accounts in our bank account, which are classified as cash equivalents and measured at fair value. The fair
value of these investments is based on their closing published net asset value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We assess the levels of the investments at each
measurement date, and transfers between levels are recognized on the actual date of the event or change in circumstances that caused the
transfer in accordance with our accounting policy regarding the recognition of transfers between levels of the fair value hierarchy. During
the nine-month periods ended September 30, 2024 and 2023, there were no transfers between levels. As of September 30, 2024 and December
31, 2023, our Level 1 assets measured at fair value by quoted prices in active markets consisted of cash and money market accounts. There
were no assets or liabilities measured at fair value on a nonrecurring basis as of September 30, 2024 or December 31, 2023. The carrying
values of our cash and money market accounts as of September 30, 2024 and December 31, 2023 approximated their fair market values. Due
to inflation and the changing interest rate environment, the carrying values of our fixed rate bank debt as of September 30, 2024 and
December 31, 2023 differed from their fair market values. These values are reflected in the following tables:</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 0.25in">Cash and money market accounts</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">3,808,633</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">&#8212;</div></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">&#8212;</div></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">3,808,633</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 20pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt">Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Bank debt</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,703,821</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,703,821</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Cash and money market accounts</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">978,741</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">&#8212;</div></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">&#8212;</div></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">978,741</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 20pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt">Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Bank debt</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,431,817</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,431,817</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Risk</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(j) Concentration of Risk</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Concentration of credit risk with respect to
accounts receivable is principally limited to certain customers to whom we make substantial sales. To reduce risk, we routinely assess
the financial strength of our customers and, as a consequence, believe that our accounts receivable credit risk exposure is limited. We
maintain an allowance for potential credit losses when deemed necessary, but historically we have not experienced significant credit losses
related to an individual customer or groups of customers in any particular industry or geographic area. Sales to significant customers
that amounted to 10% or more of total product sales are detailed in the following table:</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>During
the Three-Month <br/>
Periods Ended September 30,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>During
the Nine-Month<br/>
Periods Ended September 30,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">Company A</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">43</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">50</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">44</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">48</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Company B</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31</td><td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Trade accounts receivable due from significant
customers that amounted to 10% or more of our total trade accounts receivable are detailed in the following table:</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>As of <br/>
 September 30, 2024</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>As of  <br/>
December 31, 2023</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Company A</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">37</td>
    <td style="width: 1%; text-align: left">%</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">43</td>
    <td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Company B</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">34</td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">36</td>
    <td style="text-align: left">%</td></tr>
  </table><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(k) Revenue Recognition</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We recognize revenue in accordance with Codification
Topic 606, <i>Revenue from Contracts with Customers (ASC 606)</i>. ASC 606 is a single comprehensive model for companies to use in accounting
for revenue arising from contracts with customers. The core principle is that we recognize the amount of revenue to which we expect to
be entitled for the transfer of promised goods or services to customers when a customer obtains control of promised goods or services
in an amount that reflects the consideration we expect to receive in exchange for those goods or services. In addition, the standard requires
disclosure of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. We conduct our
business with customers through valid purchase orders or sales orders which are considered contracts and are not interdependent on one
another. A performance obligation is a promise in a contract to transfer a distinct product to the customer. The transaction price is
the amount of consideration we expect to receive under the arrangement. Revenue is measured based on consideration specified in a contract
with a customer. The transaction price of a contract is allocated to each distinct performance obligation and recognized when or as the
customer receives the benefit of the performance obligation. Product transaction prices on a purchase or sales order are discrete and
stand-alone. We recognize revenue when we satisfy a performance obligation in a contract by transferring control over a product to a customer
when product ships to a customer. Amounts due are typically paid approximately 30 days from the time control is transferred. Shipping
and handling costs associated with outbound freight are accounted for as a fulfillment cost in costs of goods sold. We do not bill for
or collect sales tax because our sales are generally made to distributors and thus our sales to them are not subject to sales tax. We
generally have experienced an immaterial amount of product returns. See Note 14 for additional information.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_ExpenseRecognitionPolicyTextBlock', window );">Expense Recognition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(l) Expense Recognition</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We do not incur costs in connection with product
sales to customers that are eligible for capitalization. Advertising costs are expensed when incurred, which is generally during the month
in which the advertisement is published. All product development expenses are expensed as incurred, as are all related patent costs. We
capitalize costs to produce inventory during the production cycle, and these costs are charged to costs of goods sold when the inventory
is sold to a customer or is deemed to be in excess or obsolete.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>(m) Income Taxes </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We account for income taxes in accordance with
Codification Topic 740, <i>Income Taxes</i>, which requires that we recognize a current tax liability or asset for current taxes payable
or refundable and a deferred tax liability or asset for the estimated future tax effects of temporary differences and carryforwards to
the extent they are realizable. We consider future taxable income and feasible tax planning strategies in assessing the need for a valuation
allowance against our deferred tax assets at the end of each quarter. If we determine that it is more likely than not that we will realize
our deferred tax assets in the future in excess of the net recorded amount over a reasonably short period of time, a reduction of the
valuation allowance would increase income in the period such determination was made. Likewise, if we determine that it is more likely
than not that we will not realize all or part of our net deferred tax asset in the future, an increase to the valuation allowance would
be charged to income in the period such determination was made.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Codification Topic 740-10 clarifies the accounting
for income taxes by prescribing a minimum recognition threshold that a tax position must meet before being recognized in the financial
statements. In the ordinary course of business, there are transactions and calculations where the ultimate tax outcome is uncertain. In
addition, we are subject to periodic audits and examinations by the Internal Revenue Service and other taxing authorities. With few exceptions,
we are no longer subject to income tax examinations by tax authorities for years before 2021. We have evaluated the positions taken on
our filed tax returns and have concluded that no uncertain tax positions existed as of September 30, 2024 or December 31, 2023. Although
we believe that our estimates are reasonable, actual results could differ from these estimates. See Note 16.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(n) Stock-Based Compensation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We account for stock-based compensation in accordance
with Codification Topic 718, <i>Compensation-Stock Compensation</i>, which generally requires us to recognize non-cash compensation expense
for stock-based payments using the fair-value-based method. The fair value of each stock option grant has been estimated on the date of
grant using the Black-Scholes option pricing model. Accordingly, we recorded compensation expense pertaining to stock-based compensation
of $77,557 and $96,434 during the three-month periods ended September 30, 2024 and 2023, respectively, and $256,688 and $268,207 during
the nine-month periods ended September 30, 2024 and 2023, respectively. See Note 13.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(o) Net Loss Per Common Share</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Net loss per common share has been computed in
accordance with Codification Topic 260-10, <i>Earnings Per Share</i>. The net loss per share has been computed by dividing the net loss
by the weighted average number of common shares outstanding during the period. All stock options have been excluded from the denominator
in the calculation of dilutive earnings per share when we are in a loss position because their inclusion would be anti-dilutive. Outstanding
stock options that were not included in this calculation because the effect would be anti-dilutive amounted to 661,000 and 616,500 during
the three-month periods ended September 30, 2024 and 2023, respectively, and 661,000 and 616,500 during the nine-month periods ended September
30, 2024 and 2023, respectively.</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>During the Three-Month <br/>
Periods Ended September 30, </b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>During the Nine-Month  <br/>
Periods Ended September 30, </b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Net loss attributable to stockholders</td>
    <td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="width: 9%; border-bottom: Black 4pt double; text-align: right">(701,690</td>
    <td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="width: 9%; border-bottom: Black 4pt double; text-align: right">(940,000</td>
    <td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="width: 9%; border-bottom: Black 4pt double; text-align: right">(2,671,184</td>
    <td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="width: 9%; border-bottom: Black 4pt double; text-align: right">(4,634,767</td>
    <td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Weighted average common shares outstanding - Basic</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">8,164,423</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">7,746,864</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">7,908,425</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">7,746,864</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Dilutive impact of share-based compensation awards</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">&#8212;</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">&#8212;</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">&#8212;</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">&#8212;</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Weighted average common shares outstanding - Diluted</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">8,164,423</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">7,746,864</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">7,908,425</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">7,746,864</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Net loss per share:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">Basic</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(0.09</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(0.12</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(0.34</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(0.60</td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">Diluted</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(0.09</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(0.12</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(0.34</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(0.60</td>
    <td style="text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(p) Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The <span style="font-family: Times New Roman, Times, Serif">preparation
of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported
amounts of revenues and expenses during the period. Although we regularly assess these estimates, actual amounts could differ from those
estimates and are subject to change in the near term. Changes in estimates are recorded during the period in which they become known.
Significant estimates include our valuation of inventory, deferred tax assets and costs of goods sold</span>.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(q) New Accounting Pronouncements Not Yet Adopted</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In November of 2023, the FASB issued ASU 2023-07,
<i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,</i> which is intended to improve reportable segment
disclosure requirements, primarily through enhanced disclosures about significant expenses. The amendments will require disclosure of
significant segment expenses that are regularly provided to our chief operating decision-maker and included within segment profit and
loss. The amendments are effective for annual periods beginning after December 15, 2023, and interim periods beginning after December
15, 2024, with early adoption permitted, and will be applied retrospectively to all prior periods presented in the financial statements.
We are currently evaluating ASU 2023-07 to determine its impact on our financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In December of 2023, the FASB issued ASU 2023-09<i>,
Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>, which includes amendments that further enhance income tax disclosures,
primarily through standardization and disaggregation of income tax rate reconciliation categories and income taxes paid by jurisdiction.
The amendments are effective for annual periods beginning after December 15, 2024, with early adoption permitted, and may be applied either
prospectively or retrospectively. We are currently evaluating ASU 2023-09 to determine its impact on our financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_ExpenseRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entire disclosure of accounting policy for expense recognition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_ExpenseRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390238018080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock', window );">Schedule of Assets or Liabilities Measured at Fair Value on a Nonrecurring Basis</a></td>
<td class="text">These values are reflected in the following tables:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 0.25in">Cash and money market accounts</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">3,808,633</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">&#8212;</div></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">&#8212;</div></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">3,808,633</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 20pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt">Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Bank debt</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,703,821</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,703,821</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Cash and money market accounts</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">978,741</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">&#8212;</div></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">&#8212;</div></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">978,741</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 20pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt">Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Bank debt</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,431,817</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,431,817</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Concentration of Risk</a></td>
<td class="text">Sales to significant customers
that amounted to 10% or more of total product sales are detailed in the following table:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>During
the Three-Month <br/>
Periods Ended September 30,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>During
the Nine-Month<br/>
Periods Ended September 30,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">Company A</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">43</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">50</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">44</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">48</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Company B</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31</td><td style="text-align: left">%</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>As of <br/>
 September 30, 2024</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>As of  <br/>
December 31, 2023</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Company A</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">37</td>
    <td style="width: 1%; text-align: left">%</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">43</td>
    <td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Company B</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">34</td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">36</td>
    <td style="text-align: left">%</td></tr>
  </table><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Net Income (Loss) Per Common Share</a></td>
<td class="text">Outstanding
stock options that were not included in this calculation because the effect would be anti-dilutive amounted to 661,000 and 616,500 during
the three-month periods ended September 30, 2024 and 2023, respectively, and 661,000 and 616,500 during the nine-month periods ended September
30, 2024 and 2023, respectively.<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>During the Three-Month <br/>
Periods Ended September 30, </b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>During the Nine-Month  <br/>
Periods Ended September 30, </b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Net loss attributable to stockholders</td>
    <td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="width: 9%; border-bottom: Black 4pt double; text-align: right">(701,690</td>
    <td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="width: 9%; border-bottom: Black 4pt double; text-align: right">(940,000</td>
    <td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="width: 9%; border-bottom: Black 4pt double; text-align: right">(2,671,184</td>
    <td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="width: 9%; border-bottom: Black 4pt double; text-align: right">(4,634,767</td>
    <td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Weighted average common shares outstanding - Basic</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">8,164,423</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">7,746,864</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">7,908,425</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">7,746,864</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Dilutive impact of share-based compensation awards</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">&#8212;</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">&#8212;</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">&#8212;</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">&#8212;</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Weighted average common shares outstanding - Diluted</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">8,164,423</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">7,746,864</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">7,908,425</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">7,746,864</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Net loss per share:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">Basic</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(0.09</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(0.12</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(0.34</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(0.60</td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">Diluted</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(0.09</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(0.12</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(0.34</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(0.60</td>
    <td style="text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities by class, including financial instruments measured at fair value that are classified in shareholders' equity, if any, that are measured at fair value on a nonrecurring basis in periods after initial recognition (for example, impaired assets). Disclosures may include, but are not limited to: (a) the fair value measurements recorded and the reasons for the measurements and (b) the level within the fair value hierarchy in which the fair value measurements are categorized in their entirety (levels 1, 2, 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-16<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390227719408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text">Inventory consisted of the following:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of <br/> September 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of <br/> December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Raw materials</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,313,766</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,594,028</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">Work-in-process</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,124,394</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,815,194</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Finished goods</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,292</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">402,619</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,460,452</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,811,841</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390227756384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expenses and Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text">Prepaid expenses and other current assets consisted
of the following:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of <br/> September 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<br/> December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Prepaid expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">277,146</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">454,152</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Other receivables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">33,342</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">39,733</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">310,488</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">493,885</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390146693152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, Plant and Equipment</a></td>
<td class="text">Property, plant and equipment consisted of the
following:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Estimated Useful Lives <br/> (in years)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<br/> September 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<br/> December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt">Laboratory and manufacturing equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">3-10</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">21,183,888</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">20,953,601</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Buildings and improvements</td><td>&#160;</td>
    <td style="text-align: center">10-39</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,858,708</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,784,565</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: center">3-10</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,053,436</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,036,374</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Construction in progress</td><td>&#160;</td>
    <td style="text-align: center"><div style="-sec-ix-hidden: hidden-fact-54">n/a</div></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,588,630</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,768,224</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Land</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt"><div style="-sec-ix-hidden: hidden-fact-55">n/a</div></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">516,867</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">516,867</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Property, plant and equipment, gross</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46,201,529</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46,059,631</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(20,381,196</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(18,483,948</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Property, plant and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">25,820,333</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">27,575,683</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390227691200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets</a></td>
<td class="text">Intangible assets as of September 30, 2024 consisted
of the following:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Gross Carrying<br/>
 Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Accumulated<br/>
 Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Net Book<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt">Developed technology</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">184,100</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(161,087</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">23,013</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Customer relationships</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,138</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">162</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Non-compete agreements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,640</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,935</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">705</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 0.25in">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">191,040</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(167,160</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">23,880</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>Intangible assets as of December 31, 2023 consisted
of the following:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Gross Carrying<br/>
 Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Accumulated<br/>
 Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Net Book<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt">Developed technology</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">184,100</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(147,280</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">36,820</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Customer relationships</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,040</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">260</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Non-compete agreements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,640</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,512</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,128</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">191,040</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(152,832</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">38,208</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390149993136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accounts Payable and Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Expenses</a></td>
<td class="text">Accounts payable and accrued expenses consisted
of the following:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<br/> September 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<br/> December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Accounts payable &#8211; trade</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">876,836</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">874,558</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Accounts payable &#8211; capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,378</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,175</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Accrued payroll</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,142,318</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">942,999</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Accrued professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">101,725</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">97,800</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Accrued other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">376,112</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">192,754</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Income tax payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,166</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,051</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,504,535</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,124,337</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390146115168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Bank Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Bank Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Debt Proceeds Received and Principal Repayments</a></td>
<td class="text">Debt proceeds received and principal repayments
made (excluding our $1,000,000 line of credit) are reflected by loan during the periods as described in the tables below:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>During the Three-Month <br/>
</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Period Ended September 30, 2024</b></p></td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>During
the Three-Month <br/>
Period Ended September 30, 2023</b></p></td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Proceeds&#160;from<br/>
 Debt Issuance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Debt&#160;Principal<br/>
 Repayments</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Proceeds&#160;from <br/>
Debt Issuance</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Debt&#160;Principal<br/>
 Repayments</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -10pt; padding-left: 10pt">Loan #1</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">57,671</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">55,619</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">Loan #2</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">128,534</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">124,020</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Loan #3</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,173</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,002</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">Loan #4</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53,505</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51,622</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt">Loan #5</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,719</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,909</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt">Loan #6</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">59,191</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36,582</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt">Loan #7</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">28,456</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,000,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,983</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">368,249</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,000,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">325,737</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>During the Nine-Month </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Period Ended September 30, 2024</b></p></td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>During the Nine-Month </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Period Ended September 30, 2023</b></p></td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Proceeds&#160;from<br/>
 Debt Issuance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Debt&#160;Principal<br/>
 Repayments</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Proceeds&#160;from <br/>
Debt Issuance</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Debt&#160;Principal<br/>
 Repayments</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -10pt; padding-left: 10pt">Loan #1</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">172,017</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">166,527</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">Loan #2</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">382,324</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">369,154</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Loan #3</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71,629</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68,156</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">Loan #4</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">159,171</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">153,704</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt">Loan #5</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49,542</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,909</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt">Loan #6</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">174,804</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36,582</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt">Loan #7</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">84,619</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,000,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,983</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,094,106</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,000,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">829,015</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>During the Year<br/>
 Ended December 31,
                                                                                 2023</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>During
the Year<br/>
 Ended December 31, 2022</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Proceeds&#160;from<br/>
 Debt Issuance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Debt&#160;Principal<br/>
 Repayments</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Proceeds&#160;from <br/>
Debt Issuance</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Debt&#160;Principal<br/>
 Repayments</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -10pt; padding-left: 10pt">Loan #1</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">223,222</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,000,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">199,013</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">Loan #2</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">494,455</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">477,237</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Loan #3</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">91,446</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,160</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">Loan #4</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">205,884</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">198,715</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt">Loan #5</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,017</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt">Loan #6</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">93,054</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt">Loan #7</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,000,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">45,696</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,000,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,185,774</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,000,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">897,125</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Principal Payments Bank Loans Outstanding</a></td>
<td class="text">Principal payments (net of debt issuance
and debt discount costs) due under bank loans outstanding as of September 30, 2024 (excluding our $1,000,000 line of credit) are reflected
in the following table by the year that payments are due:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">During the<br/> Three-Month<br/> Period Ending<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">During the Years Ending December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2027</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2028</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Thereafter</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 16%">Loan #1</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">58,765</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">239,876</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">248,604</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">257,649</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">266,537</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,598,457</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,669,888</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Loan #2</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">129,801</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">530,738</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">549,881</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">140,436</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,350,856</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Loan #3</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,476</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">101,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">106,146</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">83,143</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">314,765</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Loan #4</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">54,055</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">220,994</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">228,965</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">240,442</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">744,456</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Loan #5</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,929</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">69,856</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73,415</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">77,156</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">81,086</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">318,442</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Loan #6</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60,581</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">253,003</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,418,558</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,732,142</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Loan #7</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">29,617</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">124,364</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">715,704</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">869,685</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Subtotal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">374,224</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,539,831</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,341,273</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">798,826</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">347,623</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,598,457</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,000,234</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Debt issuance cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,583</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(21,314</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(13,580</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,420</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,513</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11,347</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(60,757</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Debt discount cost</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,223</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(20,891</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(11,344</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(37,458</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">363,418</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,497,626</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,316,349</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">793,406</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">344,110</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,587,110</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,902,019</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390146666112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Lease (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Operating Lease [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Costs and Other Lease Information</a></td>
<td class="text">Variable lease cost primarily represents variable payments such as
real estate taxes and common area maintenance. The following tables describe our lease costs and other lease information:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">During the Three-Month<br/> Periods Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">During the Nine-Month <br/> Periods Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>Lease Cost</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; text-indent: -10.1pt; padding-left: 0.25in">Operating lease cost</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">106,880</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">98,714</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">320,639</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">244,954</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 20.2pt">Variable lease cost</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,486</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,720</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">50,638</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">27,054</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt">Total lease cost</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">128,366</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">108,434</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">371,277</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">272,008</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Operating Lease</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt">Cash paid for operating lease liabilities</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">144,315</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">69,742</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">432,945</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">131,476</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Weighted average remaining lease term (in years)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">18.3</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">19.3</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">18.3</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">19.3</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -10.1pt; padding-left: 20.2pt">Weighted average discount rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6.6</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6.3</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6.6</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6.3</td><td style="text-align: left">%</td></tr> </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Lease Payments Required Under Non-Cancelable Operating Leases</a></td>
<td class="text">Future lease payments required under non-cancelable
operating leases in effect as of September 30, 2024 were as follows:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Amount</b></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">During the three-month period ending December 31, 2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">144,315</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline">During the years ending December 31,</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">711,623</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">349,744</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">356,732</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">363,870</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,949,488</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total lease payments (undiscounted cash flows)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,875,772</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: imputed interest (discount effect of cash flows)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,245,124</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total operating liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,630,648</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390144681712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders&#8217; Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Activity Under the Stock Option Plans</a></td>
<td class="text">Activity under the stock option plans described
above was as follows:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2010 Plan</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2017 Plan</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate Intrinsic Value<sup>(1)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding as of December 31, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">202,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">402,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7.19</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(661,310</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in">Grants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">122,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5.16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Terminations/forfeitures<b><sup>(2)</sup></b></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(94,500</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7.12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 10.1pt">Exercises</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">4.69</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">188,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">430,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6.82</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(1,071,121</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10.1pt">Grants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.80</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Terminations/forfeitures<b><sup>(2)</sup></b></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(25,500</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 10.1pt">Exercises</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Outstanding as of September 30, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">183,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">477,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">6.49</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">(1,891,421</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Vested as of September 30, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">183,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">136,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">6.97</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">(1,068,740</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Vested and expected to vest as of September 30, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">183,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">477,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">6.49</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">(1,891,421</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Reserved for future grants</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">154,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><sup>(1)</sup></td><td style="text-align: justify">Intrinsic value is the difference between the fair market value
of the underlying common stock as of the date indicated and as of the date of the option grant (which is equal to the option exercise
price).</td>
</tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><sup>(2)</sup></td><td style="text-align: justify">Terminations and forfeitures are recognized when they occur.</td>
</tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock', window );">Schedule of Additional Information About the Stock Option Plans</a></td>
<td class="text">The following table displays additional information
about the stock option plans described above:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average <br/> Fair Value at Grant Date</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-indent: -10pt; padding-left: 10pt">Non-vested stock options as of December 31, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">337,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3.66</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7.14</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">Non-vested stock options as of September 30, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">341,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6.04</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock options granted during the nine-month period ended September 30, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.72</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.80</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Stock options that vested during the nine-month period ended September 30, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">54,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4.31</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9.73</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Stock options that were terminated or forfeited during the nine-month period ended September 30, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.36</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value Stock Option Grant Using Black-Scholes Option Pricing Model with Weighted-Average Assumptions</a></td>
<td class="text">The fair value of each stock option grant has been estimated on the date
of grant using the Black-Scholes option pricing model, for the purpose discussed in Note 2(n), with the following weighted-average assumptions:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">During the Three-Month<br/> Periods Ended September 30,</td><td style="padding-bottom: 3pt; font-weight: bold"><sup>&#160;</sup></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">During the Nine-Month <br/> Periods Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 3pt; font-weight: bold"><sup>&#160;</sup></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate<sup>(1)</sup></span></td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3.48</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-119; font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="padding-bottom: 3pt; width: 1%; text-align: left"><sup>(4)</sup></td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3.70</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3.48</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend yield<sup>(2)</sup></span></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="padding-bottom: 0pt; text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility<sup>(2)</sup></span></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">52</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-120; font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="padding-bottom: 3pt; text-align: left"><sup>(4)</sup></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">51</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">54</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected life<sup>(3)</sup></span></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">4.1 years</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-121; font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="padding-bottom: 3pt; text-align: left"><sup>(4)</sup></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">4.3 years</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6.2 years</td><td style="text-align: left">&#160;</td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><sup>(1)</sup></td><td style="text-align: justify">The risk-free interest rate is based on U.S. Treasury yields
for a maturity approximating the expected option term.</td>
</tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><sup>(2)</sup></td><td style="text-align: justify">The dividend yield and expected volatility are derived from
averages of our historical data.</td>
</tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><sup>(3)</sup></td><td style="text-align: left">The expected life is calculated utilizing the simplified method,
which uses the mid-point between the vesting period and the contractual term as the expected life.</td>
</tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><sup>(4)</sup></td><td style="text-align: justify">These values are not applicable because <span style="-sec-ix-hidden: hidden-fact-122">no</span> stock options were
granted during this period.</td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock options and stock appreciation rights that were outstanding at the beginning and end of the year, exercisable at the end of the year, and the number of stock options and stock appreciation rights that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390146124608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of Product Sales Disaggregated by Geographic Area</a></td>
<td class="text">The following table presents our product sales disaggregated
by geographic area:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><b>&#160;</b></td><td style="white-space: nowrap; font-weight: normal; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="14" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"><b>During the Three-Month<br/>
 Periods
    Ended September 30,</b></td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: normal"><b>&#160;</b></td><td style="white-space: nowrap; font-weight: normal; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="14" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"><b>During the Nine-Month<br/>
 Periods
    Ended September 30,</b></td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: normal"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="font-weight: normal; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"><b>2024</b></td><td style="padding-bottom: 1.5pt; font-weight: normal"><b>&#160;</b></td><td style="font-weight: normal; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"><b>%</b></td><td style="padding-bottom: 1.5pt; font-weight: normal"><b>&#160;</b></td><td style="font-weight: normal; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"><b>2023</b></td><td style="padding-bottom: 1.5pt; font-weight: normal"><b>&#160;</b></td><td style="font-weight: normal; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"><b>%</b></td><td style="padding-bottom: 1.5pt; font-weight: normal"><b>&#160;</b></td><td style="font-weight: normal; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"><b>2024</b></td><td style="padding-bottom: 1.5pt; font-weight: normal"><b>&#160;</b></td><td style="font-weight: normal; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"><b>%</b></td><td style="padding-bottom: 1.5pt; font-weight: normal"><b>&#160;</b></td><td style="font-weight: normal; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"><b>2023</b></td><td style="padding-bottom: 1.5pt; font-weight: normal"><b>&#160;</b></td><td style="font-weight: normal; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"><b>%</b></td><td style="padding-bottom: 1.5pt; font-weight: normal"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; text-align: left; text-indent: -10pt; padding-left: 10pt">United States</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">5,216,401</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">87</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">4,923,265</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">91</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">16,449,178</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">88</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">11,173,686</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">90</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">795,172</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">473,235</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,292,862</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,202,022</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Total Product Sales</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,011,573</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,396,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">18,742,040</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">12,375,708</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Product Sales Disaggregated by Major Product Category</a></td>
<td class="text">The following table presents our product sales disaggregated
by major product category:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">During the Three-Month<br/> Periods Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">During the Nine-Month<br/> Periods Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt"><b>First
    Defense<span style="font-family: Times New Roman, Times, Serif"><sup>&#174;</sup> </span></b><span style="font-family: Times New Roman, Times, Serif"><span style="font-style: normal; font-weight: normal">product
    line</span></span></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">5,951,344</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">99</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">5,360,063</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">99</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">18,602,053</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">99</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">12,253,555</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">99</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Other animal health</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">60,229</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">36,437</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">139,987</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">122,153</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt">Total Product Sales</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,011,573</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,396,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">18,742,040</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">12,375,708</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390146107120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Expenses, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpensesAbstract', window );"><strong>Other Expenses, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of Other Expenses Net</a></td>
<td class="text">Other expenses net, consisted of the following:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>During the Three-Month  <br/>
Periods Ended September 30,</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>During the Nine-Month <br/>
Periods Ended September 30,</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest expense<sup>(1)</sup></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">144,141</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">144,616</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">432,529</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">323,177</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Loss (gain) on disposal of property, plant and equipment</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">&#8212;</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(68</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">14,557</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">8,099</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Interest income</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(18,685</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(23,696</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(41,476</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(79,134</td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insurance recoveries<sup>(2)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">&#8212;</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(365,127</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">&#8212;</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(365,127</td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Income - other</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">&#8212;</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-127">&#8212;</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-128">&#8212;</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(107</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Other expenses (income), net</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">125,456</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">(244,275</td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">405,610</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">(113,092</td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><sup>(1)</sup></td><td style="text-align: left">Interest expense includes amortization of debt issuance and
debt discount costs of $10,805 and $8,687 during the three-month periods ended September 30, 2024 or 2023, respectively, and $31,859
and $12,525 during the nine-month periods ended September 30, 2024 and 2023, respectively.</td>
</tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0in"></td><td style="width: 0.25in; text-align: left"><sup>(2)</sup></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
income from insurance recoveries resulted from claim benefits paid to us under our business interruption policy related to product contamination
losses and a recovery from a vendor&#8217;s policy related to an equipment malfunction.</span></td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390145768496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Information</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">During the Three-Month <br/>
Period Ended
    September 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Scours</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Mastitis</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Other</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">Product sales</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,951,344</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">60,229</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,011,573</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Costs of goods sold</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,364,950</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">63,069</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,428,019</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt">Gross margin</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,586,394</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,840</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,583,554</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Product development expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">59,140</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">690,052</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36,944</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">786,136</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Sales and marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">699,584</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">144,461</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">844,045</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt">Administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-133">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-134">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">528,267</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">528,267</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">758,724</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">834,513</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">565,211</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,158,448</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt">NET OPERATING INCOME (LOSS)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">827,670</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(837,353</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(565,211</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(574,894</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>During the Three-Month <br/>
Period Ended
                                                                                                                                                                                    September 30, 2023</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Scours</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Mastitis</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Other</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">Product sales</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,360,063</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">36,437</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-135">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,396,500</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Costs of goods sold</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,095,164</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">34,455</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-136">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,129,619</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt">Gross margin</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,264,899</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,982</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-137">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,266,881</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Product development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-138">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,082,346</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36,143</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,118,489</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Sales and marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">641,682</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">175,804</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-139">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">817,486</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt">Administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-140">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-141">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">514,952</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">514,952</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 20.2pt">Operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">641,682</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,258,150</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">551,095</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,450,927</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt">NET OPERATING INCOME (LOSS)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">623,217</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,256,168</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(551,095</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,184,046</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Scours</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Mastitis</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Other</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -10pt; padding-left: 10pt">Total Assets as of September 30, 2024</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">23,672,583</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">16,798,955</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">3,977,335</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">44,448,873</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">Total Assets as of September 30, 2023</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">24,119,683</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">18,132,922</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">2,292,417</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">44,545,022</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Depreciation and amortization expense during the three-month period ended September 30, 2024</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">346,430</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">319,815</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">19,682</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">685,927</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Depreciation and amortization expense during the three-month period ended September 30, 2023</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">355,673</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">328,381</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">25,044</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">709,098</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt">Capital Expenditures during the three-month period ended September 30, 2024</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">87,286</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">1,126</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-142">&#8212;</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">88,412</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt">Capital Expenditures during the three-month period ended September 30, 2023</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">341,386</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">79,129</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-143">&#8212;</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">420,515</td>
    <td style="text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">During the Nine-Month<br/>
 Period Ended
    September 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Scours</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Mastitis</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Other</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">Product sales</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">18,602,054</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">139,986</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-144">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">18,742,040</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Costs of goods sold</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,487,348</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">145,294</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-145">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,632,642</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt">Gross margin</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,114,706</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,308</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-146">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,109,398</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Product development expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">154,233</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,821,525</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">103,431</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,079,189</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Sales and marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,224,836</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">405,089</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-147">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,629,925</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt">Administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-148">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-149">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,661,838</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,661,838</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10.1pt">Operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,379,069</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,226,614</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,765,269</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,370,952</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt">NET OPERATING INCOME (LOSS)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,735,637</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(3,231,922</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,765,269</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(2,261,554</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>During the Nine-Month<br/>
 Period Ended
                                                                                                                                                                                    September 30, 2023</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Scours</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Mastitis</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Other</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">Product sales</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">12,253,555</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">122,153</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-150">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">12,375,708</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Costs of goods sold</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,652,292</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">111,872</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-151">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,764,164</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt">Gross margin</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,601,263</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,281</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-152">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,611,544</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Product development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,543</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,220,075</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">105,779</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,328,397</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Sales and marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,890,404</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">526,297</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-153">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,416,701</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt">Administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-154">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-155">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,611,026</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,611,026</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 20.2pt">Operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,892,947</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,746,372</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,716,805</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,356,124</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt">NET OPERATING INCOME (LOSS)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">708,316</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(3,736,091</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,716,805</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(4,744,580</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Scours</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Mastitis</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Other</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -10pt; padding-left: 10pt">Total Assets as of September 30, 2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">23,672,583</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">16,798,955</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,977,335</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">44,448,873</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">Total Assets as of September 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">24,119,683</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">18,132,922</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,292,417</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">44,545,022</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Depreciation and amortization expense during the nine-month period ended September 30, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,027,711</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">958,260</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">59,221</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,045,192</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Depreciation and amortization expense during the nine-month period ended September 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,020,909</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">969,666</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">64,066</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,054,641</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt">Capital Expenditures during the nine-month period ended September 30, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">235,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">33,909</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-156">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">269,509</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt">Capital Expenditures during the nine-month period ended September 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,038,033</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">773,136</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-157">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,811,169</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">During the Year Ended December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Scours</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Mastitis</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Other</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">Product sales</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">17,293,933</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">177,736</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-158">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">17,471,669</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Costs of goods sold</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,453,514</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">148,871</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-159">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,602,385</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt">Gross margin</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,840,419</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,865</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-160">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,869,284</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Product development expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,103</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,242,329</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">141,420</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,394,852</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Sales and marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,447,137</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">641,078</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-161">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,088,215</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt">Administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-162">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-163">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,134,295</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,134,295</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10.1pt">Operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,458,240</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,883,407</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,275,715</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,617,362</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt">NET OPERATING INCOME (LOSS)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,382,179</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(4,854,542</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(2,275,715</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(5,748,078</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>During the Year Ended December 31, 2022</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Scours</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Mastitis</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Other</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">Product sales</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">18,411,949</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">154,558</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,455</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">18,567,962</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Costs of goods sold</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,754,189</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">136,347</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">28,647</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,919,183</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt">Gross margin</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,657,760</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,211</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(27,192</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,648,779</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Product development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66,346</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,317,921</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">109,605</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,493,872</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Sales and marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,871,926</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,318,107</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-164">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,190,033</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt">Administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-165">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-166">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,263,817</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,263,817</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 20.2pt">Operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,938,272</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,636,028</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,373,422</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,947,722</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt">NET OPERATING INCOME (LOSS)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,719,488</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(5,617,817</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(2,400,614</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(2,298,943</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Scours</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Mastitis</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Other</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -10pt; padding-left: 10pt">Total Assets as of December 31, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">24,735,413</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">17,827,839</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,244,850</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">43,808,102</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">Total Assets as of December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">20,539,523</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">18,315,492</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6,005,634</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">44,860,649</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Depreciation and amortization expense during the year ended December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,365,988</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,287,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">86,032</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,739,620</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Depreciation and amortization expense during the year ended December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,169,011</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,263,318</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">62,912</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,495,241</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Capital Expenditures during the year ended December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,096,819</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">795,694</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-167">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,892,513</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Capital Expenditures during the year ended December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,497,834</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">429,988</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">47,452</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,975,274</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390142920496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Federal deposit insurance corporation limits</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage', window );">Asset depreciated percentage</a></td>
<td class="nump">86.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 77,557<span></span>
</td>
<td class="nump">$ 96,434<span></span>
</td>
<td class="nump">$ 256,688<span></span>
</td>
<td class="nump">$ 268,207<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive amounted (in Shares)</a></td>
<td class="nump">661,000<span></span>
</td>
<td class="nump">616,500<span></span>
</td>
<td class="nump">661,000<span></span>
</td>
<td class="nump">616,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=iccc_NisinDrugSubstanceMember', window );">Nisin Drug Substance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stated as a percentage, the estimated or actual value of the asset at the end of its useful life or when it is no longer serviceable (cannot be used for its original purpose) divided by its [historical] capitalized cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=iccc_NisinDrugSubstanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=iccc_NisinDrugSubstanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390142926992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Assets or Liabilities Measured at Fair Value on a Nonrecurring Basis - Fair Value, Nonrecurring [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and money market accounts</a></td>
<td class="nump">$ 3,808,633<span></span>
</td>
<td class="nump">$ 978,741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Bank debt</a></td>
<td class="nump">9,703,821<span></span>
</td>
<td class="nump">10,431,817<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and money market accounts</a></td>
<td class="nump">3,808,633<span></span>
</td>
<td class="nump">978,741<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Bank debt</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and money market accounts</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Bank debt</a></td>
<td class="nump">9,703,821<span></span>
</td>
<td class="nump">10,431,817<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and money market accounts</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Bank debt</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390147819200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Concentration of Risk - Customer Concentration Risk [Member]<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Company A [Member] | Product sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Schedule of Concentration of Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">43.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">44.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Company A [Member] | Trade accounts receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Schedule of Concentration of Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.00%<span></span>
</td>
<td class="nump">43.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Company B [Member] | Product sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Schedule of Concentration of Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">31.00%<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Company B [Member] | Trade accounts receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Schedule of Concentration of Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=iccc_CompanyAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=iccc_CompanyAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=iccc_CompanyBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=iccc_CompanyBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390144978096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Net Income (Loss) Per Common Share - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Schedule of Net Income (Loss) Per Common Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to stockholders (in Dollars)</a></td>
<td class="num">$ (701,690)<span></span>
</td>
<td class="num">$ (940,000)<span></span>
</td>
<td class="num">$ (2,671,184)<span></span>
</td>
<td class="num">$ (4,634,767)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding - Basic</a></td>
<td class="nump">8,164,423<span></span>
</td>
<td class="nump">7,746,864<span></span>
</td>
<td class="nump">7,908,425<span></span>
</td>
<td class="nump">7,746,864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive impact of share-based compensation awards</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding - Diluted</a></td>
<td class="nump">8,164,423<span></span>
</td>
<td class="nump">7,746,864<span></span>
</td>
<td class="nump">7,908,425<span></span>
</td>
<td class="nump">7,746,864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in Dollars per share)</a></td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.34)<span></span>
</td>
<td class="num">$ (0.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in Dollars per share)</a></td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.34)<span></span>
</td>
<td class="num">$ (0.6)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480454/718-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390238186432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Cash Equivalents (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 3,808,633<span></span>
</td>
<td class="nump">$ 978,741<span></span>
</td>
<td class="nump">$ 1,989,462<span></span>
</td>
<td class="nump">$ 5,791,562<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390144786896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade Accounts Receivable (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Trade Accounts Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade accounts receivable, net</a></td>
<td class="nump">$ 2,307,913<span></span>
</td>
<td class="nump">$ 2,185,383<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Trade Accounts Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade accounts receivable, net</a></td>
<td class="nump">$ 35,364<span></span>
</td>
<td class="nump">$ 42,507<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 40<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481628/310-20-40-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390146454112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write off</a></td>
<td class="nump">$ 368,723<span></span>
</td>
<td class="nump">$ 527,133<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390240783824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - Schedule of Inventory - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Schedule of Inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 1,313,766<span></span>
</td>
<td class="nump">$ 1,594,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work-in-process</a></td>
<td class="nump">6,124,394<span></span>
</td>
<td class="nump">5,815,194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">22,292<span></span>
</td>
<td class="nump">402,619<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total</a></td>
<td class="nump">$ 7,460,452<span></span>
</td>
<td class="nump">$ 7,811,841<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390227517120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Details) - Schedule of Prepaid Expenses and Other Current Assets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>Schedule of Prepaid Expenses and Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">$ 277,146<span></span>
</td>
<td class="nump">$ 454,152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">33,342<span></span>
</td>
<td class="nump">39,733<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total</a></td>
<td class="nump">$ 310,488<span></span>
</td>
<td class="nump">$ 493,885<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390144962272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisposals', window );">Property, plant and equipment disposals</a></td>
<td class="nump">$ 49,652<span></span>
</td>
<td class="nump">$ 43,503<span></span>
</td>
<td class="nump">$ 120,814<span></span>
</td>
<td class="nump">$ 100,142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 670,346<span></span>
</td>
<td class="nump">$ 695,635<span></span>
</td>
<td class="nump">$ 1,999,005<span></span>
</td>
<td class="nump">$ 2,027,788<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisposals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisposals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390147511904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net (Details) - Schedule of Property, Plant and Equipment - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 46,201,529<span></span>
</td>
<td class="nump">$ 46,059,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(20,381,196)<span></span>
</td>
<td class="num">(18,483,948)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">25,820,333<span></span>
</td>
<td class="nump">27,575,683<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember', window );">Laboratory and manufacturing equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">21,183,888<span></span>
</td>
<td class="nump">20,953,601<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember', window );">Buildings and improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">20,858,708<span></span>
</td>
<td class="nump">20,784,565<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 1,053,436<span></span>
</td>
<td class="nump">1,036,374<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, Estimated Useful Lives (in years)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 2,588,630<span></span>
</td>
<td class="nump">2,768,224<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, Estimated Useful Lives (in years)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 516,867<span></span>
</td>
<td class="nump">$ 516,867<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Laboratory and manufacturing equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, Estimated Useful Lives (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Buildings and improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, Estimated Useful Lives (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Office furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, Estimated Useful Lives (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Laboratory and manufacturing equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, Estimated Useful Lives (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Buildings and improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, Estimated Useful Lives (in years)</a></td>
<td class="text">39 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Office furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, Estimated Useful Lives (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390143700640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets</a></td>
<td class="nump">$ 191,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 191,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 191,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset amortized, useful lives</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Intangible amortization expense</a></td>
<td class="nump">$ 4,776<span></span>
</td>
<td class="nump">$ 4,776<span></span>
</td>
<td class="nump">$ 14,328<span></span>
</td>
<td class="nump">$ 14,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net value</a></td>
<td class="nump">$ 23,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,208<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Intangible amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390146213520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets (Details) - Schedule of Intangible Assets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="nump">$ 191,040<span></span>
</td>
<td class="nump">$ 191,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(167,160)<span></span>
</td>
<td class="num">(152,832)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Book Value</a></td>
<td class="nump">23,880<span></span>
</td>
<td class="nump">38,208<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="nump">184,100<span></span>
</td>
<td class="nump">184,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(161,087)<span></span>
</td>
<td class="num">(147,280)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Book Value</a></td>
<td class="nump">23,013<span></span>
</td>
<td class="nump">36,820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,138)<span></span>
</td>
<td class="num">(1,040)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Book Value</a></td>
<td class="nump">162<span></span>
</td>
<td class="nump">260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Non-compete agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="nump">5,640<span></span>
</td>
<td class="nump">5,640<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(4,935)<span></span>
</td>
<td class="num">(4,512)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Book Value</a></td>
<td class="nump">$ 705<span></span>
</td>
<td class="nump">$ 1,128<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390145826320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses (Details) - Schedule of Accounts Payable and Accrued Expenses - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Schedule of Accounts Payable and Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Accounts payable &#8211; trade</a></td>
<td class="nump">$ 876,836<span></span>
</td>
<td class="nump">$ 874,558<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Accounts payable &#8211; capital</a></td>
<td class="nump">6,378<span></span>
</td>
<td class="nump">13,175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedPayrollTaxesCurrent', window );">Accrued payroll</a></td>
<td class="nump">1,142,318<span></span>
</td>
<td class="nump">942,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">101,725<span></span>
</td>
<td class="nump">97,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">376,112<span></span>
</td>
<td class="nump">192,754<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income tax payable</a></td>
<td class="nump">1,166<span></span>
</td>
<td class="nump">3,051<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 2,504,535<span></span>
</td>
<td class="nump">$ 2,124,337<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedPayrollTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedPayrollTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390137509760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Bank Debt (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2027</div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th">
<div>Sep. 30, 2026 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Bearing interest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.53%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.58%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount', window );">Mortgage debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentGross', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestCostsIncurred', window );">Incurred costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,037<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=iccc_GorhamSavingsBankMember', window );">Gorham Savings Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Debt financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=iccc_BankLoansMember', window );">Bank Loans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Balloon principal payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,145,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized', window );">Outstanding principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,233,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Balloon principal payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,687,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized', window );">Outstanding principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,233,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember', window );">Loan #1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Balloon principal payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,145,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember', window );">Loan #1 [Member] | Gorham Savings Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EscrowDeposit', window );">Escrow account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Bearing interest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_InterestPaymentsTerm', window );">Interest payments, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember', window );">Loan #2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Bearing interest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Balloon principal payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember', window );">Loan #3 [Member] | Maine Technology Institute [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Loan amortization, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFourMember', window );">Loans #4 [Member] | Gorham Savings Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Debt financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Bearing interest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Loan amortization, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSixMember', window );">Loan #6 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Debt financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Bearing interest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableLoanInProcess', window );">Finance loan provided</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSixMember', window );">Loan #6 [Member] | Maine Technology Institute [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Debt financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 624,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_LoanToValueRatio', window );">Loan to value ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFiveMember', window );">Loan #5 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest fixed rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFiveMember', window );">Loan #5 [Member] | Gorham Savings Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Loan amortization, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSevenMember', window );">Loan #7 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Debt financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Bearing interest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Balloon principal payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 649,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_DebtServiceCoverageRatio', window );">DSC ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member] | Maine Technology Institute [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Loan amortization, term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member] | Loan #3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest fixed rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member] | Loan #6 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Balloon principal payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,285,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member] | Loan #6 [Member] | Mortgage Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Loan amortization, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member] | Loan #7 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Loan amortization, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_DebtServiceCoverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the debt service coverage ratio.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_DebtServiceCoverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_InterestPaymentsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payments term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_InterestPaymentsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_LoanToValueRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ratio of loan to value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_LoanToValueRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsCurrentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsCurrentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsCurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsCurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed interest rate related to the interest rate derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EscrowDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EscrowDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableLoanInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of undisbursed portion of financing receivable balance. Excludes financing receivable covered under loss sharing agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableLoanInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total interest costs incurred during the period and either capitalized or charged against earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the related debt discount at the end of the accounting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481212/470-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is the sum of principal amount outstanding for both securitized and unsecuritized loans of all types.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (a)<br> -Paragraph 4<br> -SubTopic 20<br> -Topic 860<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=iccc_GorhamSavingsBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=iccc_GorhamSavingsBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=iccc_BankLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=iccc_BankLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=iccc_MaineTechnologyInstituteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=iccc_MaineTechnologyInstituteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_MortgageBankingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_MortgageBankingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390146378208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Bank Debt (Details) - Schedule of Debt Proceeds Received and Principal Repayments - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Schedule of Debt Proceeds Received and Principal Repayments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from Debt Issuance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfBankDebt', window );">Debt Principal Repayments</a></td>
<td class="nump">368,249<span></span>
</td>
<td class="nump">325,737<span></span>
</td>
<td class="nump">1,094,106<span></span>
</td>
<td class="nump">829,015<span></span>
</td>
<td class="nump">1,185,774<span></span>
</td>
<td class="nump">897,125<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember', window );">Loan #1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Schedule of Debt Proceeds Received and Principal Repayments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from Debt Issuance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfBankDebt', window );">Debt Principal Repayments</a></td>
<td class="nump">57,671<span></span>
</td>
<td class="nump">55,619<span></span>
</td>
<td class="nump">172,017<span></span>
</td>
<td class="nump">166,527<span></span>
</td>
<td class="nump">223,222<span></span>
</td>
<td class="nump">199,013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember', window );">Loan #2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Schedule of Debt Proceeds Received and Principal Repayments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from Debt Issuance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfBankDebt', window );">Debt Principal Repayments</a></td>
<td class="nump">128,534<span></span>
</td>
<td class="nump">124,020<span></span>
</td>
<td class="nump">382,324<span></span>
</td>
<td class="nump">369,154<span></span>
</td>
<td class="nump">494,455<span></span>
</td>
<td class="nump">477,237<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember', window );">Loan #3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Schedule of Debt Proceeds Received and Principal Repayments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from Debt Issuance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfBankDebt', window );">Debt Principal Repayments</a></td>
<td class="nump">24,173<span></span>
</td>
<td class="nump">23,002<span></span>
</td>
<td class="nump">71,629<span></span>
</td>
<td class="nump">68,156<span></span>
</td>
<td class="nump">91,446<span></span>
</td>
<td class="nump">22,160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFourMember', window );">Loan #4 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Schedule of Debt Proceeds Received and Principal Repayments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from Debt Issuance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfBankDebt', window );">Debt Principal Repayments</a></td>
<td class="nump">53,505<span></span>
</td>
<td class="nump">51,622<span></span>
</td>
<td class="nump">159,171<span></span>
</td>
<td class="nump">153,704<span></span>
</td>
<td class="nump">205,884<span></span>
</td>
<td class="nump">198,715<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFiveMember', window );">Loan #5 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Schedule of Debt Proceeds Received and Principal Repayments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from Debt Issuance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfBankDebt', window );">Debt Principal Repayments</a></td>
<td class="nump">16,719<span></span>
</td>
<td class="nump">15,909<span></span>
</td>
<td class="nump">49,542<span></span>
</td>
<td class="nump">15,909<span></span>
</td>
<td class="nump">32,017<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSixMember', window );">Loan #6 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Schedule of Debt Proceeds Received and Principal Repayments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from Debt Issuance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfBankDebt', window );">Debt Principal Repayments</a></td>
<td class="nump">59,191<span></span>
</td>
<td class="nump">36,582<span></span>
</td>
<td class="nump">174,804<span></span>
</td>
<td class="nump">36,582<span></span>
</td>
<td class="nump">93,054<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSevenMember', window );">Loan #7 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Schedule of Debt Proceeds Received and Principal Repayments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from Debt Issuance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfBankDebt', window );">Debt Principal Repayments</a></td>
<td class="nump">$ 28,456<span></span>
</td>
<td class="nump">$ 18,983<span></span>
</td>
<td class="nump">$ 84,619<span></span>
</td>
<td class="nump">$ 18,983<span></span>
</td>
<td class="nump">$ 45,696<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfBankDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle a bank borrowing during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfBankDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390136248544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Bank Debt (Details) - Schedule of Principal Payments Bank Loans Outstanding<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Schedule of Principal Payments Bank Loans Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_DebtIssuanceCosts2024', window );">Debt issuance costs During the Three-Month Period Ending December 31, 2024</a></td>
<td class="num">$ (5,583)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_DebtIssuanceCosts2025', window );">Debt issuance costs 2025</a></td>
<td class="num">(21,314)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_DebtIssuanceCosts2026', window );">Debt issuance costs 2026</a></td>
<td class="num">(13,580)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_DebtIssuanceCosts2027', window );">Debt issuance costs 2027</a></td>
<td class="num">(5,420)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_DebtIssuanceCosts2028', window );">Debt issuance costs 2028</a></td>
<td class="num">(3,513)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_DebtIssuanceCostshereafter', window );">Debt issuance costs Thereafter</a></td>
<td class="num">(11,347)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs, Total</a></td>
<td class="num">(60,757)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_DebtDiscountCost', window );">Debt discount cost During the Three-Month Period Ending December 31, 2024</a></td>
<td class="num">(5,223)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_DebtDiscountCost2025', window );">Debt discount cost 2025</a></td>
<td class="num">(20,891)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_DebtDiscountCost2026', window );">Debt discount cost 2026</a></td>
<td class="num">(11,344)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_DebtDiscountCost2027', window );">Debt discount cost 2027</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_DebtDiscountCost2028', window );">Debt discount cost 2028</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_DebtDiscountCostThereafter', window );">Debt discount cost Thereafter</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_DebtDiscountCostTotal', window );">Debt discount cost Total</a></td>
<td class="num">(37,458)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_LongTermDebt2024', window );">Total During the Three-Month Period Ending December 31, 2024</a></td>
<td class="nump">363,418<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_LongTermDebt2025', window );">Total 2025</a></td>
<td class="nump">1,497,626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_LongTermDebt2026', window );">Total 2026</a></td>
<td class="nump">3,316,349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_LongTermDebt2027', window );">Total 2027</a></td>
<td class="nump">793,406<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_LongTermDebtTotal2028', window );">Total 2028</a></td>
<td class="nump">344,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_LongTermDebtThereafter', window );">Total Thereafter</a></td>
<td class="nump">4,587,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total</a></td>
<td class="nump">10,902,019<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember', window );">Loan #1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Schedule of Principal Payments Bank Loans Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">During the Three-Month Period Ending December 31, 2024</a></td>
<td class="nump">58,765<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">During the Three-Month Period Ending December 31, 2025</a></td>
<td class="nump">239,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">During the Three-Month Period Ending December 31, 2026</a></td>
<td class="nump">248,604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">During the Three-Month Period Ending December 31, 2027</a></td>
<td class="nump">257,649<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">During the Three-Month Period Ending December 31, 2028</a></td>
<td class="nump">266,537<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">During the Three-Month Period Ending ,Thereafter</a></td>
<td class="nump">4,598,457<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">During the Three-Month Period Ending, Total</a></td>
<td class="nump">5,669,888<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember', window );">Loan #2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Schedule of Principal Payments Bank Loans Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">During the Three-Month Period Ending December 31, 2024</a></td>
<td class="nump">129,801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">During the Three-Month Period Ending December 31, 2025</a></td>
<td class="nump">530,738<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">During the Three-Month Period Ending December 31, 2026</a></td>
<td class="nump">549,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">During the Three-Month Period Ending December 31, 2027</a></td>
<td class="nump">140,436<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">During the Three-Month Period Ending December 31, 2028</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">During the Three-Month Period Ending ,Thereafter</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">During the Three-Month Period Ending, Total</a></td>
<td class="nump">1,350,856<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember', window );">Loan #3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Schedule of Principal Payments Bank Loans Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">During the Three-Month Period Ending December 31, 2024</a></td>
<td class="nump">24,476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">During the Three-Month Period Ending December 31, 2025</a></td>
<td class="nump">101,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">During the Three-Month Period Ending December 31, 2026</a></td>
<td class="nump">106,146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">During the Three-Month Period Ending December 31, 2027</a></td>
<td class="nump">83,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">During the Three-Month Period Ending December 31, 2028</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">During the Three-Month Period Ending ,Thereafter</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">During the Three-Month Period Ending, Total</a></td>
<td class="nump">314,765<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFourMember', window );">Loan #4 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Schedule of Principal Payments Bank Loans Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">During the Three-Month Period Ending December 31, 2024</a></td>
<td class="nump">54,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">During the Three-Month Period Ending December 31, 2025</a></td>
<td class="nump">220,994<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">During the Three-Month Period Ending December 31, 2026</a></td>
<td class="nump">228,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">During the Three-Month Period Ending December 31, 2027</a></td>
<td class="nump">240,442<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">During the Three-Month Period Ending December 31, 2028</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">During the Three-Month Period Ending ,Thereafter</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">During the Three-Month Period Ending, Total</a></td>
<td class="nump">744,456<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFiveMember', window );">Loan #5 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Schedule of Principal Payments Bank Loans Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">During the Three-Month Period Ending December 31, 2024</a></td>
<td class="nump">16,929<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">During the Three-Month Period Ending December 31, 2025</a></td>
<td class="nump">69,856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">During the Three-Month Period Ending December 31, 2026</a></td>
<td class="nump">73,415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">During the Three-Month Period Ending December 31, 2027</a></td>
<td class="nump">77,156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">During the Three-Month Period Ending December 31, 2028</a></td>
<td class="nump">81,086<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">During the Three-Month Period Ending ,Thereafter</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">During the Three-Month Period Ending, Total</a></td>
<td class="nump">318,442<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSixMember', window );">Loan #6 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Schedule of Principal Payments Bank Loans Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">During the Three-Month Period Ending December 31, 2024</a></td>
<td class="nump">60,581<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">During the Three-Month Period Ending December 31, 2025</a></td>
<td class="nump">253,003<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">During the Three-Month Period Ending December 31, 2026</a></td>
<td class="nump">1,418,558<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">During the Three-Month Period Ending December 31, 2027</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">During the Three-Month Period Ending December 31, 2028</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">During the Three-Month Period Ending ,Thereafter</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">During the Three-Month Period Ending, Total</a></td>
<td class="nump">1,732,142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSevenMember', window );">Loan #7 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Schedule of Principal Payments Bank Loans Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">During the Three-Month Period Ending December 31, 2024</a></td>
<td class="nump">29,617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">During the Three-Month Period Ending December 31, 2025</a></td>
<td class="nump">124,364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">During the Three-Month Period Ending December 31, 2026</a></td>
<td class="nump">715,704<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">During the Three-Month Period Ending December 31, 2027</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">During the Three-Month Period Ending December 31, 2028</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">During the Three-Month Period Ending ,Thereafter</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">During the Three-Month Period Ending, Total</a></td>
<td class="nump">869,685<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_SubtotalMember', window );">Subtotal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Schedule of Principal Payments Bank Loans Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">During the Three-Month Period Ending December 31, 2024</a></td>
<td class="nump">374,224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">During the Three-Month Period Ending December 31, 2025</a></td>
<td class="nump">1,539,831<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">During the Three-Month Period Ending December 31, 2026</a></td>
<td class="nump">3,341,273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">During the Three-Month Period Ending December 31, 2027</a></td>
<td class="nump">798,826<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">During the Three-Month Period Ending December 31, 2028</a></td>
<td class="nump">347,623<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">During the Three-Month Period Ending ,Thereafter</a></td>
<td class="nump">4,598,457<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">During the Three-Month Period Ending, Total</a></td>
<td class="nump">$ 11,000,234<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_DebtDiscountCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt discount cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_DebtDiscountCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_DebtDiscountCost2025">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt discount cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_DebtDiscountCost2025</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_DebtDiscountCost2026">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt discount cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_DebtDiscountCost2026</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_DebtDiscountCost2027">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt discount cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_DebtDiscountCost2027</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_DebtDiscountCost2028">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of debt discount cost 2028.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_DebtDiscountCost2028</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_DebtDiscountCostThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt discount cost thereafter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_DebtDiscountCostThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_DebtDiscountCostTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of total debt discount cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_DebtDiscountCostTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_DebtIssuanceCosts2024">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_DebtIssuanceCosts2024</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_DebtIssuanceCosts2025">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_DebtIssuanceCosts2025</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_DebtIssuanceCosts2026">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_DebtIssuanceCosts2026</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_DebtIssuanceCosts2027">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_DebtIssuanceCosts2027</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_DebtIssuanceCosts2028">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of debt issuance costs 2028.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_DebtIssuanceCosts2028</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_DebtIssuanceCostshereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_DebtIssuanceCostshereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_LongTermDebt2024">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_LongTermDebt2024</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_LongTermDebt2025">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_LongTermDebt2025</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_LongTermDebt2026">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_LongTermDebt2026</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_LongTermDebt2027">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_LongTermDebt2027</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_LongTermDebtThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long term debt thereafter</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_LongTermDebtThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_LongTermDebtTotal2028">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of long term debt total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_LongTermDebtTotal2028</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_SubtotalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_SubtotalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390137175360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingent Liabilities and Commitments (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jan. 01, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Contingent Liabilities and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet', window );">Total accrued amount</a></td>
<td class="nump">$ 222,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 275,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent', window );">Deferred compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_CapitalExpendituresCommitted', window );">Capital expenditures committed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_PurchaseofInventory', window );">Purchase of inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,818,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_CommitmentsRelatedToInformationTechnologyServicesAndOtherObligations', window );">Commitments related to information technology services and other obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">711,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=iccc_ReTainMember', window );">Re-Tain [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Contingent Liabilities and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_CommitmentsRelatedToCommercialManufacture', window );">Commitments related to commercial manufacture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iccc_MrBrighamMember', window );">Mr. Brigham [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Contingent Liabilities and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent', window );">Deferred compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage', window );">Deferred compensation agreement annual base salary percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_CapitalExpendituresCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital expenditures committed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_CapitalExpendituresCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_CommitmentsRelatedToCommercialManufacture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments related to commercial manufacture.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_CommitmentsRelatedToCommercialManufacture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_CommitmentsRelatedToInformationTechnologyServicesAndOtherObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments related to information technology services and other obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_CommitmentsRelatedToInformationTechnologyServicesAndOtherObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_PurchaseofInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of purchase of inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_PurchaseofInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitment made to pay deferred cash remuneration expressed as a percentage of the individual's base salary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the liabilities, classified as other, for deferred compensation arrangements payable within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483070/710-10-25-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483043/710-10-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=iccc_ReTainMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=iccc_ReTainMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iccc_MrBrighamMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iccc_MrBrighamMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390143325024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Lease (Details)<br></strong></div></th>
<th class="th">
<div>Jul. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 01, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 12, 2019 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansAndLeasesReceivableDisclosureLineItems', window );"><strong>Operating Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Square feet (in Square Feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,592,718<span></span>
</td>
<td class="nump">$ 4,571,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,630,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansAndLeasesReceivableDisclosureLineItems', window );"><strong>Operating Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Square feet (in Square Feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renew term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Additional rent payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,592,718<span></span>
</td>
<td class="nump">4,571,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,630,648<span></span>
</td>
<td class="nump">$ 4,721,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member] | Building [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansAndLeasesReceivableDisclosureLineItems', window );"><strong>Operating Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Additional rent payment</a></td>
<td class="nump">$ 248,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansAndLeasesReceivableDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansAndLeasesReceivableDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390136753072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Lease (Details) - Schedule of Lease Costs and Other Lease Information - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 106,880<span></span>
</td>
<td class="nump">$ 98,714<span></span>
</td>
<td class="nump">$ 320,639<span></span>
</td>
<td class="nump">$ 244,954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">21,486<span></span>
</td>
<td class="nump">9,720<span></span>
</td>
<td class="nump">50,638<span></span>
</td>
<td class="nump">27,054<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">128,366<span></span>
</td>
<td class="nump">108,434<span></span>
</td>
<td class="nump">371,277<span></span>
</td>
<td class="nump">272,008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Operating Lease</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating lease liabilities</a></td>
<td class="nump">$ 144,315<span></span>
</td>
<td class="nump">$ 69,742<span></span>
</td>
<td class="nump">$ 432,945<span></span>
</td>
<td class="nump">$ 131,476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (in years)</a></td>
<td class="text">18 years 3 months 18 days<span></span>
</td>
<td class="text">19 years 3 months 18 days<span></span>
</td>
<td class="text">18 years 3 months 18 days<span></span>
</td>
<td class="text">19 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">6.60%<span></span>
</td>
<td class="nump">6.30%<span></span>
</td>
<td class="nump">6.60%<span></span>
</td>
<td class="nump">6.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOperatingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOperatingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390143699184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Lease (Details) - Schedule of Future Lease Payments Required Under Non-Cancelable Operating Leases<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Schedule of Future Lease Payments Required Under Non-Cancelable Operating Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">During the three-month period ending December 31, 2024</a></td>
<td class="nump">$ 144,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_DuringTheYearsEndingDecember31Abstract', window );"><strong>During the years ending December 31,</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">711,623<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">349,744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">356,732<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">363,870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">5,949,488<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments (undiscounted cash flows)</a></td>
<td class="nump">7,875,772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest (discount effect of cash flows)</a></td>
<td class="num">(3,245,124)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating liabilities</a></td>
<td class="nump">$ 4,630,648<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_DuringTheYearsEndingDecember31Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_DuringTheYearsEndingDecember31Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390134578880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">63 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 09, 2024</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Jul. 31, 2017</div></th>
<th class="th"><div>Oct. 31, 2016</div></th>
<th class="th"><div>Feb. 29, 2016</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 10, 2020</div></th>
<th class="th"><div>Jun. 14, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Common stock shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">515,156<span></span>
</td>
<td class="nump">1,636,364<span></span>
</td>
<td class="nump">417,807<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,123,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,250,038<span></span>
</td>
<td class="nump">$ 9,000,002<span></span>
</td>
<td class="nump">$ 3,049,991<span></span>
</td>
<td class="nump">$ 1,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,900,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,833,090<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.25<span></span>
</td>
<td class="nump">$ 5.5<span></span>
</td>
<td class="nump">$ 7.3<span></span>
</td>
<td class="nump">$ 5.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_NetProceedsFromIssuanceOfCommonStock', window );">Net proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,233,026<span></span>
</td>
<td class="nump">$ 8,303,436<span></span>
</td>
<td class="nump">$ 2,734,173<span></span>
</td>
<td class="nump">$ 1,034,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,313,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_FeesInitiallyCapitalizedAndLaterOffset', window );">Legal, accounting and other fees amount (in Dollars)</a></td>
<td class="nump">$ 152,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares sold under at-the-market offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,082,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.49<span></span>
</td>
<td class="nump">$ 5.19<span></span>
</td>
<td class="nump">$ 6.49<span></span>
</td>
<td class="nump">$ 5.19<span></span>
</td>
<td class="nump">$ 6.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,000<span></span>
</td>
<td class="nump">108,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Stock-based compensation related to non-vested stock options (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 433,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 433,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased', window );">Common stock purchase price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_ExercisableAndTransferableDescription', window );">Exercisable and transferable, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Rights (as amended) become exercisable and transferable
apart from the common stock upon the earlier of i) 10 days following a public announcement that a person or group (Acquiring Person) has,
without the prior consent of the Continuing Directors (as such term is defined in the Rights Agreement), acquired beneficial ownership
of 20% or more of the outstanding common stock or ii) 10 days following commencement of a tender offer or exchange offer the consummation
of which would result in ownership by a person or group of 20% or more of the outstanding common stock (the earlier of such dates being
called the Distribution Date).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentCompanyPurchasePremiumPerShare', window );">Purchase price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostChangeDueToSubsequentInterimMeasurementWeightedAverageExpectedLongTermRateOfReturnOnPlanAssets', window );">Common stock were changed percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_RightToAcquirePerShare', window );">Price per Right (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription', window );">Extend the rights plan, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Our Board of Directors decided to seek an advisory vote by stockholders at the Annual Meeting of Stockholders
held in June of 2022, as to whether to extend the Rights Plan by one year to September 19, 2023. Of the votes actually cast on this proposal,
65% voted in favor, 32% voted against and 3% abstained. On the basis of this vote, our Board of Directors voted to extend the Rights Plan
by one year to September 19, 2023. Our Board of Directors decided to seek another advisory vote by stockholders at the Annual Meeting
of Stockholders held in June of 2023, as to whether to extend the Rights Plan by another year to September 19, 2024. Of the votes actually
cast on this proposal, 65.10% voted in favor, 34.60% voted against and 0.30% abstained. On the basis of this vote, our Board of Directors
voted to extend the Rights Plan by one year to September 19, 2024. Recognizing that there might be a substantial number of broker non-votes,
our Board of Directors disclosed that it would be guided by the votes actually cast on these proposals in deciding whether to extend the
expiration date of such plan by one year.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=iccc_CommonStockIssuancesMember', window );">Common Stock Issuances [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Issuance and sale (in Dollars)</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000,000<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_AcquiringPersonPercentage', window );">Percentage of acquiring person</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">11,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_AcquiringPersonPercentage', window );">Percentage of acquiring person</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares sold under at-the-market offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,082,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=iccc_TwoThousandTenPlansMember', window );">2010 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock option expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life of options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining life of the options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=iccc_TwoThousandTenPlansMember', window );">2010 Plan [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=iccc_TwoThousandTenPlansMember', window );">2010 Plan [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=iccc_TwoThousandSeventeenPlansMember', window );">2017 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock option expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">477,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">477,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=iccc_TwoThousandSeventeenPlansMember', window );">2017 Plan [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=iccc_TwoThousandSeventeenPlansMember', window );">2017 Plan [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=iccc_TwoThousandSeventeenPlansMember', window );">2017 Plan [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=iccc_AcquiringPersonMember', window );">Acquiring Person [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage', window );">Acquisition percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue', window );">Stock options granted (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iccc_ATMAgreementMember', window );">ATM Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,833,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesCommissionsAndFees', window );">Sales commissions (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 123,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Common stock shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,553,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,714,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Common stock shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">659,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,464,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_NetProceedsFromIssuanceOfCommonStock', window );">Net proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,160,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_AcquiringPersonPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of acquiring person.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_AcquiringPersonPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_ExercisableAndTransferableDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercisable and transferable, description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_ExercisableAndTransferableDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_FeesInitiallyCapitalizedAndLaterOffset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fees initially capitalized and later offset. Fees include legal, accounting and fees categorized as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_FeesInitiallyCapitalizedAndLaterOffset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_NetProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net proceeds incurred from issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_NetProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_RightToAcquirePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right to Acquire, Per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_RightToAcquirePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIssuedPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of principal of debt issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIssuedPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostChangeDueToSubsequentInterimMeasurementWeightedAverageExpectedLongTermRateOfReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate of return on plan assets, used to determine net periodic benefit cost (credit) of defined benefit plan, in subsequent interim measurement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostChangeDueToSubsequentInterimMeasurementWeightedAverageExpectedLongTermRateOfReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the plan, including the basis for determining contributions, the employee groups covered, and the nature and effect of significant matters affecting comparability of information for all periods presented. For leveraged ESOPs and pension reversion ESOPs, the description generally includes the basis for releasing shares and how dividends on allocated and unallocated shares are used.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480489/718-40-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average purchase price of capital shares purchased through an employee stock ownership plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentCompanyPurchasePremiumPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of premium paid by investor to purchase shares of investment company. Includes, but is not limited to, per unit, membership interest, or other ownership interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478494/946-205-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentCompanyPurchasePremiumPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesCommissionsAndFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesCommissionsAndFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=iccc_CommonStockIssuancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=iccc_CommonStockIssuancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=iccc_TwoThousandTenPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=iccc_TwoThousandTenPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=iccc_TwoThousandSeventeenPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=iccc_TwoThousandSeventeenPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=iccc_AcquiringPersonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=iccc_AcquiringPersonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iccc_ATMAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iccc_ATMAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390136739392">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details) - Schedule of Activity Under the Stock Option Plans - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Schedule of Activity Under the Stock Option Plans [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Weighted Average Exercise Price, Outstanding, Beginning balance (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,071,121)<span></span>
</td>
<td class="num">$ (661,310)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Aggregate Intrinsic Value, Outstanding, Beginning balance (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.82<span></span>
</td>
<td class="nump">$ 7.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Weighted Average Exercise Price, Outstanding, Ending balance (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (1,891,421)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,891,421)<span></span>
</td>
<td class="num">$ (1,071,121)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Aggregate Intrinsic Value, Outstanding, Ending balance (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6.49<span></span>
</td>
<td class="nump">$ 5.19<span></span>
</td>
<td class="nump">$ 6.49<span></span>
</td>
<td class="nump">$ 6.82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested', window );">Weighted Average Exercise Price, Vested (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (1,068,740)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,068,740)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Weighted Average Exercise Price, Vested and expected to vest (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (1,891,421)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,891,421)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Aggregate Intrinsic Value, Vested and expected to vest (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Grants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Grants (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.8<span></span>
</td>
<td class="nump">5.16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Terminations/forfeitures (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.75<span></span>
</td>
<td class="nump">7.12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercises</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercises (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4.69<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=iccc_TwoThousandTenPlanMember', window );">2010 Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Schedule of Activity Under the Stock Option Plans [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188,500<span></span>
</td>
<td class="nump">202,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">183,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,500<span></span>
</td>
<td class="nump">188,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested', window );">Vested</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">183,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">183,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved for future grants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Grants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Terminations/forfeitures</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercises</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=iccc_TwoThousandSeventeenPlanMember', window );">2017 Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Schedule of Activity Under the Stock Option Plans [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,000<span></span>
</td>
<td class="nump">402,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">477,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">477,500<span></span>
</td>
<td class="nump">430,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested', window );">Vested</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">136,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">477,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">477,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved for future grants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">154,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Grants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,000<span></span>
</td>
<td class="nump">122,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Terminations/forfeitures</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,500)<span></span>
</td>
<td class="num">(94,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercises</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Intrinsic value is the difference between the fair market value
of the underlying common stock as of the date indicated and as of the date of the option grant (which is equal to the option exercise
price).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Terminations and forfeitures are recognized when they occur.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options exercisable weighted average vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=iccc_TwoThousandTenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=iccc_TwoThousandTenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=iccc_TwoThousandSeventeenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=iccc_TwoThousandSeventeenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390143395056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details) - Schedule of Additional Information About the Stock Option Plans - Stock Option [Member]<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansLineItems', window );"><strong>Stockholders&#8217; Equity (Details) - Schedule of Additional Information About the Stock Option Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Shares, Non-vested stock options as of beginning balance (in Shares) | shares</a></td>
<td class="nump">337,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Fair Value at Grant Date, Non-vested stock options as of beginning balance</a></td>
<td class="nump">$ 3.66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Non-vested stock options as of beginning balance</a></td>
<td class="nump">$ 7.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Shares, Non-vested stock options as of ending balance (in Shares) | shares</a></td>
<td class="nump">341,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Fair Value at Grant Date, Non-vested stock options as of ending balance</a></td>
<td class="nump">$ 3.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Non-vested stock options as of ending balance</a></td>
<td class="nump">$ 6.04<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares, Stock options granted (in Shares) | shares</a></td>
<td class="nump">73,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Fair Value at Grant Date, Stock options granted</a></td>
<td class="nump">$ 1.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Stock options granted</a></td>
<td class="nump">$ 3.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of Shares, Stock options that vested (in Shares) | shares</a></td>
<td class="nump">54,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted Average Fair Value at Grant Date, Stock options that vested</a></td>
<td class="nump">$ 4.31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Stock options that vested</a></td>
<td class="nump">$ 9.73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Number of Shares, Stock options that were forfeited (in Shares) | shares</a></td>
<td class="nump">30,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Weighted Average Fair Value at Grant Date, Stock options that were forfeited</a></td>
<td class="nump">$ 3.36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Stock options that were forfeited</a></td>
<td class="nump">$ 6.75<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390146520992">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details) - Schedule of Fair Value Stock Option Grant Using Black-Scholes Option Pricing Model with Weighted-Average Assumptions<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th" colspan="2"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Schedule of Fair Value Stock Option Grant Using Black-Scholes Option Pricing Model with Weighted-Average Assumptions [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3.48%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">3.48%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">52.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">51.00%<span></span>
</td>
<td class="nump">54.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">4 years 3 months 18 days<span></span>
</td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The risk-free interest rate is based on U.S. Treasury yields
for a maturity approximating the expected option term.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">These values are not applicable because <span style="-sec-ix-hidden: hidden-fact-122">no</span> stock options were
granted during this period.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">The dividend yield and expected volatility are derived from
averages of our historical data.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">The expected life is calculated utilizing the simplified method,
which uses the mid-point between the vesting period and the contractual term as the expected life.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390146354560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Details) - Schedule of Product Sales Disaggregated by Geographic Area - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Schedule of Product Sales Disaggregated by Geographic Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product Sales</a></td>
<td class="nump">$ 6,011,573<span></span>
</td>
<td class="nump">$ 5,396,500<span></span>
</td>
<td class="nump">$ 18,742,040<span></span>
</td>
<td class="nump">$ 12,375,708<span></span>
</td>
<td class="nump">$ 17,471,669<span></span>
</td>
<td class="nump">$ 18,567,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_RevenueSalesObligationPercentage', window );">Percentage of product sales</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Schedule of Product Sales Disaggregated by Geographic Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product Sales</a></td>
<td class="nump">$ 5,216,401<span></span>
</td>
<td class="nump">$ 4,923,265<span></span>
</td>
<td class="nump">$ 16,449,178<span></span>
</td>
<td class="nump">$ 11,173,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_RevenueSalesObligationPercentage', window );">Percentage of product sales</a></td>
<td class="nump">87.00%<span></span>
</td>
<td class="nump">91.00%<span></span>
</td>
<td class="nump">88.00%<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=iccc_OtherStatesMember', window );">Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Schedule of Product Sales Disaggregated by Geographic Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product Sales</a></td>
<td class="nump">$ 795,172<span></span>
</td>
<td class="nump">$ 473,235<span></span>
</td>
<td class="nump">$ 2,292,862<span></span>
</td>
<td class="nump">$ 1,202,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_RevenueSalesObligationPercentage', window );">Percentage of product sales</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_RevenueSalesObligationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of product sales is an act of selling a product or service in return of money or compensation or service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_RevenueSalesObligationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=iccc_OtherStatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=iccc_OtherStatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390143465728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Details) - Schedule of Product Sales Disaggregated by Major Product Category - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Schedule of Product Sales Disaggregated by Major Product Category [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">$ 6,011,573<span></span>
</td>
<td class="nump">$ 5,396,500<span></span>
</td>
<td class="nump">$ 18,742,040<span></span>
</td>
<td class="nump">$ 12,375,708<span></span>
</td>
<td class="nump">$ 17,471,669<span></span>
</td>
<td class="nump">$ 18,567,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Percentage of product sales</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=iccc_FirstDefenseProductLineMember', window );">First Defense&#174; product line [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Schedule of Product Sales Disaggregated by Major Product Category [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">$ 5,951,344<span></span>
</td>
<td class="nump">$ 5,360,063<span></span>
</td>
<td class="nump">$ 18,602,053<span></span>
</td>
<td class="nump">$ 12,253,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Percentage of product sales</a></td>
<td class="nump">99.00%<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=iccc_OtherAnimalHealthMember', window );">Other animal health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Schedule of Product Sales Disaggregated by Major Product Category [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">$ 60,229<span></span>
</td>
<td class="nump">$ 36,437<span></span>
</td>
<td class="nump">$ 139,987<span></span>
</td>
<td class="nump">$ 122,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Percentage of product sales</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=iccc_FirstDefenseProductLineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=iccc_FirstDefenseProductLineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=iccc_OtherAnimalHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=iccc_OtherAnimalHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390238025984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Expenses, Net (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpensesAbstract', window );"><strong>Other Expenses, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">$ 10,805<span></span>
</td>
<td class="nump">$ 8,687<span></span>
</td>
<td class="nump">$ 31,859<span></span>
</td>
<td class="nump">$ 12,525<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390146568544">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Other Expenses, Net (Details) - Schedule of Other Expenses Net - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_ScheduleOfOtherExpensesNetAbstract', window );"><strong>Schedule of Other Expenses Net [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 144,141<span></span>
</td>
<td class="nump">$ 144,616<span></span>
</td>
<td class="nump">$ 432,529<span></span>
</td>
<td class="nump">$ 323,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Loss (gain) on disposal of property, plant and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="num">(68)<span></span>
</td>
<td class="nump">14,557<span></span>
</td>
<td class="nump">8,099<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(18,685)<span></span>
</td>
<td class="num">(23,696)<span></span>
</td>
<td class="num">(41,476)<span></span>
</td>
<td class="num">(79,134)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceRecoveries', window );">Insurance recoveries</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text"> <span></span>
</td>
<td class="num">(365,127)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(365,127)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Income - other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(107)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expenses (income), net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 125,456<span></span>
</td>
<td class="num">$ (244,275)<span></span>
</td>
<td class="nump">$ 405,610<span></span>
</td>
<td class="num">$ (113,092)<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Interest expense includes amortization of debt issuance and
debt discount costs of $10,805 and $8,687 during the three-month periods ended September 30, 2024 or 2023, respectively, and $31,859
and $12,525 during the nine-month periods ended September 30, 2024 and 2023, respectively.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
income from insurance recoveries resulted from claim benefits paid to us under our business interruption policy related to product contamination
losses and a recovery from a vendor&#8217;s policy related to an equipment malfunction.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_ScheduleOfOtherExpensesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_ScheduleOfOtherExpensesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recovered from insurance. These recoveries reduce costs and losses that are reported as a separate line item under operating expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390144941520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 1,340<span></span>
</td>
<td class="nump">$ 229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,020<span></span>
</td>
<td class="nump">$ 3,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther', window );">Loss income before income taxes, rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeTaxExpense', window );">Non-cash income tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 563,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Value of our deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,759,519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Net operating loss carryforwards not expire</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,047,612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards expire</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,711,907<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardDescription', window );">Expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">expire in 2034 through 2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards expire</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,681,644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardDescription', window );">Expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">expire in 2037 through 2038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=iccc_FederalGeneralBusinessMember', window );">Federal General Business [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards expire</a></td>
<td class="nump">726,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 726,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardDescription', window );">Expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">expire in 2028 through 2044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=iccc_StateTaxCreditMember', window );">State Tax Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards expire</a></td>
<td class="nump">$ 981,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 981,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardDescription', window );">Expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">expire in 2024 through 2042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the noncash component of income tax expense for the period other than the portion from the net change in the entity's deferred tax assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the origin, nature, and characteristics of the tax credit carryforward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=iccc_FederalGeneralBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=iccc_FederalGeneralBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=iccc_StateTaxCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=iccc_StateTaxCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390145880944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Reportable business segments</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390143180304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Details) - Schedule of Segment Information - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Schedule of Segment Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales</a></td>
<td class="nump">$ 6,011,573<span></span>
</td>
<td class="nump">$ 5,396,500<span></span>
</td>
<td class="nump">$ 18,742,040<span></span>
</td>
<td class="nump">$ 12,375,708<span></span>
</td>
<td class="nump">$ 17,471,669<span></span>
</td>
<td class="nump">$ 18,567,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Costs of goods sold</a></td>
<td class="nump">4,428,019<span></span>
</td>
<td class="nump">4,129,619<span></span>
</td>
<td class="nump">13,632,642<span></span>
</td>
<td class="nump">9,764,164<span></span>
</td>
<td class="nump">13,602,385<span></span>
</td>
<td class="nump">10,919,183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross margin</a></td>
<td class="nump">1,583,554<span></span>
</td>
<td class="nump">1,266,881<span></span>
</td>
<td class="nump">5,109,398<span></span>
</td>
<td class="nump">2,611,544<span></span>
</td>
<td class="nump">3,869,284<span></span>
</td>
<td class="nump">7,648,779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Product development expense</a></td>
<td class="nump">786,136<span></span>
</td>
<td class="nump">1,118,489<span></span>
</td>
<td class="nump">3,079,189<span></span>
</td>
<td class="nump">3,328,397<span></span>
</td>
<td class="nump">4,394,852<span></span>
</td>
<td class="nump">4,493,872<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="nump">844,045<span></span>
</td>
<td class="nump">817,486<span></span>
</td>
<td class="nump">2,629,925<span></span>
</td>
<td class="nump">2,416,701<span></span>
</td>
<td class="nump">3,088,215<span></span>
</td>
<td class="nump">3,190,033<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Administrative expenses</a></td>
<td class="nump">528,267<span></span>
</td>
<td class="nump">514,952<span></span>
</td>
<td class="nump">1,661,838<span></span>
</td>
<td class="nump">1,611,026<span></span>
</td>
<td class="nump">2,134,295<span></span>
</td>
<td class="nump">2,263,817<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">2,158,448<span></span>
</td>
<td class="nump">2,450,927<span></span>
</td>
<td class="nump">7,370,952<span></span>
</td>
<td class="nump">7,356,124<span></span>
</td>
<td class="nump">9,617,362<span></span>
</td>
<td class="nump">9,947,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">NET OPERATING INCOME (LOSS)</a></td>
<td class="num">(574,894)<span></span>
</td>
<td class="num">(1,184,046)<span></span>
</td>
<td class="num">(2,261,554)<span></span>
</td>
<td class="num">(4,744,580)<span></span>
</td>
<td class="num">(5,748,078)<span></span>
</td>
<td class="num">(2,298,943)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">44,448,873<span></span>
</td>
<td class="nump">44,545,022<span></span>
</td>
<td class="nump">44,448,873<span></span>
</td>
<td class="nump">44,545,022<span></span>
</td>
<td class="nump">43,808,102<span></span>
</td>
<td class="nump">44,860,649<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostDepreciationAmortizationAndDepletion', window );">Depreciation and amortization expense</a></td>
<td class="nump">685,927<span></span>
</td>
<td class="nump">709,098<span></span>
</td>
<td class="nump">2,045,192<span></span>
</td>
<td class="nump">2,054,641<span></span>
</td>
<td class="nump">2,739,620<span></span>
</td>
<td class="nump">2,495,241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital Expenditures</a></td>
<td class="nump">88,412<span></span>
</td>
<td class="nump">420,515<span></span>
</td>
<td class="nump">269,509<span></span>
</td>
<td class="nump">1,811,169<span></span>
</td>
<td class="nump">1,892,513<span></span>
</td>
<td class="nump">3,975,274<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=iccc_ScoursMember', window );">Scours [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Schedule of Segment Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales</a></td>
<td class="nump">5,951,344<span></span>
</td>
<td class="nump">5,360,063<span></span>
</td>
<td class="nump">18,602,054<span></span>
</td>
<td class="nump">12,253,555<span></span>
</td>
<td class="nump">17,293,933<span></span>
</td>
<td class="nump">18,411,949<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Costs of goods sold</a></td>
<td class="nump">4,364,950<span></span>
</td>
<td class="nump">4,095,164<span></span>
</td>
<td class="nump">13,487,348<span></span>
</td>
<td class="nump">9,652,292<span></span>
</td>
<td class="nump">13,453,514<span></span>
</td>
<td class="nump">10,754,189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross margin</a></td>
<td class="nump">1,586,394<span></span>
</td>
<td class="nump">1,264,899<span></span>
</td>
<td class="nump">5,114,706<span></span>
</td>
<td class="nump">2,601,263<span></span>
</td>
<td class="nump">3,840,419<span></span>
</td>
<td class="nump">7,657,760<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Product development expense</a></td>
<td class="nump">59,140<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">154,233<span></span>
</td>
<td class="nump">2,543<span></span>
</td>
<td class="nump">11,103<span></span>
</td>
<td class="nump">66,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="nump">699,584<span></span>
</td>
<td class="nump">641,682<span></span>
</td>
<td class="nump">2,224,836<span></span>
</td>
<td class="nump">1,890,404<span></span>
</td>
<td class="nump">2,447,137<span></span>
</td>
<td class="nump">1,871,926<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Administrative expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">758,724<span></span>
</td>
<td class="nump">641,682<span></span>
</td>
<td class="nump">2,379,069<span></span>
</td>
<td class="nump">1,892,947<span></span>
</td>
<td class="nump">2,458,240<span></span>
</td>
<td class="nump">1,938,272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">NET OPERATING INCOME (LOSS)</a></td>
<td class="nump">827,670<span></span>
</td>
<td class="nump">623,217<span></span>
</td>
<td class="nump">2,735,637<span></span>
</td>
<td class="nump">708,316<span></span>
</td>
<td class="nump">1,382,179<span></span>
</td>
<td class="nump">5,719,488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">23,672,583<span></span>
</td>
<td class="nump">24,119,683<span></span>
</td>
<td class="nump">23,672,583<span></span>
</td>
<td class="nump">24,119,683<span></span>
</td>
<td class="nump">24,735,413<span></span>
</td>
<td class="nump">20,539,523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostDepreciationAmortizationAndDepletion', window );">Depreciation and amortization expense</a></td>
<td class="nump">346,430<span></span>
</td>
<td class="nump">355,673<span></span>
</td>
<td class="nump">1,027,711<span></span>
</td>
<td class="nump">1,020,909<span></span>
</td>
<td class="nump">1,365,988<span></span>
</td>
<td class="nump">1,169,011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital Expenditures</a></td>
<td class="nump">87,286<span></span>
</td>
<td class="nump">341,386<span></span>
</td>
<td class="nump">235,600<span></span>
</td>
<td class="nump">1,038,033<span></span>
</td>
<td class="nump">1,096,819<span></span>
</td>
<td class="nump">3,497,834<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=iccc_MastitisMember', window );">Mastitis [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Schedule of Segment Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales</a></td>
<td class="nump">60,229<span></span>
</td>
<td class="nump">36,437<span></span>
</td>
<td class="nump">139,986<span></span>
</td>
<td class="nump">122,153<span></span>
</td>
<td class="nump">177,736<span></span>
</td>
<td class="nump">154,558<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Costs of goods sold</a></td>
<td class="nump">63,069<span></span>
</td>
<td class="nump">34,455<span></span>
</td>
<td class="nump">145,294<span></span>
</td>
<td class="nump">111,872<span></span>
</td>
<td class="nump">148,871<span></span>
</td>
<td class="nump">136,347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross margin</a></td>
<td class="num">(2,840)<span></span>
</td>
<td class="nump">1,982<span></span>
</td>
<td class="num">(5,308)<span></span>
</td>
<td class="nump">10,281<span></span>
</td>
<td class="nump">28,865<span></span>
</td>
<td class="nump">18,211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Product development expense</a></td>
<td class="nump">690,052<span></span>
</td>
<td class="nump">1,082,346<span></span>
</td>
<td class="nump">2,821,525<span></span>
</td>
<td class="nump">3,220,075<span></span>
</td>
<td class="nump">4,242,329<span></span>
</td>
<td class="nump">4,317,921<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="nump">144,461<span></span>
</td>
<td class="nump">175,804<span></span>
</td>
<td class="nump">405,089<span></span>
</td>
<td class="nump">526,297<span></span>
</td>
<td class="nump">641,078<span></span>
</td>
<td class="nump">1,318,107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Administrative expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">834,513<span></span>
</td>
<td class="nump">1,258,150<span></span>
</td>
<td class="nump">3,226,614<span></span>
</td>
<td class="nump">3,746,372<span></span>
</td>
<td class="nump">4,883,407<span></span>
</td>
<td class="nump">5,636,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">NET OPERATING INCOME (LOSS)</a></td>
<td class="num">(837,353)<span></span>
</td>
<td class="num">(1,256,168)<span></span>
</td>
<td class="num">(3,231,922)<span></span>
</td>
<td class="num">(3,736,091)<span></span>
</td>
<td class="num">(4,854,542)<span></span>
</td>
<td class="num">(5,617,817)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">16,798,955<span></span>
</td>
<td class="nump">18,132,922<span></span>
</td>
<td class="nump">16,798,955<span></span>
</td>
<td class="nump">18,132,922<span></span>
</td>
<td class="nump">17,827,839<span></span>
</td>
<td class="nump">18,315,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostDepreciationAmortizationAndDepletion', window );">Depreciation and amortization expense</a></td>
<td class="nump">319,815<span></span>
</td>
<td class="nump">328,381<span></span>
</td>
<td class="nump">958,260<span></span>
</td>
<td class="nump">969,666<span></span>
</td>
<td class="nump">1,287,600<span></span>
</td>
<td class="nump">1,263,318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital Expenditures</a></td>
<td class="nump">1,126<span></span>
</td>
<td class="nump">79,129<span></span>
</td>
<td class="nump">33,909<span></span>
</td>
<td class="nump">773,136<span></span>
</td>
<td class="nump">795,694<span></span>
</td>
<td class="nump">429,988<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Schedule of Segment Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product sales</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Costs of goods sold</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">28,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross margin</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(27,192)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Product development expense</a></td>
<td class="nump">36,944<span></span>
</td>
<td class="nump">36,143<span></span>
</td>
<td class="nump">103,431<span></span>
</td>
<td class="nump">105,779<span></span>
</td>
<td class="nump">141,420<span></span>
</td>
<td class="nump">109,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Administrative expenses</a></td>
<td class="nump">528,267<span></span>
</td>
<td class="nump">514,952<span></span>
</td>
<td class="nump">1,661,838<span></span>
</td>
<td class="nump">1,611,026<span></span>
</td>
<td class="nump">2,134,295<span></span>
</td>
<td class="nump">2,263,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">565,211<span></span>
</td>
<td class="nump">551,095<span></span>
</td>
<td class="nump">1,765,269<span></span>
</td>
<td class="nump">1,716,805<span></span>
</td>
<td class="nump">2,275,715<span></span>
</td>
<td class="nump">2,373,422<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">NET OPERATING INCOME (LOSS)</a></td>
<td class="num">(565,211)<span></span>
</td>
<td class="num">(551,095)<span></span>
</td>
<td class="num">(1,765,269)<span></span>
</td>
<td class="num">(1,716,805)<span></span>
</td>
<td class="num">(2,275,715)<span></span>
</td>
<td class="num">(2,400,614)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">3,977,335<span></span>
</td>
<td class="nump">2,292,417<span></span>
</td>
<td class="nump">3,977,335<span></span>
</td>
<td class="nump">2,292,417<span></span>
</td>
<td class="nump">1,244,850<span></span>
</td>
<td class="nump">6,005,634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostDepreciationAmortizationAndDepletion', window );">Depreciation and amortization expense</a></td>
<td class="nump">19,682<span></span>
</td>
<td class="nump">25,044<span></span>
</td>
<td class="nump">59,221<span></span>
</td>
<td class="nump">64,066<span></span>
</td>
<td class="nump">86,032<span></span>
</td>
<td class="nump">62,912<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital Expenditures</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 47,452<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostDepreciationAmortizationAndDepletion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of tangible and intangible assets over their useful lives, and reduction in quantity of natural resource due to consumption directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostDepreciationAmortizationAndDepletion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=iccc_ScoursMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=iccc_ScoursMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=iccc_MastitisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=iccc_MastitisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390144786768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Related party products purchased</a></td>
<td class="nump">$ 390,322<span></span>
</td>
<td class="nump">$ 128,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="nump">$ 35,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,507<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479196/954-310-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390142929664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_EmployeesSalaryPercentage', window );">Employee&#8217;s salary percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_EmployeesSalaryContributionPercentage', window );">Employee&#8217;s salary contribution percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Employee benefits paid</a></td>
<td class="nump">$ 55,989<span></span>
</td>
<td class="nump">$ 50,126<span></span>
</td>
<td class="nump">$ 159,504<span></span>
</td>
<td class="nump">$ 135,698<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iccc_EmployeeMember', window );">Employee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_EmployeesSalaryPercentage', window );">Employee&#8217;s salary percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iccc_EmployeeOneMember', window );">Employee One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_EmployeesSalaryContributionPercentage', window );">Employee&#8217;s salary contribution percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_EmployeesSalaryContributionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee&#8217;s salary contribution percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_EmployeesSalaryContributionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_EmployeesSalaryPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee&#8217;s salary percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_EmployeesSalaryPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480266/715-60-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iccc_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iccc_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iccc_EmployeeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iccc_EmployeeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46390145035120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - ATM Agreement [Member] - Subsequent Event [Member]<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Oct. 30, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares sold during period | shares</a></td>
<td class="nump">78,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from at-the-market offering | $</a></td>
<td class="nump">$ 289,719<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=iccc_ATMAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=iccc_ATMAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>89
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( *F ;5D'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " "I@&U9^(-.5.X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2L0P$(9?17)OIVG50^CFHGA2$%Q0O(5D=C?8I"$9:??M3>-N%]$'$'+)S)]O
MOH'T.@@]1GR.8\!(%M/5[ :?A X;=B * B#I SJ5ZISPN;D;HU.4KW$/0>D/
MM4=HF^86')(RBA0LP"JL1"9[HX6.J&B,)[S1*SY\QJ' C 8<T*&G!+SFP.0R
M,1SGH8<+8($11I>^"VA68JG^B2T=8*?DG.R:FJ:IGKJ2RSMP>'MZ?"GK5M8G
M4EYC?I6LH&/ #3M/?NWN[K</3+9->UUQ7O%NVW+1W.3SOKC^\+L(N]'8G?W'
MQF=!V<.O?R&_ %!+ P04    " "I@&U9F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M *F ;5D;37O9/ 8  -PB   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MM9IK;]LV%(;_"N$-0PLDD4@YL=TE!A+%Z8+EXL;IAF[8!T:B;:&2Z)&TG?S[
M'4JRY!04[0E6/S2ZG==\>7AY*/%\S<5W.6=,H=<D3N5%9Z[4XI/CR&#.$BI/
M^(*E<&?*14(5G(J9(Q>"T3 +2F*'N.Z9D] H[0S/LVMC,3SG2Q5'*1L+))=)
M0L7;%8OY^J*#.YL+3]%LKO0%9WB^H#,V8>KK8BS@S"E5PBAAJ8QXB@2;7G0N
M\2??.],!V1-_1&PMMXZ1MO+"^7=]<AM>=%Q=(A:S0&D)"G]6S&=QK)6@'/\6
MHIWR-W7@]O%&_28S#V9>J&0^C_^,0C6_Z/0[*&13NHS5$U__Q@I#IUHOX+',
M_D?K_-ENMX."I50\*8*A!$F4YG_I:U$1VP%N30 I L@/ ;CN%[PBP,N,YB7+
M;%U318?G@J^1T$^#FC[(ZB:+!C=1JM,X40+N1A"GACY?,8&.D9Q3P>2YHT!3
MWW&"(OXJCR<U\0-TSU,UEVB4ABQ\'^] 6<H"D4V!KHA5<,(6)\ASCQ!Q2==0
M'M\>_ABHNO!WQ?'*^O$R/:]&[YH'2VBU"MVF>9_1;>_O.W@*W2J6R'],599+
M=LV2NF-^D@L:L(L.]#S)Q(IUAK_\A,_<7TU^#R3VSGVW=-^UJ5?NG]\6S.34
M'H[=XR\F2]:HAI9.2TNG^UGZLJ1",1&_H2>VX$*9[-FEE%B:*L6W1C6T=U;:
M.]LS8X+"6)LUUWI_=JTIC:71H#6LH<%>:;!G+=0H59%Z@^X(N<OG *0'/N0O
MA0#?)I=VP6_&8<^W!C7TV"\]]JU%NH0,AED6;V(Z,UFRQ]<FSAK6T-2@-#78
MKV6.F8AXJ"<,G3GCL&)7*J>(VCG"&M_0)W:K*=7=S^E-) ,:HV^,"G0#%\WS
MJUVLSJ(]K*G'+6S _\MCD=1ZEW:Y+Y[1HS6HJ4=2>236N;\<:O:?^0O% TW]
MAU)[[[]"'VQEBXW_)S:+I(+I1*$'FAC[ZPZAV_O[K_[H[@[YCT]CY%R/'*/;
M-D@'5ZB#[;!2N/6A40MHT+? LZ_H=_9F]&N7<N%?'^.S+C;Z; -_<,4_V$XM
MA<^;*&;H89F\,&%T:!=Q77R,R< S#TUM !"N" C;L:4P^$Q?T6T(V8RF49#W
M7HM=NR2X=;T^&?1=H]\V> A70(3W)** "P"]S.H1FBB86Q$7R.=+:-'0L'EH
M[KMV]>N1T7(;>(0K/L)VP"E@[]T$:^.)'7+'T)://7-G;0.9<,5,V(XZFT&I
M\)N3?)3.LO36S+1VQ1K<M4<U]$DJ9")VRBE\3N8LCJ&E)@N:&@?>'3*UX&N/
M:VJOHB5BQYNM,1<Z)#32&1=F?W:=!YX>TR!@( ,B82YH]-L&.9&*G(B53,IT
M)A32>;64<%L:&^L.G;H5MCVLJ;T*C,A>8#1*F)CISO@9%-3<VF[M@O7MM@TF
M(A43D>X^!.SS5,%:6T.^Y&G*XIT<3 [$.$4MM$%,I"(FLA<Q788AJ,NCS0'*
MZN Q-<XX.R1/S]!H!:U',):B:Q&MS-EO Z1(!5)D+Y J??OZ#(CBF:]3HV>[
MW!BFKIBFH=%I&PA%*H0B>R%4Z;2$I['@JR@-S"FV:]X;P<D>U-1H!4[$3CH_
M&AUSJ0"@_HH6M7RX0]'M8M>X>+?'-75:D1,9[#-TC><<.ND-K 5R^)>[AZX#
MD5!1"VUPE5=QE6<'HJS+7@I&:].[0^ #<7L?C9\EVB JKR(JSTY"=SQ[ZY1E
MMWY9MT.DW^L?DU[/N*BSAS;U5Q&4M]>[I[M(:MS?W6J]@[YX.I3:>_-;W]SL
M./0<J1B&WRG"Y,/+1S1AP5) ;1A]VY4 R1)8^$\4#[X?H9_=$^RB!2P65S1>
M,K0 &L\^?!KKH WT\BKT\NSOD)X%#;.%WEORPF.C=;O K>_[1E]MP)17P91G
M)Y]-,M'H-9C3=,9J7RKN$'JXG%Q?&C\OV@.;.JRPR=L+F]XWO4GV?1T]+A5,
MN*G.K-'R@3"HJ(=<[313T_LY5L/^ ./3_N#<66U;=+;V#^@U3;:M0J) OSG*
MMQ*45\NM&Y?9A@6G>CS?]W%/]9)(HIA-(=0]Z<&OBWPK17ZB^"+;C?#"E>))
M=CAG-&1"/P#WIYRKS8G^@7)#R_ _4$L#!!0    ( *F ;5DQ]< \V 8  )D:
M   8    >&PO=V]R:W-H965T<R]S:&5E=#(N>&ULK5EM3^,X$/XK5G>UVI,"
M]5L2AX5*;.%VJ^/M:+G3?32)H=&F<3=Q8;E??Y,T-&WB!-"!!.3EF<DSCF>>
ML7/XJ+,?^5PI@WXMDC0_&LR-61X,AWDX5PN9[^NE2N'.G<X6TL!I=C_,EYF2
M46FT2(848V^XD'$Z&!V6UZZRT:%>F21.U56&\M5B(;.GKRK1CT<#,GB^<!W?
MSTUQ83@Z7,I[-57F9GF5P=EPXR6*%RK-8YVB3-T=#8[)P9B5!B7BKU@]YEO'
MJ CE5NL?Q<DD.AK@@I%*5&@*%Q+^/:BQ2I+"$_#X63D=;)Y9&&X?/WO_O0P>
M@KF5N1KKY.\X,O.C@1B@2-W)56*N]>-W507D%OY"G>3E7_188?$ A:O<Z$5E
M# P6<;K^+W]5 [%E0'B' :T,Z&L-6&7 RD#7S,JP3J21H\-,/Z*L0(.WXJ <
MF](:HHG3XC5.309W8[ SHZ\RD6FHT+3PD*//-ZE<1;%1T6]H#]U,3]#GC[\=
M#@T\J< /P\KKU[57VN%UJI;[B&$'44RYQ7S<;WZB0C GI3G;-1]"?)L@Z29(
M6OIC'?[&-]?7IQ<S=#R=GLZF![9XU@ZXW4&12P?Y4H;J: #)DJOL00U&GSX0
M#W^Q1?=.SG9B99M869_WT5CF<R33"(7%@?JYBA]DHE*3VZ)>N_)*5T7"/XR8
MP,)C,.@/VP&U<8$O?$XVL!VJ?$.5]U*=93)2D,BA7@$_* JA K*WB;)17;MR
MMRA0AOV -*E:<$2X3# [5W?#U>WE.DD?8!!U]F3CYK:>Z7,/<Y<VN%EP@A#1
M-8[>AIO7R^TJ4TL91TC]@N*>J[Q\_=K,5085),N -Y)YKNQ3P&MQ8@1S(1K4
MVS >,"%<.W-_P]SOGP':R.05)/W6TPD\W.?":]"T  GW N%B.U&Q(2I>&&(0
MSLP\.6@)]=*4(USDUA(4S3@H5<9&6[3GHBLH9JW\L@!]UW>]KED;;&@'O;0O
M@;0T<7J/$@5:A[)"U/;TW=X*3LKAMM$.VN_:#:A/FG/"AO-AO ,[:8)K3<*]
MM+]I'3W&26(5'MQZ:N"ZKM_@]B)LE]J67)(7ZH"1Z7T,1:J:KITOOW*T6[&$
MP$VB;1B#.2(ZB-:21WI59G19YG]W2E7F._2$"((FO3;,]3VW(^])K5*D7Z9F
ME[/CLTJ0K?18>W+!#R1],W=LR$+%"*8=)&M](OQ5?</9Y/CKY&PRFYS:FP?2
MJW-O[1[>R]MNT+70D7ZE&U?5>*FSLM'6=] 6WQJD;Y/X7A:7[/.I+6Z$^P%V
MFU7#"H2IA[MRLY9!TJ^#%N:Z40"36-[&26RL,DXL(B<HY;P901OG<4Y]KR.
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M R&M/=B.!;$-:5\0#[>^&Q0?;<YE=A^G.;16=V"*]WT8C&S]'61]8O2R_)0
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M5P+P_4P(^?I!_<#V'9#^/U!+ P04    " "I@&U9(>83[P,$  !R"   &
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M\2CK0%81)/T)R">XU<J5%FY4COE_[4=$J&>5'EBMTC<!-]@,83H^@72<SM[
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M-D?#"G1>:*I$MV$'_=^,Y3]02P,$%     @ J8!M6??QI3H<%P  2C\  !@
M  !X;"]W;W)K<VAE971S+W-H965T.2YX;6RU6VMOV\B2_<Y?T?"=64@ +4NV
M8CN9)(#M)+,&\C!B9X*+Q7Z@R);4$XK4=)-V?'_]GJKJYD,/3^;.76#&H4AV
M=[WK5'7SY4-IO[FEUI7ZOLH+]^I@657K%T='+EWJ5>)&Y5H7>#(O[2JI\-,N
MCMS:ZB3C0:O\Z'@\/CU:):8X>/V2[]W8UR_+NLI-H6^L<O5JE=C'2YV7#Z\.
M)@?AQF>S6%9TX^CURW6RT+>Z^K*^L?AUU,R2F94NG"D+9?7\U<'%Y,7EE-[G
M%WXS^L%UKA5Q,BO+;_3C.GMU,":"=*[3BF9(\,^]OM)Y3A.!C#_\G ?-DC2P
M>QUF?\>\@Y=9XO15F7\U6;5\=7!^H#(]3^J\^EP^_+?V_#RC^=(R=_Q7/<B[
MSZ8'*JU=5:[\8%"P,H7\FWSW<N@,.!_O&7#L!QPSW;(04_DFJ9+7+VWYH"R]
MC=GH@EGET2#.%*24V\KBJ<&XZO6M*$.5<W5K%H69FS0I*G61IF5=5*98J)LR
M-ZG1[N51A?5HU%'JY[Z4N8_WS/U<?2B+:NG4VR+367_\$>ALB#T.Q%X>/SGA
MK5Z/U,DX5L?CX^D3\YTTS)_P?"=_FWGU/Q<S5UG8T/_NDH,L,]V]#/G5"[=.
M4OWJ ([CM+W7!Z__ZQ^3T_$O3S Q;9B8/C7[Z]LO'SY<?/ZG^O1.W5[_^O'Z
MW?75Q<<[=7%U]>G+Q[OKC[^JFT_OKZ^NW][NHOSIN8]'ZL>G5X-DJ"X39QP)
M](8X+:J$?>^K5LOD7BNPOTZLSE2UU'#(M%RMD^*1!%T729V9"H_FIDB*U"1Y
MY#!:(P!4CMR?_1AO)GFNDNQWN(8\&CPL3;I4F):6351!SIIC1%I;2P.*I*JM
M'F+-I*+78F4*5=96E6M3@+I8%3K5SI$ET!.;::NJ4B'R8%S$PXC>AC#5(8R6
M+<H*KNERQ$2L-R)NYV6.<,<L>DO"F")+;.:40ZB=/?*4[YHI.S9WV[QY6>(?
M-7AW<7LY'$5W- "7-(%3O^I"6\CBD8;J-4FN:[?@/#7K')8[^/7BXL9S_]!0
MUO!']T!F;<$2)H."2ENQ>%I^T[* ;EA4T"KBG8L@:B0&R^IUL=*)+;"N4[BG
MW)*D B94FKBEFF,]-U*?]5Q;74#2M#@11=*&%!P155:0HA9YXG$5>-TIEZLR
M8U]EVQK,ANJ*UJ$%^>+M'[6Y3W+6#W0!ZITAG9+E+!&EP69N\$X& NZUV!$N
MX=\U*U54OF*S03BNEDRGU5JM))Z!>1!HK%K7-ETB)Z@LJ82OF1:F=4O#2*CJ
MW&$NUZ(B5J'0H8D@:!?*@+2UBV9)^@TWO;%\&=V.U**\U[8@,MG.EF6>P?YD
MS=)NK4T3ZN]DW43T.YV1S:@W4+(SE;HF"X".-21JH7<OT'=OKJ^&$-'*5#0L
M^NGXV3@>C\>LW-8J2&*FJGD,/<EDUM(B:$!6'Z%/=3)2@W2H[FR2Z:!+!U-(
M-2B<Y9U[MKU'TDD3."]X][Y76K/ PGD$294&!"<K&J9RXBP!CR %"H.&:"%@
M%965]:R:UV2\>8  #TL-'+!>(Z;30B/U(2F /%C_F:ZT18(E-5)P(B]AT?0F
M\PX-^\=$8@Y0WXR#'M0$,X.MSCFB51:#<F(AL$@&BI=J1X^7!KG=@I <"H+X
M#+F&$$?QL22ND@6]25&M.T4)^BSDE>M[9*MHCJ146EC97E%Z^Y=I8:#KQ('?
M6BM#\9+\G80C1MT=/$MRE@ %]+KB $;TD$!6)?GI$C2>C&'\CVX4W819DSUT
MN'KV.Q3A>3,%Y VU*3B074 7UPA/B>-@VL9CO"O/V_?)VK:6RFH.]6 @0AS2
MAZP9LDI3(EYHPA\P2D3)U0RR"Q""/ ;_GD H:5([S0* (75$%$AR+3Z(60ND
MA/"8Z+ U-$FB<36R4: V$NJA.'; W22\ ;MR<\(W3_;K\@&1H=*DK+E8<Z9A
MOAG29S!SMNN/Y2XM1 ]Z8XI6;.K?$!O%])3B$0&DKI5VB$;&OS=E[> E?N&(
M%B9>\!;EVHQD@U!80NS,DHS6&;/!TK3M,LQ",_)OTA]=[-,*:7A++3'ERB9.
M9))22?M/QPHQDF#2G> X17#,AHC"]X@:):R]O8(\\CH#OS9YH$P$CI(<>99*
MG$-3'*YM2?-%1"<BLD$!D"$W$-=TR[B.="6"@D2P F[3TL&$R\)C&NLJ3!C[
M*_BY6NEJ668Q2:D 5$&IEYM_L3*15. 2@XX($HZ640B_&;)7GI-*D-TH<L@J
M'I)!'-8Q2IM1# 3]L01P+.'* DL\DKUD)JUX.:+4"<DK0!D!()EQ2#.8C9T0
MV<M1 ./,!8STM2\?M4,^Q@N9K,F+N2OA/)F!<1JW2HJ:@JO8&!G@$@@/OED!
M[L J0WB4XID0 !N()BGA1T082DO([*Y)-N)3\A\UP@FG>@GL,U="'BEE@E%C
M#(8SDH"W!LJ$G&[]H*H?'K+RH6"(%_02[=+D2'WB\-Y:G>O/0$0!4*.T)E7X
M-(?_,"UF8:$"3%=TBV)D&$NP1=5K!B@SC7QVKX4#5W-Z$[/M639+A4P%BLOJ
M-"0D$J&_(Z IN4],SAS,;;GJI*&R %.0-DD$("6Q*W!'HZF 8\X@#FI25/B_
M'1?1.(=E4K9+)O"Q(8;L#B^0#R,[9*%N:"CB<#6'\4K4;1S[&1P;!<>-)8A<
M/<;J)J>ZDK@F;+HFP!&S<WVE@ *;!Z"JF'D_8-T,T&& =]F(RE!J-1Q2L>:=
ME6!%R#3@LT7F@L*#'XD#.,*,8$4@E&N-A"T&6*3PF9"5[F%!XKCJ8*D3%63N
M=/'(:N'@ 31,,!J34(E+[N^!O";;EFG:M2!0"I(Y(KWK+S)25.G \TQNJD<R
M>ZX=R?:!T--*8MK)"6!UEAD=O4\*7DK4(J1_- @PZHVM43;4,X(N>#!X<SMD
MW7[6AW=D!JC!SZ:_J,O:Y.RFF/,=<_(&M0I)8?.%R=FSB]ZO2S68#]4GD3=N
MO8<Q:*XZ?/3G]<AHR/G8<2"W7-X2()@HR^HLYX>02;0J,YTCD'!12T$<N.-?
M(03X6,["E[BXHF A]I1P,-4D+NB] ]1+^.I"L#T[P3=/ 5#.HU2Q7E$TGKRG
MM!%#0:*+G@5H5".AVIS1+:NJFW]E1DH,;',=RA/0:0&&UJ4$PRZ[:O#YTY>A
MGPV0-I@A:BXG+XXBO!',CV:6A7*3S,@^C*\9F_7:A,?O=44D<J,>7A;RWUJZ
M%#ZS>3.<UUSY]64440(0&X:+L!6V+(O)-H12N$%0*WV?@IH:G%,>PYS4!O&B
MIX(E]O>1CJA^((\(($C2>0%&H<C,X#8P)?LS7JXA5B2D=V1BC0EZXZ*Z=4O-
M9$/S'#Y4LP4%CEI&8H' 9875@@!=M25BJGXV I$DAQU32AP6JF)6#@ VKE9)
M W- O40K#D"5%G@MQN1UPN.142CB2L9I04.4(F@FC#4D33Z8G*HJ;5/C+5<6
MX/P<UJ3;9K5&@@]KR$L!M'0,FK2'4A^X0V)5 $!<#76,)0J2%IU0OZ'C,FE.
MQB%(F<V9R>&"E6J]MM'A<U;3N894*+TV\@_>@"6Z;D!4BI@C5G[2"O!!Y_=M
M]\*&LEGJS$Z@(HH[28^2A)<#RO&D\*4RAQ>*78S15C-&@HV[R6!DPR5PV2&1
M$&V8X0YC4CN,::2NO%X]$O"4+*SVS;>@ROL$(() @27RPCJQP"57>3RZPELP
M%A*_SWSKQ&0;L:^)#I+\+,]1K[SY<#62. $2NN"L(M&N#>Y5\EU+#MOG/6)@
MD90I]$N"/9M@&ZI-U\4O?8':B $EKUB%0S R\T<NJ5?4V8!WV(!%:0C7VJEE
MD8%*H%M;/G <;J)AQ%8O.SR\5=*@K#^)I9!=4PSLCZ=]]3,L#""9&6KB9D0V
M2#YI+*_!^$K?LZY)%4LR03;+U-BT7DE>IQL9=0,]RF3H GMEI^L1(L&9 @])
M;J9#89GTX)N+C@?+(>MU<BQND4G[DYM>C9@ \A94O8&(A>%>5IND?@72XBCT
ME5M5MB*W->VKP8,EU/2,/]H)Z?X?,)QZ"L-%?Q?#A99_4X=N<]_)][+3)6TM
M0:Y+LW9Q5)3%(<44+G!:QR<19S",'&D/XW6Z+,J\7#S&4IEQ^,OTG -3ET@4
M;UW7[S5'.?/#\OHF0R!=R(T&$FX8\"3?X1J5-;,:]C+<:F<L@OHY_/O=#@!Y
MQV840'O;,@G;!IP@7).:O!O@O59XD1<>FSI+&-9/K!H"EJR)P4:?4VRYH6G@
M?41:_;+Y8JB5"GD..1K3?P7ULR2I#Z1YU>F'P&*I.4-N\AL[LJ_7WI?%XO ]
MXQ;O#&!*XAQU.E%:]1P_I]=S@3F2$:-^R&X:Y)C[R>(HW@1 ?90ICL_EK#@C
M![<MBXPETR,&%(2WHE8'5(ZSLFS&09\MC-7:2+F;P1>UR9J&$$,99(@J*'.;
M;8K5U"A#I;T=O:*0_C:'44P4SA:VK-=B$M#74N>"&ZEHC55KMMLNV.W)>LE(
MIML1B6$?-O+1F,O*?S\&N[U!^$OC,,P%D<$*7$/]<.VXG2/:Y)Y[VY5N\':'
M?+<LZYS2=,A/H2/FO-WS $G#OH<O@*+=P&(?SRD>\WX-JG9J+Q95Y/GJO$GZ
MXAX]$]8!?%*_M)"-.YP#,U3O*.[\QF+Z .NMK8]SUT4?:[;A:=5Y+6[W]2+?
M0[DWC@$UENYMEMV5:Y.J\^-QO'=-;GT:E^8EW7/1>Y;/!+7P^?'D^!?:6DS%
MF) K1"Q_U"4)G7M^KH,>3#AU$0%[?>/<0WIA =/&QVX<FS3AN,,D)ZN1)^;X
MSXF)/#'<D3<K$&1W+\=]3C\\[!!34PWICWA 1C&L2ZF]*!19MG7Y%?N6/[<8
M*&;DC[Z$1*!E[%LM802+)=? Y2SLL7'\:%=1(A]B,@E,GCS%9%VT@Z,09/;P
MY\-"W./2;ZAO) )23/7(ZY[]@IFH!^@"_,7*,^H/^Z6:NT([:A_,0?&:6][L
M;S77M&P7H4T@'MLA\9%#:ZC@4JD2.0$*M=QXH[:%V +[0.1] #%D3B4+-YU@
MY;S![#UZ5TY?&H09FRYE30;SG04E$)"S%CO(;#>"NU-&S904>'NMA5YXX12^
M9N%)C.[L)P6(M=N[I7P68! 2"&/&9H*4,T2B1 $U6;I?ZZEY23&TOTLJM[JB
MG7\D4SB\^KW.%E+G<>]0.LY.^7U&7W @BOCIVSWT4400AOH>O"V-<A/0TEMV
MLQGB>ZBSI/@6;H9N%V]64I&,Z05';6UG<U]>F.!&3\M;Z!HVUB%R<ET"W::2
M,)CB'*.-VG>T6\@7)NX#L[YU=2=/9&,@V@Q;<;M7,2=)SC0*<B T/]-V.2QX
ML2($%EI]#+SO6?^A$-JN@]BXN%#D!DH4EI1 W <OI(3MGH/5B\1FP5D]5<WV
M\#X.GO2T-]PCC/[J'AV)3#;=_$ZKYI,V>XD M/^1S;RHW<PC"83D%E#)3M.B
M4JR?XIK$ID)B\[A5,ZI/PW&4G2[ EFK];BQM'^[,@GM(X68)JJ+V>)-@]+^X
MOWS7P6?B+RYT69XF?O]".[=,!;A]#[4I>QQSXZ>5I<E(8*TE5=>Y;T'X'B";
MNL>NLO_/;0M=W!M;%@+]M\%FP\S<?-=9Z'0@XF1Z5CW)0K3-@D\L65,X[^%!
M.CY^?7%JSK%-Q\=C-"D@D;C=B[T;T WJ"H G8(([:LU&4ER]B*Z>UM5/ZB0^
M'Y_'IR<GN YPHGO5/(_>M[;W(KIL9-5]^7E\-L: X\GNNYZ9+0'^IWAY?G8>
MGTTG>SCQ3W^$C\DXGH*X\\G9OMN#WX? S=R-MTUQ^]FX;]MW4]JPAE720PZL
MM-,A)56TZT $?+5;V/(I*]\#"1C(]T*X[_.PA,UQF_B;[N),Y9 1R>A*3,[;
M7D2!%)( :0BTF%RR5K1Y>!$@:4$9P/M[LQR$'TMSEZ(9TBXU^^+^%FXG;?38
MZHI!?U]S[4"\>OXHB4;-]BL!K-Z9B:;D#O,@*?,F1N>(2W." A0!W+3GI_)V
MCY JRO8T5=9#6;V9HT[OB1NDF;DW&27<IA-5=NNW5DA,_F,?;&5X:KDR6.AR
M89,UX Q%@&2D;DE-M$J/E#";G#24)IX0,QG_K,+Y*DJKO!/C-YQ%YQQ:4!6B
MR-H;65Y$G:Q[1T<7#_DH=C<9?Z1DS'<C#GX<ZYJKZ$K.YJH+-3U1/ZMG8_R9
M3NG/N?JY>7I)S:"?U?%S_#FA]_BG'/?;929TI(K#:$<<4<?@_T0<9'TBDFKO
M$C\D'@E5_+?#Z<D9\7?2YX]X/CG%G\&WH?I,& P\?.X@HZ\=^$9=''YA!^+J
M%N*1%.*GX].XF9/E@OC"Q\S]!MY5(YK!Q>T5O3]4@WRHWOH6[P8=?D^ ]PU4
MV"8D;R[""4B:U)M3Y()M;BH $H3/2Z-HSJ=*UZ;BLR/2][[([A&K#./F=H?#
MMYTS\=JP=Q' /6+!HCFRW-DW9C@8]39!$C^]KU-<B\VQ=-ZZ@^\ \UM^\0U*
M$M>A(_%'2/*\Z3RO$XH[P@.'J(;3L'73.5?0GI/ID-\YKY(^IKEN#@?V-G^D
MD9_M:^2SP$(UP4M$QC^B^-2+27C@ Z(TO#H][/8PT$@-5K0UP8?J[FA#:O-(
M@C]PQYM5.XPUVM$U.IL"G/3FW/W2X61,99RE*LX?IFWJC&AK[1F?^7*I-3,Y
M#4&]KE6]ZA4?=/K:<5$I!LH->#YMS.UTB =XF8[5ZSE%BIGF_:W-';>=GQ9P
M*T".&*/NH3.GNXZI20W"A].I_DC2SNF:)*<\(#<>^#T^*Y'[$\E$*C(RLPSE
MU87/\[1P%':6.'%O')(-?7/%7T;(8OI[ OGXQ?RY\&M"QK0W%0+)K=^Z:0\+
M@P86;ETM2^M;CU\I%,SU YN/M'+BR%.!JH2ZS=IVZ6G5MDT&[8>TD[.%/>J$
MBS36"%+*I-T3"IL  O&#'F$K #ETE"L2Z$X!G&:VNJJMEW8X"L0;O^T1S$:J
M/<M >?E=BK*_>OPV!R_U8DGRV((_8?\K@'Q_#(%<7VIV_XT$&1(L5LJ'IGAP
M[0::ZQP9FYS"9XNANJW*]-OA)?<H* DACC6?T'3]U_%[TLM(N^_U?#G:2CS!
M32?G<6_^0UZXO^2@'*J/\*KW@$SJ!CS@*<*UNN7O.^@)@2D^^Y_*$_GR@\X?
MS:@R)\)JJ7^BI[*A)^KXE&)'K-Z&CTEH35[,PQFU&\ZH'X S#;5AVXZQ N$R
MXIM""Z6_G]3@;#R)3Y^/U9!^/)_*AP_\XS@^/9O$D_.I_)RB;)K&9Z=G:AA]
MY8__R,YH(V.A>_+HGYX_Y$^D4G4>3TZG\11$GJ%N.8W/3Z>X>HYJ;'K\K+T7
MO3%YS9V&]JP*S[I+]\D#?QX32IH]__XU:GE]O/NC]/;,@F>D,HPXALS&H_%S
MD=YX-#D.5R?3<'4*44=AQ1]\7PW60_5% O;;QC7OEN%K,\%;>+CS^RV!1[2G
M'WJ\\FE2TPU=M9^(A,-SG0!09+U6N&0G^'NOLZZSL$\?[=T*DBWM9MM%3O=Q
MRI03-[O'](\#;M9Y[4=JOID2R(G"L0$,\H UI!>/HKH(A]-0&Q-EKW)!I4]3
M8FX&MB84AH5VA<+2M0?'O2C[";!M<\I./&HM.5!VU1X$V0S&VQ\&[#AF\T@?
M?% N^U:4#\4HZG[\V4[8'$ZKI?G6E/P-2HOID(&VUN>ICI9VH;S!'Q1.'_J?
MZ95%6?LC-8XR@?HG_.<B*_F#/B"3C^6])"?,U;1#Y=,X \.CC?;;+_SD<'P6
M1[=:6O>?FRV=@8^MY^/A"W6]HKU!W1SZE-<X%(:1G:T_0GMM=OP! IZK..H!
MQ$$#"G<LWK[97737%[%'G>^; 8,7_!4W&U51R:?.S=WF0_$+^3ZZ?5V^,O\
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MW\?*KEG[QUE=UUSJDJ8X(;8M-*H=DN3+Y]X@_'I"<[_5W#_%GLRGJVN8+J_
M&XOOCS=/T]O%\L?JF-#35'$7/F2#]FQ29^#!V5 N*V$P R/A+.Z,PE%G$,>?
M7.[9Q7#4&?9[0#7(#=C[,LC7J-I+\XQ7F#;1GH_&'=O-ND3?C^RM:W$(2VD0
M>G'WV)$%!\^;H]KZ)M:0.EWU2V^C[9R8UNWQ-[T>,G=4;0NA@>'&0L/N\)R
MJANW=HPL?;.LI;&MY\W<SCI4+L&N;Z05VCAN@W9Z)G\ 4$L#!!0    ( *F
M;5DJB'=A7@,  ) '   9    >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;*55
MP6[;.!"]^RL&VJ GPY(E)W&SM@';\6(+M-W 3MM#T0,EC2RB%*F25!S__0XI
M1<EB;0.+O=CD:.;->\/A<'90^J<I$2T\5T*:>5!:6]^%H<E*K)@9J1HE?2F4
MKIBEK=Z'IM;(<A]4B3".HINP8EP&BYFW/>C%3#56<(D/&DQ354P?5RC481Z,
M@Q?#EN]+ZPSA8E:S/>[0?JD?-.W"'B7G%4K#E02-Q3Q8CN]6$^?O';YR/)@W
M:W!*4J5^NLV'?!Y$CA *S*Q#8/3WA&L4P@$1C5\=9M"G=(%OUR_H?WCMI"5E
M!M=*?..Y+>?!-( <"]8(NU6'/['3<^WP,B6,_X5#ZYO<!I UQJJJ"R8&%9?M
M/WONZO F8!J="8B[@-CS;A-YEO?,LL5,JP-HYTUH;N&E^F@BQZ4[E)W5])53
MG%T\:I8C++-,-=(:V&*&_(FE F>A)7CG%&8=U*J%BL] O8=/2MK2P$;FF/\S
M/B1:/;?XA=LJO@BXPWH$232$.(HG%_"27FOB\9+_JA6^+U-C-77(CU.R6]3)
M:51W:^Y,S3*<!W0M#.HG#!;O?AO?1+]?X#SI.4\NH2\>M\O[#2S7Z[^^?'[<
MP7:SWGSXNEQ]W)PB>AEJ,H*S:-#6AKW41K_6AE7.A#E8!5?Q,(ENA^_'R8#)
MW&W'T^MA,DV &5 %T(E9K%+4_;&!\[LGM-8Z]M9D2 E,C?Y&BN,(/BM@@N8#
MDQD"31JZ:#G=K=0"K6NM\B:S%&(;+0T<F.>G-'79X&Q>"OQ7VA%\(SW2\HS7
MS")(!45#H CXA$XV!65*YMP-# .V9):&2B-RX!6=,+%I-+"4"VZ/KAQT^=QT
M<>;!B=*-8(49:PPZBK9$V*-$34*/8$JE+>2-9GXV%5I5WB-EPM>@'<BY(TEY
MW!>_)IPN)T4-/9W7/1 8#K@A61;PV96W/;64\/A>\H)G))ZRMVKH8WKLE6=9
MHS67>V"%I9*=)D,=1'9[ME>Z"#/@,A,-G0]<)=0?-VT;7$WBX75T2[*Q5<PH
M5C!'I&::2OK_FFB'2(U$51I/1Z=N7OAF2E:H]_XM,.!5M .SM_;/S;*=LJ_N
M[5OUB>D]IPX16%!H-+J]#D"W\[_=6%7[F9LJ2Q/<+TMZ,E$[!_I>*"+:;5R"
M_A%>_ U02P,$%     @ J8!M6>Y)4D4B P  9@8  !D   !X;"]W;W)K<VAE
M971S+W-H965T,3(N>&ULA57;;MLX$'WW5PS48)^42*+D6VH;2'I!\]!ND*0)
M%HL^T-+((DJ16I*.Z[_?(66K*9"Z+Q(YG'/FHN'18J?-=]L@.OC12F674>-<
M=YDDMFRPY?9"=ZCHI-:FY8ZV9I/8SB"O JB5"4O32=)RH:+5(MANS6JAMTX*
MA;<&[+9MN=E?H]2[991%1\.=V#3.&Y+5HN,;O$?WM;LUM$L&EDJTJ*S0"@S6
MR^@JN[PNO']P>!2XLR_6X"M9:_W=;VZJ993ZA%!BZ3P#I]<SOD,I/1&E\=^!
M,QI">N#+]9']8ZB=:EESB^^T?!*5:Y;1+((*:[Z5[D[O/N&AGK'G*[6TX0F[
MWI=1Q')KG6X/8-JW0O5O_N/0AQ> 6?H; #L 6,B[#Q2R?,\=7RV,WH'QWL3F
M%Z'4@*;DA/(?Y=X9.A6$<ZL;]8S*:;-?)([HO#$I#]#K'LI^ YW#9ZU<8^&#
MJK#Z%9]0&D,N[)C+-3M)>(_=!>1I#"QEQ0F^?*@M#WSYGVJ#?Z_6UAF:@&^O
ME=FS%*^S^%MQ:3M>XC*BL;=HGC%:_?4FFZ1O3^18##D6I]A7-U\>/WQY^/ON
MG]<2.PT=7\" AI^UEIINC'58@:[!-0BUEG3UA-I<CJZL-X;GZ([O:) <&L&E
MA3/(XCS+X^ED$M;C>1&G;#9ZHCMU+M1Y9W2)UL(DSE@1Y_,"QO$L&\?9O!A]
M%$K0!%:PT;JRP%C,Y@R*E,63;#YZT(Y+XIS&Q22-BS$+ZUF6Q;,B@X>&6@KB
MF/VH%ILM=1FX05"D293NS@B'Y[JN0_*V-+SK*-B H56HD[=ZJUQP.LLGLWC*
M<N"J@K,QF\99GD.U-=2%X*NHE^>M'U_HJ .Z O1###2"#MLUFM%Q#@.%A^R1
MFX/7>RR#$^19<,ICTB?;85 8N8_)GSMO(FD@]X["EJ+C4NZA-KKUG\AQNLP\
M"!/Z.FR(HRF0(7]=;8-HC8YME]I:M*_-6_+B[K=H-D'A+(6@7O0R,%@'$;WJ
MM>.G>Z_ G[G9"$7!L"9H>C$=1V!Z5>LW3G=!2=;:D2Z%94,_ C3>@<YKK=UQ
MXP,,OY;5_U!+ P04    " "I@&U9RC9VN)8"  #'!0  &0   'AL+W=O<FMS
M:&5E=',O<VAE970Q,RYX;6RE5$V/VC 0O?,K1FG5$R(A"1]+(5)@4^T>=A<1
MMJU4]6"2@42;V*EM8/OO:SLAI2J+*O42>^QY;]Z,,S,],OXB,D0)KV5!Q<S*
MI*PFMBV2#$LB>JQ"JFZVC)=$*I/O;%%Q)*D!E87M.L[0+DE.K6!JSI8\F+*]
M+'**2PYB7Y:$_YQCP8XSJV^=#E;Y+I/ZP ZF%=EAC/*Y6G)EV2U+FI=(1<XH
M<-S.K+ _F?O:WSA\SO$HSO:@,]DP]J*-^W1F.5H0%IA(S4#4<L %%H4F4C)^
M-)Q6&U(#S_<G]D\F=Y7+A@A<L.)+GLIL9HTM2'%+]H5<L>,=-OD,-%_""F&^
M<*Q]!YX%R5Y(5C9@I:#,:;V2UZ8.9X"Q\P; ;0"NT5T',BIOB23!E+,C<.VM
MV/3&I&K02EQ.]:/$DJO;7.%DL.18D3R%Z%4]LT !A*;P)#/DL-ASCE1"* 1*
M,;6E"J=!=M)0SVMJ]PWJ&WA@5&8"(IIB^B?>5C);K>Y)Z]R]2AACU0//Z8+K
MN/X5/J_-W3-\WO_F#M_"C9!<_4'?+Y6ACN)?CJ*[:B(JDN#,4FTCD!_0"CZ\
MZP^=CU=R\-L<_&OLP7(5+</[6XB^+J/'.(HA?+R%I_5=M(+%\VH5/:XAC.-H
M'5\2?I7ZLO!A#_XY))P*C.<%9J; 25-@4A<X8:K-A<2TP[:@'&#+"C4O<KJ;
M=$(!ZM!\.W\QO@=W-.KV_:':^0._VQ^XG?H).2:8'\BF4%Z>U_5\%[R;[LCS
M.FLF2:'\O;[3]<=CC;SQNN/Q "X]B'W67"7RG1DA6O&>RKK/VM-V2H5U<_YV
MKT?< ^&[G HH<*N@3F\TL(#78Z,V)*M,JVZ85(UOMIF:M,BU@[K?,B9/A@[0
MSN[@%U!+ P04    " "I@&U9K^$W'X@#  "'!P  &0   'AL+W=O<FMS:&5E
M=',O<VAE970Q-"YX;6R=56UOVS80_NY?<5"'H068Z%V64]N G;A8@21UG63#
M,.P#+5$V44E422JN__V.E*UX0^("^R+=D7?/O?'NQCLAOZDM8QI^5&6M)LY6
MZ^;*=56V9155EZ)A-=X40E94(RLWKFHDH[E5JDHW\+S$K2BOG>G8GBWE="Q:
M7?*:+26HMJJHW,]9*783QW>.!RN^V6ISX$['#=VP!Z:?FJ5$SNU1<EZQ6G%1
M@V3%Q)GY5_/(R%N!WSG;J1,:3"1K(;X9YG,^<3SC$"M9I@T"Q=\SNV9E:8#0
MC>\'3*<W:11/Z2/Z)QL[QK*FBEV+\@^>Z^W$21W(64';4J_$[C=VB"<V>)DH
ME?W"KI.-$@>R5FE1'931@XK7W9_^..3A1"'UWE (#@J!];LS9+V\H9I.QU+L
M0!II1#.$#=5JHW.\-D5YT!)O.>KIZ5)B?:7>$UB6M-9 ZQP6WUO>8.(U@7NF
MQZY&.T;:S0Z8\PXS> -S!'>BUEL%BSIG^;_U7?2O=S(X.CD/S@(^L.820H]
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M=2]&H06R&V7=1HNF'1\KH6D8M>:&IC]*$T#O<R'T86,2]/^3Z6]02P,$%
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MEBW3E%F@<*ZKA39,"I<;DK._=3AW3!7.D#EVV#*L.6,?"BJVU49[VPR%<,E
MFE>ZVE!5!#+ C$)1TI$&8?U9.U@&6UTX*VH2&56AHNHJ!E^8R8 .>2Y.9#CY
M<J<S0[93Y![:$/:(UW5'A/"P';UD9;4Y8>]K1*JNAWJ]+1 (O&X1OYZNJRPO
MRL(6NN5P!%" ;61:=GMK]"U [Z->M&WGL*.#W,JR:/.FJRW4M]8!]5+$DDL_
M9$<O0^[+V*.]+WUZM5T7^9IMLW9WP$ "<HT ?Q2D)R#HX0*3-SKO(WU\PCY#
M458UQA:_9LY7'.L\]7Z? Z#Z0I-%1N<@/(4 "8*7U::IP2K2!Z)J2B"FOZ&!
MMYJ3.V5'FY%:#<5]?(5PUMKRGM^#:F^P#]NI=S(JG]3@7E$5HCZ(C6!UCW='
MG"GO7(RTJ=K!'U8W5@\9VE*%<>D7.EYU]5@L:/%AXA(3BYI<U\M:MZV'M;_<
M7+J][UY_?'O"WF5%"7%'R^P+GK@I@,6;[*Y/*UBP 6AYL4%"#XGKXL$92.K<
MWQ:MDZ>P073DVWT7,E!+CRJ]!YZ ADU7+L$ 6]A2.X&/G]^3TBS/<?,P1$I:
MQ?4!'+)WI+;MP"\':X]O10^C!],)G557EHXE,+!T1U89,E13RFZR8NF1K;AA
M@8)U5D)K1KKN7!!.^HZW,4VN-=@)BFB7[G3*+B33>:U794O-CO0W8L=8$5\*
M[OL^_;%RZ!E]$AX/5<'5SZ'44P'>2Y$Q+\#)I6YS4RQZSKG89HM2$\5P&3SU
MKG9"G]>(\RMWH6#73D%_K7@LKWHQ[X&8=SVZO#)-U4?A>O+WN9=>WT($>\E^
M>)$$(O@1HS#F4?Q@*>212(?=P?1"! D/I=J;*^X'OC?VU7$=RZ@ZNZE$> -O
M[+KC<BAYB+HT306/@G'7;EE$/!;I;AKRU!\MBW;"*1>I8,&$I8QXF(S:XITI
M"5=AQ':8BX2GB?0^-Q:AVP^!C!(>J)1&TV:,@Y#'**)[>/Y$=?*/P/G'I.2?
MC+:($201WU^+$*T@/L!;)@&7P0XQ&2',H3K .R;H=A@A<B*,#O 6!!*(MIM+
M'OOJ '&5\E %WT-<Q(HGOOH^Y(DB+O\>R+$E!7/]Z 'H29 B9.$^Z/^FOK^7
MG33_DX$*D#9!$-!HSQ:1DBWR "H%RU6X%\0XYH&,#Z!*!5=J%\4@X+C>'T 5
M^"%/DCWHT@19&!Y )7LNC=/A.6&U,SQ%/$/UQ,9X#QR%RI-&!QM'L/9A$5PD
MR,98/0A1DL9<X/:UB_W4*X_0_:G"W[M\>$]</HY1ZH>.CVL _L'J&Q2Z$5WS
M70/)7/=\)-/_SR;C#<UCU91H&XYLU$:H]TRW3;M&#YP\(G&8>:_#/."I^[?U
MX075<V:Z6RI^(OJ)Z2>A9CS<4YF+^AXY0[ @"BG<,N5)3'D2J(1'OH. ^H@K
MF &5$TDE1O$PI8I+8P"+\I$DR<1=@;Q*?(%&X*.H)BQ4]%XPH7RNY $) +@,
M?9Y,I452HU$P0_BBSVP_X@+L3B0>\D!>"D7V3VP/T;V0,D'@\S1%,- <4K@7
MT/%[!6BJ<HI2+)J2 )TI1=4CI]!2<,M6(F1(.]0^EL"@)-H[.2&54V)$/DH5
MVE5(?)9P3&%#&"8'9^Y<CY%K0NW*&V(7(?6H!<M(H02'5$R?5)# S"@)O9MN
M85TN2=3/ !00@ H>2('<DDKP (T[!F@)2"$5(,6_@SL814_D0"KOZMX%GC*&
M'85P2[)C=A0 *Z%H)-#E$Y]&(5>!&V!%N%W0AB-HA(#$4'_<:[V7AR2(6NBT
M GUT^5&2]#_E[Y&,87 "C5/IB BAQ!4.E9)C?9V7P%$ZWL:H4JJO_H!:"+]G
M<!(/8P&>^%3Q4O;8]Y#YWK>I2IM;]P6N9<Z3_C/5M#I]Y'O=?]O:;>^_$'[,
MS&V!6E/J%43]DSB<,=-_=>LGMMFX+UV+QMJF<L.UQNW6T :\7S7XAV28T '3
MI\^+WP!02P,$%     @ J8!M625KIFA'"@  I!@  !D   !X;"]W;W)K<VAE
M971S+W-H965T,3@N>&ULI5E=<]LV%GWGK\"HV8X]H]BR;"=I8GO&=M+6.W&2
MB=WF86<?(/)2PIHD&("4HG^_YUZ %.4J3F?WH;%$ 1?WX]QS#]BSE74/?D'4
MJ&]E4?GST:)IZM>'ASY=4*G]@:VIPB^Y=:5N\-7-#WWM2&>RJ2P.IY/)B\-2
MFVIT<2;//KF+,]LVA:GHDU.^+4OMUE=4V-7YZ&C4/?ALYHN&'QQ>G-5Z3G?4
M_%%_<OAVV%O)3$F5-[92CO+ST>71ZZL37B\+_C2T\H//BB.96?O 7VZR\]&$
M':*"TH8M:/Q9TC45!1N"&U^CS5%_)&\<?NZL_RJQ(Y:9]G1MBR\F:Q;GHU<C
ME5&NVZ+Y;%>_4XSGE.VEMO#RKUJ%M:>3D4I;W]@R;H8'I:G"7_TMYF&PX=7W
M-DSCAJGX'0X2+]_J1E^<.;M2CE?#&G^04&4WG#,5%^6N<?C58%]S<6VKQE1S
MJAKUWNB9*4QCR"M=9>K:EJ5I4(#&GQTV.(MW'*;1[E6P._V.W5_4+2POO'I7
M991M[S^$C[VCT\[1J^F3!N^H/E#'D[&:3J8G3]@[[@,_%GO'_U?@ZE^7,]\X
M8.??NW(0CCC9?03WTVM?ZY3.1V@83VY)HXN??SIZ,7GS1  G?0 G3UF_N/[X
MX?[FPV_O/MRK]S>75S?O;^YOWMVIRP]OU?7'V]N;^UO\=+?+ZZ?M'AT=J+]G
M6WULT1+K0J_\6&GD#BE#L<?*5(KR''VG:F>7)B/5+'2#?RA!;FM=K8'RHL"Z
MC,K*Y&MED&J;YR8E%VJ0&8?]EK_-02V^4;RKB)5:*^V,1_E4[FS)AHT#1?C:
M@BTVM?R>S:2QO(?[R)1MJ>A;PSBHR:'N#64(2KTEQ*4=*?PY4#?@CRPS3"1C
MM>*=#Z2\*4VA71<&O&KQR37Z 9YYA-@L%.ETT1^,0YUMYPNEE:=:.]U0TN7
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MG<QU*<L*V0''0^YYD@"GLB1N;P6\HC1:O&?88RI'9SF-_'@6^]%\\G251S[
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MQEAGTZ"9S^WI=)_CL";8[>QH PU52R\;]SO$E7O\EOS*@+8-/Y)%TX0.0YQ
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MN._IT_N"Q:)0W)AEA:0_IFY+.GRN6X>$<:ZAX]P23)*_<[C*ENEB=012=CJ
M!,S?2\7];D<R=L8$3!?)WW<;$K_(OD7 )\BQL>96A0&')P]4*Y3#=/%DT?1A
MRCQL$U:P= Z)8JR5DFMX]GLA&SB2D 3PR3SO"^6QS['X#*U; (#SWB;E(486
MT78;6PH=3OM0,.2\JD//V+2^M<%30IL-RB'0@:)IC,4\%X7"74LZ)RY#OR/2
M@L=QP,J,>IP:?,V.&2:'X1[$H2A>/Z0<U1YPW/D.$L(%#/@"J7)=T3AY<U_?
MCG(#%W^VTH([WBB;SDZ#OGA'_!6A68 !;ZS*H3'>4I.T+YGL/DIPLU'^P"^6
M6'BVW"F>G2S1DDXR3KHV^F4N7=G1G S;+8#G'#%VAM>J$K>R:F4\BU0X#$DP
MA9Z,@Y/S 1,7X# 7/4?/8[DC, ?4HI)VBS[$L7VS9!EX7U/W\H[21F/D\PSX
MT"R&"F2 S:%^L%H7(0ELV_#H5#G+Z,K'6H,TZ%"[H* -T&7 %="P IVZ2Q@[
MY2UWT#XW+@U67"!KEDK/." P(+$/*3$O"T8,H) L:B"GXVW\*UU\MNJ@FR\0
M+!6)/'2= TCJ8'*9=,ZVIBL?9K$O6TM0ANX&T -]C,5-:=JJ."Z>=2]6IH8K
M5\B"0(*GI"),E$#@+MAC:2  &U@<7"6KB&OUF'*>HTAQ]&0\BOEZ),4@H#7:
M*)"\Z 0<0#!_\#L46M()[;X_[;O&-A:_ 9N">)%![-4&;+&28B*(.X.QX>*H
MP-$CN3/U%0DD*0,.-7T;2YI9R7TKJR3&Y+I>(C;6U!W>O@]!-MB-R[GX@N/Q
MXZ?LNL]"G.^!WEKN(U1&'PVYXHX 'HMK5K'V?!1YL,W7P@N1Q+G\(-*0Q*+M
M%,O&U!]5CE4YEO]%UHS%S]\HZK2OWS0>!^#=AL8CO;=JW3(+W"%=NV;11QRW
M_((42@'^5*CS$%AHQ^M]@/A. S97QD=.#-#>X)BKF)*;[AUJ?IJ%GG]L\;4I
MB.O<<T.['VPNYC</^FXJR9QIC5RC[=<H$A_6F"B(+G-Q8$:JOZ/+Q:$1.>FD
ME41I\9P1.8Z)VS"BS0ZG"E>JI@_BVM2-U#A^2!ZV&YZT0?$;50W/D%WI]\[%
MY_'-^-!6OV#XN$(%@D*_==B;'\1>.WSL@O.\UQ?Z']JA-MTA76+2=W2HT YQ
M6G?11%;.]*N]:*1")[EO9&%L<U$A(\3*M@DFD*SB0,6?B&45HGZ\E48U%2;V
M\%O.S5ZTFF?=5H>.-6@CL4_RBHZ^_@3=T<*3(_#):6JU;($0+1>THE14SP@K
MSHV/O31-!J^Q-6'(\<NZ$V$<Q3?:P]W#[P%7\37X?GG\,>$]9B3+L*(-3*?C
MU<E(V/B"'B^\:<)+\=IXO&*'KR6A+UM>@.<;8WQ_P1L<?B6Y_#]02P,$%
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MU?0"GM]45;NXH 66'[,._PM02P,$%     @ J8!M64\^Z^Z* @  > 4  !D
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MH+DG\"@1"(F^I8X>-'5TXH!W;AXX]8H6A;!=%U<[-N4=FX/6FJ.AV/>J]:H
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MB?19^2]EL>5?BUD4)<)*_DAOXVE##^ ^_=R#_T(+U+\?].I_ 5!+ P04
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M$-924&VP>HUCV-2;:P<%U@;+%:H>:N\3/J* $-IWU+UCN)>&":_U>NK=,%T
MJW(H985/E"[J@<H;:]'4\!/$_C@8^VD<T_CG-^,HC-Z_&/7[WE[XIMZ"50^4
M\BOSXO#$'P5T(0H/KW;.W&+6^1(Z7^+_RY?):.R/DO 53[K=4_P( S\AX\;A
MZ+7E(R2][$EZ>3));V25847)Y.HS+7SE^N$0ZXZ*/,RZ)2,B@9&@]_*YK:>H
MM&<*2@%6VA@2#^E8&+RUV5)*Y4PS%@.HE<R;S(!VPBQW<S2,BU>I._5N&YM
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MBWM\CT [ SROE;(GQ0487[CE/U!+ P04    " "I@&U9Q[3<+.@"  "E!@
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M(P%U":,L/((7]&*#%B_X9['?YRMM%%Z-'X?D=FCA831;+A-=\P1F#M:#!O4
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MF-I.MC>+=J!%;?_F&Z'I;F#-G"YC*,T"^KX50A\&)D!_O5O_"U!+ P04
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MP=NN'9; ,3(D@-]7$NO1O] &PS\L+O\&4$L#!!0    ( *F ;5F7\PH<<@,
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M5#: [C=2FJ-A"TS_A"S_ E!+ P04    " "I@&U9O=#LE @$  "H"   &0
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MR>:7&_HK@=H9T/>54G;_X@(<_IPLO@%02P,$%     @ J8!M67%)J0:'"
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MZ+@5XBLH$-%RZ0Q#O,;:-11(%;G[+0J4(]\C1C&H-0@HYW@(<A<$FK7715!
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M\:BZS%;WI7OZ^B;\'K,E*3C*8"%->5=]&1BK+Y?K%T%+=7LZIT+07#VN *?
MJ@GR^P6EXOFE,M!<\8__!U!+ P04    " "I@&U9ST_BTJ<#   ^%   &0
M 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6RM6-%NVS84_15"*X86:"-1<FPE
MLP4D#HH-:(:@1KN'80^T=&T3H4B/I.SV[T=*CF0NBA#'?+%)Z9[C>WBIJV-.
M]T(^J@V 1C]*QM4LV&B]O0Y#E6^@).I";(&;.RLA2Z+-5*Y#M95 BAI4LC".
MHG%8$LJ#;%I?>Y#95%2:40X/$JFJ+(G\>0M,[&<!#IXN?*7KC;87PFRZ)6M8
M@/ZV?9!F%K8L!2V!*RHXDK":!3?X>AY'%E!'?*>P5T=C9*4LA7BTDS^*61#9
MC(!!KBT%,5\[F -CELGD\>^!-&A_TP*/QT_LGVOQ1LR2*)@+]A<M]&86I $J
M8$4JIK^*_>]P$'1I^7+!5/V)]H?8*$!YI;0H#V"304EY\TU^'!;B"(!'+P#B
M R!^+2 Y ))::)-9+>N.:))-I=@C::,-FQW4:U.CC1K*;1D76IJ[U.!TMFC*
MA\0*+>B:TQ7-"=?H)L]%Q37E:_0@&,TI*/3^#C2A3'U G]#";*>B8F!Q-TJ!
M5DA(](62)654V^A[(*J24""BT6=")?I.6&7B3>70GX)+R"LI+?\M4509RB[H
MHQOP]SV42Y#_F)AOBSOT_MV'::B-="L@S \R;QN9\4LR87N!DN@CBJ-XU .?
M#\/O(#=P7,,3%QZ:!6]7/6Y7/:[YDA?XFB6[[M/1 $?]0/M07ZLMR6$6F*=6
M@=Q!D/WZ"QY'O_6I\D3F:$Q:C<D0>S8G:H,(+U I./PT>U8^FJY$FHVE^J0W
M?..:S[:?79:D43I.S(KOCE4]C[N:I),1;L.<?$=MOJ/!FAQMWM["C'P6QA.9
M(_2R%7HY6)A;PA]-IUOJ/I4-]-)9VRA)8_R_&CR/P]$HP2F>]%=AW"8W'DSN
M"^R (=P^]'TY#C*<6@E/9([822MV\M8V,/&IT1.9HS%M-::>VT#Z;&OUMX'G
M<4-MX*K-]^JL-G#ELS">R!RA..I>_=';&\$PMC\WU/MF/9_(U7=D;? K>DD\
MV$N&*4ZMIR\V5W#G*O";;07VZBM\L;DZ.V>!?5N+8<)3=O/Y1*[HSI[@\_P)
M]FI0?+&Y8CN+@L_P*/BU)J4G<-BEX,ZFX-?XE&2XMW@U*K[87,&=5<%O]BK8
MJUGQQ>;J[.P*]NU7A@E/Z2WG$[FB.\^#SS,]V*OK\<7F_O7N;$]\ANT9QIY0
M3 ]$C;[PZ'#'GJS=$[FF7"$&*\,<74Q,>Y/-854ST6);G_<LA=:BK(<;( 5(
M&V#NKX303Q-[A-0>&6;_ 5!+ P04    " "I@&U9 )'>*A,$  !?&P  &0
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MF_,^/N\AYX0U%X\R!U#HJ2R8C'"N5+5P')GD4!(YX14P_2;CHB1*;\7!D94
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MK87(!@V&1X4)(1-R8.\8978OPI-A=U'G+CKI[KO0E ^9BH[>UV40>4%X:&L
M-\9X'. #7VZO[=B6_XW*-2L4XK R3._BTB2331MM)EJ4=2=:"FWZ6CW<F#\/
M2 LPSU="Z+>);6[=ORSY U!+ P04    " "I@&U9 &6@S'<"  "6!@  &0
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M>V9U+ZTG@E:Z62RHD*U'#S/Y^P%, >3S):5B-U$!VA^:Z!]02P,$%     @
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MR+Q8<SPW'4&K^H2;42'/R[JYD'\TP)1 /D\I%=N..C2[?Z31+U!+ P04
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M9A@>!@S/'3 Z#!@=;]+DE0'Y84!^[@SCPX#QN0,FAP&3<P=,#P.FQ_=A_,J
MMX<!;\^=H=_[\<SUSA[R]&0?/]NO#_GQ=/?WS_?EXR_6_K>R*)ORZOVZ_IZM
M=S^_]79_V?]J[\=O?QGGJUT*OS3K[7?GVW'-U<=R]4M65%^;[$]%U93SQ>;?
MWE\V6WCW[<O9 2D>D<$KR##[7*^:NTTF5M?5=<MXD1X_/C5>IL>_/37>I,?W
M!PG@<ON(/CVL@Q\/Z\=!4OQ2W;_)AKT_9X/>8-*R09_2P^W#ZFEX/_O;ER+[
MT[^T/B]IYG.YWC+]/=-+,.+\K1FU/3OG/Q;CQ%:H\YE1@M'G,\,$8]),4<V>
M'MJ\9;@]?WCJF7'G/\&#!.//?X)?V9HH!<.G?UR&>W=X\A^7O_OMMS+35,O-
M_[9LW\='9]3N[/9$WFWNRUGUX6*[J[&IUM^JBZM__:D_[OU[6[9(K" Q06*2
MQ!2):1(S)&9)S)&8A[ HIZ.GG(Y2^M7'JES/5[?9?-546[W)[JOUK%HUV]WP
MMK FL:YA);&"Q 2)21)3C]ANAW.K[8ZSOEWUWO2&^?#]Y;?G.20G-21F2<R]
M]G!,XX?#0Y-&$<N?(I8G(_:Y7C>WVSQMCQ"_-FVA2@[O&BH2*TA,D)@D,45B
MFL0,B5D2<X_8^%GP!KW]GZ/D09-&R1L_)6^<3-Y^S[.^R6;KZGK>&KWD^*[1
M([%B_.+Q[;<]OH*<5)*8.O,>:')20V*6Q!R)>0B+4C5Y2M4DF:K]4=U\LWDH
M5[,JF]6;9M,6K232-5HD5I"8(#%)8NH1RY_G;S(<]O*C^)%S&A*S).9(S$-8
M%+_I4_RFR?B9U>QAO7U!>SUYR?%=DT=B!8D)$I,DIJ8ODI?WAI.CW$U?O#P>
MO3 :<ILLB3D2\Q 6A>GM4YC>)L.DZO5=N<R^E-_FJ]M-MC]K^??/U?)KM6X]
M69G4ND:+Q H2$R0F24R1F"8Q0V*6Q!R)>0B+TMKOA;<L>]#;"@<(BBJJ%:@F
M4$VBFD(UC6H&U2RJ.53SE!:']EG/H'_Z@/%FOMH>+VY?95O#F@0ZAY74BH/V
M?&]N.FX[$X-.*U%-H9I&-8-J%M4<JGE*BW,X"#D<I-_KV[UX^KI<;9+[N&FE
M<QA)K4 U@6H2U12J:50SJ&91S:&:I[0XL:%$TZ=:-'VT1H-J!:H)5).HIE!-
MHYI!-8MJ#M4\I<6A#8V:?KI2<_I=QS30.:QHCP;5!*I)5%,'+7J#I/4-2G1:
M@VH6U1RJ>4J+<QAJ-_T3O9OY:KY\6*;W=='N#:H5J"903:*:0C6-:@;5+*HY
M5/.4%L<U='7Z8VI?%VWMH%J!:@+5)*HI5-.H9E#-HII#-4]I<6A#%:B?[@)]
M+!>+NEYE]^OY:C:_+Q?9??G;LEJU[_:BE2!4*U!-H)I$-=5_V0L:]D?Y=#H]
MWNU%FT&H9E'-H9JGM#B2H1[43_>#_O.AV33EZGKWJ8X0RZ_E8E?7:XTEVA="
MM0+5!*I)5%/]EZ6AT6 X?)L?]X;0:0VJ651SJ.8I+8YE*!KUTTVCS^6OIX]&
MT7H1JA6H)E!-HII"-8UJ!M4LJCE4\Y06?X8_%(T&5-%H@!:-4*U -8%J$M44
MJFE4,ZAF4<VAFJ>T.+2A:#1(%XTZ'8VFK<ZY13M'J"903:*:&KQL5PW'TTD^
M.=[M1:<UJ&91S:&:I[0XDJ%S-$AWCCH?C::]SK%$VT>H)E!-HIHZ:,\_G3)N
M/1I%IS6H9E'-H9JGM#B6H5@T2'8@KG8MP.RG?O)H-$UT3B):*4(U@6H2U12J
M:50SJ&91S:&:I[0XKJ%2-!A11Z-HM0C5"E03J"913:&:1C6#:A;5'*IY2HM#
M&_I'@W3_J-O1*%I$0K7BH)U\QU"@TTI44ZBF4<V@FD4UAVJ>TN)(AH[1X,2"
M0$>[O=D_LJZ? $_/T#FH:/D(U02J2513J*91S:":136':I[2XC2'\M%@0NT5
MH\TC5"M03:":1#6%:AK5#*I95'.HYBDM#FVH)PW2]22QF>W&E+-9_?#*KC#:
M1T*U8O!RU9Z\W_9A<'1:B6H*U32J&52SJ.90S5-:G,/01QJD^T@=%WY.:YU#
MB5:3#MK+58"/,XF6CE!-H9I&-8-J%M4<JGE*BR^9$$I'PV0_XLH\9?'Q1-'F
MS]GVAF5;'M-2USRB6G'B7O9[V6_;?WS:EBX4Z(9(5%.HIE'-H)I%-8=JGM+B
MB(:*T3!=,7H\@S1(GB)*$YVSB3:+4$V@FD0UA6H:U0RJ651SJ.8I+8YKJ!\-
M!] IHB':.T*U M4$JDE44ZBF4<V@FD4UAVJ>TN+0/KMT6+J<U/'0-*UU3BY[
M";'A>8>FZ*P2U12J:50SJ&91S:&:I[0XDZ&!-$R6);J5&=)6YT2B):2#]OP,
M[C!O.X.+3BM13:&:1C6#:A;5'*IY2HLC&?I%PW2_Z/%0=/B\S/"YW.WD_E<U
MNUO5B_KVM\RL-LV\>6BJ] $K6CY"M0+5!*I)5%.HIE'-H)I%-8=JGM+B4(>&
MTI!:!6F(%I%0K4 U@6H2U12J:50SJ&91S:&:I[0XM*&(-$RO@O3S63O%: <)
MU0I4$Z@F44VAFD8U@VH6U1RJ^8,6U6CB8[ XB:%=-$RWB_;[Q.6R7C?S_R^;
M>;U*O(.*UHQ0K4 U<>(Q&SR^'9L-LV6]:N[:WI>5Z 8I5-.H9E#-HII#-4]I
M<51# 6F8+B ]7HCBI]$?*>.GI^B<8;25A&H"U22J*533J&90S:*:0S5/:5&<
M1Z&[-*(63!JAU254*U!-H)I$-85J&M4,JEE4<ZCF*2T.;6@SC?[HE=G20.>P
MHETF5!.H)E%-H9I&-8-J]J ]/S+LM[T]Y]!I/:7%.0PUI=&)*[-U:SRDM<ZA
M1+M*J"903:*:0C6-:@;5[$$[U6)QZ*R>TN),AA;2Z(PEDLX[E926.N<1;2"A
MFD UB6H*U32J&52S)WYS)Z]^OL*AV^$I+4YHZ"2-TIVDQP+$.'F&*$UTCB9:
M14(U@6H2U12J:50SJ&91S:&:I[0XKJ&O-,JI,T1H'PG5"E03J"913:&:1C6#
M:A;5'*IY2HM#&_I(H_2*26><(4)[2*A6H)I -8EJ"M7T07M^%F;0=FE4@TYK
M4<VAFJ>T.(>A8C0Z<:&UCF>(T+(1JA6H)E!-HII"-7W0WL8G82:]Z$__.*!H
MIPC5'*IY2HL#&II'HW2+1NY?(ZMLL3LHO5_7W^;7U75K--'>$:H5J"903:*:
M0C4]>KDL5.NEQ TZK44UAVJ>TN(XAG;1Z'2[Z/FYH=__X9CT1)WSBG:,4$V@
MFD0UA6H:U0RJ651SJ.8I+0IU'CI&.=4QRM&.$:H5J"903:*:0C6-:@;5+*HY
M5/.4%H<V=(SR/]HQ2@.=PXIVC%!-H)I$-85J&M4,JMF\I6,T:NL8H=-Z2HMS
M&#I&>;IC]/.ZGE75]2:[6=?+;+[9/.R/5^N;_2%K:R[1FA&J%:@F4$VBFD(U
MC6H&U6S>=M&Y47\\.8XE6C.BM#B6H6:4GU$S:NKL6[EXJ++UKFG4FD6T8H1J
M!:H)5).HIE!-HYI!-7O0XI/-T^,@HFTB2HN#&-I$^3EMHCQY+BA-=$XAVB9"
M-8%J$M44JFE4,ZAF4<VAFJ>T.*ZA3913;:(<;1.A6H%J M4DJBE4TZAF4,VB
MFD,U3VEQ:$.;*$^WB<Y:*"5M=,[KRRI+V[%^@<XJ4$VBFD(UC6H&U2RJ.53S
ME!8G,?2)\G2?Z.E2$S?S7ZOKW7%G:X\HK73.8FN#)3].(MH/0C6):@K5-*H9
M5+.HYE#-4UJ<Q% <RL]8LNC9<>?O6 8E/4/GE**5(E03J"913:&:1C6#:A;5
M'*IY2HO3''I'^5OJL!3M%:%:@6H"U22J*533J&90S:*:0S5/:5%HQZ%7-$Y?
MD:S#1[W34M?4GMBN_+ RW_CUE?D*=(,$JDE44ZBF4<V@FD4UAVJ>TN*HAC;1
M^)SKKTV2N\-IHG-&T3X1J@E4DZBF4$VCFD$UBVH.U3REQ7$-I:,Q=?VU,5HV
M0K4"U02J2513J*91S:":136':I[2XM"&2M(X74DZW=A- YW#BK:14$V@FD0U
MA6KZH)W^#!LZK44UAVJ>TN(<AD;2.-U(ZOB9[[36.91H.0G5!*I)5%.HI@_:
MT3MFT^-$HJ4C5'.HYBDM3F0H'8W3EUR3];J:E=LD)@\_T;X1JA6H)E!-HII"
M-8UJ!M4LJCE4\Y06YS7TC<;4U=3&:.D(U0I4$Z@F44VAFD8U@VH6U1RJ>4J+
M0QNJ2>,32QUUN=1PVNJ<6W2A(U03J";'+Z_ -1Z]'0^/U@]2Z*P:U0RJ651S
MJ.8I+4YDJ"B-TQ6EXLNGUS^9EA[;.8%H^0C5!*I)5%.HIE'-'+1^__FII3?'
MJ\=;=%*':I[2X@"&5M$XO9K1B^/.W[^<47JFSG%%:T>H)E!-HII"-8UJ!M4L
MJCE4\Y06I7H2:D<3:CFC"=HZ0K4"U02J2513J*91S:":136':I[2XM"& M+D
MC +2>5W!$U+^ZF4Z/J5'=DXHVCE"-8EJ"M4TJAE4LZCF4,U36IS0T#F:I!<Z
M:MM9?JP-#I-[QFFV\XLLVD!"-8%J$M44JFE4,ZAF4<VAFJ>T.,*A@3094GO&
M:!,)U0I4$Z@F44VAFD8U@VH6U1RJ>4J+0QOJ2I-T7>G,CY1/6BLM1R<#/Z7G
MZIQ$M'Z$:A+5%*II5#.H9E'-H9JGM#B)H:8TZ5A3>MH#3E\L,<UV?C%%FTNH
M)E!-HII"-8UJ!M4LJCE4\Y061S@TER94<VF"-I=0K4 U@6H2U12J:50SJ&91
MS:&:I[0XM*&Y- &;2VFK<V[1YA*J"523DY?-I?Y@FO?R\5%U"9U6HYI!-8MJ
M#M4\I<61#-6ER8G+LIVQ*[PK4]3KYK:\K;+_J$_T)]+S=8XM6G="-8%J$M44
MJFE4,ZAF4<VAFJ>T.-NA%36AUEJ:H*4G5"M03:":1#6%:AK5#*I95'.HYBDM
M"NTTE)ZFV%I+::EK:E&M0#6!:O+$,S!YM7>BT.W0J&90S:*:0S5/:7%"0\-I
MFNXEO;[+G%YV*<UVCBM:@4(U@6H2U12J:50SJ&91S:&:I[0XPJ$"-:6679JB
MI2=4*U!-H)I$-85J&M4,JEE4<ZCF*2T.;2@]3<^X$MR9>\9HZPG5"E03J"9/
M/ .I/6.TX81J!M4LJCE4\Y3VF-#+S5U5-479E%?OE]7ZMOI4+1:;;%8_K)K=
M:^NS6[-U=;--</_=7P87ER]NE_UWNM]RN^F_L_O;+P-_]?Z^O*T^E^O;^6J3
M+:J;[52]-[MWF]?SV[NG+YKZ_L/%=B?B:]TT]7+_U[NJO*[6NQ_8?O^FKIL?
M7^PF^%ZO?]G?G:M_ E!+ P04    " "I@&U9@_),6A$'  ":0@  &0   'AL
M+W=O<FMS:&5E=',O<VAE970U."YX;6S%G&UOVS80Q[^*X Y#"VRU2.HQ<PPT
M%JD6:(&@0;<7Q5XH-I,8M21/4I+VVX]ZB&52#"NE![@O&DN^^Y$^GO6W3B<M
M'O/B6WG'>65]3W=9>3Z[JZK]V7Q>KN]XFI1O\SW/Q#LW>9$FE=@L;N?EON#)
MIG%*=W-LV]X\3;;9;+EH]ET6RT5^7^VV&;\LK/(^39/BQP7?Y8_G,S1[VO%Y
M>WM7U3OFR\4^N>57O/JRORS$UOQ V6Q3GI7;/+,*?G,^>X?.8D)JA\;B[RU_
M+(]>6_5'N<[S;_7&A\WYS*YGQ'=\7=6(1/QYX"N^V]4D,8__.NCL,&;M>/SZ
MB<Z:#R\^S'52\E6^^V>[J>[.9\',VO";Y'Y7?<X?W_/N [DU;YWORN9_Z[&S
MM6?6^KZL\K1S%C-(MUG[-_G>!>+(07#T#KASP*J#\XP#Z1S(V!&<SL$9.X+;
M.;BJ@_>,@]<Y>&-'\#L'OUFL-KK-TD1)E2P71?YH%;6UH-4OFO5MO,6*;+,Z
M%:^J0KR[%7[5\B+)OED1OZZLUQ&ODNVN?&/]:5V)C-_<[[B5W[1O7A;YFO--
M:7WF:RYR9V,EV4;LW6;K[3[9B=W[Y(?(T*H4WE^N(NOU;V\6\TI,L!YFONXF
M<]%.!C\S&6)]RK/JKK1HMN$;C7]D]@]_YL_,_@@; ',1V4-X\5-X+["1>,7W
M;RUB_V%A&SN:":W&NQ-=/'YM=/IKHS.S>\37PAT]ZQZ/=\>&I2"'3"<-CSSW
M:7XAI[]^%##K0\73\E]=6K<C._J1:S4Y*_?)FI_/A%R4O'C@L^7OKY!G_Z5+
M"4A8! FCD# &"8N!8%)B.8?$<DSTY2&/;HH\;5/K0UG>)]F:ZW+%"--/U=*E
M2<OQ&D[]@^-A2>SFWV+^<)P!0./1D>.QD7;QT XK=M)JN(?5<(VKT7VUAU]B
MW5JT*/=XKEZ G5">ZDICAEV?^$JDAV;(#AUD>[(='=H%.+21JP12@T.!Z_N.
M$D@-+O01=O5Q] YQ](QQ_)@GF?4*65\_\?2:%]K#GI$P]; '"8L@8102QB!A
M,1!,2A#_D"#^R?34ATPL2%@$":.0, 8)BX%@4F(%A\0*(/74")N@IT"<"(A#
M@3@,B!,' YDQZG5X6.T03J_#P1Q<W_.1(M<:*]=#BJA'0ROD8QLIHDXU9I[G
M8L6,#<TP)K@^<9&T6D,+A?03?0R1W9_%VR/4&AO5VHR8>E0%I46@- I*8Z"T
M&(HF)\I1N0>=3+6[H:$2#)(6@=(H*(V!TF(HFIQ@N$\P#*G>9MH$^88"15 @
M"@5B4* 8 "1G15][0\8*S#25[UB22N+ )<J)[TIKY]A8K8!H[$@@U%GA49V=
M%R)7L6,:.R=T'%<Y@8]U=KZ/C^H&<C3[@A,R5YQ:M2=FM7]!W<=P,(:D1: T
M"DICH+08BB8G2E\+0^[IU-Y8AYN<8)"T")1&06D,E!9#T>0$ZXN$R%PEG*KV
M+RA8Z=4>"!1!@2@4B$&!8@"0G!5]91 9ZT,3U=X?GCH[R">JV&O,B&UC5>N'
M9C[R<*A*_=#,"Y#KJ4H_- N1XWBJT&OFAL5W[!F=[PMAR%P):W7>,>O\"^H[
MAL,P)"T"I5%0&@.EQ5 T.5'Z&AH*3Z?SQOK=Y 2#I$6@- I*8Z"T&(HF=['T
M]45LKB].U'DS;8+.0X$B*!"% C$H4 P DK.B+R9B8RUIFLYW+*DL3UQ;.6E>
MZ<R$@*LZKS%#;HC4:P%4:T=\6SVGU]AAVPT"]6*[CA<&/GKF:CONZV;87#=K
MM=XU:KT9,?50#$J+0&D4E,9 :3$434Z4OI2&3]?'AD$;V4!I$2B-@M(8*"V&
MHLD)UE<7,6@_FYDV1>N!0!$4B$*!&!0H!@#)6=&7$C%@7QW6]*YYOGH)?J4S
M<T-;O5*O,7-"U\&JU(^B,8T9&5[WC\WA>$&D^YH:'M-YYYE_"8"VWH'2(E :
M!:4Q4%H,19,3I2^SX=-UX&'0%CQ06@1*HZ T!DJ+H6AR@O7U1PS:B6>F3?DE
M\/->LRX3H)KMQH[(QAK& %.35ZTO!F+ CCJL:98+4:BVU&G,B.<&@[-R75.=
M$ZAGVW0<CFG,0F*KU^-C<SRFAYKT93$RINW.-TJU&3'YYB#0MCM0&@6E,5!:
M#$63$Z6OE)'3M=T1T+8[4%H$2J.@- 9*BZ%H<H+UY4,"VG9GIDV0Z@XDW_2D
MDVJH$>G8$=E8PQA@:O*J'=V2"M@6U[&D.^8"1[UFO=*8H2 ,B+H>0[/ &73)
MTW$TIC$3,PO5"^7F<$R(]/SHCO>4%[?-PPQ*:YW?9U7-/]I[>&#"N^8Q <K^
M"W2V0IK]$3JCNOT,G<7M8Q+Z8=NG-GQ*BMMM5EH[?B.F8+_U1>(5[8,0VHTJ
MWS?WX5_G596GS<L[GFQX41N(]V_RO'K:J <X/(YB^3]02P,$%     @ J8!M
M658,*HM'"   Y3\  !D   !X;"]W;W)K<VAE971S+W-H965T-3DN>&ULQ9M=
M;]LV%(;_BN -PP:TM?A-=HF!==FP 2L6+.UV,>Q"L9E8J&UYDMQT_W[Z<'V<
M\I!*%!.Y22S;/.>E);X/#T6=W17EAVII;9U\6J\VU?ED6=?;U]-I-5_:=5:]
M*K9VTWQR4Y3KK&X.R]MIM2UMMN@:K5=3FJ9RNL[RS61VUKUW6<[.BEV]RC?V
MLDRJW7J=E?^]L:OB[GQ")I_?^"._7=;M&]/9V3:[M5>V?K^]+)NCZ2'*(E_;
M3947FZ2T-^>3'\CK-T:T#;IO_)G;N^KH==)VY;HH/K0'OR[.)VFKR*[LO&Y#
M9,V_C_9'NUJUD1H=_^Z#3@XYVX;'KS]'_[GK?-.9ZZRR/Q:KO_)%O3R?Z$FR
ML#?9;E7_4=S]8O<=Z@3.BU75_4WN^N\J.4GFNZHNUOO&C8)UONG_9Y_V/\11
M TH]#>B^ >UT]XDZE1=9G<W.RN(N*=MO-]':%UU7N]:-N'S3GI6KNFP^S9MV
M]>Q-MOF07-CK.OGVPM99OJJ^2UXF5\W)7^Q6-BENDLLRW\SS;;9*+K/_FO-1
M5TG7Z+<BVU3)[[NZJK/-(M_<GDWK1E ;=CK?)W_3)Z>>Y%=V^RIAZ8N$II0G
M[Z\NDF^__NY^F&G3GT.GZ*%3M(O+?'''R$_^_JT)D_Q:VW7U#]:7/B?'<[:C
MYW6US>;V?-(,C\J6'^UD]LU71*;?!WK$#CUBH>BS[@SE5;7+-G.;S(NJZ<;%
MKFQEUTN;O%N6UKY\6VSJ97)IR[Q8)#_UG;JP<[N^MF7"2/\S8SWK<\LN=SN,
M/\Y>"J'9V?0C(ID?)/-'2VX$"$Q 'TD<"Z"$$8XK$ <%8HP"B2D0K@+"A$YQ
M!?*@0(Y1H# %TE4@./4(4 <!:HP C0E0K@ FB.<JT <!^M$"WBUM Y";VI:8
M#(V<"<*XPG68@P[S6!TODG=%G:TP#<;5(%,E/!I("F:;#JM8Y-6\V&WJ3L4)
M1_$^]_TKB%+/"21'A""/%>T;Q_M(]P=RJ@WQ: !#)T%W]6A 1_(^DG,!><R$
M@ 63!WBPHP$=R^%(."N2 "8(F"YY@.LZ(M'Q'HXT0B3X,GF ,=\7&?:$<+P1
M4L' R0,<_ NI/M<@B(4SQ87V7'E@XB3LXEW&4SJ%:_5,,DY\0L'L2=CM>Z%>
M=W"MG7"C9#N.T;Q@[B3L[H>\N".X=LX8:3IL\+P4_)R&_?R0%W4!ZAJR,HRG
MGNY2<&0:=N1#6G1<4]>$&_<CQ#.5H$>SZK )]VG#(Y6Z[ML, .7/#O9+P_;K
M'7;[=O<NJ]2D-"6^\PMN2L-NVA8)R5<D^?MM-ZCPLF"$C0[6!12\E(KGJ'5&
M&.YPI\!UZ8#KGLSJJ.O)S>4HA>?* $NF Q/K,0I15Z2N&5-F&HT>B6#&=&#J
M/48B:J#4-6[*M4P]4RH*ODT'9N5C).)>ZWH\%4KZ+)Z!Q;.!*?L8B:@O,Q<'
M5$K!/%4% QRP@0GZ0R2^"/LV<Z'!A='<5_,PH 8;F+H_0%V@%&,N4(241FO/
M9(4=+:F$@=*;.PV:>SC$V$4?X _CSV#N+ :Q&!"+#<S^3[=NY:[:$&ITZBDW
M&?"'1> /ZNX,X0]+%?-=O0 @%@% J+LS%T""-P/,]RL"@%@$ *'NSK#*(>7,
MPT@& &(1 (2[>S#1XTM4#H3B)R#4@/V'4XQ0#_#B3X=7  _<Y19A(M7"<VEP
MX!8/<ZO' POB(1QBI)-R(!AGSX ''H-Y_.BVP< *ULGPP-W;"I1SW\2: \!X
M!(#A]ST0@*4D33W%,@> \0@ 0^G 78"15!+N^Q4!8#P"P% Z<!=@FA'NNW\%
M_.(1^(7"(9QHA+T"X/@) #<$AQ.C30#:Q-/1%H"#<"NNYKKP5O\"H"7"T.K9
MP(-L"(<8::,"\"6>XQZXB $\ < 3 [=@3L8&X2X:"IX*WY4!]!(1Z(6R02#T
MHJDQOIOB1W?%(^ +OVGNXHM2;;SC"_ E(N +98-P\46;RH%3CT3 EXB +Q0.
MX40C[!4 )TX N $XA%.,4 ]H$T]'6P@.[HJAXIS["@<)T))A:/5P$$$XA$.,
M]%$)_)+D&> @8Q!/ O'DTQ<:'P8'Z:XY$FFH9RU9 KYD!'RA<) NOJ3Q%KT2
M\"4CX ME@W3QI1@G'C1(H)>,0"]\PY5++Z6(]S<\VO,5 5XH&:0++TU2[5,(
M[)(G8-> [X=3/-[W)5!+/IU: =^7[EHB(]H[(Y# (QGF4>_[,NS[(TJI08M4
M@":5/H/OJQ@P4P S=8+;7P_R?>4N)LI4^!;"%9!)12 3ZOO*)1,5+$T]:QT*
MT*0BH DU?H5LQ^!$"]\V* 5P4A'@A%I_.-'CS4L!OE0$?.';=4^\)TX!X-0)
M #> CW"*$>J/=D0_'7X!?"AWL9$H1HF/'PJXIL)<Z_FA@OP(AQAKM8 X99Z#
M'S&@J &*.L(.#Y0?&MGA823Q;*'00#@=@7 H/S1RNXQR)CV+2AH0IR,@#N6'
M=A'7S,J5;[.1!L3I"(A#\1%.]'CSTH! '0&!*#["B4;T 1"H3X#  7R$4XQ0
M#_#33X=? !\:*>FDD=I3%VO F@YC[6IW77?[<T/X",<8Z[1'SP+I9\"'CL%$
M#4S4$;:0X/A ]JDK3JG'^0P0SD0@',H/XQ*."&8T\]1(!AAG(C .!8A!]K\S
M3JCR%$D&(&<B0 XEB$$@9[3V/0EA '(F N100!BWCF-<2=_S9 889D[ L '_
M-^[J8G"[J@$ZF:?3*?3D8!_]^%E:TF[HH.S+43P]>FB[?0#^;5;>YHWUK>Q-
MTS1]U=9W9?],>7]0%]ON.>[KHJZ+=?=R:;.%+=LO-)_?%$7]^:!]-/SP9/_L
M?U!+ P04    " "I@&U9>B,"V.$$  !-(   &0   'AL+W=O<FMS:&5E=',O
M<VAE970V,"YX;6R]FMMNXS80AE^%4(MB%^A&)Q]3VT!B2>@6&R!(=MN+12]H
M>6P3*XDN1<?)VY>4%-F*&39NIWL3Z_1_0\U/4=0PDST7W\H-@"2/>5:44V<C
MY?;2=<MT SDM+_@6"G5FQ45.I=H5:[?<"J#+2I1G;N!Y S>GK'!FD^K8K9A-
M^$YFK(!;0<I=GE/Q= T9WT\=WWD^<,?6&ZD/N+/)EJ[A'N27[:U0>VY+6;(<
MBI+Q@@A839TK_S+QAUI07?$[@WUYM$WTK2PX_Z9W/BZGCJ=;!!FD4B.H^GF
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M^)/4@B::;\TR87[!H;:%%ECOA&1Y#58[R&E17?'O.A G ->_ '!K@'LM -4
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M461'2V>T]"VTU(:6GJ+%21H&=K1L1LO>0LML:-DI6A)FJ6='6\QHBXMHO]>
ME:O2(&V8BQ/,>!$MHBRS@_K>UQ3K7885FG+"AP33'1+,58_G7!6B;S5FF8*J
MFE18(M6U-4MZIR<K2^,T/1-^_RC]^Q>Y?02E[@AKNM[08$@&KXLF5P=N!*H*
M"ZA)E&]Q]$\XWH1!%/O!F1/I?\W6_L4,.050S$F7,[IEG&EVIJ8$)YDJ2D(O
MB;[=2?>H;IHWR"]4[EBK<*LJM/1N4Q0CQ[(^=K3HAE*Z%1H+\]"L\2D$TBS
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MA $_/T\2]K(C NP^'YS\#U!+ P04    " "I@&U9VNSIC]@#  !9#P  &0
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MFNK>%X59H+_/.5</ [-!W4V/_P902P,$%     @ J8!M6926BUT4!   (0\
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M!:AEVF$5S'T9C'<A&%]1IW(C8)I&&!GPLV9\OP%OJ\36V?4.V;WW&@D7F+7
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M6EVU@_*R(2L'DF5%/[!D4G47Q>-&];#(M8-ZOV),'@9Z@KHK'O\%4$L#!!0
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M!J($6&4@OE]1RI]O*@?=Z=?\/U!+ P04    " "I@&U9"^?9\'D$  !$&P
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M?K^)>P"Z7-UZB?'S$M_@7N("ME?(,GY%V,!VQX!FP^U6UWJ\K??P;;U'_?8
MEM)NOFJ?#[?CGE!8=;9;)<]Z;39OSNPO?T@D^B0@X_]V)?>A?[N[_Z*N7/,M
M6<)$DX6# WL$;?K+3Z9K?.A*#)6P0"4L5 F+5,+FBF"-]++K]++[Z-._J" I
MVE8YPXO$ZLJ1 \0M(<6MPN/4-4S3\>0%\G@<_E.=8_FN8QA-77"J,T>>C0V[
M)0P[A-CR',\8-851A]"S/=-U_:9PWM6UXWJ^BVMA8R6=>B6=WI6\ [:$7,B;
MH>)2/;NB!YA_/(S66IY5!&<5X5E%U#NI2S-9$:RQ_FZ]_F[O^D<)XP(%L)(W
MG2"IGOVACD*A15]N(7L UOD?V(N^]#]0)2Q0"0M5PB*5L+DB6"-SO#ISO!]<
M8CV5Z:42%JB$A2IAD4K87!&LD5ZC.KU&*DKLZ+1T^HYIV7:K+'3H+%<^Q;=*
M<7"J,T>N@0VG)0P[A!@[EN,XK5+1.\U+(Z((UHB(7T?$5UFJ_9,B:ESYK=N*
MV1!1,$04#A%%O1.\-!:*8(U8F,;+X[S1&XT_Q088(GF2R<MD R05F]Y:W8^[
M]-]4*2U02@N5TB*EM+DJ6C-ICMX!F3^X9E<#4)5F*FF!4EJHE!8II<U5T9II
MAE_2#*NHW16E^7R,<;M&=,@LU[:\5I7HD)F6[X]:NK!+A['9+O!1_QPOCH@B
M6C,B+Z_#S-[7(9?6[HK6K*9&^U%[D"H8I H'J:+^65X<$Z6OD/2C=_,9L'6Y
M[<+1DNYR<7BS5+?66SL?RPV-5ON->3TS.]H#\SKL:H^*+:)RC^"EV\/^TBUA
MZR3G*(65'()QY3D:8H<MF\.)H-MRQ^"!"D&S\E#>2L3 "H'\?46I>#XI.J@W
MSJ;_ U!+ P04    " "I@&U9V+!TOY$"  #"!P  &0   'AL+W=O<FMS:&5E
M=',O<VAE970W,"YX;6RM5=]OTS 0_E>L@-"0QIQ?[;J21FJ;(G@83*L&#X@'
M-[DVUA([V&X[^.NQG31KMZP:L)?&/M_WG;\[]R[:<G$K<P"%[LJ"R9&3*U4-
M,99I#B619[P"ID^67)1$Z:U885D)()D%E07V7;>/2T*9$T?6=B7BB*]501E<
M"23794G$KPD4?#MR/&=GN*:K7!D#CJ.*K& .ZJ:Z$GJ'6Y:,EL DY0P)6(Z<
ML3><A<;?.GREL)5[:V24+#B_-9M/V<AQS86@@%09!J(_&YA"41@B?8V?#:?3
MAC3 _?6._8/5KK4LB(0I+[[13.4C9^"@#)9D7:AKOOT(C9Z>X4MY(>TOVM:^
MH>N@="T5+QNPOD%)6?TE=TT>]@":IQO@-P#_(2!\ A T@."Y$<(&$#XW0J\!
M6.FXUFX3EQ!%XDCP+1+&6[.9A<V^1>M\46;>R5P)?4HU3L5?5 X"S>[TNY,@
M3]%G_31/$E"$%O(M>H=NY@DZ>?TVPDH',Q"<-L23FMA_@CA EYRI7*(9RR#K
MP"?'\1='\%B+;)7Z.Z43_RCA'*HS%+BGR'?]L.,^T^?#@RXY_Q=]]L_1#Y(1
MM&4/+%_P%V7_/EY()?0_]T=7M6N^L)O/=+.AK$@*(T>W*PEB T[\YI77=]]W
MI?HER9*7))N]$-E!4<*V*.$Q]GA<<J'H;V([*%_J?K=0B$JY)BP%E'*I9%=E
M:M*^)35C81-[[L#M17BSG_+'7H/^X/S0*7GL%'B#WL6AUZPCH-_S[P/6XO%>
M4RI!K.PTD%K&FJGZH;;6=N",;9]]8)]XPZG784_T@*KGR3U]/=TNB5A1)E$!
M2QW*/3O7/5/4$Z/>*%[9EKC@2C=8N\SUD 5A'/3YDG.UVY@ [=B._P!02P,$
M%     @ J8!M60B_Z&S<!   MQ   !D   !X;"]W;W)K<VAE971S+W-H965T
M-S$N>&ULK5AM;]LV$/Z>7T&X09$ 3B3JW:EM(/4+5F#=@F;=/@3[0$NT+502
M59*RD_WZ'2E;M67:23=_2")1=\_QGCO>\=)?,_Y-+"F5Z#G/"C'H+*4L[RQ+
MQ$N:$W'+2EK ESGC.9'PRA>6*#DEB5;*,\NQ[<#*25ITAGV]]L"'?5;)+"WH
M T>BRG/"7S[2C*T''=S9+GQ)%TNI%JQAOR0+^DCEU_*!PYO5H"1I3@N1L@)Q
M.A]T[O'=%&L%+?%G2M=BYQDI5V:,?5,OGY)!QU8[HAF-I8(@\&=%1S3+%!+L
MX_L&M-/85(J[SUOTJ78>G)D104<L^RM-Y'+0B3HHH7-29?(+6_]"-P[Y"B]F
MF="_T7HC:W=07 G)\HTR["!/B_HO>=X0L:. W2,*SD;!:2OX1Q3<C8+;5O".
M*'@;!>^M%OR-@O]6"\%&(=#<UV1IIL=$DF&?LS7B2AK0U(,.E]8&@M-"9=:C
MY/ U!3TY_%TN*4>39\A40447_0;)?#6FDJ29N$8WZ!%2.:DRBM@<[<MJT1OT
M]7&,KBZO^Y:$W2A,*]Y8'M66G2.67?29%7(IT*1(:&+0GYS6[YW0MX"%A@IG
M2\7(.0GX2,M;Y-I=Y-B.9]C/^.WJKLF=_V=]^I^M[Y'A-GGA:CSW&-[IN#_=
MSX3D4!;^-@6^AO;,T*I6WHF2Q'30@6(H*%_1SO#].QS8'TRLGQ-L<DZPZ9G
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MPNLIN7Z1K-13W8Q)F!'UXY(2"(L2@.]SQN3V11EH_E<Q_!=02P,$%     @
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M(M] _?_$N=PNY WL)H9-_P=02P,$%     @ J8!M6>!01=X2 @  E00  !D
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M_PW0+L&>'Y3"4^ *3'^B_#=02P,$%     @ J8!M6;Q^A\71#   3U0  !D
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M(DO\CO?PFK15P>B>$#@_MAG>".4$SN_<%7?!+$ !E?2[3AQ? FB\< "&PTL
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M%>]S5A8G%*>R6H1:@@""]J(#^R\$4'$N#=,XD(0XU<R3"AS($"AZ$8.=R(H
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M)W.6%-)8,%8$RRK%*?QNV8V8Q&)0K")^$OO5)IP@CC_]S@X7<DTH'%@1/&U
MX)RRH+%Q1.&TTQJ[Q02.@S6!$U610"W\(DO'5@Y"3L:%W*D6G*1.-G%Q]81
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M?*BGLWK= _S?/S9-]^67OH/].T1O_@]02P,$%     @ J8!M62M!L^;. @
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M-:Z(N*:[K]#H&2N^F!*NGVA7Q[J^@>**"YHW8)E!GA7U&]\W/AP )$\WP&X
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MP) XMN_!G?=1M'I/1>O_7@[_ %!+ P04    " "I@&U9EXJ[',     3 @
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M*?<\]@NF1?MLQD)Y-:7.N#VAID6#AX=R14LJ<D::6M/DY%]!ZX(;5OSA\44
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M4$L! A0#%     @ J8!M61WS)QK' @  UP<  !@              ("!C14
M 'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( *F ;5EOIQ"D
MIP4  .$6   8              " @8H8  !X;"]W;W)K<VAE971S+W-H965T
M-"YX;6Q02P$"% ,4    " "I@&U95#<6B>X&  !Q+0  &
M@(%G'@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ J8!M
M66;>2QF! @  &@8  !@              ("!BR4  'AL+W=O<FMS:&5E=',O
M<VAE970V+GAM;%!+ 0(4 Q0    ( *F ;5F<V$69P@<   \B   8
M      " @4(H  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M" "I@&U9(>83[P,$  !R"   &               @($Z,   >&PO=V]R:W-H
M965T<R]S:&5E=#@N>&UL4$L! A0#%     @ J8!M6??QI3H<%P  2C\  !@
M             ("!<S0  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4
M Q0    ( *F ;5GB\ST97@(  $D%   9              " @<5+  !X;"]W
M;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ J8!M62J(=V%> P
MD <  !D              ("!6DX  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX
M;6Q02P$"% ,4    " "I@&U9[DE212(#  !F!@  &0              @('O
M40  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( *F ;5G*
M-G:XE@(  ,<%   9              " @4A5  !X;"]W;W)K<VAE971S+W-H
M965T,3,N>&UL4$L! A0#%     @ J8!M6:_A-Q^( P  AP<  !D
M     ("!%5@  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *F ;5E!6U3ME 0  ,<)   9              "
M@7%V  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ J8!M
M68?PHU")%   +T,  !D              ("!/'L  'AL+W=O<FMS:&5E=',O
M<VAE970R,"YX;6Q02P$"% ,4    " "I@&U9@C)]J@8%   ="P  &0
M        @('\CP  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0
M   ( *F ;5E!A9Z@# 0  *P(   9              " @3F5  !X;"]W;W)K
M<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ J8!M66E@;,L=!P  ,1$
M !D              ("!?)D  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q0
M2P$"% ,4    " "I@&U9#784"C()  #8&@  &0              @('0H
M>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( *F ;5E//NON
MB@(  '@%   9              " @3FJ  !X;"]W;W)K<VAE971S+W-H965T
M,C4N>&UL4$L! A0#%     @ J8!M65+A\X10 P  1 <  !D
M ("!^JP  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " "I
M@&U9%0RO8_0"  !F!@  &0              @(&!L   >&PO=V]R:W-H965T
M<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( *F ;5EU_9Y^?P(  +H'   9
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M970S,BYX;6Q02P$"% ,4    " "I@&U9GL=-0GL"  "O!0  &0
M    @($UV0  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    (
M *F ;5D2OXO(,P,  .T&   9              " @>?;  !X;"]W;W)K<VAE
M971S+W-H965T,S0N>&UL4$L! A0#%     @ J8!M6<>TW"SH @  I08  !D
M             ("!4=\  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"
M% ,4    " "I@&U9$-8YBLL"  !'!@  &0              @(%PX@  >&PO
M=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( *F ;5F6(9UB#@8
M /T/   9              " @7+E  !X;"]W;W)K<VAE971S+W-H965T,S<N
M>&UL4$L! A0#%     @ J8!M6<JY7YE5!   Z@D  !D              ("!
MM^L  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " "I@&U9
MR2L8#Y<&  "\$   &0              @(%#\   >&PO=V]R:W-H965T<R]S
M:&5E=#,Y+GAM;%!+ 0(4 Q0    ( *F ;5F7\PH<<@,  ) (   9
M      " @1'W  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%
M  @ J8!M6;W0[)0(!   J @  !D              ("!NOH  'AL+W=O<FMS
M:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " "I@&U9<4FI!H<(  "7&0
M&0              @('Y_@  >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+
M 0(4 Q0    ( *F ;5F=#@^68 0  .X7   9              " @;<' 0!X
M;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ J8!M6<]/XM*G
M P  /A0  !D              ("!3@P! 'AL+W=O<FMS:&5E=',O<VAE970T
M-"YX;6Q02P$"% ,4    " "I@&U9 )'>*A,$  !?&P  &0
M@($L$ $ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( *F
M;5GFHYJ_ZP,  '\/   9              " @784 0!X;"]W;W)K<VAE971S
M+W-H965T-#8N>&UL4$L! A0#%     @ J8!M6?E\.TM/ @  T 8  !D
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M=#4Q+GAM;%!+ 0(4 Q0    ( *F ;5EL"4>'S@(  -P(   9
M  " @:DE 0!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @
MJ8!M6>'>HXJ7!0  F"H  !D              ("!KB@! 'AL+W=O<FMS:&5E
M=',O<VAE970U,RYX;6Q02P$"% ,4    " "I@&U9EDH=P*X#  #;%0  &0
M            @(%\+@$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4
M Q0    ( *F ;5E\_"@*R0,  $H2   9              " @6$R 0!X;"]W
M;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ J8!M6?7@&\CX @
M+PD  !D              ("!838! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX
M;6Q02P$"% ,4    " "I@&U9X]_P+Q@1  #'+P$ &0              @(&0
M.0$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( *F ;5F#
M\DQ:$0<  )I"   9              " @=]* 0!X;"]W;W)K<VAE971S+W-H
M965T-3@N>&UL4$L! A0#%     @ J8!M658,*HM'"   Y3\  !D
M     ("!)U(! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *F ;5E^N1X-01P  '79 0 9              "
M@>MK 0!X;"]W;W)K<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @ J8!M
M6<,E,\ZW!P  2C@  !D              ("!8X@! 'AL+W=O<FMS:&5E=',O
M<VAE970V-2YX;6Q02P$"% ,4    " "I@&U9VNSIC]@#  !9#P  &0
M        @(%1D $ >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0
M   ( *F ;5F4EHM=% 0  "$/   9              " @6"4 0!X;"]W;W)K
M<VAE971S+W-H965T-C<N>&UL4$L! A0#%     @ J8!M68/#1^UT!   "1L
M !D              ("!JY@! 'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q0
M2P$"% ,4    " "I@&U9"^?9\'D$  !$&P  &0              @(%6G0$
M>&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    ( *F ;5G8L'2_
MD0(  ,('   9              " @0:B 0!X;"]W;W)K<VAE971S+W-H965T
M-S N>&UL4$L! A0#%     @ J8!M60B_Z&S<!   MQ   !D
M ("!SJ0! 'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q02P$"% ,4    " "I
M@&U9#TO=O0L&   D-@  &0              @('AJ0$ >&PO=V]R:W-H965T
M<R]S:&5E=#<R+GAM;%!+ 0(4 Q0    ( *F ;5G@4$7>$@(  )4$   9
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M970W-RYX;6Q02P$"% ,4    " "I@&U92_4GA$@#  #*%   #0
M    @ '2R $ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( *F ;5F7BKL<P
M !,"   +              "  47, 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    (
M *F ;5EG*>[ND04  %8R   /              "  2[- 0!X;"]W;W)K8F]O
M:RYX;6Q02P$"% ,4    " "I@&U9>NU.;58"  ".+0  &@
M@ 'LT@$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "I
M@&U95:BY9Q("  !S+   $P              @ %ZU0$ 6T-O;G1E;G1?5'EP
=97-=+GAM;%!+!08     50!5 $H7  "]UP$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>301</ContextCount>
  <ElementCount>349</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>69</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995100 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995301 - Statement - Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995302 - Statement - Balance Sheets (Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Balance Sheets (Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995303 - Statement - Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995304 - Statement - Statements of Stockholders??? Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Statements of Stockholders??? Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995305 - Statement - Statements of Stockholders??? Equity (Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ShareholdersEquityType2or3_Parentheticals</Role>
      <ShortName>Statements of Stockholders??? Equity (Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995306 - Statement - Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995307 - Disclosure - Business Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/BusinessOperations</Role>
      <ShortName>Business Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995308 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995309 - Disclosure - Cash and Cash Equivalents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/CashandCashEquivalents</Role>
      <ShortName>Cash and Cash Equivalents</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995310 - Disclosure - Trade Accounts Receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/TradeAccountsReceivable</Role>
      <ShortName>Trade Accounts Receivable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995311 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995312 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/PrepaidExpensesandOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995313 - Disclosure - Property, Plant and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/PropertyPlantandEquipmentNet</Role>
      <ShortName>Property, Plant and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995314 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995315 - Disclosure - Accounts Payable and Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/AccountsPayableandAccruedExpenses</Role>
      <ShortName>Accounts Payable and Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995316 - Disclosure - Bank Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/BankDebt</Role>
      <ShortName>Bank Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995317 - Disclosure - Contingent Liabilities and Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ContingentLiabilitiesandCommitments</Role>
      <ShortName>Contingent Liabilities and Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995318 - Disclosure - Operating Lease</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/OperatingLease</Role>
      <ShortName>Operating Lease</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995319 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995320 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995321 - Disclosure - Other Expenses, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/OtherExpensesNet</Role>
      <ShortName>Other Expenses, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995322 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995323 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995324 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995325 - Disclosure - Employee Benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/EmployeeBenefits</Role>
      <ShortName>Employee Benefits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995326 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>996000 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://immucell.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>996001 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immucell.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>996002 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immucell.com/role/Inventory</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>996003 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/PrepaidExpensesandOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immucell.com/role/PrepaidExpensesandOtherCurrentAssets</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>996004 - Disclosure - Property, Plant and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/PropertyPlantandEquipmentNetTables</Role>
      <ShortName>Property, Plant and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immucell.com/role/PropertyPlantandEquipmentNet</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immucell.com/role/IntangibleAssets</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>996006 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/AccountsPayableandAccruedExpensesTables</Role>
      <ShortName>Accounts Payable and Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immucell.com/role/AccountsPayableandAccruedExpenses</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>996007 - Disclosure - Bank Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/BankDebtTables</Role>
      <ShortName>Bank Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immucell.com/role/BankDebt</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>996008 - Disclosure - Operating Lease (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/OperatingLeaseTables</Role>
      <ShortName>Operating Lease (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immucell.com/role/OperatingLease</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>996009 - Disclosure - Stockholders??? Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders??? Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immucell.com/role/StockholdersEquity</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>996010 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/RevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immucell.com/role/Revenue</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>996011 - Disclosure - Other Expenses, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/OtherExpensesNetTables</Role>
      <ShortName>Other Expenses, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immucell.com/role/OtherExpensesNet</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>996012 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immucell.com/role/SegmentInformation</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>996013 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>996014 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Assets or Liabilities Measured at Fair Value on a Nonrecurring Basis</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of Assets or Liabilities Measured at Fair Value on a Nonrecurring Basis</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Concentration of Risk</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofConcentrationofRiskTable</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of Concentration of Risk</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>996016 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Net Income (Loss) Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of Net Income (Loss) Per Common Share</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>996017 - Disclosure - Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/CashandCashEquivalentsDetails</Role>
      <ShortName>Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/CashandCashEquivalents</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>996018 - Disclosure - Trade Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/TradeAccountsReceivableDetails</Role>
      <ShortName>Trade Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/TradeAccountsReceivable</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>996019 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/InventoryTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>996020 - Disclosure - Inventory (Details) - Schedule of Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofInventoryTable</Role>
      <ShortName>Inventory (Details) - Schedule of Inventory</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/InventoryTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>996021 - Disclosure - Prepaid Expenses and Other Current Assets (Details) - Schedule of Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Details) - Schedule of Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/PrepaidExpensesandOtherCurrentAssetsTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>996022 - Disclosure - Property, Plant and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/PropertyPlantandEquipmentNetDetails</Role>
      <ShortName>Property, Plant and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/PropertyPlantandEquipmentNetTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>996023 - Disclosure - Property, Plant and Equipment, Net (Details) - Schedule of Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable</Role>
      <ShortName>Property, Plant and Equipment, Net (Details) - Schedule of Property, Plant and Equipment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/PropertyPlantandEquipmentNetTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>996024 - Disclosure - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/IntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/IntangibleAssetsTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Intangible Assets (Details) - Schedule of Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofIntangibleAssetsTable</Role>
      <ShortName>Intangible Assets (Details) - Schedule of Intangible Assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/IntangibleAssetsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>996026 - Disclosure - Accounts Payable and Accrued Expenses (Details) - Schedule of Accounts Payable and Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable</Role>
      <ShortName>Accounts Payable and Accrued Expenses (Details) - Schedule of Accounts Payable and Accrued Expenses</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/AccountsPayableandAccruedExpensesTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>996027 - Disclosure - Bank Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/BankDebtDetails</Role>
      <ShortName>Bank Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/BankDebtTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>996028 - Disclosure - Bank Debt (Details) - Schedule of Debt Proceeds Received and Principal Repayments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable</Role>
      <ShortName>Bank Debt (Details) - Schedule of Debt Proceeds Received and Principal Repayments</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/BankDebtTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>996029 - Disclosure - Bank Debt (Details) - Schedule of Principal Payments Bank Loans Outstanding</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable</Role>
      <ShortName>Bank Debt (Details) - Schedule of Principal Payments Bank Loans Outstanding</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/BankDebtTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>996030 - Disclosure - Contingent Liabilities and Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails</Role>
      <ShortName>Contingent Liabilities and Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/ContingentLiabilitiesandCommitments</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>996031 - Disclosure - Operating Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/OperatingLeaseDetails</Role>
      <ShortName>Operating Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/OperatingLeaseTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>996032 - Disclosure - Operating Lease (Details) - Schedule of Lease Costs and Other Lease Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable</Role>
      <ShortName>Operating Lease (Details) - Schedule of Lease Costs and Other Lease Information</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/OperatingLeaseTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996033 - Disclosure - Operating Lease (Details) - Schedule of Future Lease Payments Required Under Non-Cancelable Operating Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable</Role>
      <ShortName>Operating Lease (Details) - Schedule of Future Lease Payments Required Under Non-Cancelable Operating Leases</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/OperatingLeaseTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996034 - Disclosure - Stockholders??? Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders??? Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/StockholdersEquityTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996035 - Disclosure - Stockholders??? Equity (Details) - Schedule of Activity Under the Stock Option Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable</Role>
      <ShortName>Stockholders??? Equity (Details) - Schedule of Activity Under the Stock Option Plans</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/StockholdersEquityTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996036 - Disclosure - Stockholders??? Equity (Details) - Schedule of Additional Information About the Stock Option Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable</Role>
      <ShortName>Stockholders??? Equity (Details) - Schedule of Additional Information About the Stock Option Plans</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/StockholdersEquityTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>996037 - Disclosure - Stockholders??? Equity (Details) - Schedule of Fair Value Stock Option Grant Using Black-Scholes Option Pricing Model with Weighted-Average Assumptions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofFairValueStockOptionGrantUsingBlackScholesOptionPricingModelwithWeightedAverageAssumptionsTable</Role>
      <ShortName>Stockholders??? Equity (Details) - Schedule of Fair Value Stock Option Grant Using Black-Scholes Option Pricing Model with Weighted-Average Assumptions</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/StockholdersEquityTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>996038 - Disclosure - Revenue (Details) - Schedule of Product Sales Disaggregated by Geographic Area</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyGeographicAreaTable</Role>
      <ShortName>Revenue (Details) - Schedule of Product Sales Disaggregated by Geographic Area</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/RevenueTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>996039 - Disclosure - Revenue (Details) - Schedule of Product Sales Disaggregated by Major Product Category</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable</Role>
      <ShortName>Revenue (Details) - Schedule of Product Sales Disaggregated by Major Product Category</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/RevenueTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>996040 - Disclosure - Other Expenses, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/OtherExpensesNetDetails</Role>
      <ShortName>Other Expenses, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/OtherExpensesNetTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>996041 - Disclosure - Other Expenses, Net (Details) - Schedule of Other Expenses Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofOtherExpensesNetTable</Role>
      <ShortName>Other Expenses, Net (Details) - Schedule of Other Expenses Net</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/OtherExpensesNetTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>996042 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/IncomeTaxes</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>996043 - Disclosure - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/SegmentInformationDetails</Role>
      <ShortName>Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/SegmentInformationTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>996044 - Disclosure - Segment Information (Details) - Schedule of Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofSegmentInformationTable</Role>
      <ShortName>Segment Information (Details) - Schedule of Segment Information</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/SegmentInformationTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>996045 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/RelatedPartyTransactions</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>996046 - Disclosure - Employee Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/EmployeeBenefitsDetails</Role>
      <ShortName>Employee Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/EmployeeBenefits</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="ea0220527-10q_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>996047 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/SubsequentEvents</ParentRole>
      <Position>77</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="ea0220527-10q_immucell.htm">ea0220527-10q_immucell.htm</File>
    <File>iccc-20240930.xsd</File>
    <File>iccc-20240930_cal.xml</File>
    <File>iccc-20240930_def.xml</File>
    <File>iccc-20240930_lab.xml</File>
    <File>iccc-20240930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1250">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>96
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0220527-10q_immucell.htm": {
   "nsprefix": "iccc",
   "nsuri": "http://immucell.com/20240930",
   "dts": {
    "inline": {
     "local": [
      "ea0220527-10q_immucell.htm"
     ]
    },
    "schema": {
     "local": [
      "iccc-20240930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_def.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_lab.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_pre.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-sub-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "iccc-20240930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "iccc-20240930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "iccc-20240930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "iccc-20240930_pre.xml"
     ]
    }
   },
   "keyStandard": 308,
   "keyCustom": 41,
   "axisStandard": 26,
   "axisCustom": 0,
   "memberStandard": 39,
   "memberCustom": 27,
   "hidden": {
    "total": 173,
    "http://fasb.org/us-gaap/2024": 164,
    "http://xbrl.sec.gov/dei/2024": 6,
    "http://immucell.com/20240930": 3
   },
   "contextCount": 301,
   "entityCount": 1,
   "segmentCount": 69,
   "elementCount": 792,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 1250,
    "http://xbrl.sec.gov/dei/2024": 29,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/dei/role/document/Cover",
     "longName": "995100 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://immucell.com/role/ConsolidatedBalanceSheet",
     "longName": "995301 - Statement - Balance Sheets (Unaudited)",
     "shortName": "Balance Sheets (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:AssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://immucell.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "longName": "995302 - Statement - Balance Sheets (Unaudited) (Parentheticals)",
     "shortName": "Balance Sheets (Unaudited) (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://immucell.com/role/ConsolidatedIncomeStatement",
     "longName": "995303 - Statement - Statements of Operations (Unaudited)",
     "shortName": "Statements of Operations (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://immucell.com/role/ShareholdersEquityType2or3",
     "longName": "995304 - Statement - Statements of Stockholders\u2019 Equity (Unaudited)",
     "shortName": "Statements of Stockholders\u2019 Equity (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c42",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c42",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://immucell.com/role/ShareholdersEquityType2or3_Parentheticals",
     "longName": "995305 - Statement - Statements of Stockholders\u2019 Equity (Unaudited) (Parentheticals)",
     "shortName": "Statements of Stockholders\u2019 Equity (Unaudited) (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "iccc:OfferingCostsOnFollowUpOfferingOfCommonStock",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "iccc:OfferingCostsOnFollowUpOfferingOfCommonStock",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://immucell.com/role/ConsolidatedCashFlow",
     "longName": "995306 - Statement - Statements of Cash Flows (Unaudited)",
     "shortName": "Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AmortizationOfFinancingCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://immucell.com/role/BusinessOperations",
     "longName": "995307 - Disclosure - Business Operations",
     "shortName": "Business Operations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://immucell.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "995308 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://immucell.com/role/CashandCashEquivalents",
     "longName": "995309 - Disclosure - Cash and Cash Equivalents",
     "shortName": "Cash and Cash Equivalents",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://immucell.com/role/TradeAccountsReceivable",
     "longName": "995310 - Disclosure - Trade Accounts Receivable",
     "shortName": "Trade Accounts Receivable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://immucell.com/role/Inventory",
     "longName": "995311 - Disclosure - Inventory",
     "shortName": "Inventory",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://immucell.com/role/PrepaidExpensesandOtherCurrentAssets",
     "longName": "995312 - Disclosure - Prepaid Expenses and Other Current Assets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://immucell.com/role/PropertyPlantandEquipmentNet",
     "longName": "995313 - Disclosure - Property, Plant and Equipment, Net",
     "shortName": "Property, Plant and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://immucell.com/role/IntangibleAssets",
     "longName": "995314 - Disclosure - Intangible Assets",
     "shortName": "Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://immucell.com/role/AccountsPayableandAccruedExpenses",
     "longName": "995315 - Disclosure - Accounts Payable and Accrued Expenses",
     "shortName": "Accounts Payable and Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://immucell.com/role/BankDebt",
     "longName": "995316 - Disclosure - Bank Debt",
     "shortName": "Bank Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://immucell.com/role/ContingentLiabilitiesandCommitments",
     "longName": "995317 - Disclosure - Contingent Liabilities and Commitments",
     "shortName": "Contingent Liabilities and Commitments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://immucell.com/role/OperatingLease",
     "longName": "995318 - Disclosure - Operating Lease",
     "shortName": "Operating Lease",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://immucell.com/role/StockholdersEquity",
     "longName": "995319 - Disclosure - Stockholders\u2019 Equity",
     "shortName": "Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://immucell.com/role/Revenue",
     "longName": "995320 - Disclosure - Revenue",
     "shortName": "Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://immucell.com/role/OtherExpensesNet",
     "longName": "995321 - Disclosure - Other Expenses, Net",
     "shortName": "Other Expenses, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://immucell.com/role/IncomeTaxes",
     "longName": "995322 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://immucell.com/role/SegmentInformation",
     "longName": "995323 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://immucell.com/role/RelatedPartyTransactions",
     "longName": "995324 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://immucell.com/role/EmployeeBenefits",
     "longName": "995325 - Disclosure - Employee Benefits",
     "shortName": "Employee Benefits",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://immucell.com/role/SubsequentEvents",
     "longName": "995326 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R29": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "ecd:Rule10b51ArrTrmntdFlag",
       "ecd:NonRule10b51ArrTrmntdFlag",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "ecd:Rule10b51ArrTrmntdFlag",
       "ecd:NonRule10b51ArrTrmntdFlag",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://immucell.com/role/AccountingPoliciesByPolicy",
     "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://immucell.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "996001 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://immucell.com/role/InventoryTables",
     "longName": "996002 - Disclosure - Inventory (Tables)",
     "shortName": "Inventory (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://immucell.com/role/PrepaidExpensesandOtherCurrentAssetsTables",
     "longName": "996003 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://immucell.com/role/PropertyPlantandEquipmentNetTables",
     "longName": "996004 - Disclosure - Property, Plant and Equipment, Net (Tables)",
     "shortName": "Property, Plant and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://immucell.com/role/IntangibleAssetsTables",
     "longName": "996005 - Disclosure - Intangible Assets (Tables)",
     "shortName": "Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://immucell.com/role/AccountsPayableandAccruedExpensesTables",
     "longName": "996006 - Disclosure - Accounts Payable and Accrued Expenses (Tables)",
     "shortName": "Accounts Payable and Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://immucell.com/role/BankDebtTables",
     "longName": "996007 - Disclosure - Bank Debt (Tables)",
     "shortName": "Bank Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://immucell.com/role/OperatingLeaseTables",
     "longName": "996008 - Disclosure - Operating Lease (Tables)",
     "shortName": "Operating Lease (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://immucell.com/role/StockholdersEquityTables",
     "longName": "996009 - Disclosure - Stockholders\u2019 Equity (Tables)",
     "shortName": "Stockholders\u2019 Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://immucell.com/role/RevenueTables",
     "longName": "996010 - Disclosure - Revenue (Tables)",
     "shortName": "Revenue (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://immucell.com/role/OtherExpensesNetTables",
     "longName": "996011 - Disclosure - Other Expenses, Net (Tables)",
     "shortName": "Other Expenses, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://immucell.com/role/SegmentInformationTables",
     "longName": "996012 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "longName": "996013 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:CashFDICInsuredAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable",
     "longName": "996014 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Assets or Liabilities Measured at Fair Value on a Nonrecurring Basis",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of Assets or Liabilities Measured at Fair Value on a Nonrecurring Basis",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c56",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c56",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://immucell.com/role/ScheduleofConcentrationofRiskTable",
     "longName": "996015 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Concentration of Risk",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of Concentration of Risk",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c61",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c61",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable",
     "longName": "996016 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Net Income (Loss) Per Common Share",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of Net Income (Loss) Per Common Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R47": {
     "role": "http://immucell.com/role/CashandCashEquivalentsDetails",
     "longName": "996017 - Disclosure - Cash and Cash Equivalents (Details)",
     "shortName": "Cash and Cash Equivalents (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R48": {
     "role": "http://immucell.com/role/TradeAccountsReceivableDetails",
     "longName": "996018 - Disclosure - Trade Accounts Receivable (Details)",
     "shortName": "Trade Accounts Receivable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c73",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://immucell.com/role/InventoryDetails",
     "longName": "996019 - Disclosure - Inventory (Details)",
     "shortName": "Inventory (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InventoryWriteDown",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InventoryWriteDown",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://immucell.com/role/ScheduleofInventoryTable",
     "longName": "996020 - Disclosure - Inventory (Details) - Schedule of Inventory",
     "shortName": "Inventory (Details) - Schedule of Inventory",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://immucell.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable",
     "longName": "996021 - Disclosure - Prepaid Expenses and Other Current Assets (Details) - Schedule of Prepaid Expenses and Other Current Assets",
     "shortName": "Prepaid Expenses and Other Current Assets (Details) - Schedule of Prepaid Expenses and Other Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://immucell.com/role/PropertyPlantandEquipmentNetDetails",
     "longName": "996022 - Disclosure - Property, Plant and Equipment, Net (Details)",
     "shortName": "Property, Plant and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:PropertyPlantAndEquipmentDisposals",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:PropertyPlantAndEquipmentDisposals",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable",
     "longName": "996023 - Disclosure - Property, Plant and Equipment, Net (Details) - Schedule of Property, Plant and Equipment",
     "shortName": "Property, Plant and Equipment, Net (Details) - Schedule of Property, Plant and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://immucell.com/role/IntangibleAssetsDetails",
     "longName": "996024 - Disclosure - Intangible Assets (Details)",
     "shortName": "Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://immucell.com/role/ScheduleofIntangibleAssetsTable",
     "longName": "996025 - Disclosure - Intangible Assets (Details) - Schedule of Intangible Assets",
     "shortName": "Intangible Assets (Details) - Schedule of Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable",
     "longName": "996026 - Disclosure - Accounts Payable and Accrued Expenses (Details) - Schedule of Accounts Payable and Accrued Expenses",
     "shortName": "Accounts Payable and Accrued Expenses (Details) - Schedule of Accounts Payable and Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:AccountsPayableTradeCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:AccountsPayableTradeCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://immucell.com/role/BankDebtDetails",
     "longName": "996027 - Disclosure - Bank Debt (Details)",
     "shortName": "Bank Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:LongTermDebtPercentageBearingFixedInterestRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:LongTermDebtPercentageBearingFixedInterestRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable",
     "longName": "996028 - Disclosure - Bank Debt (Details) - Schedule of Debt Proceeds Received and Principal Repayments",
     "shortName": "Bank Debt (Details) - Schedule of Debt Proceeds Received and Principal Repayments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:ProceedsFromIssuanceOfDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:ProceedsFromIssuanceOfDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable",
     "longName": "996029 - Disclosure - Bank Debt (Details) - Schedule of Principal Payments Bank Loans Outstanding",
     "shortName": "Bank Debt (Details) - Schedule of Principal Payments Bank Loans Outstanding",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "iccc:DebtIssuanceCosts2024",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "iccc:DebtIssuanceCosts2024",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails",
     "longName": "996030 - Disclosure - Contingent Liabilities and Commitments (Details)",
     "shortName": "Contingent Liabilities and Commitments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c176",
      "name": "us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c176",
      "name": "us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://immucell.com/role/OperatingLeaseDetails",
     "longName": "996031 - Disclosure - Operating Lease (Details)",
     "shortName": "Operating Lease (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c183",
      "name": "us-gaap:AreaOfLand",
      "unitRef": "sqft",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c183",
      "name": "us-gaap:AreaOfLand",
      "unitRef": "sqft",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable",
     "longName": "996032 - Disclosure - Operating Lease (Details) - Schedule of Lease Costs and Other Lease Information",
     "shortName": "Operating Lease (Details) - Schedule of Lease Costs and Other Lease Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable",
     "longName": "996033 - Disclosure - Operating Lease (Details) - Schedule of Future Lease Payments Required Under Non-Cancelable Operating Leases",
     "shortName": "Operating Lease (Details) - Schedule of Future Lease Payments Required Under Non-Cancelable Operating Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://immucell.com/role/StockholdersEquityDetails",
     "longName": "996034 - Disclosure - Stockholders\u2019 Equity (Details)",
     "shortName": "Stockholders\u2019 Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c201",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c201",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable",
     "longName": "996035 - Disclosure - Stockholders\u2019 Equity (Details) - Schedule of Activity Under the Stock Option Plans",
     "shortName": "Stockholders\u2019 Equity (Details) - Schedule of Activity Under the Stock Option Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c46",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable",
     "longName": "996036 - Disclosure - Stockholders\u2019 Equity (Details) - Schedule of Additional Information About the Stock Option Plans",
     "shortName": "Stockholders\u2019 Equity (Details) - Schedule of Additional Information About the Stock Option Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c236",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c236",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://immucell.com/role/ScheduleofFairValueStockOptionGrantUsingBlackScholesOptionPricingModelwithWeightedAverageAssumptionsTable",
     "longName": "996037 - Disclosure - Stockholders\u2019 Equity (Details) - Schedule of Fair Value Stock Option Grant Using Black-Scholes Option Pricing Model with Weighted-Average Assumptions",
     "shortName": "Stockholders\u2019 Equity (Details) - Schedule of Fair Value Stock Option Grant Using Black-Scholes Option Pricing Model with Weighted-Average Assumptions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyGeographicAreaTable",
     "longName": "996038 - Disclosure - Revenue (Details) - Schedule of Product Sales Disaggregated by Geographic Area",
     "shortName": "Revenue (Details) - Schedule of Product Sales Disaggregated by Geographic Area",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "iccc:RevenueSalesObligationPercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable",
     "longName": "996039 - Disclosure - Revenue (Details) - Schedule of Product Sales Disaggregated by Major Product Category",
     "shortName": "Revenue (Details) - Schedule of Product Sales Disaggregated by Major Product Category",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c247",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://immucell.com/role/OtherExpensesNetDetails",
     "longName": "996040 - Disclosure - Other Expenses, Net (Details)",
     "shortName": "Other Expenses, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:AmortizationOfFinancingCostsAndDiscounts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "link:footnote",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:AmortizationOfFinancingCostsAndDiscounts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "link:footnote",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://immucell.com/role/ScheduleofOtherExpensesNetTable",
     "longName": "996041 - Disclosure - Other Expenses, Net (Details) - Schedule of Other Expenses Net",
     "shortName": "Other Expenses, Net (Details) - Schedule of Other Expenses Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:InterestExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:InterestExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://immucell.com/role/IncomeTaxesDetails",
     "longName": "996042 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "unique": true
     }
    },
    "R73": {
     "role": "http://immucell.com/role/SegmentInformationDetails",
     "longName": "996043 - Disclosure - Segment Information (Details)",
     "shortName": "Segment Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://immucell.com/role/ScheduleofSegmentInformationTable",
     "longName": "996044 - Disclosure - Segment Information (Details) - Schedule of Segment Information",
     "shortName": "Segment Information (Details) - Schedule of Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c75",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "unique": true
     }
    },
    "R75": {
     "role": "http://immucell.com/role/RelatedPartyTransactionsDetails",
     "longName": "996045 - Disclosure - Related Party Transactions (Details)",
     "shortName": "Related Party Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://immucell.com/role/EmployeeBenefitsDetails",
     "longName": "996046 - Disclosure - Employee Benefits (Details)",
     "shortName": "Employee Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "iccc:EmployeesSalaryPercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "iccc:EmployeesSalaryPercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://immucell.com/role/SubsequentEventsDetails",
     "longName": "996047 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c300",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c300",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220527-10q_immucell.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "iccc_ATMAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "ATMAgreementMember",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails",
      "http://immucell.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ATM Agreement [Member]",
        "label": "ATMAgreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "presentation": [
      "http://immucell.com/role/TradeAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade Accounts Receivable [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r990"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet",
      "http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accounts Payable and Accrued Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Accounts Payable and Accrued Liabilities",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r125"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://immucell.com/role/AccountsPayableandAccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ACCOUNTS PAYABLE AND ACCRUED EXPENSES",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r60",
      "r64",
      "r1050"
     ]
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableOtherCurrent",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable \u2013 capital",
        "label": "Accounts Payable, Other, Current",
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableTradeCurrent",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable \u2013 trade",
        "label": "Accounts Payable, Trade, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r58"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofConcentrationofRiskTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade accounts receivable [Member]",
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "us-gaap_AccountsReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNet",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."
       }
      }
     },
     "auth_ref": [
      "r667",
      "r732",
      "r823",
      "r1092",
      "r1093"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet",
      "http://immucell.com/role/TradeAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade accounts receivable",
        "verboseLabel": "Trade accounts receivable, net",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r987"
     ]
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax payable",
        "label": "Accrued Income Taxes, Current",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r124"
     ]
    },
    "us-gaap_AccruedPayrollTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedPayrollTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued payroll",
        "label": "Accrued Payroll Taxes, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued professional fees",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r159",
      "r587"
     ]
    },
    "iccc_AcquiringPersonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "AcquiringPersonMember",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquiring Person [Member]",
        "label": "Acquiring Person Member"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_AcquiringPersonPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "AcquiringPersonPercentage",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of acquiring person",
        "documentation": "Percentage of acquiring person.",
        "label": "Acquiring Person Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://immucell.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r633",
      "r973",
      "r974",
      "r975",
      "r977",
      "r1059",
      "r1124"
     ]
    },
    "dei_AdditionalSecurities462b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecurities462b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities. 462(b)"
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "dei_AdditionalSecurities462bFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecurities462bFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities, 462(b), File Number"
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "dei_AdditionalSecuritiesEffective413b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecuritiesEffective413b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities Effective, 413(b)"
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash provided by (used for) operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r851",
      "r862",
      "r878",
      "r913"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r854",
      "r865",
      "r881",
      "r916"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r855",
      "r866",
      "r882",
      "r908",
      "r917",
      "r921",
      "r929"
     ]
    },
    "us-gaap_AllOtherSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllOtherSegmentsMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other [Member]",
        "label": "Other Operating Segment [Member]",
        "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r255",
      "r764",
      "r765"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r432",
      "r438"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt issuance costs and debt discounts",
        "label": "Amortization of Debt Issuance Costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r353",
      "r966",
      "r1075"
     ]
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/OtherExpensesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt issuance costs",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r775",
      "r776",
      "r966",
      "r1075"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow",
      "http://immucell.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of intangible assets",
        "verboseLabel": "Intangible amortization expense",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r292",
      "r299",
      "r771"
     ]
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Anti-dilutive amounted (in Shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": {
     "xbrltype": "dateOrAsapItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Approximate Date of Commencement of Proposed Sale to Public",
        "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AreaOfLand": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AreaOfLand",
     "presentation": [
      "http://immucell.com/role/OperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Square feet (in Square Feet)",
        "label": "Area of Land",
        "documentation": "Area of land held."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet",
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "terseLabel": "Total Assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r135",
      "r163",
      "r189",
      "r223",
      "r231",
      "r250",
      "r254",
      "r268",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r472",
      "r474",
      "r494",
      "r577",
      "r672",
      "r764",
      "r765",
      "r802",
      "r830",
      "r1015",
      "r1016",
      "r1081"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "verboseLabel": "Assets:",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r170",
      "r189",
      "r268",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r472",
      "r474",
      "r494",
      "r802",
      "r1015",
      "r1016",
      "r1081"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CURRENT ASSETS:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r843",
      "r846",
      "r858"
     ]
    },
    "dei_AuditorLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r843",
      "r846",
      "r858"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r843",
      "r846",
      "r858"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "dei_AuditorTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r404",
      "r405",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "iccc_BankDebtDetailsScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "BankDebtDetailsScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable",
     "presentation": [
      "http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bank Debt (Details) - Schedule of Debt Proceeds Received and Principal Repayments [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_BankDebtDetailsScheduleofPrincipalPaymentsBankLoansOutstandingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "BankDebtDetailsScheduleofPrincipalPaymentsBankLoansOutstandingTable",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bank Debt (Details) - Schedule of Principal Payments Bank Loans Outstanding [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_BankDebtDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "BankDebtDetailsTable",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bank Debt (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_BankLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "BankLoansMember",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bank Loans [Member]",
        "label": "Bank Loans Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BuildingImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BuildingImprovementsMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Buildings and improvements [Member]",
        "label": "Building Improvements [Member]",
        "documentation": "Addition, improvement, or renovation to a facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_BuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BuildingMember",
     "presentation": [
      "http://immucell.com/role/OperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Building [Member]",
        "label": "Building [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r469",
      "r788",
      "r789"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r47",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r469",
      "r788",
      "r789"
     ]
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition percentage",
        "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage",
        "documentation": "Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r846",
      "r858"
     ]
    },
    "iccc_CapitalExpendituresCommitted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "CapitalExpendituresCommitted",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital expenditures committed",
        "documentation": "Capital expenditures committed.",
        "label": "Capital Expenditures Committed"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital Expenditures",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r22"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and money market accounts",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r157",
      "r752"
     ]
    },
    "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsDisclosureTextBlock",
     "presentation": [
      "http://immucell.com/role/CashandCashEquivalents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH AND CASH EQUIVALENTS",
        "label": "Cash and Cash Equivalents Disclosure [Text Block]",
        "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r581"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/CashandCashEquivalentsDetails",
      "http://immucell.com/role/ConsolidatedBalanceSheet",
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "BEGINNING CASH AND CASH EQUIVALENTS",
        "periodEndLabel": "ENDING CASH AND CASH EQUIVALENTS",
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r91",
      "r186"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r91"
     ]
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal deposit insurance corporation limits",
        "label": "Cash, FDIC Insured Amount",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease in capital expenditures included in accounts payable and accrued expenses",
        "documentation": "Change in capital expenditures included in accounts payable and accrued expenses.",
        "label": "Change In Capital Expenditures Included In Accounts Payable And Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r164",
      "r165",
      "r166",
      "r189",
      "r211",
      "r215",
      "r217",
      "r219",
      "r225",
      "r226",
      "r268",
      "r322",
      "r324",
      "r325",
      "r326",
      "r329",
      "r330",
      "r360",
      "r361",
      "r363",
      "r364",
      "r366",
      "r494",
      "r624",
      "r625",
      "r626",
      "r627",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r659",
      "r681",
      "r704",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r952",
      "r968",
      "r978"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r165",
      "r166",
      "r225",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r624",
      "r625",
      "r626",
      "r627",
      "r777",
      "r952",
      "r968"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CONTINGENT LIABILITIES AND COMMITMENTS (See Note 11)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r127",
      "r580",
      "r658"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Liabilities and Commitments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://immucell.com/role/ContingentLiabilitiesandCommitments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CONTINGENT LIABILITIES AND COMMITMENTS",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r314",
      "r315",
      "r734",
      "r1007",
      "r1012"
     ]
    },
    "iccc_CommitmentsRelatedToCommercialManufacture": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "CommitmentsRelatedToCommercialManufacture",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments related to commercial manufacture",
        "documentation": "Commitments related to commercial manufacture.",
        "label": "Commitments Related To Commercial Manufacture"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_CommitmentsRelatedToInformationTechnologyServicesAndOtherObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "CommitmentsRelatedToInformationTechnologyServicesAndOtherObligations",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments related to information technology services and other obligations",
        "documentation": "Commitments related to information technology services and other obligations.",
        "label": "Commitments Related To Information Technology Services And Other Obligations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable",
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserved for future grants",
        "verboseLabel": "Common stock reserved for future issuance",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "iccc_CommonStockIssuancesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "CommonStockIssuancesMember",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock Issuances [Member]",
        "label": "Common Stock Issuances Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://immucell.com/role/ShareholdersEquityType2or3",
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "verboseLabel": "Common Stock [Member]",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r820",
      "r821",
      "r822",
      "r824",
      "r825",
      "r826",
      "r827",
      "r973",
      "r974",
      "r977",
      "r1059",
      "r1123",
      "r1124"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in Dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r659"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://immucell.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in Shares)",
        "periodEndLabel": "Balance (in Shares)",
        "terseLabel": "Common stock, shares outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r68",
      "r659",
      "r678",
      "r1124",
      "r1125"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.10 par value per share, 15,000,000 and 15,000,000 shares authorized, 8,896,398 and 7,814,165 shares issued and 8,833,097 and 7,750,864 shares outstanding, as of September 30, 2024 and December 31, 2023, respectively.",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r582",
      "r802"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "iccc_CompanyAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "CompanyAMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofConcentrationofRiskTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company A [Member]",
        "label": "Company AMember"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_CompanyBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "CompanyBMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofConcentrationofRiskTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company B [Member]",
        "label": "Company BMember"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "presentation": [
      "http://immucell.com/role/EmployeeBenefits"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EMPLOYEE BENEFITS",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r109",
      "r110",
      "r111"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://immucell.com/role/ScheduleofConcentrationofRiskTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r55",
      "r56",
      "r261",
      "r621",
      "r733"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://immucell.com/role/ScheduleofConcentrationofRiskTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r55",
      "r56",
      "r261",
      "r733",
      "r957"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r141"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://immucell.com/role/ScheduleofConcentrationofRiskTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Concentration of Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://immucell.com/role/ScheduleofConcentrationofRiskTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration risk, percentage",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r55",
      "r56",
      "r261"
     ]
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://immucell.com/role/ScheduleofConcentrationofRiskTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk [Table]",
        "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r28",
      "r55",
      "r120",
      "r733"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in progress [Member]",
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelEmailAddress": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelEmailAddress",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Email Address",
        "documentation": "Email address of contact personnel."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelFaxNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelFaxNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Fax Number",
        "documentation": "Fax Number of contact personnel."
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Description",
        "documentation": "The description of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Name",
        "documentation": "The name of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Number",
        "documentation": "The SEC Document Number of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileType": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Type",
        "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.)."
       }
      }
     },
     "auth_ref": []
    },
    "iccc_ContingentLiabilitiesandCommitmentsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "ContingentLiabilitiesandCommitmentsDetailsTable",
     "presentation": [
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Liabilities and Commitments (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostDepreciationAmortizationAndDepletion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostDepreciationAmortizationAndDepletion",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization expense",
        "label": "Cost, Depreciation, Amortization and Depletion",
        "documentation": "Amount of expense for allocation of cost of tangible and intangible assets over their useful lives, and reduction in quantity of natural resource due to consumption directly used in production of good and rendering of service."
       }
      }
     },
     "auth_ref": [
      "r962"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedIncomeStatement",
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Costs of goods sold",
        "label": "Cost of Goods and Services Sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80",
      "r540"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofConcentrationofRiskTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk [Member]",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r261"
     ]
    },
    "us-gaap_CustomerRelationshipsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerRelationshipsMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer relationships [Member]",
        "label": "Customer Relationships [Member]",
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1002",
      "r1003",
      "r1004"
     ]
    },
    "us-gaap_DebtConversionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionLineItems",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bank Debt [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Bank Debt [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://immucell.com/role/BankDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BANK DEBT",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r188",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r320",
      "r321",
      "r331",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r347",
      "r354",
      "r355",
      "r357",
      "r504"
     ]
    },
    "iccc_DebtDiscountCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "DebtDiscountCost",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt discount cost During the Three-Month Period Ending December 31, 2024",
        "documentation": "Debt discount cost.",
        "label": "Debt Discount Cost"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_DebtDiscountCost2025": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "DebtDiscountCost2025",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt discount cost 2025",
        "documentation": "Amount of debt discount cost.",
        "label": "Debt Discount Cost2025"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_DebtDiscountCost2026": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "DebtDiscountCost2026",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt discount cost 2026",
        "documentation": "Amount of debt discount cost.",
        "label": "Debt Discount Cost2026"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_DebtDiscountCost2027": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "DebtDiscountCost2027",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt discount cost 2027",
        "documentation": "Amount of debt discount cost.",
        "label": "Debt Discount Cost2027"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_DebtDiscountCost2028": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "DebtDiscountCost2028",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt discount cost 2028",
        "documentation": "Represent the amount of debt discount cost 2028.",
        "label": "Debt Discount Cost2028"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_DebtDiscountCostThereafter": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "DebtDiscountCostThereafter",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt discount cost Thereafter",
        "documentation": "Amount of debt discount cost thereafter.",
        "label": "Debt Discount Cost Thereafter"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_DebtDiscountCostTotal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "DebtDiscountCostTotal",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt discount cost Total",
        "documentation": "Amount of total debt discount cost.",
        "label": "Debt Discount Cost Total"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r59",
      "r60",
      "r123",
      "r126",
      "r193",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r338",
      "r343",
      "r344",
      "r345",
      "r346",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r800",
      "r969",
      "r1008",
      "r1009",
      "r1010",
      "r1074",
      "r1076"
     ]
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r126",
      "r358"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal payment",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r332",
      "r504",
      "r505",
      "r773",
      "r774",
      "r800"
     ]
    },
    "us-gaap_DebtInstrumentIssuedPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentIssuedPrincipal",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance and sale (in Dollars)",
        "label": "Debt Instrument, Issued, Principal",
        "documentation": "Amount of principal of debt issued."
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Debt Proceeds Received and Principal Repayments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r338",
      "r343",
      "r344",
      "r345",
      "r346",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r356",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r800",
      "r969",
      "r1074",
      "r1076"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r193",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r338",
      "r343",
      "r344",
      "r345",
      "r346",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r800",
      "r969",
      "r1008",
      "r1009",
      "r1010",
      "r1074",
      "r1076"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balloon principal payment",
        "label": "Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid",
        "documentation": "Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable",
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "documentation": "Information by period of debt redemption feature under terms of debt agreement."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable",
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentRedemptionPeriodFiveMember",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable",
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan #5 [Member]",
        "label": "Debt Instrument, Redemption, Period Five [Member]",
        "documentation": "Period five representing fifth most current period of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentRedemptionPeriodFourMember",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable",
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan #4 [Member]",
        "verboseLabel": "Loans #4 [Member]",
        "label": "Debt Instrument, Redemption, Period Four [Member]",
        "documentation": "Period four representing fourth most current period of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable",
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan #1 [Member]",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "iccc_DebtInstrumentRedemptionPeriodSevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "DebtInstrumentRedemptionPeriodSevenMember",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable",
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan #7 [Member]",
        "label": "Debt Instrument Redemption Period Seven Member"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_DebtInstrumentRedemptionPeriodSixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "DebtInstrumentRedemptionPeriodSixMember",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable",
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan #6 [Member]",
        "label": "Debt Instrument Redemption Period Six Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentRedemptionPeriodThreeMember",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable",
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan #3 [Member]",
        "label": "Debt Instrument, Redemption, Period Three [Member]",
        "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable",
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan #2 [Member]",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan amortization, term",
        "label": "Debt Instrument, Term",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "iccc_DebtIssuanceCosts2024": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "DebtIssuanceCosts2024",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt issuance costs During the Three-Month Period Ending December 31, 2024",
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs2024"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_DebtIssuanceCosts2025": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "DebtIssuanceCosts2025",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt issuance costs 2025",
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs2025"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_DebtIssuanceCosts2026": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "DebtIssuanceCosts2026",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt issuance costs 2026",
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs2026"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_DebtIssuanceCosts2027": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "DebtIssuanceCosts2027",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt issuance costs 2027",
        "documentation": "Amount of debt issuance costs.",
        "label": "Debt Issuance Costs2027"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_DebtIssuanceCosts2028": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "DebtIssuanceCosts2028",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt issuance costs 2028",
        "documentation": "Represent the amount of debt issuance costs 2028.",
        "label": "Debt Issuance Costs2028"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_DebtIssuanceCostshereafter": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "DebtIssuanceCostshereafter",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt issuance costs Thereafter",
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costshereafter"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_DebtServiceCoverageRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "DebtServiceCoverageRatio",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DSC ratio",
        "documentation": "Ratio applied to the debt service coverage ratio.",
        "label": "Debt Service Coverage Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in operating lease right-of-use asset and operating lease liability",
        "documentation": "Represent the amount of (Decrease) increase in operating lease right-of-use asset and operating lease liability.",
        "label": "Decrease Increase In Operating Lease Rightofuse Asset And Operating Lease Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage",
     "presentation": [
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred compensation agreement annual base salary percentage",
        "label": "Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage",
        "documentation": "Commitment made to pay deferred cash remuneration expressed as a percentage of the individual's base salary."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://immucell.com/role/PrepaidExpensesandOtherCurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFinanceCostsCurrentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsCurrentGross",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt issuance costs",
        "label": "Debt Issuance Costs, Gross, Current",
        "documentation": "Amount, before accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r1074",
      "r1076"
     ]
    },
    "us-gaap_DeferredFinanceCostsCurrentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsCurrentNet",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt financing",
        "label": "Debt Issuance Costs, Current, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r1073",
      "r1074",
      "r1076"
     ]
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt issuance costs, Total",
        "label": "Debt Issuance Costs, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r1018",
      "r1073",
      "r1074",
      "r1076"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Value of our deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1054"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1058"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards not expire",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates."
       }
      }
     },
     "auth_ref": [
      "r1058"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards expire",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates."
       }
      }
     },
     "auth_ref": [
      "r1058"
     ]
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostChangeDueToSubsequentInterimMeasurementWeightedAverageExpectedLongTermRateOfReturnOnPlanAssets": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostChangeDueToSubsequentInterimMeasurementWeightedAverageExpectedLongTermRateOfReturnOnPlanAssets",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock were changed percentage",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Change Due to Subsequent Interim Measurement, Weighted-Average Expected Long-Term Rate of Return on Plan Assets",
        "documentation": "Weighted average rate of return on plan assets, used to determine net periodic benefit cost (credit) of defined benefit plan, in subsequent interim measurement."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://immucell.com/role/EmployeeBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefits [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/EmployeeBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee benefits paid",
        "label": "Defined Benefit Plan, Plan Assets, Benefits Paid",
        "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services."
       }
      }
     },
     "auth_ref": [
      "r387",
      "r1022"
     ]
    },
    "dei_DelayedOrContinuousOffering": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DelayedOrContinuousOffering",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Delayed or Continuous Offering"
       }
      }
     },
     "auth_ref": [
      "r870",
      "r871",
      "r885"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow",
      "http://immucell.com/role/PropertyPlantandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "verboseLabel": "Depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r36"
     ]
    },
    "us-gaap_DerivativeFixedInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeFixedInterestRate",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest fixed rate",
        "label": "Derivative, Fixed Interest Rate",
        "documentation": "Fixed interest rate related to the interest rate derivative."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51",
      "r52",
      "r118",
      "r648",
      "r650",
      "r664",
      "r665",
      "r666",
      "r668",
      "r669",
      "r670",
      "r671",
      "r673",
      "r674",
      "r675",
      "r676",
      "r692",
      "r693",
      "r694",
      "r695",
      "r698",
      "r699",
      "r700",
      "r701",
      "r717",
      "r718",
      "r719",
      "r720",
      "r755",
      "r820",
      "r822",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070"
     ]
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DevelopedTechnologyRightsMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Developed technology [Member]",
        "label": "Developed Technology Rights [Member]",
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1002",
      "r1003",
      "r1004"
     ]
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyGeographicAreaTable",
      "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Product Sales Disaggregated by Geographic Area [Line Items]",
        "terseLabel": "Schedule of Product Sales Disaggregated by Major Product Category [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://immucell.com/role/RevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Product Sales Disaggregated by Major Product Category",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r1020"
     ]
    },
    "dei_DividendOrInterestReinvestmentPlanOnly": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DividendOrInterestReinvestmentPlanOnly",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend or Interest Reinvestment Plan Only"
       }
      }
     },
     "auth_ref": [
      "r870",
      "r871",
      "r885"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r843",
      "r846",
      "r858"
     ]
    },
    "dei_DocumentCopyrightInformation": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentCopyrightInformation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Copyright Information",
        "documentation": "The copyright information for the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentCreationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentCreationDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Creation Date",
        "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Description",
        "documentation": "The description of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document [Domain]",
        "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentEffectiveDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentEffectiveDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Effective Date",
        "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r843",
      "r846",
      "r858",
      "r909"
     ]
    },
    "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Restatement Recovery Analysis [Flag]",
        "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)."
       }
      }
     },
     "auth_ref": [
      "r843",
      "r846",
      "r858",
      "r909"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationDocumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationDocumentAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information, Document [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Text Block]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Name",
        "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the &lt;FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v105727_8k.txt'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "dei_DocumentSubtitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentSubtitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Subtitle",
        "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentSynopsis": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentSynopsis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Synopsis",
        "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Title",
        "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentVersion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentVersion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Version",
        "documentation": "The version identifier of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal [Member]",
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "iccc_DuringTheYearsEndingDecember31Abstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "DuringTheYearsEndingDecember31Abstract",
     "presentation": [
      "http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "During the years ending December 31,",
        "label": "During The Years Ending December31 Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://immucell.com/role/ConsolidatedIncomeStatement",
      "http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic net loss per share (in Dollars per share)",
        "verboseLabel": "Basic (in Dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r209",
      "r211",
      "r217",
      "r218",
      "r219",
      "r222",
      "r467",
      "r471",
      "r483",
      "r484",
      "r574",
      "r592",
      "r757"
     ]
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasicAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Net Income (Loss) Per Common Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://immucell.com/role/ConsolidatedIncomeStatement",
      "http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted net loss per share (in Dollars per share)",
        "verboseLabel": "Diluted (in Dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r211",
      "r217",
      "r218",
      "r219",
      "r222",
      "r467",
      "r471",
      "r483",
      "r484",
      "r574",
      "r592",
      "r757"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Common Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r221"
     ]
    },
    "dei_EffectiveAfter60Days486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveAfter60Days486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective after 60 Days, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsOther",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss income before income taxes, rate",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits."
       }
      }
     },
     "auth_ref": [
      "r792",
      "r971",
      "r1052",
      "r1053"
     ]
    },
    "dei_EffectiveOnDate486a": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "dei_EffectiveOnDate486b": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "dei_EffectiveOnSetDate486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnSetDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "dei_EffectiveOnSetDate486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnSetDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "dei_EffectiveUponFiling462e": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveUponFiling462e",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Upon Filing, 462(e)"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "dei_EffectiveUponFiling486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveUponFiling486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective upon Filing, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "dei_EffectiveWhenDeclaredSection8c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveWhenDeclaredSection8c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective when Declared, Section 8(c)"
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "iccc_EmployeeBenefitsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "EmployeeBenefitsDetailsTable",
     "presentation": [
      "http://immucell.com/role/EmployeeBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefits (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_EmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "EmployeeMember",
     "presentation": [
      "http://immucell.com/role/EmployeeBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee [Member]",
        "label": "Employee Member"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_EmployeeOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "EmployeeOneMember",
     "presentation": [
      "http://immucell.com/role/EmployeeBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee One [Member]",
        "label": "Employee One Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average period",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation related to non-vested stock options (in Dollars)",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock Options [Member]",
        "netLabel": "Employee Stock Option [Member]",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOwnershipPlanESOPPlanDescription",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Extend the rights plan, description",
        "label": "Employee Stock Ownership Plan (ESOP), Plan Description",
        "documentation": "Description of the plan, including the basis for determining contributions, the employee groups covered, and the nature and effect of significant matters affecting comparability of information for all periods presented. For leveraged ESOPs and pension reversion ESOPs, the description generally includes the basis for releasing shares and how dividends on allocated and unallocated shares are used."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock purchase price (in Dollars per share)",
        "label": "Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased",
        "documentation": "Weighted average purchase price of capital shares purchased through an employee stock ownership plan."
       }
      }
     },
     "auth_ref": []
    },
    "iccc_EmployeesSalaryContributionPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "EmployeesSalaryContributionPercentage",
     "presentation": [
      "http://immucell.com/role/EmployeeBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee\u2019s salary contribution percentage",
        "documentation": "Employee\u2019s salary contribution percentage.",
        "label": "Employees Salary Contribution Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_EmployeesSalaryPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "EmployeesSalaryPercentage",
     "presentation": [
      "http://immucell.com/role/EmployeeBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee\u2019s salary percentage",
        "documentation": "Employee\u2019s salary percentage.",
        "label": "Employees Salary Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitiesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAccountingStandard": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Accounting Standard",
        "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'. This is distinct from the Document Accounting Standard element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Description",
        "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityContactPersonnelLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityContactPersonnelLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Contact Personnel [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "dei_EntityHomeCountryISOCode": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityHomeCountryISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Home Country ISO Code",
        "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State Country Code' element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, Date of Incorporation",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "dei_EntityInvCompanyType": {
     "xbrltype": "invCompanyType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInvCompanyType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Inv Company Type",
        "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)."
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "dei_EntityLegalForm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityLegalForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Legal Form",
        "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDepositoryReceiptRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingDepositoryReceiptRatio",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Depository Receipt Ratio",
        "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Description",
        "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingForeign": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingForeign",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Foreign",
        "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingParValuePerShare",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Par Value Per Share",
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingPrimary": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingPrimary",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Primary",
        "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingSecurityTradingCurrency": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingSecurityTradingCurrency",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Security Trading Currency",
        "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsExchangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsExchangeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings, Exchange [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Table]",
        "documentation": "Container for exchange listing information for an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityNumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityNumberOfEmployees",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Number of Employees",
        "documentation": "Number of persons employed by the Entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPhoneFaxNumbersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPhoneFaxNumbersLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Phone Fax Numbers [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "dei_EntityReportingCurrencyISOCode": {
     "xbrltype": "currencyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityReportingCurrencyISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Reporting Currency ISO Code",
        "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "dei_EntityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Text Block]",
        "documentation": "Container to serve as parent of six Entity related Table concepts."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://immucell.com/role/ShareholdersEquityType2or3",
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r151",
      "r174",
      "r175",
      "r176",
      "r194",
      "r195",
      "r196",
      "r198",
      "r203",
      "r205",
      "r207",
      "r224",
      "r269",
      "r270",
      "r305",
      "r367",
      "r457",
      "r458",
      "r464",
      "r465",
      "r466",
      "r468",
      "r470",
      "r471",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r506",
      "r508",
      "r521",
      "r591",
      "r615",
      "r616",
      "r617",
      "r633",
      "r704"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r851",
      "r862",
      "r878",
      "r913"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r848",
      "r859",
      "r875",
      "r910"
     ]
    },
    "us-gaap_EscrowDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EscrowDeposit",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Escrow account",
        "label": "Escrow Deposit",
        "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r735"
     ]
    },
    "dei_ExchangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExchangeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange [Domain]",
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "iccc_ExercisableAndTransferableDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "ExercisableAndTransferableDescription",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable and transferable, description",
        "documentation": "Exercisable and transferable, description.",
        "label": "Exercisable And Transferable Description"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ExhibitsOnly462d": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExhibitsOnly462d",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d)"
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "dei_ExhibitsOnly462dFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExhibitsOnly462dFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d), File Number"
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "iccc_ExpenseRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "ExpenseRecognitionPolicyTextBlock",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expense Recognition",
        "documentation": "Entire disclosure of accounting policy for expense recognition.",
        "label": "Expense Recognition Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Assets or Liabilities Measured at Fair Value on a Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r487",
      "r492",
      "r793"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnNonrecurringBasisTextBlock",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assets or Liabilities Measured at Fair Value on a Nonrecurring Basis",
        "label": "Fair Value Measurements, Nonrecurring [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities by class, including financial instruments measured at fair value that are classified in shareholders' equity, if any, that are measured at fair value on a nonrecurring basis in periods after initial recognition (for example, impaired assets). Disclosures may include, but are not limited to: (a) the fair value measurements recorded and the reasons for the measurements and (b) the level within the fair value hierarchy in which the fair value measurements are categorized in their entirety (levels 1, 2, 3)."
       }
      }
     },
     "auth_ref": [
      "r1060",
      "r1061"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r485",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r533",
      "r534",
      "r535",
      "r773",
      "r774",
      "r785",
      "r786",
      "r787",
      "r793",
      "r796"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r487",
      "r488",
      "r490",
      "r793",
      "r1062",
      "r1071"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1 [Member]",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r389",
      "r394",
      "r487",
      "r492",
      "r533",
      "r785",
      "r786",
      "r787",
      "r793"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2 [Member]",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r389",
      "r394",
      "r487",
      "r488",
      "r492",
      "r534",
      "r773",
      "r774",
      "r785",
      "r786",
      "r787",
      "r793"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3 [Member]",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r487",
      "r488",
      "r489",
      "r490",
      "r492",
      "r535",
      "r773",
      "r774",
      "r785",
      "r786",
      "r787",
      "r793",
      "r796"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r485",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r533",
      "r534",
      "r535",
      "r773",
      "r774",
      "r785",
      "r786",
      "r787",
      "r793",
      "r796"
     ]
    },
    "us-gaap_FairValueMeasurementsNonrecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsNonrecurringMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Nonrecurring [Member]",
        "label": "Fair Value, Nonrecurring [Member]",
        "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r487",
      "r488",
      "r490",
      "r793",
      "r1062"
     ]
    },
    "iccc_FederalGeneralBusinessMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "FederalGeneralBusinessMember",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal General Business [Member]",
        "label": "Federal General Business Member"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_FeesInitiallyCapitalizedAndLaterOffset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "FeesInitiallyCapitalizedAndLaterOffset",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal, accounting and other fees amount (in Dollars)",
        "documentation": "Fees initially capitalized and later offset. Fees include legal, accounting and fees categorized as other.",
        "label": "Fees Initially Capitalized And Later Offset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancingReceivableLoanInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancingReceivableLoanInProcess",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance loan provided",
        "label": "Financing Receivable, Loan in Process",
        "documentation": "Amount of undisbursed portion of financing receivable balance. Excludes financing receivable covered under loss sharing agreement."
       }
      }
     },
     "auth_ref": [
      "r989"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://immucell.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible asset amortized, useful lives",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated Amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r277",
      "r298",
      "r771"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://immucell.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r293",
      "r294",
      "r295",
      "r297",
      "r298",
      "r300",
      "r301",
      "r541",
      "r542",
      "r748"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/IntangibleAssetsDetails",
      "http://immucell.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Carrying Value",
        "verboseLabel": "Intangible assets",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r298",
      "r542",
      "r771"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://immucell.com/role/IntangibleAssetsDetails",
      "http://immucell.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Intangible Assets [Line Items]",
        "terseLabel": "Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r298",
      "r300",
      "r301",
      "r303",
      "r541",
      "r748",
      "r771"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://immucell.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r293",
      "r294",
      "r295",
      "r297",
      "r298",
      "r300",
      "r301",
      "r748"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet",
      "http://immucell.com/role/IntangibleAssetsDetails",
      "http://immucell.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "verboseLabel": "Net Book Value",
        "netLabel": "Net value",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r541",
      "r1002"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_FirstDefenseProductLineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "FirstDefenseProductLineMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First Defense\u00ae product line [Member]",
        "label": "First Defense Product Line Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r855",
      "r866",
      "r882",
      "r917"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r855",
      "r866",
      "r882",
      "r917"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r855",
      "r866",
      "r882",
      "r917"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r855",
      "r866",
      "r882",
      "r917"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r855",
      "r866",
      "r882",
      "r917"
     ]
    },
    "dei_FormerAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "FormerAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Address [Member]",
        "documentation": "Former address for entity"
       }
      }
     },
     "auth_ref": [
      "r845",
      "r869"
     ]
    },
    "dei_FormerFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "FormerFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Fiscal Year End Date",
        "documentation": "Former end date of previous fiscal years"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnDispositionOfAssets",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ScheduleofOtherExpensesNetTable": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofOtherExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss (gain) on disposal of property, plant and equipment",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r966",
      "r1005",
      "r1006"
     ]
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on disposal of property, plant and equipment",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedIncomeStatement",
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Administrative expenses",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r684"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r278",
      "r573",
      "r765",
      "r770",
      "r795",
      "r802",
      "r993",
      "r994"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets and Goodwill",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r992",
      "r995"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill impairments",
        "label": "Goodwill, Impairment Loss",
        "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r279",
      "r285",
      "r289",
      "r770",
      "r795"
     ]
    },
    "iccc_GorhamSavingsBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "GorhamSavingsBankMember",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gorham Savings Bank [Member]",
        "label": "Gorham Savings Bank Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedIncomeStatement",
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross margin",
        "terseLabel": "Gross margin",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r81",
      "r134",
      "r189",
      "r268",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r494",
      "r759",
      "r764",
      "r980",
      "r982",
      "r983",
      "r984",
      "r985",
      "r1015"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r843",
      "r846",
      "r858"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of recognized",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r35",
      "r101",
      "r794"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation of Long-Lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r102"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "LOSS BEFORE INCOME TAXES",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r129",
      "r134",
      "r575",
      "r589",
      "r759",
      "r764",
      "r980",
      "r982",
      "r983",
      "r984",
      "r985"
     ]
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract",
     "presentation": [
      "http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share:",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r445",
      "r446",
      "r450",
      "r455",
      "r792",
      "r1057"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r445",
      "r446",
      "r450",
      "r455",
      "r792",
      "r1057"
     ]
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxContingencyLineItems",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://immucell.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INCOME TAXES",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r441",
      "r445",
      "r447",
      "r448",
      "r449",
      "r451",
      "r454",
      "r459",
      "r461",
      "r462",
      "r463",
      "r629",
      "r792"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedIncomeStatement",
      "http://immucell.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax expense",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r147",
      "r206",
      "r207",
      "r223",
      "r239",
      "r254",
      "r444",
      "r445",
      "r460",
      "r594",
      "r792"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r442",
      "r443",
      "r451",
      "r452",
      "r453",
      "r456",
      "r623"
     ]
    },
    "iccc_IncomeTaxesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "IncomeTaxesDetailsTable",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes",
        "label": "Income Taxes Paid",
        "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r93",
      "r967",
      "r1055",
      "r1056"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Trade accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedInterestReceivableNet",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total accrued amount",
        "label": "Increase (Decrease) in Accrued Interest Receivable, Net",
        "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventory",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other assets",
        "label": "Increase (Decrease) in Other Current Assets",
        "documentation": "Amount of increase (decrease) in current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r965"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dilutive impact of share-based compensation awards",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r219",
      "r402"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r855",
      "r866",
      "r882",
      "r908",
      "r917",
      "r921",
      "r929"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r847",
      "r933"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r847",
      "r933"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r847",
      "r933"
     ]
    },
    "us-gaap_InsuranceRecoveries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InsuranceRecoveries",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ScheduleofOtherExpensesNetTable": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofOtherExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Insurance recoveries",
        "label": "Insurance Recoveries",
        "documentation": "The amount recovered from insurance. These recoveries reduce costs and losses that are reported as a separate line item under operating expenses."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "iccc_IntangibleAssetsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "IntangibleAssetsDetailsTable",
     "presentation": [
      "http://immucell.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://immucell.com/role/IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INTANGIBLE ASSETS",
        "label": "Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r302",
      "r304",
      "r747",
      "r748"
     ]
    },
    "us-gaap_InterestCostsIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestCostsIncurred",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incurred costs",
        "label": "Interest Costs Incurred",
        "documentation": "Total interest costs incurred during the period and either capitalized or charged against earnings."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r503"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofOtherExpensesNetTable": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofOtherExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense",
        "label": "Interest Expense, Operating and Nonoperating",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r231",
      "r235",
      "r241",
      "r254",
      "r502",
      "r764",
      "r765"
     ]
    },
    "us-gaap_InterestIncomeOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeOther",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ScheduleofOtherExpensesNetTable": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofOtherExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest income",
        "label": "Interest Income, Other",
        "documentation": "Amount of interest income earned from interest bearing assets classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r183",
      "r184"
     ]
    },
    "iccc_InterestPaymentsTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "InterestPaymentsTerm",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest payments, term",
        "documentation": "Amount of interest payments term.",
        "label": "Interest Payments Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://immucell.com/role/Inventory"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INVENTORY",
        "label": "Inventory Disclosure [Text Block]",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r271"
     ]
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofInventoryTable": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofInventoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Gross",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://immucell.com/role/ScheduleofInventoryTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet",
      "http://immucell.com/role/ScheduleofInventoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Inventory",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r753",
      "r802"
     ]
    },
    "us-gaap_InventoryNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventory [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r156",
      "r167",
      "r271",
      "r272",
      "r274",
      "r539",
      "r756"
     ]
    },
    "us-gaap_InventoryRawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryRawMaterials",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofInventoryTable": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofInventoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raw materials",
        "label": "Inventory, Raw Materials, Gross",
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r960"
     ]
    },
    "us-gaap_InventoryWorkInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWorkInProcess",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofInventoryTable": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofInventoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work-in-process",
        "label": "Inventory, Work in Process, Gross",
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "us-gaap_InventoryWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWriteDown",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/InventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory write off",
        "label": "Inventory Write-down",
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels."
       }
      }
     },
     "auth_ref": [
      "r273"
     ]
    },
    "dei_InvestmentCompanyActFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyActFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act File Number"
       }
      }
     },
     "auth_ref": [
      "r871",
      "r872",
      "r873",
      "r874"
     ]
    },
    "dei_InvestmentCompanyActRegistration": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyActRegistration",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act Registration"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "us-gaap_InvestmentCompanyPurchasePremiumPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentCompanyPurchasePremiumPerShare",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price (in Dollars per share)",
        "label": "Investment Company, Purchase Premium, Per Share",
        "documentation": "Per share amount of premium paid by investor to purchase shares of investment company. Includes, but is not limited to, per unit, membership interest, or other ownership interest."
       }
      }
     },
     "auth_ref": [
      "r641"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyRegistrationAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyRegistrationAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment Number"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "us-gaap_LandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LandMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land [Member]",
        "label": "Land [Member]",
        "documentation": "Part of earth's surface not covered by water."
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r801"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostAbstract",
     "presentation": [
      "http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Cost",
        "label": "Lease, Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://immucell.com/role/OperatingLeaseTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Lease Costs and Other Lease Information",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1078"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold Improvements [Member]",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r520"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeasesOperatingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesOperatingAbstract",
     "presentation": [
      "http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease",
        "label": "Leases, Operating [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://immucell.com/role/SubsequentEventsDetails",
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityIdentifier": {
     "xbrltype": "legalEntityIdentifierItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityIdentifier",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity Identifier",
        "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI."
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "us-gaap_LesseeDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Lease Costs and Other Lease Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://immucell.com/role/OperatingLeaseTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Lease Payments Required Under Non-Cancelable Operating Leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1079"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments (undiscounted cash flows)",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "During the three-month period ending December 31, 2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r1079"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest (discount effect of cash flows)",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://immucell.com/role/OperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Renew term",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1077"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://immucell.com/role/OperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease term",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1077"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://immucell.com/role/OperatingLease"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OPERATING LEASE",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r59",
      "r60",
      "r61",
      "r63",
      "r64",
      "r65",
      "r66",
      "r189",
      "r268",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r473",
      "r474",
      "r475",
      "r494",
      "r657",
      "r758",
      "r830",
      "r1015",
      "r1081",
      "r1082"
     ]
    },
    "us-gaap_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities:",
        "label": "Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r128",
      "r584",
      "r802",
      "r970",
      "r991",
      "r1072"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r155",
      "r189",
      "r268",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r473",
      "r474",
      "r475",
      "r494",
      "r802",
      "r1015",
      "r1081",
      "r1082"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CURRENT LIABILITIES:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total long-term liabilities",
        "label": "Liabilities, Noncurrent",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r63",
      "r64",
      "r65",
      "r66",
      "r189",
      "r268",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r473",
      "r474",
      "r475",
      "r494",
      "r1015",
      "r1081",
      "r1082"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LONG-TERM LIABILITIES:",
        "label": "Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of credit",
        "label": "Long-Term Line of Credit",
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r126",
      "r1091"
     ]
    },
    "iccc_LoanToValueRatio": {
     "xbrltype": "percentItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "LoanToValueRatio",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan to value ratio",
        "documentation": "The ratio of loan to value.",
        "label": "Loan To Value Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoansAndLeasesReceivableDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LoansAndLeasesReceivableDisclosureLineItems",
     "presentation": [
      "http://immucell.com/role/OperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "presentation": [
      "http://immucell.com/role/TradeAccountsReceivable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TRADE ACCOUNTS RECEIVABLE",
        "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]",
        "documentation": "The entire disclosure for claims held for amounts due to entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses."
       }
      }
     },
     "auth_ref": [
      "r504",
      "r986"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "During the Three-Month Period Ending, Total",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r126",
      "r344",
      "r359",
      "r773",
      "r774",
      "r800",
      "r1091"
     ]
    },
    "iccc_LongTermDebt2024": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "LongTermDebt2024",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total During the Three-Month Period Ending December 31, 2024",
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long Term Debt2024"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_LongTermDebt2025": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "LongTermDebt2025",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total 2025",
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long Term Debt2025"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_LongTermDebt2026": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "LongTermDebt2026",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total 2026",
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long Term Debt2026"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_LongTermDebt2027": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "LongTermDebt2027",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total 2027",
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long Term Debt2027"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt obligations, net of current portion",
        "label": "Long-Term Debt and Lease Obligation",
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r578"
     ]
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of debt obligations",
        "label": "Long-Term Debt and Lease Obligation, Current",
        "documentation": "Amount of long-term debt and lease obligation, classified as current."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "During the Three-Month Period Ending ,Thereafter",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r193",
      "r1019"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "During the Three-Month Period Ending December 31, 2025",
        "label": "Long-Term Debt, Maturity, Year One",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r193",
      "r349"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "During the Three-Month Period Ending December 31, 2028",
        "label": "Long-Term Debt, Maturity, Year Four",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r193",
      "r349"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "During the Three-Month Period Ending December 31, 2027",
        "label": "Long-Term Debt, Maturity, Year Three",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r193",
      "r349"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "During the Three-Month Period Ending December 31, 2026",
        "label": "Long-Term Debt, Maturity, Year Two",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r193",
      "r349"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "During the Three-Month Period Ending December 31, 2024",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r972"
     ]
    },
    "us-gaap_LongTermDebtPercentageBearingFixedInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtPercentageBearingFixedInterestRate",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bearing interest percentage",
        "label": "Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate",
        "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "iccc_LongTermDebtThereafter": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "LongTermDebtThereafter",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Thereafter",
        "documentation": "Long term debt thereafter",
        "label": "Long Term Debt Thereafter"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_LongTermDebtTotal2028": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "LongTermDebtTotal2028",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total 2028",
        "documentation": "Represent the amount of long term debt total.",
        "label": "Long Term Debt Total2028"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermPurchaseCommitmentLineItems",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Principal Payments Bank Loans Outstanding [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "iccc_MaineTechnologyInstituteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "MaineTechnologyInstituteMember",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maine Technology Institute [Member]",
        "label": "Maine Technology Institute Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://immucell.com/role/ScheduleofConcentrationofRiskTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r261",
      "r780",
      "r812",
      "r817",
      "r1020",
      "r1094",
      "r1095",
      "r1096",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122"
     ]
    },
    "us-gaap_ManufacturingFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ManufacturingFacilityMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory and manufacturing equipment [Member]",
        "label": "Manufacturing Facility [Member]",
        "documentation": "Structure used in the manufacturing of goods."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "iccc_MastitisMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "MastitisMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mastitis [Member]",
        "label": "Mastitis Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable",
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r316",
      "r317",
      "r318",
      "r319",
      "r397",
      "r439",
      "r490",
      "r538",
      "r613",
      "r614",
      "r620",
      "r649",
      "r650",
      "r710",
      "r712",
      "r714",
      "r715",
      "r721",
      "r745",
      "r746",
      "r769",
      "r777",
      "r790",
      "r796",
      "r797",
      "r798",
      "r799",
      "r813",
      "r1017",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable",
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r316",
      "r317",
      "r318",
      "r319",
      "r397",
      "r439",
      "r490",
      "r538",
      "r613",
      "r614",
      "r620",
      "r649",
      "r650",
      "r710",
      "r712",
      "r714",
      "r715",
      "r721",
      "r745",
      "r746",
      "r769",
      "r777",
      "r790",
      "r796",
      "r797",
      "r798",
      "r813",
      "r1017",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "us-gaap_MortgageBankingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MortgageBankingMember",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mortgage Note [Member]",
        "label": "Mortgage Banking [Member]",
        "documentation": "Origination or servicing of loan secured by real property."
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "iccc_MrBrighamMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "MrBrighamMember",
     "presentation": [
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mr. Brigham [Member]",
        "label": "Mr Brigham Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "dei_NameChangeEventDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event Date [Axis]",
        "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them. The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Line Items]",
        "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Table]",
        "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://immucell.com/role/BusinessOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BUSINESS OPERATIONS",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r148"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (used for) provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used for investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used for) operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r92",
      "r94"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://immucell.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow",
      "http://immucell.com/role/ConsolidatedIncomeStatement",
      "http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable",
      "http://immucell.com/role/ShareholdersEquityType2or3",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET LOSS",
        "verboseLabel": "Net loss",
        "netLabel": "Net loss attributable to stockholders (in Dollars)",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r94",
      "r130",
      "r153",
      "r171",
      "r172",
      "r176",
      "r189",
      "r197",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r206",
      "r207",
      "r216",
      "r268",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r467",
      "r471",
      "r484",
      "r494",
      "r590",
      "r680",
      "r702",
      "r703",
      "r828",
      "r1015"
     ]
    },
    "iccc_NetProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "NetProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds (in Dollars)",
        "documentation": "The net proceeds incurred from issuance of common stock.",
        "label": "Net Proceeds From Issuance Of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Accounting Pronouncements Not Yet Adopted",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NewEffectiveDateForPreviousFiling": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NewEffectiveDateForPreviousFiling",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Effective Date for Previous Filing"
       }
      }
     },
     "auth_ref": [
      "r871",
      "r872",
      "r873",
      "r874"
     ]
    },
    "iccc_NisinDrugSubstanceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "NisinDrugSubstanceMember",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nisin Drug Substance [Member]",
        "label": "Nisin Drug Substance Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoSubstantiveChanges462c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoSubstantiveChanges462c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c)"
       }
      }
     },
     "auth_ref": [
      "r945"
     ]
    },
    "dei_NoSubstantiveChanges462cFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoSubstantiveChanges462cFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c), File Number"
       }
      }
     },
     "auth_ref": [
      "r945"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r855",
      "r866",
      "r882",
      "r908",
      "r917"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NON-CASH ACTIVITIES:",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncompeteAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncompeteAgreementsMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-compete agreements [Member]",
        "label": "Noncompete Agreements [Member]",
        "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1002",
      "r1003",
      "r1004"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other expenses (income), net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://immucell.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reportable business segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r760",
      "r768",
      "r981"
     ]
    },
    "iccc_OfferingCostsOnFollowUpOfferingOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "OfferingCostsOnFollowUpOfferingOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ShareholdersEquityType2or3_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering costs on at-the-market offering of common stock",
        "documentation": "Offering costs on follow-up offering of common stock.",
        "label": "Offering Costs On Follow Up Offering Of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office furniture and equipment [Member]",
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedIncomeStatement",
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating expenses",
        "terseLabel": "Operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedIncomeStatement",
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET OPERATING LOSS",
        "terseLabel": "NET OPERATING INCOME (LOSS)",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r759",
      "r980",
      "r982",
      "r983",
      "r984",
      "r985"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r514",
      "r801"
     ]
    },
    "iccc_OperatingLeaseDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "OperatingLeaseDetailsTable",
     "presentation": [
      "http://immucell.com/role/OperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Future Lease Payments Required Under Non-Cancelable Operating Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/OperatingLeaseDetails",
      "http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total operating liabilities",
        "verboseLabel": "Operating lease liability",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of operating lease liability",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability, net of current portion",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for operating lease liabilities",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r511",
      "r516"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet",
      "http://immucell.com/role/OperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use asset",
        "verboseLabel": "Operating lease right of use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r801"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term (in years)",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r517",
      "r801"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OptionIndexedToIssuersEquityTypeAxis",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Indexed to Issuer's Equity, Type [Axis]",
        "documentation": "Information by type of freestanding contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r53",
      "r54",
      "r119"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OptionIndexedToIssuersEquityTypeDomain",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Indexed to Issuer's Equity, Type [Domain]",
        "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "dei_OtherAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Address [Member]",
        "documentation": "Other address for entity"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_OtherAnimalHealthMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "OtherAnimalHealthMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other animal health [Member]",
        "label": "Other Animal Health Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Liabilities and Commitments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCurrentAssetsTextBlock",
     "presentation": [
      "http://immucell.com/role/PrepaidExpensesandOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PREPAID EXPENSES AND OTHER CURRENT ASSETS",
        "label": "Other Current Assets [Text Block]",
        "documentation": "The entire disclosure for other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherDeferredCompensationArrangementsLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred compensation",
        "label": "Other Deferred Compensation Arrangements, Liability, Current",
        "documentation": "Amount of the liabilities, classified as other, for deferred compensation arrangements payable within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r108"
     ]
    },
    "us-gaap_OtherExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherExpensesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Expenses, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIncome",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ScheduleofOtherExpensesNetTable": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofOtherExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income - other",
        "label": "Other Income",
        "documentation": "Amount of revenue and income classified as other."
       }
      }
     },
     "auth_ref": [
      "r593",
      "r682",
      "r722",
      "r723",
      "r724"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Non-cash rent (benefit) expense",
        "label": "Other Noncash Income (Expense)",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_OtherNoncashIncomeTaxExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncashIncomeTaxExpense",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash income tax expense",
        "label": "Other Noncash Income Tax Expense",
        "documentation": "The portion of the noncash component of income tax expense for the period other than the portion from the net change in the entity's deferred tax assets and liabilities."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeAndExpenseTextBlock",
     "presentation": [
      "http://immucell.com/role/OtherExpensesNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER EXPENSES, NET",
        "label": "Other Nonoperating Income and Expense [Text Block]",
        "documentation": "The entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ScheduleofOtherExpensesNetTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofOtherExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Other expenses (income), net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables",
        "label": "Other Receivables, Net, Current",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product development expense",
        "label": "Other Research and Development Expense",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r1051"
     ]
    },
    "iccc_OtherStatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "OtherStatesMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyGeographicAreaTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other [Member]",
        "documentation": "Continent of Other States.",
        "label": "Other States Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r853",
      "r864",
      "r880",
      "r915"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r856",
      "r867",
      "r883",
      "r918"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r856",
      "r867",
      "r883",
      "r918"
     ]
    },
    "dei_ParentEntityLegalName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ParentEntityLegalName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Entity Legal Name",
        "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ParticipatingMortgageLoansUnamortizedDebtDiscountAmount",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mortgage debt",
        "label": "Participating Mortgage Loans, Unamortized Debt Discount, Amount",
        "documentation": "The amount of the related debt discount at the end of the accounting period."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "us-gaap_PaymentsForRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRent",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/OperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional rent payment",
        "label": "Payments for Rent",
        "documentation": "Cash payments to lessor's for use of assets under operating leases."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments of debt issuance costs and debt discounts",
        "label": "Payments of Debt Issuance Costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_PaymentsToAcquireOtherProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireOtherProductiveAssets",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Payments to Acquire Other Productive Assets",
        "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property, plant and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "dei_PhoneFaxNumberDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PhoneFaxNumberDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phone Fax Number Description",
        "documentation": "Description of Phone or Fax Number"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable",
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable",
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "dei_PostEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PostEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "dei_PostEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PostEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "dei_PreEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "dei_PreEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Prepaid Expenses and Other Current Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://immucell.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet",
      "http://immucell.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses and Other Current Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r275",
      "r276",
      "r754"
     ]
    },
    "us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrincipalAmountOutstandingOnLoansManagedAndSecuritized",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding principal balance",
        "label": "Loan, Managed and Securitized or Asset-Backed Financing Arrangement, Principal Outstanding",
        "documentation": "This is the sum of principal amount outstanding for both securitized and unsecuritized loans of all types."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement [Member]",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow",
      "http://immucell.com/role/StockholdersEquityDetails",
      "http://immucell.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from At-The-Market Offering, net",
        "verboseLabel": "Gross proceeds (in Dollars)",
        "netLabel": "Gross proceeds from at-the-market offering",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow",
      "http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from debt issuance",
        "verboseLabel": "Proceeds from Debt Issuance",
        "label": "Proceeds from Issuance of Debt",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r963"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of loan",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r624"
     ]
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromLinesOfCredit",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from line of credit",
        "label": "Proceeds from Lines of Credit",
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r969"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of property, plant and equipment",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails",
      "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r257",
      "r540",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r750",
      "r778",
      "r811",
      "r813",
      "r814",
      "r818",
      "r819",
      "r1013",
      "r1014",
      "r1020",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails",
      "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r257",
      "r540",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r750",
      "r778",
      "r811",
      "r813",
      "r814",
      "r818",
      "r819",
      "r1013",
      "r1014",
      "r1020",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://immucell.com/role/OperatingLeaseDetails",
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable",
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r520"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://immucell.com/role/PropertyPlantandEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PROPERTY, PLANT AND EQUIPMENT, net",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r142",
      "r145",
      "r146"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisposals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisposals",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/PropertyPlantandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment disposals",
        "label": "Property, Plant and Equipment, Disposals",
        "documentation": "Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r158",
      "r588"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet",
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Property, plant and equipment, net",
        "terseLabel": "Property, plant and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r520",
      "r576",
      "r588",
      "r802"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, net",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r142",
      "r145",
      "r586"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentSalvageValuePercentage",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset depreciated percentage",
        "label": "Property, Plant and Equipment, Salvage Value, Percentage",
        "documentation": "Stated as a percentage, the estimated or actual value of the asset at the end of its useful life or when it is no longer serviceable (cannot be used for its original purpose) divided by its [historical] capitalized cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://immucell.com/role/PropertyPlantandEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property, Plant and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://immucell.com/role/OperatingLeaseDetails",
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable",
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r520"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable",
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, Estimated Useful Lives (in years)",
        "verboseLabel": "Useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "iccc_PurchaseofInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "PurchaseofInventory",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase of inventory",
        "documentation": "Represent the amount of purchase of inventory.",
        "label": "Purchaseof Inventory"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable",
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r316",
      "r317",
      "r318",
      "r319",
      "r388",
      "r397",
      "r428",
      "r429",
      "r430",
      "r439",
      "r490",
      "r536",
      "r537",
      "r538",
      "r613",
      "r614",
      "r620",
      "r649",
      "r650",
      "r710",
      "r712",
      "r714",
      "r715",
      "r721",
      "r745",
      "r746",
      "r769",
      "r777",
      "r790",
      "r796",
      "r797",
      "r798",
      "r799",
      "r813",
      "r822",
      "r1011",
      "r1017",
      "r1062",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable",
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r316",
      "r317",
      "r318",
      "r319",
      "r388",
      "r397",
      "r428",
      "r429",
      "r430",
      "r439",
      "r490",
      "r536",
      "r537",
      "r538",
      "r613",
      "r614",
      "r620",
      "r649",
      "r650",
      "r710",
      "r712",
      "r714",
      "r715",
      "r721",
      "r745",
      "r746",
      "r769",
      "r777",
      "r790",
      "r796",
      "r797",
      "r798",
      "r799",
      "r813",
      "r822",
      "r1011",
      "r1017",
      "r1062",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088"
     ]
    },
    "iccc_ReTainMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "ReTainMember",
     "presentation": [
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Re-Tain [Member]",
        "documentation": "Re-Tain [Member]",
        "label": "Re Tain Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReceivablesNetCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesNetCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade Accounts Receivable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesPolicyTextBlock",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade Accounts Receivable",
        "label": "Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r267",
      "r988"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r848",
      "r859",
      "r875",
      "r910"
     ]
    },
    "dei_RegistrationStatementAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "RegistrationStatementAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration Statement Amendment Number",
        "documentation": "Amendment number to registration statement under the Investment Company Act of 1940."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails",
      "http://immucell.com/role/EmployeeBenefitsDetails",
      "http://immucell.com/role/RelatedPartyTransactionsDetails",
      "http://immucell.com/role/StockholdersEquityDetails",
      "http://immucell.com/role/TradeAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r395",
      "r525",
      "r526",
      "r579",
      "r585",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r677",
      "r679",
      "r709"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://immucell.com/role/RelatedPartyTransactionsDetails",
      "http://immucell.com/role/TradeAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Member]",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r192",
      "r525",
      "r526",
      "r527",
      "r528",
      "r579",
      "r585",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r677",
      "r679",
      "r709"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://immucell.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r685",
      "r686",
      "r689"
     ]
    },
    "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionPurchasesFromRelatedParty",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party products purchased",
        "label": "Related Party Transaction, Purchases from Related Party",
        "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails",
      "http://immucell.com/role/EmployeeBenefitsDetails",
      "http://immucell.com/role/RelatedPartyTransactionsDetails",
      "http://immucell.com/role/StockholdersEquityDetails",
      "http://immucell.com/role/TradeAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r395",
      "r525",
      "r526",
      "r579",
      "r585",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r677",
      "r679",
      "r709",
      "r1080"
     ]
    },
    "iccc_RelatedPartyTransactionsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "RelatedPartyTransactionsDetailsTable",
     "presentation": [
      "http://immucell.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://immucell.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RELATED PARTY TRANSACTIONS",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r523",
      "r524",
      "r526",
      "r529",
      "r630",
      "r631",
      "r632",
      "r687",
      "r688",
      "r689",
      "r707",
      "r708"
     ]
    },
    "us-gaap_RepaymentsOfBankDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfBankDebt",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Principal Repayments",
        "label": "Repayments of Bank Debt",
        "documentation": "The cash outflow to settle a bank borrowing during the year."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_RepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt principal repayments",
        "label": "Repayments of Debt",
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": [
      "r964"
     ]
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfLinesOfCredit",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Line of credit repayments",
        "label": "Repayments of Lines of Credit",
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r969"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product development expenses",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r748",
      "r764",
      "r1089"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r849",
      "r860",
      "r876",
      "r911"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r850",
      "r861",
      "r877",
      "r912"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r857",
      "r868",
      "r884",
      "r919"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r106",
      "r583",
      "r618",
      "r619",
      "r628",
      "r660",
      "r802"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://immucell.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r194",
      "r195",
      "r196",
      "r198",
      "r203",
      "r205",
      "r207",
      "r269",
      "r270",
      "r305",
      "r457",
      "r458",
      "r464",
      "r465",
      "r466",
      "r468",
      "r470",
      "r471",
      "r476",
      "r478",
      "r479",
      "r481",
      "r482",
      "r506",
      "r508",
      "r615",
      "r617",
      "r633",
      "r1124"
     ]
    },
    "iccc_RevenueDetailsScheduleofProductSalesDisaggregatedbyGeographicAreaTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "RevenueDetailsScheduleofProductSalesDisaggregatedbyGeographicAreaTable",
     "presentation": [
      "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyGeographicAreaTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue (Details) - Schedule of Product Sales Disaggregated by Geographic Area [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyGeographicAreaTable",
      "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable",
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total product Sales",
        "verboseLabel": "Total product sales",
        "netLabel": "Product sales",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r223",
      "r232",
      "r233",
      "r248",
      "r254",
      "r257",
      "r259",
      "r261",
      "r384",
      "r385",
      "r540"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r749"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://immucell.com/role/Revenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "REVENUE",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r386"
     ]
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "presentation": [
      "http://immucell.com/role/RevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Product Sales Disaggregated by Geographic Area",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRemainingPerformanceObligationPercentage",
     "presentation": [
      "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of product sales",
        "label": "Revenue, Remaining Performance Obligation, Percentage",
        "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "iccc_RevenueSalesObligationPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "RevenueSalesObligationPercentage",
     "presentation": [
      "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyGeographicAreaTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of product sales",
        "documentation": "Percentage of product sales is an act of selling a product or service in return of money or compensation or service.",
        "label": "Revenue Sales Obligation Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product sales",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r177",
      "r189",
      "r223",
      "r232",
      "r233",
      "r248",
      "r254",
      "r257",
      "r259",
      "r261",
      "r268",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r494",
      "r575",
      "r764",
      "r1015"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_RightToAcquirePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "RightToAcquirePerShare",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price per Right (in Dollars per share)",
        "documentation": "Right to Acquire, Per share.",
        "label": "Right To Acquire Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock shares sold",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, per share (in Dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesCommissionsAndFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalesCommissionsAndFees",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales commissions (in Dollars)",
        "label": "Sales Commissions and Fees",
        "documentation": "Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller)."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofConcentrationofRiskTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product sales [Member]",
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r956"
     ]
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/IntangibleAssetsDetails",
      "http://immucell.com/role/OperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forecast [Member]",
        "label": "Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r398",
      "r976"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/IntangibleAssetsDetails",
      "http://immucell.com/role/OperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r208",
      "r398",
      "r953",
      "r976"
     ]
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://immucell.com/role/AccountsPayableandAccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts Payable and Accrued Expenses",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "iccc_ScheduleOfActivityUnderTheStockOptionPlansAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "ScheduleOfActivityUnderTheStockOptionPlansAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Activity Under The Stock Option Plans Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_ScheduleOfAdditionalInformationAboutTheStockOptionPlansAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "ScheduleOfAdditionalInformationAboutTheStockOptionPlansAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Additional Information About the Stock Option Plans [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_ScheduleOfAssetsOrLiabilitiesMeasuredAtFairValueOnANonrecurringBasisAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "ScheduleOfAssetsOrLiabilitiesMeasuredAtFairValueOnANonrecurringBasisAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Assets Or Liabilities Measured At Fair Value On ANonrecurring Basis Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_ScheduleOfConcentrationOfRiskAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "ScheduleOfConcentrationOfRiskAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Concentration Of Risk Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Debt Proceeds Received And Principal Repayments Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDebtTableTextBlock",
     "presentation": [
      "http://immucell.com/role/BankDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Debt Proceeds Received and Principal Repayments",
        "label": "Schedule of Debt [Table Text Block]",
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Net Income (Loss) Per Common Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r979"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://immucell.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset, Finite-Lived [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r298",
      "r300",
      "r301",
      "r303",
      "r541",
      "r748",
      "r771"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://immucell.com/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Intangible Assets",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r771",
      "r1001"
     ]
    },
    "iccc_ScheduleOfIntangibleAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "ScheduleOfIntangibleAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Intangible Assets Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://immucell.com/role/InventoryTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventory",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r74",
      "r75",
      "r76"
     ]
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://immucell.com/role/BankDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Principal Payments Bank Loans Outstanding",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "iccc_ScheduleOfOtherExpensesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "ScheduleOfOtherExpensesNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Expenses Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "presentation": [
      "http://immucell.com/role/OtherExpensesNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Expenses Net",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items."
       }
      }
     },
     "auth_ref": []
    },
    "iccc_ScheduleOfPrincipalPaymentsBankLoansOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "ScheduleOfPrincipalPaymentsBankLoansOutstandingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Principal Payments Bank Loans Outstanding Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_ScheduleOfProductSalesDisaggregatedByGeographicAreaAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "ScheduleOfProductSalesDisaggregatedByGeographicAreaAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Product Sales Disaggregated By Geographic Area Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_ScheduleOfProductSalesDisaggregatedByMajorProductCategoryAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "ScheduleOfProductSalesDisaggregatedByMajorProductCategoryAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Product Sales Disaggregated By Major Product Category Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_ScheduleOfPropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "ScheduleOfPropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Property Plant And Equipment Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r520"
     ]
    },
    "iccc_ScheduleOfSegmentInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "ScheduleOfSegmentInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Segment Information Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r34"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://immucell.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Information",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r34"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Activity Under the Stock Option Plans",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r10",
      "r112"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Additional Information About the Stock Option Plans",
        "label": "Share-Based Payment Arrangement, Option and Stock Appreciation Rights, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock options and stock appreciation rights that were outstanding at the beginning and end of the year, exercisable at the end of the year, and the number of stock options and stock appreciation rights that were granted, exercised or converted, forfeited, and expired during the year."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value Stock Option Grant Using Black-Scholes Option Pricing Model with Weighted-Average Assumptions",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Concentration of Risk",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r28",
      "r55",
      "r120"
     ]
    },
    "iccc_ScoursMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "ScoursMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scours [Member]",
        "label": "Scours Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r135",
      "r223",
      "r228",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r242",
      "r243",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r254",
      "r255",
      "r256",
      "r261",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r303",
      "r312",
      "r313",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r761",
      "r764",
      "r765",
      "r770",
      "r816",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyGeographicAreaTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r259",
      "r260",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r645",
      "r646",
      "r647",
      "r711",
      "r713",
      "r716",
      "r725",
      "r731",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r751",
      "r779",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r815",
      "r822",
      "r1020",
      "r1094",
      "r1095",
      "r1096",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://immucell.com/role/SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEGMENT INFORMATION",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r223",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r244",
      "r246",
      "r247",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r261",
      "r760",
      "r762",
      "r763",
      "r764",
      "r766",
      "r767",
      "r768"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingAndMarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedIncomeStatement",
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales and marketing expenses",
        "label": "Selling and Marketing Expense",
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Stock options that were forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Stock options granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price, Non-vested stock options as of beginning balance",
        "periodEndLabel": "Weighted Average Exercise Price, Non-vested stock options as of ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r416"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Stock options that vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value Stock Option Grant Using Black-Scholes Option Pricing Model with Weighted-Average Assumptions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://immucell.com/role/ScheduleofFairValueStockOptionGrantUsingBlackScholesOptionPricingModelwithWeightedAverageAssumptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://immucell.com/role/ScheduleofFairValueStockOptionGrantUsingBlackScholesOptionPricingModelwithWeightedAverageAssumptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://immucell.com/role/ScheduleofFairValueStockOptionGrantUsingBlackScholesOptionPricingModelwithWeightedAverageAssumptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Activity Under the Stock Option Plans [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431"
     ]
    },
    "iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Vested (in Dollars per share)",
        "documentation": "Share based compensation arrangement by share based payment award options exercisable weighted average vested.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Vested"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Terminations/forfeitures",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r1030"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options granted (in Dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value",
        "documentation": "The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable",
      "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable",
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grants",
        "verboseLabel": "Number of Shares, Stock options granted (in Shares)",
        "netLabel": "Stock options granted during period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Fair Value at Grant Date, Stock options granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding, Beginning balance (in Dollars)",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding, Ending balance (in Dollars)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable",
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, Beginning balance",
        "periodEndLabel": "Outstanding, Ending balance",
        "terseLabel": "Options outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r408"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable",
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Aggregate Intrinsic Value, Outstanding, Beginning balance (in Dollars per share)",
        "periodEndLabel": "Aggregate Intrinsic Value, Outstanding, Ending balance (in Dollars per share)",
        "terseLabel": "Exercise price (in Dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r408"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Vested and expected to vest (in Dollars)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest (in Dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Vested (in Dollars)",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Aggregate Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r404",
      "r405",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Exercises (in Dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Terminations/forfeitures (in Dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Grants (in Dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r406",
      "r425",
      "r426",
      "r427",
      "r428",
      "r431",
      "r434",
      "r435",
      "r436",
      "r437"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock option expiration period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://immucell.com/role/ScheduleofFairValueStockOptionGrantUsingBlackScholesOptionPricingModelwithWeightedAverageAssumptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected life",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining life of the options exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "presentation": [
      "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Shares, Non-vested stock options as of beginning balance (in Shares)",
        "periodEndLabel": "Number of Shares, Non-vested stock options as of ending balance (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "documentation": "Number of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
     "presentation": [
      "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares, Stock options that were forfeited (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares",
        "documentation": "Number of non-vested options forfeited."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Fair Value at Grant Date, Stock options that were forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Fair Value at Grant Date, Non-vested stock options as of beginning balance",
        "periodEndLabel": "Weighted Average Fair Value at Grant Date, Non-vested stock options as of ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining life of options outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares, Stock options that vested (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Fair Value at Grant Date, Stock options that vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average grant-date fair value of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average price (in Dollars per share)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price",
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r114"
     ]
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "presentation": [
      "http://immucell.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY",
        "label": "Shareholders' Equity and Share-Based Payments [Text Block]",
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r111"
     ]
    },
    "us-gaap_ShortTermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermBorrowings",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bank debt",
        "label": "Short-Term Debt",
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r123",
      "r802",
      "r1090"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r187"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State [Member]",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "iccc_StateTaxCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "StateTaxCreditMember",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State Tax Credit [Member]",
        "label": "State Tax Credit Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r135",
      "r152",
      "r223",
      "r228",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r242",
      "r243",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r254",
      "r255",
      "r256",
      "r261",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r303",
      "r306",
      "r312",
      "r313",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r761",
      "r764",
      "r765",
      "r770",
      "r816",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r164",
      "r165",
      "r166",
      "r189",
      "r211",
      "r215",
      "r217",
      "r219",
      "r225",
      "r226",
      "r268",
      "r322",
      "r324",
      "r325",
      "r326",
      "r329",
      "r330",
      "r360",
      "r361",
      "r363",
      "r364",
      "r366",
      "r494",
      "r624",
      "r625",
      "r626",
      "r627",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r659",
      "r681",
      "r704",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r952",
      "r968",
      "r978"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://immucell.com/role/ShareholdersEquityType2or3",
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r68",
      "r71",
      "r72",
      "r151",
      "r174",
      "r175",
      "r176",
      "r194",
      "r195",
      "r196",
      "r198",
      "r203",
      "r205",
      "r207",
      "r224",
      "r269",
      "r270",
      "r305",
      "r367",
      "r457",
      "r458",
      "r464",
      "r465",
      "r466",
      "r468",
      "r470",
      "r471",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r506",
      "r508",
      "r521",
      "r591",
      "r615",
      "r616",
      "r617",
      "r633",
      "r704"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyGeographicAreaTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r259",
      "r260",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r645",
      "r646",
      "r647",
      "r711",
      "r713",
      "r716",
      "r725",
      "r731",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r751",
      "r779",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r815",
      "r822",
      "r1020",
      "r1094",
      "r1095",
      "r1096",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://immucell.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r195",
      "r196",
      "r224",
      "r508",
      "r540",
      "r622",
      "r644",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r659",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r668",
      "r669",
      "r670",
      "r671",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r679",
      "r683",
      "r684",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r704",
      "r823"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/IntangibleAssetsDetails",
      "http://immucell.com/role/OperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r208",
      "r398",
      "r953",
      "r954",
      "r976"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://immucell.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r195",
      "r196",
      "r224",
      "r262",
      "r508",
      "r540",
      "r622",
      "r644",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r659",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r668",
      "r669",
      "r670",
      "r671",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r679",
      "r683",
      "r684",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r704",
      "r823"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r852",
      "r863",
      "r879",
      "r914"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://immucell.com/role/ShareholdersEquityType2or3",
      "http://immucell.com/role/StockholdersEquityDetails",
      "http://immucell.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At-The-Market Offering of common stock, net of offering costs (in Shares)",
        "verboseLabel": "Shares sold under at-the-market offering",
        "netLabel": "Shares sold during period",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r67",
      "r68",
      "r106",
      "r624",
      "r704",
      "r727"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable",
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercises",
        "terseLabel": "Stock options exercised during period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r67",
      "r68",
      "r106",
      "r412"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At-The-Market Offering of common stock, net of offering costs",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r67",
      "r68",
      "r106",
      "r633",
      "r704",
      "r727",
      "r829"
     ]
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockOptionMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Option [Member]",
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet",
      "http://immucell.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL STOCKHOLDERS\u2019 EQUITY",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r71",
      "r72",
      "r98",
      "r661",
      "r678",
      "r705",
      "r706",
      "r802",
      "r830",
      "r970",
      "r991",
      "r1072",
      "r1124"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCKHOLDER\u2019 EQUITY:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_StockholdersEquityDetailsScheduleofActivityUndertheStockOptionPlansTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "StockholdersEquityDetailsScheduleofActivityUndertheStockOptionPlansTable",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity (Details) - Schedule of Activity Under the Stock Option Plans [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansLineItems",
     "presentation": [
      "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity (Details) - Schedule of Additional Information About the Stock Option Plans [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "StockholdersEquityDetailsScheduleofAdditionalInformationAbouttheStockOptionPlansTable",
     "presentation": [
      "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity (Details) - Schedule of Additional Information About the Stock Option Plans [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_StockholdersEquityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "StockholdersEquityDetailsTable",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://immucell.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r501",
      "r531"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://immucell.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Member]",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r501",
      "r531"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://immucell.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r501",
      "r531"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_SubsequentEventsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "SubsequentEventsDetailsTable",
     "presentation": [
      "http://immucell.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://immucell.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUBSEQUENT EVENTS",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r530",
      "r532"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "iccc_SubtotalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "SubtotalMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subtotal [Member]",
        "label": "Subtotal Member"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_SummaryofSignificantAccountingPoliciesDetailsScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable",
     "presentation": [
      "http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) - Schedule of Assets or Liabilities Measured at Fair Value on a Nonrecurring Basis [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_SummaryofSignificantAccountingPoliciesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "SummaryofSignificantAccountingPoliciesDetailsTable",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH PAID FOR:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "us-gaap_TaxCreditCarryforwardDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardDescription",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration term",
        "label": "Tax Credit Carryforward, Description",
        "documentation": "A description of the origin, nature, and characteristics of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "iccc_TradeAccountsReceivableDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "TradeAccountsReceivableDetailsTable",
     "presentation": [
      "http://immucell.com/role/TradeAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade Accounts Receivable (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://immucell.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury Stock",
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury stock",
        "label": "Treasury Stock, Common, Shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_TreasuryStockCommonValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonValue",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Treasury stock, at cost, 63,301 shares as of both September 30, 2024 and December 31, 2023",
        "label": "Treasury Stock, Common, Value",
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41",
      "r71"
     ]
    },
    "iccc_TwoThousandSeventeenPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "TwoThousandSeventeenPlanMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2017 Plan [Member]",
        "documentation": "Two thousand seventeen plan.",
        "label": "Two Thousand Seventeen Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_TwoThousandSeventeenPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "TwoThousandSeventeenPlansMember",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2017 Plan [Member]",
        "label": "Two Thousand Seventeen Plans Member"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_TwoThousandTenPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "TwoThousandTenPlanMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2010 Plan [Member]",
        "documentation": "Two thousand ten plan.",
        "label": "Two Thousand Ten Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_TwoThousandTenPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20240930",
     "localname": "TwoThousandTenPlansMember",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2010 Plan [Member]",
        "verboseLabel": "Two Thousand Ten Plans [Member]",
        "label": "Two Thousand Ten Plans Member"
       }
      }
     },
     "auth_ref": []
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "US",
     "presentation": [
      "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyGeographicAreaTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States [Member]",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r31",
      "r139",
      "r140",
      "r143",
      "r144"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease cost",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r801"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedIncomeStatement",
      "http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted average common shares outstanding - Diluted",
        "terseLabel": "Diluted weighted average common shares outstanding (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r219"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedIncomeStatement",
      "http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic weighted average common shares outstanding (in Shares)",
        "verboseLabel": "Weighted average common shares outstanding - Basic",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r219"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r943"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(a)",
   "Paragraph": "4",
   "SubTopic": "20",
   "Topic": "860",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481212/470-30-50-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "63",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-63"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "710",
   "SubTopic": "10",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483043/710-10-30-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480489/718-40-50-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-4"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/710/tableOfContent"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483070/710-10-25-9"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/712/tableOfContent"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-3"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "470",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-8"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "Global LEI Foundation"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "249",
   "Section": "308",
   "Subsection": "a"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Number": "249",
   "Section": "308"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form F-3"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-3"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-4"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-6"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form S-3"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Investment Company Act",
   "Number": "270"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "313"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "413",
   "Subsection": "b"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "b"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "c"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "d"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "e"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "a"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "b"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Section": "8",
   "Subsection": "c"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(1)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/310-10/tableOfContent"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-3"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "40",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481628/310-20-40-7"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-4"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>97
<FILENAME>0001213900-24-097450-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-24-097450-xbrl.zip
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MQR6)A>=0XE2,GY6Q,1QRF$W\6QGI Z\"JO+U9#*[Y*99NK2=J1PKH*000>5
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M0J<P =*"95,MC(#48*D59D!JL*RF:@B\]_2^R;L?A\9SMP3_^_@>?_LX]0?
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M W;:5:WU@>T]U]7?OE\__L,?,!*@!\;TN^\^5S\+UG,8DB:Q"^LU36D&D1Z
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MFOEJA5QK)U']TVR%#%"K4ROD=G7/4A2'X8SQH7F<!J( QP8F8,$)K^[#9G(
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M,5S C\<'8PL>>#*X*S"!>BT(O"60@P2?T0%FPR <C+"7\=^7,4#7 %JU$$R
M"00H0)9 \#PS+3C_?813SZ42"[ B(IH2\D*FM0*:?.!/R/S8M25T>Y@R(%M;
M5. !LF7]F8LE7USFBN==G!-L9( T;AGHX %,9<<-(":*ML-#A"5XQ$:B=CU
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M 3I7<]#!3O[%@6Z0=W'' ^" *>S^\-V)^,J0HS>(=% @VQ_\M01K!,8QG,%
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M1BBKJ#41AU@8S,\%+*%+17!%X&)]L@^ 6TF3GS1<SZ&R ,-Y_B"Y?E^9<+:
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MW'6YA9<"[ (/^WI^NHA^LL9\SS-M*.";):1!/).&0W.0^B>O[B JJ*H4D>7
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MN@@LG))JG@1V=-@?3T1< 1N5[!U46\4I?1:!8Q,36< 6M:TGLO$QF/ OX:_
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MV!&"*;1]\GF%04"Y&;!6&VNM_!MI3E1Z*2V_N  *(39EQ54Q<T6$B\.Q4\J
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MP&H#J"Y0A@L+!2-?:.21C:N1WZRDKJ&Z#WN9/8T1'BN%,GRYZ?>3EPP9^=#
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M-#>!5^&:;:6J1E#G<%Z1Q,**)(D0&]8K:N=1.4V'34I<2-(Y?@)BM4A 7)>
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M44Q_IXV\:"KGB93F%LJK8'Q^O_A\)5Q<7M[^ 7)$^'YU>05"Y=/7J[<@4@C
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M-564"KC]V\N*-!D*)OV7*"4]1(.SJ&BUO:!DZ:B!;2N*J*B'B/"V^+XNQ@:
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M3Q9]Y'YB=R98DX6H%R.ZHJ1JXB!]!R5+[J%<$E<"B2NE?Q+")P\$-3RO=D&
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M="4JXI\)GQA0E8-DDI1M[MR#YZWY6B%U@=DTAKL)_GST+S8.4&J$7[5?DS0
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M%@!;,Q#\_IM3?AI7?K>.\+<Y6/=A\[]$<73V$\@(RRTF&/6WT&SJ+28@ GV
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M"_<BI%N./_<B2S:$0Z1&X)]D49-9PR.A>?Y-8X&K8;9_DUZI$[I?J_F'?+M
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MO@^U'S N2'M&_T!["]I3=U$&*^.P6UT7-;E!VGM_S3[&7A9>J[LHB95QW?U
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MQ((7)(!DV 6?F#C)6>^/&1S97\ @"L M!6H6#KZ8_'48#_)S@09F+##N$@@
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MW71 G:ZNW^VLQW&<4F_5.(IK%" W@&*#4&Q(HI0R1*TA%#=VPY(H'N#=#-P
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M [  ]3(.OK>">;C@A5:_C,= *Q:/K3\S^ DN!@QR>4C=M>0%V9\G>;-D8J^
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M'9T/SPQEKTS>6L*95FD'83(:1#"60?),]$%D5W>8EP<Y59;B.A@"_1V,%NZ
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M> *2\LN&%]IRDO'17X85/8O+I4E22*% #5PRN,!KP7"HQ<V[U0N))!*G7/:
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MNIH(@(>EVB]65IHI5I;;6ZO#H70:N#."5/Q!A#WZ;&G!S@:;"IZRC.A_S?W
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M1-3D%/I,H-;!4OR"F,7+KZ/VC)X?B8A0P9&*VJ2?TE>GU=8=;TGHKSO5-=6
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MMZV1>_*E.$V$!:-P"P;=+W4RM[T9.>+^@P?F[=Q9RDU<^XNE[6%%%?J@=^B
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MQP&UX$\/=C"]='W_!SX]0UX>Z_3N?1<\U, )?_"GQG#B MPF2FE'_>HQR<B
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M">_S"(QH./%RB_'DE5BU"$*&% LSNF_7QROI _I;BAF+@.6"V1Z5)/'PZ[?
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MD\&7.F.N&L5C)I@MD8^4W4?02H($S//O[2@[[=SE!S155)&J6WVXD:8Q3B<
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M^/]9=2[$L9>1V:4?,>(2=Q_)X,YY1:'ZGWU-_<\!_-<B3OWG4'7N%)Z]=7B
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M0#YZG*L+N0&7BB* X)UH/%8NQH\CK<E>ICH,F[P4^&;BIV3SQF0C)@5+,L.
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M)63Z[.6N-WX^8PNFZ(__?7XETMT[]F80Q8#WT4PI!@Z42'J+&IB732 7AO.
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MPG?H]6);ZJ<D(_\0=_;.IW<_[=(M;V(R'DPVHE_+1\@ ^(R#SI:FF&7<L!K
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MU>J!1);=+JO-Q/TOJJ)M/M+E>B(^,3CC6H/XP,@U=TU7/S<3U=W\]><>+5>
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M,\/655S>O&2VKIY)L3CP\>@)\HV,'#_PH./=X,)A_/WJ"BO??ID85ZMS8<3
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M8#,NLHV\=AGK5T_L/2M6KR7X4L3<?VGUG_.YZ.%-BOC%@=2:.F\2Z@<P-G'
MX!E9,J['"OV$AZ2)8+]P^\X'7]M!N9[NZ^-0QKK?W7_%E4;]J"1#LAQ%0&VY
M\QTNCN:U%(&U57WKW6HDV'?W#A[@W2TO97%4Y(%VY(5/T23S\#T_#__7;5!X
MCPWR;DZ[4(='-R[4$BT<+)COZCWR+E_[^I/]^[Q^44'"IASTS5)+?Z L]JK5
MZ;>HL .H^E.RN*ZEB]7!G%IS1*S*<%@KYX,[ RUY/6<Q60"EC9+EH8F!<;CJ
M[1I /^V>65&[^;EZ=F[UU*/N:> >^B%KGGAP@">2?<Y"2U=F^+K6$M?_S/ME
M>#ZH7*6.47[C-+IV] B72:EUH>,H-BV()T$_<(CYOW<ONE@X,O2N 9B0V?A9
M-%]R-="$K:QT(7WR]GEZ-F_<1VXKQ&_ZT>!SV7&8F1,C02:X1LU+_'9>JYCH
MQ6(P^W.TIJ6;S_Q Q<0\/'K)A>F]EZ++/+GA#\4)P*4$4%2*8[D\65J=[8>$
M%B3QX-^T2U>A,M.IUCQKA3?-D&N?!?R!:W4!S=F"_8+<Q(;>S88ZO2DJ2^"!
M!ZTV8-'Y#KUKV5,=E!EZ!FW#NE6 -D2E!==\9'(@I6_UW:.,]ET66*9[ZX%9
MG(@9[G3U@FA3+J!!%*5Y: MG\ZP-E2QE_RW4 =OXO> AKZ-R%/R4 L]2#S/W
MT:*R&I)19]P88ORB^[)Y@.L6EQ%C+D*@]X_^#[\D_ULSC0]_ZK76LO]FH1.D
MMU7)X;GEO00!CM2]ER/+@L$:IX$*Q@1<$_"F@YX]&O+S$Y7&G6U+XY:6QIU\
M^Z5QVT.U_C5Q:SNQ9X"\_UK ^]<%W=8 JCX?#"Q=[T=22P,E: K?EA6G@\M-
M0O+?+*N)+/Q@E4U2"%^9X:YBA7"!VR]=9,W>D;U.7YZDQ@./;O#M!9#"(8N%
MOV?\2K:>R/X^%P*3H6&K!W DS8,9U<WS3XVPX2BZ!OLVDPG)3:3,;S53X]'@
M%L0ZFN9*@,EEXM%9>X[50< I%X-0B)KRBY9%G"/YG*MX6+A^VM;88"LQ4HJQ
MLLWC_U<=7\JG9>5X<H'8L+ [8;IR7[>L.?LL'=\%[SCT&2D8<!4]@I$F#;7M
MIE#I';UD;#Q^H* GM<)0R$L%>;8G8+F\Z0+CKP![;#^ZJ73#"\__;6:HA2ZA
M\/Y9-\K'M^HL<LH4'*?D20>7.6)VP#>2WD_D0%IOAVB2MT:/8_#XII57&U:9
M)"Y'"RQG+N@=]7@B';=V9ZS)+SY@5.8,Z:8F./O,23&HQP(EK9"-ULF@Z4BH
MS^'KR1F!8ZI(TLTNDYDN=(+BI>./C/+D;>_L;K@S%8BW&<7PC$GP(^ZN]3([
M%DL-P0MIT)41 I5('&]'Y%'Z@BC3E$^H5+@5RHNF-YBAE22X- !W(_M;8"E(
M&?QK8 I C8/F3U2Y75WG-0U4\5L_K7% %K8G-\B.#*LCGW!'+9@YDX!^M\_W
M=$@SS48#.(;$2E:2-C_>>N>/%8UD.#8'5&91]AC.30PS$W.?]SME4?SW?SL[
M.COXNX7VL@1Y,P2Z@ZBJ&,;-APQ47<B ! .$<C@&Y%KTAX);9R;A.(\->";"
M\XO7X<G^B94@J['XT[D2O'P?)KN6EP0H<:K$)&"'VLA!U= 76-JE3IC,?2NP
M6&X^L%>?3D_D^&/]A^(1] P+"MMZ,2-Z1@.E6DT0DTJN=CE$-;CY@X$>OE)N
ML%N/1E@L=^UJVW?8)9]%N%CVU(A;\J<!TY=%@+U*3+QD&Q6LC XP7USE2(OA
M=IH@J@\$F!?E+JO=%L@=-^TW:+MX?U*E?#D$%HV+(ZF3R.-2T5T,N5P@31A9
MWO$I,EV2TM(*[1F#[-HA"6Q7"A!%&W%)RN9>F;*"+736<<YZO8_8.]-O%?:[
M%DR4[D5'@^'@"-LV%L>@9Y9"8TIU"YB49S!VL<N&>BQP+^-1-8\60$@/'@/0
M'V-H5*$V=9B5MEI%4%C+[O_9%!6U60KUG36= M55)%G1=6@W!&9:7GRFU^TI
ME*E%^DB8NEBL*?R*15)3G'K0!/:03430-JG)SSC#],"._@L6S-A4(_""YT6
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MKEWC0Z)5S%!*TQ769R1_^^9 WTS7-%]Y[1&<=@_];>(C =9K)DU<L%0,G=@
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MK:-XH5+&P/K5U])R)!GDQ]>?G[/\NAM^1'>_=5&<!+A:(%-.<K4PE"S*O1U
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M3<I89?NG-^>26KX22KE5);4+6ZB=,1]8 N;6[H7 +\7%K;8)!QYI?26=/ .
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M85(AP(Q-)<U2Y'UHMLH,1ADH.*8*WA9>)>8:)S<O$ZW@V6'2/\TZ(X*M^9<
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M%27L393EF=6)!3I_8$M2;5'&842?'34;A#T@5^F)])A2VMBS-1BZ44J;7.Q
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MZ)-@#(04\ .UO\0/&;=#?JP[&#P]YTH^[%NN/^1#3TI[)[?G^R6MQP@%$'W
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M?TR9(4AL !_"] A^"G E+%-":@D]&X2E^ 5,((A07T-9DQ+2$454"&]&P*<
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M!2[(JTS]4*?2E#OMU@KN+8^%!U?/+IN4CKLCJE&K5-\FK@UM'K-B'EY^N]V
M=?_/R<T73"''F+9L\W1 20;BM[;XK6IBCO.PAD,6M7"]!&33HNR=,PA*74#
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MM"NQ8"Q\4XZ7-'X_,G]ADM^K_ =02P,$%     @ J8!M66S>2@YU!0  C!(
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M9P$VC8NU#PBM1P2G_%,F4AXBLB05RBHZ3M=Z@R9K ?9&[Z+IM0H )'C894[
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M'I.ZAE-!X*T)/?=]R!)41:YSJ7X<D].%BWY-*GY>HE^A_@502P,$%     @
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M+PM.Z,A)U9?(MD08?4U1#$LW\:V\H!@$E#Q!%E@1FJ(;"=LL\G/.:^QK0*)
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M.R]J-BW30HX$RR6F76!OGE+OR,BG1UW4Z4I3S4[$??81,YE/YRPP!ALPJZM
ME_(UN-__E1@VP^5941"$:8CM6$,K)?0#:&U,_[;+;C)EV .7M9U1^"[<2D?[
M3JYZ%QIMUB@'K3\F=3FL(+*3IF4ALPUB/OMD.IUI)P>HQX!EN#-D=5Q8 ^*)
M@:%S+J.0G<W16#E?5)%(F^$'K84RQ_UD<.?(<4<L6UKN*V*""(>FDU"6N"]/
MPA:B:587*,84"#D8*HAP>)H(88ESG=&6RI%$A+MU6\[WZIFMB?>1PBH/9O%
M8@+<9NMYUY/2^Y[-,P:#.S,96<_'(FUS0'(G^L[_ %!+ P04    " "I@&U9
MCFQ<FII-   0X@0 %0   &EC8V,M,C R-# Y,S!?9&5F+GAM;.U]6W/<1I+N
M^_X*K<[+.;&AD26-;,LQWHWF34,/R>:0E+R>C0T'"%1WPT(#;5R:;/WZ4X5+
M-VYU1697@^+#[L@D45GU95955E[_]E^/R^#%FL2)'X4_OWSSE^]>OB"A&WE^
M./_YY:?;5Y/;X_/SE__UGR]>_-O?_OW5JQ<?24AB)R7>B_O-B^-HN;IU_1=W
ML1,FLRA>OOB_Z?+_O7CU8I&FJY]>OWYX>/B+2_\F<?V8)%$6NR1A/WCQZA4=
ML!KR."9LP)]>7$;ABZMH_>+-FQ=OW_STYOU/[]Z]^'1W_.+M=V__6GSR;W\+
M_/#+O9.0%W3>8?+SRQJEQ_LX^$L4SU^__>Z[=Z^K/WQ9_.5/C^P'C;]_>)?_
M]9L/'SZ\SG^[_=/$[_M#.NR;U_]]>7'K+LC2>>6'2>J$+B.0^#\E^0\O(M=)
M<R2E\WK!_0OV7Z^J/WO%?O3JS=M7[][\Y3'QME.D?^.E6S+U =Z_+G[YDN'U
MXL7?XB@@-V3V(E_B3^EF17Y^F?C+5<!FGO]L$9/9SR]]UW5?,:B_^_#N.T;K
M_["?_![_?AR%213X'F/2D1.P-=\N"$E?OF!#?[HYWT[#7RXSEP0!X_%K]LO7
MW&]?_R?NY'Z_=F(2I@N2^JX3)$/FVAX*8^KG=,\MR6U*_[VDM'2GV_[\-13O
M;Q=T[8LH\.@)<?IGYJ>;.SK(VRA^IS)%P=>O\P, >Y(&4J ^&.02ZLP\=I+%
M61 ]Z K!]KM\8B#3.LH2/R1),EVQ0Y\>;$H0]GQ58 7#[6RY=.)--+OUYZ$_
MH[P(TXGK1EF8TDOKFJ+A^D2-U6HC <Z=L<@)<TXQV5H[ 14HM<.I_TNPC4ZO
M<(^4BT]NB$LHB7OVM7QJO$\!<3L/UW2Y4;Q1F<_NCZ%.ZNN8K!S?.WU<D3 A
M">7#E!X#\7$6LP-ADB1$C8E*XT >*]=Q1/=@NKFFMQE55CPF.BMV0URI7=_"
M[T'Y2T>?^U1JU,'L? ,)7"7.U\Z&R3)=.OU)G)$M[U1F*!\$$,(C)_QR0NZ5
MV+K]6\BC+<I/32H;%[YS[P=^ZN<23M\(2S]=*I]S"L/ W6_E#17.+TC^5)#/
MK_4%U ESFT;NEX;6H72!=;\"Y.@-H>=HIH1*]:=@UU%^+E;;1/&PZGP#>2 4
M&O:=\ZBV]>M_#JKJDCG; ^<A>VWGNI62G'2_ I63@*F?5#NFNC*S!#BNLJK(
M_19J8YW2OXTVA!R1D,Q\M3.H\PTH![/[A/R947:<KE4/Q<XW"%==3>,]VN3_
M4CJ"!%_#HJ:BJM^Q:Q90]2_'@Y+%K6*J/L_V)W!7GXHNJCY/C=' [@B1<JHS
M<^DH</QO:JPZ8M#[)1B44DU5?:JJ0T&!6NFRZC-L?0$UD:9FJ#Z=WN_@]GE7
M1]0X)7G?0F%6ZHWJ,VI^ *C$M)5'#?[U?PEG@NTH;QH,Y'T+]FYQ%\3+ A+-
MBH,IBFO/MDLJT%E,/"<]<_SXLQ-D) J=JRB,B4LO!BKR1T[B%P>"TFK B$&:
M([>3HD]7EX)=F#RCV8V??#%8&G<4>)9182W>*1=1DES3VYJ^L:,P-X ;3%PZ
M&MR.V-)LJD=Z\VU]"P^OLDZD-V_U84$5\!I]CL)DM!;A6("W8(WM/:J4KN3T
M#8&#MIHZI7EZJHV)<D@RQ8MRW27$*WT%],@.O6MZ0+O^R@ENJ'!O<C.?P<)T
M!T<XD;:TKDM*3-N\B)PPF68I"QA@D15&.T5Y7(15Y:KI<92DV^,F_TE;K]!;
MDNJ@\"?S699252&G5L%Y0^C10]6'3R%5=JG6<,S<_P&CW]3/3<1R.#F,@W#B
MIOZ:JO3Y%"CZN;(_73'<V7%L=K"H#(D@GQ//\QD5)ZA)S^0^RE*@A>F/C\&R
MK69;(_DQIE?GIX3IMX'C?J%_3.DEY71BWZ6_N(P\$CSXZ>)7XL\7*?$F:RIC
M<W9[9<O\#XVD&GDR& #2R\'+W/36H;,Z\1-G/H_)G!F@[S<?232/G=7"=R<Q
M<<QT&9VQT90SWB0NG3^BN/S],?W1W$QM-J* L.5[G]UZ2^D? H<QG)>XWH1Y
M@^P]NN:$I(ZO&$^E-2#<IN\/F-&8N'@ **6$$SRC,4_)"'"(;A_,&I/K?+.O
MZ!:-.:H, XEB\_&H!6;_IPA1)!JS:G\"N(7EL2 Z^UE]-+@PAH8RKS'9_@]!
MKZ:.;5_G4.=^#!B;T[J===#C? H:L;8-\-#:P9VO(._NCGJ@PU+NQW LY45[
M:$Q3-@3D%FG'@6A,D_<IJ*;6# K1TLGZ/]W-SHE=U0ER\EBJ-!26P/(^G[?G
M4P%C>4:O/#)SLB!]^:(D4Y_M=@P_3%_33UZ7?_.Z^WFI@R'/-5HZ?F@\U>)K
M7& 7=(C8S>[)JRUAO?GV#5#;2"@ Y\"\6I+E/8DUT6U\NCV=,&;I!('>W-@'
MVQE1.?7#W&YT06F7,V!_9I(PU5@4>4Q)Z!'O9257E%H0N8V_"5@N6A17'P;.
M/0E^?IDEK^:.L_I]FRLTG9WY(27C.\%UE/B%82M)8WJN=D%+JK7/G.0^!Z <
M[S4[H5Z3($VJG^1G5@ZB%LEB3VLOIU"(*Q\8SOS[:6PGO./V)&Y.G0I'-952
M3G2%O/QZ%D=+,Q:FD12K**;:W,\OOZ.?Y+O@)S>($N+]_#*-L[I51)LW[ 7=
M>D7?$$K5=\NDI4GH-7_0R(T!Y>&PN=CCM5"^Z\P="#::$'0-%%0O+]<#O4]%
MI!I+.%PVBN$JN?2&SR43%FUM-5<$FB6-H:O[\: 9T 2C!/PM%W 3O)N!')/2
M!]J8(3 ;5"B^_L\Q[ \E[$JNO1,=9H.5#4PE8S2G52_N?X4]GAIFVDD[EQ%X
MGPA(C80G8KA*%KV'95'3:GG#_+O3V:>D,%<#\TA,:[>"P^60!*V21=\+3B\3
M'GV,(N_!9^]:4'9LAQW)]MC!4.+\ ^Q6.&/K)A<L JWMMH$_KR3$QG&ERQ K
M^?0C]&U>TQRNHM!%N=7[:8S@.<D!I^3%!_AG8IG^CZ!3C0'N:OG5 X__#C<!
MM^;WQ+64"0B-SUPF0DW^$#?<!Q=1.+\C\9(YUB<L"&7EITZ0*PK3^\"?%V5U
M<)X@>K2M7BYRB6YP4@]4%5O8<"VY6L(&AYD28B/BG@PVE;TXQ')99DM,MMD2
MW>DC&3)5*-M5N_4XJ86HU/0&=!6B7X&C8I& $P)SVD!.[#1,?+VDAY9%FP&
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MH;LNB/*$K#*)$?P@$M&R:&?4.IJ$>*GD=YH9)^A=2G4L2O;2B;\0YA/%89*
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M*(KCZ($5G(+V(?=0L,@^@;PV"_?VX*)B:,7R^3:*P$5Y$3B9,Q>F90&6:U9
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MIXNX]%EG*%.<9M$=QR]VS^V+1OW38<6,^2VP$5+UE,GB[11N]IXZ>_O+%<N
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MS\Q/<I^>YV'DF 4)>%1,V\X<.>$7-N8)21T_2 9C*6Q8 T9L_[$;$NYN>]S
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MD>M\-&ID=]K;6\B'7HN*FNK6^6C4R.[TM;>0#[TZE?PX5];8^K\<+\:UU5=
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MA;CA&W)JOB&ZM[">C%Q_%+>N*9[_KU4#%70Y14E))]A;A.2.X"&&_DCJIZG
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MFK(PPT=>GT;CN&Y_<T 7:-?9VHB\;JP4JPC2"9D1UF_PS ]9?Q?6:#(I*_C
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MT2DSBQ'K3.P[]WZ0=Z=D/1^CY=)/ETK]'DU$9)HN2%PCT@$,2$SX= P/?G7
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MPYX=4KA@%7X!.10#&I_.7K+%!68TB7Q*>*-S*('R!]R()N2015,:!'_4CC<
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M6X+]N7*-WD+,0'(T/D?,F]*\9:8E:C?N!H B)L8R? 1FKGJ+%=#C[5Q1LVS
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M@#VT<48W[_#M"/0F#6YU9=D0F1*$WUGA(B1OXQPR\AT,20ZLX4#/I&C NR+
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M N0?TW]^F'V<W$SGZY710+&N8FYWP;)61'[SN DL!/4@AA%YBYX_03R^U]:
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M;14R /'UTMTM,O[JZ>Z-Z*SNLJ\5P^RV1/T*9M-I:4?G&#'9S8S+,P'>%9D
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MU$A_._,W0;@C)85-7XWQ)5K%%7LIY"]R\T$'*BK>'-_ #5>=!P9ZCH@Q&Q?
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M^:KE<U(K0WTE2A3.(.+N8YST#J%*+Y(RZVN0E[JJ631SOZIX%HSOO.T59OR
M3(K'8[1$VFH4ER<#(;'QV0XAB+Y7J+UY,K+7:^#:V+/ZX>>F^CA0^K2-[]OZ
M\*S^\^Y@_H_+^D_9__*L_Z[S^I*L_XYS5V/]TS3)Y^9<&.IKT7,*D!&[H5/
M//!3J%1?&H[\8"#*]>=H?PC.K<\)X@F&$&SR<:DGB<_0].@(996F1Q>9]3,]
MAF#R<SM]])B((>/"R&0'.:%45<<(8JJ,?A!:=,CP]L,@1E I9\&7<YCI-*G/
MYR6(TGDK/,4PM<T7=IJ1^5;T'&4Z"[Z/+Y42"U)FMAP+@@FFDXRB9)?^3GN@
M5 _FC)Q,E$Y!I!3HT;*HA#NE-L:'".<#O/ L^],IZH6F$!7Q4$@CX#_>!@Y:
MF"<W?@ Y^DYS]5%BS/3]QR"X;8N2ZBDY_1[00D^4&%NZT:?K$.)W*$C51Z0"
M\%B, 6%^/R./I>B<6+'@J.GI!K4%;M:X7I[Z\]J8NT)2R9[;20:ZS7H:<_D#
MCROWT76@[XS](Z7R^YE_I+0YL0J]9DW P86>^<M$'2@<[+MD+ON8OLN/@8>&
MP75=/I<OL\;QYW-0%I\4X^/,&X/'HO4(G&AZ$#GX5TJ1@(G0'AZ+.'7J^5C\
MZ>V,FLIP.<ALVCY)S]T8?O V/.24>*S%5EJVXOH2/D(_@==H92X#GU1P_]&-
M'RZ3* YV,!S*P2-,UL W(<H;Z]@V_3B=?Y@:S</<5:IEH'::O@+839^11'S+
MRPE$%X?W,-B&UO[!M2<AM(9U-?;A1+LIU8-9 0_B71@XB1V#E86]@U=N9.4I
M(1QP?P#'X0$>?RP E\4/ _-2Z]K#\&GYW&:^[24DBTP4X;*QSMIZUJN+J1SH
M?GXHP2.WTNN^#'73'K4>$.B@N)EKI'Z+%<BN(,DL+;]"5:)13:+_Z^1YIO2Z
M2ZS>E22KM'I6=[_+,5\<B5V%Y#;-"!+=MKCWW"TY:MQ!)',_MK9B>7E;!]'G
MXQ7BAZ'NCPVPA4-7$KJ3WHK*ITA6*S3W'C9(R=1#XRXV&;U![6XQFOHO$H3X
MZF],WUJ_!&'1Z!+]>AN$!Z,V=2<4E!6<^))).O*S 9=P9[D^TI0(^23+"YI2
MNWY391\+4]>/V8X<]E"51C?BKO*G;,*=ED@2K22J:Q[XP1Z&:%A_BW9XM-%G
MR?O\:#"5VH&P?HR*,\> YV+]PW0)IO^ZF\Y7T]4)F$_7)J];NTNY#,>.J]$[
M/QJ#7DY,3RQ?)R;T7U-*\2E@"9#A0-8[ G,8CR:$3@86]%"YSFO6PUS-XW:R
MP17CM3ZZ@1N(&@L,C.6M2$Y>U,RD-F2(I(P5VJ1DKP]2<*&#,C(];2^(DG P
M]<4E92*PF,<0"RGSR\7M%*PG_YJN3#L[1417A4W+=.5C:^$67[(NX3X(L<8:
M'DLB%$T$ ;2SQ=KFIN]OI_,UF,VO%\O;R7JVF)O>V\2%6MG(!)= 5F&58LIK
ME$H)2R\.V1\U/*OHQ(4)3,JQ*F".95W*F6*-AFWV0P;CX4+G-9,%-K'[<'9G
M-.4'='RY0N=L+]AC L.89P($M1\=VGEBN5PR)XMS[# &:TY<J(TS;?LJ]##\
M+X,HOH+'?,23'8;W;^F_,<&]!_&_%4-.F*P!/2G*&RM\O=25U/>P2OT;4#23
MEKZ;S*O9Z#LLCJP&S/+<$X@[>=EX.PE#Z%PD\3R(?X+QG>4ZJD$I2M8$* 5Y
M8X RZP[*_4T?6[I*N0+#+LLA'U'GX;NE.RN,#^O0\B/+)J&BPY]JNE V<6#N
MP!\SI/-FLIY>@;O)<OT36"\G\]7D$A]V5L8O1CH+O7HITFUEI(_:E9!GWYGN
M]EYP@/ "^G#CQJ0@PU#H[$3:1-T@8>Y8$?6W=S>+GZ93<#&=3Z]GZY5)RU%&
MT+7Z,=W6H\^3D^0^@K\FV#Q]Q-D8!CMU,^F8.%>SF&&=G#]<K*;__("=/#BN
MO80N(X?E-I%5CL/<J<KNLQ/;3G8)T9MET[*P)1%JRV8F.N'M(5*O&+HQ1O2O
MB4N.1(I!IHPM=3?#1>@@"7KA@5(5\ZS*AL?AT4G[.+[9Z$+50"I#7^F"2EX^
M7[N^&\,;]Q$GYXR1/-Q[#[]A@G%48J_,AN)/0H(!A0I9'/W=^13 >;FY28-
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M:QE>;<LA>0B^2%P//R&9[?9A\)@Z:@8!%X>0;DN&S0H#6'F'B.#*+75K@LD
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MZWR57F9E?4$<@+3W'ZU]$/TY ND@)P /8]+$D9%V)7F)Z!+)G^(ODLCU<;U
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M-CII32-?I\[;D>( /.*&@+P:,9==D+7,A=>4.BGI3>@ZO]E<0ALB-77O$2\
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M<.([&;$;U[IW/?)((E.6Z&^X8GGZ@V*D2K.A&[.RC+*>XV3#8<>T12*(?:<
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M6I?5D;Z<V6S0H<9]A#/?#G9P;3WC8PV^^T'$/#=-\V<]IR6((Y+;3[4JE>!
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MV>HZB%>H;FC3L.I\=%NBA:+&-DD=ULJC:?)GULAR[B1='$9N>>5"8::!P9!
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M[ F8OEES4 Q6]IN=8!V6MQC7L^7.(*$_;>JVE#VR_K/I#'5*$R*I$[\"_'0
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MW1J*1XI3#9"?4G'-U[H]!(9]O /CS\F>7Y=7^YN:_W,O")'!>?F]95 <A+J
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M8\4W>0-_\T )=UT8M!3<E;WT/Q9:*]%#*F[%"7"&TIQPM).7.]_@'NU W=]
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M5 RK5%!+,:_N?WK%O=\EMMA5J5;=_H<)+&)3OPIGG;OV%=>15"*,A[Q[H0J
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MM>8'02R?Q?C-B;A2VH?A%4.@U%29-5<-==V(V8X"I/)".[:10"@Y;0;SMB)
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MTQ\SF,-I_D/F*7#QB09JVKB6J^NR8K(3,[UDY:'$UY6'(-Q\$:"?-/1C:LT
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M'FXS*C/#2EVZ'9AU(Z/>AX3NA_F; W%,S&0PH?:M"G!^*>O:X.;EQ5[HB=H
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MJE/J7>:D!EOU .FT.9!E<0O@T !K+/;*6NPEL4&.>2;SSO(?EH'!4P\71OD
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MT$O%#U4(M:IAYDPM,4,Q*QP%1F/]X5;R%VK$E4+];+.S4Y_.&>S #M]LKBX
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M>>+90V;U'*&R"BV=2_'7)3 CD+1MGW3F4#<=(]-HB&3"X+BC]3_WN2ZE4\M
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M. HG<;2D ?F,77-(URC9WB-[ UR7'=CU @35RS",S2.:4;%OP0#AF4O-;F9
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M \"]:,=RMC2RVKE&=*A.941^(J&@H I!Z.XDI1: T*= :>P1H541"EB="!V
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MP>@GW::6W+G?KU)1FYT)#ERG73YP"+N$I=_$K!',@P6$92O=?/'QX>F<8<K
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M?!P\/@_8'5YP&Z_PG!;^-I*2N,5KWEO67YBZAXC(Z-[(JP.:7Q,R%&V_Q>X
MLW2]D!'@D*_JM]CC)<IF*(BV]P'R0S;1UL=T>I9[,Q%C%XX.<MJ'AVAD\^M&
MA;+MHT46[O+-1$&R@SYNSE=KCVXQ/L$^GA/P#)QBX^JDV$Y$ ES.53(77)&F
MW",7IT*F(DZ>HF7,'Z9$VFJFFX865,(J"C(>[DN%N_@AQ'_&[,/S3<=S.KU*
M4>7AC96&$I#1-NLJ QHSYH1T;)MP'<"5:U@)A35DPZW^$/9DF_RK+=;RA;W
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M*W42H=30HT-7?LIG- MXIEBTY?7P(W:V\>+UZ[3XX3W[W$ 6A@Q%6REWVAM
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M<=8F;N\9V?-_/]!C/^M\6M"S9M;+XX+!/BZXQ?=L#(6-J?3!<$56GM>8&Q
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MC*2'R%"TG-^@H.Q20!=EV;\9T4G,&#=5WZHRN%4_B28,5?E IYD,=J-1NB6
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M,L\&!D>]>.YO]U$/Q QB)+-.,U)IENIEX#Y!%W/+F=I\U$8:JC.7C9TJPGY
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MN'V>C1Y/+1KKK)Y!Z37<VW7A^6#];.5A$'''/R"_HRXTJGCD4!DSQQ5^0YR
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M#60M:$AAN"")JOU36;37$'Q-_=1@XBW_3<T+JH[XL<B#"L%E7<_SR6NQ4E@
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M.,84&8'1 ,62GQ]=1-C"GM9DB)1 -?:,["11#[0UBNQG#%[-8B?+L]<LE"1
MYL)"@HU@!WZ2&SN]IDC4E4%IP"FZ!]!*$7<R%[;VAPX-2YWOJ[&D#NLUAO#4
M: ,J9^=F=O76ZC?S5V-B%\(<".H9F/B8)7C,0;N7/7C;;[/FMVJW8!'Q/%XY
M-:I?).FMTH08^$WR_;,<K^\E.),E26^@K89'_ZR5*1J"G%F2[HP#A#,?P73T
M'3*D?8?)A6K1LPGX9DV8*+;@0<M6N6;]KIT'&LC[WWV:W!ILI9K^P'KG=24Y
M1>6PBTIGY4_",B $Z,9:HU>K1=CRH6N:H* "*5XA#K 4KA)-&I\=S<N?1O@
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M']^77ZGWD&J\5MVQ4YTLANJ%(_#^4]K?L8-H+BT!)2MJ8BD1#^"]DON3:A0
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MS<VZM0!ZJI&OO7"S!X(+G"'K[EHY4,*3KQM5NQ6,#.6:&S4LD6.)V\9?++H
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MT;7K\+[<,@UDKU='C1J0TB1@5OP?]MX\JHFL:Q>/[8 3H""@(*05$)1)97)
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ME8A<GR\<X_PV?T2A;QHG_F67M'W+N"5']O/;]]X.FLX*1:7%-[UY_D.J:BQ
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M-*P;1XT+)8TZGF).'$(]@]MF)/+SGYLAHD#(EDA@QN)A;4EA(L#"J@]+L L
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M.2#,1I9?\IR;@#]#4)FCOO39;B'P4K&"SC]XBCF5PZ)7E5IC"KXK@7=C^IB
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M\%''4OI@M./1CH^#)-TA)3-JTVCI>\M/TSB"S=\H"_]J-VLW6R>G6J=6V_4
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M-?SFRX(XJ1WQ!GN5]B*[!F94 N::S7BI2TQXO2U.=(O"%-FYNH\1K])'K;N
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MEFC7ZS>/*26_SQ)EG:Y0\/;QPF:)GE0.6IP2JE)YUBS\4<IG_.QSIJ!0Y>]
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MS@IX.!=K;U1C=*HI]/*RF3,;_/[@K\,X4DEP$80$=MR5LA/YVM8T8]5^N -
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M(K(#@P/%A\JMV$-.H^I?(=>O/ZG=YG]3C;OAR&I&KJ;(FO&&L[B4/.,>J@N
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MDWA(ZG*(GLS34O>IU_8Z[RNDX$5+"!/:?EH_S:J[A)B[:4!HC]K@[ %0N,N
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M]!BH3$I^Y=2AKW*'R16PL\H>;!6B&<$ZD#U31M>=-$=!R-O3O.VO:NL;/Q3
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MIG-+O[5K'J>80%]/,X)933R'ZD[.'_I#"[&"Y\2I?&+468*?8V5N;%3AQ-T
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M0G;<>#)!!YDCZ=>XCK8%!,)[!+4-^JQ,A^O D #8%$SB:!*$KL^S&,?K47T
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M =H&DSZ/0L28QF3=[AO*8N51V$P U<KX#25?]IW9\'MO0/WJJ<.M/<U#;-^
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M\//(O0/2""<QA]Q>"])WRA!93DU*S?+"H==KE*TE>1C[;E)IELKX>W,OE78
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M^]NCR+(L "M.8&I(82\##TIA/1Z%8;VP4TY:_Z.1)^&SKD"V:Z30+],*FL8
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MHL4&B_NK69I>WMXC,NH,GGARQ9^I"T<M,9FK)Z&U,A7@LYK "IQ[.3I)5VZ
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ML:J36'J+N?U5'%E#U<-0^&/(T>IBQ5ZM(B$.HC64Y G2&K *HEW5 #XIL03
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M.5DE.E>BYQM26I-XCV)WCW- A5U7QQ\5>X$KW;1^])E#-W.:...V([[C!N+
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MRG:;FP4M/(IJB04LM7O.7:]4GF:J/UA9$A)0X/(('^UL,58@=( _$I28W.U
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M<KE] 2^'(U^E5#16\63&\591O,F+)P,];GT[\_Q.--?QO!)3>U/[C!K:$<H
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M#E=WXCXOH.J^3#+H90'.^)ME\G,9\,?O$U8UUJG]Q.D@C[KM'&QVKEUM,S:
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MQ!7)Z.C^C?+-*^2MSP._3;S(COP1I&ZP027LR%W5?V56!^5G S;^P:1?RZM
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MO*\MF'T]W8A&D8.H7/.!)K3LB#$Z/J0EH'%^(I;L4TCRX2DRZ^CR+B3V_A)
M*YG;8K*?T853#>%-K(#@J8;0ZLC*A*)>DJG,\I!79MWZ%!,1@1";*U@&JVK7
MRN![E5B"\Z^ CAIU$,=4# JQ,JM+G5T.+NUN6LY?0];T\T G&IK(JC&6&['Z
MWL60MP2&\K;SGU>$1Y-U@A8)QO]?PB?,/2;@0$VT$%"14W@9;E/'EC.4+BV@
MHD7*VG4#,@HWS"_V=C?HY.-6S:J$*]EB@P-53W:*S%6W#"A<,BA;[QV]!7:$
M=40K\2A3!;BA7^YEF5+Z BJ&>H:X3&0'[B/5AUH_$=E">2"M\4,MY4IF5;HI
MK7"H7_WF,;75%HE[4#?5F9YXSG/'- )&,FVC%D_ET'LWU=\R:B3&"RAX4/R*
MT:(P3XS4Q6H [AE/#FU(\0ZW#%1VA'(*C^XJU"&=4__T[O?[YAQ)O9>+I1M>
M\ CR\_ DRN:DI(WQ.7V6)BZD+@F:J]$@.T;U]R^[\6OBFM._)>[ND,P(1J%T
M^N9QB)/+;,/@WM-?17&#5M0#E7(3BG>^EV^[9Y:Y>]HN<LEM#W_#QY"J<R.!
M>7D3E>].83.7/M?'/V\E7P*I,3@23YJZQ/^>VFO3@=H%U(J";F<K;LF>)Z+?
MV+_'!MP*U#7?W>&:,@P;_PQX95V"H_"<:_BI$.JL&77V6;? .AX_&?2<!@]3
MYY^_QGPG1A$F7<XP9X\CUL][&QR%0 ]8%5_TRT_@%L',D8VOZ$;,DF2(JO>4
M9(BJ?55,0'LS_FL(@HP^#6HC%ZD\\;LW<W)K"W[,\2YB!ZNVX2.=-S]D?FR'
M2 LH,TDID"0:B=P&!>]"X'0A!K&9?Y8GW8%"_U$7\U-L]N]'$Q$S;S:!F/EH
M/&+F=25F'DAGGBF$7M:S$4OO(K'T _,)J?0.!F+S-A)ED:4\I</T)D1\"2LN
M^\T-_H,BJ?^@R!'/JH9W_5G4_X3:?$T4AFRXFZ2FG_N%JAHBOLR1$MWL21/?
M)C'%CEX^4];Q]$D[#G7,(DH"35[/J_X4<HFVPF^8D@DP91(464L4.YFJ%/]X
M7*,Z+"N)>ZV1Q+T\)'$OGRY(1Q(0%L*-=[!BA_<2GEW"^TG_%'?],;+F9V&Y
M2(E@OAE%T-*851JR@;T/H*H$PN36-]0QOP3)R!IT5L#/VQ8D2[Q%K46V_VLM
MO)CZQ492<0;*UPPV+:#F-$L'A)L!^OS3%O0M@ @?(8>*HT'\?&8:_<%M&W/J
M>GI;[4]Q%\(0L J6N2:!_H 0H;^..E]4H]O]6=+[H+T8<?@O6"R@;,HTOSZ?
M@@_U(X25N%F+\5?QJ2KB%?^@4D3^!Y6//7F;*&$_06K_-%BU$4&-HAE\>43L
MYOOH*;8DT+X-?XW]H_ /EAV7L*R?@K"L$N@,ET*N9042$? T"Z<_'6V2)#>0
M5?70X)9!3A4B?;*.STC_N4R;V:H[ 5LX=8L3+R2)7;SS9E?:2SA9##>$(>)Z
M'OA;;4SG>T@'N<)RZJ>R^PNHX<=MU?Y3*P%)38)D/*MC/;;7AY-*>T16!P\F
M<3'Q3&G*5A*:3ZL+=*EW]P7F0"9+^/*%KIXA+8IML]WE<\^((Z_7R6!TU+[#
M]HU[GS@A+Q7[0F?*$I:F\]BQSMJOL31W6<B.+_;D[LH&RP0W("Q@63^@P,!3
M=Z4405)UIGN[?HQ7J(4?ZQ@G&HR^6VO:YY?K-RO?,[)+6?YD_Q?GN'>DIYMN
MH,@R_.)?$&WKA0_2PUB(,YA^^ C"+S"*O!Q$1^.VAX+A/.5(QO[[_L[?B^]#
M+O5*IIN2K=K.!C/CJ?+%<'M!ANR>L?O/ '$D(_U+^M,'/#V,9>J/M^BAQ#6W
MEIV.P$5S$S3V'3OVID/CZZS)ON8? 5 &6(5@97F1/C POKT08L+2BF ?K"0U
MUBT\T4/>5 7):3=:$0Y('CO/-8.26"K^I.+:CU^@XA/59:!6V2/_WJ["/(:I
M"KB+EH=>^24W9W&VB;GXF?.JKLKWN:=S^^5EFY=RKJG<\-&\MGW=6XLEL\>7
MQ$+?!P6X-I%C =1E'3>@7+.5? KH+WX$(?H><<M$>KR,I.7#AX'D.NKJX!;C
M=PT7C3&QN"W<R^C&FJW=C#Z7C$"I!O<]H'*TH>QBA/B>2_:WM4^4=9+-B\4)
MYBAR&9?=,U4/RW<%?KO&:XHC7P[D8^0^(YA-#6<''NCFBA=0<; &B7 $6(+(
M/P,#-+8?!AQ9"+#19,$*98P.3U -+N2*E?>!,FY^._O<7$=]&JH;OB5MR87K
ML^1* %&OU03B+B9>@JMR_>AH VQ4_]YN0S9M"GK'^1X)E-5;\I*6#+LORGK'
M+:+1)KKZ[!,W@4L+04W6P"KR?G[1#IG+JDWI33'E&21=OO!@+ IBVXAC&3IA
M.3VUGN U?AJ-81'J"2H?AN+XXS*N$)7(Q\8;XQL""<<0U)0+"<+94=V]2NE5
MCI?<[IFJ=5#6^F)6SC!1?OF]UJPOCG75 14%PX;$GL%Z4[T$?'G-%E(>MZ+[
MJH@<DG1EGE:G2ES$*B#K &K%K%$J3;NV3Q0&\!N<I>)T&?;>O0/1C/V>?+0,
ME*B'.=$Y/8I!^TOWK_H0\F#&7&$1^$8<:ZKF_(XKM%)MPBA.HY?U#&'0(CP_
M">4WOX"*"F(8@HF8J'1DBV-$>PK(QVJZR6I/2&V#SB^[*DR&16X%)*.&_A49
M31<O9"HW>KI]:-MK:&(FW$'RJ-G: FYA7  WE3N)0HF@K?6U)AO@/G2"LKF7
M9(N6JN4SRXJOI34U'4^RKJ0A.NMZ&(-"7M:ODX [W2]/5-#P+YQ.^>-Y0UR\
M]!>V7N= %!D?<@&7H#NKK+(KTV#JR"!V8VGSV;;#FO*6)F4[U0]K_<?(#9U:
MYO062;;A5V-'1*<@2GF9XS7JD"W AI<%%\.__6-LA#1 %$N[2SHS5Z8@^O\V
MM4Z1,S"O(,D)1:@A9N6FSI]C(PY(:F0/I$51 ;,<ZN0F#!!),H(CL9+F.YJD
M^>[(GV,C5A5+>HIRN'31JF&"*,9"M$&2''E@R<)#&]J8<_+_,3;B?ZC[/XBZ
MPG>P$?EXF^ERLBI4 ,81)EN3@)?<B7A<.%4AZ5M</EGG/F&4X)% >]\^\"K=
MR<5BS8Z6<^<4;'2.#.5MG2GPR'>H[TZ7-!Q7:E0<]E,)]K4M="\Z''8@1269
M8G.QJWG6*\S;Q+AEQ_L,'=:)QN]W&[W2OJWU7AG[O2CN_057BHSN.Z \S?G.
MO8N>$:SVFGLSO#X;VW.B1>),,OX!I1-!XF[4W@N\&Q^FX]A1])(T%A^@LY1&
M<WO>Y?:2OG"27Z>EMKOH!IYROGQ^ED]Y$+@^X8Q9P-F+:_FIY[[B 1<U[-$V
MJC\=Y>+G'))X-PC!6[.1/B0#H67X9G=O* %TWG7W866B@9^39H+*@9RW!V./
MR>T3JL*R,Y#;$S]"*:$>TZO=N.@'(U!H1_8%J8G8BH*.HM8B[@)*IO\+*:@U
M((+SY@>\"R]7\>O-S%N'*@R",3L/:[_Y(X@L06<(ZB&:2E!/,NA=DS84>?!)
M6;SZA9CK#^)Y;]=Y-I!2\(G;6_V/%Z2U)8_.D+-E4VT2A\V=34<3F*?%N7-9
M2].BG6A1=[6TLK2CX"31'B[ARIY-1TUJ5"J(LN>E3Q[3;_H0^Y$:0*)E@JV>
M3KT[,_WV.+CW*]YCJ@;,2PR%HF_UKI(%E*REN/C1<'I>SP**>TA,%QZLZQ*^
MF6)R@^9JK'M/I[V=(N<S6C)"Y_Q>FBACV)U4,PRPGSY7S10^8 H_!0A7-V+F
MC%S-$#S,%+N>0D\16=@YO5*",)\Z4K:&,O<WV=O\=SEVM#*GRM*[:#O_*L_%
M=&8 ?AETK$]2.*$?R-C.'0V/H_8(^0: ]=*XW :#U>; 8/TM<X,=36>+UY54
M%S9I[*@VCK)=MK0FKSCK[\TE>;>H;T8W(:"JU1H!L&?S.2W4K_;IU$_%R)T[
M@TY1I<L18)J=!X#P5<+?#@/^K^<JI=V&\#U,S+F _Y<^NP_3F"92U'_[1UNL
ML=.P(/7/MEA)0_<X[\^V6$#@A'N^_K<8H[<3FN,VU18^9\OD_VR+_4DUQI#C
M$FJS6AU=<.P,<_XIB][ 0,S()KP<]=.4(>)>_"_VWCPNJ77?'Z?1RA1G2U,J
M-2M3*J=R@"8SLR(;-+6D,G,@H\E$1:C,.65G.]UI26EF9DKEE(:0.%5F."6E
M*0*5.:^5BBN!Y0_:YWQ?][3WN;M[[OT-]_4[?ZP_6.+B6<_SF8?WI[]^7"Y$
M9NX"Q!?S*:^ZL>5OSSFB]C[%=2C5[C:>C+GA%[%V$UN5HO7BT<.RU=L&-)@I
M=G4+%H<97&AXC'U$_\,K2:_]BS'LGQ1(K 63K=\'GPBH*H'\1['UKHURYTH[
M2<ZH#\D9^8[+..V?T98BU'=@@$M=)CM!^SK)@9-)[_57UJ#^Z>"3OZJJN$T]
M]F*)HF_\> 3AMZ._]XW/KW+0K/N];QSX<*;::L]L1=]XRK8N3X,%^=/G:LMJ
MY*?VXPO\J\-/_OBH?\(@CJCBF]P?%0,[EMCQ9DXP.XC><;2C8T'!T) "U.!*
MT\:9ZG=W5\W'JS-=%NVNUCJR9UVVT[YDJ_U;G.;=1LRBAHS_BR"CCVB026ZT
M]#LHP?01:Z3JE^^8!(K.;JN,OV$2J&717F=&A%X7;XG7.^E;:K7OX,H+?\,D
M^&.7SEG1%$+N(1/E'C).YG$\]B7)5G$^]O+SH<MV-7#+V3]%/.Q?<'V^?Z(A
M/41\J4Y]=<=WW(?IO=N;QOZ&^S#O^6C?I-_?<!\*C#:U=&Y4X#[4#2T\&BW:
M:K3\+N7MGW< E<METRXEN1?VF09G'W=^>;I7>I7I(C_>"OHD=3IUE?6DDJ+"
MY$E1&U51/G$^/#JG8/PN'RAB#GC+/:*"G*^P*OD[-D"S,#(E:UO&KT-7M7GS
M;].XK_[<>Z4&@ SIU0_RMSGV.42!U[I16L+A?]T+C,AH:QFR75E4//_G9)4B
MN_#3LJJ7[J3E,7F8JD3OP@Y&:>V&7_*+-)P6G5XBHV-47KE;[=N[2N':V%NU
M:.^>EA)X-\7S8%++]A&CE,$:">K_/7=8[@8/*(:M+WTOW0N.##+ Q!Y<#>H*
M?BYY%@/";8<^@;J[@$&[D0L40]+5DB0[B?-35E%)AL0G@+F^T.E$F5=2\>3)
M!]9)MKM;F>MS"1/G^U3X0T/4M1@K@"'58@N"ZX=DP&9![.#>>V0GR$.N^$_(
M;C,]@D'YVFH-]1,],(;0XZ.PWB-VR^'8NO/M0P:E\;,*'^=Z![6[A@3>/X2;
M-<[<8YP*7@C+X0\M!'2%$T,&P!1"_!J2,\+,?)!R$?"0BQ<U!\LL$E7\H(WL
M(OJMN,RO[033$9 (T<E231UZEG0U:%[!]^YK.OBAO\SVJG.0^YO60V#RG=N!
MB@$,;Y\ON>"W. ]Q:<[B2VOG&%V:\U&]2EOZD/2U$Y[' RW%:YNI1PU<Q<JM
MY[BSWT&Z@M#JWZ2$8!%.M5ZXK!76"S+4?M9JO5!4"?8U'RUG4Y6]++*X&EZU
M!HT-M1^CM^+ZPSFF,75O%GJ<N.KE7;OTHPTO6<OC8-[*4\^OY"T>GYD<,/VM
MECLYO/2Z35[8G>J\OJ\#7I')] ?X+V!W)R;/]UY0:[][A7MV6.[#F.&.^KWE
MS241P9CA@#W=XDBS/3$=+L:/*PY<L%*$!?\G+C-0&5:> %-'!;V#1J% _09;
M2U*9. FB]7"C*P[%9!J,VR<M?0-!/+S-HSH]%U&E7(80=@"UK]?$A*75-#_7
MBL] E95(/U(^*,LMI2-3B%EW93%8/VA_"78VI3%]$=V0LL3[DL\;KC?AHDAT
M)-][YK'T]LGZY^SY5K6!B7<310O-IW-2WHR2=>,/I+=!.-U4P3(!37C"QYOS
M5-? 3Z\<MDE64G=?$00STE9QU2T2M#I/KAAUGFS]XIKB]Y1Q5Q=YNDSMB"A>
M@)NYCIKD$"E,"%EU?_]SDE/U0KJ6WX*518%U2%O1>F"KVZ:)LS5'^^INFNV+
M?9PGB9"82Q<6R3*Q_JA+J)FK6F9AYU,6DC9SO*Z42N9[=, 9V5Z,^)#@Y@=&
M+Q]"T26.[F'JZL<ROSKOW_T<V4O\'GTSQ0,2.<-RJ)-/**MXXX[X!J1"'NYB
MR^5A!E<A#X])/1E]> 30=NI@<&H/T+0/@#"&C:M_"R<$[*[V^W;>\(J-QZ><
M3>DG.TI6.![C"HB&ELR&^">%1L(=O9JKCI^N.>@M8V<<[:6<V!68Z1_6?OHW
MH=Y)=_&[P5;==?4W[F]LS=5]N7TNQ>:GXMEC_O\0S[Y \I,KDE+7*40(4N;N
MB_QR-&$Y0U TV6362Y>+B)V;O_>>ABEZ3Q]TUI2,69-'%1GL^Y16N5&.U:..
M>Y-2_Z+X=O]_*+Y-,)-RL4S%( BDB/AGQMH=N@*/'$O['8]\!]F>P95[ )N>
MFL';AK6F$$_.FB@,E$6P^;_AT?__"X_^I^68,;\'V&',WP+L:T -=K%<?6X;
M-E/0C9WB5!;#7@*BG&Y"Y73C >>Z89]L7Y[UO9)2(02G$ Z3\H^M,R 'N)_]
ME[J82?WK$+=4^$:^II!;U'>]ZQ2YGB#JJ4_XKRM?32$&/5*I_65HY%]-8&&L
M'E'_;6G18\Z#5-]+I[0T=LUV>6Z ,&UA60#XH5&) ZE3@.80DVPJ&/%6M-GD
M$U K 5!^CNKH1H65)([$5<3&A;!5 E/M,C-N'R(DW7[7K]LQ:[Q&MX+93MEU
M4^R1]JC#Y.,\?J#:G,57HJJ4[AC&L&]Q._7A.5&2Q>9U>6#G-BBGD,*%-6CU
MD\1$EB4Z7GKDKFEUI:Z@\M-X6[=MXG/& \AUW]LQ[,+^M++4TZ2=(06A7L"G
MDD$Y.?]"HH2DU[U9C?R2G  [4Y0I'!2PF4VC8%M@?>D*60DUX-#9>J^'#8:Q
MMP?"8Q)[/'CH+1><[GU)Z\;(;CB@[Q'L"JJO>/7I'1IOSR5-LRE]<F$;7'8X
M.K@GIDM9Z])RP::/.F8:,_?4S)H5M]MEWK3USV<D(%+9.L'W9/1A<K!D.PFY
M"XP=9 BW4=#D];*[!91EE%8P8%+G.L@3GWG4/NZ=[^A:A2JYVEZR?%S%NRI5
M+S,_,(NT:;0&MH%<S=Z3T"Z %Z01$:P&U?'$Z46#8[?,=I6_)5K)+'&/GO&(
MV6^MG^7;FQ&\;_GN3=SUJ%G8%N+9DV32ALYJ.5> =DT>'KKW=*?]SD>//6>5
MW&*Z7:"<AQLHUL#)ZT"BD!L%+]@I6?ON0"?$]0;H52,H^#5F;C,%25X*B42-
MSH+]:0E\6 VE7)9()F038%O@TZ>8_-NDF-[J3#NP)&="NH07JGFP+TT/\^QV
M $H]( 5^@P62(?_=4(CIQ2F$P*D+FB'V3!1_JFSNH@HTRL$M=*T[>C>IQ2$-
M-W>* HV9H!KT(=/^/+@7\AFJKP/()H[WIA!=77LY%,/V<>Y\Z)I[ZQ[) >#$
M9 X_QL(_LR^K>:3DEMU.U.ZV@H=;1+A@M['X$:MGD7LB/$.45>SWOAT\81%<
M4)*TQ^Q-P@7L]! 2]3AVD*T6.(70.*K@^OGUH0)J1QW^G;#>8QM;<*B+]("H
M1SK<^5*"]=Z$:;25[]N(]35@HW1>DC"T:;C$"%A.G\\]RQ[D)ON80&YY7[!/
M8)IDKURWJ)8@8WT,VV\WRQV4 K0P.5^0R$8$4+6'X1G=I,2J#H^Z1/-=80YK
M[AWL\N'C"J$S]?7J&[,:A?K<>4'AYW8R#I)L0F4K"T.K84U@(OHN.'-2)SW5
MUG EJ#*2P'0^YU_QC-EN+8',5WUN0Y\<\2\OOWZG=4QFO_U1V:C3O>O9?14G
M:?>\.P+#(V_=1: NAQ_#(K$"@V:Y$Q_G)G];@&7N,$UBY2I1/@ U6\@/(M +
M.H]*\#'!Z%SKJ2Q]BA68QDR:V6.1] 1<;M9 7L_ (6-IH%$5X#4XB1F M:/K
MA_;+51;D;"I[])!*D!E);$.OHVLEV/=5L-8[9?Z3WO,%1& A$QGV4)9[G!LS
M)&K(IUEB=?P/\0O&=D\[**OE)J2&N;=N!:3M#49S3)Z"-MD$AZLSOCJ4@M"N
MX77'CEQJSFGKS[UHEHS;Z(0XBR6 :3*$ A4L^J3<;'B]'_7CC7-MNY4LQ>R%
MU"8EN3_MWL^6UKK]XT>YW_WO!_WO?-#LT;K%&N?0\Q'3C.DZ_1<0ZXVO]3Q$
M*!EG7I?*)7C54A,>.Y#828#G+9%0G>\%VK%N"?&+J)P;T.F\(+W&H8>N@FWH
M$^/()YY=M8+.T3.3U$OD)4#JC!67ZC:K-,M:C._9R>0L>^E7\MDI1,Q960PU
M$)=@,T$_TCX(ZP>QM(%;')<G)+(O.*L'0$4/#_VJ]K7Q'@&SM/AMNM5'[W<X
MH^L)ZPW(MO"<$L"*K/#[SY/GEE04V:3+W4A[%6=1:)S+[J00=$U\ZVZ@LL'"
M93[&T)NT]GV904VGSA++3XS>,)[4#(KF>&Z?>"1=GW;\PY'D9/! Q8#LT(M?
MV_-<]M4<?_<@M*C2=OFS>W0Q+H8.,C"QU&UXM1S)%7[=R;5RE_.+B#-.F5>R
MCKHB [Q6&_Y;6. *MTQ-4T!B5%<17%6OKZ>=);([B<KA_W@ 5#06\%YHO1X;
M1$?8Y ?Z^IW"^H\HVE':3EJO\T)!!_C?VU'ZPEWOYKQ.:$KT=]KBK/GX:C9M
M\B'C4^R?N1:HB^ROIU;SQ<NXV'']V=1;%'/J2WT\7'<#!]-KZ$DE,D4">5Y.
M^U'Y5N? +QZUHLNHG*L29W%R04C.MP/RE3W[%(8]WAQ"PU+\1FUE]%?O,L@C
M:YB,WOX?BI)ERB*D-*-PB=R-P,.%JY6$W0NI+X-3Y/IA\Q1B_V_5$PU#%$67
M"3*&"A2\I7Y+R/[ALP)D41];H.K_PWU%I-J>KF,[6"#98?XF4?"EH%-,@5Z;
MIB(U^STTG>="9X4;5_U297HY."7,S=;J5&5CQ;8>(YR:[U(9#N^@L&B#4,4*
MOTINT+IWFS!PQE.(J^UR[\7W)GT*X?[>K2I= :4C-X,?^_C+S<D/SV'M  4
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MA2RO>"=*@(UF"PRQJ@7G\F_D/"UMISA")18.?L)$Y!SH&:?B8,5#RLIF:+\
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MDV?*[F(<I2&0IPB?Z*,#$24.I/R=;\<CYZ$NR4_>?VAA(3\H_,S!VMSW<B[
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M?16;N;R-K"R(X*N35#GOMW>^@RR]RUL^M3'1_M-3'G4&A-JLKKE[V6G1_L<
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MMN$/86D5]W(CK"8ZHC^RF>7/,CV]]2_H$$MNH5S+FP=+'#UVMC(<-M]_>3=
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M:-B>#WF+,W6CA%.(!&^.AE2I&)PC?W8%?W=,77UU,!@V]J*UQ@W2XSIC#>,
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M&)4>8O*4"BB-V" ("%%16C$B(D%#HB*$/J4(* A1$:,"1MHH1B(0H*0QTD9
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ML00#> T\OD^1H!_&QR;UKA,F$O:!&?V(1/0ZX4?#D_D@XA!NN7B/4">/+EX
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M?OD*>^7(,WI&6Y4?'%P9X'<],.DZJPC\O^1E+/^3,.!?G_F&0KKT25JD'_W
MWW^_AJB774.$J<_!\E<7B#/J7&;6;\%,HVI(P\N.$B.Y?Z-5.W.,/N]@X AD
M17K-DL;PNT&].5C[[6,SM*NLKQ[[9(.+(7.P!UOJ1]-6[L?6UD]M^/^\'PH-
M$RC-:+[]M+'+0/YA\#=A8[4;I _TWM$9=&@_MC&0CY,+;EST>Q>>5M7=EV8T
MN_DE;:;P4U.\69JDA),7[&:=DWPQBN9-PD"+P7J13*$.CB+=$ZM)\KS86"E$
MSR%NZ-R;"N0+W-).AI+XR*O'ST>&3#HF8JQYDY.E9$)%1DUC8WIQ9=F502SH
M^VB/<2R+E\@:UGW&BJ,N8RH(@ZM\], P(;(ZTR"9J<3_8!ZEQ_99)52ZX3[K
M]LC7<M']MPTF*X'=1>^[?'J8%A51H^;?.M75N.F "V*&S"882&CQN3D?;W)&
M-QN]:IW&HWK3T!=6O;<FC&_B/+UV)B7P1F=P6G6>\/!&QY%5\I./=W9Q)'Z
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M%,Y\\XP13W>:7W,,#U7$B2%I.MU2J0ERIB<EC]'ZI"H/-.8S0RU'A^S:@49
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MLSU7/M[A*@!+3MXA8 %T# V,?D4J]A];0!_!+D?+B2^ AP2%*G7*!#6 FEQ
MW"IV$HYEL!TI2=!VW#*QJS#BTCTP0JA>F[-6F%/XQ!88J46;"NF7C<>,3,<0
MO-@7@6$A_K3SFG)7P^=@,:Q5D/:(SPKPF,A1O*T%TJ&1GY "^B@ZQN"M_-]$
M6PGNX$5@O'\U"8X< +Z-BOR%I'KJ">&A20@!K"[WV=!9N4B\H?-<,&)1;U!F
M1DKODIZ=PHR1LJ/@O0FOME(EEWW E^QE](+#KY#&YVYEWX/:'3U\<\:=R],\
M%EG'3%T_XCF4ZN1<:IU47NQMV+/NX1]_B.^!T9A:4J+Z'&SY9I2J:#O!![<8
M>M?[BR1S:A73E^^,J:G4Q%U& ,E!WSB"*!L!_"H=M1.92.LXQY$[$MC=1S8F
MJ@\A5MSC,NW#PGC;SPY6I9?;LR=F,A(@.($DY%PJ@);92I,)I(V]5(XHK:/S
ML''6DKH;O<O H0*POM9]EER=O+!*C8AXP64&\PX)UR>2C""+CLKUH&-5)[2P
M@Q_MU#(&K?$XXES8!75]]NS-XCMK.7(G+UX.SQM1,^].3N)Y*/1X[RJN'[#K
MWZ/XA]8)P"'?5,7H]X9X7>MD3QA8,AW9(?;-!R<$U#IL''9II:Y8$Z."A+2'
M=#3!2('QID8VT;2TI5('W.N,'L$*M?NJQW;65_[Z- 3GTSEU,4IO3ROJ)%_A
M:HMIHA+VT+.V<&T_$CR@-U":2=9(*E$F(A6H&;T!C*'E?>+4XE2,>I5 0]Y+
M;,V%L>O!Z.WM8Q]"IJSZ.TP;=]--L4MZ-%#VA?_2=INVL?%>X1<[X5GL)UG1
M7F9L8]=6IN3KSBIIG<S>U#!RH,-L^XX!+1LEF[U%5QSS>T0CC>24WLXWK=T;
M3V\^[7]M[955O1[>^SW($[^)K .[R6*UA9"\X1.(JV-<Q'PF223Y1ITD&(HP
M^(MN99G;D?65VXN?DUV+N:=+1VXDZZ=?_&,4T@4S;>)\*\J+7&)]X!TAXX5K
MV\W%+IJ#A]_K:"W^_>-!RBR'/?7X9)=385/Q*.IH7N8@&)=?%OOZZ<%'GLOV
M;'HV^TP1Y77[N<O0'"S7():PE7V+JX(OXC_1R0<L7C$92^N(:UH/N!K41=8>
M<7H(R%WUL W\6OT@@N^NP@.>^^EF;W1]=(EGI*[FK\IS4; ]1))=O*^=@YUX
MS3J)O5Q!9[.2W'R0[=*,ANQVV8^-1VB$-_M7ZVQI-QO3-[-Z4N:M4A5Q(37@
MK"FCT_FQSTBE<=KJ++IZL&<VDZ'>F8E.M28R?D8\#^Y51NN^/G-D^XVCVTY5
M*J>H+]AAFKNQ,JACF+'IYFT?W0L5SPK\UN<1W-87W,ZS[AB8N>VK0+3E,^)O
MNP@0<;<]^-A5QS=V<O E9OF4PIU*<HZ;&\Z8\EP6IYZ!G&-:5ZVFD+<YZ1SZ
M_>,SS7UYC@KIG_#XQZ&/O)8/S@.^Q))@B:*A>&)D]L7GL3F8683D+>O;8Y(N
MV#4',^5*.N9@WVZK2MC0ZQR#MI YF&Q\:*DQ<P=';E0"^*D'H/3XC3<]!& 8
MK]17J;D\T?@E>]>CK9Q%Q3LW'=]]_]Q)7[&-^[PG!9C[%N)XO*^TXR=#CP-O
MR\@K?W#1LBM!A3F8V\'MT9#R!T,H"N4L12ON2:R9G?9B_0IW\:Q,6&\)78/T
M-?:_)H=^Q%8D) ;PTK;K.RAY3%BPO32BY1Z1TZMZ]<G=O.$+3K5<OD6MOWY(
MF9>C(3E1>8-'Z_J8VZC@M?B/KE#^WQT^SL[!+K.^GMG2-[V>@YG2^I48R.>*
MKY7-P48#;\S!AL1[P![L6Z1X>;Y;6>L<C/>(V*9&0U)EPT/^T^<3"T:T"'30
MZP5S?#118;QDL F+'--QSR9_9<P<&(6(^?,X-;VMW")]B H^0I0W!QL6P(C&
MO QQ>A=2THZ9\DC"$%@_H&M3TL\AQHKEC.R4N1TS9!:5+BHDGJH ">WC<OK*
MJ/&3/139!-$5&]SR?(X(0_"+T20M 8N[52/1J\%K*YO#PN[5XG#+C113.49G
MV+>N>ZQ0O1GE\C^7I?GE/WKRI@G1JP'2?_";ES#)2'"3]WOW/@:IWO&A\I!N
M!J2:TL$L9K8]L>-$4_\T'&64O2 ;7:5E_Q)Y+2U]>XNU#9'H_D^5;[2@)=E/
M/ *IQ0Q*__/HP]?ZIB\+7:M*YV#29J5TK1:/4WUCP9-SA=NF/^@WG?*42_-S
MW:AGI[Q;NIN._=02S1C\G>=K(M-)=L!7RYJV*I0=\ 5*'%^1OMH!?9*$(5G
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M#UMS[(=TUND?84K_C,*^$2E WJ.I<S82,B*IMB#CCLS\.;'M1H!P&B60[^U
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M(>T]L/\J//'_.58!<#XJ26J)U^*HRP=SM0$%QL70=2]!Z2):[ I,9\_<7 W
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MGMD56-+()LC0ZB[XGO)C%^64W/Q5)1A!3Z :M9KPOU*P*[#U<;'KRD3V3J>
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M_M*B">[7^-F5 U+KC:<&^&A-^U4$ X-B"?.T>-'"<POZ$V<J*+C$]8'*C2D
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M+FAT;5!+ 0(4 Q0    ( *F ;5ELWDH.=04  (P2   <              "
M =8= @!E83 R,C U,C<P,65X,S)?:6UM=6-E;&PN:'1M4$L! A0#%     @
MJ8!M60H'OEKJ%   CNT  !$              ( !A2," &EC8V,M,C R-# Y
M,S N>'-D4$L! A0#%     @ J8!M63#,<[,%#@  :J4  !4
M ( !GC@" &EC8V,M,C R-# Y,S!?8V%L+GAM;%!+ 0(4 Q0    ( *F ;5F.
M;%R:FDT  !#B!  5              "  =9& @!I8V-C+3(P,C0P.3,P7V1E
M9BYX;6Q02P$"% ,4    " "I@&U9J!)*((^N   0MP@ %0
M@ &CE ( :6-C8RTR,#(T,#DS,%]L86(N>&UL4$L! A0#%     @ J8!M68(F
M@?B430  31T% !4              ( !94,# &EC8V,M,C R-# Y,S!?<')E
M+GAM;%!+ 0(4 Q0    ( *F ;5D7@E-A(HH! -WK 0 -              "
M 2R1 P!I;6%G95\P,#$N:G!G4$L! A0#%     @ J8!M64$5)LU+40$ -*\!
M  T              ( !>1L% &EM86=E7S P,BYJ<&=02P4&      H "@"=
) @  [VP&

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>ea0220527-10q_immucell_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iccc="http://immucell.com/20240930"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="iccc-20240930.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <instant>2024-10-30</instant>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iccc:NisinDrugSubstanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:GorhamSavingsBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:GorhamSavingsBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:GorhamSavingsBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:MaineTechnologyInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:MaineTechnologyInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2027-09-30</instant>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:MaineTechnologyInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2027-09-30</startDate>
            <endDate>2027-09-30</endDate>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:GorhamSavingsBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:GorhamSavingsBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:MaineTechnologyInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:MaineTechnologyInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:GorhamSavingsBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-30</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:MortgageBankingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iccc:BankLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:SubtotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iccc:MrBrighamMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iccc:MrBrighamMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="c180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <instant>2024-01-01</instant>
        </period>
    </context>
    <context id="c181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iccc:MrBrighamMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:ReTainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <instant>2019-09-12</instant>
        </period>
    </context>
    <context id="c184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-01</endDate>
        </period>
    </context>
    <context id="c187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-31</startDate>
            <endDate>2025-07-31</endDate>
        </period>
    </context>
    <context id="c188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="c190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="c191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <startDate>2016-02-01</startDate>
            <endDate>2016-02-29</endDate>
        </period>
    </context>
    <context id="c192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <instant>2016-02-29</instant>
        </period>
    </context>
    <context id="c193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-10-01</startDate>
            <endDate>2016-10-31</endDate>
        </period>
    </context>
    <context id="c194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-10-31</instant>
        </period>
    </context>
    <context id="c195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <startDate>2017-07-01</startDate>
            <endDate>2017-07-31</endDate>
        </period>
    </context>
    <context id="c196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <instant>2017-07-31</instant>
        </period>
    </context>
    <context id="c197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="c199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="c200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="c201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="c202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="c203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iccc:CommonStockIssuancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-09</startDate>
            <endDate>2024-04-09</endDate>
        </period>
    </context>
    <context id="c204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <instant>2024-04-09</instant>
        </period>
    </context>
    <context id="c205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <startDate>2024-04-09</startDate>
            <endDate>2024-04-09</endDate>
        </period>
    </context>
    <context id="c206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iccc:ATMAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">iccc:AcquiringPersonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-14</instant>
        </period>
    </context>
    <context id="c223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-14</instant>
        </period>
    </context>
    <context id="c224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-10</instant>
        </period>
    </context>
    <context id="c225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-10</instant>
        </period>
    </context>
    <context id="c226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">iccc:OtherStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">iccc:OtherStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">iccc:OtherStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">iccc:OtherStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:FirstDefenseProductLineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:FirstDefenseProductLineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:FirstDefenseProductLineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:FirstDefenseProductLineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:FirstDefenseProductLineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:FirstDefenseProductLineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:OtherAnimalHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:OtherAnimalHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:OtherAnimalHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:OtherAnimalHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:OtherAnimalHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:OtherAnimalHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">iccc:FederalGeneralBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">iccc:FederalGeneralBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">iccc:StateTaxCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">iccc:StateTaxCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="c268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:ScoursMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:MastitisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:ScoursMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:MastitisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:ScoursMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:MastitisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:ScoursMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:MastitisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:ScoursMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:MastitisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:ScoursMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:MastitisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:ScoursMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:MastitisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:ScoursMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:MastitisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:ScoursMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:MastitisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:ScoursMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:MastitisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iccc:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iccc:EmployeeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">iccc:ATMAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-10-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:DocumentType contextRef="c0" id="ixv-13825">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c0" id="ixv-13826">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c0" id="ixv-13827">2024-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0" id="ixv-13828">2024</dei:DocumentFiscalYearFocus>
    <dei:EntityFileNumber contextRef="c0" id="ixv-44">001-12934</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-68">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c0" id="ixv-72">01-0382980</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c0" id="ixv-13829">56 Evergreen Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c0" id="ixv-13830">Portland</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c0" id="ixv-13831">ME</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c0" id="ixv-91">04103</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c0" id="ixv-13832">(207)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c0" id="ixv-13833">878-2770</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c0" id="ixv-130">Common Stock, $0.10 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0" id="ixv-134">ICCC</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0" id="ixv-13834">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c0" id="ixv-13835">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0" id="ixv-13836">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0" id="ixv-166">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c0" id="ixv-173">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-181">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c0" id="ixv-13837">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c1"
      decimals="INF"
      id="ixv-13838"
      unitRef="shares">8911589</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="0" id="ixv-13839" unitRef="usd">3808633</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="0" id="ixv-13840" unitRef="usd">978741</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c2" decimals="0" id="ixv-13841" unitRef="usd">2307913</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c3" decimals="0" id="ixv-13842" unitRef="usd">2185383</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c2" decimals="0" id="ixv-13843" unitRef="usd">7460452</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c3" decimals="0" id="ixv-13844" unitRef="usd">7811841</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c2" decimals="0" id="ixv-13845" unitRef="usd">310488</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="0" id="ixv-13846" unitRef="usd">493885</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c2" decimals="0" id="ixv-13847" unitRef="usd">13887486</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="0" id="ixv-13848" unitRef="usd">11469850</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="0" id="ixv-13849" unitRef="usd">25820333</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="0" id="ixv-13850" unitRef="usd">27575683</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c2" decimals="0" id="ixv-13851" unitRef="usd">4592718</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="0" id="ixv-13852" unitRef="usd">4571149</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill contextRef="c2" decimals="0" id="ixv-13853" unitRef="usd">95557</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c3" decimals="0" id="ixv-13854" unitRef="usd">95557</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c2" decimals="0" id="ixv-13855" unitRef="usd">23880</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c3" decimals="0" id="ixv-13856" unitRef="usd">38208</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:OtherAssetsNoncurrent contextRef="c2" decimals="0" id="ixv-13857" unitRef="usd">28899</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c3" decimals="0" id="ixv-13858" unitRef="usd">57655</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c2" decimals="0" id="ixv-13859" unitRef="usd">44448873</us-gaap:Assets>
    <us-gaap:Assets contextRef="c3" decimals="0" id="ixv-13860" unitRef="usd">43808102</us-gaap:Assets>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent contextRef="c2" decimals="0" id="ixv-13861" unitRef="usd">1479058</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent contextRef="c3" decimals="0" id="ixv-13862" unitRef="usd">1428807</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c2" decimals="0" id="ixv-13863" unitRef="usd">482244</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c3" decimals="0" id="ixv-13864" unitRef="usd">644276</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c2" decimals="0" id="ixv-13865" unitRef="usd">2504535</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c3" decimals="0" id="ixv-13866" unitRef="usd">2124337</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c2" decimals="0" id="ixv-13867" unitRef="usd">4465837</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="0" id="ixv-13868" unitRef="usd">4197420</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="c2" decimals="0" id="ixv-13869" unitRef="usd">9422961</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="c3" decimals="0" id="ixv-13870" unitRef="usd">10540496</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c2" decimals="0" id="ixv-13871" unitRef="usd">4148404</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c3" decimals="0" id="ixv-13872" unitRef="usd">4077109</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c2" decimals="0" id="ixv-13873" unitRef="usd">13571365</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c3" decimals="0" id="ixv-13874" unitRef="usd">14617605</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c2" decimals="0" id="ixv-13875" unitRef="usd">18037202</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c3" decimals="0" id="ixv-13876" unitRef="usd">18815025</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c2"
      decimals="2"
      id="ixv-13877"
      unitRef="usdPershares">0.1</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c3"
      decimals="2"
      id="ixv-13878"
      unitRef="usdPershares">0.1</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c2"
      decimals="0"
      id="ixv-13879"
      unitRef="shares">15000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c3"
      decimals="0"
      id="ixv-13880"
      unitRef="shares">15000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c2"
      decimals="0"
      id="ixv-13881"
      unitRef="shares">8896398</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="c3"
      decimals="0"
      id="ixv-13882"
      unitRef="shares">7814165</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c2"
      decimals="0"
      id="ixv-13883"
      unitRef="shares">8833097</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c3"
      decimals="0"
      id="ixv-13884"
      unitRef="shares">7750864</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c2" decimals="0" id="ixv-13885" unitRef="usd">889641</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c3" decimals="0" id="ixv-13886" unitRef="usd">781417</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c2" decimals="0" id="ixv-13887" unitRef="usd">40338793</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c3" decimals="0" id="ixv-13888" unitRef="usd">36357239</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c2" decimals="0" id="ixv-13889" unitRef="usd">-14678281</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="0" id="ixv-13890" unitRef="usd">-12007097</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c2"
      decimals="0"
      id="ixv-13891"
      unitRef="shares">63301</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c3"
      decimals="0"
      id="ixv-13892"
      unitRef="shares">63301</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue contextRef="c2" decimals="0" id="ixv-13893" unitRef="usd">138482</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue contextRef="c3" decimals="0" id="ixv-13894" unitRef="usd">138482</us-gaap:TreasuryStockCommonValue>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="0" id="ixv-13895" unitRef="usd">26411671</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="0" id="ixv-13896" unitRef="usd">24993077</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c2" decimals="0" id="ixv-13897" unitRef="usd">44448873</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="0" id="ixv-13898" unitRef="usd">43808102</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c4" decimals="0" id="ixv-13899" unitRef="usd">6011573</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c5" decimals="0" id="ixv-13900" unitRef="usd">5396500</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c0" decimals="0" id="ixv-13901" unitRef="usd">18742040</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c6" decimals="0" id="ixv-13902" unitRef="usd">12375708</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c4" decimals="0" id="ixv-13903" unitRef="usd">4428019</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c5" decimals="0" id="ixv-13904" unitRef="usd">4129619</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c0" decimals="0" id="ixv-13905" unitRef="usd">13632642</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c6" decimals="0" id="ixv-13906" unitRef="usd">9764164</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit contextRef="c4" decimals="0" id="ixv-13907" unitRef="usd">1583554</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c5" decimals="0" id="ixv-13908" unitRef="usd">1266881</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c0" decimals="0" id="ixv-13909" unitRef="usd">5109398</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c6" decimals="0" id="ixv-13910" unitRef="usd">2611544</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c4" decimals="0" id="ixv-13911" unitRef="usd">786136</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c5" decimals="0" id="ixv-13912" unitRef="usd">1118489</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="0" id="ixv-13913" unitRef="usd">3079189</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c6" decimals="0" id="ixv-13914" unitRef="usd">3328397</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c4" decimals="0" id="ixv-13915" unitRef="usd">844045</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c5" decimals="0" id="ixv-13916" unitRef="usd">817486</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c0" decimals="0" id="ixv-13917" unitRef="usd">2629925</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c6" decimals="0" id="ixv-13918" unitRef="usd">2416701</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c4" decimals="0" id="ixv-13919" unitRef="usd">528267</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c5" decimals="0" id="ixv-13920" unitRef="usd">514952</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="0" id="ixv-13921" unitRef="usd">1661838</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c6" decimals="0" id="ixv-13922" unitRef="usd">1611026</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c4" decimals="0" id="ixv-13923" unitRef="usd">2158448</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c5" decimals="0" id="ixv-13924" unitRef="usd">2450927</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="0" id="ixv-13925" unitRef="usd">7370952</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c6" decimals="0" id="ixv-13926" unitRef="usd">7356124</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c4" decimals="0" id="ixv-13927" unitRef="usd">-574894</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c5" decimals="0" id="ixv-13928" unitRef="usd">-1184046</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="0" id="ixv-13929" unitRef="usd">-2261554</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c6" decimals="0" id="ixv-13930" unitRef="usd">-4744580</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense contextRef="c4" decimals="0" id="ixv-13931" unitRef="usd">-125456</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c5" decimals="0" id="ixv-13932" unitRef="usd">244275</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c0" decimals="0" id="ixv-13933" unitRef="usd">-405610</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c6" decimals="0" id="ixv-13934" unitRef="usd">113092</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c4" decimals="0" id="ixv-13935" unitRef="usd">-700350</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c5" decimals="0" id="ixv-13936" unitRef="usd">-939771</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c0" decimals="0" id="ixv-13937" unitRef="usd">-2667164</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c6" decimals="0" id="ixv-13938" unitRef="usd">-4631488</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c4" decimals="0" id="ixv-13939" unitRef="usd">1340</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c5" decimals="0" id="ixv-13940" unitRef="usd">229</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c0" decimals="0" id="ixv-13941" unitRef="usd">4020</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c6" decimals="0" id="ixv-13942" unitRef="usd">3279</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c4" decimals="0" id="ixv-13943" unitRef="usd">-701690</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="0" id="ixv-13944" unitRef="usd">-940000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" id="ixv-13945" unitRef="usd">-2671184</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="0" id="ixv-13946" unitRef="usd">-4634767</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c4"
      decimals="0"
      id="ixv-13947"
      unitRef="shares">8164423</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c5"
      decimals="0"
      id="ixv-13948"
      unitRef="shares">7746864</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="0"
      id="ixv-13949"
      unitRef="shares">7908425</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c6"
      decimals="0"
      id="ixv-13950"
      unitRef="shares">7746864</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c4"
      decimals="2"
      id="ixv-13951"
      unitRef="usdPershares">-0.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c5"
      decimals="2"
      id="ixv-13952"
      unitRef="usdPershares">-0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="2"
      id="ixv-13953"
      unitRef="usdPershares">-0.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c6"
      decimals="2"
      id="ixv-13954"
      unitRef="usdPershares">-0.6</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c4"
      decimals="0"
      id="ixv-13955"
      unitRef="shares">8164423</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c5"
      decimals="0"
      id="ixv-13956"
      unitRef="shares">7746864</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="0"
      id="ixv-13957"
      unitRef="shares">7908425</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c6"
      decimals="0"
      id="ixv-13958"
      unitRef="shares">7746864</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c4"
      decimals="2"
      id="ixv-13959"
      unitRef="usdPershares">-0.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c5"
      decimals="2"
      id="ixv-13960"
      unitRef="usdPershares">-0.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="ixv-13961"
      unitRef="usdPershares">-0.34</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c6"
      decimals="2"
      id="ixv-13962"
      unitRef="usdPershares">-0.6</us-gaap:EarningsPerShareDiluted>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c7"
      decimals="INF"
      id="ixv-13963"
      unitRef="shares">7896381</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c7" decimals="0" id="ixv-13964" unitRef="usd">789639</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c8" decimals="0" id="ixv-13965" unitRef="usd">36780897</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c9" decimals="0" id="ixv-13966" unitRef="usd">-13976591</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c10"
      decimals="INF"
      id="ixv-13967"
      unitRef="shares">63301</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c10" decimals="0" id="ixv-13968" unitRef="usd">-138482</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c11" decimals="0" id="ixv-13969" unitRef="usd">23455463</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c14" decimals="0" id="ixv-13970" unitRef="usd">-701690</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c4" decimals="0" id="ixv-13971" unitRef="usd">-701690</us-gaap:NetIncomeLoss>
    <iccc:OfferingCostsOnFollowUpOfferingOfCommonStock contextRef="c4" decimals="0" id="ixv-13972" unitRef="usd">110838</iccc:OfferingCostsOnFollowUpOfferingOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c12"
      decimals="INF"
      id="ixv-13973"
      unitRef="shares">1000017</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c12" decimals="0" id="ixv-13974" unitRef="usd">100002</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c13" decimals="0" id="ixv-13975" unitRef="usd">3480339</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c4" decimals="0" id="ixv-13976" unitRef="usd">3580341</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c13" decimals="0" id="ixv-13977" unitRef="usd">77557</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c4" decimals="0" id="ixv-13978" unitRef="usd">77557</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c16"
      decimals="INF"
      id="ixv-13979"
      unitRef="shares">8896398</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c16" decimals="0" id="ixv-13980" unitRef="usd">889641</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c17" decimals="0" id="ixv-13981" unitRef="usd">40338793</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c18" decimals="0" id="ixv-13982" unitRef="usd">-14678281</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c19"
      decimals="INF"
      id="ixv-13983"
      unitRef="shares">63301</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c19" decimals="0" id="ixv-13984" unitRef="usd">-138482</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="0" id="ixv-13985" unitRef="usd">26411671</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20"
      decimals="INF"
      id="ixv-13986"
      unitRef="shares">7814165</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c20" decimals="0" id="ixv-13987" unitRef="usd">781417</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c21" decimals="0" id="ixv-13988" unitRef="usd">36150137</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c22" decimals="0" id="ixv-13989" unitRef="usd">-9927266</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c23"
      decimals="INF"
      id="ixv-13990"
      unitRef="shares">67301</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c23" decimals="0" id="ixv-13991" unitRef="usd">-147233</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c24" decimals="0" id="ixv-13992" unitRef="usd">26857055</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c27" decimals="0" id="ixv-13993" unitRef="usd">-940000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="0" id="ixv-13994" unitRef="usd">-940000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c26" decimals="0" id="ixv-13995" unitRef="usd">96434</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c5" decimals="0" id="ixv-13996" unitRef="usd">96434</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c29"
      decimals="INF"
      id="ixv-13997"
      unitRef="shares">7814165</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c29" decimals="0" id="ixv-13998" unitRef="usd">781417</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c30" decimals="0" id="ixv-13999" unitRef="usd">36246571</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c31" decimals="0" id="ixv-14000" unitRef="usd">-10867266</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c32"
      decimals="INF"
      id="ixv-14001"
      unitRef="shares">67301</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c32" decimals="0" id="ixv-14002" unitRef="usd">-147233</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c33" decimals="0" id="ixv-14003" unitRef="usd">26013489</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c34"
      decimals="INF"
      id="ixv-14004"
      unitRef="shares">7814165</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c34" decimals="0" id="ixv-14005" unitRef="usd">781417</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c35" decimals="0" id="ixv-14006" unitRef="usd">36357239</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c36" decimals="0" id="ixv-14007" unitRef="usd">-12007097</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c37"
      decimals="INF"
      id="ixv-14008"
      unitRef="shares">63301</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c37" decimals="0" id="ixv-14009" unitRef="usd">-138482</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="0" id="ixv-14010" unitRef="usd">24993077</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c40" decimals="0" id="ixv-14011" unitRef="usd">-2671184</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" id="ixv-14012" unitRef="usd">-2671184</us-gaap:NetIncomeLoss>
    <iccc:OfferingCostsOnFollowUpOfferingOfCommonStock contextRef="c0" decimals="0" id="ixv-14013" unitRef="usd">275640</iccc:OfferingCostsOnFollowUpOfferingOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c38"
      decimals="INF"
      id="ixv-14014"
      unitRef="shares">1082233</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c38" decimals="0" id="ixv-14015" unitRef="usd">108224</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c39" decimals="0" id="ixv-14016" unitRef="usd">3724866</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c0" decimals="0" id="ixv-14017" unitRef="usd">3833090</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c39" decimals="0" id="ixv-14018" unitRef="usd">256688</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c0" decimals="0" id="ixv-14019" unitRef="usd">256688</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c16"
      decimals="INF"
      id="ixv-14020"
      unitRef="shares">8896398</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c16" decimals="0" id="ixv-14021" unitRef="usd">889641</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c17" decimals="0" id="ixv-14022" unitRef="usd">40338793</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c18" decimals="0" id="ixv-14023" unitRef="usd">-14678281</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c19"
      decimals="INF"
      id="ixv-14024"
      unitRef="shares">63301</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c19" decimals="0" id="ixv-14025" unitRef="usd">-138482</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="0" id="ixv-14026" unitRef="usd">26411671</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c42"
      decimals="INF"
      id="ixv-14027"
      unitRef="shares">7814165</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c42" decimals="0" id="ixv-14028" unitRef="usd">781417</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c43" decimals="0" id="ixv-14029" unitRef="usd">35978364</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c44" decimals="0" id="ixv-14030" unitRef="usd">-6232499</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c45"
      decimals="INF"
      id="ixv-14031"
      unitRef="shares">67301</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c45" decimals="0" id="ixv-14032" unitRef="usd">-147233</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c46" decimals="0" id="ixv-14033" unitRef="usd">30380049</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c49" decimals="0" id="ixv-14034" unitRef="usd">-4634767</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="0" id="ixv-14035" unitRef="usd">-4634767</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c48" decimals="0" id="ixv-14036" unitRef="usd">268207</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c6" decimals="0" id="ixv-14037" unitRef="usd">268207</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c29"
      decimals="INF"
      id="ixv-14038"
      unitRef="shares">7814165</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c29" decimals="0" id="ixv-14039" unitRef="usd">781417</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c30" decimals="0" id="ixv-14040" unitRef="usd">36246571</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c31" decimals="0" id="ixv-14041" unitRef="usd">-10867266</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c32"
      decimals="INF"
      id="ixv-14042"
      unitRef="shares">67301</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c32" decimals="0" id="ixv-14043" unitRef="usd">-147233</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c33" decimals="0" id="ixv-14044" unitRef="usd">26013489</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" id="ixv-14045" unitRef="usd">-2671184</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="0" id="ixv-14046" unitRef="usd">-4634767</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation contextRef="c0" decimals="0" id="ixv-14047" unitRef="usd">1999005</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c6" decimals="0" id="ixv-14048" unitRef="usd">2027788</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c0" decimals="0" id="ixv-14049" unitRef="usd">14328</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c6" decimals="0" id="ixv-14050" unitRef="usd">14328</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c0" decimals="0" id="ixv-14051" unitRef="usd">31859</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c6" decimals="0" id="ixv-14052" unitRef="usd">12525</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="0" id="ixv-14053" unitRef="usd">256688</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c6" decimals="0" id="ixv-14054" unitRef="usd">268207</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c0" decimals="0" id="ixv-14055" unitRef="usd">-14557</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c6" decimals="0" id="ixv-14056" unitRef="usd">-8099</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c0" decimals="0" id="ixv-14057" unitRef="usd">112306</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c6" decimals="0" id="ixv-14058" unitRef="usd">-95881</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c0" decimals="0" id="ixv-14059" unitRef="usd">122530</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c6" decimals="0" id="ixv-14060" unitRef="usd">105985</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c0" decimals="0" id="ixv-14061" unitRef="usd">-351389</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c6" decimals="0" id="ixv-14062" unitRef="usd">1347124</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c0" decimals="0" id="ixv-14063" unitRef="usd">-183397</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c6" decimals="0" id="ixv-14064" unitRef="usd">201211</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c0" decimals="0" id="ixv-14065" unitRef="usd">-28756</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c6" decimals="0" id="ixv-14066" unitRef="usd">-6587</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c0" decimals="0" id="ixv-14067" unitRef="usd">386995</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c6" decimals="0" id="ixv-14068" unitRef="usd">-95493</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="0" id="ixv-14069" unitRef="usd">360954</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c6" decimals="0" id="ixv-14070" unitRef="usd">-3951165</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c0" decimals="0" id="ixv-14071" unitRef="usd">269509</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c6" decimals="0" id="ixv-14072" unitRef="usd">1811169</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets contextRef="c6" decimals="0" id="ixv-14073" unitRef="usd">115127</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c0" decimals="0" id="ixv-14074" unitRef="usd">4500</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c6" decimals="0" id="ixv-14075" unitRef="usd">2474</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="0" id="ixv-14076" unitRef="usd">-265009</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c6" decimals="0" id="ixv-14077" unitRef="usd">-1923822</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c6" decimals="0" id="ixv-14078" unitRef="usd">3000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c0" decimals="0" id="ixv-14079" unitRef="usd">3833090</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="c6" decimals="0" id="ixv-14080" unitRef="usd">2000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit contextRef="c6" decimals="0" id="ixv-14081" unitRef="usd">2000000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfDebt contextRef="c0" decimals="0" id="ixv-14082" unitRef="usd">1094106</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt contextRef="c6" decimals="0" id="ixv-14083" unitRef="usd">829015</us-gaap:RepaymentsOfDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c0" decimals="0" id="ixv-14084" unitRef="usd">5037</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c6" decimals="0" id="ixv-14085" unitRef="usd">98098</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="0" id="ixv-14086" unitRef="usd">2733947</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c6" decimals="0" id="ixv-14087" unitRef="usd">2072887</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c0" decimals="0" id="ixv-14088" unitRef="usd">2829892</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c6" decimals="0" id="ixv-14089" unitRef="usd">-3802100</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="0" id="ixv-14090" unitRef="usd">978741</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c46" decimals="0" id="ixv-14091" unitRef="usd">5791562</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="0" id="ixv-14092" unitRef="usd">3808633</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c33" decimals="0" id="ixv-14093" unitRef="usd">1989462</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaid contextRef="c0" decimals="0" id="ixv-14094" unitRef="usd">5905</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c6" decimals="0" id="ixv-14095" unitRef="usd">7205</us-gaap:IncomeTaxesPaid>
    <us-gaap:InterestPaidNet contextRef="c0" decimals="0" id="ixv-14096" unitRef="usd">404077</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c6" decimals="0" id="ixv-14097" unitRef="usd">303752</us-gaap:InterestPaidNet>
    <iccc:ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses contextRef="c0" decimals="0" id="ixv-14098" unitRef="usd">6797</iccc:ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses>
    <iccc:ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses contextRef="c6" decimals="0" id="ixv-14099" unitRef="usd">56441</iccc:ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses>
    <iccc:DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability contextRef="c0" decimals="0" id="ixv-14100" unitRef="usd">103115</iccc:DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability>
    <iccc:DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability contextRef="c6" decimals="0" id="ixv-14101" unitRef="usd">2090298</iccc:DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability>
    <us-gaap:NatureOfOperations contextRef="c0" id="ixv-2967">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;1. BUSINESS OPERATIONS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;ImmuCell Corporation (the &#x201c;Company&#x201d;,
&#x201c;we&#x201d;, &#x201c;us&#x201d;, &#x201c;our&#x201d;) was originally incorporated in Maine in 1982 and reincorporated in Delaware in
1987, in conjunction with an initial public offering of common stock. We are an animal health company whose purpose is to create scientifically
proven and practical products that improve the health and productivity of dairy and beef cattle. We focus on the two most critical stages
of dairy productivity, those being the first 30 days of life and the first 30 days of lactation. Our concentrated colostrum and purified
Nisin technologies offer unique animal health solutions during these periods when immunity is at its most vulnerable. As disclosed in
Note 17, &#x201c;Segment Information&#x201d;, one of our business segments is dedicated to Scours and the other is focused on Mastitis.
We manufacture and market the &lt;b&gt;First Defense&lt;sup&gt;&#xae;&lt;/sup&gt;&lt;/b&gt; product line, providing &lt;b&gt;Immediate Immunity&#x2122;&lt;/b&gt; to prevent
scours in newborn dairy and beef calves. We have expanded this line into four different products with formulations targeting &lt;i&gt;E. coli&lt;/i&gt;,
coronavirus and rotavirus pathogens. We are also in the late stages of developing &lt;b&gt;Re-Tain&lt;sup&gt;&#xae;&lt;/sup&gt;&lt;/b&gt;, a treatment for lactating
dairy cows with subclinical mastitis. Mastitis is the most significant cause of economic loss to the dairy industry. These products help
reduce the need to use traditional antibiotics in food producing animals. We are subject to certain risks including dependence on key
individuals and third-party providers of critical goods and services, competition from other larger companies, the successful sale of
existing products and the development of new viable products with appropriate regulatory approvals, where applicable. A combination of
the conditions, trends and concerns related to or arising from inflation, rising interest rates and potential recessionary conditions
in the United States and/or internationally, could have a corresponding negative effect on our business and operations. We are experiencing
price increases in key components, supportive services, transportation and other supplies that are causing our costs of goods sold to
increase. We have experienced contamination events from time to time in our production process, beginning in the third quarter of 2022,
as disclosed previously. We implemented a production slowdown during 2023 to remediate this problem, which led to the recognition of lower
sales and gross margin. The last identified contamination event occurred during the first half of April of 2024, and we have been operating
without further contamination events since then and through the date of this filing.&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0" id="ixv-2982">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(a) Basis of Presentation&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;We have prepared the accompanying unaudited financial
statements reflecting all adjustments (which are of a normal recurring nature) that are, in our opinion, necessary in order to ensure
that the financial statements are not misleading. We follow accounting standards set by the Financial Accounting Standards Board (FASB).
The FASB sets Generally Accepted Accounting Principles (GAAP) that we follow to ensure we accurately report our financial condition, results
of operations, earnings per share and cash flows. References to GAAP in these footnotes are to the FASB &lt;i&gt;Accounting Standards Codification&lt;/i&gt;&#x2122;
(Codification). We believe that the disclosures are adequate to ensure that the information presented is not misleading.&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(b) Cash and Cash Equivalents&lt;/b&gt; &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;We consider all highly liquid investment instruments
that mature within three months of their purchase dates to be cash equivalents. Cash equivalents are principally invested in securities
backed by the U.S. government. We hold no cash or cash equivalents in excess of Federal Deposit Insurance Corporation (FDIC) limits of
$250,000 per financial institution per depositor. See Note 3.&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(c) Trade Accounts Receivable&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Accounts receivable are carried at the original
invoice amount less an estimate made for doubtful collection when applicable. Management determines the allowance for doubtful accounts
on a monthly basis by identifying troubled accounts and by using historical experience applied to an aging of accounts and other relevant
factors. Accounts receivable are considered to be past due if a portion of the receivable balance is outstanding for more than 30 days.
Past due accounts receivable are subject to an interest charge. It was not necessary to charge interest on past due accounts during the
nine-month periods ended September 30, 2024 or 2023 because the time past due was not significant, and there was no accrual for such interest
charges as of September 30, 2024 or December 31, 2023. Accounts receivable are written off when deemed uncollectible. No accounts receivable
were written off during the nine-month periods ended September 30, 2024 or 2023. Recoveries of accounts receivable previously written
off are recorded as income when received. No such recoveries were recorded during the nine-month periods ended September 30, 2024 or 2023.
As of September 30, 2024 and December 31, 2023, we determined that no allowance for doubtful accounts was necessary. See Note 4.&lt;/p&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(d) Inventory&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Inventory includes raw materials, work-in-process
and finished goods and is recorded at the lower of cost, on the first-in, first-out method, or net realizable value (determined as the
estimated selling price in the normal course of business, less reasonably predictable costs of completion, disposal and transportation).
Work-in-process and finished goods inventories include materials, labor and manufacturing overhead. At each balance sheet date, we evaluate
our ending inventories for excess quantities and obsolescence. Inventories that we consider excess or obsolete are written down to estimated
net realizable value. Once inventory is written down and a new cost basis is established, it is not written back up. We believe that supplies
and raw materials for the production of our products are available from more than one vendor or farm. Our policy is to maintain more than
one source of supply for the components used in our products when feasible. See Note 5.&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(e) Property, Plant and Equipment, net&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;We depreciate property, plant and equipment on the
straight-line method by charges to operations and costs of goods sold in amounts estimated to expense the cost of the assets from the
date they are first put into service to the end of the estimated useful lives of the assets. The facility we have constructed at 33 Caddie
Lane to produce the Nisin Drug Substance (DS) for &lt;b&gt;Re-Tain&lt;sup&gt;&#xae;&lt;/sup&gt;&lt;/b&gt; (&lt;b&gt;Building 33&lt;/b&gt;) is being depreciated over 39 years
from when a Certificate of Occupancy was issued during the fourth quarter of 2017. We began depreciating the equipment for our Nisin DS
facility when it was placed in service during the third quarter of 2018. Approximately 86% of these assets are being depreciated over
10 years. We began depreciating the leasehold improvements to our new &lt;b&gt;First Defense&lt;sup&gt;&#xae; &lt;/sup&gt;&lt;/b&gt;production facility at 175
Industrial Way (&lt;b&gt;Building 175A&lt;/b&gt;) over the remainder of the 10-year lease term beginning when a Certificate of Occupancy was issued
during the second quarter of 2020. During August of 2022, this lease term was extended to January of 2043 in connection with a new lease
covering additional space at 175 Industrial Way (&lt;b&gt;Building 175B&lt;/b&gt;). As a result, the net book value of these leasehold improvements
as of August 31, 2022 is now being depreciated over the remainder of the extended lease term. Significant repairs to property, plant and
equipment that benefit more than a current period are capitalized and depreciated over their useful lives. Insignificant repairs are expensed
when incurred. See Notes 2(h) and 7 for additional information.&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(f) Operating Leases&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;We account for our real estate leases using a right-of-use
model, which recognizes that at the date of commencement, a lessee has a financial obligation to make lease payments to the lessor for
the right to use the underlying asset during the lease term and recognizes a corresponding right-of-use (ROU) asset related to this right.
ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the future lease payments
over the expected lease term. The ROU asset is also adjusted for any lease prepayments made, lease incentives received and initial direct
costs incurred. For operating leases with lease payments that fluctuate over the lease term, the total lease costs are recognized on a
straight-line basis over the lease term. Our leases, at times, may include options to extend the term of the lease. When it is reasonably
certain that we will exercise the option, we include the impact of the option in the lease term for purposes of determining future lease
payments. For all underlying classes of assets, we made an accounting policy election to not recognize assets or liabilities for leases
with a term of twelve months or less and to account for all components in a lease arrangement as a single combined lease component. Short-term
lease payments are recognized on a straight-line basis. Certain of our lease agreements include variable rent payments, consisting primarily
of amounts paid to the lessor based on cost or consumption, such as maintenance and real estate taxes. These costs are recognized in the
period in which the obligation is incurred. Because our leases do not specify an implicit rate, we use an incremental borrowing rate based
on information available at the lease commencement date to determine the present value of the lease payments. We evaluate our ROU asset
for impairment when events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. See Notes
2(h) and 12 for additional information.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(g) Intangible Assets and Goodwill&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;We amortize intangible assets on the straight-line
method by charges to costs of goods sold in amounts estimated to expense the cost of the assets from the date they are first put into
service to the end of the estimated useful lives of the assets. We have recorded intangible assets related to customer relationships,
non-compete agreements and developed technology, each with defined useful lives. Amounts paid in excess of the fair value of the net assets
(including tax attributes) are recorded as goodwill under the acquisition method of accounting. We assess the impairment of intangible
assets that have indefinite lives (when applicable) and goodwill (at the reporting unit level) on an annual basis (as of December 31&lt;sup&gt;st&lt;/sup&gt;)
and whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. We would record
an impairment charge if such an assessment were to indicate that the fair value of such assets was less than the carrying value. Judgment
is required in determining whether an event has occurred that may impair the value of goodwill or identifiable intangible assets. Factors
that could indicate that an impairment may exist include significant under-performance relative to plan or long-term projections, significant
changes in business strategy and significant negative industry or economic trends. Although we believe intangible assets and goodwill
are properly stated in the accompanying financial statements, changes in strategy or market conditions could significantly impact these
judgments and require an adjustment to the recorded balance in the future. &lt;span style="-sec-ix-hidden: hidden-fact-50"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-51"&gt;No&lt;/span&gt;&lt;/span&gt; goodwill impairments were recorded during the nine-month
periods ended September 30, 2024 or 2023. See Notes 2(h) and 8 for additional information.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"&gt;&lt;b&gt;(h) Valuation of Long-Lived Assets&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;We periodically evaluate our long-lived assets,
consisting principally of property, plant and equipment, operating lease right-of-use asset and amortizable intangible assets, for potential
impairment. In accordance with the applicable accounting guidance for the treatment of long-lived assets, we review the carrying value
of our long-lived assets or asset group that is held and used, including intangible assets subject to amortization, for impairment whenever
events and circumstances indicate that the carrying value of the assets may not be recoverable. Under the held for use approach, the asset
or asset group to be tested for impairment should represent the lowest level for which identifiable cash flows are largely independent
of the cash flows of other groups of assets and liabilities. &lt;span style="-sec-ix-hidden: hidden-fact-52"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-53"&gt;No&lt;/span&gt;&lt;/span&gt; impairment was recognized during the nine-month periods ended September
30, 2024 or 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"&gt;&lt;b&gt;(i) Fair Value Measurements&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;In determining fair value measurements, we follow
the provisions of Codification Topic 820, &lt;i&gt;Fair Value Measurements and Disclosures&lt;/i&gt;. Codification Topic 820 defines fair value,
establishes a framework for measuring fair value under GAAP and enhances disclosures about fair value measurements. The topic provides
a consistent definition of fair value which focuses on an exit price, which is the price that would be received to sell an asset or paid
to transfer a liability in an orderly transaction between market participants at the measurement date. The topic also prioritizes, within
the measurement of fair value, the use of market-based information over entity-specific information and establishes a three-level hierarchy
for fair value measurements based on the nature of inputs used in the valuation of an asset or liability as of the measurement date.
As of September 30, 2024 and December 31, 2023, the carrying amounts of cash and cash equivalents, accounts receivable, inventory, prepaid
expenses and other current assets, other assets, accounts payable and accrued expenses approximate fair value because of their short-term
nature. The amount outstanding under our bank debt facilities is measured at carrying value in our accompanying balance sheets. Our bank
debt facilities are valued using Level 2 inputs. The three-level hierarchy is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.1pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in; text-align: left"&gt;Level 1&lt;/td&gt;
    &lt;td style="text-align: center; width: 0.25in"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;  Pricing inputs are quoted prices available in active
markets for identical assets or liabilities as of the measurement date.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -43.9pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5in; text-align: left"&gt;Level 2&lt;/td&gt;
    &lt;td style="text-align: center; width: 0.25in"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Pricing inputs are quoted
prices for similar assets or liabilities, or inputs that are observable, either directly or indirectly, for substantially the full term
through corroboration with observable market data.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -43.9pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5in; text-align: left"&gt;Level 3&lt;/td&gt;
    &lt;td style="text-align: center; width: 0.25in"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Pricing inputs are unobservable
for the assets or liabilities, that is, inputs that reflect the reporting entity&#x2019;s own assumptions about the assumptions market
participants would use in pricing the asset or liability.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -43.9pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;In certain cases, the inputs used to measure fair
value may fall into different levels of the fair value hierarchy. In such cases, the level of an asset or liability within the fair value
hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance
of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the investment.
We also hold money market accounts in our bank account, which are classified as cash equivalents and measured at fair value. The fair
value of these investments is based on their closing published net asset value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;We assess the levels of the investments at each
measurement date, and transfers between levels are recognized on the actual date of the event or change in circumstances that caused the
transfer in accordance with our accounting policy regarding the recognition of transfers between levels of the fair value hierarchy. During
the nine-month periods ended September 30, 2024 and 2023, there were no transfers between levels. As of September 30, 2024 and December
31, 2023, our Level 1 assets measured at fair value by quoted prices in active markets consisted of cash and money market accounts. There
were no assets or liabilities measured at fair value on a nonrecurring basis as of September 30, 2024 or December 31, 2023. The carrying
values of our cash and money market accounts as of September 30, 2024 and December 31, 2023 approximated their fair market values. Due
to inflation and the changing interest rate environment, the carrying values of our fixed rate bank debt as of September 30, 2024 and
December 31, 2023 differed from their fair market values. These values are reflected in the following tables:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 0.25in"&gt;Cash and money market accounts&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;3,808,633&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-38"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-39"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;3,808,633&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 20pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 10.1pt"&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"&gt;Bank debt&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-40"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,703,821&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-41"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,703,821&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"&gt;Cash and money market accounts&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;978,741&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-42"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-43"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;978,741&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 20pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 10.1pt"&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"&gt;Bank debt&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-44"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,431,817&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-45"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,431,817&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(j) Concentration of Risk&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Concentration of credit risk with respect to
accounts receivable is principally limited to certain customers to whom we make substantial sales. To reduce risk, we routinely assess
the financial strength of our customers and, as a consequence, believe that our accounts receivable credit risk exposure is limited. We
maintain an allowance for potential credit losses when deemed necessary, but historically we have not experienced significant credit losses
related to an individual customer or groups of customers in any particular industry or geographic area. Sales to significant customers
that amounted to 10% or more of total product sales are detailed in the following table:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;During
the Three-Month &lt;br/&gt;
Periods Ended September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;During
the Nine-Month&lt;br/&gt;
Periods Ended September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Company A&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;43&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;50&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;44&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;48&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Company B&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;31&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;31&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Trade accounts receivable due from significant
customers that amounted to 10% or more of our total trade accounts receivable are detailed in the following table:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;As of &lt;br/&gt;
 September 30, 2024&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;As of  &lt;br/&gt;
December 31, 2023&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Company A&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;37&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;43&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Company B&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;34&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;36&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(k) Revenue Recognition&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;We recognize revenue in accordance with Codification
Topic 606, &lt;i&gt;Revenue from Contracts with Customers (ASC 606)&lt;/i&gt;. ASC 606 is a single comprehensive model for companies to use in accounting
for revenue arising from contracts with customers. The core principle is that we recognize the amount of revenue to which we expect to
be entitled for the transfer of promised goods or services to customers when a customer obtains control of promised goods or services
in an amount that reflects the consideration we expect to receive in exchange for those goods or services. In addition, the standard requires
disclosure of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. We conduct our
business with customers through valid purchase orders or sales orders which are considered contracts and are not interdependent on one
another. A performance obligation is a promise in a contract to transfer a distinct product to the customer. The transaction price is
the amount of consideration we expect to receive under the arrangement. Revenue is measured based on consideration specified in a contract
with a customer. The transaction price of a contract is allocated to each distinct performance obligation and recognized when or as the
customer receives the benefit of the performance obligation. Product transaction prices on a purchase or sales order are discrete and
stand-alone. We recognize revenue when we satisfy a performance obligation in a contract by transferring control over a product to a customer
when product ships to a customer. Amounts due are typically paid approximately 30 days from the time control is transferred. Shipping
and handling costs associated with outbound freight are accounted for as a fulfillment cost in costs of goods sold. We do not bill for
or collect sales tax because our sales are generally made to distributors and thus our sales to them are not subject to sales tax. We
generally have experienced an immaterial amount of product returns. See Note 14 for additional information.&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(l) Expense Recognition&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;We do not incur costs in connection with product
sales to customers that are eligible for capitalization. Advertising costs are expensed when incurred, which is generally during the month
in which the advertisement is published. All product development expenses are expensed as incurred, as are all related patent costs. We
capitalize costs to produce inventory during the production cycle, and these costs are charged to costs of goods sold when the inventory
is sold to a customer or is deemed to be in excess or obsolete.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"&gt;&lt;b&gt;(m) Income Taxes &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;We account for income taxes in accordance with
Codification Topic 740, &lt;i&gt;Income Taxes&lt;/i&gt;, which requires that we recognize a current tax liability or asset for current taxes payable
or refundable and a deferred tax liability or asset for the estimated future tax effects of temporary differences and carryforwards to
the extent they are realizable. We consider future taxable income and feasible tax planning strategies in assessing the need for a valuation
allowance against our deferred tax assets at the end of each quarter. If we determine that it is more likely than not that we will realize
our deferred tax assets in the future in excess of the net recorded amount over a reasonably short period of time, a reduction of the
valuation allowance would increase income in the period such determination was made. Likewise, if we determine that it is more likely
than not that we will not realize all or part of our net deferred tax asset in the future, an increase to the valuation allowance would
be charged to income in the period such determination was made.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Codification Topic 740-10 clarifies the accounting
for income taxes by prescribing a minimum recognition threshold that a tax position must meet before being recognized in the financial
statements. In the ordinary course of business, there are transactions and calculations where the ultimate tax outcome is uncertain. In
addition, we are subject to periodic audits and examinations by the Internal Revenue Service and other taxing authorities. With few exceptions,
we are no longer subject to income tax examinations by tax authorities for years before 2021. We have evaluated the positions taken on
our filed tax returns and have concluded that no uncertain tax positions existed as of September 30, 2024 or December 31, 2023. Although
we believe that our estimates are reasonable, actual results could differ from these estimates. See Note 16.&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(n) Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;We account for stock-based compensation in accordance
with Codification Topic 718, &lt;i&gt;Compensation-Stock Compensation&lt;/i&gt;, which generally requires us to recognize non-cash compensation expense
for stock-based payments using the fair-value-based method. The fair value of each stock option grant has been estimated on the date of
grant using the Black-Scholes option pricing model. Accordingly, we recorded compensation expense pertaining to stock-based compensation
of $77,557 and $96,434 during the three-month periods ended September 30, 2024 and 2023, respectively, and $256,688 and $268,207 during
the nine-month periods ended September 30, 2024 and 2023, respectively. See Note 13.&lt;/p&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(o) Net Loss Per Common Share&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Net loss per common share has been computed in
accordance with Codification Topic 260-10, &lt;i&gt;Earnings Per Share&lt;/i&gt;. The net loss per share has been computed by dividing the net loss
by the weighted average number of common shares outstanding during the period. All stock options have been excluded from the denominator
in the calculation of dilutive earnings per share when we are in a loss position because their inclusion would be anti-dilutive. Outstanding
stock options that were not included in this calculation because the effect would be anti-dilutive amounted to 661,000 and 616,500 during
the three-month periods ended September 30, 2024 and 2023, respectively, and 661,000 and 616,500 during the nine-month periods ended September
30, 2024 and 2023, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;During the Three-Month &lt;br/&gt;
Periods Ended September 30, &lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;During the Nine-Month  &lt;br/&gt;
Periods Ended September 30, &lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Net loss attributable to stockholders&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;(701,690&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;(940,000&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;(2,671,184&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;(4,634,767&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Weighted average common shares outstanding - Basic&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;8,164,423&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;7,746,864&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;7,908,425&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;7,746,864&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Dilutive impact of share-based compensation awards&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-46"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-47"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-48"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-49"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Weighted average common shares outstanding - Diluted&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;8,164,423&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,746,864&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,908,425&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,746,864&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Net loss per share:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;Basic&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(0.09&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(0.12&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(0.34&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(0.60&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;Diluted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(0.09&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(0.12&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(0.34&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(0.60&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(p) Use of Estimates&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The &lt;span style="font-family: Times New Roman, Times, Serif"&gt;preparation
of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported
amounts of revenues and expenses during the period. Although we regularly assess these estimates, actual amounts could differ from those
estimates and are subject to change in the near term. Changes in estimates are recorded during the period in which they become known.
Significant estimates include our valuation of inventory, deferred tax assets and costs of goods sold&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(q) New Accounting Pronouncements Not Yet Adopted&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;In November of 2023, the FASB issued ASU 2023-07,
&lt;i&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,&lt;/i&gt; which is intended to improve reportable segment
disclosure requirements, primarily through enhanced disclosures about significant expenses. The amendments will require disclosure of
significant segment expenses that are regularly provided to our chief operating decision-maker and included within segment profit and
loss. The amendments are effective for annual periods beginning after December 15, 2023, and interim periods beginning after December
15, 2024, with early adoption permitted, and will be applied retrospectively to all prior periods presented in the financial statements.
We are currently evaluating ASU 2023-07 to determine its impact on our financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;In December of 2023, the FASB issued ASU 2023-09&lt;i&gt;,
Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/i&gt;, which includes amendments that further enhance income tax disclosures,
primarily through standardization and disaggregation of income tax rate reconciliation categories and income taxes paid by jurisdiction.
The amendments are effective for annual periods beginning after December 15, 2024, with early adoption permitted, and may be applied either
prospectively or retrospectively. We are currently evaluating ASU 2023-09 to determine its impact on our financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c0" id="ixv-2987">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(a) Basis of Presentation&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;We have prepared the accompanying unaudited financial
statements reflecting all adjustments (which are of a normal recurring nature) that are, in our opinion, necessary in order to ensure
that the financial statements are not misleading. We follow accounting standards set by the Financial Accounting Standards Board (FASB).
The FASB sets Generally Accepted Accounting Principles (GAAP) that we follow to ensure we accurately report our financial condition, results
of operations, earnings per share and cash flows. References to GAAP in these footnotes are to the FASB &lt;i&gt;Accounting Standards Codification&lt;/i&gt;&#x2122;
(Codification). We believe that the disclosures are adequate to ensure that the information presented is not misleading.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c0" id="ixv-2996">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(b) Cash and Cash Equivalents&lt;/b&gt; &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;We consider all highly liquid investment instruments
that mature within three months of their purchase dates to be cash equivalents. Cash equivalents are principally invested in securities
backed by the U.S. government. We hold no cash or cash equivalents in excess of Federal Deposit Insurance Corporation (FDIC) limits of
$250,000 per financial institution per depositor. See Note 3.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashFDICInsuredAmount contextRef="c2" decimals="0" id="ixv-14102" unitRef="usd">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:ReceivablesPolicyTextBlock contextRef="c0" id="ixv-3004">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(c) Trade Accounts Receivable&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Accounts receivable are carried at the original
invoice amount less an estimate made for doubtful collection when applicable. Management determines the allowance for doubtful accounts
on a monthly basis by identifying troubled accounts and by using historical experience applied to an aging of accounts and other relevant
factors. Accounts receivable are considered to be past due if a portion of the receivable balance is outstanding for more than 30 days.
Past due accounts receivable are subject to an interest charge. It was not necessary to charge interest on past due accounts during the
nine-month periods ended September 30, 2024 or 2023 because the time past due was not significant, and there was no accrual for such interest
charges as of September 30, 2024 or December 31, 2023. Accounts receivable are written off when deemed uncollectible. No accounts receivable
were written off during the nine-month periods ended September 30, 2024 or 2023. Recoveries of accounts receivable previously written
off are recorded as income when received. No such recoveries were recorded during the nine-month periods ended September 30, 2024 or 2023.
As of September 30, 2024 and December 31, 2023, we determined that no allowance for doubtful accounts was necessary. See Note 4.&lt;/p&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="c0" id="ixv-3036">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(d) Inventory&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Inventory includes raw materials, work-in-process
and finished goods and is recorded at the lower of cost, on the first-in, first-out method, or net realizable value (determined as the
estimated selling price in the normal course of business, less reasonably predictable costs of completion, disposal and transportation).
Work-in-process and finished goods inventories include materials, labor and manufacturing overhead. At each balance sheet date, we evaluate
our ending inventories for excess quantities and obsolescence. Inventories that we consider excess or obsolete are written down to estimated
net realizable value. Once inventory is written down and a new cost basis is established, it is not written back up. We believe that supplies
and raw materials for the production of our products are available from more than one vendor or farm. Our policy is to maintain more than
one source of supply for the components used in our products when feasible. See Note 5.&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c0" id="ixv-3044">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(e) Property, Plant and Equipment, net&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;We depreciate property, plant and equipment on the
straight-line method by charges to operations and costs of goods sold in amounts estimated to expense the cost of the assets from the
date they are first put into service to the end of the estimated useful lives of the assets. The facility we have constructed at 33 Caddie
Lane to produce the Nisin Drug Substance (DS) for &lt;b&gt;Re-Tain&lt;sup&gt;&#xae;&lt;/sup&gt;&lt;/b&gt; (&lt;b&gt;Building 33&lt;/b&gt;) is being depreciated over 39 years
from when a Certificate of Occupancy was issued during the fourth quarter of 2017. We began depreciating the equipment for our Nisin DS
facility when it was placed in service during the third quarter of 2018. Approximately 86% of these assets are being depreciated over
10 years. We began depreciating the leasehold improvements to our new &lt;b&gt;First Defense&lt;sup&gt;&#xae; &lt;/sup&gt;&lt;/b&gt;production facility at 175
Industrial Way (&lt;b&gt;Building 175A&lt;/b&gt;) over the remainder of the 10-year lease term beginning when a Certificate of Occupancy was issued
during the second quarter of 2020. During August of 2022, this lease term was extended to January of 2043 in connection with a new lease
covering additional space at 175 Industrial Way (&lt;b&gt;Building 175B&lt;/b&gt;). As a result, the net book value of these leasehold improvements
as of August 31, 2022 is now being depreciated over the remainder of the extended lease term. Significant repairs to property, plant and
equipment that benefit more than a current period are capitalized and depreciated over their useful lives. Insignificant repairs are expensed
when incurred. See Notes 2(h) and 7 for additional information.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage contextRef="c2" decimals="2" id="ixv-14103" unitRef="pure">0.86</us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c51" id="ixv-14104">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c52" id="ixv-14105">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c0" id="ixv-3059">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(f) Operating Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;We account for our real estate leases using a right-of-use
model, which recognizes that at the date of commencement, a lessee has a financial obligation to make lease payments to the lessor for
the right to use the underlying asset during the lease term and recognizes a corresponding right-of-use (ROU) asset related to this right.
ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the future lease payments
over the expected lease term. The ROU asset is also adjusted for any lease prepayments made, lease incentives received and initial direct
costs incurred. For operating leases with lease payments that fluctuate over the lease term, the total lease costs are recognized on a
straight-line basis over the lease term. Our leases, at times, may include options to extend the term of the lease. When it is reasonably
certain that we will exercise the option, we include the impact of the option in the lease term for purposes of determining future lease
payments. For all underlying classes of assets, we made an accounting policy election to not recognize assets or liabilities for leases
with a term of twelve months or less and to account for all components in a lease arrangement as a single combined lease component. Short-term
lease payments are recognized on a straight-line basis. Certain of our lease agreements include variable rent payments, consisting primarily
of amounts paid to the lessor based on cost or consumption, such as maintenance and real estate taxes. These costs are recognized in the
period in which the obligation is incurred. Because our leases do not specify an implicit rate, we use an incremental borrowing rate based
on information available at the lease commencement date to determine the present value of the lease payments. We evaluate our ROU asset
for impairment when events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. See Notes
2(h) and 12 for additional information.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="c0" id="ixv-3093">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(g) Intangible Assets and Goodwill&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;We amortize intangible assets on the straight-line
method by charges to costs of goods sold in amounts estimated to expense the cost of the assets from the date they are first put into
service to the end of the estimated useful lives of the assets. We have recorded intangible assets related to customer relationships,
non-compete agreements and developed technology, each with defined useful lives. Amounts paid in excess of the fair value of the net assets
(including tax attributes) are recorded as goodwill under the acquisition method of accounting. We assess the impairment of intangible
assets that have indefinite lives (when applicable) and goodwill (at the reporting unit level) on an annual basis (as of December 31&lt;sup&gt;st&lt;/sup&gt;)
and whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. We would record
an impairment charge if such an assessment were to indicate that the fair value of such assets was less than the carrying value. Judgment
is required in determining whether an event has occurred that may impair the value of goodwill or identifiable intangible assets. Factors
that could indicate that an impairment may exist include significant under-performance relative to plan or long-term projections, significant
changes in business strategy and significant negative industry or economic trends. Although we believe intangible assets and goodwill
are properly stated in the accompanying financial statements, changes in strategy or market conditions could significantly impact these
judgments and require an adjustment to the recorded balance in the future. &lt;span style="-sec-ix-hidden: hidden-fact-50"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-51"&gt;No&lt;/span&gt;&lt;/span&gt; goodwill impairments were recorded during the nine-month
periods ended September 30, 2024 or 2023. See Notes 2(h) and 8 for additional information.&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c0" id="ixv-3103">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"&gt;&lt;b&gt;(h) Valuation of Long-Lived Assets&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;We periodically evaluate our long-lived assets,
consisting principally of property, plant and equipment, operating lease right-of-use asset and amortizable intangible assets, for potential
impairment. In accordance with the applicable accounting guidance for the treatment of long-lived assets, we review the carrying value
of our long-lived assets or asset group that is held and used, including intangible assets subject to amortization, for impairment whenever
events and circumstances indicate that the carrying value of the assets may not be recoverable. Under the held for use approach, the asset
or asset group to be tested for impairment should represent the lowest level for which identifiable cash flows are largely independent
of the cash flows of other groups of assets and liabilities. &lt;span style="-sec-ix-hidden: hidden-fact-52"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-53"&gt;No&lt;/span&gt;&lt;/span&gt; impairment was recognized during the nine-month periods ended September
30, 2024 or 2023.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c0" id="ixv-3113">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"&gt;&lt;b&gt;(i) Fair Value Measurements&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;In determining fair value measurements, we follow
the provisions of Codification Topic 820, &lt;i&gt;Fair Value Measurements and Disclosures&lt;/i&gt;. Codification Topic 820 defines fair value,
establishes a framework for measuring fair value under GAAP and enhances disclosures about fair value measurements. The topic provides
a consistent definition of fair value which focuses on an exit price, which is the price that would be received to sell an asset or paid
to transfer a liability in an orderly transaction between market participants at the measurement date. The topic also prioritizes, within
the measurement of fair value, the use of market-based information over entity-specific information and establishes a three-level hierarchy
for fair value measurements based on the nature of inputs used in the valuation of an asset or liability as of the measurement date.
As of September 30, 2024 and December 31, 2023, the carrying amounts of cash and cash equivalents, accounts receivable, inventory, prepaid
expenses and other current assets, other assets, accounts payable and accrued expenses approximate fair value because of their short-term
nature. The amount outstanding under our bank debt facilities is measured at carrying value in our accompanying balance sheets. Our bank
debt facilities are valued using Level 2 inputs. The three-level hierarchy is as follows:&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in; text-align: left"&gt;Level 1&lt;/td&gt;
    &lt;td style="text-align: center; width: 0.25in"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;  Pricing inputs are quoted prices available in active
markets for identical assets or liabilities as of the measurement date.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5in; text-align: left"&gt;Level 2&lt;/td&gt;
    &lt;td style="text-align: center; width: 0.25in"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Pricing inputs are quoted
prices for similar assets or liabilities, or inputs that are observable, either directly or indirectly, for substantially the full term
through corroboration with observable market data.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5in; text-align: left"&gt;Level 3&lt;/td&gt;
    &lt;td style="text-align: center; width: 0.25in"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Pricing inputs are unobservable
for the assets or liabilities, that is, inputs that reflect the reporting entity&#x2019;s own assumptions about the assumptions market
participants would use in pricing the asset or liability.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -43.9pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;In certain cases, the inputs used to measure fair
value may fall into different levels of the fair value hierarchy. In such cases, the level of an asset or liability within the fair value
hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance
of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the investment.
We also hold money market accounts in our bank account, which are classified as cash equivalents and measured at fair value. The fair
value of these investments is based on their closing published net asset value.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;We assess the levels of the investments at each
measurement date, and transfers between levels are recognized on the actual date of the event or change in circumstances that caused the
transfer in accordance with our accounting policy regarding the recognition of transfers between levels of the fair value hierarchy. During
the nine-month periods ended September 30, 2024 and 2023, there were no transfers between levels. As of September 30, 2024 and December
31, 2023, our Level 1 assets measured at fair value by quoted prices in active markets consisted of cash and money market accounts. There
were no assets or liabilities measured at fair value on a nonrecurring basis as of September 30, 2024 or December 31, 2023. The carrying
values of our cash and money market accounts as of September 30, 2024 and December 31, 2023 approximated their fair market values. Due
to inflation and the changing interest rate environment, the carrying values of our fixed rate bank debt as of September 30, 2024 and
December 31, 2023 differed from their fair market values. These values are reflected in the following tables:&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 0.25in"&gt;Cash and money market accounts&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;3,808,633&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-38"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-39"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;3,808,633&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 20pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 10.1pt"&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"&gt;Bank debt&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-40"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,703,821&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-41"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,703,821&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"&gt;Cash and money market accounts&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;978,741&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-42"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-43"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;978,741&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 20pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 10.1pt"&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"&gt;Bank debt&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-44"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,431,817&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-45"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,431,817&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock contextRef="c0" id="ixv-14106">These values are reflected in the following tables:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 0.25in"&gt;Cash and money market accounts&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;3,808,633&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-38"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-39"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;3,808,633&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 20pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 10.1pt"&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"&gt;Bank debt&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-40"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,703,821&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-41"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,703,821&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"&gt;Cash and money market accounts&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;978,741&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-42"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-43"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;978,741&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 20pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 10.1pt"&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"&gt;Bank debt&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-44"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,431,817&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-45"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,431,817&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c53" decimals="0" id="ixv-14107" unitRef="usd">3808633</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c56" decimals="0" id="ixv-14108" unitRef="usd">3808633</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermBorrowings contextRef="c54" decimals="0" id="ixv-14109" unitRef="usd">9703821</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c56" decimals="0" id="ixv-14110" unitRef="usd">9703821</us-gaap:ShortTermBorrowings>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c57" decimals="0" id="ixv-14111" unitRef="usd">978741</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c60" decimals="0" id="ixv-14112" unitRef="usd">978741</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermBorrowings contextRef="c58" decimals="0" id="ixv-14113" unitRef="usd">10431817</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c60" decimals="0" id="ixv-14114" unitRef="usd">10431817</us-gaap:ShortTermBorrowings>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c0" id="ixv-3400">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(j) Concentration of Risk&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Concentration of credit risk with respect to
accounts receivable is principally limited to certain customers to whom we make substantial sales. To reduce risk, we routinely assess
the financial strength of our customers and, as a consequence, believe that our accounts receivable credit risk exposure is limited. We
maintain an allowance for potential credit losses when deemed necessary, but historically we have not experienced significant credit losses
related to an individual customer or groups of customers in any particular industry or geographic area. Sales to significant customers
that amounted to 10% or more of total product sales are detailed in the following table:&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;During
the Three-Month &lt;br/&gt;
Periods Ended September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;During
the Nine-Month&lt;br/&gt;
Periods Ended September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Company A&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;43&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;50&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;44&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;48&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Company B&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;31&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;31&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Trade accounts receivable due from significant
customers that amounted to 10% or more of our total trade accounts receivable are detailed in the following table:&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;As of &lt;br/&gt;
 September 30, 2024&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;As of  &lt;br/&gt;
December 31, 2023&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Company A&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;37&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;43&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Company B&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;34&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;36&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="c0" id="ixv-14115">Sales to significant customers
that amounted to 10% or more of total product sales are detailed in the following table:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;During
the Three-Month &lt;br/&gt;
Periods Ended September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;During
the Nine-Month&lt;br/&gt;
Periods Ended September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Company A&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;43&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;50&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;44&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;48&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Company B&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;31&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;31&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;As of &lt;br/&gt;
 September 30, 2024&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;As of  &lt;br/&gt;
December 31, 2023&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Company A&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;37&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;43&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Company B&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;34&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;36&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c61" decimals="2" id="ixv-14116" unitRef="pure">0.43</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c62" decimals="2" id="ixv-14117" unitRef="pure">0.50</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c63" decimals="2" id="ixv-14118" unitRef="pure">0.44</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c64" decimals="2" id="ixv-14119" unitRef="pure">0.48</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c65" decimals="2" id="ixv-14120" unitRef="pure">0.31</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c66" decimals="2" id="ixv-14121" unitRef="pure">0.29</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c67" decimals="2" id="ixv-14122" unitRef="pure">0.33</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c68" decimals="2" id="ixv-14123" unitRef="pure">0.31</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c69" decimals="2" id="ixv-14124" unitRef="pure">0.37</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c70" decimals="2" id="ixv-14125" unitRef="pure">0.43</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c71" decimals="2" id="ixv-14126" unitRef="pure">0.34</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c72" decimals="2" id="ixv-14127" unitRef="pure">0.36</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c0" id="ixv-3541">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(k) Revenue Recognition&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;We recognize revenue in accordance with Codification
Topic 606, &lt;i&gt;Revenue from Contracts with Customers (ASC 606)&lt;/i&gt;. ASC 606 is a single comprehensive model for companies to use in accounting
for revenue arising from contracts with customers. The core principle is that we recognize the amount of revenue to which we expect to
be entitled for the transfer of promised goods or services to customers when a customer obtains control of promised goods or services
in an amount that reflects the consideration we expect to receive in exchange for those goods or services. In addition, the standard requires
disclosure of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. We conduct our
business with customers through valid purchase orders or sales orders which are considered contracts and are not interdependent on one
another. A performance obligation is a promise in a contract to transfer a distinct product to the customer. The transaction price is
the amount of consideration we expect to receive under the arrangement. Revenue is measured based on consideration specified in a contract
with a customer. The transaction price of a contract is allocated to each distinct performance obligation and recognized when or as the
customer receives the benefit of the performance obligation. Product transaction prices on a purchase or sales order are discrete and
stand-alone. We recognize revenue when we satisfy a performance obligation in a contract by transferring control over a product to a customer
when product ships to a customer. Amounts due are typically paid approximately 30 days from the time control is transferred. Shipping
and handling costs associated with outbound freight are accounted for as a fulfillment cost in costs of goods sold. We do not bill for
or collect sales tax because our sales are generally made to distributors and thus our sales to them are not subject to sales tax. We
generally have experienced an immaterial amount of product returns. See Note 14 for additional information.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <iccc:ExpenseRecognitionPolicyTextBlock contextRef="c0" id="ixv-3550">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(l) Expense Recognition&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;We do not incur costs in connection with product
sales to customers that are eligible for capitalization. Advertising costs are expensed when incurred, which is generally during the month
in which the advertisement is published. All product development expenses are expensed as incurred, as are all related patent costs. We
capitalize costs to produce inventory during the production cycle, and these costs are charged to costs of goods sold when the inventory
is sold to a customer or is deemed to be in excess or obsolete.&lt;/p&gt;</iccc:ExpenseRecognitionPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0" id="ixv-3557">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"&gt;&lt;b&gt;(m) Income Taxes &lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;We account for income taxes in accordance with
Codification Topic 740, &lt;i&gt;Income Taxes&lt;/i&gt;, which requires that we recognize a current tax liability or asset for current taxes payable
or refundable and a deferred tax liability or asset for the estimated future tax effects of temporary differences and carryforwards to
the extent they are realizable. We consider future taxable income and feasible tax planning strategies in assessing the need for a valuation
allowance against our deferred tax assets at the end of each quarter. If we determine that it is more likely than not that we will realize
our deferred tax assets in the future in excess of the net recorded amount over a reasonably short period of time, a reduction of the
valuation allowance would increase income in the period such determination was made. Likewise, if we determine that it is more likely
than not that we will not realize all or part of our net deferred tax asset in the future, an increase to the valuation allowance would
be charged to income in the period such determination was made.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Codification Topic 740-10 clarifies the accounting
for income taxes by prescribing a minimum recognition threshold that a tax position must meet before being recognized in the financial
statements. In the ordinary course of business, there are transactions and calculations where the ultimate tax outcome is uncertain. In
addition, we are subject to periodic audits and examinations by the Internal Revenue Service and other taxing authorities. With few exceptions,
we are no longer subject to income tax examinations by tax authorities for years before 2021. We have evaluated the positions taken on
our filed tax returns and have concluded that no uncertain tax positions existed as of September 30, 2024 or December 31, 2023. Although
we believe that our estimates are reasonable, actual results could differ from these estimates. See Note 16.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c0" id="ixv-3569">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(n) Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;We account for stock-based compensation in accordance
with Codification Topic 718, &lt;i&gt;Compensation-Stock Compensation&lt;/i&gt;, which generally requires us to recognize non-cash compensation expense
for stock-based payments using the fair-value-based method. The fair value of each stock option grant has been estimated on the date of
grant using the Black-Scholes option pricing model. Accordingly, we recorded compensation expense pertaining to stock-based compensation
of $77,557 and $96,434 during the three-month periods ended September 30, 2024 and 2023, respectively, and $256,688 and $268,207 during
the nine-month periods ended September 30, 2024 and 2023, respectively. See Note 13.&lt;/p&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c4" decimals="0" id="ixv-14128" unitRef="usd">77557</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c5" decimals="0" id="ixv-14129" unitRef="usd">96434</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c0" decimals="0" id="ixv-14130" unitRef="usd">256688</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c6" decimals="0" id="ixv-14131" unitRef="usd">268207</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0" id="ixv-3604">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(o) Net Loss Per Common Share&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Net loss per common share has been computed in
accordance with Codification Topic 260-10, &lt;i&gt;Earnings Per Share&lt;/i&gt;. The net loss per share has been computed by dividing the net loss
by the weighted average number of common shares outstanding during the period. All stock options have been excluded from the denominator
in the calculation of dilutive earnings per share when we are in a loss position because their inclusion would be anti-dilutive. Outstanding
stock options that were not included in this calculation because the effect would be anti-dilutive amounted to 661,000 and 616,500 during
the three-month periods ended September 30, 2024 and 2023, respectively, and 661,000 and 616,500 during the nine-month periods ended September
30, 2024 and 2023, respectively.&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;During the Three-Month &lt;br/&gt;
Periods Ended September 30, &lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;During the Nine-Month  &lt;br/&gt;
Periods Ended September 30, &lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Net loss attributable to stockholders&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;(701,690&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;(940,000&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;(2,671,184&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;(4,634,767&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Weighted average common shares outstanding - Basic&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;8,164,423&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;7,746,864&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;7,908,425&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;7,746,864&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Dilutive impact of share-based compensation awards&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-46"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-47"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-48"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-49"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Weighted average common shares outstanding - Diluted&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;8,164,423&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,746,864&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,908,425&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,746,864&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Net loss per share:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;Basic&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(0.09&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(0.12&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(0.34&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(0.60&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;Diluted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(0.09&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(0.12&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(0.34&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(0.60&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c0" id="ixv-14132">Outstanding
stock options that were not included in this calculation because the effect would be anti-dilutive amounted to 661,000 and 616,500 during
the three-month periods ended September 30, 2024 and 2023, respectively, and 661,000 and 616,500 during the nine-month periods ended September
30, 2024 and 2023, respectively.&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;During the Three-Month &lt;br/&gt;
Periods Ended September 30, &lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;During the Nine-Month  &lt;br/&gt;
Periods Ended September 30, &lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Net loss attributable to stockholders&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;(701,690&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;(940,000&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;(2,671,184&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;(4,634,767&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Weighted average common shares outstanding - Basic&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;8,164,423&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;7,746,864&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;7,908,425&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;7,746,864&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Dilutive impact of share-based compensation awards&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-46"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-47"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-48"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-49"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Weighted average common shares outstanding - Diluted&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;8,164,423&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,746,864&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,908,425&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,746,864&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Net loss per share:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;Basic&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(0.09&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(0.12&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(0.34&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(0.60&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;Diluted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(0.09&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(0.12&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(0.34&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(0.60&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c4"
      decimals="0"
      id="ixv-14133"
      unitRef="shares">661000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c5"
      decimals="0"
      id="ixv-14134"
      unitRef="shares">616500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c0"
      decimals="0"
      id="ixv-14135"
      unitRef="shares">661000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c6"
      decimals="0"
      id="ixv-14136"
      unitRef="shares">616500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NetIncomeLoss contextRef="c4" decimals="0" id="ixv-14137" unitRef="usd">-701690</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="0" id="ixv-14138" unitRef="usd">-940000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" id="ixv-14139" unitRef="usd">-2671184</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="0" id="ixv-14140" unitRef="usd">-4634767</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c4"
      decimals="0"
      id="ixv-14141"
      unitRef="shares">8164423</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c5"
      decimals="0"
      id="ixv-14142"
      unitRef="shares">7746864</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="0"
      id="ixv-14143"
      unitRef="shares">7908425</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c6"
      decimals="0"
      id="ixv-14144"
      unitRef="shares">7746864</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c4"
      decimals="0"
      id="ixv-14145"
      unitRef="shares">8164423</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c5"
      decimals="0"
      id="ixv-14146"
      unitRef="shares">7746864</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="0"
      id="ixv-14147"
      unitRef="shares">7908425</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c6"
      decimals="0"
      id="ixv-14148"
      unitRef="shares">7746864</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c4"
      decimals="2"
      id="ixv-14149"
      unitRef="usdPershares">-0.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c5"
      decimals="2"
      id="ixv-14150"
      unitRef="usdPershares">-0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="2"
      id="ixv-14151"
      unitRef="usdPershares">-0.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c6"
      decimals="2"
      id="ixv-14152"
      unitRef="usdPershares">-0.6</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c4"
      decimals="2"
      id="ixv-14153"
      unitRef="usdPershares">-0.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c5"
      decimals="2"
      id="ixv-14154"
      unitRef="usdPershares">-0.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="ixv-14155"
      unitRef="usdPershares">-0.34</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c6"
      decimals="2"
      id="ixv-14156"
      unitRef="usdPershares">-0.6</us-gaap:EarningsPerShareDiluted>
    <us-gaap:UseOfEstimates contextRef="c0" id="ixv-3809">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(p) Use of Estimates&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The &lt;span style="font-family: Times New Roman, Times, Serif"&gt;preparation
of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported
amounts of revenues and expenses during the period. Although we regularly assess these estimates, actual amounts could differ from those
estimates and are subject to change in the near term. Changes in estimates are recorded during the period in which they become known.
Significant estimates include our valuation of inventory, deferred tax assets and costs of goods sold&lt;/span&gt;.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0" id="ixv-3818">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(q) New Accounting Pronouncements Not Yet Adopted&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;In November of 2023, the FASB issued ASU 2023-07,
&lt;i&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,&lt;/i&gt; which is intended to improve reportable segment
disclosure requirements, primarily through enhanced disclosures about significant expenses. The amendments will require disclosure of
significant segment expenses that are regularly provided to our chief operating decision-maker and included within segment profit and
loss. The amendments are effective for annual periods beginning after December 15, 2023, and interim periods beginning after December
15, 2024, with early adoption permitted, and will be applied retrospectively to all prior periods presented in the financial statements.
We are currently evaluating ASU 2023-07 to determine its impact on our financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;In December of 2023, the FASB issued ASU 2023-09&lt;i&gt;,
Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/i&gt;, which includes amendments that further enhance income tax disclosures,
primarily through standardization and disaggregation of income tax rate reconciliation categories and income taxes paid by jurisdiction.
The amendments are effective for annual periods beginning after December 15, 2024, with early adoption permitted, and may be applied either
prospectively or retrospectively. We are currently evaluating ASU 2023-09 to determine its impact on our financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsDisclosureTextBlock contextRef="c0" id="ixv-3832">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;3. CASH AND CASH EQUIVALENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Cash and cash equivalents amounted to $3,808,633
and $978,741 as of September 30, 2024 and December 31, 2023, respectively. See Note 13.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="0" id="ixv-14157" unitRef="usd">3808633</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="0" id="ixv-14158" unitRef="usd">978741</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock contextRef="c0" id="ixv-3841">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;4. TRADE ACCOUNTS RECEIVABLE&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Trade accounts receivable amounted to $2,307,913
and $2,185,383 as of September 30, 2024 and December 31, 2023, respectively. No allowance for bad debt or product returns was recorded
as of September 30, 2024 or December 31, 2023. We anticipate no future events or conditions that would impact our ability to collect our
accounts receivable. Because of the generally short duration from the balance sheet date to the date of collection, our collection rate
is not expected to be significantly impacted by events occurring after the balance sheet date. The trade accounts receivable balances
included $35,364 and $42,507 due from a related party as of September 30, 2024 and December 31, 2023, respectively. See Note 18.&lt;/p&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c2" decimals="0" id="ixv-14159" unitRef="usd">2307913</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c3" decimals="0" id="ixv-14160" unitRef="usd">2185383</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c73" decimals="0" id="ixv-14161" unitRef="usd">35364</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c74" decimals="0" id="ixv-14162" unitRef="usd">42507</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryDisclosureTextBlock contextRef="c0" id="ixv-3873">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;5. INVENTORY&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Inventory consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.25pt; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of &lt;br/&gt; September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of &lt;br/&gt; December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Raw materials&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,313,766&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,594,028&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Work-in-process&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,124,394&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,815,194&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Finished goods&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;22,292&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;402,619&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,460,452&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,811,841&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-weight: normal"&gt;These &lt;span style="font-family: Times New Roman, Times, Serif"&gt;inventory
figures are net of write-offs of scrapped inventory in the amounts of $368,723 and $527,133 during the nine-month period ended September
30, 2024 and the year ended December 31, 2023, respectively, that resulted principally from contamination events and other production
process losses&lt;/span&gt;. &lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c0" id="ixv-14163">Inventory consisted of the following:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of &lt;br/&gt; September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of &lt;br/&gt; December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Raw materials&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,313,766&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,594,028&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Work-in-process&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,124,394&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,815,194&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Finished goods&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;22,292&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;402,619&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,460,452&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,811,841&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials contextRef="c2" decimals="0" id="ixv-14164" unitRef="usd">1313766</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials contextRef="c3" decimals="0" id="ixv-14165" unitRef="usd">1594028</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess contextRef="c2" decimals="0" id="ixv-14166" unitRef="usd">6124394</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess contextRef="c3" decimals="0" id="ixv-14167" unitRef="usd">5815194</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods contextRef="c2" decimals="0" id="ixv-14168" unitRef="usd">22292</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="c3" decimals="0" id="ixv-14169" unitRef="usd">402619</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet contextRef="c2" decimals="0" id="ixv-14170" unitRef="usd">7460452</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c3" decimals="0" id="ixv-14171" unitRef="usd">7811841</us-gaap:InventoryNet>
    <us-gaap:InventoryWriteDown contextRef="c0" decimals="0" id="ixv-14172" unitRef="usd">368723</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown contextRef="c75" decimals="0" id="ixv-14173" unitRef="usd">527133</us-gaap:InventoryWriteDown>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="c0" id="ixv-3940">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;6. PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Prepaid expenses and other current assets consisted
of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.95pt; text-indent: -0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of &lt;br/&gt; September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of&lt;br/&gt; December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Prepaid expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;277,146&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;454,152&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Other receivables&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;33,342&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;39,733&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;310,488&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;493,885&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="c0" id="ixv-14174">Prepaid expenses and other current assets consisted
of the following:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of &lt;br/&gt; September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of&lt;br/&gt; December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Prepaid expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;277,146&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;454,152&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Other receivables&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;33,342&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;39,733&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;310,488&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;493,885&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidExpenseCurrent contextRef="c2" decimals="0" id="ixv-14175" unitRef="usd">277146</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c3" decimals="0" id="ixv-14176" unitRef="usd">454152</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c2" decimals="0" id="ixv-14177" unitRef="usd">33342</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c3" decimals="0" id="ixv-14178" unitRef="usd">39733</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c2" decimals="0" id="ixv-14179" unitRef="usd">310488</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="0" id="ixv-14180" unitRef="usd">493885</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c0" id="ixv-3991">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;7. PROPERTY, PLANT AND EQUIPMENT, net&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Property, plant and equipment consisted of the
following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Estimated Useful Lives &lt;br/&gt; (in years)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of&lt;br/&gt; September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of&lt;br/&gt; December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Laboratory and manufacturing equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;3-10&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;21,183,888&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;20,953,601&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Buildings and improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;10-39&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,858,708&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,784,565&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;3-10&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,053,436&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,036,374&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Construction in progress&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-54"&gt;n/a&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,588,630&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,768,224&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Land&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-55"&gt;n/a&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;516,867&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;516,867&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 20pt"&gt;Property, plant and equipment, gross&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;46,201,529&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;46,059,631&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(20,381,196&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(18,483,948&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"&gt;Property, plant and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;25,820,333&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;27,575,683&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;As of September 30, 2024 and December 31, 2023,
construction in progress consisted principally of payments toward the &lt;b&gt;First Defense&lt;sup&gt;&#xae;&lt;/sup&gt;&lt;/b&gt; production capacity expansion
project and equipment needed to bring the formulation and aseptic filling for &lt;b&gt;Re-Tain&lt;sup&gt;&#xae;&lt;/sup&gt;&lt;/b&gt; in-house. Property, plant
and equipment disposals were $49,652 and $43,503 during the three-month periods ended September 30, 2024 and 2023, respectively, and $120,814
and $100,142 during the nine-month periods ended September 30, 2024 and 2023, respectively. Depreciation expense was $670,346 and $695,635
during the three-month periods ended September 30, 2024 and 2023, respectively, and $1,999,005 and $2,027,788 during the nine-month periods
ended September 30, 2024 and 2023, respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c0" id="ixv-14181">Property, plant and equipment consisted of the
following:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Estimated Useful Lives &lt;br/&gt; (in years)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of&lt;br/&gt; September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of&lt;br/&gt; December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Laboratory and manufacturing equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;3-10&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;21,183,888&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;20,953,601&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Buildings and improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;10-39&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,858,708&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,784,565&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;3-10&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,053,436&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,036,374&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Construction in progress&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-54"&gt;n/a&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,588,630&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,768,224&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Land&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-55"&gt;n/a&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;516,867&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;516,867&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 20pt"&gt;Property, plant and equipment, gross&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;46,201,529&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;46,059,631&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(20,381,196&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(18,483,948&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"&gt;Property, plant and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;25,820,333&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;27,575,683&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c76" id="ixv-14182">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c77" id="ixv-14183">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c78" decimals="0" id="ixv-14184" unitRef="usd">21183888</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c79" decimals="0" id="ixv-14185" unitRef="usd">20953601</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c80" id="ixv-14186">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c81" id="ixv-14187">P39Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c82" decimals="0" id="ixv-14188" unitRef="usd">20858708</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c83" decimals="0" id="ixv-14189" unitRef="usd">20784565</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c84" id="ixv-14190">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c85" id="ixv-14191">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c86" decimals="0" id="ixv-14192" unitRef="usd">1053436</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c87" decimals="0" id="ixv-14193" unitRef="usd">1036374</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c88" decimals="0" id="ixv-14194" unitRef="usd">2588630</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c89" decimals="0" id="ixv-14195" unitRef="usd">2768224</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c90" decimals="0" id="ixv-14196" unitRef="usd">516867</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c91" decimals="0" id="ixv-14197" unitRef="usd">516867</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c2" decimals="0" id="ixv-14198" unitRef="usd">46201529</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c3" decimals="0" id="ixv-14199" unitRef="usd">46059631</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c2" decimals="0" id="ixv-14200" unitRef="usd">20381196</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c3" decimals="0" id="ixv-14201" unitRef="usd">18483948</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="0" id="ixv-14202" unitRef="usd">25820333</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="0" id="ixv-14203" unitRef="usd">27575683</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentDisposals contextRef="c4" decimals="0" id="ixv-14204" unitRef="usd">49652</us-gaap:PropertyPlantAndEquipmentDisposals>
    <us-gaap:PropertyPlantAndEquipmentDisposals contextRef="c5" decimals="0" id="ixv-14205" unitRef="usd">43503</us-gaap:PropertyPlantAndEquipmentDisposals>
    <us-gaap:PropertyPlantAndEquipmentDisposals contextRef="c0" decimals="0" id="ixv-14206" unitRef="usd">120814</us-gaap:PropertyPlantAndEquipmentDisposals>
    <us-gaap:PropertyPlantAndEquipmentDisposals contextRef="c6" decimals="0" id="ixv-14207" unitRef="usd">100142</us-gaap:PropertyPlantAndEquipmentDisposals>
    <us-gaap:Depreciation contextRef="c4" decimals="0" id="ixv-14208" unitRef="usd">670346</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c5" decimals="0" id="ixv-14209" unitRef="usd">695635</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c0" decimals="0" id="ixv-14210" unitRef="usd">1999005</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c6" decimals="0" id="ixv-14211" unitRef="usd">2027788</us-gaap:Depreciation>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="c0" id="ixv-4143">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;8. INTANGIBLE ASSETS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Intangible assets of $191,040 were valued using
the relief from royalty method and are being amortized to costs of goods sold over their useful lives, which are estimated to be 10 years.
Intangible amortization expense was $4,776 during both of the three-month periods ended September 30, 2024 and 2023 and $14,328 during
both of the nine-month periods ended September 30, 2024 and 2023. The net value of these intangibles was $23,880 and $38,208 as of September
30, 2024 and December 31, 2023, respectively. Intangible asset amortization expense is estimated to be $19,104 per year through December
31, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Intangible assets as of September 30, 2024 consisted
of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Gross Carrying&lt;br/&gt;
 Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Accumulated&lt;br/&gt;
 Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Net Book&lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Developed technology&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;184,100&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(161,087&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;23,013&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Customer relationships&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,138&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;162&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Non-compete agreements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,640&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,935&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;705&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 0.25in"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;191,040&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(167,160&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;23,880&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Intangible assets as of December 31, 2023 consisted
of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Gross Carrying&lt;br/&gt;
 Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Accumulated&lt;br/&gt;
 Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Net Book&lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Developed technology&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;184,100&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(147,280&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;36,820&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Customer relationships&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,040&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;260&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Non-compete agreements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,640&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,512&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,128&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;191,040&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(152,832&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;38,208&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c2" decimals="0" id="ixv-14212" unitRef="usd">191040</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c2" id="ixv-14213">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c4" decimals="0" id="ixv-14214" unitRef="usd">4776</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c5" decimals="0" id="ixv-14215" unitRef="usd">4776</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c0" decimals="0" id="ixv-14216" unitRef="usd">14328</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c6" decimals="0" id="ixv-14217" unitRef="usd">14328</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c2" decimals="0" id="ixv-14218" unitRef="usd">23880</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c3" decimals="0" id="ixv-14219" unitRef="usd">38208</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c92" decimals="0" id="ixv-14220" unitRef="usd">19104</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="c0" id="ixv-14221">Intangible assets as of September 30, 2024 consisted
of the following:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Gross Carrying&lt;br/&gt;
 Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Accumulated&lt;br/&gt;
 Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Net Book&lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Developed technology&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;184,100&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(161,087&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;23,013&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Customer relationships&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,138&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;162&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Non-compete agreements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,640&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,935&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;705&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 0.25in"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;191,040&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(167,160&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;23,880&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;Intangible assets as of December 31, 2023 consisted
of the following:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Gross Carrying&lt;br/&gt;
 Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Accumulated&lt;br/&gt;
 Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Net Book&lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Developed technology&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;184,100&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(147,280&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;36,820&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Customer relationships&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,040&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;260&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Non-compete agreements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,640&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,512&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,128&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;191,040&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(152,832&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;38,208&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c93" decimals="0" id="ixv-14222" unitRef="usd">184100</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c93" decimals="0" id="ixv-14223" unitRef="usd">161087</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c93" decimals="0" id="ixv-14224" unitRef="usd">23013</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c94" decimals="0" id="ixv-14225" unitRef="usd">1300</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c94" decimals="0" id="ixv-14226" unitRef="usd">1138</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c94" decimals="0" id="ixv-14227" unitRef="usd">162</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c95" decimals="0" id="ixv-14228" unitRef="usd">5640</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c95" decimals="0" id="ixv-14229" unitRef="usd">4935</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c95" decimals="0" id="ixv-14230" unitRef="usd">705</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c2" decimals="0" id="ixv-14231" unitRef="usd">191040</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c2" decimals="0" id="ixv-14232" unitRef="usd">167160</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c2" decimals="0" id="ixv-14233" unitRef="usd">23880</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c96" decimals="0" id="ixv-14235" unitRef="usd">184100</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c96" decimals="0" id="ixv-14236" unitRef="usd">147280</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c96" decimals="0" id="ixv-14237" unitRef="usd">36820</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c97" decimals="0" id="ixv-14238" unitRef="usd">1300</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c97" decimals="0" id="ixv-14239" unitRef="usd">1040</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c97" decimals="0" id="ixv-14240" unitRef="usd">260</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c98" decimals="0" id="ixv-14241" unitRef="usd">5640</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c98" decimals="0" id="ixv-14242" unitRef="usd">4512</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c98" decimals="0" id="ixv-14243" unitRef="usd">1128</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c3" decimals="0" id="ixv-14244" unitRef="usd">191040</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c3" decimals="0" id="ixv-14245" unitRef="usd">152832</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c3" decimals="0" id="ixv-14246" unitRef="usd">38208</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c0" id="ixv-4301">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;9. ACCOUNTS PAYABLE AND ACCRUED EXPENSES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Accounts payable and accrued expenses consisted
of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of&lt;br/&gt; September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of&lt;br/&gt; December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Accounts payable &#x2013; trade&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;876,836&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;874,558&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Accounts payable &#x2013; capital&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,378&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,175&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Accrued payroll&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,142,318&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;942,999&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Accrued professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;101,725&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;97,800&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Accrued other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;376,112&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;192,754&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Income tax payable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,166&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,051&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,504,535&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,124,337&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="c0" id="ixv-14247">Accounts payable and accrued expenses consisted
of the following:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of&lt;br/&gt; September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of&lt;br/&gt; December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Accounts payable &#x2013; trade&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;876,836&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;874,558&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Accounts payable &#x2013; capital&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,378&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,175&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Accrued payroll&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,142,318&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;942,999&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Accrued professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;101,725&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;97,800&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Accrued other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;376,112&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;192,754&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Income tax payable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,166&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,051&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,504,535&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,124,337&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableTradeCurrent contextRef="c2" decimals="0" id="ixv-14248" unitRef="usd">876836</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent contextRef="c3" decimals="0" id="ixv-14249" unitRef="usd">874558</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="c2" decimals="0" id="ixv-14250" unitRef="usd">6378</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="c3" decimals="0" id="ixv-14251" unitRef="usd">13175</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccruedPayrollTaxesCurrent contextRef="c2" decimals="0" id="ixv-14252" unitRef="usd">1142318</us-gaap:AccruedPayrollTaxesCurrent>
    <us-gaap:AccruedPayrollTaxesCurrent contextRef="c3" decimals="0" id="ixv-14253" unitRef="usd">942999</us-gaap:AccruedPayrollTaxesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c2" decimals="0" id="ixv-14254" unitRef="usd">101725</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c3" decimals="0" id="ixv-14255" unitRef="usd">97800</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c2" decimals="0" id="ixv-14256" unitRef="usd">376112</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c3" decimals="0" id="ixv-14257" unitRef="usd">192754</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c2" decimals="0" id="ixv-14258" unitRef="usd">1166</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c3" decimals="0" id="ixv-14259" unitRef="usd">3051</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c2" decimals="0" id="ixv-14260" unitRef="usd">2504535</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c3" decimals="0" id="ixv-14261" unitRef="usd">2124337</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="c0" id="ixv-4415">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;10. BANK DEBT&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;Loans #1 and #2&lt;/b&gt;: During the first quarter
of 2020, we closed on a debt financing with Gorham Savings Bank (GSB) aggregating $8,600,000, which was comprised of a $5,100,000 mortgage
note (Loan #1) that bears interest at a fixed rate of 3.50% per annum (with a 10-year term and 25-year amortization schedule and a balloon
principal payment of $3,145,888 due during the first quarter of 2030) and a $3,500,000 note (Loan #2) that bears interest at a fixed rate
of 3.50% per annum (with a 7-year term and amortization schedule). The proceeds from the 2020 debt refinancing were used to repay all
bank debt outstanding at the time of closing and to provide some additional working capital. During the first quarter of 2022, we closed
on an additional $2,000,000 in mortgage debt, which bears interest at the fixed rate of 3.58% per annum. This was accomplished through
an amendment of the original mortgage note (Loan #1) that increased the then outstanding principal balance from $4,233,957 to $6,233,957
bearing interest at the blended fixed rate of 3.53% per annum. This increased the balloon payment from $3,145,888 to $3,687,577 and extended
the due date of the balloon payment from the first quarter of 2030 to the first quarter of 2032.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;Line of Credit (LOC)&lt;/b&gt;: Also during the first
quarter of 2020, GSB extended a $1,000,000 LOC to us that is available, as needed, through September 11, 2025. Interest on borrowings
against the LOC is variable at the National Prime Rate per annum. There was no outstanding balance under this LOC as of September 30,
2024 or December 31, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;Loan #3&lt;/b&gt;: During the second quarter of 2020,
we received a loan from the Maine Technology Institute (MTI) in the aggregate principal amount of $500,000. The first 2.25 years of this
loan were interest-free with no interest accrual or required principal payments. Beginning during the fourth quarter of 2022, Loan #3
became subject to quarterly principal and interest payments at a fixed rate of 5% per annum over the final five years of the loan, through
the third quarter of 2027 if not repaid before then.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;Loan #4&lt;/b&gt;: During the fourth quarter of 2020,
we closed on a $1,500,000 note with GSB that bears interest at a fixed rate of 3.50% per annum (with a 7-year term and amortization schedule).
Proceeds of $624,167 were used to prepay a portion of the outstanding principal on our mortgage note (Loan #1), which reduced the outstanding
balance to 80% of the most recent appraised value of the property securing the debt, which allowed GSB to release the $1,400,000 that
had been held in escrow. The remaining proceeds were available for general working capital purposes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;Loan #5&lt;/b&gt;: On June 30, 2021, we executed definitive
agreements covering a second loan from the MTI in the aggregate principal amount of $400,000, proceeds from which were received in July
of 2021. The first two years of this loan were interest-free with no interest accrual or required principal payments. Principal and interest
payments at a fixed rate of 5% per annum are due quarterly over the final 5.5 years of the loan, beginning during the third quarter of
2023 and continuing through the fourth quarter of 2028 if not repaid before then.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;Loan #6: &lt;/b&gt;During the third quarter of 2023,
we closed on a $2,000,000 term loan bearing interest at a fixed rate of 7% per annum from GSB. The Finance Authority of Maine (FAME) provided
$1,000,000 of loan insurance to GSB. This loan is repayable under a 7-year amortization schedule with a balloon payment of $1,285,056
due during the third quarter of 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;Loan #7:&lt;/b&gt; Also during the third quarter of
2023, we closed on a $1,000,000 term loan bearing interest at a fixed rate of 8% per annum from FAME. The loan is repayable under a 7-year
amortization schedule with a balloon payment of $649,631 due during the third quarter of 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Loans #1, #2, #4, #6 and #7 are secured by liens
on substantially all of our assets and are subject to certain restrictions and financial covenants. Loan #7 is subordinated to Loans #1,
#2, #4 and #6. Reflecting our poor financial performance during 2023 and into the first nine months of 2024, the debt service covenant
(DSC) requirements for the twelve-month periods ended December 31, 2023, June 30, 2024, September 30, 2024 and December 31, 2024 were
waived pre-emptively by our lenders. We are required to meet a minimum DSC ratio of 1.35 for the year ending December 31, 2025 and annually
thereafter. In connection with these credit facilities, we incurred aggregate debt issuance and debt discount costs of $173,305 ($5,037
and $0 of which was incurred during the nine-month periods ended September 30, 2024 and 2023, respectively). The amortization of these
debt issuance and debt discount costs is being recorded as a component of interest expense, included in other expenses, net, and is being
amortized on a straight-line basis over the underlying terms of the notes. Loans #3 and #5 are unsecured and subordinated to our indebtedness
to GSB and FAME. Failure to make timely payments of principal and interest, or otherwise to comply with the terms of the agreements of
Loans #3 and #5, would entitle the MTI to accelerate the maturity of such debt and demand repayment in full. These loans may be prepaid
without penalty at any time.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Debt proceeds received and principal repayments
made (excluding our $1,000,000 line of credit) are reflected by loan during the periods as described in the tables below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;During the Three-Month &lt;br/&gt;
&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Period Ended September 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;During
the Three-Month &lt;br/&gt;
Period Ended September 30, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Proceeds&#160;from&lt;br/&gt;
 Debt Issuance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Debt&#160;Principal&lt;br/&gt;
 Repayments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Proceeds&#160;from &lt;br/&gt;
Debt Issuance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Debt&#160;Principal&lt;br/&gt;
 Repayments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-indent: -10pt; padding-left: 10pt"&gt;Loan #1&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-56"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;57,671&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-57"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;55,619&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Loan #2&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-58"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;128,534&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-59"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;124,020&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Loan #3&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-60"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,173&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-61"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23,002&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Loan #4&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-62"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;53,505&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-63"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;51,622&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 10.1pt"&gt;Loan #5&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-64"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,719&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-65"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,909&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 10.1pt"&gt;Loan #6&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-66"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;59,191&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;36,582&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Loan #7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-67"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;28,456&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,000,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,983&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-68"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;368,249&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,000,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;325,737&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;During the Nine-Month &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Period Ended September 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;During the Nine-Month &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Period Ended September 30, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Proceeds&#160;from&lt;br/&gt;
 Debt Issuance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Debt&#160;Principal&lt;br/&gt;
 Repayments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Proceeds&#160;from &lt;br/&gt;
Debt Issuance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Debt&#160;Principal&lt;br/&gt;
 Repayments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-indent: -10pt; padding-left: 10pt"&gt;Loan #1&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-69"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;172,017&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-70"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;166,527&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Loan #2&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-71"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;382,324&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-72"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;369,154&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Loan #3&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-73"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;71,629&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-74"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;68,156&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Loan #4&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-75"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;159,171&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-76"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;153,704&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 10.1pt"&gt;Loan #5&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-77"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;49,542&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-78"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,909&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 10.1pt"&gt;Loan #6&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-79"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;174,804&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;36,582&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Loan #7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-80"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;84,619&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,000,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,983&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-81"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,094,106&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,000,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;829,015&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;During the Year&lt;br/&gt;
 Ended December 31,
                                                                                 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;During
the Year&lt;br/&gt;
 Ended December 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Proceeds&#160;from&lt;br/&gt;
 Debt Issuance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Debt&#160;Principal&lt;br/&gt;
 Repayments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Proceeds&#160;from &lt;br/&gt;
Debt Issuance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Debt&#160;Principal&lt;br/&gt;
 Repayments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-indent: -10pt; padding-left: 10pt"&gt;Loan #1&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-82"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;223,222&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,000,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;199,013&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Loan #2&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-83"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;494,455&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-84"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;477,237&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Loan #3&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-85"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;91,446&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-86"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22,160&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Loan #4&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-87"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;205,884&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-88"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;198,715&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 10.1pt"&gt;Loan #5&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-89"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32,017&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-90"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-91"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 10.1pt"&gt;Loan #6&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;93,054&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-92"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-93"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Loan #7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,000,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;45,696&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-94"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-95"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,000,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,185,774&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,000,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;897,125&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Principal payments (net of debt issuance
and debt discount costs) due under bank loans outstanding as of September 30, 2024 (excluding our $1,000,000 line of credit) are reflected
in the following table by the year that payments are due:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;During the&lt;br/&gt; Three-Month&lt;br/&gt; Period Ending&lt;br/&gt; December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;During the Years Ending December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2027&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2028&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 16%"&gt;Loan #1&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;58,765&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;239,876&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;248,604&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;257,649&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;266,537&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,598,457&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,669,888&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Loan #2&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;129,801&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;530,738&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;549,881&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;140,436&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-96"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-97"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,350,856&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Loan #3&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,476&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;101,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;106,146&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;83,143&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-98"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-99"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;314,765&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Loan #4&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;54,055&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;220,994&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;228,965&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;240,442&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-100"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-101"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;744,456&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Loan #5&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,929&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;69,856&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;73,415&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;77,156&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;81,086&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-102"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;318,442&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Loan #6&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;60,581&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;253,003&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,418,558&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-103"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-104"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-105"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,732,142&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Loan #7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;29,617&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;124,364&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;715,704&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-106"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-107"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-108"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;869,685&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Subtotal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;374,224&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,539,831&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,341,273&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;798,826&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;347,623&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,598,457&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,000,234&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Debt issuance cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,583&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(21,314&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(13,580&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,420&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,513&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(11,347&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(60,757&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Debt discount cost&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5,223&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(20,891&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(11,344&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-109"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-110"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-111"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(37,458&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;363,418&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,497,626&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,316,349&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;793,406&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;344,110&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,587,110&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,902,019&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DeferredFinanceCostsCurrentNet contextRef="c99" decimals="0" id="ixv-14262" unitRef="usd">8600000</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:EscrowDeposit contextRef="c100" decimals="0" id="ixv-14263" unitRef="usd">5100000</us-gaap:EscrowDeposit>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate
      contextRef="c100"
      decimals="4"
      id="ixv-14264"
      unitRef="pure">0.035</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <iccc:InterestPaymentsTerm contextRef="c101" id="ixv-14265">P10Y</iccc:InterestPaymentsTerm>
    <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid contextRef="c102" decimals="0" id="ixv-14266" unitRef="usd">3145888</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
    <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid contextRef="c103" decimals="0" id="ixv-14267" unitRef="usd">3500000</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate
      contextRef="c103"
      decimals="4"
      id="ixv-14268"
      unitRef="pure">0.035</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:ParticipatingMortgageLoansUnamortizedDebtDiscountAmount contextRef="c104" decimals="0" id="ixv-14269" unitRef="usd">2000000</us-gaap:ParticipatingMortgageLoansUnamortizedDebtDiscountAmount>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate
      contextRef="c104"
      decimals="4"
      id="ixv-14270"
      unitRef="pure">0.0358</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:PrincipalAmountOutstandingOnLoansManagedAndSecuritized contextRef="c105" decimals="0" id="ixv-14271" unitRef="usd">4233957</us-gaap:PrincipalAmountOutstandingOnLoansManagedAndSecuritized>
    <us-gaap:PrincipalAmountOutstandingOnLoansManagedAndSecuritized contextRef="c106" decimals="0" id="ixv-14272" unitRef="usd">6233957</us-gaap:PrincipalAmountOutstandingOnLoansManagedAndSecuritized>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate contextRef="c2" decimals="4" id="ixv-14273" unitRef="pure">0.0353</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid contextRef="c105" decimals="0" id="ixv-14274" unitRef="usd">3145888</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
    <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid contextRef="c106" decimals="0" id="ixv-14275" unitRef="usd">3687577</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
    <us-gaap:LineOfCredit contextRef="c107" decimals="0" id="ixv-14276" unitRef="usd">1000000</us-gaap:LineOfCredit>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c108" decimals="0" id="ixv-14277" unitRef="usd">500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm contextRef="c109" id="ixv-14278">P2Y3M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="c110"
      decimals="2"
      id="ixv-14279"
      unitRef="pure">0.05</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DebtInstrumentTerm contextRef="c111" id="ixv-14280">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DeferredFinanceCostsCurrentNet contextRef="c112" decimals="0" id="ixv-14281" unitRef="usd">1500000</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate
      contextRef="c112"
      decimals="4"
      id="ixv-14282"
      unitRef="pure">0.035</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:DebtInstrumentTerm contextRef="c113" id="ixv-14283">P7Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c114" decimals="0" id="ixv-14284" unitRef="usd">624167</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <iccc:LoanToValueRatio
      contextRef="c114"
      decimals="2"
      id="ixv-14285"
      unitRef="pure">0.80</iccc:LoanToValueRatio>
    <us-gaap:DeferredFinanceCostsCurrentNet contextRef="c115" decimals="0" id="ixv-14286" unitRef="usd">1400000</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c116" decimals="0" id="ixv-14287" unitRef="usd">400000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="c116"
      decimals="2"
      id="ixv-14288"
      unitRef="pure">0.05</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DebtInstrumentTerm contextRef="c117" id="ixv-14289">P5Y6M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DeferredFinanceCostsCurrentNet contextRef="c118" decimals="0" id="ixv-14290" unitRef="usd">2000000</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate
      contextRef="c118"
      decimals="2"
      id="ixv-14291"
      unitRef="pure">0.07</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:FinancingReceivableLoanInProcess contextRef="c118" decimals="0" id="ixv-14292" unitRef="usd">1000000</us-gaap:FinancingReceivableLoanInProcess>
    <us-gaap:DebtInstrumentTerm contextRef="c119" id="ixv-14293">P7Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid contextRef="c120" decimals="0" id="ixv-14294" unitRef="usd">1285056</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
    <us-gaap:DeferredFinanceCostsCurrentNet contextRef="c121" decimals="0" id="ixv-14295" unitRef="usd">1000000</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate
      contextRef="c121"
      decimals="2"
      id="ixv-14296"
      unitRef="pure">0.08</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:DebtInstrumentTerm contextRef="c122" id="ixv-14297">P7Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid contextRef="c123" decimals="0" id="ixv-14298" unitRef="usd">649631</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
    <iccc:DebtServiceCoverageRatio contextRef="c92" decimals="2" id="ixv-14299" unitRef="pure">1.35</iccc:DebtServiceCoverageRatio>
    <us-gaap:DeferredFinanceCostsCurrentGross contextRef="c2" decimals="0" id="ixv-14300" unitRef="usd">173305</us-gaap:DeferredFinanceCostsCurrentGross>
    <us-gaap:InterestCostsIncurred contextRef="c0" decimals="0" id="ixv-14301" unitRef="usd">5037</us-gaap:InterestCostsIncurred>
    <us-gaap:InterestCostsIncurred contextRef="c6" decimals="0" id="ixv-14302" unitRef="usd">0</us-gaap:InterestCostsIncurred>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="c0" id="ixv-14303">Debt proceeds received and principal repayments
made (excluding our $1,000,000 line of credit) are reflected by loan during the periods as described in the tables below:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;During the Three-Month &lt;br/&gt;
&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Period Ended September 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;During
the Three-Month &lt;br/&gt;
Period Ended September 30, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Proceeds&#160;from&lt;br/&gt;
 Debt Issuance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Debt&#160;Principal&lt;br/&gt;
 Repayments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Proceeds&#160;from &lt;br/&gt;
Debt Issuance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Debt&#160;Principal&lt;br/&gt;
 Repayments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-indent: -10pt; padding-left: 10pt"&gt;Loan #1&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-56"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;57,671&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-57"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;55,619&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Loan #2&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-58"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;128,534&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-59"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;124,020&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Loan #3&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-60"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,173&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-61"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23,002&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Loan #4&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-62"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;53,505&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-63"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;51,622&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 10.1pt"&gt;Loan #5&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-64"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,719&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-65"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,909&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 10.1pt"&gt;Loan #6&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-66"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;59,191&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;36,582&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Loan #7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-67"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;28,456&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,000,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,983&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-68"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;368,249&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,000,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;325,737&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;During the Nine-Month &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Period Ended September 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;During the Nine-Month &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Period Ended September 30, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Proceeds&#160;from&lt;br/&gt;
 Debt Issuance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Debt&#160;Principal&lt;br/&gt;
 Repayments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Proceeds&#160;from &lt;br/&gt;
Debt Issuance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Debt&#160;Principal&lt;br/&gt;
 Repayments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-indent: -10pt; padding-left: 10pt"&gt;Loan #1&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-69"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;172,017&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-70"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;166,527&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Loan #2&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-71"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;382,324&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-72"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;369,154&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Loan #3&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-73"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;71,629&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-74"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;68,156&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Loan #4&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-75"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;159,171&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-76"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;153,704&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 10.1pt"&gt;Loan #5&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-77"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;49,542&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-78"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,909&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 10.1pt"&gt;Loan #6&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-79"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;174,804&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;36,582&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Loan #7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-80"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;84,619&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,000,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,983&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-81"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,094,106&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,000,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;829,015&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;During the Year&lt;br/&gt;
 Ended December 31,
                                                                                 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;During
the Year&lt;br/&gt;
 Ended December 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Proceeds&#160;from&lt;br/&gt;
 Debt Issuance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Debt&#160;Principal&lt;br/&gt;
 Repayments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Proceeds&#160;from &lt;br/&gt;
Debt Issuance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Debt&#160;Principal&lt;br/&gt;
 Repayments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-indent: -10pt; padding-left: 10pt"&gt;Loan #1&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-82"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;223,222&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,000,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;199,013&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Loan #2&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-83"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;494,455&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-84"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;477,237&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Loan #3&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-85"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;91,446&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-86"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22,160&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Loan #4&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-87"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;205,884&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-88"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;198,715&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 10.1pt"&gt;Loan #5&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-89"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32,017&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-90"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-91"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 10.1pt"&gt;Loan #6&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;93,054&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-92"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-93"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Loan #7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,000,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;45,696&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-94"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-95"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,000,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,185,774&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,000,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;897,125&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:LineOfCredit contextRef="c2" decimals="0" id="ixv-14304" unitRef="usd">1000000</us-gaap:LineOfCredit>
    <us-gaap:RepaymentsOfBankDebt contextRef="c125" decimals="0" id="ixv-14305" unitRef="usd">57671</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c126" decimals="0" id="ixv-14306" unitRef="usd">55619</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c127" decimals="0" id="ixv-14307" unitRef="usd">128534</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c128" decimals="0" id="ixv-14308" unitRef="usd">124020</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c129" decimals="0" id="ixv-14309" unitRef="usd">24173</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c130" decimals="0" id="ixv-14310" unitRef="usd">23002</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c131" decimals="0" id="ixv-14311" unitRef="usd">53505</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c132" decimals="0" id="ixv-14312" unitRef="usd">51622</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c133" decimals="0" id="ixv-14313" unitRef="usd">16719</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c134" decimals="0" id="ixv-14314" unitRef="usd">15909</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c135" decimals="0" id="ixv-14315" unitRef="usd">59191</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c136" decimals="0" id="ixv-14316" unitRef="usd">2000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c136" decimals="0" id="ixv-14317" unitRef="usd">36582</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c137" decimals="0" id="ixv-14318" unitRef="usd">28456</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c138" decimals="0" id="ixv-14319" unitRef="usd">1000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c138" decimals="0" id="ixv-14320" unitRef="usd">18983</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c4" decimals="0" id="ixv-14321" unitRef="usd">368249</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c5" decimals="0" id="ixv-14322" unitRef="usd">3000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c5" decimals="0" id="ixv-14323" unitRef="usd">325737</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c139" decimals="0" id="ixv-14324" unitRef="usd">172017</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c140" decimals="0" id="ixv-14325" unitRef="usd">166527</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c141" decimals="0" id="ixv-14326" unitRef="usd">382324</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c142" decimals="0" id="ixv-14327" unitRef="usd">369154</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c143" decimals="0" id="ixv-14328" unitRef="usd">71629</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c144" decimals="0" id="ixv-14329" unitRef="usd">68156</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c145" decimals="0" id="ixv-14330" unitRef="usd">159171</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c146" decimals="0" id="ixv-14331" unitRef="usd">153704</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c147" decimals="0" id="ixv-14332" unitRef="usd">49542</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c148" decimals="0" id="ixv-14333" unitRef="usd">15909</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c149" decimals="0" id="ixv-14334" unitRef="usd">174804</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c150" decimals="0" id="ixv-14335" unitRef="usd">2000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c150" decimals="0" id="ixv-14336" unitRef="usd">36582</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c151" decimals="0" id="ixv-14337" unitRef="usd">84619</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c152" decimals="0" id="ixv-14338" unitRef="usd">1000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c152" decimals="0" id="ixv-14339" unitRef="usd">18983</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c0" decimals="0" id="ixv-14340" unitRef="usd">1094106</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c6" decimals="0" id="ixv-14341" unitRef="usd">3000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c6" decimals="0" id="ixv-14342" unitRef="usd">829015</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c153" decimals="0" id="ixv-14343" unitRef="usd">223222</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c154" decimals="0" id="ixv-14344" unitRef="usd">2000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c154" decimals="0" id="ixv-14345" unitRef="usd">199013</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c155" decimals="0" id="ixv-14346" unitRef="usd">494455</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c156" decimals="0" id="ixv-14347" unitRef="usd">477237</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c157" decimals="0" id="ixv-14348" unitRef="usd">91446</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c158" decimals="0" id="ixv-14349" unitRef="usd">22160</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c159" decimals="0" id="ixv-14350" unitRef="usd">205884</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c160" decimals="0" id="ixv-14351" unitRef="usd">198715</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c161" decimals="0" id="ixv-14352" unitRef="usd">32017</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c163" decimals="0" id="ixv-14353" unitRef="usd">2000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c163" decimals="0" id="ixv-14354" unitRef="usd">93054</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c165" decimals="0" id="ixv-14355" unitRef="usd">1000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c165" decimals="0" id="ixv-14356" unitRef="usd">45696</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c75" decimals="0" id="ixv-14357" unitRef="usd">3000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c75" decimals="0" id="ixv-14358" unitRef="usd">1185774</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c167" decimals="0" id="ixv-14359" unitRef="usd">2000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c167" decimals="0" id="ixv-14360" unitRef="usd">897125</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="c0" id="ixv-14361">Principal payments (net of debt issuance
and debt discount costs) due under bank loans outstanding as of September 30, 2024 (excluding our $1,000,000 line of credit) are reflected
in the following table by the year that payments are due:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;During the&lt;br/&gt; Three-Month&lt;br/&gt; Period Ending&lt;br/&gt; December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;During the Years Ending December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2027&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2028&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 16%"&gt;Loan #1&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;58,765&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;239,876&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;248,604&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;257,649&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;266,537&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,598,457&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,669,888&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Loan #2&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;129,801&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;530,738&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;549,881&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;140,436&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-96"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-97"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,350,856&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Loan #3&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,476&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;101,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;106,146&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;83,143&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-98"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-99"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;314,765&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Loan #4&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;54,055&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;220,994&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;228,965&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;240,442&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-100"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-101"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;744,456&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Loan #5&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,929&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;69,856&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;73,415&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;77,156&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;81,086&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-102"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;318,442&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Loan #6&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;60,581&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;253,003&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,418,558&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-103"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-104"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-105"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,732,142&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Loan #7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;29,617&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;124,364&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;715,704&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-106"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-107"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-108"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;869,685&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Subtotal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;374,224&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,539,831&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,341,273&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;798,826&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;347,623&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,598,457&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,000,234&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Debt issuance cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,583&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(21,314&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(13,580&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,420&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,513&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(11,347&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(60,757&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Debt discount cost&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5,223&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(20,891&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(11,344&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-109"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-110"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-111"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(37,458&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;363,418&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,497,626&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,316,349&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;793,406&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;344,110&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,587,110&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,902,019&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LineOfCredit contextRef="c124" decimals="0" id="ixv-14362" unitRef="usd">1000000</us-gaap:LineOfCredit>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear contextRef="c168" decimals="0" id="ixv-14363" unitRef="usd">58765</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c168" decimals="0" id="ixv-14364" unitRef="usd">239876</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c168" decimals="0" id="ixv-14365" unitRef="usd">248604</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c168" decimals="0" id="ixv-14366" unitRef="usd">257649</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="c168" decimals="0" id="ixv-14367" unitRef="usd">266537</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive contextRef="c168" decimals="0" id="ixv-14368" unitRef="usd">4598457</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:LongTermDebt contextRef="c168" decimals="0" id="ixv-14369" unitRef="usd">5669888</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear contextRef="c169" decimals="0" id="ixv-14370" unitRef="usd">129801</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c169" decimals="0" id="ixv-14371" unitRef="usd">530738</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c169" decimals="0" id="ixv-14372" unitRef="usd">549881</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c169" decimals="0" id="ixv-14373" unitRef="usd">140436</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebt contextRef="c169" decimals="0" id="ixv-14374" unitRef="usd">1350856</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear contextRef="c170" decimals="0" id="ixv-14375" unitRef="usd">24476</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c170" decimals="0" id="ixv-14376" unitRef="usd">101000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c170" decimals="0" id="ixv-14377" unitRef="usd">106146</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c170" decimals="0" id="ixv-14378" unitRef="usd">83143</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebt contextRef="c170" decimals="0" id="ixv-14379" unitRef="usd">314765</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear contextRef="c171" decimals="0" id="ixv-14380" unitRef="usd">54055</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c171" decimals="0" id="ixv-14381" unitRef="usd">220994</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c171" decimals="0" id="ixv-14382" unitRef="usd">228965</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c171" decimals="0" id="ixv-14383" unitRef="usd">240442</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebt contextRef="c171" decimals="0" id="ixv-14384" unitRef="usd">744456</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear contextRef="c172" decimals="0" id="ixv-14385" unitRef="usd">16929</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c172" decimals="0" id="ixv-14386" unitRef="usd">69856</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c172" decimals="0" id="ixv-14387" unitRef="usd">73415</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c172" decimals="0" id="ixv-14388" unitRef="usd">77156</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="c172" decimals="0" id="ixv-14389" unitRef="usd">81086</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebt contextRef="c172" decimals="0" id="ixv-14390" unitRef="usd">318442</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear contextRef="c173" decimals="0" id="ixv-14391" unitRef="usd">60581</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c173" decimals="0" id="ixv-14392" unitRef="usd">253003</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c173" decimals="0" id="ixv-14393" unitRef="usd">1418558</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebt contextRef="c173" decimals="0" id="ixv-14394" unitRef="usd">1732142</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear contextRef="c174" decimals="0" id="ixv-14395" unitRef="usd">29617</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c174" decimals="0" id="ixv-14396" unitRef="usd">124364</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c174" decimals="0" id="ixv-14397" unitRef="usd">715704</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebt contextRef="c174" decimals="0" id="ixv-14398" unitRef="usd">869685</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear contextRef="c175" decimals="0" id="ixv-14399" unitRef="usd">374224</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c175" decimals="0" id="ixv-14400" unitRef="usd">1539831</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c175" decimals="0" id="ixv-14401" unitRef="usd">3341273</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c175" decimals="0" id="ixv-14402" unitRef="usd">798826</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="c175" decimals="0" id="ixv-14403" unitRef="usd">347623</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive contextRef="c175" decimals="0" id="ixv-14404" unitRef="usd">4598457</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:LongTermDebt contextRef="c175" decimals="0" id="ixv-14405" unitRef="usd">11000234</us-gaap:LongTermDebt>
    <iccc:DebtIssuanceCosts2024 contextRef="c2" decimals="0" id="ixv-14406" unitRef="usd">5583</iccc:DebtIssuanceCosts2024>
    <iccc:DebtIssuanceCosts2025 contextRef="c2" decimals="0" id="ixv-14407" unitRef="usd">21314</iccc:DebtIssuanceCosts2025>
    <iccc:DebtIssuanceCosts2026 contextRef="c2" decimals="0" id="ixv-14408" unitRef="usd">13580</iccc:DebtIssuanceCosts2026>
    <iccc:DebtIssuanceCosts2027 contextRef="c2" decimals="0" id="ixv-14409" unitRef="usd">5420</iccc:DebtIssuanceCosts2027>
    <iccc:DebtIssuanceCosts2028 contextRef="c2" decimals="0" id="ixv-14410" unitRef="usd">3513</iccc:DebtIssuanceCosts2028>
    <iccc:DebtIssuanceCostshereafter contextRef="c2" decimals="0" id="ixv-14411" unitRef="usd">11347</iccc:DebtIssuanceCostshereafter>
    <us-gaap:DeferredFinanceCostsNet contextRef="c2" decimals="0" id="ixv-14412" unitRef="usd">60757</us-gaap:DeferredFinanceCostsNet>
    <iccc:DebtDiscountCost contextRef="c2" decimals="0" id="ixv-14413" unitRef="usd">5223</iccc:DebtDiscountCost>
    <iccc:DebtDiscountCost2025 contextRef="c2" decimals="0" id="ixv-14414" unitRef="usd">20891</iccc:DebtDiscountCost2025>
    <iccc:DebtDiscountCost2026 contextRef="c2" decimals="0" id="ixv-14415" unitRef="usd">11344</iccc:DebtDiscountCost2026>
    <iccc:DebtDiscountCostTotal contextRef="c2" decimals="0" id="ixv-14416" unitRef="usd">37458</iccc:DebtDiscountCostTotal>
    <iccc:LongTermDebt2024 contextRef="c2" decimals="0" id="ixv-14417" unitRef="usd">363418</iccc:LongTermDebt2024>
    <iccc:LongTermDebt2025 contextRef="c2" decimals="0" id="ixv-14418" unitRef="usd">1497626</iccc:LongTermDebt2025>
    <iccc:LongTermDebt2026 contextRef="c2" decimals="0" id="ixv-14419" unitRef="usd">3316349</iccc:LongTermDebt2026>
    <iccc:LongTermDebt2027 contextRef="c2" decimals="0" id="ixv-14420" unitRef="usd">793406</iccc:LongTermDebt2027>
    <iccc:LongTermDebtTotal2028 contextRef="c2" decimals="0" id="ixv-14421" unitRef="usd">344110</iccc:LongTermDebtTotal2028>
    <iccc:LongTermDebtThereafter contextRef="c2" decimals="0" id="ixv-14422" unitRef="usd">4587110</iccc:LongTermDebtThereafter>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c2" decimals="0" id="ixv-14423" unitRef="usd">10902019</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0" id="ixv-5477">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;11. CONTINGENT LIABILITIES AND COMMITMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Our bylaws, as amended, in effect provide that the
Company will indemnify its officers and directors against any liability arising from their responsibilities as officers and directors
to the maximum extent permitted by Delaware law. In addition, we make similar indemnity undertakings with each director through a separate
indemnification agreement with that director. The maximum payment that we may be required to make under such provisions is theoretically
unlimited and is impossible to determine. We maintain directors&#x2019; and officers&#x2019; liability insurance, which may provide reimbursement
to the Company for payments made to, or on behalf of, officers and directors pursuant to the indemnification provisions. Our indemnification
obligations were grandfathered under the provisions of Codification Topic 460&lt;i&gt;, Guarantees&lt;/i&gt;. Accordingly, we have recorded no liability
for such obligations as of September 30, 2024 or December 31, 2023. Since our incorporation, we have had no occasion to make any indemnification
payment to any of our officers or directors for any reason.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The development, manufacturing and marketing of
animal health care products entails an inherent risk that liability claims will be asserted against us during the normal course of business.
We are aware of no such claims against us as of the date of this filing. We believe that we have reasonable levels of liability insurance
to support our operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;We enter into agreements with third parties in the
ordinary course of business under which we are obligated to indemnify such third parties from and against various risks and losses. The
precise terms of such indemnities vary with the nature of the agreement. In many cases, we limit the maximum amount of our indemnification
obligations, but in some cases those obligations may be theoretically unlimited. We have not incurred material expenses in discharging
any of these indemnification obligations and based on our analysis of the nature of the risks involved, we believe that the fair value
of the liabilities potentially arising under these agreements is minimal. Accordingly, we recorded no liabilities for such obligations
as of September 30, 2024 or December 31, 2023.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;We plan to purchase certain key parts (syringes)
and services (formulation, aseptic filling and final packaging) pertaining to &lt;b&gt;Re-Tain&lt;sup&gt;&#xae;&lt;/sup&gt;&lt;/b&gt; Drug Product (DP), our Nisin-based
intramammary treatment of subclinical mastitis in lactating dairy cows, exclusively from contractors. The contract for formulation, aseptic
filling and final packaging of DP is scheduled to terminate on November 30, 2024. We initiated an investment in the necessary equipment
to perform the DP formulation and aseptic filling services in-house, but this investment has been paused at the present time.&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Effective March 28, 2022, we entered into an Amended
and Restated Separation and Deferred Compensation Agreement (the &#x201c;Deferred Compensation Agreement&#x201d;) with Mr. Brigham (our
President and CEO) that superseded and replaced in its entirety a March 2020 severance agreement between the Company and Mr. Brigham.
Upon separation from the Company for any reason, Mr. Brigham&#x2019;s Deferred Compensation Agreement allows Mr. Brigham to be paid, among
other amounts, all earned and unused paid time off (which expense totaling $222,379 was accrued during the first quarter of 2022 and $230,162
was included in accounts payable and accrued expenses on the accompanying balance sheets as of both September 30, 2024 and December 31,
2023) and to receive up to an additional $300,000 in deferred compensation (which amount is being accrued over the three-year period ending
in January 2025). This deferred compensation payment vested as to $100,000 on January 1, 2023 and an additional $100,000 on January 1,
2024. An additional $100,000 will vest on January 1, 2025, provided that Mr. Brigham is employed by the Company as of such date. The vested
amounts would be paid upon the earlier of January 31, 2025 or within thirty (30) days following his separation from the Company. As of
September 30, 2024 and December 31, 2023, $275,000 and $200,000, respectively, was included in accounts payable and accrued expenses on
the accompanying balance sheets. In addition, upon termination of Mr. Brigham&#x2019;s employment (a) by the Company other than for cause,
(b) due to death or disability or (c) by Mr. Brigham for good reason, in each case as described and defined in the Deferred Compensation
Agreement, the Company agrees to pay Mr. Brigham 100% of his then current annual base salary and a lump sum payment equal to the employer
portion of the costs of continued health benefits for Mr. Brigham and his covered dependents for a twelve-month period following termination,
and certain equity incentive awards granted to Mr. Brigham would continue to vest following such termination in accordance with the terms
of the Deferred Compensation Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Incentive
compensation agreements may be entered into with Mr. Brigham, Ms. Brockmann (our Vice President of Sales and Marketing) and Ms. Williams
(our Vice President of Manufacturing Operations) which, at times, allow these executives to earn incentive compensation if certain regulatory
and financial objectives are met during the year to which the agreement relates, as specified in their agreements. Amounts related to
these incentive compensation agreements are accrued over the period they are earned (when it is probable that the amounts will be earned)
based on our best estimate of the amounts expected to be &lt;/span&gt;earned.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
addition to the commitments discussed above, we had committed $186,000 to increase our production capacity for the &lt;b&gt;First Defense&lt;sup&gt;&#xae;&lt;/sup&gt;&lt;/b&gt;
product line, $1,818,000 to the purchase of inventory, $22,000 related to the commercial manufacture of &lt;b&gt;Re-Tain&lt;sup&gt;&#xae;&lt;/sup&gt;&lt;/b&gt;
and $711,000 to information technology services and other obligations as of September 30, 2024&lt;/span&gt;.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet contextRef="c176" decimals="0" id="ixv-14424" unitRef="usd">222379</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="c177" decimals="0" id="ixv-14425" unitRef="usd">230162</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="c178" decimals="0" id="ixv-14426" unitRef="usd">230162</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OtherDeferredCompensationArrangementsLiabilityCurrent contextRef="c2" decimals="0" id="ixv-14427" unitRef="usd">300000</us-gaap:OtherDeferredCompensationArrangementsLiabilityCurrent>
    <us-gaap:OtherDeferredCompensationArrangementsLiabilityCurrent contextRef="c179" decimals="0" id="ixv-14428" unitRef="usd">100000</us-gaap:OtherDeferredCompensationArrangementsLiabilityCurrent>
    <us-gaap:OtherDeferredCompensationArrangementsLiabilityCurrent contextRef="c180" decimals="0" id="ixv-14429" unitRef="usd">100000</us-gaap:OtherDeferredCompensationArrangementsLiabilityCurrent>
    <us-gaap:OtherDeferredCompensationArrangementsLiabilityCurrent contextRef="c177" decimals="0" id="ixv-14430" unitRef="usd">100000</us-gaap:OtherDeferredCompensationArrangementsLiabilityCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="c2" decimals="0" id="ixv-14431" unitRef="usd">275000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="c3" decimals="0" id="ixv-14432" unitRef="usd">200000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage
      contextRef="c181"
      decimals="2"
      id="ixv-14433"
      unitRef="pure">1</us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage>
    <iccc:CapitalExpendituresCommitted contextRef="c2" decimals="0" id="ixv-14434" unitRef="usd">186000</iccc:CapitalExpendituresCommitted>
    <iccc:PurchaseofInventory contextRef="c0" decimals="0" id="ixv-14435" unitRef="usd">1818000</iccc:PurchaseofInventory>
    <iccc:CommitmentsRelatedToCommercialManufacture contextRef="c182" decimals="0" id="ixv-14436" unitRef="usd">22000</iccc:CommitmentsRelatedToCommercialManufacture>
    <iccc:CommitmentsRelatedToInformationTechnologyServicesAndOtherObligations contextRef="c2" decimals="0" id="ixv-14437" unitRef="usd">711000</iccc:CommitmentsRelatedToInformationTechnologyServicesAndOtherObligations>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c0" id="ixv-5551">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;12. OPERATING LEASE&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;On September 12, 2019, we entered into a lease
covering approximately 14,300 square feet of office and warehouse space with a possession date of November 15, 2019 and a commencement
date of February 13, 2020. The property is located at 175 Industrial Way in Portland (&lt;b&gt;Building 175A&lt;/b&gt;), which is a short distance
from our headquarters and manufacturing facility at 56 Evergreen Drive. We renovated this space to meet our needs in expanding our production
capacity for the &lt;b&gt;First Defense&lt;sup&gt;&#xae;&lt;/sup&gt;&lt;/b&gt; product line. The original lease term was ten years with a right to renew for a
second 10-year term and a right of first offer to purchase. At the time we entered into this lease, we were not reasonably assured that
we would exercise this renewal option in place of other real estate options. For that reason, a 10-year period was reflected in the right-of-use
(ROU) asset and lease liability on our balance sheet. During the third quarter of 2022, we committed to lease an additional 15,400 square
feet of space at 175 Industrial Way (&lt;b&gt;Building 175B&lt;/b&gt;), which is connected to the original space, over a 20-year term. The ROU asset
and lease liability for the committed space at &lt;b&gt;Building 175B&lt;/b&gt; was recorded as of April 1, 2023 after construction of the building
shell was completed in accordance with the lease agreement. Monthly lease payments commenced as of August 1, 2023. In connection with
the lease commitment for space at &lt;b&gt;Building 175B, &lt;/b&gt;the term of the original lease for &lt;b&gt;Building 175A&lt;/b&gt; was extended by approximately
13 years. On November 14, 2023, June 11, 2024 and September 20, 2024, we amended this lease further to provide for certain tenant improvements
on the leased premises to be paid for by our landlord. These improvements will provide heat to an unfinished space, provide additional
warehouse space, and create a new primary shipping and receiving facility. As a result of these three amendments and in consideration
for the landlord agreeing to pay for the cost of those certain tenant improvements, we agreed to make additional rent payments of $20,000
per month from November of 2023 through June of 2025 and a one-time additional rent payment of $248,743 in July of 2025. Because of these
modifications to the lease payments, the ROU asset and lease liability associated with the space at &lt;b&gt;Building 175B&lt;/b&gt; were remeasured
as of the modification dates. Our leases include variable non-lease components. Such payments primarily include common area maintenance
charges. As of September 30, 2024, the balance of the operating lease ROU asset was $4,592,718 and the operating lease liability was $4,630,648.
As of December 31, 2023, the balance of the operating lease ROU asset was $4,571,149 and the operating lease liability was $4,721,385.
The calculated amount of the ROU asset and lease liability is impacted by the length of the lease term and the discount rate used for
the present value of the minimum lease payments. We elected not to separate lease and non-lease components for all classes of underlying
assets, and instead to account for them as a single lease component. Variable lease cost primarily represents variable payments such as
real estate taxes and common area maintenance. The following tables describe our lease costs and other lease information:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;During the Three-Month&lt;br/&gt; Periods Ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;During the Nine-Month &lt;br/&gt; Periods Ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;Lease Cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%; text-align: left; text-indent: -10.1pt; padding-left: 0.25in"&gt;Operating lease cost&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;106,880&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;98,714&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;320,639&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;244,954&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 20.2pt"&gt;Variable lease cost&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21,486&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,720&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;50,638&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;27,054&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt"&gt;Total lease cost&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;128,366&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;108,434&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;371,277&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;272,008&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Operating Lease&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt"&gt;Cash paid for operating lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;144,315&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;69,742&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;432,945&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;131,476&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-left: 0.125in; text-align: left"&gt;Weighted average remaining lease term (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18.3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19.3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18.3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19.3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;Weighted average discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.6&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.3&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.6&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.3&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;Future lease payments required under non-cancelable
operating leases in effect as of September 30, 2024 were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;During the three-month period ending December 31, 2024&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;144,315&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-decoration: underline"&gt;During the years ending December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;711,623&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;349,744&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;356,732&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;363,870&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,949,488&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Total lease payments (undiscounted cash flows)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,875,772&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: imputed interest (discount effect of cash flows)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,245,124&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total operating liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,630,648&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:AreaOfLand
      contextRef="c183"
      decimals="0"
      id="ixv-14438"
      unitRef="sqft">14300</us-gaap:AreaOfLand>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c184" id="ixv-14439">P10Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c184" id="ixv-14440">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:AreaOfLand
      contextRef="c185"
      decimals="0"
      id="ixv-14441"
      unitRef="sqft">15400</us-gaap:AreaOfLand>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c185" id="ixv-14442">P20Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:PaymentsForRent contextRef="c186" decimals="0" id="ixv-14443" unitRef="usd">20000</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent contextRef="c187" decimals="0" id="ixv-14444" unitRef="usd">248743</us-gaap:PaymentsForRent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c184" decimals="0" id="ixv-14445" unitRef="usd">4592718</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability contextRef="c184" decimals="0" id="ixv-14446" unitRef="usd">4630648</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c188" decimals="0" id="ixv-14447" unitRef="usd">4571149</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability contextRef="c188" decimals="0" id="ixv-14448" unitRef="usd">4721385</us-gaap:OperatingLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock contextRef="c0" id="ixv-14449">Variable lease cost primarily represents variable payments such as
real estate taxes and common area maintenance. The following tables describe our lease costs and other lease information:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;During the Three-Month&lt;br/&gt; Periods Ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;During the Nine-Month &lt;br/&gt; Periods Ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;Lease Cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%; text-align: left; text-indent: -10.1pt; padding-left: 0.25in"&gt;Operating lease cost&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;106,880&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;98,714&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;320,639&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;244,954&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 20.2pt"&gt;Variable lease cost&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21,486&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,720&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;50,638&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;27,054&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt"&gt;Total lease cost&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;128,366&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;108,434&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;371,277&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;272,008&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Operating Lease&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt"&gt;Cash paid for operating lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;144,315&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;69,742&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;432,945&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;131,476&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-left: 0.125in; text-align: left"&gt;Weighted average remaining lease term (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18.3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19.3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18.3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19.3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;Weighted average discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.6&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.3&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.6&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.3&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost contextRef="c4" decimals="0" id="ixv-14450" unitRef="usd">106880</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c5" decimals="0" id="ixv-14451" unitRef="usd">98714</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c0" decimals="0" id="ixv-14452" unitRef="usd">320639</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c6" decimals="0" id="ixv-14453" unitRef="usd">244954</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c4" decimals="0" id="ixv-14454" unitRef="usd">21486</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c5" decimals="0" id="ixv-14455" unitRef="usd">9720</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c0" decimals="0" id="ixv-14456" unitRef="usd">50638</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c6" decimals="0" id="ixv-14457" unitRef="usd">27054</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost contextRef="c4" decimals="0" id="ixv-14458" unitRef="usd">128366</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c5" decimals="0" id="ixv-14459" unitRef="usd">108434</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c0" decimals="0" id="ixv-14460" unitRef="usd">371277</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c6" decimals="0" id="ixv-14461" unitRef="usd">272008</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments contextRef="c4" decimals="0" id="ixv-14462" unitRef="usd">144315</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c5" decimals="0" id="ixv-14463" unitRef="usd">69742</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c0" decimals="0" id="ixv-14464" unitRef="usd">432945</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c6" decimals="0" id="ixv-14465" unitRef="usd">131476</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c2" id="ixv-14466">P18Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c33" id="ixv-14467">P19Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c2" id="ixv-14468">P18Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c33" id="ixv-14469">P19Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c2" decimals="3" id="ixv-14470" unitRef="pure">0.066</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c33" decimals="3" id="ixv-14471" unitRef="pure">0.063</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c2" decimals="3" id="ixv-14472" unitRef="pure">0.066</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c33" decimals="3" id="ixv-14473" unitRef="pure">0.063</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c0" id="ixv-14474">Future lease payments required under non-cancelable
operating leases in effect as of September 30, 2024 were as follows:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;During the three-month period ending December 31, 2024&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;144,315&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-decoration: underline"&gt;During the years ending December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;711,623&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;349,744&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;356,732&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;363,870&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,949,488&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Total lease payments (undiscounted cash flows)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,875,772&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: imputed interest (discount effect of cash flows)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,245,124&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total operating liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,630,648&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="c2" decimals="0" id="ixv-14475" unitRef="usd">144315</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c2" decimals="0" id="ixv-14476" unitRef="usd">711623</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c2" decimals="0" id="ixv-14477" unitRef="usd">349744</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c2" decimals="0" id="ixv-14478" unitRef="usd">356732</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c2" decimals="0" id="ixv-14479" unitRef="usd">363870</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c2" decimals="0" id="ixv-14480" unitRef="usd">5949488</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c2" decimals="0" id="ixv-14481" unitRef="usd">7875772</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c2" decimals="0" id="ixv-14482" unitRef="usd">3245124</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c2" decimals="0" id="ixv-14483" unitRef="usd">4630648</us-gaap:OperatingLeaseLiability>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock contextRef="c0" id="ixv-5844">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;13. STOCKHOLDERS&#x2019; EQUITY&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Common Stock Issuances&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;From February of 2016 to April of 2021, we sold
the aggregate of 4,553,017 shares of common stock in six different transactions raising gross proceeds of $26,714,403 at the weighted
average price of $5.87 per share. These funds have been essential to funding our business growth plans. The details of each transaction
are discussed below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;1) During February of 2016, we sold 1,123,810 shares
of common stock at a price to the public of $5.25 per share in an underwritten public offering pursuant to our effective shelf registration
statement on Form S-3, raising gross proceeds of $5,900,003 and resulting in net proceeds to the Company of $5,313,224 (after deducting
underwriting discounts and offering expenses incurred in connection with the equity financing).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;2) During October of 2016, we sold, in a private
placement, 659,880 shares of common stock to nineteen institutional and accredited investors at $5.25 per share, raising gross proceeds
of $3,464,370 and resulting in net proceeds to the Company of $3,160,923 (after deducting placement agent fees and other expenses incurred
in connection with the equity financing).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;3) During July of 2017, we sold 200,000 shares of
our common stock at a price of $5.25 per share in a public, registered sale to two related investors pursuant to our effective shelf registration
statement on Form S-3, raising gross proceeds of $1,050,000 and resulting in net proceeds of $1,034,164 (after deducting expenses incurred
in connection with the equity financing).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;4) During December of 2017, we sold 417,807 shares
of common stock at a price to the public of $7.30 per share in an underwritten public offering pursuant to our effective shelf registration
statement on Form S-3, raising gross proceeds of $3,049,991 and resulting in net proceeds to the Company of $2,734,173 (after deducting
underwriting discounts and offering expenses incurred in connection with the equity financing).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;5) During March of 2019, we sold 1,636,364 shares
of common stock at a price to the public of $5.50 per share in an underwritten public offering pursuant to our effective shelf registration
statement on Form S-3, raising gross proceeds of $9,000,002 and resulting in net proceeds to the Company of $8,303,436 (after deducting
underwriting discounts and offering expenses incurred in connection with the equity financing).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;6) During April of 2021, we sold 515,156 shares
of our common stock at a price of $8.25 per share in a public, registered sale to seven investors pursuant to our effective shelf registration
statement on Form S-3, raising gross proceeds of $4,250,038 and resulting in net proceeds of $4,233,026 (after deducting expenses incurred
in connection with the equity financing).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;At-The-Market Offering&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;On April 9, 2024, our shelf registration on Form
S-3 (File No. 333-278438) relating to the offer, issuance and sale by the Company of up to $20,000,000 of securities was declared effective
by the Securities and Exchange Commission. Also on April 9, 2024, we entered into an At-The-Market Agreement (ATM Agreement) with Craig-Hallum
Capital Group LLC, pursuant to which we may offer and sell up to $11,000,000 of shares of our common stock. Legal, accounting and other
fees in the amount of $152,272 associated with the completion of the shelf registration and the ATM Agreement were initially capitalized
and then were offset against the initial proceeds received during the second quarter of 2024. As of September 30, 2024, we had sold 1,082,233
shares under the at the market offering conducted pursuant to the ATM Agreement. Net proceeds through September 30, 2024 from shares sold
pursuant to the ATM Agreement (net of the upfront legal, accounting and other fees), less sales commissions of $123,368, were $3,833,090.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Stock Option Plans&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;In June of 2010, our stockholders approved the 2010
Stock Option and Incentive Plan (the &#x201c;2010 Plan&#x201d;) pursuant to the provisions of the Internal Revenue Code of 1986, under which
employees and certain service providers may be granted options to purchase shares of the Company&#x2019;s common stock at no less than
fair market value on the date of grant. At that time, 300,000 shares of common stock were reserved for issuance under the 2010 Plan and
subsequently no additional shares have been reserved for the 2010 Plan. Vesting requirements are determined by the Compensation and Stock
Option Committee of the Board of Directors on a case-by-case basis. All options granted under the 2010 Plan expire no later than 10 years
from the date of grant. The 2010 Plan expired in June of 2020, after which date no further options can be granted under the 2010 Plan.
However, options outstanding under the 2010 Plan at that time can be exercised in accordance with their terms. There were 183,500 and
188,500 options outstanding under the 2010 Plan as of September 30, 2024 and December 31, 2023, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;In June of 2017, our stockholders approved the 2017
Stock Option and Incentive Plan (the &#x201c;2017 Plan&#x201d;) pursuant to the provisions of the Internal Revenue Code of 1986, under which
employees and certain service providers may be granted options to purchase shares of the Company&#x2019;s common stock at no less than
fair market value on the date of grant. At that time, 300,000 shares of common stock were reserved for issuance under the 2017 Plan. An
amendment to the 2017 Plan increasing the number of shares reserved for issuance under the 2017 Plan from 300,000 shares to 650,000 shares
was approved by a vote of stockholders at the Annual Meeting of Stockholders in June of 2022. Vesting requirements are determined by the
Compensation and Stock Option Committee of the Board of Directors on a case-by-case basis. All options granted under the 2017 Plan expire
no later than 10 years from the date of grant. The 2017 Plan expires in March of 2027, after which date no further options can be granted
under the 2017 Plan. However, options outstanding under the 2017 Plan at that time can be exercised in accordance with their terms. As
of September 30, 2024 and December 31, 2023, there were 477,500 and 430,000 options outstanding under the 2017 Plan, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Activity under the stock option plans described
above was as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2010 Plan&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2017 Plan&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Aggregate Intrinsic Value&lt;sup&gt;(1)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Outstanding as of December 31, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;202,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;402,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.19&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(661,310&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in"&gt;Grants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-112"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;122,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5.16&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Terminations/forfeitures&lt;b&gt;&lt;sup&gt;(2)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(10,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(94,500&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;7.12&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10.1pt"&gt;Exercises&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-113"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;4.69&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding as of December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;188,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;430,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;6.82&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,071,121&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 10.1pt"&gt;Grants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-114"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;73,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Terminations/forfeitures&lt;b&gt;&lt;sup&gt;(2)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(25,500&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;6.75&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10.1pt"&gt;Exercises&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-115"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-116"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-117"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding as of September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;183,500&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;477,500&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;6.49&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;(1,891,421&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Vested as of September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;183,500&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;136,500&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;6.97&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;(1,068,740&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Vested and expected to vest as of September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;183,500&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;477,500&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;6.49&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;(1,891,421&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Reserved for future grants&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-118"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;154,500&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Intrinsic value is the difference between the fair market value
of the underlying common stock as of the date indicated and as of the date of the option grant (which is equal to the option exercise
price).&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;sup&gt;(2)&lt;/sup&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Terminations and forfeitures are recognized when they occur.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The following table displays additional information
about the stock option plans described above:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted Average &lt;br/&gt; Fair Value at Grant Date&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-indent: -10pt; padding-left: 10pt"&gt;Non-vested stock options as of December 31, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;337,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3.66&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.14&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Non-vested stock options as of September 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;341,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;6.04&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock options granted during the nine-month period ended September 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;73,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1.72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Stock options that vested during the nine-month period ended September 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;54,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4.31&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;9.73&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Stock options that were terminated or forfeited during the nine-month period ended September 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.36&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;6.75&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;No stock options were exercised during the three-month
or nine-month periods ended September 30, 2024 and 2023. The weighted average remaining life of the options outstanding under the 2010
Plan and the 2017 Plan as of September 30, 2024 was approximately 5 years. The weighted average remaining life of the options exercisable
under these plans as of September 30, 2024 was approximately 2 years and 11 months. The exercise price of the options outstanding under
these plans as of September 30, 2024, ranged from $3.60 to $10.04 per share. The 73,000 stock options granted during the nine-month period
ended September 30, 2024 had an average exercise price of $3.80 per share. The 108,000 stock options granted during the nine-month period
ended September 30, 2023 had an average exercise price of $5.19 per share. The weighted-average grant date fair values of options granted
during the nine-month periods ended September 30, 2024 and 2023 were $1.72 and $2.80 per share, respectively. As of September 30, 2024,
total unrecognized stock-based compensation related to non-vested stock options aggregated $433,317 which will be recognized over a weighted
average remaining period of approximately 1 year and 5 months. The fair value of each stock option grant has been estimated on the date
of grant using the Black-Scholes option pricing model, for the purpose discussed in Note 2(n), with the following weighted-average assumptions:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;During the Three-Month&lt;br/&gt; Periods Ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 3pt; font-weight: bold"&gt;&lt;sup&gt;&#160;&lt;/sup&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;During the Nine-Month &lt;br/&gt; Periods Ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 3pt; font-weight: bold"&gt;&lt;sup&gt;&#160;&lt;/sup&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free interest rate&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3.48&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-119; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 3pt; width: 1%; text-align: left"&gt;&lt;sup&gt;(4)&lt;/sup&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3.70&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3.48&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividend yield&lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="padding-bottom: 0pt; text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected volatility&lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;52&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-120; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 3pt; text-align: left"&gt;&lt;sup&gt;(4)&lt;/sup&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;51&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;54&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected life&lt;sup&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.1 years&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-121; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 3pt; text-align: left"&gt;&lt;sup&gt;(4)&lt;/sup&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.3 years&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.2 years&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;sup&gt;&#160;&lt;/sup&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;The risk-free interest rate is based on U.S. Treasury yields
for a maturity approximating the expected option term.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;sup&gt;(2)&lt;/sup&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;The dividend yield and expected volatility are derived from
averages of our historical data.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;sup&gt;(3)&lt;/sup&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;The expected life is calculated utilizing the simplified method,
which uses the mid-point between the vesting period and the contractual term as the expected life.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;sup&gt;(4)&lt;/sup&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;These values are not applicable because &lt;span style="-sec-ix-hidden: hidden-fact-122"&gt;no&lt;/span&gt; stock options were
granted during this period.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Common Stock Rights Plan&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;In September of 1995, our Board of Directors adopted
a Common Stock Rights Plan (the &#x201c;Rights Plan&#x201d;) and declared a dividend of one common share purchase right (a &#x201c;Right&#x201d;)
for each of the then outstanding shares of the common stock of the Company. Each Right entitles the registered holder to purchase from
the Company one share of common stock at an initial purchase price of $70.00 per share, subject to adjustment. The description and terms
of the Rights are set forth in a Rights Agreement between the Company and Equiniti Trust Company, LLC, as Rights Agent.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The Rights (as amended) become exercisable and transferable
apart from the common stock upon the earlier of i) 10 days following a public announcement that a person or group (Acquiring Person) has,
without the prior consent of the Continuing Directors (as such term is defined in the Rights Agreement), acquired beneficial ownership
of 20% or more of the outstanding common stock or ii) 10 days following commencement of a tender offer or exchange offer the consummation
of which would result in ownership by a person or group of 20% or more of the outstanding common stock (the earlier of such dates being
called the Distribution Date).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Upon the Distribution Date, the holder of each Right
not owned by the Acquiring Person would be entitled to purchase common stock at a discount to the initial purchase price of $70.00 per
share, effectively equal to one half of the market price of a share of common stock on the date the Acquiring Person becomes an Acquiring
Person. If, after the Distribution Date, the Company should consolidate or merge with any other entity and the Company were not the surviving
company, or, if the Company were the surviving company, all or part of the Company&#x2019;s common stock were changed or exchanged into
the securities of any other entity, or if more than 50% of the Company&#x2019;s assets or earning power were sold, each Right would entitle
its holder to purchase, at the Rights&#x2019; then-current purchase price, a number of shares of the acquiring company&#x2019;s common stock
having a market value at that time equal to twice the Right&#x2019;s exercise price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;At any time after a person or group becomes an Acquiring
Person and prior to the acquisition by such person or group of 50% or more of the outstanding common stock, the Board of Directors of
the Company may exchange the Rights (other than Rights owned by such person or group which have become void), in whole or in part, at
an exchange ratio of one share of common stock per Right (subject to adjustment). At any time prior to 14 days following the date that
any person or group becomes an Acquiring Person (subject to extension by the Board of Directors), the Board of Directors of the Company
may redeem the then outstanding Rights in whole, but not in part, at a price of $0.005 per Right, subject to adjustment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;During the third quarter of 2011, our Board of
Directors voted to authorize an amendment to the Rights Plan to increase the ownership threshold for determining &#x201c;Acquiring Person&#x201d;
status to 20%. During the second quarter of 2015, our Board of Directors also voted to authorize an amendment to remove a provision that
prevented a new group of directors elected following the emergence of an Acquiring Person (an owner of more than 20% of our stock) from
controlling the Rights Plan by maintaining exclusive authority over the Rights Plan with pre-existing directors. We did this because such
provisions have come to be viewed with disfavor by Delaware courts. Each time that we made such amendments we entered into amendments
to the Rights Agreement with the Rights Agent reflecting such extensions, threshold increases or provision changes. No other changes have
been made to the terms of the Rights or the Rights Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;At various times over the years, our Board of
Directors, which has the authority to amend the Rights Plan, has voted to authorize amendments to the Rights Plan to extend the expiration
date of the Rights Plan. Our Board of Directors decided to seek an advisory vote by stockholders at the Annual Meeting of Stockholders
held in June of 2022, as to whether to extend the Rights Plan by one year to September 19, 2023. Of the votes actually cast on this proposal,
65% voted in favor, 32% voted against and 3% abstained. On the basis of this vote, our Board of Directors voted to extend the Rights Plan
by one year to September 19, 2023. Our Board of Directors decided to seek another advisory vote by stockholders at the Annual Meeting
of Stockholders held in June of 2023, as to whether to extend the Rights Plan by another year to September 19, 2024. Of the votes actually
cast on this proposal, 65.10% voted in favor, 34.60% voted against and 0.30% abstained. On the basis of this vote, our Board of Directors
voted to extend the Rights Plan by one year to September 19, 2024. Recognizing that there might be a substantial number of broker non-votes,
our Board of Directors disclosed that it would be guided by the votes actually cast on these proposals in deciding whether to extend the
expiration date of such plan by one year. Our Board of Directors determined not to further extend the Rights Plan because these plans
are generally considered not to be stockholder friendly. With no further extension, the Rights Plan expired as of September 19, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Authorized Common Stock&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;At the June 14, 2018 Annual Meeting of Stockholders,
our stockholders voted to approve an amendment to our Certificate of Incorporation to increase the number of shares of common stock authorized
for issuance from 8,000,000 to 11,000,000. At the June 10, 2020 Annual Meeting of Stockholders, our stockholders voted to approve an amendment
to our Certificate of Incorporation to increase the number of shares of common stock authorized for issuance from 11,000,000 to 15,000,000.&lt;/p&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c189"
      decimals="0"
      id="ixv-14484"
      unitRef="shares">4553017</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c189" decimals="0" id="ixv-14485" unitRef="usd">26714403</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c190"
      decimals="2"
      id="ixv-14486"
      unitRef="usdPershares">5.87</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c191"
      decimals="0"
      id="ixv-14487"
      unitRef="shares">1123810</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c192"
      decimals="2"
      id="ixv-14488"
      unitRef="usdPershares">5.25</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c191" decimals="0" id="ixv-14489" unitRef="usd">5900003</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <iccc:NetProceedsFromIssuanceOfCommonStock contextRef="c191" decimals="0" id="ixv-14490" unitRef="usd">5313224</iccc:NetProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c193"
      decimals="0"
      id="ixv-14491"
      unitRef="shares">659880</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c194"
      decimals="2"
      id="ixv-14492"
      unitRef="usdPershares">5.25</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c193" decimals="0" id="ixv-14493" unitRef="usd">3464370</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <iccc:NetProceedsFromIssuanceOfCommonStock contextRef="c193" decimals="0" id="ixv-14494" unitRef="usd">3160923</iccc:NetProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c195"
      decimals="0"
      id="ixv-14495"
      unitRef="shares">200000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c196"
      decimals="2"
      id="ixv-14496"
      unitRef="usdPershares">5.25</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c195" decimals="0" id="ixv-14497" unitRef="usd">1050000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <iccc:NetProceedsFromIssuanceOfCommonStock contextRef="c195" decimals="0" id="ixv-14498" unitRef="usd">1034164</iccc:NetProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c197"
      decimals="0"
      id="ixv-14499"
      unitRef="shares">417807</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c198"
      decimals="2"
      id="ixv-14500"
      unitRef="usdPershares">7.3</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c197" decimals="0" id="ixv-14501" unitRef="usd">3049991</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <iccc:NetProceedsFromIssuanceOfCommonStock contextRef="c197" decimals="0" id="ixv-14502" unitRef="usd">2734173</iccc:NetProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c199"
      decimals="0"
      id="ixv-14503"
      unitRef="shares">1636364</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c200"
      decimals="2"
      id="ixv-14504"
      unitRef="usdPershares">5.5</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c199" decimals="0" id="ixv-14505" unitRef="usd">9000002</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <iccc:NetProceedsFromIssuanceOfCommonStock contextRef="c199" decimals="0" id="ixv-14506" unitRef="usd">8303436</iccc:NetProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c201"
      decimals="0"
      id="ixv-14507"
      unitRef="shares">515156</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c202"
      decimals="2"
      id="ixv-14508"
      unitRef="usdPershares">8.25</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c201" decimals="0" id="ixv-14509" unitRef="usd">4250038</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <iccc:NetProceedsFromIssuanceOfCommonStock contextRef="c201" decimals="0" id="ixv-14510" unitRef="usd">4233026</iccc:NetProceedsFromIssuanceOfCommonStock>
    <us-gaap:DebtInstrumentIssuedPrincipal contextRef="c203" decimals="0" id="ixv-14511" unitRef="usd">20000000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c204"
      decimals="0"
      id="ixv-14512"
      unitRef="shares">11000000</us-gaap:CommonStockSharesAuthorized>
    <iccc:FeesInitiallyCapitalizedAndLaterOffset contextRef="c205" decimals="0" id="ixv-14513" unitRef="usd">152272</iccc:FeesInitiallyCapitalizedAndLaterOffset>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c0"
      decimals="0"
      id="ixv-14514"
      unitRef="shares">1082233</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SalesCommissionsAndFees contextRef="c206" decimals="0" id="ixv-14515" unitRef="usd">123368</us-gaap:SalesCommissionsAndFees>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c206" decimals="0" id="ixv-14516" unitRef="usd">3833090</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c207"
      decimals="0"
      id="ixv-14517"
      unitRef="shares">300000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c208" id="ixv-14518">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c207"
      decimals="0"
      id="ixv-14519"
      unitRef="shares">183500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c209"
      decimals="0"
      id="ixv-14520"
      unitRef="shares">188500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c210"
      decimals="0"
      id="ixv-14521"
      unitRef="shares">300000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c211"
      decimals="0"
      id="ixv-14522"
      unitRef="shares">300000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c212"
      decimals="0"
      id="ixv-14523"
      unitRef="shares">650000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c213" id="ixv-14524">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c214"
      decimals="0"
      id="ixv-14525"
      unitRef="shares">477500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c215"
      decimals="0"
      id="ixv-14526"
      unitRef="shares">430000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0" id="ixv-14527">Activity under the stock option plans described
above was as follows:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2010 Plan&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2017 Plan&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Aggregate Intrinsic Value&lt;sup&gt;(1)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Outstanding as of December 31, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;202,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;402,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.19&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(661,310&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in"&gt;Grants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-112"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;122,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5.16&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Terminations/forfeitures&lt;b&gt;&lt;sup&gt;(2)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(10,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(94,500&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;7.12&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10.1pt"&gt;Exercises&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-113"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;4.69&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding as of December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;188,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;430,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;6.82&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,071,121&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 10.1pt"&gt;Grants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-114"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;73,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Terminations/forfeitures&lt;b&gt;&lt;sup&gt;(2)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(25,500&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;6.75&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10.1pt"&gt;Exercises&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-115"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-116"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-117"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding as of September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;183,500&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;477,500&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;6.49&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;(1,891,421&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Vested as of September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;183,500&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;136,500&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;6.97&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;(1,068,740&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Vested and expected to vest as of September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;183,500&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;477,500&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;6.49&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;(1,891,421&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Reserved for future grants&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-118"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;154,500&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Intrinsic value is the difference between the fair market value
of the underlying common stock as of the date indicated and as of the date of the option grant (which is equal to the option exercise
price).&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;sup&gt;(2)&lt;/sup&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Terminations and forfeitures are recognized when they occur.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c226"
      decimals="INF"
      id="ixv-14528"
      unitRef="shares">202500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c227"
      decimals="INF"
      id="ixv-14529"
      unitRef="shares">402500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c46"
      decimals="2"
      id="ixv-14530"
      unitRef="usdPershares">7.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c46" decimals="0" id="ix_0_fact" unitRef="usd">-661310</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c229"
      decimals="INF"
      id="ixv-14532"
      unitRef="shares">122000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c75"
      decimals="2"
      id="ixv-14533"
      unitRef="usdPershares">5.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c228"
      decimals="INF"
      id="ix_5_fact"
      unitRef="shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c229"
      decimals="INF"
      id="ix_6_fact"
      unitRef="shares">94500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c75"
      decimals="2"
      id="ix_7_fact"
      unitRef="usdPershares">7.12</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c228"
      decimals="INF"
      id="ixv-14537"
      unitRef="shares">4000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c75"
      decimals="2"
      id="ixv-14538"
      unitRef="usdPershares">4.69</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c230"
      decimals="INF"
      id="ixv-14539"
      unitRef="shares">188500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c231"
      decimals="INF"
      id="ixv-14540"
      unitRef="shares">430000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c3"
      decimals="2"
      id="ixv-14541"
      unitRef="usdPershares">6.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c3" decimals="0" id="ix_1_fact" unitRef="usd">-1071121</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c233"
      decimals="INF"
      id="ixv-14543"
      unitRef="shares">73000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      decimals="2"
      id="ixv-14544"
      unitRef="usdPershares">3.8</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c232"
      decimals="INF"
      id="ix_8_fact"
      unitRef="shares">5000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c233"
      decimals="INF"
      id="ix_9_fact"
      unitRef="shares">25500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      decimals="2"
      id="ix_10_fact"
      unitRef="usdPershares">6.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c234"
      decimals="INF"
      id="ixv-14548"
      unitRef="shares">183500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c235"
      decimals="INF"
      id="ixv-14549"
      unitRef="shares">477500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c2"
      decimals="2"
      id="ixv-14550"
      unitRef="usdPershares">6.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c2" decimals="0" id="ix_2_fact" unitRef="usd">-1891421</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <iccc:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested
      contextRef="c234"
      decimals="INF"
      id="ixv-14552"
      unitRef="shares">183500</iccc:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested>
    <iccc:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested
      contextRef="c235"
      decimals="INF"
      id="ixv-14553"
      unitRef="shares">136500</iccc:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested>
    <iccc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested
      contextRef="c2"
      decimals="2"
      id="ixv-14554"
      unitRef="usdPershares">6.97</iccc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested>
    <iccc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue contextRef="c2" decimals="0" id="ix_3_fact" unitRef="usd">-1068740</iccc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c234"
      decimals="INF"
      id="ixv-14556"
      unitRef="shares">183500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c235"
      decimals="INF"
      id="ixv-14557"
      unitRef="shares">477500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c2"
      decimals="2"
      id="ixv-14558"
      unitRef="usdPershares">6.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c2" decimals="0" id="ix_4_fact" unitRef="usd">-1891421</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c235"
      decimals="INF"
      id="ixv-14560"
      unitRef="shares">154500</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock contextRef="c0" id="ixv-14563">The following table displays additional information
about the stock option plans described above:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted Average &lt;br/&gt; Fair Value at Grant Date&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-indent: -10pt; padding-left: 10pt"&gt;Non-vested stock options as of December 31, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;337,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3.66&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.14&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Non-vested stock options as of September 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;341,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;6.04&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock options granted during the nine-month period ended September 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;73,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1.72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Stock options that vested during the nine-month period ended September 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;54,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4.31&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;9.73&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Stock options that were terminated or forfeited during the nine-month period ended September 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.36&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;6.75&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="c236"
      decimals="INF"
      id="ixv-14564"
      unitRef="shares">337500</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c236"
      decimals="2"
      id="ixv-14565"
      unitRef="usdPershares">3.66</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c236"
      decimals="2"
      id="ixv-14566"
      unitRef="usdPershares">7.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="c237"
      decimals="INF"
      id="ixv-14567"
      unitRef="shares">341000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c237"
      decimals="2"
      id="ixv-14568"
      unitRef="usdPershares">3.14</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c237"
      decimals="2"
      id="ixv-14569"
      unitRef="usdPershares">6.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c238"
      decimals="INF"
      id="ixv-14570"
      unitRef="shares">73000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c238"
      decimals="2"
      id="ixv-14571"
      unitRef="usdPershares">1.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c238"
      decimals="2"
      id="ixv-14572"
      unitRef="usdPershares">3.8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c238"
      decimals="INF"
      id="ixv-14573"
      unitRef="shares">54000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="c238"
      decimals="2"
      id="ixv-14574"
      unitRef="usdPershares">4.31</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c238"
      decimals="2"
      id="ixv-14575"
      unitRef="usdPershares">9.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="c238"
      decimals="INF"
      id="ixv-14576"
      unitRef="shares">30500</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="c238"
      decimals="2"
      id="ixv-14577"
      unitRef="usdPershares">3.36</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c238"
      decimals="2"
      id="ixv-14578"
      unitRef="usdPershares">6.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c4"
      decimals="0"
      id="ixv-14579"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c0"
      decimals="0"
      id="ixv-14580"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c208" id="ixv-14581">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c208" id="ixv-14582">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c216"
      decimals="2"
      id="ixv-14583"
      unitRef="usdPershares">3.6</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c217"
      decimals="2"
      id="ixv-14584"
      unitRef="usdPershares">10.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="c0"
      decimals="0"
      id="ixv-14585"
      unitRef="shares">73000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c218"
      decimals="2"
      id="ixv-14586"
      unitRef="usdPershares">3.8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="c6"
      decimals="0"
      id="ixv-14587"
      unitRef="shares">108000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c33"
      decimals="2"
      id="ixv-14588"
      unitRef="usdPershares">5.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
      contextRef="c219"
      decimals="2"
      id="ixv-14589"
      unitRef="usdPershares">1.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
      contextRef="c220"
      decimals="2"
      id="ixv-14590"
      unitRef="usdPershares">2.8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c2" decimals="0" id="ixv-14591" unitRef="usd">433317</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c0" id="ixv-14592">P1Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c0" id="ixv-14593">The fair value of each stock option grant has been estimated on the date
of grant using the Black-Scholes option pricing model, for the purpose discussed in Note 2(n), with the following weighted-average assumptions:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;During the Three-Month&lt;br/&gt; Periods Ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 3pt; font-weight: bold"&gt;&lt;sup&gt;&#160;&lt;/sup&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;During the Nine-Month &lt;br/&gt; Periods Ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 3pt; font-weight: bold"&gt;&lt;sup&gt;&#160;&lt;/sup&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free interest rate&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3.48&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-119; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 3pt; width: 1%; text-align: left"&gt;&lt;sup&gt;(4)&lt;/sup&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3.70&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3.48&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividend yield&lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="padding-bottom: 0pt; text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected volatility&lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;52&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-120; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 3pt; text-align: left"&gt;&lt;sup&gt;(4)&lt;/sup&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;51&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;54&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected life&lt;sup&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.1 years&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-121; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 3pt; text-align: left"&gt;&lt;sup&gt;(4)&lt;/sup&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.3 years&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.2 years&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;The risk-free interest rate is based on U.S. Treasury yields
for a maturity approximating the expected option term.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;sup&gt;(2)&lt;/sup&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;The dividend yield and expected volatility are derived from
averages of our historical data.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;sup&gt;(3)&lt;/sup&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;The expected life is calculated utilizing the simplified method,
which uses the mid-point between the vesting period and the contractual term as the expected life.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;sup&gt;(4)&lt;/sup&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;These values are not applicable because &lt;span style="-sec-ix-hidden: hidden-fact-122"&gt;no&lt;/span&gt; stock options were
granted during this period.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c4" decimals="4" id="ix_11_fact" unitRef="pure">0.0348</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c0" decimals="4" id="ix_12_fact" unitRef="pure">0.037</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c6" decimals="4" id="ix_13_fact" unitRef="pure">0.0348</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c4" decimals="2" id="ix_14_fact" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c5" decimals="2" id="ix_15_fact" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c0" decimals="2" id="ix_16_fact" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c6" decimals="2" id="ix_17_fact" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c4" decimals="2" id="ix_18_fact" unitRef="pure">0.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c0" decimals="2" id="ix_19_fact" unitRef="pure">0.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c6" decimals="2" id="ix_20_fact" unitRef="pure">0.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c4" id="ix_21_fact">P4Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c0" id="ix_22_fact">P4Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c6" id="ix_23_fact">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased
      contextRef="c0"
      decimals="2"
      id="ixv-14610"
      unitRef="usdPershares">70</us-gaap:EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased>
    <iccc:ExercisableAndTransferableDescription contextRef="c0" id="ixv-14611">The Rights (as amended) become exercisable and transferable
apart from the common stock upon the earlier of i) 10 days following a public announcement that a person or group (Acquiring Person) has,
without the prior consent of the Continuing Directors (as such term is defined in the Rights Agreement), acquired beneficial ownership
of 20% or more of the outstanding common stock or ii) 10 days following commencement of a tender offer or exchange offer the consummation
of which would result in ownership by a person or group of 20% or more of the outstanding common stock (the earlier of such dates being
called the Distribution Date).</iccc:ExercisableAndTransferableDescription>
    <us-gaap:InvestmentCompanyPurchasePremiumPerShare
      contextRef="c0"
      decimals="2"
      id="ixv-14612"
      unitRef="usdPershares">70</us-gaap:InvestmentCompanyPurchasePremiumPerShare>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostChangeDueToSubsequentInterimMeasurementWeightedAverageExpectedLongTermRateOfReturnOnPlanAssets contextRef="c0" decimals="2" id="ixv-14613" unitRef="pure">0.50</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostChangeDueToSubsequentInterimMeasurementWeightedAverageExpectedLongTermRateOfReturnOnPlanAssets>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage
      contextRef="c221"
      decimals="2"
      id="ixv-14614"
      unitRef="pure">0.50</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage>
    <iccc:RightToAcquirePerShare
      contextRef="c0"
      decimals="3"
      id="ixv-14615"
      unitRef="usdPershares">0.005</iccc:RightToAcquirePerShare>
    <iccc:AcquiringPersonPercentage
      contextRef="c105"
      decimals="2"
      id="ixv-14616"
      unitRef="pure">0.20</iccc:AcquiringPersonPercentage>
    <iccc:AcquiringPersonPercentage
      contextRef="c106"
      decimals="2"
      id="ixv-14617"
      unitRef="pure">0.20</iccc:AcquiringPersonPercentage>
    <us-gaap:EmployeeStockOwnershipPlanESOPPlanDescription contextRef="c0" id="ixv-14618">Our Board of Directors decided to seek an advisory vote by stockholders at the Annual Meeting of Stockholders
held in June of 2022, as to whether to extend the Rights Plan by one year to September 19, 2023. Of the votes actually cast on this proposal,
65% voted in favor, 32% voted against and 3% abstained. On the basis of this vote, our Board of Directors voted to extend the Rights Plan
by one year to September 19, 2023. Our Board of Directors decided to seek another advisory vote by stockholders at the Annual Meeting
of Stockholders held in June of 2023, as to whether to extend the Rights Plan by another year to September 19, 2024. Of the votes actually
cast on this proposal, 65.10% voted in favor, 34.60% voted against and 0.30% abstained. On the basis of this vote, our Board of Directors
voted to extend the Rights Plan by one year to September 19, 2024. Recognizing that there might be a substantial number of broker non-votes,
our Board of Directors disclosed that it would be guided by the votes actually cast on these proposals in deciding whether to extend the
expiration date of such plan by one year.</us-gaap:EmployeeStockOwnershipPlanESOPPlanDescription>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c222"
      decimals="0"
      id="ixv-14619"
      unitRef="shares">8000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c223"
      decimals="0"
      id="ixv-14620"
      unitRef="shares">11000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c224"
      decimals="0"
      id="ixv-14621"
      unitRef="shares">11000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c225"
      decimals="0"
      id="ixv-14622"
      unitRef="shares">15000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c0" id="ixv-6466">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;14. REVENUE&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;We
primarily offer the &lt;b&gt;First Defense&lt;/b&gt;&lt;/span&gt;&lt;b&gt;&lt;span style="font-family: Symbol"&gt;&lt;sup&gt;&#xd2;&lt;/sup&gt;&lt;/span&gt;&lt;/b&gt; &lt;span style="font-family: Times New Roman, Times, Serif"&gt;product
line to dairy and beef producers to prevent scours in newborn calves. Generally, our products are promoted to veterinarians as well as
dairy and beef producers by our sales team and then sold through distributors. Our primary market is North America. We do sell into select
international regions and may expand this international reach in the future. There were no material changes between the allocation and
timing of revenue recognition during the three-month or nine-month periods ended September 30, 2024 or 2023. We do not have any contract
assets for which we have satisfied the performance obligations, but do not yet have the right to bill for, or contract liabilities such
as customer advances. All trade receivables on our balance sheet are from contracts with customers. We incur no material costs to obtain
contracts.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The following table presents our product sales disaggregated
by geographic area:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: normal; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="14" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"&gt;&lt;b&gt;During the Three-Month&lt;br/&gt;
 Periods
    Ended September 30,&lt;/b&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: normal"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: normal; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="14" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"&gt;&lt;b&gt;During the Nine-Month&lt;br/&gt;
 Periods
    Ended September 30,&lt;/b&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: normal"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: normal"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"&gt;&lt;b&gt;%&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: normal"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: normal"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"&gt;&lt;b&gt;%&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: normal"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: normal"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"&gt;&lt;b&gt;%&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: normal"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: normal"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"&gt;&lt;b&gt;%&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: normal"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 20%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;United States&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;5,216,401&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;87&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;4,923,265&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;91&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;16,449,178&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;88&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;11,173,686&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;90&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;795,172&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;473,235&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,292,862&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,202,022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"&gt;Total Product Sales&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,011,573&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,396,500&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;18,742,040&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;12,375,708&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in"&gt;The following table presents our product sales disaggregated
by major product category:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;During the Three-Month&lt;br/&gt; Periods Ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;During the Nine-Month&lt;br/&gt; Periods Ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 20%; font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;First
    Defense&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;sup&gt;&#xae;&lt;/sup&gt; &lt;/span&gt;&lt;/b&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-style: normal; font-weight: normal"&gt;product
    line&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;5,951,344&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;99&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;5,360,063&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;99&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;18,602,053&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;99&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;12,253,555&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;99&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Other animal health&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;60,229&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;36,437&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;139,987&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;122,153&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt"&gt;Total Product Sales&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,011,573&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,396,500&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;18,742,040&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;12,375,708&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock contextRef="c0" id="ixv-14623">The following table presents our product sales disaggregated
by geographic area:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: normal; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="14" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"&gt;&lt;b&gt;During the Three-Month&lt;br/&gt;
 Periods
    Ended September 30,&lt;/b&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: normal"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: normal; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="14" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"&gt;&lt;b&gt;During the Nine-Month&lt;br/&gt;
 Periods
    Ended September 30,&lt;/b&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: normal"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: normal"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"&gt;&lt;b&gt;%&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: normal"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: normal"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"&gt;&lt;b&gt;%&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: normal"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: normal"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"&gt;&lt;b&gt;%&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: normal"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: normal"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: center"&gt;&lt;b&gt;%&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: normal"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 20%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;United States&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;5,216,401&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;87&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;4,923,265&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;91&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;16,449,178&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;88&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;11,173,686&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;90&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;795,172&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;473,235&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,292,862&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,202,022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"&gt;Total Product Sales&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,011,573&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,396,500&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;18,742,040&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;12,375,708&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c239" decimals="0" id="ixv-14624" unitRef="usd">5216401</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <iccc:RevenueSalesObligationPercentage
      contextRef="c239"
      decimals="2"
      id="ixv-14625"
      unitRef="pure">0.87</iccc:RevenueSalesObligationPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c240" decimals="0" id="ixv-14626" unitRef="usd">4923265</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <iccc:RevenueSalesObligationPercentage
      contextRef="c240"
      decimals="2"
      id="ixv-14627"
      unitRef="pure">0.91</iccc:RevenueSalesObligationPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c241" decimals="0" id="ixv-14628" unitRef="usd">16449178</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <iccc:RevenueSalesObligationPercentage
      contextRef="c241"
      decimals="2"
      id="ixv-14629"
      unitRef="pure">0.88</iccc:RevenueSalesObligationPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c242" decimals="0" id="ixv-14630" unitRef="usd">11173686</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <iccc:RevenueSalesObligationPercentage
      contextRef="c242"
      decimals="2"
      id="ixv-14631"
      unitRef="pure">0.90</iccc:RevenueSalesObligationPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c243" decimals="0" id="ixv-14632" unitRef="usd">795172</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <iccc:RevenueSalesObligationPercentage
      contextRef="c243"
      decimals="2"
      id="ixv-14633"
      unitRef="pure">0.13</iccc:RevenueSalesObligationPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c244" decimals="0" id="ixv-14634" unitRef="usd">473235</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <iccc:RevenueSalesObligationPercentage
      contextRef="c244"
      decimals="2"
      id="ixv-14635"
      unitRef="pure">0.09</iccc:RevenueSalesObligationPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c245" decimals="0" id="ixv-14636" unitRef="usd">2292862</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <iccc:RevenueSalesObligationPercentage
      contextRef="c245"
      decimals="2"
      id="ixv-14637"
      unitRef="pure">0.12</iccc:RevenueSalesObligationPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c246" decimals="0" id="ixv-14638" unitRef="usd">1202022</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <iccc:RevenueSalesObligationPercentage
      contextRef="c246"
      decimals="2"
      id="ixv-14639"
      unitRef="pure">0.10</iccc:RevenueSalesObligationPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c4" decimals="0" id="ixv-14640" unitRef="usd">6011573</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <iccc:RevenueSalesObligationPercentage contextRef="c4" decimals="2" id="ixv-14641" unitRef="pure">1</iccc:RevenueSalesObligationPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c5" decimals="0" id="ixv-14642" unitRef="usd">5396500</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <iccc:RevenueSalesObligationPercentage contextRef="c5" decimals="2" id="ixv-14643" unitRef="pure">1</iccc:RevenueSalesObligationPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c0" decimals="0" id="ixv-14644" unitRef="usd">18742040</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <iccc:RevenueSalesObligationPercentage contextRef="c0" decimals="2" id="ixv-14645" unitRef="pure">1</iccc:RevenueSalesObligationPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c6" decimals="0" id="ixv-14646" unitRef="usd">12375708</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <iccc:RevenueSalesObligationPercentage contextRef="c6" decimals="2" id="ixv-14647" unitRef="pure">1</iccc:RevenueSalesObligationPercentage>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c0" id="ixv-14648">The following table presents our product sales disaggregated
by major product category:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;During the Three-Month&lt;br/&gt; Periods Ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;During the Nine-Month&lt;br/&gt; Periods Ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 20%; font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;First
    Defense&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;sup&gt;&#xae;&lt;/sup&gt; &lt;/span&gt;&lt;/b&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-style: normal; font-weight: normal"&gt;product
    line&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;5,951,344&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;99&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;5,360,063&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;99&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;18,602,053&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;99&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;12,253,555&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;99&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Other animal health&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;60,229&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;36,437&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;139,987&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;122,153&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt"&gt;Total Product Sales&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,011,573&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,396,500&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;18,742,040&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;12,375,708&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c247" decimals="0" id="ixv-14649" unitRef="usd">5951344</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="c248"
      decimals="2"
      id="ixv-14650"
      unitRef="pure">0.99</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c249" decimals="0" id="ixv-14651" unitRef="usd">5360063</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="c250"
      decimals="2"
      id="ixv-14652"
      unitRef="pure">0.99</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c251" decimals="0" id="ixv-14653" unitRef="usd">18602053</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="c248"
      decimals="2"
      id="ixv-14654"
      unitRef="pure">0.99</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c252" decimals="0" id="ixv-14655" unitRef="usd">12253555</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="c250"
      decimals="2"
      id="ixv-14656"
      unitRef="pure">0.99</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c253" decimals="0" id="ixv-14657" unitRef="usd">60229</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="c254"
      decimals="2"
      id="ixv-14658"
      unitRef="pure">0.01</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c255" decimals="0" id="ixv-14659" unitRef="usd">36437</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="c256"
      decimals="2"
      id="ixv-14660"
      unitRef="pure">0.01</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c257" decimals="0" id="ixv-14661" unitRef="usd">139987</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="c254"
      decimals="2"
      id="ixv-14662"
      unitRef="pure">0.01</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c258" decimals="0" id="ixv-14663" unitRef="usd">122153</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="c256"
      decimals="2"
      id="ixv-14664"
      unitRef="pure">0.01</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c4" decimals="0" id="ixv-14665" unitRef="usd">6011573</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage contextRef="c2" decimals="2" id="ixv-14666" unitRef="pure">1</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c5" decimals="0" id="ixv-14667" unitRef="usd">5396500</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage contextRef="c33" decimals="2" id="ixv-14668" unitRef="pure">1</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c0" decimals="0" id="ixv-14669" unitRef="usd">18742040</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage contextRef="c2" decimals="2" id="ixv-14670" unitRef="pure">1</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c6" decimals="0" id="ixv-14671" unitRef="usd">12375708</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage contextRef="c33" decimals="2" id="ixv-14672" unitRef="pure">1</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock contextRef="c0" id="ixv-6826">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;15. OTHER EXPENSES, NET&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Other expenses net, consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;During the Three-Month  &lt;br/&gt;
Periods Ended September 30,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;During the Nine-Month &lt;br/&gt;
Periods Ended September 30,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Interest expense&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;144,141&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;144,616&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;432,529&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;323,177&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Loss (gain) on disposal of property, plant and equipment&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-123"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(68&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;14,557&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;8,099&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Interest income&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(18,685&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(23,696&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(41,476&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(79,134&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Insurance recoveries&lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-124"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(365,127&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-125"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(365,127&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Income - other&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-126"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-127"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-128"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(107&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Other expenses (income), net&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;125,456&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(244,275&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;405,610&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(113,092&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;sup&gt;&#160;&lt;/sup&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;Interest expense includes amortization of debt issuance and
debt discount costs of $10,805 and $8,687 during the three-month periods ended September 30, 2024 or 2023, respectively, and $31,859
and $12,525 during the nine-month periods ended September 30, 2024 and 2023, respectively.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="text-align: left; width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;sup&gt;(2)&lt;/sup&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
income from insurance recoveries resulted from claim benefits paid to us under our business interruption policy related to product contamination
losses and a recovery from a vendor&#x2019;s policy related to an equipment malfunction.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock contextRef="c0" id="ixv-14673">Other expenses net, consisted of the following:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;During the Three-Month  &lt;br/&gt;
Periods Ended September 30,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;During the Nine-Month &lt;br/&gt;
Periods Ended September 30,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Interest expense&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;144,141&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;144,616&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;432,529&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;323,177&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Loss (gain) on disposal of property, plant and equipment&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-123"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(68&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;14,557&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;8,099&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Interest income&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(18,685&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(23,696&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(41,476&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(79,134&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Insurance recoveries&lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-124"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(365,127&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-125"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(365,127&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Income - other&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-126"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-127"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-128"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(107&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Other expenses (income), net&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;125,456&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(244,275&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;405,610&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(113,092&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;Interest expense includes amortization of debt issuance and
debt discount costs of $10,805 and $8,687 during the three-month periods ended September 30, 2024 or 2023, respectively, and $31,859
and $12,525 during the nine-month periods ended September 30, 2024 and 2023, respectively.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="text-align: left; width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;sup&gt;(2)&lt;/sup&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
income from insurance recoveries resulted from claim benefits paid to us under our business interruption policy related to product contamination
losses and a recovery from a vendor&#x2019;s policy related to an equipment malfunction.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InterestExpense contextRef="c4" decimals="0" id="ix_24_fact" unitRef="usd">144141</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c5" decimals="0" id="ix_25_fact" unitRef="usd">144616</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c0" decimals="0" id="ix_26_fact" unitRef="usd">432529</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c6" decimals="0" id="ix_27_fact" unitRef="usd">323177</us-gaap:InterestExpense>
    <us-gaap:GainLossOnDispositionOfAssets contextRef="c5" decimals="0" id="ixv-14678" unitRef="usd">68</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets contextRef="c0" decimals="0" id="ixv-14679" unitRef="usd">-14557</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets contextRef="c6" decimals="0" id="ixv-14680" unitRef="usd">-8099</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:InterestIncomeOther contextRef="c4" decimals="0" id="ixv-14681" unitRef="usd">18685</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther contextRef="c5" decimals="0" id="ixv-14682" unitRef="usd">23696</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther contextRef="c0" decimals="0" id="ixv-14683" unitRef="usd">41476</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther contextRef="c6" decimals="0" id="ixv-14684" unitRef="usd">79134</us-gaap:InterestIncomeOther>
    <us-gaap:InsuranceRecoveries contextRef="c5" decimals="0" id="ix_28_fact" unitRef="usd">365127</us-gaap:InsuranceRecoveries>
    <us-gaap:InsuranceRecoveries contextRef="c6" decimals="0" id="ix_29_fact" unitRef="usd">365127</us-gaap:InsuranceRecoveries>
    <us-gaap:OtherIncome contextRef="c6" decimals="0" id="ixv-14687" unitRef="usd">107</us-gaap:OtherIncome>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c4" decimals="0" id="ixv-14688" unitRef="usd">-125456</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c5" decimals="0" id="ixv-14689" unitRef="usd">244275</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c0" decimals="0" id="ixv-14690" unitRef="usd">-405610</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c6" decimals="0" id="ixv-14691" unitRef="usd">113092</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c4" decimals="0" id="ixv-14693" unitRef="usd">10805</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c5" decimals="0" id="ixv-14694" unitRef="usd">8687</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c0" decimals="0" id="ixv-14695" unitRef="usd">31859</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c6" decimals="0" id="ixv-14696" unitRef="usd">12525</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0" id="ixv-6999">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;16. INCOME TAXES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Our income tax expense aggregated $1,340 and $229
(amounting to less than 1% of our loss before income taxes) during the three-month periods ended September 30, 2024 and 2023, respectively,
and $4,020 and $3,279 (amounting to less than 1% of our loss before income taxes) during the nine-month periods ended September 30, 2024
and 2023, respectively. As of December 31, 2023, we had federal net operating loss carryforwards of $17,759,519 of which $16,047,612 do
not expire and of which $1,711,907 expire in 2034 through 2037 (if not utilized before then) and state net operating loss carryforwards
of $4,681,644 that expire in 2037 through 2038 (if not utilized before then). Additionally, we had federal general business tax credit
carryforwards of $726,474 that expire in 2028 through 2044 (if not utilized before then) and state tax credit carryforwards of $981,604
that expire in 2024 through 2042 (if not utilized before then).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The provision for income taxes is determined using
the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the estimated future tax
effects of temporary differences between book and tax treatment of assets and liabilities and carryforwards to the extent they are realizable.
During the second quarter of 2018, we assessed our historical and near-term future profitability and recorded $563,252 in non-cash income
tax expense to create a full valuation allowance against our net deferred tax assets (which consist largely of net operating loss carryforwards
and federal and state credits) based on applicable accounting standards and practices. At that time, we had incurred a net loss for six
consecutive quarters, had not been profitable on a year-to-date basis since the nine-month period ended September 30, 2017 and projected
additional net losses for some period going forward before returning to profitability. Should future profitability be realized at an adequate
level, we would be able to release this valuation allowance (resulting in a non-cash income tax benefit) and realize these deferred tax
assets before they expire. We will continue to assess the need for the valuation allowance at each quarter and, in the event that actual
results differ from these estimates, or we adjust these estimates in future periods, we may need to adjust our valuation allowance. Currently,
we adjust the valuation allowance at the end of each quarter to reduce the value of our deferred tax assets to zero.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Net operating loss carryforwards, credits, and other
tax attributes are subject to review and possible adjustment by the Internal Revenue Service. Section 382 of the Internal Revenue Code
contains provisions that could place annual limitations on the future utilization of net operating loss carryforwards and credits in the
event of a change in ownership of the Company, as defined.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;We file income tax returns in the U.S. federal jurisdiction
and several state jurisdictions. We currently have no tax examinations in progress. We also have not paid additional taxes, interest or
penalties as a result of tax examinations nor do we have any unrecognized tax benefits for any of the periods in the accompanying unaudited
financial statements.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c4" decimals="0" id="ixv-14697" unitRef="usd">1340</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c5" decimals="0" id="ixv-14698" unitRef="usd">229</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther contextRef="c4" decimals="2" id="ixv-14699" unitRef="pure">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c0" decimals="0" id="ixv-14700" unitRef="usd">4020</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c6" decimals="0" id="ixv-14701" unitRef="usd">3279</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther contextRef="c0" decimals="2" id="ixv-14702" unitRef="pure">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c259" decimals="0" id="ixv-14703" unitRef="usd">17759519</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration contextRef="c259" decimals="0" id="ixv-14704" unitRef="usd">16047612</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="c259" decimals="0" id="ixv-14705" unitRef="usd">1711907</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:TaxCreditCarryforwardDescription contextRef="c260" id="ixv-14706">expire in 2034 through 2037</us-gaap:TaxCreditCarryforwardDescription>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="c261" decimals="0" id="ixv-14707" unitRef="usd">4681644</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:TaxCreditCarryforwardDescription contextRef="c262" id="ixv-14708">expire in 2037 through 2038</us-gaap:TaxCreditCarryforwardDescription>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="c263" decimals="0" id="ixv-14709" unitRef="usd">726474</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:TaxCreditCarryforwardDescription contextRef="c264" id="ixv-14710">expire in 2028 through 2044</us-gaap:TaxCreditCarryforwardDescription>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="c265" decimals="0" id="ixv-14711" unitRef="usd">981604</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:TaxCreditCarryforwardDescription contextRef="c266" id="ixv-14712">expire in 2024 through 2042</us-gaap:TaxCreditCarryforwardDescription>
    <us-gaap:OtherNoncashIncomeTaxExpense contextRef="c267" decimals="0" id="ixv-14713" unitRef="usd">563252</us-gaap:OtherNoncashIncomeTaxExpense>
    <us-gaap:DeferredTaxAssetsNet contextRef="c2" decimals="0" id="ixv-14714" unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c0" id="ixv-7037">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;17. SEGMENT INFORMATION&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Our business operations (being the development,
manufacture and sale of products that improve the health and productivity of dairy and beef cattle) are described in Note 1. Pursuant
to Codification Topic 280, &lt;i&gt;Segment Reporting&lt;/i&gt;, we operate in the following two reportable business segments: i) Scours and ii) Mastitis.
The Scours segment consists of the &lt;b&gt;First Defense&lt;sup&gt;&#xae;&lt;/sup&gt;&lt;/b&gt; product line. The core technology underlying the Scours segment
is focused on polyclonal antibodies. The Mastitis segment includes our products, &lt;b&gt;CMT &lt;/b&gt;and &lt;b&gt;Re-Tain&lt;sup&gt;&#xae;&lt;/sup&gt;&lt;/b&gt;. &lt;b&gt;Re-Tain&lt;sup&gt;&#xae;
&lt;/sup&gt;&lt;/b&gt;is projected to be the driver of this segment when approved for sale. The core technology underlying the Mastitis segment is
focused on a bacteriocin called Nisin. The category we define as &#x201c;Other&#x201d; includes unallocated administrative and overhead
expenses and other products. The significant accounting policies of these segments are described in Note 2. Product sales are the primary
factor we use in determining our reportable segments. The governing regulatory authority (Center for Veterinary Biologics, U.S. Department
of Agriculture for &lt;b&gt;First Defense&lt;sup&gt;&#xae;&lt;/sup&gt;&lt;/b&gt; or Center for Veterinary Medicine, U.S. Food and Drug Administration for &lt;b&gt;Re-Tain&lt;sup&gt;&#xae;&lt;/sup&gt;&lt;/b&gt;)
is also a factor in determining our reportable segments. Management monitors and evaluates segment performance from sales to net operating
income (loss) closely. We are not organized by geographic region. No segments have been aggregated. The revenues and expenses allocated
to each segment are in some cases direct and in other cases involve reasonable and consistent estimations by management. Each operating
segment is defined as the component of our business for which financial information is available and evaluated regularly by our chief
operating decision-maker in deciding how to allocate resources and in assessing performance. Our chief operating decision-maker is our
President and CEO.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;During the Three-Month &lt;br/&gt;
Period Ended
    September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Scours&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Mastitis&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Product sales&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,951,344&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;60,229&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-129"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,011,573&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Costs of goods sold&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,364,950&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;63,069&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-130"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,428,019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt"&gt;Gross margin&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,586,394&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,840&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-131"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,583,554&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Product development expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;59,140&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;690,052&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;36,944&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;786,136&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Sales and marketing expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;699,584&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;144,461&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-132"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;844,045&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Administrative expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-133"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-134"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;528,267&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;528,267&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"&gt;Operating expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;758,724&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;834,513&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;565,211&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,158,448&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt"&gt;NET OPERATING INCOME (LOSS)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;827,670&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(837,353&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(565,211&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(574,894&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;During the Three-Month &lt;br/&gt;
Period Ended
                                                                                                                                                                                    September 30, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Scours&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Mastitis&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Product sales&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,360,063&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;36,437&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-135"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,396,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Costs of goods sold&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,095,164&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;34,455&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-136"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,129,619&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt"&gt;Gross margin&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,264,899&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,982&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-137"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,266,881&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Product development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-138"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,082,346&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;36,143&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,118,489&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Sales and marketing expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;641,682&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;175,804&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-139"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;817,486&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Administrative expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-140"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-141"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;514,952&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;514,952&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 20.2pt"&gt;Operating expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;641,682&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,258,150&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;551,095&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,450,927&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt"&gt;NET OPERATING INCOME (LOSS)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;623,217&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(1,256,168&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(551,095&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(1,184,046&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Scours&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Mastitis&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Other&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-indent: -10pt; padding-left: 10pt"&gt;Total Assets as of September 30, 2024&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;23,672,583&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;16,798,955&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;3,977,335&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;44,448,873&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Total Assets as of September 30, 2023&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;24,119,683&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;18,132,922&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,292,417&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;44,545,022&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Depreciation and amortization expense during the three-month period ended September 30, 2024&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;346,430&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;319,815&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;19,682&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;685,927&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Depreciation and amortization expense during the three-month period ended September 30, 2023&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;355,673&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;328,381&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;25,044&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;709,098&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 10.1pt"&gt;Capital Expenditures during the three-month period ended September 30, 2024&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;87,286&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,126&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-142"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;88,412&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 10.1pt"&gt;Capital Expenditures during the three-month period ended September 30, 2023&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;341,386&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;79,129&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-143"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;420,515&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;During the Nine-Month&lt;br/&gt;
 Period Ended
    September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Scours&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Mastitis&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Product sales&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;18,602,054&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;139,986&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-144"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;18,742,040&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Costs of goods sold&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13,487,348&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;145,294&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-145"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13,632,642&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt"&gt;Gross margin&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,114,706&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,308&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-146"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,109,398&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Product development expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;154,233&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,821,525&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;103,431&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,079,189&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Sales and marketing expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,224,836&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;405,089&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-147"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,629,925&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Administrative expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-148"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-149"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,661,838&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,661,838&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10.1pt"&gt;Operating expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,379,069&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,226,614&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,765,269&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,370,952&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt"&gt;NET OPERATING INCOME (LOSS)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,735,637&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(3,231,922&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(1,765,269&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(2,261,554&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;During the Nine-Month&lt;br/&gt;
 Period Ended
                                                                                                                                                                                    September 30, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Scours&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Mastitis&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Product sales&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;12,253,555&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;122,153&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-150"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;12,375,708&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Costs of goods sold&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,652,292&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;111,872&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-151"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,764,164&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt"&gt;Gross margin&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,601,263&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,281&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-152"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,611,544&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Product development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,543&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,220,075&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;105,779&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,328,397&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Sales and marketing expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,890,404&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;526,297&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-153"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,416,701&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Administrative expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-154"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-155"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,611,026&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,611,026&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 20.2pt"&gt;Operating expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,892,947&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,746,372&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,716,805&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,356,124&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt"&gt;NET OPERATING INCOME (LOSS)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;708,316&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(3,736,091&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(1,716,805&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(4,744,580&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Scours&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Mastitis&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-indent: -10pt; padding-left: 10pt"&gt;Total Assets as of September 30, 2024&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;23,672,583&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;16,798,955&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,977,335&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;44,448,873&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Total Assets as of September 30, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;24,119,683&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;18,132,922&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,292,417&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;44,545,022&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Depreciation and amortization expense during the nine-month period ended September 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,027,711&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;958,260&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;59,221&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,045,192&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Depreciation and amortization expense during the nine-month period ended September 30, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,020,909&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;969,666&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;64,066&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,054,641&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 10.1pt"&gt;Capital Expenditures during the nine-month period ended September 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;235,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;33,909&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-156"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;269,509&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 10.1pt"&gt;Capital Expenditures during the nine-month period ended September 30, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,038,033&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;773,136&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-157"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,811,169&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;During the Year Ended December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Scours&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Mastitis&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Product sales&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;17,293,933&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;177,736&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-158"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;17,471,669&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Costs of goods sold&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13,453,514&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;148,871&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-159"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13,602,385&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt"&gt;Gross margin&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,840,419&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,865&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-160"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,869,284&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Product development expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,103&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,242,329&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;141,420&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,394,852&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Sales and marketing expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,447,137&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;641,078&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-161"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,088,215&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Administrative expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-162"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-163"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,134,295&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,134,295&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10.1pt"&gt;Operating expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,458,240&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,883,407&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,275,715&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,617,362&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt"&gt;NET OPERATING INCOME (LOSS)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,382,179&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(4,854,542&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(2,275,715&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(5,748,078&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;During the Year Ended December 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Scours&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Mastitis&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Product sales&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;18,411,949&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;154,558&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,455&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;18,567,962&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Costs of goods sold&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,754,189&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;136,347&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;28,647&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,919,183&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt"&gt;Gross margin&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,657,760&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,211&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(27,192&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,648,779&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Product development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;66,346&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,317,921&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;109,605&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,493,872&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Sales and marketing expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,871,926&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,318,107&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-164"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,190,033&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Administrative expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-165"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-166"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,263,817&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,263,817&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 20.2pt"&gt;Operating expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,938,272&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,636,028&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,373,422&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,947,722&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt"&gt;NET OPERATING INCOME (LOSS)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,719,488&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(5,617,817&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(2,400,614&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(2,298,943&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Scours&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Mastitis&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-indent: -10pt; padding-left: 10pt"&gt;Total Assets as of December 31, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;24,735,413&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;17,827,839&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,244,850&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;43,808,102&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Total Assets as of December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;20,539,523&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;18,315,492&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;6,005,634&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;44,860,649&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Depreciation and amortization expense during the year ended December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,365,988&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,287,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;86,032&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,739,620&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Depreciation and amortization expense during the year ended December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,169,011&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,263,318&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;62,912&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,495,241&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Capital Expenditures during the year ended December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,096,819&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;795,694&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-167"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,892,513&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Capital Expenditures during the year ended December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,497,834&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;429,988&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;47,452&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,975,274&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments contextRef="c0" decimals="0" id="ixv-14715" unitRef="pure">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c0" id="ixv-7055">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;During the Three-Month &lt;br/&gt;
Period Ended
    September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Scours&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Mastitis&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Product sales&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,951,344&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;60,229&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-129"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,011,573&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Costs of goods sold&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,364,950&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;63,069&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-130"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,428,019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt"&gt;Gross margin&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,586,394&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,840&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-131"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,583,554&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Product development expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;59,140&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;690,052&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;36,944&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;786,136&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Sales and marketing expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;699,584&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;144,461&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-132"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;844,045&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Administrative expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-133"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-134"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;528,267&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;528,267&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"&gt;Operating expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;758,724&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;834,513&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;565,211&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,158,448&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt"&gt;NET OPERATING INCOME (LOSS)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;827,670&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(837,353&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(565,211&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(574,894&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;During the Three-Month &lt;br/&gt;
Period Ended
                                                                                                                                                                                    September 30, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Scours&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Mastitis&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Product sales&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,360,063&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;36,437&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-135"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,396,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Costs of goods sold&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,095,164&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;34,455&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-136"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,129,619&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt"&gt;Gross margin&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,264,899&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,982&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-137"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,266,881&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Product development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-138"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,082,346&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;36,143&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,118,489&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Sales and marketing expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;641,682&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;175,804&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-139"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;817,486&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Administrative expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-140"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-141"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;514,952&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;514,952&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 20.2pt"&gt;Operating expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;641,682&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,258,150&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;551,095&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,450,927&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt"&gt;NET OPERATING INCOME (LOSS)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;623,217&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(1,256,168&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(551,095&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(1,184,046&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Scours&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Mastitis&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Other&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-indent: -10pt; padding-left: 10pt"&gt;Total Assets as of September 30, 2024&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;23,672,583&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;16,798,955&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;3,977,335&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;44,448,873&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Total Assets as of September 30, 2023&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;24,119,683&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;18,132,922&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,292,417&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;44,545,022&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Depreciation and amortization expense during the three-month period ended September 30, 2024&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;346,430&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;319,815&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;19,682&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;685,927&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Depreciation and amortization expense during the three-month period ended September 30, 2023&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;355,673&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;328,381&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;25,044&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;709,098&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 10.1pt"&gt;Capital Expenditures during the three-month period ended September 30, 2024&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;87,286&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,126&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-142"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;88,412&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 10.1pt"&gt;Capital Expenditures during the three-month period ended September 30, 2023&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;341,386&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;79,129&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-143"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;420,515&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;During the Nine-Month&lt;br/&gt;
 Period Ended
    September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Scours&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Mastitis&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Product sales&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;18,602,054&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;139,986&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-144"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;18,742,040&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Costs of goods sold&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13,487,348&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;145,294&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-145"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13,632,642&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt"&gt;Gross margin&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,114,706&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,308&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-146"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,109,398&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Product development expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;154,233&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,821,525&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;103,431&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,079,189&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Sales and marketing expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,224,836&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;405,089&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-147"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,629,925&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Administrative expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-148"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-149"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,661,838&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,661,838&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10.1pt"&gt;Operating expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,379,069&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,226,614&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,765,269&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,370,952&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt"&gt;NET OPERATING INCOME (LOSS)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,735,637&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(3,231,922&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(1,765,269&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(2,261,554&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;During the Nine-Month&lt;br/&gt;
 Period Ended
                                                                                                                                                                                    September 30, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Scours&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Mastitis&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Product sales&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;12,253,555&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;122,153&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-150"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;12,375,708&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Costs of goods sold&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,652,292&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;111,872&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-151"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,764,164&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt"&gt;Gross margin&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,601,263&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,281&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-152"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,611,544&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Product development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,543&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,220,075&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;105,779&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,328,397&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Sales and marketing expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,890,404&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;526,297&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-153"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,416,701&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Administrative expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-154"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-155"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,611,026&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,611,026&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 20.2pt"&gt;Operating expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,892,947&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,746,372&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,716,805&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,356,124&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt"&gt;NET OPERATING INCOME (LOSS)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;708,316&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(3,736,091&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(1,716,805&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(4,744,580&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Scours&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Mastitis&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-indent: -10pt; padding-left: 10pt"&gt;Total Assets as of September 30, 2024&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;23,672,583&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;16,798,955&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,977,335&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;44,448,873&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Total Assets as of September 30, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;24,119,683&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;18,132,922&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,292,417&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;44,545,022&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Depreciation and amortization expense during the nine-month period ended September 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,027,711&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;958,260&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;59,221&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,045,192&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Depreciation and amortization expense during the nine-month period ended September 30, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,020,909&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;969,666&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;64,066&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,054,641&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 10.1pt"&gt;Capital Expenditures during the nine-month period ended September 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;235,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;33,909&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-156"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;269,509&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 10.1pt"&gt;Capital Expenditures during the nine-month period ended September 30, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,038,033&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;773,136&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-157"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,811,169&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;During the Year Ended December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Scours&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Mastitis&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Product sales&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;17,293,933&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;177,736&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-158"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;17,471,669&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Costs of goods sold&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13,453,514&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;148,871&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-159"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13,602,385&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt"&gt;Gross margin&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,840,419&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,865&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-160"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,869,284&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Product development expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,103&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,242,329&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;141,420&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,394,852&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Sales and marketing expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,447,137&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;641,078&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-161"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,088,215&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Administrative expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-162"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-163"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,134,295&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,134,295&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10.1pt"&gt;Operating expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,458,240&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,883,407&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,275,715&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,617,362&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt"&gt;NET OPERATING INCOME (LOSS)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,382,179&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(4,854,542&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(2,275,715&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(5,748,078&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;During the Year Ended December 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Scours&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Mastitis&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Product sales&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;18,411,949&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;154,558&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,455&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;18,567,962&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Costs of goods sold&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,754,189&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;136,347&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;28,647&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,919,183&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt"&gt;Gross margin&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,657,760&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,211&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(27,192&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,648,779&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Product development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;66,346&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,317,921&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;109,605&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,493,872&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Sales and marketing expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,871,926&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,318,107&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-164"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,190,033&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Administrative expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-165"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-166"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,263,817&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,263,817&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 20.2pt"&gt;Operating expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,938,272&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,636,028&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,373,422&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,947,722&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt"&gt;NET OPERATING INCOME (LOSS)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,719,488&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(5,617,817&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(2,400,614&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(2,298,943&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Scours&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Mastitis&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-indent: -10pt; padding-left: 10pt"&gt;Total Assets as of December 31, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;24,735,413&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;17,827,839&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,244,850&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;43,808,102&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Total Assets as of December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;20,539,523&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;18,315,492&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;6,005,634&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;44,860,649&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Depreciation and amortization expense during the year ended December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,365,988&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,287,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;86,032&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,739,620&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Depreciation and amortization expense during the year ended December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,169,011&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,263,318&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;62,912&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,495,241&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Capital Expenditures during the year ended December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,096,819&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;795,694&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-167"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,892,513&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Capital Expenditures during the year ended December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,497,834&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;429,988&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;47,452&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,975,274&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c268" decimals="0" id="ixv-14716" unitRef="usd">5951344</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c269" decimals="0" id="ixv-14717" unitRef="usd">60229</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c4" decimals="0" id="ixv-14718" unitRef="usd">6011573</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c268" decimals="0" id="ixv-14719" unitRef="usd">4364950</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c269" decimals="0" id="ixv-14720" unitRef="usd">63069</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c4" decimals="0" id="ixv-14721" unitRef="usd">4428019</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit contextRef="c268" decimals="0" id="ixv-14722" unitRef="usd">1586394</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c269" decimals="0" id="ixv-14723" unitRef="usd">-2840</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c4" decimals="0" id="ixv-14724" unitRef="usd">1583554</us-gaap:GrossProfit>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c268" decimals="0" id="ixv-14725" unitRef="usd">59140</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c269" decimals="0" id="ixv-14726" unitRef="usd">690052</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c270" decimals="0" id="ixv-14727" unitRef="usd">36944</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c4" decimals="0" id="ixv-14728" unitRef="usd">786136</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c268" decimals="0" id="ixv-14729" unitRef="usd">699584</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c269" decimals="0" id="ixv-14730" unitRef="usd">144461</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c4" decimals="0" id="ixv-14731" unitRef="usd">844045</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c270" decimals="0" id="ixv-14732" unitRef="usd">528267</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c4" decimals="0" id="ixv-14733" unitRef="usd">528267</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c268" decimals="0" id="ixv-14734" unitRef="usd">758724</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c269" decimals="0" id="ixv-14735" unitRef="usd">834513</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c270" decimals="0" id="ixv-14736" unitRef="usd">565211</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c4" decimals="0" id="ixv-14737" unitRef="usd">2158448</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c268" decimals="0" id="ixv-14738" unitRef="usd">827670</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c269" decimals="0" id="ixv-14739" unitRef="usd">-837353</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c270" decimals="0" id="ixv-14740" unitRef="usd">-565211</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c4" decimals="0" id="ixv-14741" unitRef="usd">-574894</us-gaap:OperatingIncomeLoss>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c271" decimals="0" id="ixv-14742" unitRef="usd">5360063</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c272" decimals="0" id="ixv-14743" unitRef="usd">36437</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c5" decimals="0" id="ixv-14744" unitRef="usd">5396500</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c271" decimals="0" id="ixv-14745" unitRef="usd">4095164</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c272" decimals="0" id="ixv-14746" unitRef="usd">34455</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c5" decimals="0" id="ixv-14747" unitRef="usd">4129619</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit contextRef="c271" decimals="0" id="ixv-14748" unitRef="usd">1264899</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c272" decimals="0" id="ixv-14749" unitRef="usd">1982</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c5" decimals="0" id="ixv-14750" unitRef="usd">1266881</us-gaap:GrossProfit>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c272" decimals="0" id="ixv-14751" unitRef="usd">1082346</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c273" decimals="0" id="ixv-14752" unitRef="usd">36143</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c5" decimals="0" id="ixv-14753" unitRef="usd">1118489</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c271" decimals="0" id="ixv-14754" unitRef="usd">641682</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c272" decimals="0" id="ixv-14755" unitRef="usd">175804</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c5" decimals="0" id="ixv-14756" unitRef="usd">817486</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c273" decimals="0" id="ixv-14757" unitRef="usd">514952</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c5" decimals="0" id="ixv-14758" unitRef="usd">514952</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c271" decimals="0" id="ixv-14759" unitRef="usd">641682</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c272" decimals="0" id="ixv-14760" unitRef="usd">1258150</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c273" decimals="0" id="ixv-14761" unitRef="usd">551095</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c5" decimals="0" id="ixv-14762" unitRef="usd">2450927</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c271" decimals="0" id="ixv-14763" unitRef="usd">623217</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c272" decimals="0" id="ixv-14764" unitRef="usd">-1256168</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c273" decimals="0" id="ixv-14765" unitRef="usd">-551095</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c5" decimals="0" id="ixv-14766" unitRef="usd">-1184046</us-gaap:OperatingIncomeLoss>
    <us-gaap:Assets contextRef="c274" decimals="0" id="ixv-14767" unitRef="usd">23672583</us-gaap:Assets>
    <us-gaap:Assets contextRef="c275" decimals="0" id="ixv-14768" unitRef="usd">16798955</us-gaap:Assets>
    <us-gaap:Assets contextRef="c276" decimals="0" id="ixv-14769" unitRef="usd">3977335</us-gaap:Assets>
    <us-gaap:Assets contextRef="c2" decimals="0" id="ixv-14770" unitRef="usd">44448873</us-gaap:Assets>
    <us-gaap:Assets contextRef="c277" decimals="0" id="ixv-14771" unitRef="usd">24119683</us-gaap:Assets>
    <us-gaap:Assets contextRef="c278" decimals="0" id="ixv-14772" unitRef="usd">18132922</us-gaap:Assets>
    <us-gaap:Assets contextRef="c279" decimals="0" id="ixv-14773" unitRef="usd">2292417</us-gaap:Assets>
    <us-gaap:Assets contextRef="c33" decimals="0" id="ixv-14774" unitRef="usd">44545022</us-gaap:Assets>
    <us-gaap:CostDepreciationAmortizationAndDepletion contextRef="c268" decimals="0" id="ixv-14775" unitRef="usd">346430</us-gaap:CostDepreciationAmortizationAndDepletion>
    <us-gaap:CostDepreciationAmortizationAndDepletion contextRef="c269" decimals="0" id="ixv-14776" unitRef="usd">319815</us-gaap:CostDepreciationAmortizationAndDepletion>
    <us-gaap:CostDepreciationAmortizationAndDepletion contextRef="c270" decimals="0" id="ixv-14777" unitRef="usd">19682</us-gaap:CostDepreciationAmortizationAndDepletion>
    <us-gaap:CostDepreciationAmortizationAndDepletion contextRef="c4" decimals="0" id="ixv-14778" unitRef="usd">685927</us-gaap:CostDepreciationAmortizationAndDepletion>
    <us-gaap:CostDepreciationAmortizationAndDepletion contextRef="c271" decimals="0" id="ixv-14779" unitRef="usd">355673</us-gaap:CostDepreciationAmortizationAndDepletion>
    <us-gaap:CostDepreciationAmortizationAndDepletion contextRef="c272" decimals="0" id="ixv-14780" unitRef="usd">328381</us-gaap:CostDepreciationAmortizationAndDepletion>
    <us-gaap:CostDepreciationAmortizationAndDepletion contextRef="c273" decimals="0" id="ixv-14781" unitRef="usd">25044</us-gaap:CostDepreciationAmortizationAndDepletion>
    <us-gaap:CostDepreciationAmortizationAndDepletion contextRef="c5" decimals="0" id="ixv-14782" unitRef="usd">709098</us-gaap:CostDepreciationAmortizationAndDepletion>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c268" decimals="0" id="ixv-14783" unitRef="usd">87286</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c269" decimals="0" id="ixv-14784" unitRef="usd">1126</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c4" decimals="0" id="ixv-14785" unitRef="usd">88412</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c271" decimals="0" id="ixv-14786" unitRef="usd">341386</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c272" decimals="0" id="ixv-14787" unitRef="usd">79129</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c5" decimals="0" id="ixv-14788" unitRef="usd">420515</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c280" decimals="0" id="ixv-14789" unitRef="usd">18602054</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c281" decimals="0" id="ixv-14790" unitRef="usd">139986</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c0" decimals="0" id="ixv-14791" unitRef="usd">18742040</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c280" decimals="0" id="ixv-14792" unitRef="usd">13487348</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c281" decimals="0" id="ixv-14793" unitRef="usd">145294</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c0" decimals="0" id="ixv-14794" unitRef="usd">13632642</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit contextRef="c280" decimals="0" id="ixv-14795" unitRef="usd">5114706</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c281" decimals="0" id="ixv-14796" unitRef="usd">-5308</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c0" decimals="0" id="ixv-14797" unitRef="usd">5109398</us-gaap:GrossProfit>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c280" decimals="0" id="ixv-14798" unitRef="usd">154233</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c281" decimals="0" id="ixv-14799" unitRef="usd">2821525</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c282" decimals="0" id="ixv-14800" unitRef="usd">103431</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c0" decimals="0" id="ixv-14801" unitRef="usd">3079189</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c280" decimals="0" id="ixv-14802" unitRef="usd">2224836</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c281" decimals="0" id="ixv-14803" unitRef="usd">405089</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c0" decimals="0" id="ixv-14804" unitRef="usd">2629925</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c282" decimals="0" id="ixv-14805" unitRef="usd">1661838</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="0" id="ixv-14806" unitRef="usd">1661838</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c280" decimals="0" id="ixv-14807" unitRef="usd">2379069</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c281" decimals="0" id="ixv-14808" unitRef="usd">3226614</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c282" decimals="0" id="ixv-14809" unitRef="usd">1765269</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="0" id="ixv-14810" unitRef="usd">7370952</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c280" decimals="0" id="ixv-14811" unitRef="usd">2735637</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c281" decimals="0" id="ixv-14812" unitRef="usd">-3231922</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c282" decimals="0" id="ixv-14813" unitRef="usd">-1765269</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="0" id="ixv-14814" unitRef="usd">-2261554</us-gaap:OperatingIncomeLoss>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c283" decimals="0" id="ixv-14815" unitRef="usd">12253555</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c284" decimals="0" id="ixv-14816" unitRef="usd">122153</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c6" decimals="0" id="ixv-14817" unitRef="usd">12375708</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c283" decimals="0" id="ixv-14818" unitRef="usd">9652292</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c284" decimals="0" id="ixv-14819" unitRef="usd">111872</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c6" decimals="0" id="ixv-14820" unitRef="usd">9764164</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit contextRef="c283" decimals="0" id="ixv-14821" unitRef="usd">2601263</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c284" decimals="0" id="ixv-14822" unitRef="usd">10281</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c6" decimals="0" id="ixv-14823" unitRef="usd">2611544</us-gaap:GrossProfit>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c283" decimals="0" id="ixv-14824" unitRef="usd">2543</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c284" decimals="0" id="ixv-14825" unitRef="usd">3220075</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c285" decimals="0" id="ixv-14826" unitRef="usd">105779</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c6" decimals="0" id="ixv-14827" unitRef="usd">3328397</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c283" decimals="0" id="ixv-14828" unitRef="usd">1890404</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c284" decimals="0" id="ixv-14829" unitRef="usd">526297</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c6" decimals="0" id="ixv-14830" unitRef="usd">2416701</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c285" decimals="0" id="ixv-14831" unitRef="usd">1611026</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c6" decimals="0" id="ixv-14832" unitRef="usd">1611026</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c283" decimals="0" id="ixv-14833" unitRef="usd">1892947</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c284" decimals="0" id="ixv-14834" unitRef="usd">3746372</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c285" decimals="0" id="ixv-14835" unitRef="usd">1716805</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c6" decimals="0" id="ixv-14836" unitRef="usd">7356124</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c283" decimals="0" id="ixv-14837" unitRef="usd">708316</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c284" decimals="0" id="ixv-14838" unitRef="usd">-3736091</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c285" decimals="0" id="ixv-14839" unitRef="usd">-1716805</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c6" decimals="0" id="ixv-14840" unitRef="usd">-4744580</us-gaap:OperatingIncomeLoss>
    <us-gaap:Assets contextRef="c274" decimals="0" id="ixv-14841" unitRef="usd">23672583</us-gaap:Assets>
    <us-gaap:Assets contextRef="c275" decimals="0" id="ixv-14842" unitRef="usd">16798955</us-gaap:Assets>
    <us-gaap:Assets contextRef="c276" decimals="0" id="ixv-14843" unitRef="usd">3977335</us-gaap:Assets>
    <us-gaap:Assets contextRef="c2" decimals="0" id="ixv-14844" unitRef="usd">44448873</us-gaap:Assets>
    <us-gaap:Assets contextRef="c277" decimals="0" id="ixv-14845" unitRef="usd">24119683</us-gaap:Assets>
    <us-gaap:Assets contextRef="c278" decimals="0" id="ixv-14846" unitRef="usd">18132922</us-gaap:Assets>
    <us-gaap:Assets contextRef="c279" decimals="0" id="ixv-14847" unitRef="usd">2292417</us-gaap:Assets>
    <us-gaap:Assets contextRef="c33" decimals="0" id="ixv-14848" unitRef="usd">44545022</us-gaap:Assets>
    <us-gaap:CostDepreciationAmortizationAndDepletion contextRef="c280" decimals="0" id="ixv-14849" unitRef="usd">1027711</us-gaap:CostDepreciationAmortizationAndDepletion>
    <us-gaap:CostDepreciationAmortizationAndDepletion contextRef="c281" decimals="0" id="ixv-14850" unitRef="usd">958260</us-gaap:CostDepreciationAmortizationAndDepletion>
    <us-gaap:CostDepreciationAmortizationAndDepletion contextRef="c282" decimals="0" id="ixv-14851" unitRef="usd">59221</us-gaap:CostDepreciationAmortizationAndDepletion>
    <us-gaap:CostDepreciationAmortizationAndDepletion contextRef="c0" decimals="0" id="ixv-14852" unitRef="usd">2045192</us-gaap:CostDepreciationAmortizationAndDepletion>
    <us-gaap:CostDepreciationAmortizationAndDepletion contextRef="c283" decimals="0" id="ixv-14853" unitRef="usd">1020909</us-gaap:CostDepreciationAmortizationAndDepletion>
    <us-gaap:CostDepreciationAmortizationAndDepletion contextRef="c284" decimals="0" id="ixv-14854" unitRef="usd">969666</us-gaap:CostDepreciationAmortizationAndDepletion>
    <us-gaap:CostDepreciationAmortizationAndDepletion contextRef="c285" decimals="0" id="ixv-14855" unitRef="usd">64066</us-gaap:CostDepreciationAmortizationAndDepletion>
    <us-gaap:CostDepreciationAmortizationAndDepletion contextRef="c6" decimals="0" id="ixv-14856" unitRef="usd">2054641</us-gaap:CostDepreciationAmortizationAndDepletion>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c280" decimals="0" id="ixv-14857" unitRef="usd">235600</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c281" decimals="0" id="ixv-14858" unitRef="usd">33909</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c0" decimals="0" id="ixv-14859" unitRef="usd">269509</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c283" decimals="0" id="ixv-14860" unitRef="usd">1038033</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c284" decimals="0" id="ixv-14861" unitRef="usd">773136</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c6" decimals="0" id="ixv-14862" unitRef="usd">1811169</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c286" decimals="0" id="ixv-14863" unitRef="usd">17293933</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c287" decimals="0" id="ixv-14864" unitRef="usd">177736</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c75" decimals="0" id="ixv-14865" unitRef="usd">17471669</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c286" decimals="0" id="ixv-14866" unitRef="usd">13453514</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c287" decimals="0" id="ixv-14867" unitRef="usd">148871</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c75" decimals="0" id="ixv-14868" unitRef="usd">13602385</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit contextRef="c286" decimals="0" id="ixv-14869" unitRef="usd">3840419</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c287" decimals="0" id="ixv-14870" unitRef="usd">28865</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c75" decimals="0" id="ixv-14871" unitRef="usd">3869284</us-gaap:GrossProfit>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c286" decimals="0" id="ixv-14872" unitRef="usd">11103</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c287" decimals="0" id="ixv-14873" unitRef="usd">4242329</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c288" decimals="0" id="ixv-14874" unitRef="usd">141420</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c75" decimals="0" id="ixv-14875" unitRef="usd">4394852</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c286" decimals="0" id="ixv-14876" unitRef="usd">2447137</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c287" decimals="0" id="ixv-14877" unitRef="usd">641078</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c75" decimals="0" id="ixv-14878" unitRef="usd">3088215</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c288" decimals="0" id="ixv-14879" unitRef="usd">2134295</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c75" decimals="0" id="ixv-14880" unitRef="usd">2134295</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c286" decimals="0" id="ixv-14881" unitRef="usd">2458240</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c287" decimals="0" id="ixv-14882" unitRef="usd">4883407</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c288" decimals="0" id="ixv-14883" unitRef="usd">2275715</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c75" decimals="0" id="ixv-14884" unitRef="usd">9617362</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c286" decimals="0" id="ixv-14885" unitRef="usd">1382179</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c287" decimals="0" id="ixv-14886" unitRef="usd">-4854542</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c288" decimals="0" id="ixv-14887" unitRef="usd">-2275715</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c75" decimals="0" id="ixv-14888" unitRef="usd">-5748078</us-gaap:OperatingIncomeLoss>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c289" decimals="0" id="ixv-14889" unitRef="usd">18411949</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c290" decimals="0" id="ixv-14890" unitRef="usd">154558</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c291" decimals="0" id="ixv-14891" unitRef="usd">1455</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c167" decimals="0" id="ixv-14892" unitRef="usd">18567962</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c289" decimals="0" id="ixv-14893" unitRef="usd">10754189</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c290" decimals="0" id="ixv-14894" unitRef="usd">136347</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c291" decimals="0" id="ixv-14895" unitRef="usd">28647</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c167" decimals="0" id="ixv-14896" unitRef="usd">10919183</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit contextRef="c289" decimals="0" id="ixv-14897" unitRef="usd">7657760</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c290" decimals="0" id="ixv-14898" unitRef="usd">18211</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c291" decimals="0" id="ixv-14899" unitRef="usd">-27192</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c167" decimals="0" id="ixv-14900" unitRef="usd">7648779</us-gaap:GrossProfit>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c289" decimals="0" id="ixv-14901" unitRef="usd">66346</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c290" decimals="0" id="ixv-14902" unitRef="usd">4317921</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c291" decimals="0" id="ixv-14903" unitRef="usd">109605</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c167" decimals="0" id="ixv-14904" unitRef="usd">4493872</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c289" decimals="0" id="ixv-14905" unitRef="usd">1871926</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c290" decimals="0" id="ixv-14906" unitRef="usd">1318107</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c167" decimals="0" id="ixv-14907" unitRef="usd">3190033</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c291" decimals="0" id="ixv-14908" unitRef="usd">2263817</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c167" decimals="0" id="ixv-14909" unitRef="usd">2263817</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c289" decimals="0" id="ixv-14910" unitRef="usd">1938272</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c290" decimals="0" id="ixv-14911" unitRef="usd">5636028</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c291" decimals="0" id="ixv-14912" unitRef="usd">2373422</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c167" decimals="0" id="ixv-14913" unitRef="usd">9947722</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c289" decimals="0" id="ixv-14914" unitRef="usd">5719488</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c290" decimals="0" id="ixv-14915" unitRef="usd">-5617817</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c291" decimals="0" id="ixv-14916" unitRef="usd">-2400614</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c167" decimals="0" id="ixv-14917" unitRef="usd">-2298943</us-gaap:OperatingIncomeLoss>
    <us-gaap:Assets contextRef="c292" decimals="0" id="ixv-14918" unitRef="usd">24735413</us-gaap:Assets>
    <us-gaap:Assets contextRef="c293" decimals="0" id="ixv-14919" unitRef="usd">17827839</us-gaap:Assets>
    <us-gaap:Assets contextRef="c294" decimals="0" id="ixv-14920" unitRef="usd">1244850</us-gaap:Assets>
    <us-gaap:Assets contextRef="c3" decimals="0" id="ixv-14921" unitRef="usd">43808102</us-gaap:Assets>
    <us-gaap:Assets contextRef="c295" decimals="0" id="ixv-14922" unitRef="usd">20539523</us-gaap:Assets>
    <us-gaap:Assets contextRef="c296" decimals="0" id="ixv-14923" unitRef="usd">18315492</us-gaap:Assets>
    <us-gaap:Assets contextRef="c297" decimals="0" id="ixv-14924" unitRef="usd">6005634</us-gaap:Assets>
    <us-gaap:Assets contextRef="c46" decimals="0" id="ixv-14925" unitRef="usd">44860649</us-gaap:Assets>
    <us-gaap:CostDepreciationAmortizationAndDepletion contextRef="c286" decimals="0" id="ixv-14926" unitRef="usd">1365988</us-gaap:CostDepreciationAmortizationAndDepletion>
    <us-gaap:CostDepreciationAmortizationAndDepletion contextRef="c287" decimals="0" id="ixv-14927" unitRef="usd">1287600</us-gaap:CostDepreciationAmortizationAndDepletion>
    <us-gaap:CostDepreciationAmortizationAndDepletion contextRef="c288" decimals="0" id="ixv-14928" unitRef="usd">86032</us-gaap:CostDepreciationAmortizationAndDepletion>
    <us-gaap:CostDepreciationAmortizationAndDepletion contextRef="c75" decimals="0" id="ixv-14929" unitRef="usd">2739620</us-gaap:CostDepreciationAmortizationAndDepletion>
    <us-gaap:CostDepreciationAmortizationAndDepletion contextRef="c289" decimals="0" id="ixv-14930" unitRef="usd">1169011</us-gaap:CostDepreciationAmortizationAndDepletion>
    <us-gaap:CostDepreciationAmortizationAndDepletion contextRef="c290" decimals="0" id="ixv-14931" unitRef="usd">1263318</us-gaap:CostDepreciationAmortizationAndDepletion>
    <us-gaap:CostDepreciationAmortizationAndDepletion contextRef="c291" decimals="0" id="ixv-14932" unitRef="usd">62912</us-gaap:CostDepreciationAmortizationAndDepletion>
    <us-gaap:CostDepreciationAmortizationAndDepletion contextRef="c167" decimals="0" id="ixv-14933" unitRef="usd">2495241</us-gaap:CostDepreciationAmortizationAndDepletion>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c286" decimals="0" id="ixv-14934" unitRef="usd">1096819</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c287" decimals="0" id="ixv-14935" unitRef="usd">795694</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c75" decimals="0" id="ixv-14936" unitRef="usd">1892513</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c289" decimals="0" id="ixv-14937" unitRef="usd">3497834</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c290" decimals="0" id="ixv-14938" unitRef="usd">429988</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c291" decimals="0" id="ixv-14939" unitRef="usd">47452</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c167" decimals="0" id="ixv-14940" unitRef="usd">3975274</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0" id="ixv-8745">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;18. RELATED PARTY TRANSACTIONS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;David
S. Tomsche (Chair of our Board of Directors) is a controlling owner of Leedstone Inc., a domestic distributor of our products (the &lt;b&gt;First
Defense&lt;/b&gt;&lt;/span&gt;&lt;b&gt;&lt;span style="font-family: Symbol"&gt;&lt;sup&gt;&#xd2;&lt;/sup&gt; &lt;/span&gt;&lt;/b&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;product
line and &lt;b&gt;CMT&lt;/b&gt;). His affiliated company purchased $390,322 and $128,521 of products from us during the nine-month periods ended
September 30, 2024 and 2023, respectively, all on terms consistent with those offered to other distributors of similar status. Our accounts
receivable (subject to standard and customary payment terms) due from this affiliated company aggregated $35,364 and $42,507 as of September
30, 2024 and December 31, 2023, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty contextRef="c0" decimals="0" id="ixv-14941" unitRef="usd">390322</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty contextRef="c6" decimals="0" id="ixv-14942" unitRef="usd">128521</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:AccountsReceivableNet contextRef="c73" decimals="0" id="ixv-14943" unitRef="usd">35364</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet contextRef="c74" decimals="0" id="ixv-14944" unitRef="usd">42507</us-gaap:AccountsReceivableNet>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="c0" id="ixv-8761">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;19. EMPLOYEE BENEFITS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;We have a 401(k) savings plan (the Plan) in which
all employees completing one month of service with the Company are eligible to participate. Participants may contribute up to the maximum
amount allowed by the Internal Revenue Service. We currently match 100% of the first 3% of each employee&#x2019;s salary that is contributed
to the Plan and 50% of the next 2% of each employee&#x2019;s salary that is contributed to the Plan. Under this matching plan, we paid
$55,989 and $50,126 into the Plan for the three-month periods ended September 30, 2024 and 2023, respectively, and $159,504 and $135,698
for the nine-month periods ended September 30, 2024 and 2023, respectively.&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <iccc:EmployeesSalaryPercentage contextRef="c0" decimals="2" id="ixv-14945" unitRef="pure">1</iccc:EmployeesSalaryPercentage>
    <iccc:EmployeesSalaryPercentage
      contextRef="c298"
      decimals="2"
      id="ixv-14946"
      unitRef="pure">0.03</iccc:EmployeesSalaryPercentage>
    <iccc:EmployeesSalaryContributionPercentage contextRef="c0" decimals="2" id="ixv-14947" unitRef="pure">0.50</iccc:EmployeesSalaryContributionPercentage>
    <iccc:EmployeesSalaryContributionPercentage
      contextRef="c299"
      decimals="2"
      id="ixv-14948"
      unitRef="pure">0.02</iccc:EmployeesSalaryContributionPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid contextRef="c4" decimals="0" id="ixv-14949" unitRef="usd">55989</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid contextRef="c5" decimals="0" id="ixv-14950" unitRef="usd">50126</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid contextRef="c0" decimals="0" id="ixv-14951" unitRef="usd">159504</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid contextRef="c6" decimals="0" id="ixv-14952" unitRef="usd">135698</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0" id="ixv-8770">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;20. SUBSEQUENT EVENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;We have evaluated subsequent events through the
time of filing on the date we have issued this Quarterly Report on Form 10-Q. Subsequent to September 30, 2024 and through October 30,
2024, we sold an additional 78,492 shares raising an additional $289,719 in gross proceeds pursuant to the at the market offering conducted
pursuant to the ATM Agreement. See Note 13. As of the time of filing, there were no other material, reportable subsequent events.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c300"
      decimals="0"
      id="ixv-14953"
      unitRef="shares">78492</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c300" decimals="0" id="ixv-14954" unitRef="usd">289719</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c4" id="ixv-14955">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c4" id="ixv-14956">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c4" id="ixv-14957">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c4" id="ixv-14958">false</ecd:Rule10b51ArrAdoptedFlag>
    <dei:EntityRegistrantName contextRef="c0" id="hidden-fact-0">IMMUCELL CORP /DE/</dei:EntityRegistrantName>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c2"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c3"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c12"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c13"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c15"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c14"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c15"
      id="hidden-fact-7"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c15"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c12"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c14"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c15"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c25"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c26"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c28"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c25"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c27"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c28"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c38"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c39"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c41"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c40"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c41"
      id="hidden-fact-22"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c41"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c38"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c40"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c41"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c47"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c48"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c50"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c47"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c49"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c50"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="c0"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c0"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c6"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="c0"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="c0"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c54"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c55"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermBorrowings
      contextRef="c53"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermBorrowings
      contextRef="c55"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c58"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c59"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermBorrowings
      contextRef="c57"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermBorrowings
      contextRef="c59"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c4"
      id="hidden-fact-46"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c5"
      id="hidden-fact-47"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c0"
      id="hidden-fact-48"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c6"
      id="hidden-fact-49"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="c0"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="c6"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="c0"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="c6"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c88" id="hidden-fact-54" xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c90" id="hidden-fact-55" xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c125"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c126"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c127"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c128"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c129"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c130"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c131"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c132"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c133"
      id="hidden-fact-64"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c134"
      id="hidden-fact-65"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c135"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c137"
      id="hidden-fact-67"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c4"
      id="hidden-fact-68"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c139"
      id="hidden-fact-69"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c140"
      id="hidden-fact-70"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c141"
      id="hidden-fact-71"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c142"
      id="hidden-fact-72"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c143"
      id="hidden-fact-73"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c144"
      id="hidden-fact-74"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c145"
      id="hidden-fact-75"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c146"
      id="hidden-fact-76"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c147"
      id="hidden-fact-77"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c148"
      id="hidden-fact-78"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c149"
      id="hidden-fact-79"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c151"
      id="hidden-fact-80"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c0"
      id="hidden-fact-81"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c153"
      id="hidden-fact-82"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c155"
      id="hidden-fact-83"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c156"
      id="hidden-fact-84"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c157"
      id="hidden-fact-85"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c158"
      id="hidden-fact-86"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c159"
      id="hidden-fact-87"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c160"
      id="hidden-fact-88"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c161"
      id="hidden-fact-89"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c162"
      id="hidden-fact-90"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfBankDebt
      contextRef="c162"
      id="hidden-fact-91"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c164"
      id="hidden-fact-92"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfBankDebt
      contextRef="c164"
      id="hidden-fact-93"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c166"
      id="hidden-fact-94"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfBankDebt
      contextRef="c166"
      id="hidden-fact-95"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="c169"
      id="hidden-fact-96"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="c169"
      id="hidden-fact-97"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="c170"
      id="hidden-fact-98"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="c170"
      id="hidden-fact-99"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="c171"
      id="hidden-fact-100"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="c171"
      id="hidden-fact-101"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="c172"
      id="hidden-fact-102"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="c173"
      id="hidden-fact-103"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="c173"
      id="hidden-fact-104"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="c173"
      id="hidden-fact-105"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="c174"
      id="hidden-fact-106"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="c174"
      id="hidden-fact-107"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="c174"
      id="hidden-fact-108"
      unitRef="usd"
      xsi:nil="true"/>
    <iccc:DebtDiscountCost2027
      contextRef="c2"
      id="hidden-fact-109"
      unitRef="usd"
      xsi:nil="true"/>
    <iccc:DebtDiscountCost2028
      contextRef="c2"
      id="hidden-fact-110"
      unitRef="usd"
      xsi:nil="true"/>
    <iccc:DebtDiscountCostThereafter
      contextRef="c2"
      id="hidden-fact-111"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c228"
      id="hidden-fact-112"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c229"
      id="hidden-fact-113"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c232"
      id="hidden-fact-114"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c232"
      id="hidden-fact-115"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c233"
      id="hidden-fact-116"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      id="hidden-fact-117"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c234"
      id="hidden-fact-118"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c5"
      id="hidden-fact-119"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c5"
      id="hidden-fact-120"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c5" id="hidden-fact-121" xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c5"
      id="hidden-fact-122"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="c4"
      id="hidden-fact-123"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InsuranceRecoveries
      contextRef="c4"
      id="hidden-fact-124"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InsuranceRecoveries
      contextRef="c0"
      id="hidden-fact-125"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherIncome
      contextRef="c4"
      id="hidden-fact-126"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherIncome
      contextRef="c5"
      id="hidden-fact-127"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherIncome
      contextRef="c0"
      id="hidden-fact-128"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="c270"
      id="hidden-fact-129"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="c270"
      id="hidden-fact-130"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GrossProfit
      contextRef="c270"
      id="hidden-fact-131"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SellingAndMarketingExpense
      contextRef="c270"
      id="hidden-fact-132"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c268"
      id="hidden-fact-133"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c269"
      id="hidden-fact-134"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="c273"
      id="hidden-fact-135"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="c273"
      id="hidden-fact-136"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GrossProfit
      contextRef="c273"
      id="hidden-fact-137"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="c271"
      id="hidden-fact-138"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SellingAndMarketingExpense
      contextRef="c273"
      id="hidden-fact-139"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c271"
      id="hidden-fact-140"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c272"
      id="hidden-fact-141"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="c270"
      id="hidden-fact-142"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="c273"
      id="hidden-fact-143"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="c282"
      id="hidden-fact-144"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="c282"
      id="hidden-fact-145"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GrossProfit
      contextRef="c282"
      id="hidden-fact-146"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SellingAndMarketingExpense
      contextRef="c282"
      id="hidden-fact-147"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c280"
      id="hidden-fact-148"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c281"
      id="hidden-fact-149"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="c285"
      id="hidden-fact-150"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="c285"
      id="hidden-fact-151"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GrossProfit
      contextRef="c285"
      id="hidden-fact-152"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SellingAndMarketingExpense
      contextRef="c285"
      id="hidden-fact-153"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c283"
      id="hidden-fact-154"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c284"
      id="hidden-fact-155"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="c282"
      id="hidden-fact-156"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="c285"
      id="hidden-fact-157"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="c288"
      id="hidden-fact-158"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="c288"
      id="hidden-fact-159"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GrossProfit
      contextRef="c288"
      id="hidden-fact-160"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SellingAndMarketingExpense
      contextRef="c288"
      id="hidden-fact-161"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c286"
      id="hidden-fact-162"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c287"
      id="hidden-fact-163"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SellingAndMarketingExpense
      contextRef="c291"
      id="hidden-fact-164"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c289"
      id="hidden-fact-165"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c290"
      id="hidden-fact-166"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="c288"
      id="hidden-fact-167"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:AmendmentFlag contextRef="c0" id="ixv-15129">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="c0" id="ixv-15130">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="c0" id="ixv-15131">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentTransitionReport contextRef="c0" id="ixv-15132">false</dei:DocumentTransitionReport>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-15133">0000811641</dei:EntityCentralIndexKey>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#ix_2_fact"
          xlink:label="ix_2_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_1_fact"
          xlink:label="ix_1_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_3_fact"
          xlink:label="ix_3_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_4_fact"
          xlink:label="ix_4_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_0_fact"
          xlink:label="ix_0_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_0_footnote" xlink:label="ix_0_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Intrinsic value is the difference between the fair market value
of the underlying common stock as of the date indicated and as of the date of the option grant (which is equal to the option exercise
price).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_2_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_1_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_3_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_4_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_0_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_10_fact"
          xlink:label="ix_10_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_5_fact"
          xlink:label="ix_5_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_8_fact"
          xlink:label="ix_8_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_9_fact"
          xlink:label="ix_9_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_6_fact"
          xlink:label="ix_6_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_7_fact"
          xlink:label="ix_7_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_1_footnote" xlink:label="ix_1_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Terminations and forfeitures are recognized when they occur.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_10_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_5_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_8_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_9_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_6_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_7_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_13_fact"
          xlink:label="ix_13_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-119"
          xlink:label="hidden-fact-119"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_11_fact"
          xlink:label="ix_11_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_12_fact"
          xlink:label="ix_12_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_2_footnote" xlink:label="ix_2_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The risk-free interest rate is based on U.S. Treasury yields
for a maturity approximating the expected option term.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_13_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-119"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_11_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_12_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_19_fact"
          xlink:label="ix_19_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_14_fact"
          xlink:label="ix_14_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-120"
          xlink:label="hidden-fact-120"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_17_fact"
          xlink:label="ix_17_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_20_fact"
          xlink:label="ix_20_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_16_fact"
          xlink:label="ix_16_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_15_fact"
          xlink:label="ix_15_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_18_fact"
          xlink:label="ix_18_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_3_footnote" xlink:label="ix_3_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The dividend yield and expected volatility are derived from
averages of our historical data.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_19_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_14_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-120"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_17_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_20_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_16_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_15_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_18_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_21_fact"
          xlink:label="ix_21_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_22_fact"
          xlink:label="ix_22_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-121"
          xlink:label="hidden-fact-121"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_23_fact"
          xlink:label="ix_23_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_4_footnote" xlink:label="ix_4_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The expected life is calculated utilizing the simplified method,
which uses the mid-point between the vesting period and the contractual term as the expected life.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_21_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_22_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-121"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_23_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnote id="ix_5_footnote" xlink:label="ix_5_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">These values are not applicable because <xhtml:span style="-sec-ix-hidden: hidden-fact-122">no</xhtml:span> stock options were
granted during this period.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-119"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-120"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-121"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_26_fact"
          xlink:label="ix_26_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_27_fact"
          xlink:label="ix_27_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_24_fact"
          xlink:label="ix_24_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_25_fact"
          xlink:label="ix_25_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_6_footnote" xlink:label="ix_6_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Interest expense includes amortization of debt issuance and
debt discount costs of $10,805 and $8,687 during the three-month periods ended September 30, 2024 or 2023, respectively, and $31,859
and $12,525 during the nine-month periods ended September 30, 2024 and 2023, respectively.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_26_fact"
          xlink:to="ix_6_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_27_fact"
          xlink:to="ix_6_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_24_fact"
          xlink:to="ix_6_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_25_fact"
          xlink:to="ix_6_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#hidden-fact-124"
          xlink:label="hidden-fact-124"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_29_fact"
          xlink:label="ix_29_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_28_fact"
          xlink:label="ix_28_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-125"
          xlink:label="hidden-fact-125"
          xlink:type="locator"/>
        <link:footnote id="ix_7_footnote" xlink:label="ix_7_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
income from insurance recoveries resulted from claim benefits paid to us under our business interruption policy related to product contamination
losses and a recovery from a vendor&#x2019;s policy related to an equipment malfunction.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-124"
          xlink:to="ix_7_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_29_fact"
          xlink:to="ix_7_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_28_fact"
          xlink:to="ix_7_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-125"
          xlink:to="ix_7_footnote"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
